SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS

PART 500—GENERAL

Subpart A [Reserved]

Subpart B—Specific Administrative Rulings and Decisions

Sec.
500.23 Thermally processed low-acid foods packaged in hermetically sealed containers.
500.24 Emergency permit control.
500.25 Anthelmintic drugs for use in animals.
500.26 Timed-release dosage form drugs.
500.27 Methylene blue-containing drugs for use in animals.
500.29 Gentian violet for use in animal feed.
500.30 Gentian violet for animal drug use.
500.45 Use of polychlorinated biphenyls (PCB’s) in the production, handling, and storage of animal feed.
500.46 Hexachlorophene in animal drugs.
500.50 Propylene glycol in or on cat food.

Subpart C—Animal Drug Labeling Requirements

500.51 Labeling of animal drugs; misbranding.
500.52 Use of terms such as “tonic”, “tone”, “toner”, or “conditioner” in the labeling of preparations intended for use in or on animals.
500.55 Exemption from certain drug-labeling requirements.

Subpart D—Requirements for Specific Animal Drugs

500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for emergency treatment of anaphylactoid shock in cattle, horses, sheep, and swine.

Subpart E—Regulation of Carcinogenic Compounds Used in Food-Producing Animals

500.80 Scope of this subpart.
500.82 Definitions.
500.84 Conditions for approval of the sponsored compound.
500.88 Regulatory method.
500.90 Waiver of requirements.

500.92 Implementation.

Subpart F—Methods for Detection of Residues of Carcinogenic Compounds Used in Food-Producing Animals

500.140 N-methyl-2-pyrrolidone.


Source: 40 FR 13802, Mar. 27, 1975, unless otherwise noted.

Subpart A [Reserved]

Subpart B—Specific Administrative Rulings and Decisions

§ 500.23 Thermally processed low-acid foods packaged in hermetically sealed containers.

Except as provided in § 507.5(b) of this chapter, the provisions of parts 507 and 113 of this chapter apply to the manufacturing, processing, or packing of low-acid foods in hermetically sealed containers, and intended for use as food for animals.

[80 FR 56337, Sept. 17, 2015]

§ 500.24 Emergency permit control.

The provisions of part 108 of this chapter shall apply to the issuance of emergency control permits for the manufacturer or packer of thermally processed low-acid foods packaged in hermetically sealed containers, and intended for use as food for animals.

[61 FR 37681, July 19, 1996]

§ 500.25 Anthelmintic drugs for use in animals.

(a) The Commissioner of Food and Drugs has determined that, in order to assure that anthelmintic drugs, including animal feeds bearing or containing such drugs, which do not carry the prescription statement are labeled to provide adequate directions for their effective use, labeling of these anthelmintic drugs shall bear, in addition to other required information, a statement that a veterinarian should be consulted for
§ 500.26 Timed-release dosage form drugs.

(a) Drugs are being offered in dosage forms that are designed to release the active ingredients over a prolonged period of time. There is a possibility of unsafe overdosage or ineffective dosage if such products are improperly made and the active ingredients are released at one time, over too short or too long a period of time, or not released at all. Drugs marketed in this form, which are referred to by such terms as timed-release, controlled-release, prolonged-release, sustained-release, or delayed-release drugs, are regarded as new animal drugs within the meaning of section 201(v) of the Federal Food, Drug, and Cosmetic Act.

(b) Timed-release dosage form animal drugs that are introduced into interstate commerce are deemed to be adulterated within the meaning of section 501(a)(5) of the act and subject to regulatory action, unless such animal drug is the subject of an approved new animal drug application, or listed in the index, as required by paragraph (a) of this section.

(c) The fact that the labeling of this kind of drug may claim delayed, prolonged, controlled, or sustained-release of all or only some of the active ingredients does not affect the new animal drug status of such articles. A new animal drug application or index listing is required in any such case.

(d) New animal drug applications for timed-release dosage form animal drugs must contain, among other things, data to demonstrate safety and effectiveness by establishing that the article is manufactured using procedures and controls to ensure release of the total dosage at a safe and effective rate. Data submitted in the new animal drug application must demonstrate that the formulation of the drug and the procedures used in its manufacture will ensure release of the active ingredient(s) of the drug at a safe and effective rate and that these release characteristics will be maintained until the expiration date of the drug. When the drug is intended for use in food-producing animals, data submitted must also demonstrate that, with respect to possible residues of the drug, food derived from treated animals is safe for consumption.


§ 500.27 Methylene blue-containing drugs for use in animals.

(a) New information requires a re-evaluation of the status of drugs containing methylene blue (tetramethylthionine chloride) for oral use in cats or dogs.

(1)(i) It has been demonstrated that two orally administered urinary antiseptic-antispasmodic preparations that contained methylene blue cause Heinz body hemolytic anemia in cats when used according to label directions. The specific cause of the reaction was determined to be the methylene blue contained in the preparations. The reaction can be severe enough to cause death of treated animals.

(ii) The Heinz body hemolytic anemia reaction to methylene blue has also
been demonstrated in dogs under laboratory conditions. The precise mechanism by which methylene blue produces the characteristic erythrocytic inclusion bodies (Heinz bodies) and associated hemolytic anemia is unclear.

(2) The effectiveness of orally administered methylene blue as a urinary antiseptic is open to question. It appears that following oral administration, methylene blue is poorly and erratically absorbed and also slowly and erratically excreted in the urine. Studies in the dog indicate it is excreted in the urine essentially as leukomethylene blue stabilized in some manner. Methylene blue itself is stepwise demethylated in alkaline solutions (alkaline urine being a frequent consequence of urinary infection) to Azure B, Azure A, and Azure C. The antiseptic efficacy of all of these excretion products is unsubstantiated.

(3) In view of the foregoing, the Commissioner has concluded that animal drugs containing methylene blue for oral use in cats or dogs are neither safe nor generally recognized as effective within the meaning of section 201(v) of the act and are therefore considered new animal drugs. Accordingly, all prior formal and informal opinions expressed by the Food and Drug Administration that such drugs are “not new drugs” or “no longer new drugs” are hereby revoked.

(b) Animal drugs that contain methylene blue for oral use in cats or dogs and not the subject of an approved new animal drug application (NADA) are deemed to be adulterated under the provisions of section 501(a) (5) and/or (6) and/or misbranded under section 502(a) of the act and subject to regulatory action as of April 10, 1978.

(c) Sponsors of animal drugs that contain methylene blue for oral use in cats or dogs and not the subject of an approved new animal drug application (NADA) may submit an application in conformity with §514.1 of this chapter. Such applications will be processed in accordance with section 512 of the act. Submission of an NADA will not constitute grounds for continued marketing of this drug substance until such application is approved.

(d) New animal drug applications required by this regulation pursuant to section 512 of the act shall be submitted to the Food and Drug Administration. Center for Veterinary Medicine, Office of New Animal Drug Evaluation (HFV-100), 7500 Standish Pl., Rockville, MD 20855.

§ 500.29 Gentian violet for use in animal feed.

The Food and Drug Administration has determined that gentian violet is not generally recognized as safe for use in animal feed and is a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act (the act), unless it is intended for use as a new animal drug, in which case it is subject to section 512 of the act. The Food and Drug Administration has determined that gentian violet is not prior sanctioned for any use in animal feed.

[56 FR 40506, Aug. 15, 1991]

§ 500.30 Gentian violet for animal drug use.

The Food and Drug Administration (FDA) has determined that gentian violet is not generally recognized as safe and effective for any veterinary drug use in food animals and is a new animal drug subject to section 512 of the Federal Food, Drug, and Cosmetic Act. FDA has determined that gentian violet is not exempted from new animal drug status under the “grandfather” provisions of the Drug Amendments of 1962 (21 U.S.C. 342).

[56 FR 40507, Aug. 15, 1991]

§ 500.45 Use of polychlorinated biphenyls (PCB’s) in the production, handling, and storage of animal feed.

(a) Polychlorinated biphenyls (PCB’s) represent a class of toxic industrial chemicals manufactured and sold under a variety of trade names, including: Aroclor (United States); Phenoclor (France); Colphen (Germany); and Kanaclor (Japan). PCB’s are highly stable, heat resistant, and nonflammable chemicals. Industrial uses of PCB’s include, or did include in the past, their
use as electrical transformer and capacitor fluids, heat transfer fluids, hydraulic fluids, plasticizers, and in formulations of lubricants, coatings, and inks. Their unique physical and chemical properties and widespread, uncontrolled industrial applications have caused PCB’s to be a persistent and ubiquitous contaminant in the environment, causing the contamination of certain foods. In addition, incidents have occurred in which PCB’s have directly contaminated animal feeds as a result of industrial accidents (leakage or spillage of PCB fluids from plant equipment). These accidents in turn cause the contamination of food intended for human consumption (meat, milk, and eggs). Investigations by the Food and Drug Administration have revealed that heat exchange fluids for certain pasteurization equipment used in processing animal feed contain PCB’s. Although heat exchange fluids in such equipment are considered to be in closed systems, leakage has occurred that resulted in direct contamination of animal feed with PCB’s and subsequently resulted in the transfer of PCB’s to human food produced by animals consuming the contaminated feed. The use of PCB-containing coatings on the inner walls of silos has resulted in the contamination of silage which has in turn caused PCB residues in the milk of dairy cows consuming the contaminated silage. Since PCB’s are toxic chemicals, the PCB contamination of food as a result of these and other incidents represent a hazard to public health. It is therefore necessary to place certain restrictions on the industrial uses of PCB’s in the production, handling, and storage of animal feed.

(b) The following special provisions are necessary to preclude accidental PCB contamination of animal feed:

(1) Coatings or paints for use on the contact surfaces of feed storage areas may not contain PCB’s or any other harmful or deleterious substances likely to contaminate feed.

(2) New equipment or machinery for handling or processing feed in or around an establishment producing animal feed shall not contain PCB’s.

(3) On or before Sept. 4, 1973, the management of establishments producing animal feed shall:

(i) Have the heat exchange fluid used in existing equipment or machinery for handling and processing feed sampled and tested to determine whether it contains PCB’s, or verify the absence of PCB’s in such formulations by other appropriate means. On or before Sept. 4, 1973, any such fluid formulated with PCB’s must to the fullest extent possible commensurate with current good manufacturing practices, be replaced with a heat exchange fluid that does not contain PCB’s.

(ii) Eliminate to the fullest extent possible commensurate with current good manufacturing practices from the animal feed producing establishment any PCB-containing lubricants for equipment or machinery used for handling or processing animal feed.

(iii) Eliminate to the fullest extent possible commensurate with current good manufacturing practices from the animal feed producing establishment any other PCB-containing materials, whenever there is a reasonable expectation that such materials could cause animal feed to become contaminated with PCB’s either as a result of normal use or as a result of accident, breakage, or other mishap.

(iv) The toxicity and other characteristics of fluids selected as PCB replacements must be adequately determined so that the least potentially hazardous replacement should be used. In making this determination with respect to a given fluid, consideration should be given to (a) its toxicity; (b) the maximum quantity that could be spilled onto a given quantity of food before it would be noticed, taking into account its color and odor; (c) possible signaling devices in the equipment to indicate a loss of fluid, etc.; (d) and its environmental stability and tendency to survive and be concentrated through the food chain. The judgment as to whether a replacement fluid is sufficiently non-hazardous is to be made on an individual installation and operation basis.

(c) For the purpose of this section, the provisions do not apply to electrical transformers and condensers containing PCB’s in sealed containers.
Food and Drug Administration, HHS

§ 500.51 Labeling of animal drugs; misbranding.

(a) Among the representations on the label or labeling of an animal drug which will render the drug misbranded are any broad statements suggesting or implying that the drug is not safe and effective for use when used in accordance with labeling direction, or that the labeling does not contain adequate warnings or directions for use.

(b) After September 29, 1977, animal drugs that contain hexachlorophene other than for preservative use on non-food-producing animals at a level not exceeding 0.1 percent that are introduced into interstate commerce shall be deemed to be adulterated within the meaning of section 501(a)(5) of the act (21 U.S.C. 351(a)(5)) unless such animal drug is the subject of a new animal drug application submitted pursuant to paragraph (c) of this section. Action to withdraw approval of new animal drug applications will be initiated if supplemental new animal drug applications have not been submitted in accordance with this section.

(c) New animal drug applications submitted for animal drugs containing hexachlorophene for use in or on food-producing animals shall include adequate data to assure that edible products from treated animals are safe for human consumption under the labeled conditions of use.

(d) For the purpose of this section, the term animal feed includes all articles used for food or drink for animals other than man.

§ 500.46 Hexachlorophene in animal drugs.

(a) The Commissioner of Food and Drugs has determined that there are no adequate data to establish that animal drugs containing hexachlorophene are safe and effective for any animal use other than in topical products for use on non-food-producing animals as part of a product preservative system at a level not to exceed 0.1 percent; that there is no information on the potential risk to humans from exposure to hexachlorophene by persons who apply animal products containing the drug at levels higher than 0.1 percent; and that there is likewise no information on human exposure to animals on which these animal drugs have been used and no information on possible residues of hexachlorophene in edible products of food-producing animals treated with new animal drugs that contain any quantity of hexachlorophene.

(b) Animal drugs containing hexachlorophene for other than preservative use on non-food-producing animals at levels not exceeding 0.1 percent are considered new animal drugs and shall be the subject of new animal drug applications (NADA’s).

(c) Any person currently marketing animal drugs that contain hexachlorophene other than as part of a product preservative system for products used on non-food-producing animals at a level not exceeding 0.1 percent shall submit a new animal drug application, supplement an existing application, or reformulate the product by September 29, 1977. Each application or supplemental application shall include adequate data to establish that the animal drug is safe and effective. If the animal drug is currently subject to an approved new animal drug application, each reformulation shall require an approved supplemental application. The interim marketing of these animal drugs may continue until the application has been approved, until it has been determined that the application is not approvable under the provisions of §514.111 of this chapter, or until an existing approved application has been withdrawn.

(d) After September 29, 1977, animal drugs that contain hexachlorophene other than for preservative use on non-food-producing animals at a level not exceeding 0.1 percent that are introduced into interstate commerce shall be deemed to be adulterated within the meaning of section 501(a)(5) of the act (21 U.S.C. 351(a)(5)) unless such animal drug is the subject of a new animal drug application submitted pursuant to paragraph (c) of this section. Action to withdraw approval of new animal drug applications will be initiated if supplemental new animal drug applications have not been submitted in accordance with this section.

§ 500.50 Propylene glycol in or on cat food.

The Food and Drug Administration has determined that propylene glycol in or on cat food is not generally recognized as safe and is a food additive subject to section 409 of the Federal Food, Drug, and Cosmetic Act (the act). The Food and Drug Administration also has determined that this use of propylene glycol is not prior sanctioned.

Subpart C—Animal Drug Labeling Requirements

§ 500.51 Labeling of animal drugs; misbranding.

(a) Among the representations on the label or labeling of an animal drug which will render the drug misbranded are any broad statements suggesting or implying that the drug is not safe and effective for use when used in accordance with labeling direction, or suggesting or implying that the labeling does not contain adequate warnings or
§ 500.52 Use of terms such as "tonic", "tone", "toner", or "conditioner" in the labeling of preparations intended for use in or on animals.

(a) The use of terms such as tonic, tone, toner, and similar terms in the labeling of a product intended for use in or on animals implies that such product is capable of a therapeutic effect(s) and causes such a product to be a drug within the meaning of section 201(g) of the act. The term conditioner and similar terms may be used in labeling only when appropriately qualified so as to fully inform the user regarding the intended use(s) of the product.

(b) The unqualified use of the term conditioner and similar terms in the labeling of a product intended for use in or on animals implies that such product is capable of a therapeutic effect(s) and causes such a product to be a drug within the meaning of section 201(g) of the act. The unqualified use of such terms in a product’s labeling fails to provide adequate directions and indications for use of such product and causes it to be misbranded within the meaning of section 502(a) and (f)(1) of the act. The term conditioner and similar terms may be used in labeling only when appropriately qualified so as to fully inform the user regarding the intended use(s) of the product. A product labeled as a “conditioner” or with a similar term can be either a food or drug depending upon the manner in which the term is qualified in the labeling to reflect the product’s intended use.

(c) An article so qualified as to be represented as a drug must be the subject of an approved new animal drug application unless the use of the article under the conditions set forth in its labeling is generally recognized as safe and effective among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs.

§ 500.55 Exemption from certain drug-labeling requirements.

(a) Section 201.105(c) of this chapter provides that in the case of certain drugs for which directions, hazards, warnings, and use information are commonly known to practitioners licensed by law, such information may be omitted from the dispensing package. Under this proviso, the Commissioner of Food and Drugs has considered submitted material covering a number of drug products and has offered the opinion that the following drugs when intended for those veterinary uses for which they are now generally employed by the veterinary medical profession, should be exempt from the requirements of
$201.105(c) of this chapter, provided that they meet the conditions prescribed in this paragraph. Preparations that are not in dosage unit form (for example, solutions) will be regarded as meeting the conditions with respect to the maximum quantity of drug per dosage unit if they are prepared in a manner that enables accurate and ready administration of a quantity of drug not in excess of the stated maximum per dosage unit:

Atropine sulfate. As an injectable for cattle, goats, horses, pigs, and sheep, not in excess of 15 milligrams per dosage unit; as an injectable for cats and dogs, not in excess of 0.6 milligram per dosage unit.

Barbital sodium. For oral use in cats and dogs, not in excess of 300 milligrams per dosage unit.

Epinephrine injection. 1:1,000. For cats, dogs, cattle, goats, horses, pigs, and sheep (except as provided in §500.65).

Morphine sulfate. As an injectable for dogs, not in excess of 15 milligrams per dosage unit.

Pentobarbital sodium. For oral use in cats and dogs, not in excess of 100 milligrams per dosage unit.

Procaine hydrochloride injection. Containing not in excess of 2 percent procaine hydrochloride, with or without epinephrine up to a concentration of 1:50,000. For use in cats, dogs, cattle, goats, horses, pigs, and sheep.

Thyroid. For oral use in dogs, not in excess of 60 milligrams per dosage unit.

Subpart D—Requirements for Specific Animal Drugs

§500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for emergency treatment of anaphylactoid shock in cattle, horses, sheep, and swine.

(a) Anaphylactoid reactions in cattle, horses, sheep, and swine occur occasionally from the injection of antibiotics, bacterins, and vaccines. Adequate directions for use of these antibiotics, bacterins, and vaccines can generally be written for use by the laity and thus are available to livestock producers. Epinephrine injection is effective for the treatment of anaphylactoid reactions in animals and would be of value in saving lives of animals if it were readily available at the time of administration of the causative agents. In connection with this problem the Food and Drug Administration has obtained the views of the Advisory Committee on Veterinary Medicine, and other experts, and has concluded that adequate directions for over-the-counter sale of epinephrine injection 1:1,000 can be prepared.

(b) In view of the above, the Commissioner of Food and Drugs has concluded that it is in the public interest to make epinephrine injection 1:1,000 available for sale without a prescription provided that it is packaged in vials not exceeding 10 milliliters and its label bears, in addition to other required information, the following statements in a prominent and conspicuous manner: "For emergency use only in treating anaphylactoid shock. Usual Dosage: Cattle, horses, sheep, and swine—1 cubic centimeter per 100 pounds of body weight. Inject subcutaneously".

(c) The labeling must also bear a description of the symptoms of anaphylactoid shock including glassy eyes, increased salivation, grinding of the teeth, rapid breathing, muscular tremors, staggering gait, and collapse with death following. These symptoms may appear shortly after injection of a bacterin, vaccine, or antibiotic.

Subpart E—Regulation of Carcinogenic Compounds Used in Food-Producing Animals

SOURCE: 52 FR 49586, Dec. 31, 1987, unless otherwise noted.

§500.80 Scope of this subpart.

(a) The Federal Food, Drug, and Cosmetic Act requires that sponsored compounds intended for use in food-producing animals be shown to be safe and that food produced from animals exposed to these compounds be shown to be safe for consumption by people. The statute prohibits the use in food-producing animals of any compound found to induce cancer when ingested by people or animals unless it can be determined by methods of examination prescribed or approved by the Secretary (a function delegated to the Commissioner of Food and Drugs) that no residue of that compound will be found in the food produced from those animals.
under conditions of use reasonably certain to be followed in practice. This subpart identifies the steps a sponsor of a compound shall follow to secure the approval of the compound. FDA guidance documents contain the procedures and protocols FDA recommends for the implementation of this subpart. These guidance documents are available from the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Requests for these guidance documents should be identified with Docket No. 1983D–0288.

(b) If FDA concludes on the basis of the threshold assessment that a sponsor shall conduct carcinogenicity testing on the sponsored compound, FDA will also determine whether and to what extent the sponsor shall conduct carcinogenicity testing on metabolites of the sponsored compound. The bioassays that a sponsor conducts must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.

(c) If FDA concludes on the basis of the threshold assessment or at a later time during the approval process that the data show that the sponsored compound and its metabolites should not be subject to this subpart, FDA will continue to consider the compound for approval under the general safety provisions of the act for risks other than cancer.

(d) This subpart does not apply to essential nutrients.

§ 500.82 Definitions.

(a) The definitions and interpretations contained in section 201 of the act apply to those terms when used in this subpart.

(b) The following definitions apply to this subpart:


Essential nutrients means compounds that are found in the tissues of untreated, healthy target animals and not produced in sufficient quantity to support the animal’s growth, development, function, or reproduction, e.g., vitamins, essential minerals, essential amino acids, and essential fatty acids. These compounds must be supplied from external sources.

FDA means the Food and Drug Administration.

Limit of detection (LOD) means the lowest concentration of analyte that can be confirmed by the approved regulatory method.

Marker residue means the residue selected for assay whose concentration is in a known relationship to the concentration of the residue of carcinogenic concern in the last tissue to deplete to its Sm.

Preslaughter withdrawal period or milk discard time means the time after cessation of administration of the sponsored compound at which no residue is detectable in the edible product using the approved regulatory method (i.e., the marker residue is below the LOD).

Regulatory method means the aggregate of all experimental procedures for measuring and confirming the presence of the marker residue of the sponsored compound in the target tissue of the target animal.

Rm means the concentration of the marker residue in the target tissue when the residue of carcinogenic concern is equal to Sm.

Residue means any compound present in edible tissues of the target animal which results from the use of the sponsored compound, including the sponsored compound, its metabolites, and any other substances formed in or on food because of the sponsored compound’s use.

Residue of carcinogenic concern means all compounds in the total residue of a demonstrated carcinogen excluding any compounds judged by FDA not to present a carcinogenic risk.

Sm means the concentration of a residue of carcinogenic concern in a specific edible tissue corresponding to no significant increase in the risk of cancer to the human consumer. For the purpose of §500.84(c)(1), FDA will assume that this Sm will correspond to the concentration of residue in a specific edible tissue that corresponds to a
maximum lifetime risk of cancer in the test animals of 1 in 1 million.

S₀ means the concentration of a residue of carcinogenic concern in the total human diet that represents no significant increase in the risk of cancer to the human consumer. For the purpose of §500.84(c)(1), FDA will assume that this S₀ will correspond to the concentration of test compound in the total diet of test animals that corresponds to a maximum lifetime risk of cancer in the test animals of 1 in 1 million.

Sponsor means the person or organization proposing or holding an approval by FDA for the use of a sponsored compound.

Sponsored compound means any drug or food additive or color additive proposed for use, or used, in food-producing animals or in their feed.

Target animals means the production class of animals in which a sponsored compound is proposed or intended for use.

Target tissue means the edible tissue selected to monitor for residues in the target animals, including, where appropriate, milk or eggs.

Test animals means the species selected for use in the toxicity tests.

Threshold assessment means FDA’s review of data and information about a sponsored compound to determine whether chronic bioassays in test animals are necessary to resolve questions concerning the carcinogenicity of the compound.

§ 500.84 Conditions for approval of the sponsored compound.

(a) On the basis of the results of the chronic bioassays and other information, FDA will determine whether any of the substances tested are carcinogenic.

(b) If FDA concludes that the results of the bioassays do not establish carcinogenicity, then FDA will not subject the sponsored compound to the remainder of the requirements of this subpart.

(c) For each sponsored compound that FDA decides should be regulated as a carcinogen, FDA will either analyze the data from the bioassays using a statistical extrapolation procedure as outlined in paragraph (c)(1) of this section or evaluate an alternate procedure proposed by the sponsor as provided in §500.90. In either case, paragraphs (c)(2) and (3) of this section apply.

(1) For each substance tested in separate bioassays, FDA will calculate the concentration of the residue of carcinogenic concern that corresponds to a maximum lifetime risk to the test animal of 1 in 1 million. FDA will designate as Sₘ the concentration of residue in a specific edible tissue corresponding to a maximum lifetime risk of cancer in test animals of 1 in 1 million.

(2) From the appropriate residue chemistry data FDA will calculate the Rₘ as described in §500.86(c). The sponsor must provide a regulatory method in accordance with §500.88(b). FDA will calculate the LOD of the method from data submitted by the sponsor under §500.88. The LOD must be less than or equal to Rₘ.

(3) FDA will conclude that the provisions of this subpart are satisfied when no residue of the compound is detectable (that is, the marker residue is below the LOD) using the approved regulatory method under the conditions of use of the sponsored compound, including any required pre-slaughter withdrawal period or milk discard time.

§ 500.86 Marker residue and target tissue.

(a) For each edible tissue, the sponsor shall measure the depletion of the residue of carcinogenic concern until its concentration is at or below Sₘ.

(b) In one or more edible tissues, the sponsor shall also measure the depletion of one or more potential marker residues until the concentration of the residue of carcinogenic concern is at or below Sₘ.

(c) From these data, FDA will select a target tissue and a marker residue and designate the concentration of
marker residue \( (R_m) \) that the regulatory method must be capable of measuring in the target tissue. FDA will select \( R_m \) such that the absence of the marker residue in the target tissue above \( R_m \) can be taken as confirmation that the residue of carcinogenic concern does not exceed \( S_m \) in each of the edible tissues and, therefore, that the residue of carcinogenic concern in the diet of people does not exceed \( S_o \).

(d) When a compound is to be used in milk- or egg-producing animals, milk or eggs must be the target tissue in addition to the tissue selected to monitor for residues in the edible carcass.

§ 500.88 Regulatory method.

(a) The sponsor shall submit for evaluation and validation a regulatory method developed to monitor compliance with FDA’s operational definition of no residue.

(b) The regulatory method must be able to confirm the identity of the marker residue in the target tissue at a minimum concentration corresponding to the \( R_m \). FDA will determine the LOD from the submitted analytical method validation data.

(c) FDA will publish in the Federal Register the complete regulatory method for ascertaining the marker residue in the target tissue in accordance with the provisions of sections 409(c)(3)(A), 512(d)(1)(I), and 721(b)(5)(B) of the act.

§ 500.90 Waiver of requirements.

In response to a petition or on the Commissioner’s own initiative, the Commissioner may waive, in whole or in part, the requirements of this subpart except those provided under §500.88. A petition for this waiver may be filed by any person who would be adversely affected by the application of the requirements to a particular compound. The petition shall explain and document why the requirements from which a waiver is requested are not reasonably applicable to the compound, and set forth clearly the reasons why the alternative procedures will provide the basis for concluding that approval of the compound satisfies the requirements of the anticancer provisions of the act. If the Commissioner determines that waiver of any of the requirements of this subpart is appropriate, the Commissioner will state the basis for that determination in the regulation approving marketing of the sponsored compound.

(Approved by the Office of Management and Budget under control number 0910–0228)

§ 500.92 Implementation.

(a) This subpart E applies to all new animal drug applications, food additive petitions, and color additive petitions concerning any compound intended for use in food-producing animals (including supplemental applications and amendments to petitions).

(b) This subpart E also applies in the following manner to compounds already approved:

(1) For those compounds that FDA determines may induce cancer when ingested by man or animals, i.e., suspect carcinogens, §§500.80(b), 500.82, and 500.90 apply.

(2) For those compounds that FDA determines have been shown to induce cancer when ingested by man or animals, §§500.82 through 500.90 apply.

Subpart F—Methods for Detection of Residues of Carcinogenic Compounds Used in Food-Producing Animals

SOURCE: 76 FR 72618, Nov. 25, 2011, unless otherwise noted.

§ 500.1410 N-methyl-2-pyrrolidone.

(a) Standard for residues. No residues of \( n \)-methyl-2-pyrrolidone may be found in the uncooked edible tissues of cattle as determined by a method entitled “Method of Analysis: \( n \)-methyl-2-pyrrolidone,” September 26, 2011, Center for Veterinary Medicine, Food and Drug Administration, which is incorporated by reference with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain a copy of the method from the Communications Staff (HFV-
Food and Drug Administration, HHS

12), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9120; or go to http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. You may inspect a copy at the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, (301) 827–6860, between 9 a.m. and 4 p.m., Monday through Friday or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call (202) 741–6030, or go to: http://www.archives.gov/federal-register/cfr/ibr-locations.html.

15

(b) Related conditions of use. See §§ 522.814 and 522.955 of this chapter.

[76 FR 72618, Nov. 25, 2011, as amended at 77 FR 9528, Feb. 17, 2012]

PART 501—ANIMAL FOOD LABELING

Subpart A—General Provisions

§ 501.1 Principal display panel of package form animal food.

The term principal display panel as it applies to food in package form and as used in this part, means the part of a label that is most likely to be displayed, presented, shown, or examined under customary conditions of display for retail sale. The principal display panel shall be large enough to accommodate all the mandatory label information required to be placed thereon by this part with clarity and conspicuousness and without obscuring design, vignettes, or crowding. Where packages bear alternate principal display panels, information required to be placed on the principal display panel shall be duplicated on each principal display panel. For the purpose of obtaining uniform type size in declaring the quantity of contents for all packages of substantially the same size, the term area of the principal display panel means the area of the side or surface that bears the principal display panel, which area shall be:

(a) In the case of a rectangular package where one entire side properly can be considered to be the principal display panel side, the product of the height times the width of that side;

(b) In the case of a cylindrical or nearly cylindrical container, 40 percent of the product of the height of the container times the circumference;

(c) In the case of any otherwise shaped container, 40 percent of the total surface of the container: Provided, however, That where such container presents an obvious principal display panel such as the top of a triangular or circular package, the area shall consist

501.103 Petitions requesting exemptions from or special requirements for label declaration of ingredients.

501.105 Declaration of net quantity of contents when exempt.

501.110 Animal feed labeling; collective names for feed ingredients.


SOURCE: 41 FR 38619, Sept. 10, 1976, unless otherwise noted.

Subpart A—General Provisions

§ 501.1 Principal display panel of package form animal food.

The term principal display panel as it applies to food in package form and as used in this part, means the part of a label that is most likely to be displayed, presented, shown, or examined under customary conditions of display for retail sale. The principal display panel shall be large enough to accommodate all the mandatory label information required to be placed thereon by this part with clarity and conspicuousness and without obscuring design, vignettes, or crowding. Where packages bear alternate principal display panels, information required to be placed on the principal display panel shall be duplicated on each principal display panel. For the purpose of obtaining uniform type size in declaring the quantity of contents for all packages of substantially the same size, the term area of the principal display panel means the area of the side or surface that bears the principal display panel, which area shall be:

(a) In the case of a rectangular package where one entire side properly can be considered to be the principal display panel side, the product of the height times the width of that side;

(b) In the case of a cylindrical or nearly cylindrical container, 40 percent of the product of the height of the container times the circumference;

(c) In the case of any otherwise shaped container, 40 percent of the total surface of the container: Provided, however, That where such container presents an obvious principal display panel such as the top of a triangular or circular package, the area shall consist
§ 501.2 Information panel of package for animal food.

(a) The term information panel as it applies to packaged food means that part of the label immediately contiguous and to the right of the principal display panel as observed by an individual facing the principal display panel with the following exceptions:

(1) If the part of the label immediately contiguous and to the right of the principal display panel is too small to accommodate the necessary information or is otherwise unusable label space, e.g., folded flaps or can ends, the panel immediately contiguous and to the right of this part of the label may be used.

(2) If the package has one or more alternate principal display panels, the information panel is immediately contiguous and to the right of any principal display panel.

(3) If the top of the container is the principal display panel and the package has no alternate principal display panel, the information panel is any panel adjacent to the principal display panel.

(b) All information required to appear on the label of any package of food pursuant to §§501.4, 501.5, 501.8 and 501.17 shall appear either on the principal display panel or on the information panel, unless otherwise specified by regulations in this chapter.

(c) All information appearing on the principal display panel or the information panel pursuant to this section shall appear prominently and conspicuously, but in no case may the letters and/or numbers be less than \( \frac{1}{16} \) inch in height unless an exemption pursuant to paragraph (f) of this section is established. The requirements for conspicuousness and legibility shall include the specifications of §§501.15 and 501.105(h) (1) and (2).

(1) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a surface area that can bear an information panel and/or an alternate principal display panel.

(ii) The area of surface available for labeling on the principal display panel of the package as this term is defined in §501.1 is less than 10 square inches.

(iii) The label information includes a full list of ingredients in accordance with regulations in this part.

(iv) The information required by paragraph (b) of this section appears on the principal display panel or information panel label in accordance with the provisions of this paragraph (c) except that the type size is not less than \( \frac{5}{64} \) inch in height.

(2) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a single obvious principal display panel as this term is defined in §501.1 and has no other available surface area for an information panel or alternate principal display panel.

(ii) The area of surface available for labeling on the principal display panel of the package as this term is defined in §501.1 is less than 12 square inches and bears all labeling appearing on the package.

(iii) The label information includes a full list of ingredients in accordance with regulations in this part.

(iv) The information required by paragraph (b) of this section appears on the single, obvious principal display panel in accordance with the provisions of this paragraph (c) except that the type size is not less than \( \frac{1}{32} \) inch in height.

(3) Packaged foods are exempt from the type size requirements of this paragraph: Provided, That:

(i) The package is designed such that it has a total surface area available to bear labeling of less than 12 square inches.
Food and Drug Administration, HHS

§ 501.3 Identity labeling of animal food in package form.

(a) The principal display panel of a food in package form shall bear as one of its principal features a statement of the identity of the commodity.

(b) Such statement of identity shall be in terms of:

(1) The name now or hereafter specified in or required by any applicable Federal law or regulation; or, in the absence thereof,

(2) The common or usual name of the food; or, in the absence thereof,

(3) An appropriately descriptive term, or when the nature of the food is obvious, a fanciful name commonly used by the public for such food.

(c) Where a food is marketed in various optional forms (whole, slices, diced, etc.), the particular form shall be considered to be a necessary part of the statement of identity and shall be declared in letters of a type size bearing a reasonable relation to the size of the letters forming the other components of the statement of identity; except that if the optional form is visible through the container or is depicted by an appropriate vignette, the particular form need not be included in the statement. This specification does not affect the required declarations of identity under definitions and standards for foods promulgated pursuant to section 401 of the act.

(d) This statement of identity shall be presented in bold type on the principal display panel, shall be in a size reasonably related to the most prominent printed matter on such panel, and shall be in lines generally parallel to the base on which the package rests as it is designed to be displayed.

(e) Under the provisions of section 403(c) of the Federal Food, Drug, and Cosmetic Act, a food shall be deemed to be misbranded if it is an imitation of another food unless its label bears, in type of uniform size and prominence, the word imitation and, immediately thereafter, the name of the food imitated.

(1) A food shall be deemed to be an imitation and thus subject to the requirements of section 403(c) of the act if it is a substitute for and resembles another food but is nutritionally inferior to that food.

(2) A food that is a substitute for and resembles another food shall not be deemed to be an imitation provided it
meets each of the following requirements:

(i) It is not nutritionally inferior to the food for which it substitutes and which it resembles.

(ii) Its label bears a common or usual name that complies with the provisions of §502.5 of this chapter and that is not false or misleading, or in the absence of an existing common or usual name, an appropriately descriptive term that is not false or misleading. The label may, in addition, bear a fanciful name which is not false or misleading.

(3) A food for which a common or usual name is established by regulation (e.g., in a standard of identity pursuant to section 401 of the act, in a common or usual name regulation and may, in addition, bear a fanciful name which is not false or misleading, and established pursuant to part 502 of this chapter), and which complies with all of the applicable requirements of such regulation(s), shall not be deemed to be an imitation.

(4) Nutritional inferiority includes:

(i) Any reduction in the content of an essential nutrient that is present in a measurable amount.

(ii) If the Commissioner concludes that a food is a substitute for and resembles another food but is inferior to the food imitated for reasons other than those set forth in this paragraph, he may propose appropriate revisions to this regulation or he may propose a separate regulation governing the particular food.

(f) A label may be required to bear the percentage(s) of a characterizing ingredient(s) or information concerning the presence or absence of an ingredient(s) or the need to add an ingredient(s) as part of the common or usual name of the food pursuant to part 502 of this chapter.


§501.4 Animal food; designation of ingredients.

(a) Ingredients required to be declared on the label of a food, including foods that comply with standards of identity that require labeling in compliance with this part 501, except those exempted by §501.100, shall be listed by common or usual name in descending order of predominance by weight on either the principal display panel or the information panel in accordance with the provisions of §501.2.

(b) The name of an ingredient shall be a specific name and not a collective (generic) name, except that:

(1) Spices, flavorings, colorings and chemical preservatives shall be declared according to the provisions of §501.22.

(2) An ingredient which itself contains two or more ingredients and which has an established common or usual name, conforms to a standard established pursuant to the Meat Inspection or Poultry Products Inspection Acts by the U.S. Department of Agriculture, or conforms to a definition and standard of identity established pursuant to section 401 of the Federal Food, Drug, and Cosmetic Act, shall be designated in the statement of ingredients on the label of such food by either of the following alternatives:

(i) By declaring the established common or usual name of the ingredient followed by a parenthetical listing of all ingredients contained therein in descending order of predominance except that, if the ingredient is a food subject to a definition and standard of identity established in this subchapter E, only the ingredients required to be declared by the definition and standard of identity need be listed; or

(ii) By incorporating into the statement of ingredients in descending order of predominance in the finished food, the common or usual name of every component of the ingredient without listing the ingredient itself.

(3) Skim milk, concentrated skim milk, reconstituted skim milk, and nonfat dry milk may be declared as skim milk or nonfat milk.

(4) Milk, concentrated milk, reconstituted milk, and dry whole milk may be declared as milk.

(5) Bacterial cultures may be declared by the word cultured followed by the name of the substrate, e.g., made from cultured skim milk or cultured buttermilk.

(6) Sweetcream buttermilk, concentrated sweetcream buttermilk, reconstituted sweetcream buttermilk,
and dried sweetcream buttermilk may be declared as buttermilk.

(7) Whey, concentrated whey, reconstituted whey, and dried whey may be declared as whey.

(8) Cream, reconstituted cream, dried cream, and plastic cream (sometimes known as concentrated milkfat) may be declared as cream.

(9) Butteroil and anhydrous butterfat may be declared as butterfat.

(10) Dried whole eggs, frozen whole eggs, and liquid whole eggs may be declared as eggs.

(11) Dried egg whites, frozen egg whites, and liquid egg whites may be declared as egg whites.

(12) Dried egg yolks, frozen egg yolks, and liquid egg yolks may be declared as egg yolks.

(13) A livestock or poultry feed may be declared by a collective name listed in §501.110 if it is an animal feed within the meaning of section 201(w) of the act and meets the requirements for the use of a collective name as prescribed in §501.110 for certain feed ingredients.

(c) When water is added to reconstitute, completely or partially, an ingredient permitted by paragraph (b) of this section to be declared by a class name, the position of the ingredient class name in the ingredient statement shall be determined by the weight of the unreconstituted ingredient plus the weight of the quantity of water added to reconstitute that ingredient, up to the amount of water needed to reconstitute the ingredient to single strength. Any water added in excess of the amount of water needed to reconstitute the ingredient to single strength shall be declared as water in the ingredient statement.

§ 501.5 Animal food; name and place of business of manufacturer, packer, or distributor.

(a) The label of a food in packaged form shall specify conspicuously the name and place of business of the manufacturer, packer, or distributor.

(b) The requirement for declaration of the name of the manufacturer, packer, or distributor shall be deemed to be satisfied, in the case of a corporation, only by the actual corporate name, which may be preceded or followed by the name of the particular division of the corporation. In the case of an individual, partnership, or association, the name under which the business is conducted shall be used.

(c) Where the food is not manufactured by the person whose name appears on the label, the name shall be qualified by a phrase that reveals the connection such person has with such food; such as “Manufactured for __________,” “Distributed by __________,” or any other wording that expresses the facts.

(d) The statement of the place of business shall include the street address, city, state, and ZIP Code; however, the street address may be omitted if it is shown in a current city directory or telephone directory. The requirement for inclusion of the ZIP Code shall apply only to consumer commodity labels developed or revised after the effective date of this section. In the case of nonconsumer packages, the ZIP Code shall appear either on the label or the labeling (including invoice).

(e) If a person manufactures, packs, or distributes a food at a place other than his principal place of business, the label may state the principal place of business in lieu of the actual place where such food was manufactured or
packed or is to be distributed, unless such statement would be misleading.

§ 501.8 Labeling of animal food with number of servings.

(a) The label of any package of a food which bears a representation as to the number of servings contained in such package shall bear in immediate conjunction with such statement, and in the same size type as is used for such statement, a statement of the net quantity (in terms of weight, measure, or numerical count) of each such serving; however, such statement may be expressed in terms that differ from the terms used in the required statement of net quantity of contents (for example, cupfuls, tablespoonfuls, etc.) when such differing term is common to cookery and describes a constant quantity. Such statement may not be misleading in any particular. A statement of the number of units in a package is not in itself a statement of the number of servings.

(b) If there exists a voluntary product standard promulgated pursuant to the procedures found in 15 CFR part 10 by the Department of Commerce, quantitatively defining the meaning of the term serving with respect to a particular food, then any label representation as to the number of servings in such packaged food shall correspond with such quantitative definition. (Copies of published standards are available upon request from the National Bureau of Standards, Department of Commerce, Washington, DC 20234.)

§ 501.15 Animal food; prominence of required statements.

(a) A word, statement, or other information required by or under authority of the act to appear on the label may lack that prominence and conspicuousness required by section 403(f) of the act by reason (among other reasons) of:

(1) The failure of such word, statement, or information to appear on the part or panel of the label which is presented or displayed under customary conditions of purchase;

(2) The failure of such word, statement, or information to appear on two or more parts or panels of the label, each of which has sufficient space therefor, and each of which is so designed as to render it likely to be, under customary conditions of purchase, the part or panel displayed;

(3) The failure of the label to extend over the area of the container or package available for such extension, so as to provide sufficient label space for the prominent placing of such word, statement, or information;

(4) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space for any word, statement, design, or device which is not required by or under authority of the act to appear on the label;

(5) Insufficiency of label space (for the prominent placing of such word, statement, or information) resulting from the use of label space to give materially greater conspicuousness to any other word, statement, or information, or to any design or device; or

(6) Smallness or style of type in which such word, statement, or information appears, insufficient background contrast, obscuring designs or vignettes, or crowding with other written, printed, or graphic matter.

(b) No exemption depending on insufficiency of label space, as prescribed in regulations promulgated under section 403(e) or (i) of the act, shall apply if such insufficiency is caused by:

(1) The use of label space for any word, statement, design, or device which is not required by or under authority of the act to appear on the label;

(2) The use of label space to give greater conspicuousness to any word, statement, or other information that is required by section 403(f) of the act; or

(3) The use of label space for any representation in a foreign language.

(c)(1) All words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear thereon in the English language: Provided, however, That in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a territory where the predominant language is one other than English, the predominant language may be substituted for English.
(2) If the label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label shall appear thereon in the foreign language.

(3) If any article of labeling (other than a label) contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear on such article of labeling.

§ 501.17 Animal food labeling warning statements.

(a) Self-pressurized containers. (1) The label of a food packaged in a self-pressurized container and intended to be expelled from the package under pressure shall bear the following warning:

Warning Avoid spraying in eyes. Contents under pressure. Do not puncture or incinerate. Do not store at temperature above 120 °F. Keep out of reach of children.

(2) In the case of products intended for use by children, the phrase “except under adult supervision” may be added at the end of the last sentence in the warning required by paragraph (a)(1) of this section.

(3) In the case of products packaged in glass containers, the word “break” may be substituted for the word “puncture” in the warning required by paragraph (a)(1) of this section.

(4) The words “Avoid spraying in eyes” may be deleted from the warning required by paragraph (a)(1) of this section in the case of a product not expelled as a spray.

(b) Self-pressurized containers with halocarbon or hydrocarbon propellants.

(1) In addition to the warning required by paragraph (a) of this section, the label of a food packaged in a self-pressurized container in which the propellant consists in whole or in part of a halocarbon or a hydrocarbon shall bear the following warning:

Warning Use only as directed. Intentional misuse by deliberately concentrating and inhaling the contents can be harmful or fatal.

(2) The warning required by paragraph (b)(1) of this section is not required for the following products:

(i) Products expelled in the form of a foam or cream, which contain less than 10 percent propellant in the container.

(ii) Products in a container with a physical barrier that prevents escape of the propellant at the time of use.

(iii) Products of a net quantity of contents of less than 2 ozs that are designed to release a measured amount of product with each valve actuation.

(iv) Products of a net quantity of contents of less than ½ oz.

(c) Animal food containing or manufactured with a chlorofluorocarbon or other ozone-depleting substance. Labeling requirements for animal foods that contain or are manufactured with a chlorofluorocarbon or other ozone-depleting substance designated by the Environmental Protection Agency (EPA) are set forth in 40 CFR part 82.


§ 501.18 Misbranding of animal food.

(a) Among representations in the labeling of a food which render such food misbranded is a false or misleading representation with respect to another food or a drug, device, or cosmetic.

(b) The labeling of a food which contains two or more ingredients may be misleading by reason (among other reasons) of the designation of such food in such labeling by a name which includes or suggests the name of one or more but not all such ingredients, even though the names of all such ingredients are stated elsewhere in the labeling.

(c) Among representations in the labeling of a food which render such food misbranded is any representation that expresses or implies a geographical origin of the food or any ingredient of the food except when such representation is either:

(1) A truthful representation of geographical origin.

(2) A trademark or trade name provided that as applied to the article in question its use is not deceptively misdescriptive. A trademark or trade name comprised in whole or in part of geographical words shall not be considered deceptively misdescriptive if:

(1) Has been so long and exclusively used by a manufacturer or distributor
that it is generally understood by the consumer to mean the product of a particular manufacturer or distributor; or

(ii) Is so arbitrary or fanciful that it is not generally understood by the consumer to suggest geographic origin.

(3) A part of the name required by applicable Federal law or regulation.

(4) A name whose market significance is generally understood by the consumer to connote a particular class, kind, type, or style of food rather than to indicate geographical origin.

Subpart B—Specific Animal Food Labeling Requirements

§ 501.22 Animal foods; labeling of spices, flavorings, colorings, and chemical preservatives.

(a)(1) The term artificial flavor or artificial flavoring means any substance, the function of which is to impart flavor, which is not derived from a spice, fruit or fruit juice, vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf or similar plant material, meat, fish, poultry, eggs, dairy products, or fermentation products thereof. Artificial flavor includes the substances listed in §§ 172.515(b) and 582.60 of this chapter except where these are derived from natural sources.

(2) The term spice means any aromatic vegetable substance in the whole, broken, or ground form, except for those substances which have been traditionally regarded as foods, such as onions, garlic and celery; whose significant function in food is seasoning rather than nutritional; that is true to name; and from which no portion of any volatile oil or other flavoring principle has been removed. Spices include the spices listed in subpart A of part 582 of this chapter, such as the following:

- Allspice
- Anise
- Basil
- Bay leaves
- Caraway seed
- Cardamom
- Celery seed
- Chervil
- Cinnamon
- Cloves
- Coriander
- Cumin seed
- Dill seed
- Fennel seed
- Fennugreek
- Ginger
- Horseradish
- Mace
- Marjoram
- Mustard flour
- Nutmeg
- Oregano
- Paprika
- Parsley
- Pepper, black
- Pepper, white
- Pepper, red
- Rosemary
- Saffron
- Sage
- Savory
- Star anise seed
- Tarragon
- Thyme
- Turmeric

Paprika, turmeric, and saffron or other spices which are also colors, shall be declared as spice and coloring unless declared by their common or usual name.

(3) The term natural flavor or natural flavoring means the essential oil, oleoresin, essence or extractive, protein hydrolysate, distillate, or any product of roasting, heating or enzymolysis, which contains the flavoring constituents derived from a spice, fruit or fruit juice, vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf or similar plant material, meat, seafood, poultry, eggs, dairy products, or fermentation products thereof, whose significant function in food is flavoring rather than nutritional. Natural flavors include the natural essence or extractives obtained from plants listed in subpart A of part 582 of this chapter, and the substances listed in § 172.510 of this chapter.

(4) The term artificial color or artificial coloring means any color additive as defined in § 70.3(f) of this chapter.

(5) The term chemical preservative means any chemical that, when added to food, tends to prevent or retard deterioration thereof, but does not include common salt, sugars, vinegars, spices, or oils extracted from spices, substances added to food by direct exposure thereof to wood smoke, or chemicals applied for their insecticidal or herbicidal properties.

(b) A food which is subject to the requirements of section 403(k) of the act shall bear labeling, even though such food is not in package form.

(c) A statement of artificial flavoring, artificial coloring, or chemical preservative shall be placed on the food, or on its container or wrapper, or on any two or all of these, as may be necessary to render such statement likely to be read by the ordinary individual under customary conditions of purchase and use of such food.

(d) A food shall be exempt from compliance with the requirements of section 403(k) of the act if it is not in package form and the units thereof are so small that a statement of artificial flavoring, artificial coloring, or chemical preservative, as the case may be, cannot be placed on such units with such conspicuousness as to render it likely to be read by the ordinary individual under customary conditions of purchase and use.
(e) A food shall be exempt while held for sale from the requirements of section 403(k) of the act (requiring label statement of any artificial flavoring, artificial coloring, or chemical preservatives) if said food, having been received in bulk containers at a retail establishment, is displayed to the purchaser with either (1) the labeling of the bulk container plainly in view or (2) a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required to be stated on the label pursuant to section 403(k) of the act.

(f) A fruit or vegetable shall be exempt from compliance with the requirements of section 403(k) of the act with respect to a chemical preservative applied to the fruit or vegetable as a pesticide chemical prior to harvest.

(g) A flavor shall be labeled in the following way when shipped to a food manufacturer or processor (but not a consumer) for use in the manufacture of a fabricated food, unless it is a flavor for which a standard of identity has been promulgated, in which case it shall be labeled as provided in the standard:

(1) If the flavor consists of one ingredient, it shall be declared by its common or usual name.

(2) If the flavor consists of two or more ingredients, the label either may declare each ingredient by its common or usual name or may state ‘‘All flavor ingredients contained in this product are approved for use in a regulation of the Food and Drug Administration.’’ Any flavor ingredient not contained in one of these regulations, and any non-flavor ingredient, shall be separately listed on the label.

(3) In cases where the flavor contains a solely natural flavor(s), the flavor shall be so labeled, e.g., strawberry flavor, banana flavor, or natural strawberry flavor. In cases where the flavor contains both a natural flavor and an artificial flavor, the flavor shall be so labeled, e.g., natural and artificial strawberry flavor. In cases where the flavor contains a solely artificial flavor(s), the flavor shall be so labeled, e.g., artificial strawberry flavor.

(h) The label of a food to which flavor is added shall declare the flavor in the statement of ingredients in the following way:

(1) Spice, natural flavor, and artificial flavor may be declared as spice, natural flavor, or artificial flavor, or any combination thereof, as the case may be.

(2) An incidental additive in a food, originating in a spice or flavor used in the manufacture of the food, need not be declared in the statement of ingredients if it meets the requirements of §501.100(a)(3).

(3) Substances obtained by cutting, grinding, drying, pulping, or similar processing of tissues derived from fruit, vegetable, meat, fish, or poultry, e.g., powdered or granulated onions, garlic powder, and celery powder, are commonly understood by consumers to be food rather than flavor and shall be declared by their common or usual name.

(4) Any salt (sodium chloride) used as an ingredient in food shall be declared by its common or usual name salt.

(5) Any monosodium glutamate used as an ingredient in food shall be declared by its common or usual name monosodium glutamate.

(6) Any pyroligneous acid or other artificial smoke flavors used as an ingredient in a food may be declared as artificial smoke flavor or artificial smoke flavor. No representation may be made, either directly or implied, that a food flavored with pyroligneous acid or other artificial smoke flavor has been smoked or has a true smoked flavor, or that a seasoning sauce or similar product containing pyroligneous acid or other artificial smoke flavor used to season or flavor other foods will result in a smoked product or one having a true smoked flavor.

(i) If the label, labeling, or advertising of a food makes any direct or indirect representations with respect to the primary recognizable flavor(s), by word, vignette, e.g., depiction of a fruit, or other means, or if for any other reason the manufacturer or distributor of a food wishes to designate the type of flavor in the food other than through the statement of ingredients, such flavor shall be considered the characterizing flavor and shall be declared in the following way:

(1) If the food contains no artificial flavor which simulates, resembles or
reinforces the characterizing flavor, the name of the food on the principal display panel or panels of the label shall be accompanied by the common or usual name of the characterizing flavor in letters not less than one-half the height of the letters used in the name of the food, except that:

(i) If the food is one that is commonly expected to contain a characterizing food ingredient, and the food contains natural flavor derived from such ingredient and an amount of characterizing ingredient insufficient to independently characterize the food, or the food contains no such ingredient, the name of the characterizing flavor may be immediately preceded by the word natural and shall be immediately followed by the word flavored in letters not less than one-half the height of the letters in the name of the characterizing flavor.

(ii) If none of the natural flavor used in the food is derived from the product whose flavor is simulated, the food in which the flavor is used shall be labeled either with the flavor of the product from which the flavor is derived or as artificially flavored.

(iii) If the food contains both a characterizing flavor from the product whose flavor is simulated and other natural flavor which simulates, resembles or reinforces the characterizing flavor, the food shall be labeled in accordance with the introductory text and paragraph (i)(1)(i) of this section and the name of the food shall be immediately followed by the words with other natural flavor in letters not less than one-half the height of the letters used in the name of the characterizing flavor.

(2) If the food contains any artificial flavor which simulates, resembles or reinforces the characterizing flavor, the name of the food on the principal display panel or panels of the label shall be accompanied by the common or usual name(s) of the characterizing flavor, in letters not less than one-half the height of the letters used in the name of the food and the name of the characterizing flavor shall be accompanied by the words(s) artificial or artificially flavored, in letters not less than one-half the height of the letters in the name of the characterizing flavor.

(3) Wherever the name of the characterizing flavor appears on the label (other than in the statement of ingredients) so conspicuously as to be easily seen under customary conditions of purchase, the words prescribed by this paragraph shall immediately and conspicuously precede or follow the name, without any intervening written, printed, or graphic matter, except:

(i) Where the characterizing flavor and a trademark or brand are presented together, other written, printed, or graphic matter that is a part of or is associated with the trademark or brand may intervene if the required words are in such relationship with the trademark or brand as to be clearly related to the characterizing flavor; and

(ii) If the finished product contains more than one flavor subject to the requirements of this paragraph, the statements required by this paragraph need appear only once in each statement of characterizing flavors present in such food.

(iii) If the finished product contains three or more distinguishable characterizing flavors, or a blend of flavors with no primary recognizable flavor, the flavor may be declared by an appropriately descriptive generic term in lieu of naming each flavor.

(4) A flavor supplier shall certify, in writing, that any flavor he supplies which is designated as containing no artificial flavor does not, to the best of his knowledge and belief, contain any artificial flavor, and that he has added no artificial flavor to it. The requirement for such certification may be satisfied by a guarantee under section 303(c)(2) of the act which contains such a specific statement. A flavor used shall be required to make such a written certification only where he adds to or combines another flavor with a flavor which has been certified by a flavor supplier as containing no artificial flavor, but otherwise such user may rely upon the supplier’s certification and need make no separate certification. All such certifications shall be retained by the certifying party throughout the period in which the flavor is supplied and for a minimum of 3 years thereafter, and shall be subject to the following conditions:
(i) The certifying party shall make such certifications available upon re-
quest at all reasonable hours to any duly authorized officer, or employee of the Food and Drug Administration or any other employee acting on behalf of the Secretary of Health and Human Services. Such certifications are re-
garded by the Food and Drug Admin-
istration as reports to the government and as guarantees or other under-
takings within the meaning of section 301(h) of the act and subject the certi-
fying party to the penalties for making any false report to the government under 18 U.S.C. 1001 and any false guar-
antee or undertaking under section 303(a) of the act. The defenses provided under section 303(c)(2) of the act shall be applicable to the certifications pro-
voked for in this section.

(ii) Wherever possible, the Food and Drug Administration shall verify the accuracy of a reasonable number of certifications made pursuant to this section, constituting a representative sample of such certifications, and shall not request all such certifications.

(iii) Where no person authorized to provide such information is reasonably available at the time of inspection, the certifying party shall arrange to have such person and the relevant materials and records ready for verification as soon as practicable; provided that, whenever the Food and Drug Administra-
tion has reason to believe that the supplier or user may utilize this period to alter inventories or records, such ad-
ditional time shall not be permitted. Where such additional time is pro-
vided, the Food and Drug Administra-
tion may require the certifying party to certify that relevant inventories and records have not been altered or concealed during such period.

(iv) The certifying party shall pro-
vide, to an officer or representative duly designated by the Secretary, such qualita-
tive statement of the composi-
tion of the flavor or product covered by the certification as may be reasonably expected to enable the Secretary’s re-
presentatives to determine which rel-
levant raw and finished materials and flavor ingredient records are reason-
ably necessary to verify the certifi-
cations. The examination conducted by the Secretary’s representative shall be limited to inspection and review of in-
ventories and ingredient records for those certifications which are to be verified.

(v) Review of flavor ingredient records shall be limited to the quali-
tative formula and shall not include the quantitative formula. The person verifying the certifications may make only such notes as are necessary to en-
able him to verify such certification. Only such notes or such flavor ingre-
dient records as are necessary to verify such certification or to show a potential or actual violation may be re-
moved or transmitted from the certi-
fying party’s place of business: Pro-
vided, That, where such removal or transmittal is necessary for such pur-
poses the relevant records and notes shall be retained as separate docu-
ments in Food and Drug Administra-
tion files, shall not be copied in other reports, and shall not be disclosed pub-
licly other than in a judicial pro-
ceeding brought pursuant to the act or 18 U.S.C. 1001.

(j) A food to which a chemical pre-
servative(s) is added shall, except when exempt pursuant to §501.100, bear a label declaration stating both the com-
mon or usual name of the ingredient(s) and a separate description of its func-
tion, e.g., preservative, to retard spoilage, a mold inhibitor, to help protect flavor or to promote color retention.

(k) The label of an animal food to which any coloring has been added shall declare the coloring in the state-
ment of ingredients in the manner specified in paragraphs (k)(1) and (k)(2) of this section.

(1) A color additive or the lake of a color additive subject to certification under section 721(c) of the act shall be declared by the name of the color addi-
tive listed in the applicable regulation in part 74 or part 82 of this chapter, ex-
cept that it is not necessary to include the “FD&C” prefix or the term “No.” in the declaration, but the term “Lake” shall be included in the declar-
ation of the lake of the certified color additive (e.g., Blue 1 Lake). Man-
ufacturers may parenthetically declare an appropriate alternative name of its certified color additive following its
§ 501.100 Animal food; exemptions from labeling.

(a) The following foods are exempt from compliance with the requirements of section 403(i)(2) of the act (requiring a declaration on the label of the common or usual name of each ingredient when the food is fabricated from two or more ingredients).

(1) An assortment of different items of food, when variations in the items that make up different packages packed from such assortment normally occur in good packing practice and when such variations result in variations in the ingredients in different packages, with respect to any ingredient that is not common to all packages. Such exemption, however, shall be on the condition that the label shall bear, in conjunction with the names of such ingredients as are common to all packages, a statement (in terms that are as informative as practicable and that are not misleading) indicating by name other ingredients which may be present.

(2) A food having been received in bulk containers at a retail establishment, if displayed to the purchaser with either (i) the labeling of the bulk container plainly in view or (ii) a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required to be stated on the label pursuant to section 403(i)(2) of the act.

(3) Incidental additives that are present in a food at insignificant levels and do not have any technical or functional effect in that food. For the purposes of this paragraph (a)(3), incidental additives are:

(i) Substances that have no technical or functional effect but are present in a food by reason of having been incorporated into the food as an ingredient of another food, in which the substance did have a functional or technical effect.

(ii) Processing aids, which are as follows:

(a) Substances that are added to a food during the processing of such food but are removed in some manner from the food before it is packaged in its finished form.

(b) Substances that are added to a food during processing, are converted into constituents normally present in the food, and do not significantly increase the amount of the constituents naturally found in the food.

(c) Substances that are added to a food for their technical or functional effect in the processing but are present in the finished food at insignificant levels and do not have any technical or functional effect in that food.

(iii) Substances migrating to food from equipment or packaging or otherwise affecting food that are not food additives as defined in section 201(s) of the act; or if they are food additives as so defined, they are used in conformity with regulations established pursuant to section 409 of the act.

(b) A food repackaged in a retail establishment is exempt from the following provisions of the act if the conditions specified are met.

(1) Section 403(e)(1) of the act (requiring a statement on the label of the name and place of business of the manufacturer, packer, or distributor).

(2) Section 403(g)(2) of the act (requiring the label of a food which purports to be or is represented as one for which a definition and standard of identity has been prescribed to bear the name of the food specified in the definition and standard and, insofar as may be required by the regulation establishing
Food and Drug Administration, HHS

§ 501.100

the standard the common names of the optional ingredients present in the food), if the food is displayed to the purchaser with its interstate labeling clearly in view, or with a counter card, sign, or other appropriate device bearing prominently and conspicuously the information required by these provisions.

(3) Section 403(i)(1) of the act (requiring the label to bear the common or usual name of the food), if the food is displayed to the purchaser with its interstate labeling clearly in view, or with a counter card, sign, or other appropriate device bearing prominently and conspicuously the common or usual name of the food, or if the common or usual name of the food is clearly revealed by its appearance.

(c) [Reserved]

(d) Except as provided by paragraphs (e) and (f) of this section, a shipment or other delivery of a food which is, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantity at an establishment other than that where originally processed or packed, shall be exempt, during the time of introduction into and movement in interstate commerce and the time of holding in such establishment, from compliance with the labeling requirements of section 403 (c), (e), (g), (h), (i), (j) and (k) of the act if:

(1) The person who introduced such shipment or delivery into interstate commerce is the operator of the establishment where such food is to be processed, labeled, or repacked; or

(2) In case such person is not such operator, such shipment or delivery is made to such establishment under a written agreement, signed by and containing the post office addresses of such person and such operator, and containing such specifications for the processing, labeling, or repacking, as the case may be, of such food in such establishment as will ensure, if such specifications are followed, that such food will not be adulterated or misbranded within the meaning of the act upon completion of such processing, labeling, or repacking. Such person and such operator shall each keep a copy of such agreement until 2 years after the final shipment or delivery of such food from such establishment, and shall make such copies available for inspection at any reasonable hour to any officer or employee of the Department who requests them.

(e) Conditions affecting expiration of exemptions.

(1) An exemption of a shipment or other delivery of a food under paragraph (d)(1) of this section shall, at the beginning of the act of removing such shipment or delivery, or any part thereof, from such establishment become void ab initio if the food comprising such shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed.

(2) An exemption of a shipment or other delivery of a food under paragraph (d)(2) of this section shall become void ab initio with respect to the person who introduced such shipment or delivery into interstate commerce upon refusal by such person to make available for inspection a copy of the agreement, as required by paragraph (d)(2) of this section.

(3) An exemption of a shipment or other delivery of a food under paragraph (d)(2) of this section shall expire:

(i) At the beginning of the act of removing such shipment or delivery, or any part thereof, from such establishment if the food comprising such shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed; or

(ii) Upon refusal by the operator of the establishment where such food is to be processed, labeled, or repacked, to make available for inspection a copy of the agreement as required by such paragraph.

(f) [Reserved]

(g) The label declaration of a harmless marker used to identify a particular manufacturer’s product may result in unfair competition through revealing a trade secret. Exemption from the label declaration of such a marker is granted, therefore, provided that the following conditions are met:

(1) The person desiring to use the marker without label declaration of its presence has submitted to the Commissioner of Food and Drugs full information concerning the proposed usage and
§ 501.103 Petitions requesting exemptions from or special requirements for label declaration of ingredients.

The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition pursuant to part 10 of this chapter may issue a proposal to amend §501.4 to specify the manner in which an ingredient(s) shall be declared, i.e., by specific or class name, or §501.100 to exempt an ingredient(s) from the requirements for label declaration.

§ 501.105 Declaration of net quantity of contents when exempt.

(a) The principal display panel of a food in package form shall bear a declaration of the net quantity of contents. This shall be expressed in the terms of weight, measure, numerical count, or a combination of numerical count and weight or measure. The statement shall be in terms of fluid measure if the food is liquid, or in terms of weight if the food is solid, semisolid, or viscous; or a mixture of solid and liquid; except that such statement may be in terms of dry measure if the food is a fresh fruit, fresh vegetable, or other dry commodity that is customarily sold by dry measure. If there is a firmly established general consumer usage and trade custom of declaring the contents of a liquid by weight, or a solid, semisol, or viscous product by fluid measure, it may be used. Whenever the Commissioner determines that an existing practice of declaring net quantity of contents by weight, measure, numerical count, or a combination in the case of a specific packaged food does not facilitate value comparisons by consumers and offers opportunity for consumer confusion, he will by regulation designate the appropriate term or terms to be used for such commodity.

(b)(1) Statements of weight shall be in terms of avoirdupois pound and ounce.

(2) Statements of fluid measure shall be in terms of the U.S. gallon of 231 cubic inches and quart, pint, and fluid ounce subdivisions thereof, and shall:

(i) In the case of frozen food that is sold and consumed in a frozen state, express the volume at the frozen temperature.

(ii) In the case of refrigerated food that is sold in the refrigerated state, express the volume at 40°F (4°C).

(iii) In the case of other foods, express the volume at 68°F (20°C).

(3) Statements of dry measure shall be in terms of the U.S. bushel of 2,150.42 cubic inches and peck, dry quart, and dry pint subdivisions thereof.

(c) When the declaration of quantity of contents by numerical count does not give adequate information as to the quantity of food in the package, it shall be combined with such statement of weight, measure, or size of the individual units of the foods as will provide such information.

(d) The declaration may contain common or decimal fractions. A common fraction shall be in terms of halves, quarters, eighths, sixteenths, or thirty-seconds; except that if there exists a firmly established general consumer usage and trade custom of employing different common fractions in the net quantity declaration of a particular commodity, they may be employed. A common fraction shall be reduced to its lowest terms; a decimal fraction shall not be carried out to more than two places. A statement that includes small fractions of an ounce shall be deemed to permit smaller variations than one which does not include such fractions.

(e) The declaration shall be located on the principal display panel of the label, and with respect to packages bearing alternate principal panels it shall be duplicated on each principal display panel.

(f) The declaration shall appear as a distinct item on the principal display panel, shall be separated (by at least a
space equal to the height of the lettering used in the declaration) from other printed label information appearing above or below the declaration and (by at least a space equal to twice the width of the letter “N” of the style of type used in the quantity of contents statement) from other printed label information appearing to the left or right of the declaration. It shall not include any term qualifying a unit of weight, measure, or count (such as jumbo quart and full gallon) that tends to exaggerate the amount of the food in the container. It shall be placed on the principal display panel within the bottom 30 percent of the area of the label panel in lines generally parallel to the base on which the package rests as it is designed to be displayed: Provided, That on packages having a principal display panel of 5 square inches or less, the requirement for placement within the bottom 30 percent of the area of the label panel shall not apply when the declaration of net quantity of contents meets the other requirements of this part.

(g) The declaration shall accurately reveal the quantity of food in the package exclusive of wrappers and other material packed therewith; provided that in the case of foods packed in containers designed to deliver the food under pressure, the declaration shall state the net quantity of the contents that will be expelled when the instructions for use as shown on the container are followed. The propellant is included in the net quantity declaration.

(h) The declaration shall appear in conspicuous and easily legible boldface print or type in distinct contrast (by typography, layout, color, embossing, or molding) to other matter on the package; except that a declaration of net quantity blown, embossed, or molded on a glass or plastic surface rather than by printing, typing, or coloring, the lettering sizes specified in paragraphs (i) (1) through (4) of this section shall be increased by 1/16 of an inch. Where the declaration is blown, embossed, or molded on a glass or plastic surface rather than by printing, typing, or coloring, the lettering sizes specified in paragraphs (i) (1) through (4) of this section shall be increased by 1/16 of an inch.

(i) The declaration shall be in letters and numerals in a type size established in relationship to the area of the principal display panel of the package and shall be uniform for all packages of substantially the same size by complying with the following type specifications:

1. Not less than 1/16 inch in height on packages the principal display panel of which has an area of 5 square inches or less.
2. Not less than 1/8 inch in height on packages the principal display panel of which has an area of more than 5 but not more than 25 square inches.
3. Not less than 3/16 inch in height on packages the principal display panel of which has an area of more than 25 but not more than 100 square inches.
4. Not less than 1/4 inch in height on packages the principal display panel of which has an area of more than 100 square inches, except not less than 1/2 inch in height if the area is more than 400 square inches.

(j) On packages containing less than 4 pounds or 1 gallon and labeled in terms of weight or fluid measure:

1. The declaration shall be expressed both in ounces, with identification by weight or by liquid measure and, if applicable (1 pound or 1 pint or more) followed in parentheses by a declaration in pounds for weight units, with any remainder in terms of ounces or common or decimal fractions of the pound (see examples set forth in paragraphs (m) (1) and (2) of this section), or in the case of liquid measure, in the largest whole units (quarts, quarts and pints, or pints, as appropriate) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart (see examples in paragraphs (m) (3) and (4) of this section).
§ 501.105

(2) If the net quantity of contents declaration appears on a random package, that is a package which is one of a lot, shipment, or delivery of packages of the same consumer commodity with varying weights and with no fixed weight pattern, it may, when the net weight exceeds 1 pound, be expressed in terms of pounds and decimal fractions of the pound carried out to not more than two decimal places. When the net weight does not exceed 1 pound, the declaration on the random package may be in decimal fractions of the pound in lieu of ounces (see example in paragraph (m)(5) of this section).

(3) The declaration may appear in more than one line. The term net weight shall be used when stating the net quantity of contents in terms of weight. Use of the terms net or net contents in terms of fluid measure or numerical count is optional. It is sufficient to distinguish avoirdupois ounce from fluid ounce through association of terms; for example, Net wt. 6 oz. or 6 oz., net wt. and 6 fl. oz. or net contents 6 fl. oz.

(k) On packages containing 4 pounds or 1 gallon or more and labeled in terms of weight or fluid measure, the declaration shall be expressed in pounds for weight units with any remainder in terms of ounces or common or decimal fraction of the pound, or in the case of fluid measure, it shall be expressed in the largest whole unit (gallons followed by common or decimal fraction of a gallon or by the next smaller whole unit or units (quarts, or quarts and pints)) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart (see paragraph (m)(6) of this section).

(l) [Reserved]

(m) Examples: (1) A declaration of 1½ pounds weight shall be expressed as Net Wt. 24 oz. (1 lb. 8 oz.), Net Wt. 24 oz. (1½ lb.), or Net Wt. 24 oz. (1.5 lb.).

(2) A declaration of ¾ pound avoirdupois weight shall be expressed as Net Wt. 12 oz.

(3) A declaration of 1 quart liquid measure shall be expressed as Net 32 fl. oz. (1 qt.).

(4) A declaration of 1¼ quarts liquid measure shall be expressed as Net contents 56 fluid oz. (1 qt. 1 pt. 8 oz.) or as Net 56 fluid oz. (1 qt. 1 pt. 8 oz.), but not in terms of quart and ounce such as Net 56 fluid oz. (1 quart 24 ounces).

(5) On a random package, declaration of ¾ pound avoirdupois may be expressed as Net Wt. .75 lb.

(6) A declaration of 2½ gallons liquid measure shall be expressed as Net contents 2½ gallons, Net contents 2.5 gallons, or Net contents 2 gallons 2 quarts and not as 2 gallons 4 pints.

(n) For quantities, the following abbreviations and none other may be employed (periods and plural forms are optional):

- weight wt.
- ounce oz.
- pound lb.
- gallon gal.
- pint pt.
- quart qt.
- fluid fl.

(o) Nothing in this section shall prohibit supplemental statements at locations other than the principal display panel(s) describing in nondeceptive terms the net quantity of contents; provided, that such supplemental statements of net quantity of contents shall not include any term qualifying a unit of weight, measure, or count that tends to exaggerate the amount of the food contained in the package; for example, jumbo quart and full gallon. Dual or combination declarations of net quantity of contents as provided for in paragraphs (a), (c), and (j) of this section (for example, a combination of net weight plus numerical count, net contents plus dilution directions of a concentrate, etc.) are not regarded as supplemental net quantity statements and may be located on the principal display panel.

(p) A separate statement of the net quantity of contents in terms of the metric system is not regarded as a supplemental statement and an accurate statement of the net quantity of contents in terms of the metric system of weight or measure may also appear on the principal display panel or on other panels.

(q) The declaration of net quantity of contents shall express an accurate statement of the quantity of contents of the package. Reasonable variations caused by loss or gain of moisture during the course of good distribution practice or by unavoidable deviations in good manufacturing practice will be recognized. Variations from stated
quantity of contents shall not be unreasonably large.

(r) [Reserved]

(s) On a multiunit retail package, a statement of the quantity of contents shall appear on the outside of the package and shall include the number of individual units, the quantity of each individual unit, and, in parentheses, the total quantity of contents of the multiunit package in terms of avoirdupois or fluid ounces, except that such declaration of total quantity need not be followed by an additional parenthetical declaration in terms of the largest whole units and subdivisions thereof, as required by paragraph (j)(1) of this section. A multiunit retail package may thus be properly labeled: 6–16 oz. bottles—(96 fl. oz.) or 3–16 oz. cans—(net wt. 48 oz.). For the purposes of this section, multiunit retail package means a package containing two or more individually packaged units of the identical commodity and in the same quantity, intended to be sold as part of the multiunit retail package but capable of being individually sold in full compliance with all requirements of the regulations in this part. Open multiunit retail packages that do not obscure the number of units nor prevent examination of the labeling on each of the individual units are not subject to this paragraph if the labeling of each individual unit complies with the requirements of paragraphs (f) and (i) of this section.

(t) Where the declaration of net quantity of contents is in terms of net weight and/or drained weight or volume and does not accurately reflect the actual quantity of the contents or the product falls below the applicable standard of fill of container because of equipment malfunction or otherwise unintentional product variation, and the label conforms in all other respects to the requirements of this chapter (except the requirement that food falling below the applicable standard of fill of container shall bear the general statement of substandard fill specified in §501.110(b) of this chapter), the mislabeled food product, including any food product that fails to bear the general statement of substandard fill specified in §501.110(b) of this chapter, may be sold by the manufacturer or processor directly to institutions operated by Federal, State or local governments: Provided, That:

(1) The purchaser shall sign a statement at the time of sale stating that he is aware that the product is mislabeled to include acknowledgement of the nature and extent of the mislabeling, e.g., “Actual net weight may be as low as ___ % below labeled quantity” and that any subsequent distribution by him of said product except for his own institutional use is unlawful. This statement shall be kept on file at the principal place of business of the manufacturer or processor for 2 years subsequent to the date of shipment of the product and shall be available to the Food and Drug Administration upon request.

(2) The product shall be labeled on the outside of its shipping container with the statement(s):

(i) When the variation concerns net weight and/or drained weight of volume—“Product Mislabeled. Actual net weight (drained weight or volume where appropriate) may be as low as ___ % below labeled quantity. This Product Not for Retail Distribution,” the blank to be filled in with the maximum percentage variance between the labeled and actual weight or volume of contents of the individual packages in the shipping container, and

(ii) When the variation is in regard to a fill of container standard—“Product Mislabeled. Actual fill may be as low as ___ % below standard of fill. This Product Not for Retail Distribution.”

(3) The statements required by paragraphs (t)(2) (i) and (ii) of this section, which may be consolidated where appropriate, shall appear prominently and conspicuously as compared to other printed matter on the shipping container and in boldface print or type on a clear, contrasting background in order to render them likely to be read and understood by the purchaser under ordinary conditions of purchase.

[41 FR 38619, Sept. 10, 1976, as amended at 54 FR 18279, Apr. 28, 1989]

§ 501.110 Animal feed labeling; collective names for feed ingredients.

(a) An animal feed shall be exempt from the requirements of section 403(1)(2) of the act with respect to its...
(1) The animal feed is intended solely for livestock and poultry.

(2) The label of the animal feed bears the collective name(s) prescribed in paragraph (b) of this section in lieu of the corresponding common or usual names of the individual feed ingredients contained therein.

(3) The label of the animal feed otherwise conforms to the requirements of section 403(i)(2) of the act.

(4) The ingredients of any feed listed in paragraph (b) of this section neither contain nor are food additives as defined in section 201(s) of the act unless provided for by and in conformity with applicable regulations established pursuant to section 409 of the act.

(b) Each collective name referred to in this paragraph may be used for the purpose of labeling where one or more of the ingredients listed for that collective name are present. The animal feed ingredients listed under each of the collective names are the products defined by the Association of American Feed Control Officials. The collective names are as follows:

1. **Animal protein products** include one or more of the following: Animal products, marine products, and milk products.

2. **Forage products** include one or more of the following: Alfalfa meals, entire plant meals, hays, and stem meals.

3. **Grain products** include one or more of the following: Barley, grain sorghums, maize (corn), oats, rice, rye, and wheat.

4. **Plant protein products** include one or more of the following: Algae meals, coconut meals (copra), cottonseed meals, guar meal, linseed meals, peanut meals, safflower meals, soybean meals, sunflower meals, and yeasts.

5. **Processed grain byproducts** include one or more of the following: Brans, brewers dried grains, distillers grains, distillers solubles, flours, germ meals, gluten feeds, gluten meals, grits, groats, hominy feeds, malt sprouts, middlings, pearled, polishings, shorts, and wheat mill run.

6. **Roughage products** include one or more of the following: Cobs, hulls, husks, pulps, and straws.

**PART 502—COMMON OR USUAL NAMES FOR NONSTANDARDIZED ANIMAL FOODS**

Sec. 502.5 General principles.

502.19 Petitions.

**AUTHORITY:** 21 U.S.C. 321, 343, 371.

§ 502.5 **General principles.**

(a) The common or usual name of a food, which may be a coined term, shall accurately identify or describe, in as simple and direct terms as possible, the basic nature of the food or its characterizing properties or ingredients. The name shall be uniform among all identical or similar products and may not be confusingly similar to the name of any other food that is not reasonably encompassed within the same name. Each class or subclass of food shall be given its own common or usual name that states, in clear terms, what it is in a way that distinguishes it from different foods.

(b) The common or usual name of a food shall include the percentage(s) of any characterizing ingredient(s) or component(s) when the proportion of such ingredient(s) or component(s) in the food has a material bearing on price or consumer acceptance or when the labeling or the appearance of the food may otherwise create an erroneous impression that such ingredient(s) or component(s) is present in an amount greater than is actually the case. The following requirements shall apply unless modified by a specific regulation in this part.

1. The percentage of a characterizing ingredient or component shall be declared on the basis of its quantity in the finished product (i.e., weight/weight in the case of solids, or volume/volume in the case of liquids).

2. The percentage of a characterizing ingredient or component shall be declared by the words “containing (or contains) ___ percent (or %) ___” or “___ percent (or %) ___” with the first blank filled in with the percentage expressed as a whole number not greater
than the actual percentage of the ingredient or component named and the second blank filled in with the common or usual name of the ingredient or component. The word “containing” (or “contains”), when used, shall appear on a line immediately below the part of the common or usual name of the food required by paragraph (a) of this section. For each characterizing ingredient or component, the words “percent (or %)” shall appear following or directly below the word “containing” (or “contains”), or directly below the part of the common or usual name of the food required by paragraph (a) of this section when the word “containing” (or “contains”) is not used, in easily legible boldface print or type in distinct contrast to other printed or graphic matter, and in a height not less than the larger of the following alternatives:

(i) Not less than one-sixteenth inch in height on packages having a principal display panel with an area of 5 square inches or less and not less than one-eighth inch in height if the area of the principal display panel is greater than 5 square inches; or

(ii) Not less than one-half the height of the largest type appearing in the part of the common or usual name of the food required by paragraph (a) of this section.

The common or usual name of a food shall include a statement of the presence or absence of any characterizing ingredient(s) or component(s) and/or the need for the user to add any characterizing ingredient(s) or component(s) when the presence or absence of such ingredient(s) or component(s) in the food has a material bearing on price or consumer acceptance or when the labeling or the appearance of the food may otherwise create an erroneous impression that such ingredient(s) or component(s) is present when it is not, and consumers may otherwise be misled about the presence or absence of the ingredient(s) or component(s) in the food. The following requirements shall apply unless modified by a specific regulation in this part.

(1) The presence or absence of a characterizing ingredient or component shall be declared by the words “containing (or contains) ______%” or “does not contain ______%,” with the blank being filled in with the common or usual name of the ingredient or component.

(2) The need for the user of a food to add any characterizing ingredient(s) or component(s) shall be declared by an appropriate informative statement.

(3) The statement(s) required under paragraph (c) (1) and/or (2) of this section shall appear following or directly below the part of the common or usual name of the food required by paragraphs (a) and (b) of this section, in easily legible boldface print or type in distinct contrast to other printed or graphic matter, and in a height not less than the larger of the alternatives established under paragraph (b)(2) (i) and (ii) of this section.

(d) A common or usual name of a food may be established by common usage or by establishment of a regulation in this part, in a standard of identity, or in other regulations in this chapter.

§ 502.19 Petitions.

(a) The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition, may publish a proposal to issue, amend, or revoke, under this part, a regulation prescribing a common or usual name for a food, pursuant to part 10 of this chapter.

(b) If the principal display panel of a food for which a common or usual name regulation is established is too small to accommodate all mandatory requirements, the Commissioner may establish by regulation an acceptable alternative, e.g., a smaller type size. A petition requesting such a regulation, which would amend the applicable regulation, shall be submitted pursuant to part 10 of this chapter.
PART 507—CURRENT GOOD MANUFACTURING PRACTICE, HAZARD ANALYSIS, AND RISK-BASED PREVENTIVE CONTROLS FOR FOOD FOR ANIMALS

Subpart A—General Provisions

Sec. 507.1 Applicability and status.
507.3 Definitions.
507.4 Qualifications of individuals who manufacture, process, pack, or hold animal food.
507.5 Exemptions.
507.7 Requirements that apply to a qualified facility.
507.10 Applicability of subparts C and E of this part to a facility solely engaged in the storage of unexposed packaged animal food.
507.12 Applicability of this part to the holding and distribution of animal food by-products for use as animal food.

Subpart B—Current Good Manufacturing Practice

507.14 Personnel.
507.17 Plant and grounds.
507.19 Sanitation.
507.20 Water supply and plumbing.
507.22 Equipment and utensils.
507.25 Plant operations.
507.27 Holding and distribution.
507.28 Holding and distribution of human food by-products for use as animal food.

Subpart C—Hazard Analysis and Risk-Based Preventive Controls

507.31 Food safety plan.
507.33 Hazard analysis.
507.34 Preventive controls.
507.36 Circumstances in which the owner, operator, or agent in charge of a manufacturing/processing facility is not required to implement a preventive control.
507.37 Provision of assurances required under §507.36(a)(2), (3), and (4).
507.38 Recall plan.
507.39 Preventive control management components.
507.40 Monitoring.
507.42 Corrective actions and corrections.
507.45 Verification.
507.47 Validation.
507.49 Verification of implementation and effectiveness.
507.50 Reanalysis.
507.51 Modified requirements that apply to a facility solely engaged in the storage of unexposed packaged animal food.

Subpart D—Withdrawal of a Qualified Facility Exemption

507.60 Circumstances that may lead FDA to withdraw a qualified facility exemption.
507.62 Issuance of an order to withdraw a qualified facility exemption.
507.65 Contents of an order to withdraw a qualified facility exemption.
507.67 Compliance with, or appeal of, an order to withdraw a qualified facility exemption.
507.69 Procedure for submitting an appeal.
507.71 Procedure for requesting an informal hearing.
507.73 Requirements applicable to an informal hearing.
507.75 Presiding officer for an appeal and for an informal hearing.
507.77 Timeframe for issuing a decision on an appeal.
507.80 Revocation of an order to withdraw a qualified facility exemption.
507.83 Final agency action.
507.85 Reinstatement of a qualified facility exemption that was withdrawn.

Subpart E—Supply-Chain Program

507.105 Requirement to establish and implement a supply-chain program.
507.110 General requirements applicable to a supply-chain program.
507.115 Responsibilities of the receiving facility.
507.120 Using approved suppliers.
507.125 Determining appropriate supplier verification activities (including determining the frequency of conducting the activity).
507.130 Conducting supplier verification activities for raw materials and other ingredients.
507.135 Onsite audit.
507.175 Records documenting the supply-chain program.

Subpart F—Requirements Applying to Records That Must Be Established and Maintained

507.200 Records subject to the requirements of this subpart.
507.202 General requirements applying to records.
507.206 Additional requirements applying to the food safety plan.
507.208 Requirements for record retention.
507.212 Use of existing records.
507.215 Special requirements applicable to a written assurance.
Subpart A—General Provisions

§ 507.1 Applicability and status.

(a) The criteria and definitions in this part apply in determining whether an animal food is:

(1) Adulterated within the meaning of:

(i) Section 402(a)(3) of the Federal Food, Drug, and Cosmetic Act in that the food has been manufactured under such conditions that it is unfit for food; or

(ii) Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act in that the food has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health; and

(2) In violation of section 361 of the Public Health Service Act (42 U.S.C. 264).

(b) The operation of a facility that manufactures, processes, packs, or holds animal food for sale in the United States if the owner, operator, or agent in charge of such facility is required to comply with, and is not in compliance with, section 418 of the Federal Food, Drug, and Cosmetic Act or subparts C, D, E, or F of this part and §507.7 is a prohibited act under section 301(uu) of the Federal Food, Drug, and Cosmetic Act.

(c) Animal food covered by specific current good manufacturing practice regulations also is subject to the requirements of those regulations.

(d) Except as provided by §507.12, if a facility is required to comply with subpart B of part 507 and is also required to comply with subpart B of part 117 of this chapter because the facility manufactures, processes, packs, or holds human food and animal food, then the facility may choose to comply with the requirements in subpart B of part 117 instead of subpart B of part 507, provided the food safety plan also addresses hazards for the animal food, if applicable, that require a preventive control. When applying the requirements of part 117 of this chapter to animal food, the term “food” in part 117 includes animal food.

§ 507.3 Definitions.

The definitions and interpretations contained in section 201 of the Federal Food, Drug, and Cosmetic Act apply to such terms when used in this part. The following definitions also apply:

(Adequate means that which is needed to accomplish the intended purpose in keeping with good public (human and animal) health practice.

Affiliate means any facility that controls, is controlled by, or is under common control with another facility.

Animal food means food for animals other than man and includes pet food, animal feed, and raw materials and ingredients.

Audit means the systematic, independent, and documented examination (through observation, investigation, records review, discussions with employees of the audited entity, and, as appropriate, sampling and laboratory analysis) to assess an audited entity’s food safety processes and procedures.

Calendar day means every day shown on the calendar.

Correction means an action to identify and correct a problem that occurred during the production of animal food, without other actions associated with a corrective action procedure (such as actions to reduce the likelihood that the problem will recur, evaluate all affected animal food for safety, and prevent affected animal food from entering commerce).

Critical control point means a point, step, or procedure in a food process at which control can be applied and is essential to prevent or eliminate a food safety hazard or reduce such hazard to an acceptable level.
Environmental pathogen means a pathogen capable of surviving and persisting within the manufacturing, processing, packing, or holding environment such that food for animals may be contaminated and may result in foodborne illness if that animal food is not treated to significantly minimize or prevent the environmental pathogen. Examples of environmental pathogens for the purposes of this part include *Listeria monocytogenes* and *Salmonella* spp. but do not include the spores of pathogenic sporeforming bacteria.

Facility means a domestic facility or a foreign facility that is required to register under section 415 of the Federal Food, Drug, and Cosmetic Act, in accordance with the requirements of part 1, subpart H of this chapter.

Farm means farm as defined in §1.227 of this chapter.

FDA means the Food and Drug Administration.

Food means food as defined in section 201(f) of the Federal Food, Drug, and Cosmetic Act and includes raw materials and ingredients.

Food-contact surfaces are those surfaces that contact animal food and those surfaces from which drainage, or other transfer, onto the animal food or onto surfaces that contact the animal food ordinarily occurs during the normal course of operations. “Food-contact surfaces” includes utensils and animal food-contact surfaces of equipment.

Full-time equivalent employee is a term used to represent the number of employees of a business entity for the purpose of determining whether the business qualifies for the small business exemption. The number of full-time equivalent employees is determined by dividing the total number of hours of salary or wages paid directly to employees of the business entity and of all of its affiliates and subsidiaries by the number of hours of work in 1 year, 2,080 hours (i.e., 40 hours × 52 weeks). If the result is not a whole number, round down to the next lowest whole number.

Harvesting applies to farms and farm mixed-type facilities and means activities that are traditionally performed on farms for the purpose of removing raw agricultural commodities from the place they were grown or raised and preparing them for use as animal food. Harvesting is limited to activities performed on raw agricultural commodities, or on processed foods created by drying/dehydrating a raw agricultural commodity without additional manufacturing/processing, on a farm. Harvesting does not include activities that transform a raw agricultural commodity into a processed food as defined in section 201(gg) of the Federal Food, Drug, and Cosmetic Act. Examples of harvesting include cutting (or otherwise separating) the edible portion of the raw agricultural commodity from the crop plant and removing or trimming part of the raw agricultural commodity (e.g., foliage, husks, roots, or stems). Examples of harvesting also include cooling, field coring, filtering, gathering, hulling, shelling, sifting, threshing, trimming of outer leaves of, and washing raw agricultural commodities grown on a farm.

Hazard requiring a preventive control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of animal food would, based on the outcome of a hazard analysis (which includes an assessment of the severity of the illness or injury to humans or animals if the hazard were to occur and the probability that the hazard will occur in the absence of preventive controls), establish one or more preventive controls to significantly minimize or prevent the hazard in an animal food and components to manage those controls (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the animal food, the facility, and the nature of the preventive control and its role in the facility’s food safety system.

**Holding** means storage of animal food and also includes activities performed incidental to storage of an animal food (e.g., activities performed for the safe or effective storage of that animal food, such as fumigating animal food during storage, and drying/dehydrating.
raw agricultural commodities when the drying/dehydrating does not create a distinct commodity (such as drying/dehydrating hay or alfalfa). Holding also includes activities performed as a practical necessity for the distribution of that animal food (such as blending of the same raw agricultural commodity and breaking down pallets), but does not include activities that transform a raw agricultural commodity into a processed food as defined in section 201(gg) of the Federal Food, Drug, and Cosmetic Act. Holding facilities could include warehouses, cold storage facilities, storage silos, grain elevators, and liquid-storage tanks.

Known or reasonably foreseeable hazard means a biological, chemical (including radiological), or physical hazard that is known to be, or has the potential to be, associated with the facility or the animal food.

Lot means the animal food produced during a period of time and identified by an establishment’s specific code.

Manufacturing/processing means making animal food from one or more ingredients, or synthesizing, preparing, treating, modifying, or manipulating animal food, including food crops or ingredients. Examples of manufacturing/processing activities include: Baking, boiling, bottling, canning, cooking, cooling, cutting, distilling, drying/dehydrating raw agricultural commodities to create a distinct commodity (such as drying/dehydrating grapes to produce raisins), evaporating, eviscerating, extracting juice, extruding, formulating, freezing, grinding, homogenizing, irradiating, labeling, milling, mixing, packaging (including modified atmosphere packaging), pasteurizing, peeling, pelleting, rendering, treating to manipulate ripening, trimming, washing, or waxing. For farms and farm mixed-type facilities, manufacturing/processing does not include activities that are part of harvesting, packing, or holding.

Microorganisms means yeasts, molds, bacteria, viruses, protozoa, and microscopic parasites and includes species that are pathogens. The term “undesirable microorganisms” includes those microorganisms that are pathogens, that subject animal food to decomposition, that indicate that animal food is contaminated with filth, or that otherwise may cause animal food to be adulterated.

Mixed-type facility means an establishment that engages in both activities that are exempt from registration under section 415 of the Federal Food, Drug, and Cosmetic Act and activities that require the establishment to be registered. An example of such a facility is a “farm mixed-type facility,” which is an establishment that is a farm, but also conducts activities outside the farm definition that require the establishment to be registered.

Monitor means to conduct a planned sequence of observations or measurements to assess whether control measures are operating as intended.

Packing means placing animal food into a container other than packaging the animal food and also includes repacking and activities performed incidental to packing or repacking an animal food (e.g., activities performed for the safe or effective packing or repacking of that animal food (such as sorting, culling, grading, and weighing or conveying incidental to packing or repacking), but does not include activities that transform a raw agricultural commodity into a processed food as defined in section 201(gg) of the Federal Food, Drug, and Cosmetic Act.

Pathogen means a microorganism of public (human or animal) health significance.

Pest refers to any objectionable animals or insects including birds, rodents, flies, and larvae.

Plant means the building or structure, or parts thereof, used for or in connection with the manufacturing, processing, packing, or holding of animal food.

Preventive controls means those risk-based, reasonably appropriate procedures, practices, and processes that a person knowledgeable about the safe manufacturing, processing, packing, or holding of animal food would deploy to significantly minimize or prevent the hazards identified under the hazard analysis that are consistent with the current scientific understanding of safe food manufacturing, processing, packing, or holding at the time of the analysis.
Preventive controls qualified individual means a qualified individual who has successfully completed training in the development and application of risk-based preventive controls at least equivalent to that received under a standardized curriculum recognized as adequate by FDA, or is otherwise qualified through job experience to develop and apply a food safety system.

Qualified auditor means a person who is a qualified individual as defined in this part and has technical expertise obtained through education, training, or experience (or the combination thereof) necessary to perform the auditing function. Examples of potential qualified auditors include:

1. A government employee, including a foreign government employee; and
2. An audit agent of a certification body that is accredited in accordance with regulations in part 1, subpart M of this chapter.

Qualified end-user, with respect to food, means the consumer of the food (where the term consumer does not include a business); or a restaurant or retail food establishment (as those terms are defined in §1.227 of this chapter) that:

1. Is located:
   i. In the same State or the same Indian reservation as the qualified facility that sold the food to such restaurant or retail food establishment; or
   ii. Not more than 275 miles from such facility; and
2. Is purchasing the food for sale directly to consumers at such restaurant or retail food establishment.

Qualified facility means (when including the sales by any subsidiary; affiliate; or subsidiaries or affiliates, collectively, of any entity of which the facility is a subsidiary or affiliate) a facility that is a very small business as defined in this part, or a facility to which both of the following apply:

1. During the 3-year period preceding the applicable calendar year, the average annual monetary value of the food manufactured, processed, packed, or held at such facility that is sold directly to qualified end-users (as defined in this part) during such period exceeded the average annual monetary value of the food sold by such facility to all other purchasers; and
2. The average annual monetary value of all food sold during the 3-year period preceding the applicable calendar year was less than $500,000, adjusted for inflation.

Qualified facility exemption means an exemption applicable to a qualified facility under §507.5(d).

Qualified individual means a person who has the education, training, or experience (or a combination thereof) necessary to manufacture, process, pack, or hold safe animal food as appropriate to the individual's assigned duties. A qualified individual may be, but is not required to be, an employee of the establishment.

Raw agricultural commodity has the meaning given in section 201(r) of the Federal Food, Drug, and Cosmetic Act.

Receiving facility means a facility that is subject to subparts C and E of this part and that manufactures/processes a raw material or other ingredient that it receives from a supplier.

Rework means clean, unadulterated animal food that has been removed from processing for reasons other than insanitary conditions or that has been successfully reconditioned by reprocessing and that is suitable for use as animal food.

Sanitize means to adequately treat cleaned surfaces by a process that is effective in destroying vegetative cells of pathogens, and in substantially reducing numbers of other undesirable microorganisms, but without adversely affecting the product or its safety for animals or humans.

Significantly minimize means to reduce to an acceptable level, including to eliminate.

Small business means, for purposes of this part, a business (including any subsidiaries and affiliates) employing fewer than 500 full-time equivalent employees.

Subsidiary means any company which is owned or controlled directly or indirectly by another company.

Supplier means the establishment that manufactures/processes the animal food, raises the animal, or grows the food that is provided to a receiving
facility without further manufacturing/processing by another establishment, except for further manufacturing/processing that consists solely of the addition of labeling or similar activity of a de minimis nature.

Supply-chain-applied control means a preventive control for a hazard in a raw material or other ingredient when the hazard in the raw material or other ingredient is controlled before its receipt.

Unexposed packaged animal food means packaged animal food that is not exposed to the environment.

Validation means obtaining and evaluating scientific and technical evidence that a control measure, combination of control measures, or the food safety plan as a whole, when properly implemented, is capable of effectively controlling the identified hazards.

Verification means the application of methods, procedures, tests and other evaluations, in addition to monitoring, to determine whether a control measure or combination of control measures is or has been operating as intended and to establish the validity of the food safety plan.

Very small business means, for purposes of this part, a business (including any subsidiaries and affiliates) averaging less than $2,500,000, adjusted for inflation, per year, during the 3-year period preceding the applicable calendar year in sales of animal food plus the market value of animal food manufactured, processed, packed, or held without sale (e.g., held for a fee or supplied to a farm without sale).

Water activity (a_w) means a measure of the free moisture in an animal food and is the quotient of the water vapor pressure of the substance divided by the vapor pressure of pure water at the same temperature.

Written procedures for receiving raw materials and other ingredients means written procedures to ensure that raw materials and other ingredients are received only from suppliers approved by the receiving facility (or, when necessary and appropriate, on a temporary basis from unapproved suppliers whose raw materials or other ingredients are subjected to adequate verification activities before acceptance for use).

You means, for purposes of this part, the owner, operator, or agent in charge of a facility.

§ 507.4 Qualifications of individuals who manufacture, process, pack, or hold animal food.

(a)(1) The management of an establishment must ensure that all individuals who manufacture, process, pack, or hold animal food subject to subparts B and F of this part are qualified to perform their assigned duties; and

(2) The owner, operator, or agent in charge of a facility must ensure that all individuals who manufacture, process, pack, or hold animal food subject to subparts C, D, E, or F of this part are qualified to perform their assigned duties.

(b) Each individual engaged in manufacturing, processing, packing, or holding animal food (including temporary and seasonal personnel) or in the supervision thereof must:

(1) Be a qualified individual as that term is defined in §507.3, i.e., have the education, training, or experience (or a combination thereof) necessary to manufacture, process, pack, or hold safe animal food as appropriate to the individual’s assigned duties; and

(2) Receive training in the principles of animal food hygiene and animal food safety, including the importance of employee health and personal hygiene, as appropriate to the animal food, the facility and the individual’s assigned duties.

(c) Responsibility for ensuring compliance by individuals with the requirements of this part must be clearly assigned to supervisory personnel who have the education, training, or experience (or a combination thereof) necessary to supervise the production of safe animal food.
§ 507.5 Exemptions.

(a) This part does not apply to establishments, including “farms” (as defined in §1.227 of this chapter), that are not required to register under section 415 of the Federal Food, Drug, and Cosmetic Act.

(b)(1) Subparts C and E of this part do not apply with respect to activities that are subject to §500.23 and part 113 of this chapter (Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers) at an animal food facility if you are required to comply with, and are in compliance with, part 113 of this chapter with respect to those activities.

(2) The exemption in paragraph (b)(1) of this section is applicable only with respect to those microbiological hazards regulated under part 113 of this chapter.

(c) Subparts C and E of this part do not apply to activities of a facility that are subject to section 419 of the Federal Food, Drug, and Cosmetic Act (Standards for Produce Safety).

(d) Except as provided in subpart D of this part, subparts C and E of this part do not apply to a qualified facility. Qualified facilities are subject to the requirements in §507.7.

(e) For a farm mixed-type facility that is a small or very small business, subparts C and E of this part do not apply to on-farm packing or holding of processed animal food, and §507.7 does not apply to on-farm packing or holding of processed animal food by a very small business, if the only packing or holding activities subject to section 418 of the Federal Food, Drug, and Cosmetic Act that the business conducts consists of the following low-risk manufacturing/processing activity/animal food combinations:

1. Chopping or shredding hay;
2. Cracking, crimping, flaking, pearling, peeling, and wafering—grain (e.g., barley, sorghum, corn, oats, rice, rye, and wheat) or oilseed (e.g., beans, canola, cottonseed, linseed, soybeans, and sunflowers);
3. Crushing, dry rolling, grinding, milling, and pulverizing—grain, oilseed, grain by-products and processed grain products, oilseed products, hay, ensiled material, culled fruits and vegetables,
roughage (e.g., cobs, hulls, husks, and straws), or roughage products;
(4) Ensiling (including chopping, shredding, mixing, storing, or fermenting), that is, making silage or haylage from forage (e.g., sorghum (milo), corn (maize), alfalfa, and grass), grain, culled fruits and vegetables, or roughage;
(5) Extracting (mechanical) or wet rolling grain, oilseed, brewers grain by-products, or distillers grain by-products;
(6) Labeling roughage products, plant protein meals, grain by-products and processed grain products, oilseed products, molasses, animal protein meals, milk products, animal tissue-derived products, vitamins, minerals, concentrates, processing aids, finished animal food, including animal food ready for consumption, or any other processed animal food that does not require time/temperature control for safety; and
(7) Packaging roughage products, plant protein meals, grain by-products and processed grain products, oilseed products, molasses, animal protein meals, milk products, animal tissue-derived products, vitamins, minerals, concentrates, processing aids, finished animal food, including animal food ready for consumption, or any other processed animal food that does not require time/temperature control for safety.

(g) Subparts C and E of this part do not apply to facilities that are solely engaged in the storage of raw agricultural commodities (other than fruits and vegetables) intended for further distribution or processing.

(b) Subpart B of this part does not apply to any of the following:
(1) Establishments solely engaged in the holding and/or transportation of one or more raw agricultural commodities;
(2) Establishments solely engaged in hulling, shelling, drying, packing, and/or holding nuts and hulls (without manufacturing/processing, such as grinding shells or roasting nuts); and
(3) Establishments solely engaged in ginning of cotton (without manufacturing/processing, such as extracting oil from cottonseed).

§ 507.7 Requirements that apply to a qualified facility.

(a) A qualified facility must submit the following attestations to FDA:
(1) An attestation that the facility is a qualified facility as defined in § 507.3. For the purpose of determining whether a facility satisfies the definition of qualified facility, the baseline year for calculating the adjustment for inflation is 2011; and
(2)(i) An attestation that you have identified the potential hazards associated with the animal food being produced, are implementing preventive controls to address the hazards, and are monitoring the performance of the preventive controls to ensure that such controls are effective; or
(ii) An attestation that the facility is in compliance with State, local, county, tribal, or other applicable non-Federal food safety law, including relevant laws and regulations of foreign countries, including an attestation based on licenses, inspection reports, certificates, permits, credentials, certification by an appropriate agency (such as a State department of agriculture), or other evidence of oversight.

(b) The attestations required by paragraph (a) of this section must be submitted to FDA by any one of the following means:
(1) Electronic submission. To submit electronically, go to http://www.fda.gov/furls and follow the instructions. This Web site is available from wherever the Internet is accessible, including libraries, copy centers, schools, and Internet cafes. FDA encourages electronic submission.
(2) Submission by mail. (i) You must use Form FDA 3942b. You may obtain a copy of this form by any one of the following mechanisms:
(A) Download it from http://www.fda.gov/pcafrule.
(B) Write to the U.S. Food and Drug Administration (HFS–681), 5100 Paint Branch Pkwy., College Park, MD 20740; or
(C) Request a copy of this form by phone at 1–800–216–7331 or 301–575–0156.
§ 507.10 21 CFR Ch. I (4–1–16 Edition)

(i) Send a paper Form FDA 3942b to the U.S. Food and Drug Administration (HFS–681), 5100 Paint Branch Pkwy., College Park, MD 20740. We recommend that you submit a paper copy only if your facility does not have reasonable access to the Internet.

(ii) A facility must determine and document its status as a qualified facility on an annual basis no later than July 1 of each calendar year.

(2) The attestations required by paragraph (a) of this section must be:

(i) Submitted to FDA initially:

(A) By December 16, 2019 for a facility that begins manufacturing, processing, packing, or holding animal food before September 17, 2019;

(B) Before beginning operations, for a facility that begins manufacturing, processing, packing, or holding animal food after September 17, 2019; or

(C) By July 31 of the applicable calendar year, when the status of a facility changes from “not a qualified facility” to “qualified facility” based on the annual determination required by paragraph (c)(1) of this section; and

(ii) Beginning in 2020, submitted to FDA every 2 years during the period beginning on October 1 and ending on December 31.

(3) When the status of a facility changes from “qualified facility” to “not a qualified facility” based on the annual determination required by paragraph (c)(1) of this section, the facility must notify FDA of that change in status using Form FDA 3942b by July 31 of the applicable calendar year.

(d) When the status of a facility changes from “qualified facility” to “not a qualified facility,” the facility must comply with subparts C and E of this part no later than December 31 of the applicable calendar year unless otherwise agreed to by FDA and the facility.

(e) A qualified facility that does not submit attestations under paragraph (a)(2)(i) of this section must provide notification to consumers as to the name and complete business address of the facility where the animal food was manufactured or processed (including the street address or P.O. Box, city, state, and zip code for domestic facilities, and comparable full address information for foreign facilities) as follows:

(1) If an animal food packaging label is required, the notification required by paragraph (e) of this section must appear prominently and conspicuously on the label of the animal food.

(2) If an animal food packaging label is not required, the notification required by paragraph (e) of this section must appear prominently and conspicuously, at the point of purchase, on a label, poster, sign, placard, or documents delivered contemporaneously with the animal food in the normal course of business, or in an electronic notice, in the case of Internet sales.

(f)(1) A qualified facility must maintain those records relied upon to support the attestations that are required by paragraph (a) of this section.

(2) The records that a qualified facility must maintain are subject to the requirements of subpart F of this part.

§ 507.12 Applicability of this part to the holding and distribution of human food by-products for use as animal food.

(a) Except as provided by paragraph (b) of this section, the requirements of this part do not apply to by-products of

§ 507.10 Applicability of subparts C and E of this part to a facility solely engaged in the storage of unexposed packaged animal food.

(a) Subparts C and E of this part do not apply to a facility solely engaged in the storage of unexposed packaged animal food that does not require time/temperature control to significantly minimize or prevent the growth of, or toxin production by, pathogens.

(b) A facility solely engaged in the storage of unexposed packaged animal food, including unexposed packaged animal food that requires time/temperature control to significantly minimize or prevent the growth of, or toxin production by, pathogens is subject to the modified requirements in §507.51 for any unexposed packaged animal food that requires time/temperature control to significantly minimize or prevent the growth of, or toxin production by, pathogens.
Food and Drug Administration, HHS

§ 507.17

human food production, or the off-farm packing and holding of raw agricultural commodities, that are packed or held by that human food facility for distribution as animal food if:

(1)(i) The human food facility is subject to and in compliance with subpart B of part 117 of this chapter and in compliance with all applicable human food safety requirements of the Federal Food, Drug, and Cosmetic Act and implementing regulations;

(ii) For the off-farm packing and holding of produce (as defined in part 112 of this chapter), the human food facility is subject to and in compliance with §117.8 of this chapter and in compliance with all applicable human food safety requirements of the Federal Food, Drug, and Cosmetic Act and implementing regulations; and

(2) The human food facility does not further manufacture or process the by-products intended for use as animal food.

(b) The human food by-products for use as animal food identified in paragraph (a) of this section must be held and distributed by that facility in accordance with §§ 507.28 and 117.95 of this chapter.

Subpart B—Current Good Manufacturing Practice

§ 507.14 Personnel.

(a) The management of the establishment must take reasonable measures and precautions to ensure that all persons working in direct contact with animal food, animal food-contact surfaces, and animal food-packaging materials conform to hygienic practices to the extent necessary to protect against the contamination of animal food.

(b) The methods for conforming to hygienic practices and maintaining cleanliness include:

(1) Maintaining adequate personal cleanliness;

(2) Washing hands thoroughly in an adequate hand-washing facility as necessary and appropriate to protect against contamination;

(3) Removing or securing jewelry and other objects that might fall into animal food, equipment, or containers;

(4) Storing clothing or other personal belongings in areas other than where animal food is exposed or where equipment or utensils are cleaned; and

(5) Taking any other necessary precautions to protect against the contamination of animal food, animal food-contact surfaces, or animal food-packaging materials.

§ 507.17 Plant and grounds.

(a) The grounds around an animal food plant under the control of the management of the establishment must be kept in a condition that will protect against the contamination of animal food. Maintenance of grounds must include:

(1) Properly storing equipment, removing litter and waste, and cutting weeds or grass within the immediate vicinity of the plant that may constitute an attractant, breeding place, or harborage for pests;

(2) Maintaining driveways, yards, and parking areas so that they do not constitute a source of contamination in areas where animal food is exposed;

(3) Adequately draining areas that may contribute to contamination of animal food; and

(4) Treating and disposing of waste so that it does not constitute a source of contamination in areas where animal food is exposed.

(b) The plant must be suitable in size, construction, and design to facilitate cleaning, maintenance, and pest control to reduce the potential for contamination of animal food, animal food-contact surfaces, and animal food-packaging materials, including that the plant must:

(1) Provide adequate space between equipment, walls, and stored materials to permit employees to perform their duties and to allow cleaning and maintenance of equipment;

(2) Be constructed in a manner such that drip or condensate from fixtures, ducts, and pipes does not serve as a source of contamination;

(3) Provide adequate ventilation (mechanical or natural) where necessary and appropriate to minimize vapors (e.g., steam) and fumes in areas where they may contaminate animal food and in a manner that minimizes the potential for contaminating animal food;
§ 507.19 Sanitation.

(a) Buildings, structures, fixtures, and other physical facilities of the plant must be kept clean and in good repair to prevent animal food from becoming adulterated.

(b) Animal food-contact and non-contact surfaces of utensils and equipment must be cleaned and maintained and utensils and equipment stored as necessary to protect against the contamination of animal food, animal food-contact surfaces, or animal food-packaging materials. When necessary, equipment must be disassembled for thorough cleaning. In addition:

(1) When animal food-contact surfaces used for manufacturing, processing, packing, or holding animal food are wet-cleaned, the surfaces must, when necessary, be thoroughly dried before subsequent use; and

(2) In wet processing of animal food, when cleaning and sanitizing are necessary to protect against the introduction of undesirable microorganisms into animal food, all animal food-contact surfaces must be cleaned and sanitized before use and after any interruption during which the animal food-contact surfaces may have become contaminated.

(c) Cleaning compounds and sanitizing agents must be safe and adequate under the conditions of use.

(d) The following applies to toxic materials:

(1) Only the following toxic materials may be used or stored in the plant area where animal food is manufactured, processed, or exposed:

(i) Those required to maintain clean and sanitary conditions;

(ii) Those necessary for use in laboratory testing procedures;

(iii) Those necessary for plant and equipment maintenance and operation; and

(iv) Those necessary for use in the plant’s operations.

(2) Toxic materials described in paragraph (d)(1) of this section (e.g., cleaning compounds, sanitizing agents, and pesticide chemicals) must be identified, used, and stored in a manner that protects against the contamination of animal food, animal food-contact surfaces, or animal food-packaging materials; and

(3) Other toxic materials (such as fertilizers and pesticides not included in paragraph (d)(1) of this section) must be stored in an area of the plant where animal food is not manufactured, processed, or exposed.

(e) Effective measures must be taken to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against the contamination of animal food by pests. The use of pesticides in the plant is permitted only under precautions and restrictions that will protect against the contamination of animal food, animal food-contact surfaces, and animal food-packaging materials.

(f) Trash must be conveyed, stored, and disposed of in a way that protects against the contamination of animal food, animal food-contact surfaces, animal food-packaging materials, water supplies, and ground surfaces, and minimizes the potential for the trash to become an attractant and harborage or breeding place for pests.

[80 FR 56337, Sept. 17, 2015, as amended at 81 FR 3717, Jan. 22, 2016]

§ 507.20 Water supply and plumbing.

(a) The following apply to the water supply:
§ 507.22 Equipment and utensils.

(a) The following apply to plant equipment and utensils used in manufacturing, processing, packing, and holding animal food:

(1) All plant equipment and utensils, including equipment and utensils that do not come in contact with animal food, must be designed and constructed of such material and workmanship to be adequately cleanable, and must be properly maintained;

(2) Equipment and utensils must be designed, constructed, and used appropriately to avoid the adulteration of animal food with non-food grade lubricants, fuel, metal fragments, contaminated water, or any other contaminants;

(3) Equipment must be installed so as to facilitate the cleaning and maintenance of the equipment and adjacent spaces;

(4) Animal food-contact surfaces must be:
   (i) Made of materials that withstand the environment of their use and the action of animal food, and, if applicable, the action of cleaning compounds, cleaning procedures, and sanitizing agents;
   (ii) Made of nontoxic materials; and
   (iii) Maintained to protect animal food from being contaminated.

(b) Holding, conveying, manufacturing, and processing systems, including gravimetric, pneumatic, closed, and automated systems, must be designed, constructed, and maintained in a way to protect against the contamination of animal food.

(c) Each freezer and cold storage compartment used to hold animal food must be fitted with an accurate temperature-measuring device.

(d) Instruments and controls used for measuring, regulating, or recording temperatures, pH, aω, or other conditions that control or prevent the growth of undesirable microorganisms in animal food must be accurate, precise, adequately maintained, and adequate in number for their designated uses.

(e) Compressed air or other gases mechanically introduced into animal food or used to clean animal food-contact surfaces or equipment must be used in
§ 507.25 Plant operations.

(a) Management of the establishment must ensure that:

(1) All operations in the manufacturing, processing, packing, and holding of animal food (including operations directed to receiving, inspecting, transporting, and segregating) are conducted in accordance with the current good manufacturing practice requirements of this subpart;

(2) Animal food, including raw materials, other ingredients, or rework is accurately identified;

(3) Animal food-packaging materials are safe and suitable;

(4) The overall cleanliness of the plant is under the supervision of one or more competent individuals assigned responsibility for this function;

(5) Adequate precautions are taken so that plant operations do not contribute to contamination of animal food, animal food-contact surfaces, and animal food-packaging materials;

(6) Chemical, microbiological, or extraneous-material testing procedures are used where necessary to identify sanitation failures or possible animal food contamination;

(7) Animal food that has become adulterated is rejected, disposed of, or if appropriate, treated or processed to eliminate the adulteration.

(8) Animal food manufacturing, processing, packing, and holding is conducted under such conditions and controls as are necessary to minimize the potential for the growth of undesirable microorganisms to protect against the contamination of animal food.

(b) Raw materials and other ingredients:

(1) Must be examined to ensure that they are suitable for manufacturing and processing into animal food and must be handled under conditions that will protect against contamination and minimize deterioration. In addition:

(i) Shipping containers (e.g., totes, drums, and tubs) and bulk vehicles holding raw materials and other ingredients must be examined upon receipt to determine whether contamination or deterioration of animal food has occurred;

(ii) Raw materials must be cleaned as necessary to minimize contamination; and

(iii) Raw materials and other ingredients, including rework, must be stored in containers designed and constructed in a way that protects against contamination and deterioration, and held under conditions, e.g., appropriate temperature and relative humidity, that will minimize the potential for growth of undesirable microorganisms and prevent the animal food from becoming adulterated;

(2) Susceptible to contamination with mycotoxins or other natural toxins must be evaluated and used in a manner that does not result in animal food that can cause injury or illness to animals or humans;

(3) If frozen, must be kept frozen. If thawing is required prior to use, it must be done in a manner that minimizes the potential for the growth of undesirable microorganisms.

(c) For the purposes of manufacturing, processing, packing, and holding operations, the following apply:

(1) Animal food must be maintained under conditions, e.g., appropriate temperature and relative humidity, that will minimize the potential for growth of undesirable microorganisms and prevent the animal food from becoming adulterated during manufacturing, processing, packing, and holding;

(2) Measures taken during manufacturing, processing, packing, and holding of animal food to significantly minimize or prevent the growth of undesirable microorganisms (e.g., heat treating, freezing, refrigerating, irradiating, controlling pH, or controlling a) must be adequate to prevent adulteration of animal food;

(3) Work-in-process and rework must be handled in such a way that it is protected against contamination and the growth of undesirable microorganisms;

(4) Steps such as cutting, drying, defatting, grinding, mixing, extruding, pelleting, and cooling, must be performed in a way that protects against the contamination of animal food;
Food and Drug Administration, HHS

§ 507.28 Holding and distribution of human food by-products for use as animal food.

(a) Human food by-products held for distribution as animal food must be held under conditions that will protect against contamination, including the following:

(1) Containers and equipment used to convey or hold human food by-products for use as animal food before distribution must be designed, constructed of appropriate material, cleaned as necessary, and maintained to protect against the contamination of human food by-products for use as animal food;

(2) Human food by-products for use as animal food held for distribution must be held in a way to protect against contamination from sources such as trash; and

(3) During holding, human food by-products for use as animal food must be accurately identified.

(b) Labeling that identifies the product by the common or usual name must be affixed to or accompany the human food by-products for use as animal food when distributed.

(c) Shipping containers (e.g., totes, drums, and tubs) and bulk vehicles used to distribute human food by-products for use as animal food must be examined prior to use to protect against the contamination of animal food from the container or vehicle when the facility is responsible for transporting the animal food itself or arranges with a third party to transport the human food by-products for use as animal food.
§ 507.31 Food safety plan.

(a) You must prepare, or have prepared, and implement a written food safety plan.

(b) One or more preventive controls qualified individuals must prepare, or oversee the preparation of, the food safety plan.

(c) The written food safety plan must include:

1. The written hazard analysis as required by § 507.33(a)(3);
2. The written preventive controls as required by § 507.34(b);
3. The written supply-chain program as required by subpart E of this part;
4. The written recall plan as required by § 507.38(a)(1);
5. The written procedures for monitoring the implementation of the preventive controls as required by § 507.40(a)(1);
6. The written corrective action procedures as required by § 507.42(a)(1); and
7. The written verification procedures as required by § 507.49(b).

(d) The food safety plan required by this section is a record that is subject to the requirements of subpart F of this part.

§ 507.33 Hazard analysis.

(a)(1) You must conduct a hazard analysis to identify and evaluate, based on experience, illness data, scientific reports, and other information, known or reasonably foreseeable hazards for each type of animal food manufactured, processed, packed, or held at your facility to determine whether there are any hazards requiring a preventive control; and

(b) The hazard identification must consider:

1. Known or reasonably foreseeable hazards that include:
   (i) Biological hazards, including microbiological hazards such as parasites, environmental pathogens, and other pathogens;
   (ii) Chemical hazards, including radiological hazards, substances such as pesticide and drug residues, natural toxins, decomposition, unapproved food or color additives, and nutrient deficiencies or toxicities (such as inadequate thiamine in cat food, excessive vitamin D in dog food, and excessive copper in food for sheep); and
   (iii) Physical hazards (such as stones, glass, and metal fragments); and

2. Known or reasonably foreseeable hazards that may be present in the animal food for any of the following reasons:
   (i) The hazard occurs naturally;
   (ii) The hazard may be unintentionally introduced; or
   (iii) The hazard may be intentionally introduced for purposes of economic gain.

(c)(1) The hazard analysis must include an evaluation of the hazards identified in paragraph (b) of this section to assess the severity of the illness or injury to humans or animals if the hazard were to occur and the probability that the hazard will occur in the absence of preventive controls.

(d) The hazard evaluation required by paragraph (c)(1) of this section must include an evaluation of environmental pathogens whenever an animal food is exposed to the environment prior to packaging and the packaged animal food does not receive a treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen.

(e) The hazard evaluation must consider the effect of the following on the safety of the finished animal food for the intended animal:

1. The formulation of the animal food;
2. The condition, function, and design of the facility and equipment;
3. Raw materials and other ingredients;
4. Transportation practices;
5. Manufacturing/processing procedures;
6. Packaging activities and labeling activities;
7. Storage and distribution;
8. Intended or reasonably foreseeable use;
9. Sanitation, including employee hygiene; and
10. Any other relevant factors such as the temporal (e.g., weather-related)
§ 507.34 Preventive controls.

(a)(1) You must identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the animal food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Federal Food, Drug, and Cosmetic Act; and

(2) Preventive controls required by paragraph (a)(1) of this section include:

(i) Controls at critical control points (CCPs), if there are any CCPs; and

(ii) Controls, other than those at CCPs, that are also appropriate for animal food safety.

(b) Preventive controls must be written.

(c) Preventive controls include, as appropriate to the facility and animal food:

(1) Process controls. Process controls include procedures, practices, and processes to ensure the control of parameters during operations such as heat processing, irradiating, and refrigerating animal food. Process controls must include, as appropriate to the nature of the applicable control and its role in the facility’s food safety system:

(i) Parameters associated with the control of the hazard; and

(ii) The maximum or minimum value, or combination of values, to which any biological, chemical, or physical parameter must be controlled to significantly minimize or prevent a hazard requiring a process control.

(2) Sanitation controls. Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling. Sanitation controls must include, as appropriate to the facility and the animal food, procedures, practices, and processes for the:

(i) Cleanliness of animal food-contact surfaces, including animal food-contact surfaces of utensils and equipment; and

(ii) Prevention of cross-contamination from insanitary objects and from personnel to animal food, animal food-contact surfaces and from raw product to processed product.

(3) Supply-chain controls. Supply-chain controls include the supply-chain program as required by subpart E of this part;

(4) A recall plan as required by §507.38; and

(5) Other preventive controls. These include any other procedures, practices, and processes necessary to satisfy the requirements of paragraph (a) of this section. Examples of other controls include hygiene training and other current good manufacturing practices.

§ 507.36 Circumstances in which the owner, operator, or agent in charge of a manufacturing/processing facility is not required to implement a preventive control.

(a) If you are a manufacturer/processor, you are not required to implement a preventive control when you identify a hazard requiring a preventive control (identified hazard) and any of the following circumstances apply:

(1) You determine and document that the type of animal food could not be consumed without application of an appropriate control;

(2) You rely on your customer who is subject to the requirements for hazard analysis and risk-based preventive controls in this subpart to ensure that the identified hazard will be significantly minimized or prevented; and you:

(i) Disclose in documents accompanying the animal food, in accordance with the practice of the trade, that the animal food is “not processed to control [identified hazard]”; and

(ii) Annually obtain from your customer written assurance, subject to the requirements of §507.37, that the customer has established and is following procedures (identified in the written assurance) that will significantly minimize or prevent the identified hazard (except as provided in paragraph (c) of this section);
§ 507.36  21 CFR Ch. I (4–1–16 Edition)

(3) You rely on your customer who is not subject to the requirements for hazard analysis and risk-based preventive controls in this subpart to provide assurance it is manufacturing, processing, or preparing the animal food in accordance with applicable animal food safety requirements and you:

(i) Disclose in documents accompanying the animal food, in accordance with the practice of the trade, that the animal food is “not processed to control [identified hazard]”; and

(ii) Annually obtain from your customer written assurance that it is manufacturing, processing, or preparing the animal food in accordance with applicable animal food safety requirements;

(4) You rely on your customer to provide assurance that the animal food will be processed to control the identified hazard by an entity in the distribution chain subsequent to the customer and you:

(i) Disclose in documents accompanying the animal food, in accordance with the practice of the trade, that the animal food is “not processed to control [identified hazard]”; and

(ii) Annually obtain from your customer written assurance, subject to the requirements of § 507.37, that your customer:

(A) Will disclose in documents accompanying the animal food, in accordance with the practice of the trade, that the animal food is “not processed to control [identified hazard]”; and

(B) Will only sell to another entity that agrees, in writing, it will:

(1) Follow procedures (identified in a written assurance) that will significantly minimize or prevent the identified hazard (if the entity is subject to the requirements for hazard analysis and risk-based preventive controls in subpart C of this part), except as provided in paragraph (d) of this section, or manufacture, process, or prepare the animal food in accordance with applicable animal food safety requirements (if the entity is not subject to the requirements for hazard analysis and risk-based preventive controls in subpart C of this part); or

(2) Obtain a similar written assurance from the entity’s customer, subject to the requirements of § 507.37, as in paragraphs (a)(4)(ii)(A) and (B) of this section, as appropriate; or

(5) You have established, documented, and implemented a system that ensures control, at a subsequent distribution step, of the hazards in the animal food you distribute and you document the implementation of that system.

(b) You must document any circumstance specified in paragraph (a) of this section that applies to you, including:

(1) A determination in accordance with paragraph (a) of this section that the type of animal food could not be consumed without application of an appropriate control;

(2) The annual written assurance from your customer in accordance with paragraph (a)(2) of this section;

(3) The annual written assurance from your customer in accordance with paragraph (a)(3) of this section;

(4) The annual written assurance from your customer in accordance with paragraph (a)(4) of this section; and

(5) Your system, in accordance with paragraph (a)(5) of this section, that ensures control, at a subsequent distribution step, of the hazards in the animal food you distribute.

(c) For the written assurance required by paragraph (a)(2)(ii) of this section, if your customer has determined that the identified hazard in paragraph (a) of this section is not a hazard in the animal food intended for use for a specific animal species, your customer’s written assurance may provide this determination (including animal species and why the identified hazard is not a hazard) instead of providing assurance of procedures established and followed that will significantly minimize or prevent the identified hazard.

(d) For the written assurance required by paragraph (a)(4)(ii)(B) of this section, if the entity in the distribution chain subsequent to your customer is subject to subpart C of this part and has determined that the identified hazard in paragraph (a) of this section is not a hazard in the animal food intended for use for a specific animal species, that entity’s written assurance may provide this determination (including animal species and why
the identified hazard is not a hazard
instead of providing assurance that the
identified hazard will be significantly
minimized or prevented.
[80 FR 56337, Sept. 17, 2015, as amended at 81
FR 3717, Jan. 22, 2016]

§ 507.37 Provision of assurances re-
quired under § 507.36(a)(2), (3), and
(4).
A facility that provides a written as-
surance under § 507.36(a)(2), (3), or (4)
must act consistently with the assur-
ance and document its actions taken to
satisfy the written assurance.

§ 507.38 Recall plan.
(a) For animal food with a hazard re-
quiring a preventive control you must:
(1) Establish a written recall plan for
the animal food; and
(2) Assign responsibility for per-
forming all procedures in the recall
plan.
(b) The written recall plan must in-
clude procedures that describe the
steps to perform the following actions
as appropriate to the facility:
(1) Directly notify direct consignees
about the animal food being recalled,
including how to return or dispose of
the affected animal food;
(2) Notify the public about any haz-
ard presented by the animal food when
appropriate to protect human and ani-
mal health;
(3) Conduct effectiveness checks to
verify the recall has been carried out; and
(4) Appropriately dispose of recalled
animal food, e.g., through reprocessing,
reworking, diverting to another use
that would not present a safety con-
cern, or destroying the animal food.

§ 507.39 Preventive control manage-
ment components.
(a) Except as provided by paragraphs
(b) and (c) of this section, the preven-
tive controls required under § 507.34 are
subject to the following preventive
control management components as
appropriate to ensure the effectiveness
of the preventive controls, taking into
account the nature of the preventive
control and its role in the facility’s
food safety system:
(1) Monitoring in accordance with
§ 507.40;
(2) Corrective actions and corrections
in accordance with § 507.42; and
(3) Verification in accordance with
§ 507.45.
(b) The supply-chain program estab-
lished in subpart E of this part is sub-
ject to the following preventive control
management components as appro-
priate to ensure the effectiveness of the
supply-chain program, taking into ac-
count the nature of the hazard con-
trolled before receipt of the raw mate-
rial or other ingredient:
(1) Corrective actions and corrections
in accordance with § 507.42, taking into
account the nature of any supplier non-
conformance;
(2) Review of records in accordance
with § 507.49(a)(4)(ii); and
(3) Reanalysis in accordance with
§ 507.50.
(c) The recall plan established in
§ 507.38 is not subject to the require-
ments of paragraph (a) of this section.

§ 507.40 Monitoring.
As appropriate to the nature of the
preventive control and its role in the
facility’s food safety system you must:
(a) Establish and implement written
procedures, including the frequency
with which they are to be performed,
and
(1) Notify the public about any haz-
ard presented by the animal food when
appropriate to protect human and ani-
mal health;
(2) Conduct effectiveness checks to
verify the recall has been carried out; and
and
(2)(i) Records of refrigeration tem-
perature during storage of animal food
that requires time/temperature control
to significantly minimize or prevent
the growth of, or toxin production by,
pathogens may be affirmative records
demonstrating temperature is con-
trolled or exception records dem-
onstrating loss of temperature control;
and
(ii) Exception records may be ade-
quate in circumstances other than moni-
toring of refrigeration tempera-
ture.
§ 507.42 Corrective actions and corrections.

(a) As appropriate to the nature of the hazard and the nature of the preventive control, except as provided by paragraph (c) of this section:

(1) You must establish and implement written corrective action procedures that must be taken if preventive controls are not properly implemented, including procedures to address, as appropriate:

(i) The presence of a pathogen or appropriate indicator organism in animal food detected as a result of product testing conducted in accordance with § 507.49(a)(2); and

(ii) The presence of an environmental pathogen or appropriate indicator organism detected through the environmental monitoring conducted in accordance with § 507.49(a)(3).

(2) The corrective action procedures must describe the steps to be taken to ensure that:

(i) Appropriate action is taken to identify and correct a problem that has occurred with implementation of a preventive control;

(ii) Appropriate action is taken when necessary, to reduce the likelihood that the problem will recur;

(iii) All affected animal food is evaluated for safety; and

(iv) All affected animal food is prevented from entering into commerce if you cannot ensure the affected animal food is not adulterated under section 402 of the Federal Food, Drug, and Cosmetic Act.

(b)(1) Except as provided by paragraph (c) of this section, you are subject to the requirements of paragraph (b)(2) of this section if any of the following circumstances apply:

(i) A preventive control is not properly implemented and a corrective action procedure has not been established;

(ii) A preventive control, combination of preventive controls, or the food safety plan as a whole is found to be ineffective; or

(iii) A review of records in accordance with § 507.49(a)(4) finds that the records are not complete, the activities conducted did not occur in accordance with the food safety plan, or appropriate decisions were not made about corrective actions.

(2) If any of the circumstances listed in paragraph (b)(1) of this section apply, you must:

(i) Take corrective action to identify and correct the problem;

(ii) Reduce the likelihood that the problem will recur;

(iii) Evaluate all affected animal food for safety;

(iv) As necessary, prevent affected animal food from entering commerce as would be done following the corrective action procedure under paragraph (a)(2) of this section; and

(v) When appropriate, reanalyze the food safety plan in accordance with § 507.50 to determine whether modification of the food safety plan is required.

(c) You do not need to comply with the requirements of paragraphs (a) and (b) of this section if:

(1) You take action, in a timely manner, to identify and correct conditions and practices that are not consistent with the sanitation controls in § 507.34(c)(2)(i) or (ii); or

(2) You take action, in a timely manner, to identify and correct a minor and isolated problem that does not directly impact product safety.

(d) All corrective actions (and, when appropriate, corrections) taken in accordance with this section must be documented in records. These records are subject to verification in accordance with § 507.45(a)(4)(1).

§ 507.45 Verification.

(a) Verification activities must include, as appropriate to the nature of the preventive control and its role in the facility's food safety system:

(1) Validation in accordance with § 507.47;

(2) Verification that monitoring is being conducted as required by § 507.39 (and in accordance with § 507.40);

(3) Verification that appropriate decisions about corrective actions are being made as required by § 507.39 (and in accordance with § 507.42);

(4) Verification of implementation and effectiveness in accordance with § 507.48; and

(5) Reanalysis in accordance with § 507.50.
Food and Drug Administration, HHS

§ 507.47 Validation.

(a) You must validate that the preventive controls identified and implemented in accordance with §507.34 are adequate to control the hazard as appropriate to the nature of the preventive control and its role in the facility’s food safety system.

(b) The validation of the preventive controls:

(1) Must be performed (or overseen) by a preventive controls qualified individual:

(i) Prior to implementation of the food safety plan; or

(ii) When necessary to demonstrate the control measures can be implemented as designed:

(I) Within 90 calendar days after production of the applicable animal food first begins; or

(II) Within a reasonable timeframe, provided that the preventive controls qualified individual prepares (or oversees the preparation of) a written justification for a timeframe that exceeds 90 calendar days after production of the applicable animal food first begins;

(II) Whenever a change to a control measure or combination of control measures could impact whether the control measure or combination of control measures, when properly implemented, will effectively control the hazards; and

(iii) Whenever a reanalysis of the food safety plan reveals the need to do so.

2. Must include obtaining and evaluating scientific and technical evidence (or, when such evidence is not available or is inadequate, conducting studies) to determine whether the preventive controls, when properly implemented, will effectively control the hazards.

(c) You do not need to validate:

(1) The sanitation controls in §507.34(c)(2);

(2) The recall plan in §507.38;

(3) The supply-chain program in subpart E of this part; and

(4) Other preventive controls, if the preventive controls qualified individual prepares (or oversees the preparation of) a written justification that validation is not applicable based on factors such as the nature of the hazard, and the nature of the preventive control and its role in the facility’s food safety system.

[80 FR 56337, Sept. 17, 2015, as amended at 81 FR 3718, Jan. 22, 2016]

§ 507.49 Verification of implementation and effectiveness.

(a) You must verify that the preventive controls are consistently implemented and are effectively and significantly minimizing or preventing the hazards. To do so, you must conduct activities that include the following, as appropriate to the facility, the animal food, and the nature of the preventive control and its role in the facility’s food safety system:

1. Calibration of process monitoring and verification instruments (or checking them for accuracy);

2. Product testing for a pathogen (or appropriate indicator organism) or other hazard;

3. Environmental monitoring, for an environmental pathogen or for an appropriate indicator organism, if contamination of an animal food with an environmental pathogen is a hazard requiring a preventive control, by collecting and testing environmental samples; and

4. Review of the following records within the specified timeframes, by (or under the oversight of) a preventive controls qualified individual, to ensure the records are complete, the activities reflected in the records occurred in accordance with the food safety plan, the preventive controls are effective, and appropriate decisions were made about corrective actions:

(i) Monitoring and corrective action records within 7-working days after the records are created or within a reasonable timeframe, provided that the preventive controls qualified individual prepares (or oversees the preparation of) a written justification for a timeframe that exceeds 7-working days; and

(ii) Records of calibration, testing (e.g., product testing, environmental monitoring), and supplier and supply-chain verification activities, and other verification activities within a reasonable time after the records are created; and
§ 507.50

(5) Other activities appropriate for verification of implementation and effectiveness.

(b) As appropriate to the facility, the food, the nature of the preventive control, and the role of the preventive control in the facility’s food safety system, you must establish and implement written procedures for the following activities:

(1) The method and frequency of calibrating process monitoring instruments and verification instruments (or checking them for accuracy) as required by paragraph (a)(1) of this section;

(2) Product testing as required by paragraph (a)(2) of this section. Procedures for product testing must:

(i) Be scientifically valid;

(ii) Identify the test microorganism(s) or other analyte(s);

(iii) Specify the procedures for identifying samples, including their relationship to specific lots of product;

(iv) Include the procedures for sampling, including the number of samples and the sampling frequency;

(v) Identify the test(s) conducted, including the analytical method(s) used;

(vi) Identify the laboratory conducting the testing; and

(vii) Include the corrective action procedures required by §507.42(a)(1)(i).

§ 507.50 Reanalysis.

(a) You must conduct a reanalysis of the food safety plan as a whole at least once every 3 years.

(b) You must conduct a reanalysis of the food safety plan as a whole, or the applicable portion of the food safety plan:

(1) Whenever a significant change in the activities conducted at your facility creates a reasonable potential for a new hazard or creates a significant increase in a previously identified hazard;

(2) Whenever you become aware of new information about potential hazards associated with the animal food;

(3) Whenever appropriate after an unanticipated animal food safety problem in accordance with §507.42(b); and

(4) Whenever you find that a preventive control, combination of preventive controls, or the food safety plan as a whole is ineffective.

(c) You must complete the reanalysis required by paragraphs (a) and (b) of this section and validate, as appropriate to the nature of the preventive control and its role in the facility’s food safety system, any additional preventive controls needed to address the hazard identified:

(1) Before any change in activities (including any change in preventive control) at the facility is operative; or

(2) When necessary to demonstrate the control measures can be implemented as designed:

(i) Within 90 calendar days after production of the applicable animal food first begins; or

(ii) Within a reasonable timeframe, provided that the preventive controls qualified individual prepares (or oversees the preparation of) a written justification for a timeframe that exceeds 90 calendar days after production of the applicable animal food first begins.

(d) You must revise the written food safety plan if a significant change in the activities conducted at your facility creates a reasonable potential for a new hazard or a significant increase in a previously identified hazard, or document the basis for the conclusion that no revisions are needed.
§ 507.53 Requirements applicable to a preventive controls qualified individual and a qualified auditor.

(a) One or more preventive controls qualified individuals must do or oversee the following:

(1) Preparation of the food safety plan (§507.31(b));

(2) Validation of the preventive controls (§507.47(b)(1));

(3) Written justification for validation to be performed in a timeframe that exceeds the first 90 calendar days of production of the applicable animal food;

(4) Determination that validation is not required (§507.47(c)(4));

(5) Review of records (§507.49(a)(4));

(6) Written justification for review of records of monitoring and corrective actions within a timeframe that exceeds 7-working days;

(7) Reanalysis of the food safety plan (§507.50(d)); and

(8) Determination that reanalysis can be completed, and additional preventive controls validated, as appropriate.
to the nature of the preventive control and its role in the facility’s food safety system, in a timeframe that exceeds the first 90 calendar days of production of the applicable animal food.

(b) A qualified auditor must conduct an onsite audit (§507.135(a)).

(c)(1) To be a preventive controls qualified individual, the individual must have successfully completed training in the development and application of risk-based preventive controls at least equivalent to that received under a standardized curriculum recognized as adequate by FDA or be otherwise qualified through job experience to develop and apply a food safety system. Job experience may qualify an individual to perform these functions if such experience has provided an individual with knowledge at least equivalent to that provided through the standardized curriculum. This individual may be, but is not required to be, an employee of the facility; and

(2) To be a qualified auditor, a qualified individual must have technical expertise obtained through education, training, or experience (or a combination thereof) necessary to perform the auditing function.

(d) All applicable training in the development and application of risk-based preventive controls must be documented in records, including the date of the training, the type of training, and the person(s) trained.

§507.55 Implementation records required for this subpart.

(a) You must establish and maintain the following records documenting implementation of the food safety plan:

(1) Documentation, as required by §507.36(b), of the basis for not establishing a preventive control in accordance with §507.36(a);

(2) Records that document the monitoring of preventive controls;

(3) Records that document corrective actions;

(4) Records that document verification, including, as applicable, those related to:

(i) Validation;

(ii) Verification of monitoring;

(iii) Verification of corrective actions;

(iv) Calibration of process monitoring and verification instruments;

(v) Product testing;

(vi) Environmental monitoring;

(vii) Records review; and

(viii) Reanalysis;

(5) Records that document the supply-chain program; and

(6) Records that document applicable training for the preventive controls qualified individual and the qualified auditor.

(b) The records that you must establish and maintain are subject to the requirements of subpart F of this part.

Subpart D—Withdrawal of a Qualified Facility Exemption

§507.60 Circumstances that may lead FDA to withdraw a qualified facility exemption.

(a) FDA may withdraw a qualified facility exemption under §507.5(d):

(1) In the event of an active investigation of a foodborne illness outbreak that is directly linked to the qualified facility; or

(2) If FDA determines that it is necessary to protect the public (human or animal) health and prevent or mitigate a foodborne illness outbreak based on conditions or conduct associated with the qualified facility that are material to the safety of the animal food manufactured, processed, packed, or held at such facility.

(b) Before FDA issues an order to withdraw a qualified facility exemption, FDA:

(1) May consider one or more other actions to protect the public (human or animal) health or mitigate a foodborne illness outbreak, including, a warning letter, recall, administrative detention, suspension of registration, refusal of animal food offered for import, seizure, and injunction;

(2) Must notify the owner, operator, or agent in charge of the facility, in writing of circumstances that may lead FDA to withdraw the exemption, and provide an opportunity for the owner, operator, or agent in charge of the facility to respond in writing, within 15 calendar days of the date of receipt of the notification, to FDA’s notification; and
(3) Must consider the actions taken by the facility to address the circumstances that may lead FDA to withdraw the exemption.

§ 507.62 Issuance of an order to withdraw a qualified facility exemption.

(a) An FDA District Director in whose district the qualified facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine), or an FDA official senior to either such Director, must approve an order to withdraw the exemption before the order is issued.

(b) Any officer or qualified employee of FDA may issue an order to withdraw the exemption after it has been approved in accordance with paragraph (a) of this section.

(c) FDA must issue an order to withdraw the exemption to the owner, operator, or agent in charge of the facility.

(d) FDA must issue an order to withdraw the exemption in writing, signed and dated by the officer or qualified employee of FDA who is issuing the order.

§ 507.65 Contents of an order to withdraw a qualified facility exemption.

An order to withdraw a qualified facility exemption under § 507.5(d) must include the following information:

(a) The date of the order;

(b) The name, address, and location of the qualified facility;

(c) A brief, general statement of the reasons for the order, including information relevant to one or both of the following circumstances that leads FDA to issue the order:

(1) An active investigation of a foodborne illness outbreak that is directly linked to the facility; or

(2) Conditions or conduct associated with a qualified facility that are material to the safety of the animal food manufactured, processed, packed, or held at such facility.

(d) A statement that the facility must either:

(1) Comply with subparts C and E of this part on the date that is 120 calendar days from the date of receipt of the order or within a reasonable timeframe, agreed to by FDA, based on a written justification, submitted to FDA, for a timeframe that exceeds 120 calendar days from the date of receipt of the order; or

(2) Appeal the order within 15 calendar days of the date of receipt of the order in accordance with the requirements of § 507.69.

(e) A statement that a facility may request that FDA reinstate an exemption that was withdrawn by following the procedures in § 507.85;

(f) The text of section 418(l) of the Federal Food, Drug, and Cosmetic Act and of this subpart;

(g) A statement that any informal hearing on an appeal of the order must be conducted as a regulatory hearing under part 16 of this chapter, with certain exceptions described in § 507.73;

(h) The mailing address, telephone number, email address, and facsimile number of the FDA district office and the name of the FDA District Director in whose district the facility is located (or, in the case of a foreign facility, the same information for the Director of the Division of Compliance in the Center for Veterinary Medicine); and

(i) The name and the title of the FDA representative who approved the order.

§ 507.67 Compliance with, or appeal of, an order to withdraw a qualified facility exemption.

(a) If you receive an order under § 507.65 to withdraw a qualified facility exemption, you must either:

(1) Comply with applicable requirements of this part within 120 calendar days of the date of receipt of the order, or within a reasonable timeframe, agreed to by FDA, based on a written justification, submitted to FDA, for a timeframe that exceeds 120 calendar days from the date of receipt of the order; or

(2) Appeal the order within 15 calendar days of the date of receipt of the order in accordance with the requirements of § 507.69.

(b) Submission of an appeal, including submission of a request for an informal hearing, will not operate to delay or stay any administrative action, including enforcement action by FDA, unless the Commissioner of Food and Drugs, as a matter of discretion,
§ 507.69 Procedure for submitting an appeal.

(a) To appeal an order to withdraw a qualified facility exemption, you must:
(1) Submit the appeal in writing to the FDA District Director in whose district the facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine), at the mailing address, email address, or facsimile number identified in the order within 15 calendar days of the date of receipt of confirmation of the order; and
(2) Respond with particularity to the facts and issues contained in the order, including any supporting documentation upon which you rely.

(b) In a written appeal of the order withdrawing an exemption provided under §507.62 and 507.65, rather than the notice under §16.22(a) of this chapter, provides notice of opportunity for a hearing under this section and is part of the administrative record of the regulatory hearing under §16.80(a) of this chapter.

(c) If you appeal the order, and FDA confirms the order:
(1) You must comply with applicable requirements of this part within 120 calendar days of the date of receipt of the order, or within a reasonable timeframe, agreed to by FDA, based on a written justification, submitted to FDA, for a timeframe that exceeds 120 calendar days from the date of receipt of the order; and
(2) You are no longer subject to the requirements in §507.7.

§ 507.71 Procedure for requesting an informal hearing.

(a) If you appeal the order, you:
(1) May request an informal hearing; and
(2) Must submit any request for an informal hearing together with your written appeal submitted in accordance with §507.69 within 15 calendar days of the date of receipt of the order.

(b) A request for an informal hearing may be denied, in whole or in part, if the presiding officer determines that no genuine and substantial issue of material fact has been raised by the material submitted. If the presiding officer determines that a hearing is not justified, written notice of the determination will be given to you explaining the reason for the denial.

§ 507.73 Requirements applicable to an informal hearing.

If you request an informal hearing, and FDA grants the request:

(a) The hearing will be held within 15 calendar days after the date the appeal is filed or, if applicable, within a timeframe agreed upon in writing by you and FDA.

(b) The presiding officer may require that a hearing conducted under this subpart be completed within 1 calendar day, as appropriate.

(c) FDA must conduct the hearing in accordance with part 16 of this chapter, except that:
(1) The order withdrawing an exemption under §§507.62 and 507.65, rather than the notice under §16.22(a) of this chapter, provides notice of opportunity for a hearing under this section and is part of the administrative record of the regulatory hearing under §16.80(a) of this chapter.

(2) A request for a hearing under this subpart must be addressed to the FDA District Director (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine) as provided in the order withdrawing an exemption.

(3) Section 507.75, rather than §16.42(a) of this chapter, describes the FDA employees who preside at hearings under this subpart.

(4) Section 16.60(e) and (f) of this chapter does not apply to a hearing under this subpart. The presiding officer must prepare a written report of the hearing. All written material presented at the hearing will be attached to the report. The presiding officer must include as part of the report of the hearing a finding on the credibility of witnesses (other than expert witnesses) whenever credibility is a material issue, and must include a proposed decision, with a statement of reasons. The hearing participant may review and comment on the presiding officer’s report within 2 calendar days of issuance of the report. The presiding officer will then issue the final decision.
Food and Drug Administration, HHS  § 507.85

(5) Section 16.80(a)(4) of this chapter does not apply to a regulatory hearing under this subpart. The presiding officer’s report of the hearing and any comments on the report by the hearing participant under paragraph (c)(4) of this section are part of the administrative record.

(6) No party shall have the right, under §16.119 of this chapter to petition the Commissioner of Food and Drugs for reconsideration or a stay of the presiding officer’s final decision.

(7) If FDA grants a request for an informal hearing on an appeal of an order withdrawing an exemption, the hearing must be conducted as a regulatory hearing under a regulation in accordance with part 16 of this chapter, except that §16.95(b) does not apply to a hearing under this subpart. With respect to a regulatory hearing under this subpart, the administrative record of the hearing specified in §§16.80(a)(1) through (3), and (a)(5), of this chapter, and 507.73(c)(5) constitutes the exclusive record for the presiding officer’s final decision. For purposes of judicial review under §10.45 of this chapter, the record of the administrative proceeding consists of the record of the hearing and the presiding officer’s final decision.

§ 507.75 Presiding officer for an appeal and for an informal hearing.

The presiding officer for an appeal, and for an informal hearing, must be an FDA Regional Food and Drug Director or another FDA official senior to an FDA District Director.

§ 507.77 Timeframe for issuing a decision on an appeal.

(a) If you appeal the order without requesting a hearing, the presiding officer must issue a written report that includes a final decision confirming or revoking the withdrawal by the 10th calendar day after the appeal is filed.

(b) If you appeal the order and request an informal hearing:

(1) If FDA grants the request for a hearing and the hearing is held, the presiding officer must provide a 2 calendar day opportunity for the hearing participants to review and submit comments on the report of the hearing under §507.73(c)(4), and must issue a final decision within 10 calendar days after the hearing is held; or

(2) If FDA denies the request for a hearing, the presiding officer must issue a final decision on the appeal confirming or revoking the withdrawal within 10 calendar days after the date the appeal is filed.

§ 507.80 Revocation of an order to withdraw a qualified facility exemption.

An order to withdraw a qualified facility exemption is revoked if:

(a) You appeal the order and request an informal hearing, FDA grants the request for an informal hearing, and the presiding officer does not confirm the order within the 10 calendar days after the hearing, or issues a decision revoking the order within that time; or

(b) You appeal the order and request an informal hearing, FDA denies the request for an informal hearing, and FDA does not confirm the order within the 10 calendar days after the appeal is filed, or issues a decision revoking the order within that time; or

(c) You appeal the order without requesting an informal hearing, and FDA does not confirm the order within the 10 calendar days after the appeal is filed, or issues a decision revoking the order within that time.

§ 507.83 Final agency action.

Confirmation of a withdrawal order by the presiding officer is considered a final agency action for purposes of 5 U.S.C. 702.

§ 507.85 Reinstatement of a qualified facility exemption that was withdrawn.

(a) If the FDA District Director in whose district your facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine) determines that a facility has adequately resolved any problems with the conditions and conduct that are material to the safety of the animal food manufactured, processed, packed, or held at the facility and that continued withdrawal of the exemption is not necessary to protect public (human and animal) health and prevent or mitigate a foodborne illness outbreak, the FDA
§ 507.105 Requirement to establish and implement a supply-chain program.

(a)(1) Except as provided by paragraphs (a)(2) and (3) of this section, the receiving facility must establish and implement a risk-based supply-chain program for those raw materials and other ingredients for which the receiving facility has identified a hazard requiring a supply-chain-applied control.

(b) A receiving facility that is an importer, is in compliance with the foreign supplier verification requirements under part 1, subpart L of this chapter, and has documentation of verification activities conducted under §1.506(e) of this chapter (which provides assurance that the hazards requiring a supply-chain-applied control for the raw material or other ingredient have been significantly minimized or prevented) need not conduct supplier verification activities for that raw material or other ingredient.

(c) If your exemption was withdrawn under §507.60(a)(1) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will reinstate your exemption under §507.5(d), and FDA will notify you in writing that your exempt status has been reinstated.

(d) If your exemption was withdrawn under both §507.60(a)(1) and (2) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will inform you of this finding and you may ask FDA to reinstate your exemption under §507.5(d) in accordance with the requirements of paragraph (b) of this section.

Subpart E—Supply-Chain Program

§ 507.105 Requirement to establish and implement a supply-chain program.

(a)(1) Except as provided by paragraphs (a)(2) and (3) of this section, the receiving facility must establish and implement a risk-based supply-chain program for those raw materials and other ingredients for which the receiving facility has identified a hazard requiring a supply-chain-applied control.

(b) You may ask FDA to reinstate an exemption that has been withdrawn under the procedures of this subpart as follows:

(1) Submit a request, in writing, to the FDA District Director in whose district your facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine); and

(2) Present data and information to demonstrate that you have adequately resolved any problems with the conditions and conduct that are material to the safety of the animal food manufactured, processed, packed, or held at your facility, such that continued withdrawal of the exemption is not necessary to protect public (human and animal) health and prevent or mitigate a foodborne illness outbreak.

(c) If your exemption was withdrawn under §507.60(a)(1) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will reinstate your exemption under §507.5(d), and FDA will notify you in writing that your exempt status has been reinstated.

(d) If your exemption was withdrawn under both §507.60(a)(1) and (2) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will inform you of this finding and you may ask FDA to reinstate your exemption under §507.5(d) in accordance with the requirements of paragraph (b) of this section.

Subpart E—Supply-Chain Program

§ 507.105 Requirement to establish and implement a supply-chain program.

(a)(1) Except as provided by paragraphs (a)(2) and (3) of this section, the receiving facility must establish and implement a risk-based supply-chain program for those raw materials and other ingredients for which the receiving facility has identified a hazard requiring a supply-chain-applied control.

(b) You may ask FDA to reinstate an exemption that has been withdrawn under the procedures of this subpart as follows:

(1) Submit a request, in writing, to the FDA District Director in whose district your facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine); and

(2) Present data and information to demonstrate that you have adequately resolved any problems with the conditions and conduct that are material to the safety of the animal food manufactured, processed, packed, or held at your facility, such that continued withdrawal of the exemption is not necessary to protect public (human and animal) health and prevent or mitigate a foodborne illness outbreak.

(c) If your exemption was withdrawn under §507.60(a)(1) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will reinstate your exemption under §507.5(d), and FDA will notify you in writing that your exempt status has been reinstated.

(d) If your exemption was withdrawn under both §507.60(a)(1) and (2) and FDA later determines, after finishing the active investigation of a foodborne illness outbreak, that the outbreak is not directly linked to your facility, FDA will inform you of this finding and you may ask FDA to reinstate your exemption under §507.5(d) in accordance with the requirements of paragraph (b) of this section.
§ 507.110 General requirements applicable to a supply-chain program.

(a) The supply-chain program must include:

(1) Using approved suppliers as required by §507.120;

(2) Determining appropriate supplier verification activities (including determining the frequency of conducting the activity) as required by §507.125;

(3) Conducting supplier verification activities as required by §§507.130 and 507.135;

(4) Documenting supplier verification activities as required by §507.175; and

(5) When applicable, verifying a supply-chain-applied control applied by an entity other than the receiving facility’s supplier and documenting that verification as required by §507.175, or obtaining documentation of an appropriate verification activity from another entity, reviewing and assessing that documentation, and documenting the review and assessment as required by §507.175.

(b) The following are appropriate supplier verification activities for raw materials and other ingredients:

(1) Onsite audits;

(2) Sampling and testing of the raw material or other ingredient;

(3) Review of the supplier’s relevant food safety records; and

(4) Other appropriate supplier verification activities based on supplier performance and the risk associated with the raw material or other ingredient.

(c) The supply-chain program must provide assurance that a hazard requiring a supply-chain-applied control has been significantly minimized or prevented.

(d)(1) Except as provided by paragraph (d)(2) of this section, in approving suppliers and determining the appropriate supplier verification activities and the frequency with which they are conducted, the following must be considered:

(i) The hazard analysis of the animal food, including the nature of the hazard controlled before receipt of the raw material or other ingredient, applicable to the raw material and other ingredients;

(ii) The entity or entities that will be applying controls for the hazards requiring a supply-chain-applied control;

(iii) Supplier performance, including:

(A) The supplier’s procedures, processes, and practices related to the safety of the raw material and other ingredients;

(B) Applicable FDA food safety regulations and information relevant to the supplier’s compliance with those regulations, including an FDA warning letter or import alert relating to the safety of animal food and other FDA compliance actions related to animal food safety (or, when applicable, relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States, and information relevant to the supplier’s compliance with those laws and regulations); and

(C) The supplier’s food safety history relevant to the raw materials or other ingredients that the receiving facility receives from the supplier, including available information about results from testing raw materials or other ingredients for hazards, audit results relating to the safety of the animal food, and responsiveness of the supplier in correcting problems; and

(iv) Any other factors as appropriate and necessary, such as storage and transportation practices.

(2) Considering supplier performance can be limited to the supplier’s compliance history as required by paragraph (d)(1)(iii)(B) of this section, if the supplier is:

(i) A qualified facility as defined by §507.3;

(ii) A farm that grows produce and is not a covered farm under part 112 of this chapter in accordance with §112.4(a), or in accordance with §§112.4(b) and 112.5; or

(iii) A shell egg producer that is not subject to the requirements of part 118 of this chapter because it has less than 3,000 laying hens.

(e) If the owner, operator, or agent in charge of a receiving facility determines through auditing, verification testing, document review, relevant consumer, customer, or other complaints, or otherwise that the supplier
§ 507.115 Responsibilities of the receiving facility.

(a)(1) The receiving facility must approve suppliers.
(2) Except as provided by paragraphs (a)(3) and (4) of this section, the receiving facility must determine and conduct appropriate supplier verification activities, and satisfy all documentation requirements of this subpart.
(3) An entity other than the receiving facility may do any of the following, provided that the receiving facility reviews and assesses the entity’s applicable documentation, and documents that review and assessment:
   (i) Establish written procedures for receiving raw materials and other ingredients by the entity;
   (ii) Document that written procedures for receiving raw materials and other ingredients are being followed by the entity; and
   (iii) Determine, conduct, or both determine and conduct, the appropriate supplier verification activities, with appropriate documentation.
(4) The supplier may conduct and document sampling and testing of raw materials and other ingredients, for the hazard controlled by the supplier, as a supplier verification activity for a particular lot of product and provide such documentation to the receiving facility, provided that the receiving facility reviews and assesses that documentation, and documents that review and assessment.
(b) For the purposes of this subpart, a receiving facility may not accept any of the following as a supplier verification activity:
   (1) A determination by its supplier of the appropriate supplier verification activities for that supplier;
   (2) An audit conducted by its supplier;
   (3) A review by its supplier of that supplier’s own relevant food safety records; or
   (4) The conduct by its supplier of other appropriate supplier verification activities for that supplier within the meaning of §507.110(b)(4).
(c) The requirements of this section do not prohibit a receiving facility from relying on an audit provided by its supplier when the audit of the supplier was conducted by a third-party qualified auditor in accordance with §§507.130(f) and 507.135.

§ 507.120 Using approved suppliers.

(a) The receiving facility must approve suppliers in accordance with the requirements of §507.110(d), and document that approval, before receiving raw materials and other ingredients received from those suppliers;
(b)(1) Written procedures for receiving raw materials and other ingredients must be established and followed;
   (2) The written procedures for receiving raw materials and other ingredients must ensure that raw materials and other ingredients are received only from approved suppliers (or, when necessary and appropriate, on a temporary basis from unapproved suppliers whose raw materials or other ingredients are subjected to adequate verification activities before acceptance for use); and
   (3) Use of the written procedures for receiving raw materials and other ingredients must be documented.

§ 507.125 Determining appropriate supplier verification activities (including determining the frequency of conducting the activity).

Appropriate supplier verification activities (including the frequency of conducting the activity) must be determined in accordance with the requirements of §507.110(d).

§ 507.130 Conducting supplier verification activities for raw materials and other ingredients.

(a) Except as provided by paragraphs (c), (d), or (e) of this section, one or more of the supplier verification activities specified in §507.110(b), as determined under §507.110(d), must be
conducted for each supplier before using the raw material or other ingredient from that supplier and periodically thereafter.

(b)(1) Except as provided by paragraph (b)(2) of this section, when a hazard in a raw material or other ingredient will be controlled by the supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals:

(i) The appropriate supplier verification activity is an onsite audit of the supplier; and

(ii) The audit must be conducted before using the raw material or other ingredient from the supplier and at least annually thereafter.

(2) The requirements of paragraph (b)(1) of this section do not apply if there is a written determination that other verification activities and/or less frequent onsite auditing of the supplier provide adequate assurance that the hazards are controlled.

(c) If a supplier is a qualified facility as defined by § 507.3, the receiving facility does not need to comply with paragraphs (a) and (b) of this section if the receiving facility:

(1) Obtains written assurance that the supplier is a qualified facility as defined by § 507.3:

(i) Before first approving the supplier for an applicable calendar year; and

(ii) On an annual basis thereafter, by December 31 of each calendar year, for the following calendar year; and

(2) Obtains written assurance, at least every 2 years, that the supplier is producing the raw material or other ingredient in compliance with applicable FDA food safety regulations (or, when applicable, relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States).

(d) If a supplier is a farm that grows produce and is not a covered farm under part 112 of this chapter in accordance with §112.4(a), or in accordance with §§112.4(b) and 112.5, the receiving facility does not need to comply with paragraphs (a) and (b) of this section for produce that the receiving facility receives from the farm as a raw material or other ingredient if the receiving facility:

(1) Obtains written assurance that the raw material or other ingredient provided by the supplier is not subject to part 112 of this chapter in accordance with §112.4(a), or in accordance with §§112.4(b) and 112.5:

(i) Before first approving the supplier for an applicable calendar year; and

(ii) On an annual basis thereafter, by December 31 of each calendar year, for the following calendar year; and

(2) Obtains written assurance, at least every 2 years, that the farm acknowledges that its food is subject to section 402 of the Federal Food, Drug, and Cosmetic Act (or, when applicable, that its food is subject to relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States).

(e) If a supplier is a shell egg producer that is not subject to the requirements of part 118 of this chapter because it has less than 3,000 laying hens, the receiving facility does not need to comply with paragraphs (a) and (b) of this section if the receiving facility:

(1) Obtains written assurance that the shell eggs produced by the supplier are not subject to part 118 because the shell egg producer has less than 3,000 laying hens:

(i) Before first approving the supplier for an applicable calendar year; and

(ii) On an annual basis thereafter, by December 31 of each calendar year, for the following calendar year; and

(2) Obtains written assurance, at least every 2 years, that the shell egg producer acknowledges that its food is subject to section 402 of the Federal Food, Drug, and Cosmetic Act (or,
when applicable, that its food is subject to relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States.

(f) There must not be any financial conflicts of interest that influence the results of the verification activities listed in §507.110(b) and payment must not be related to the results of the activity.

§ 507.135 Onsite audit.

(a) An onsite audit of a supplier must be performed by a qualified auditor.

(b) If the raw material or other ingredient at the supplier is subject to one or more FDA food safety regulations, an onsite audit must consider such regulations and include a review of the supplier’s written plan (e.g., Hazard Analysis and Critical Control Point (HACCP) plan or other food safety plan), if any, and its implementation, for the hazard being controlled (or, when applicable, an onsite audit may consider relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States).

(c)(1) The following may be substituted for an onsite audit, provided that the inspection was conducted within 1 year of the date that the onsite audit would have been required to be conducted:

(i) The written results of an appropriate inspection of the supplier for compliance with applicable FDA food safety regulations by FDA, by representatives of other Federal Agencies (such as the United States Department of Agriculture), or by representatives of State, local, tribal, or territorial agencies; or

(ii) For a foreign supplier, the written results of an inspection by FDA or the food safety authority of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States.

(2) For inspections conducted by the food safety authority of a country whose food safety system FDA has officially recognized as comparable or determined to be equivalent, the animal food that is the subject of the onsite audit must be within the scope of the official recognition or equivalence determination, and the foreign supplier must be in, and under the regulatory oversight of, such country.

(d) If the onsite audit is solely conducted to meet the requirements of this subpart by an audit agent of a certification body that is accredited in accordance with regulations in part 1, subpart M of this chapter, the audit is not subject to the requirements in those regulations.

EFFECTIVE DATE NOTE: At 80 FR 56337, Sept. 17, 2015, part 507 was added, effective Nov. 16, 2015, with the exception of paragraph (d) in §507.135, which is not yet effective.

§ 507.175 Records documenting the supply-chain program.

(a) The records documenting the supply-chain program are subject to the requirements of subpart F of this part.

(b) The receiving facility must review the records listed in paragraph (c) of this section in accordance with §507.49(a)(4).

(c) The receiving facility must document the following in records as applicable to its supply-chain program:

(1) The written supply-chain program;

(2) Documentation that a receiving facility that is an importer is in compliance with the foreign supplier verification program requirements under part 1, subpart L of this chapter, including documentation of verification activities conducted under §1.506(e) of this chapter;

(3) Documentation of the approval of a supplier;

(4) Written procedures for receiving raw materials and other ingredients;

(5) Documentation demonstrating use of the written procedures for receiving raw materials and other ingredients;

(6) Documentation of the determination of the appropriate supplier verification activities for raw materials and other ingredients;

(7) Documentation of the conduct of an onsite audit. This documentation must include:

(i) The name of the supplier subject to the onsite audit;

(ii) Documentation of audit procedures;
Food and Drug Administration, HHS

§ 507.175

(iii) The dates the audit was conducted;
(iv) The conclusions of the audit;
(v) Corrective actions taken in response to significant deficiencies identified during the audit; and
(vi) Documentation that the audit was conducted by a qualified auditor;
(8) Documentation of sampling and testing conducted as a supplier verification activity. This documentation must include:
(i) Identification of the raw material or other ingredient tested (including lot number, as appropriate) and the number of samples tested;
(ii) Identification of the test(s) conducted, including the analytical method(s) used;
(iii) The date(s) on which the test(s) were conducted and the date of the report;
(iv) The results of the testing;
(v) Corrective actions taken in response to detection of hazards; and
(vi) Information identifying the laboratory conducting the testing;
(9) Documentation of the review of the supplier’s relevant food safety records. This documentation must include:
(i) The name of the supplier whose records were reviewed;
(ii) The date(s) of review;
(iii) The general nature of the records reviewed;
(iv) The conclusions of the review; and
(v) Corrective actions taken in response to significant deficiencies identified during the review;
(10) Documentation of other appropriate supplier verification activities based on the supplier performance and the risk associated with the raw material or other ingredient;
(11) Documentation of any determination that verification activities other than an onsite audit, and/or less frequent onsite auditing of a supplier, provide adequate assurance that the hazards are controlled when a hazard in a raw material or other ingredient will be controlled by the supplier and is one for which there is a reasonable probability that exposure to the hazard will result in serious adverse health consequences or death to humans or animals;
(12) The following documentation of an alternative verification activity for a supplier that is a qualified facility:
(i) The written assurance that the supplier is a qualified facility as defined by §507.3; and
(ii) The written assurance that the supplier is producing the raw material or other ingredient in compliance with applicable FDA food safety regulations (or, when applicable, relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States);
(13) The following documentation of an alternative verification activity for a supplier that is a farm that supplies a raw material or other ingredient and is not a covered farm under part 112 of this chapter:
(i) The written assurance that supplier is not a covered farm under part 112 of this chapter in accordance with §112.4(a), or in accordance with §§112.4(b) and 112.5; and
(ii) The written assurance that the farm acknowledges that its food is subject to section 402 of the Federal Food, Drug, and Cosmetic Act (or, when applicable, that its food is subject to relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States);
(14) The following documentation of an alternative verification activity for a supplier that is a shell egg producer that is not subject to the requirements established in part 118 of this chapter because it has less than 3,000 laying hens:
(i) The written assurance that the shell eggs provided by the supplier are not subject to part 118 of this chapter because the supplier has less than 3,000 laying hens; and
(ii) The written assurance that the shell egg producer acknowledges that its food is subject to section 402 of the Federal Food, Drug, and Cosmetic Act (or, when applicable, that its food is subject to relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or has determined to be equivalent to that of the United States);
(15) The written results of an appropriate inspection of the supplier for compliance with applicable FDA food safety regulations by FDA, by representatives of other Federal Agencies (such as the United States Department of Agriculture), or by representatives from State, local, tribal, or territorial agencies, or the food safety authority of another country when the results of such an inspection is substituted for an onsite audit;

(16) Documentation of actions taken with respect to supplier non-conformance;

(17) Documentation of verification of a supply-chain-applied control applied by an entity other than the receiving facility’s supplier; and

(18) When applicable, documentation of the receiving facility’s review and assessment of:
    (i) Applicable documentation from an entity other than the receiving facility that written procedures for receiving raw materials and other ingredients are being followed;
    (ii) Applicable documentation, from an entity other than the receiving facility, of the determination of the appropriate supplier verification activities for raw materials and other ingredients;
    (iii) Applicable documentation, from an entity other than the receiving facility, of conducting the appropriate supplier verification activities for raw materials and other ingredients;
    (iv) Applicable documentation, from its supplier, of:
        (A) The results of sampling and testing conducted by the supplier; or
        (B) The results of an audit conducted by a third-party qualified auditor in accordance with §§507.130(f) and 507.135; and
    (v) Applicable documentation, from an entity other than the receiving facility, of verification activities when a supply-chain-applied control is applied by an entity other than the receiving facility’s supplier.

EFFECTIVE DATE NOTE: At 80 FR 56337, Sept. 17, 2015, part 507 was added, effective Nov. 16, 2015, with the exception of paragraph (c)(2) in §507.175, which is not yet effective.

§ 507.200 Records subject to the requirements of this subpart.

(a) Except as provided by paragraphs (d) and (e) of this section, all records required by this part are subject to all requirements of this subpart.

(b) Records obtained by FDA in accordance with this part are subject to the disclosure requirements under part 20 of this chapter.

(c) All records required by this part must be made promptly available to a duly authorized representative of the Secretary of Health and Human Services for official review and copying upon oral or written request.

(d) The requirements of §507.206 apply only to the written food safety plan.

(e) The requirements of §507.202(a)(2), (4), and (5) and (b) do not apply to the records required by §507.7.

§ 507.202 General requirements applying to records.

(a) Records must:
    (1) Be kept as original records, true copies (such as photocopies, pictures, scanned copies, microfilm, microfiche, or other accurate reproductions of the original records), or electronic records;
    (2) Contain the actual values and observations obtained during monitoring and, as appropriate, during verification activities;
    (3) Be accurate, indelible, and legible;
    (4) Be created concurrently with performance of the activity documented; and
    (5) Be as detailed as necessary to provide history of work performed.

(b) All records must include:
    (1) Information adequate to identify the plant or facility (e.g., the name, and when necessary, the location of the plant or facility);
    (2) The date and, when appropriate, the time of the activity documented;
    (3) The signature or initials of the person performing the activity; and
    (4) Where appropriate, the identity of the product and the lot code, if any.

(c) Records that are established or maintained to satisfy the requirements of this part and that meet the definition of electronic records in §11.3(b)(6)
of this chapter are exempt from the requirements of part 11 of this chapter. Records that satisfy the requirements of this part, but that also are required under other applicable statutory provisions or regulations, remain subject to part 11 of this chapter.

§ 507.206 Additional requirements applying to the food safety plan.

The owner, operator, or agent in charge of the facility must sign and date the food safety plan upon initial completion and upon any modification.

§ 507.208 Requirements for record retention.

(a)(1) All records required by this part must be retained at the plant or facility for at least 2 years after the date they were prepared.

(2) Records that a facility relies on during the 3-year period preceding the applicable calendar year to support its status as a qualified facility must be retained at the facility as long as necessary to support the status of a facility as a qualified facility during the applicable calendar year.

(b) Records that relate to the general adequacy of the equipment or processes being used by a facility, including the results of scientific studies and evaluations, must be retained by the facility for at least 2 years after their use is discontinued (e.g., because the facility has updated the written food safety plan (§ 507.31) or records that document validation of the written food safety plan (§ 507.45(b))).

(c) Except for the food safety plan, offsite storage of records is permitted if such records can be retrieved and provided onsite within 24 hours of request for official review. The food safety plan must remain onsite. Electronic records are considered to be onsite if they are accessible from an onsite location.

(d) If the plant or facility is closed for a prolonged period, the food safety plan may be transferred to some other reasonably accessible location but must be returned to the plant or facility within 24 hours for official review upon request.

§ 507.215 Special requirements applicable to a written assurance.

(a) Any written assurance required by this part must contain the following elements:

(1) Effective date;

(2) Printed names and signatures of authorized officials;

(3) The applicable assurance under:

(i) § 507.36(a)(2);

(ii) § 507.36(a)(3);

(iii) § 507.36(a)(4);

(iv) § 507.130(c)(2);

(v) § 507.130(d)(2); or

(vi) § 507.130(e)(2).

(b) A written assurance required under § 507.36(a)(2), (3) or (4) must include:

(1) Acknowledgement that the facility that provides the written assurance assumes legal responsibility to act consistently with the assurance and document its actions taken to satisfy the written assurance; and

(2) Provision that if the assurance is terminated in writing by either entity, responsibility for compliance with the applicable provisions of this part reverts to the manufacturer/processor as of the date of termination.
PART 509—UNAVOIDABLE CONTAMINANTS IN ANIMAL FOOD AND FOOD-PACKAGING MATERIAL

Subpart A—General Provisions

§ 509.3 Definitions and interpretations.
(b) The definitions of terms contained in section 201 of the act are applicable to such terms when used in this part unless modified in this section.
(c) A naturally occurring poisonous or deleterious substance is a poisonous or deleterious substance that is an inherent natural constituent of a food and is not the result of environmental, agricultural, industrial, or other contamination.
(d) An added poisonous or deleterious substance is a poisonous or deleterious substance that is not a naturally occurring poisonous or deleterious substance. When a naturally occurring poisonous or deleterious substance is increased to abnormal levels through mishandling or other intervening acts, it is an added poisonous or deleterious substance to the extent of such increase.
(e) Food includes pet food, animal feed, and substances migrating to food from food-contact articles.

§ 509.4 Establishment of tolerances, regulatory limits, and action levels.
(a) When appropriate under the criteria of § 509.6, a tolerance for an added poisonous or deleterious substance, which may be a food additive, may be established by regulation in subpart B of this part under the provisions of section 406 of the act. A tolerance may prohibit any detectable amount of the substance in food.
(b) When appropriate under the criteria of § 509.6, and under section 402(a)(1) of the act, a regulatory limit for an added poisonous or deleterious substance, which may be a food additive, may be established by regulation in subpart C of this part under the provisions of sections 402(a)(1) and 701(a) of the act. A regulatory limit may prohibit any detectable amount of the substance in food. The regulatory limit established represents the level at which food is adulterated within the meaning of section 402(a)(1) of the act.
(c)(1) When appropriate under the criteria of § 509.6, an action level for an added poisonous or deleterious substance, which may be a food additive, may be established to define a level of contamination at which a food may be regarded as adulterated.
(2) Whenever an action level is established or changed, a notice shall be published in the Federal Register as soon as practicable thereafter. The notice shall call attention to the material supporting the action level which shall be on file with the Division of Dockets Management before the notice is published. The notice shall invite public comment on the action level.
(d) A regulation may be established in subpart D of this part to identify a food containing a naturally occurring poisonous or deleterious substance which will be deemed to be adulterated under section 402(a)(1) of the act. These
§ 509.5 Petitions.

The Commissioner of Food and Drugs, either on his own initiative or on behalf of any interested person who has submitted a petition, may issue a proposal to establish, revoke, or amend a regulation under this part. Any such petition shall include an adequate factual basis to support the petition, shall be in the form set forth in §10.30 of this chapter, and will be published in the FEDERAL REGISTER for comment if it contains reasonable grounds for the proposed regulation.

§ 509.6 Added poisonous or deleterious substances.

(a) Use of an added poisonous or deleterious substance, other than a pesticide chemical, that is also a food additive will be controlled by a regulation issued under section 409 of the act when possible. When such a use cannot be approved under the criteria of section 409 of the act, or when the added poisonous or deleterious substance is not a food additive, a tolerance, regulatory limit, or action level may be established pursuant to the criteria in paragraphs (b), (c), or (d) of this section. Residues resulting from the use of an added poisonous or deleterious substance that is also a pesticide chemical will ordinarily be controlled by a tolerance established in a regulation issued under sections 406, 408, or 409 of the act by the U.S. Environmental Protection Agency (EPA). When such a regulation has not been issued, an action level for an added poisonous or deleterious substance that is also a pesticide chemical may be established by the Food and Drug Administration. The Food and Drug Administration will request EPA to recommend such an action level pursuant to the criteria established in paragraph (d) of this section.

(b) A tolerance for an added poisonous or deleterious substance in any food may be established when the following criteria are met:

(1) The substance cannot be avoided by good manufacturing practice.

(2) The tolerance established is sufficient for the protection of the public health, taking into account the extent of which the presence of the substance cannot be avoided and the other ways in which the consumer may be affected by the same or related poisonous or deleterious substances.

(3) No technological or other changes are foreseeable in the near future that might affect the appropriateness of the tolerance established. Examples of changes that might affect the appropriateness of the tolerance include anticipated improvements in good manufacturing practice that would change the extent to which use of the substance is unavoidable and anticipated studies expected to provide significant new toxicological or use data.

(c) A regulatory limit for an added poisonous or deleterious substance in any food may be established when each of the following criteria is met:

(1) The substance cannot be avoided by current good manufacturing practices.

(2) There is no tolerance established for the substance in the particular food under sections 406, 408, or 409 of the act.

(3) There is insufficient information by which a tolerance may be established for the substance under section 406 of the act or technological changes appear reasonably possible that may affect the appropriateness of a tolerance. The regulatory limit established represents the level at which food is adulterated within the meaning of section 402(a)(1) of the act.

(d) An action level for an added poisonous or deleterious substance in any food may be established when the criteria in paragraph (b) of this section are met, except that technological or other changes that might affect the appropriateness of the tolerance are foreseeable in the near future. An action level for an added poisonous or deleterious substance in any food may be established at a level at which the Food and Drug Administration may regard the food as adulterated within the meaning of section 402(a)(1) of the act, without regard to the criteria in paragraph (b) of this section or in section 406 of the act. An action level will be
§ 509.7 Unavoidability.

(a) Tolerances and action levels in this part are established at levels based on the unavoidability of the poisonous or deleterious substance concerned and do not establish a permissible level of contamination where it is avoidable.

(b) Compliance with tolerances, regulatory limits, and action levels does not excuse failure to observe either the requirement in section 402(a)(4) of the act that food may not be prepared, packed, or held under insanitary conditions or the other requirements in this chapter that food manufacturers must observe current good manufacturing practices. Evidence obtained through factory inspection or otherwise indicating such a violation renders the food unlawful, even though the amounts of poisonous or deleterious substances are lower than the currently established tolerances, regulatory limits, or action levels. The manufacturer of food must at all times utilize quality control procedures which will reduce contamination to the lowest level currently feasible.

§ 509.15 Use of polychlorinated biphenyls (PCB’s) in establishments manufacturing food-packaging materials.

(a) Polychlorinated biphenyls (PCB’s) represent a class of toxic industrial chemicals manufactured and sold under a variety of trade names, including: Aroclor (United States); Phenoclor (France); Colphen (Germany); and Kanaclor (Japan). PCB’s are highly stable, heat resistant, and nonflammable chemicals. Industrial uses of PCB’s include, or did include in the past, their use as electrical transformer and capacitor fluids, heat transfer fluids, hydraulic fluids, and plasticizers, and in formulations of lubricants, coatings, and inks. Their unique physical and chemical properties and widespread, uncontrolled industrial applications have caused PCB’s to be a persistent and ubiquitous contaminant in the environment, causing the contamination of certain foods. In addition, incidents have occurred in which PCB’s have directly contaminated animal feeds as a result of industrial accidents (leakage or spillage of PCB fluids from plant equipment). These accidents in turn caused the contamination of food products intended for human consumption (meat, milk and eggs). Investigations by the Food and Drug Administration have revealed that a significant percentage of paper food-packaging material contains PCB’s which can migrate to the packaged food. The origin of PCB’s in such material is not fully understood. Reclaimed fibers containing carbonless copy paper (contains 3 to 5 percent PCB’s) have been identified as a primary source of PCB’s in paper products. Some virgin paper products have also been found to contain PCB’s, the source of which is generally attributed to direct contamination from industrial accidents from the use of PCB-containing equipment and machinery in food-packaging manufacturing establishments. Since PCB’s are toxic chemicals, the PCB contamination of food-packaging materials as a result of industrial accidents, which can cause the PCB contamination of food, represents a hazard to public health. It is therefore necessary to place certain restrictions on the industrial uses of PCB’s in establishments manufacturing food-packaging materials.

(b) The following special provisions are necessary to preclude the accidental PCB contamination of food-packaging materials:
(1) New equipment or machinery for manufacturing food-packaging materials shall not contain or use PCB’s.

(2) On or before September 4, 1973, the management of establishments manufacturing food-packaging materials shall:

(i) Have the heat exchange fluid used in existing equipment for manufacturing food-packaging materials sampled and tested to determine whether it contains PCB’s or verify the absence of PCB’s in such formulations by other appropriate means. On or before Sept. 4, 1973, any such fluid formulated with PCB’s must to the fullest extent possible commensurate with current good manufacturing practices be replaced with a heat exchange fluid that does not contain PCB’s.

(ii) Eliminate to the fullest extent possible commensurate with current good manufacturing practices from the establishment any other PCB-containing equipment, machinery and materials wherever there is a reasonable expectation that such articles could cause food-packaging materials to become contaminated with PCB’s either as a result of normal use or as a result of accident, breakage, or other mishap.

(iii) The toxicity and other characteristics of fluids selected as PCB replacements must be adequately determined so that the least potentially hazardous replacement is used. In making this determination with respect to a given fluid, consideration should be given to (a) its toxicity; (b) the maximum quantity that could be spilled onto a given quantity of food before it would be noticed, taking into account its color and odor; (c) possible signaling devices in the equipment to indicate a loss of fluid, etc.; and (d) its environmental stability and tendency to survive and be concentrated through the food chain. The judgment as to whether a replacement fluid is sufficiently non-hazardous is to be made on an individual installation and operation basis.

(c) The provisions of this section do not apply to electrical transformers and condensers containing PCB’s in sealed containers.

Subpart B—Tolerances for Unavoidable Poisonous or Deleterious Substances

§ 509.30 Temporary tolerances for polychlorinated biphenyls (PCB’s).

(a) Polychlorinated biphenyls (PCB’s) are toxic, industrial chemicals. Because of their widespread, uncontrolled industrial applications, PCB’s have become a persistent and ubiquitous contaminant in the environment. As a result, certain foods and animal feeds, principally those of animal and marine origin, contain PCB’s as unavoidable environmental contaminants. PCB’s are transmitted to the food portion (meat, milk, and eggs) of food producing animals ingesting PCB contaminated animal feed. In addition, a significant percentage of paper food-packaging materials contain PCB’s which may migrate to the packaged food. The source of PCB’s in paper food-packaging materials is primarily of certain types of carbonless copy paper (containing 3 to 5 percent PCB’s) in waste paper stocks used for manufacturing recycled paper. Therefore, temporary tolerances for residues of PCB’s as unavoidable environmental or industrial contaminants are established for a sufficient period of time following the effective date of this paragraph to permit the elimination of such contaminants at the earliest practicable time. For the purposes of this paragraph, the term polychlorinated biphenyls (PCB’s) is applicable to mixtures of chlorinated biphenyl compounds, irrespective of which mixture of PCB’s is present as the residue. The temporary tolerances for residues of PCB’s are as follows:

(1) 0.2 part per million in finished animal feed for food-producing animals (except the following finished animal feeds: feed concentrates, feed supplements, and feed premixes).

(2) 2 parts per million in animal feed components of animal origin, including fishmeal and other by-products of marine origin and in finished animal feed concentrates, supplements, and premixes intended for food-producing animals.

(3) 10 parts per million in paper food-packaging material intended for or used with finished animal feed and any
components intended for animal feeds. The tolerance shall not apply to paper food-packaging material separated from the food therein by a functional barrier which is impermeable to migration of PCB’s.

(b) A compilation entitled “Analytical Methodology for Polychlorinated Biphenyls, February 1973” for determining compliance with the tolerances established in this section is available from the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.


Subpart C—Regulatory Limits for Added Poisonous or Deleterious Substances [Reserved]

Subpart D—Naturally Occurring Poisonous or Deleterious Substances [Reserved]

PART 510—NEW ANIMAL DRUGS

Subpart A—General Provisions

Sec.
510.3 Definitions and interpretations.
510.4 Biologics; products subject to license control.
510.7 Consignees of new animal drugs for use in the manufacture of animal feed.
510.95 [Reserved]

Subpart B—Specific Administrative Rulings and Decisions

510.105 Labeling of drugs for use in milk-producing animals.
510.106 Labeling of antibiotic and anti-biotic-containing drugs intended for use in milk-producing animals.
510.110 Antibiotics used in food-producing animals.
510.112 Antibiotics used in veterinary medicine and for nonmedicinal purposes; required data.

Subpart C [Reserved]

Subpart D—Records and Reports

510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect.

510.305 Maintenance of copies of approved medicated feed mill licenses to manufacture animal feed bearing or containing new animal drugs.

Subpart E—Requirements for Specific New Animal Drugs

510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements.
510.440 Injectable iron preparations.
510.455 Requirements for free-choice medicated feeds.

Subpart F [Reserved]

Subpart G—Sponsors of Approved Applications

510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.


SOURCE: 40 FR 13807, Mar. 27, 1975, unless otherwise noted.

Subpart A—General Provisions

§ 510.3 Definitions and interpretations.

As used in this part:

(b) Department means the Department of Health and Human Services.

(c) Secretary means the Secretary of Health and Human Services.

(d) Commissioner means the Commissioner of Food and Drugs.

(e) Person means individuals, partnerships, corporations, and associations.

(f) The definitions and interpretations of terms contained in section 201 of the act shall be applicable to such terms when used in the regulations in this part.

(g) The term new animal drug means any drug intended for use for animals other than man, including any drug intended for use in animal feed but not including such animal feed:

(1) The composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed,
Food and Drug Administration, HHS

§ 510.4  

recommended, or suggested in the labeling thereof; except that such a drug not so recognized shall not be deemed to be a new animal drug if at any time prior to June 25, 1938, it was subject to the Food and Drug Act of June 30, 1906, as amended, and if at such time its labeling contained the same representations concerning the conditions of its use; or

(2) The composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

(h) The term animal feed means an article which is intended for use for food for animals other than man and which is intended for use as a substantial source of nutrients in the diet of the animal, and is not limited to a mixture intended to be the sole ration of the animal.

(i) The newness of an animal drug, including a new animal drug intended for use in or on animal feed, may arise by reason of: (1) The newness for its intended drug use of any substance of which the drug is comprised, in whole or in part, whether it be an active substance or a menstruum, excipient, carrier, coating, or other component; (2) the newness for its intended drug use of a combination of two or more substances, none of which is itself a new animal drug; (3) the newness for its intended drug use of the proportion of a substance in a combination, even though such combination containing such substance in other proportion is not a new animal drug; (4) the newness for its intended drug use in diagnosing, curing, mitigating, treating, or preventing a disease, or to affect a structure or function of the animal body, even though such drug is not a new animal drug when used in another disease or to affect another structure or function of the body; or (6) the newness of its dosage, or method or duration of administration or application, or any other condition of use prescribed, recommended, or suggested in the labeling of such drug, even though such drug or animal feed containing such drug when used in another dosage, or another method or duration of administration or application, or different condition, is not a new animal drug.

(j) Animals used only for laboratory research and laboratory research animals mean individual animals or groups of animals intended for use and used solely for laboratory research purposes, regardless of species, and does not include animals intended to be used for any food purposes or animals intended to be kept as livestock.

(k) Sponsor means the person requesting designation for a minor-use or minor-species drug as defined in part 516 of this chapter, who must be the real party in interest of the development and the intended or actual production and sales of such drug (in this context, the sponsor may be an individual, partnership, organization, or association). Sponsor also means the person responsible for an investigation of a new animal drug. In this context, the sponsor may be an individual, partnership, corporation, or Government agency or may be a manufacturer, scientific institution, or an investigator regularly and lawfully engaged in the investigation of new animal drugs. Sponsor also means the person submitting or receiving approval for a new animal drug application (in this context, the sponsor may be an individual, partnership, organization, or association). In all contexts, the sponsor is responsible for compliance with applicable provisions of the act and regulations.

§ 510.4  Biologics; products subject to license control.

An animal drug produced and distributed in full conformance with the animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 U.S.C. 151 et seq. ) and any regulations issued thereunder shall not be deemed to be subject to section 512 of the Federal Food, Drug, and Cosmetic Act.
§510.7 Consignees of new animal drugs for use in the manufacture of animal feed.

(a) A new animal drug intended for use in the manufacture of animal feed shall be deemed to be unsafe unless at the time of its removal from the establishment of a manufacturer, packer, or distributor of such drug, such manufacturer, packer, or distributor has an unrevoked written statement from the consignee of such drug, or a notice from the Secretary, to the effect that with respect to the use of such drug in animal feed the consignee:

(1) Holds a license issued under §515.20 of this chapter; or

(2) Will, if the consignee is not the user of the drug, ship such drug only to a holder of an approved application under §515.10 of this chapter.

(b) The requirements of paragraph (a) of this section do not apply:

(1) Where such drugs are intended for export and/or

(2) When the use of such drug in the manufacture of a finished feed has been exempted from the requirements of section 512(m) of the act under the conditions specified by regulations published in part 558 of this chapter.

[40 FR 13807, Mar. 27, 1975, as amended at 64 FR 63203, Nov. 19, 1999]

§510.95 [Reserved]

Subpart B—Specific Administrative Rulings and Decisions

§510.105 Labeling of drugs for use in milk-producing animals.

(a) Part 526 of this chapter provides for new animal drugs intended for intramammary use in animals and includes conditions of use intended to prevent the contamination of milk from the use of such drugs.

(b) Preparations containing antibiotics and other potent drugs labeled with directions for use in milk-producing animals will be misbranded under section 502(f)(2) of the act unless their labeling bears appropriate warnings and directions for use to avoid adulteration of milk under section 402(a)(2)(C)(i) of the act.

(c) It is the position of the Food and Drug Administration that the labeling for such preparations should bear a clear warning that either:

(1) The article should not be administered to animals producing milk, since to do so would result in contamination of the milk; or

(2) The label should bear the following statement: “Warning: Milk that has been taken from animals during treatment and for ____ hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the manufacturer has determined by appropriate investigation is needed to insure that the milk will not carry violative residues resulting from use of the preparation. If the use of the preparation as recommended does not result in contamination of the milk, neither of the above warning statements is required.

[40 FR 13807, Mar. 27, 1975, as amended at 63 FR 32980, June 17, 1998; 64 FR 51241, Sept. 22, 1999]

§510.106 Labeling of antibiotic and antibiotic-containing drugs intended for use in milk-producing animals.

Whenever the labeling of an antibiotic drug included in the regulations in this chapter suggests or recommends its use in milk-producing animals, the label of such drugs shall bear either the statement “Warning: Not for use in animals producing milk, since this use will result in contamination of the milk” or the statement “Warning: Milk that has been taken from animals during treatment and for ____ hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the Commissioner has authorized the manufacturer of the drug to use. The Commissioner shall determine what such figures shall be from information submitted by the manufacturer and which the Commissioner considers is adequate to prove that period of time after the latest treatment that the milk from treated animals will contain no violative residues from use of the preparation. If the Commissioner determines from the information submitted that the use of the antibiotic drug as recommended does not result in its appearance in the milk, the Commissioner may exempt
Food and Drug Administration, HHS

§ 510.110 Antibiotics used in food-producing animals.

(a) The Food and Drug Administration in the interest of fulfilling its responsibilities with regard to protection of the public health has requested an evaluation of the public health aspects of the use of antibiotics in veterinary medical and nonmedical uses. There is particular concern with regard to the potential hazards associated with the extensive use of antibiotics administered to food-producing animals. Accordingly, an ad hoc committee on the Veterinary Medical and Nonmedical Uses of Antibiotics was established by the Food and Drug Administration to study and advise the Commissioner of Food and Drugs on the uses of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to their safety and effectiveness.

(b) Based upon an evaluation of the conclusions of said committee and other relevant material, § 510.112 was published in the Federal Register of August 23, 1966 (31 FR 11141), asking sponsors of drugs containing any antibiotic intended for use in food-producing animals to submit data to establish whether such antibiotic and its metabolites are present as residues in edible tissues, milk, and eggs from treated animals. The data on the residues of antibiotics in milk from intramammary infusion preparations were requested within 60 days and the data on all other products were requested within 180 days following the date of publication of § 510.112 in the Federal Register.

(c) An evaluation of the data now available shows that use of many antibiotic preparations cause residues in edible products of treated animals for varying and, in some cases, for long periods of time following the last administration. Because of the accumulation of new information with regard to the development of resistance of bacteria to antibiotics, the ability of bacteria to transfer this resistance, and the development of sensitivity to antibiotics in humans, unauthorized and unsafe residues of antibiotics cannot be permitted in food obtained from treated animals.

(d) Based on evaluation of information available, including the conclusions of the aforementioned ad hoc Committee, the Commissioner concludes that antibiotic preparations intended for use in food-producing animals, other than topical and ophthalmic preparations, are not generally recognized among qualified experts as having been shown to be safe for their intended use(s) within the meaning of section 201(s) of the Federal Food, Drug, and Cosmetic Act.

(e) Therefore, all exemptions from the provisions of section 409 of the act for use of antibiotics in food-producing animals based on sanctions or approvals granted prior to enactment of the Food Additives Amendment of 1958 (Pub. L. 85–929; 72 Stat. 1784) will be revoked and the uses which are concluded to be safe will be covered by food additive regulations. On those products for which there are inadequate residue data, actions will be initiated to withdraw approval of new drug applications under the provisions of section 505 of the act. Antibiotic preparations, other than those for topical and ophthalmic application in food-producing animals, which are not covered by food additive regulations will be subject to regulatory action within 180 days after publication of the forthcoming revocation order.

(f) Because of the variation in the period of time that antibiotic residues may remain in edible products from treated animals, all injectable, intramammary infusion, intruterine, and oral preparations, including medicated premixes intended for use in food-producing animals, are deemed to be new drugs as well as food additives.

§ 510.112 Antibiotics used in veterinary medicine and for nonmedical purposes; required data.

(a) An ad hoc committee, Committee on the Veterinary Medical and Nonmedical Uses of Antibiotics, was
formed by the Food and Drug Administration to study, and advise the Commissioner on, the use of antibiotics in veterinary medicine and for various nonmedical purposes as such uses may affect the enforcement of the Federal Food, Drug, and Cosmetic Act with respect to the safety and effectiveness of such substances. A copy of the report may be obtained from the Food and Drug Administration, Office of Public Affairs, Room 15–05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

(b) On the basis of the report of the Committee and other information, sponsors of drugs containing any antibiotic intended for use in food-producing animals shall submit data for determining whether or not such antibiotics and their metabolites are present as residues in edible tissues, milk, and eggs from treated animals; however, in the case of a drug for which such data have already been submitted and for which a regulation has been promulgated under section 409 of the act, only such data as has been accumulated since the issuance of the regulation need be submitted.

(c) The required data shall be submitted within 180 days of the date of publication of this section in the Federal Register; except that in the case of data on intramammary infusion preparations the data shall be submitted within 60 days of such publication. Data demonstrating the absence in milk of residues of intramammary infusion preparations when used as directed in their labeling are needed within the 60-day period because of the importance of milk in the human diet.

(d) Regulatory proceedings including revocation of prior sanctions, or actions to suspend or amend new drug or antibiotic approvals granted prior to passage of the Food Additives Amendment of 1958 (72 Stat. 1784), may be initiated with regard to the continued marketing of any antibiotic preparation on which the required information is not submitted within the period of time prescribed by paragraph (c) of this section.

(e) Questions relating to the acceptability of proposed research protocols and assay methods for determining the amount of antibiotic residues in food should be directed to the Director, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

Subpart C [Reserved]

Subpart D—Records and Reports

§ 510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect.

Records and reports of clinical and other experience with the new animal drug will be maintained and reported, appropriately identified with the new animal drug application(s) or index listing(s) to which they relate, to the Center for Veterinary Medicine in duplicate in accordance with the following:

(a) Immediately upon receipt by the applicant, complete records or reports covering information of the following kinds:

(1) Information concerning any mixup in the new animal drug or its labeling with another article.

(2) Information concerning any bacteriological or any significant chemical, physical, or other change or deterioration in the drug, or any failure of one or more distributed batches of the drug to meet the specifications established for it in the new animal drug application or request for determination of eligibility for indexing.

(b) As soon as possible, and in any event within 15 working days of its receipt by the applicant, complete records or reports concerning any information of the following kinds:

(1) Information concerning any unexpected side effect, injury, toxicity, or sensitivity reaction or any unexpected incidence or severity thereof associated with clinical uses, studies, investigations, or tests, whether or not determined to be attributable to the new animal drug, except that this requirement shall not apply to the submission of information described in a written communication to the applicant from...
the Food and Drug Administration as types of information that may be submitted at other designated intervals. *Unexpected* as used in this paragraph refers to conditions or developments not previously submitted as part of the new animal drug application or in support of the index listing or not encountered during clinical trials of the drug, or conditions or developments occurring at a rate higher than shown by information previously submitted as part of the new animal drug application or in support of the index listing or at a rate higher than encountered during such clinical trials.

(2) Information concerning any unusual failure of the new animal drug to exhibit its expected pharmacological activity.

[40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 72 FR 69121, Dec. 6, 2007]

§ 510.305 Maintenance of copies of approved medicated feed mill licenses to manufacture animal feed bearing or containing new animal drugs.

Each applicant shall maintain in a single accessible location:

(a) A copy of the approved medicated feed mill license (Form FDA 3448) on the premises of the manufacturing establishment; and

(b) Approved or index listed labeling for each Type B and/or Type C feed being manufactured on the premises of the manufacturing establishment or the facility where the feed labels are generated.

[64 FR 63203, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007]

Subpart E—Requirements for Specific New Animal Drugs

§ 510.410 Corticosteroids for oral, injectable, and ophthalmic use in animals; warnings and labeling requirements.

(a) The Food and Drug Administration has received reports of side effects associated with the oral, injectable, and ophthalmic use of corticosteroid animal drugs. The use of these drugs administered orally or by injection has resulted in premature parturition when administered during the last trimester of pregnancy. Premature parturition may be followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids used in dogs, rabbits, and rodents during pregnancy have produced cleft palate in offspring. Drugs subject to this section are required to carry the veterinary prescription legend and are subject to the labeling requirements of §201.105 of this chapter.

(b) In view of these potentially serious side effects, the Food and Drug Administration has concluded that the labeling on or within packaged corticosteroid-containing preparations intended for animal use shall bear conspicuously the following warning statement:

*Warning:* Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca.

[49 FR 48535, Dec. 13, 1984]

§ 510.440 Injectable iron preparations.

There has been an increasing interest in the use of injectable iron compounds for the prevention or treatment of iron-deficiency anemia in animals. Although some such preparations have been shown to be safe, such articles are regarded as new animal drugs within the meaning of the Federal Food, Drug, and Cosmetic Act. Accordingly, an approved new animal drug application is required prior to the marketing of such preparations within the jurisdiction of the act. In addition to the need for demonstrating the safety of such articles, the labeling of such preparations should not only recommend appropriate dosages of iron but also declare the amount (in milligrams) of available iron (Fe) per milliliter of the subject product.
§ 510.455 Requirements for free-choice medicated feeds.

(a) What is free-choice medicated feed? For the purpose of this part, free-choice medicated feed is medicated feed that is placed in feeding or grazing areas and is not intended to be consumed fully at a single feeding or to constitute the entire diet of the animal. Free-choice feeds include, but are not limited to, medicated blocks (agglomerated feed compressed or rendered into a solid mass and cohesive enough to hold its form), mineral mixes, and liquid feed tank supplements (‘‘lick tank’’ supplements) containing one or more new animal drugs. The manufacture of medicated free-choice feeds is subject to the current good manufacturing practice regulations in part 225 of this chapter for medicated feeds.

(b) What is required for new animal drugs intended for use in free-choice feed? Any new animal drug intended for use in free-choice feed must be approved for such use under section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360(b)) or listed in the index under section 572 of the act (21 U.S.C. 360ccc–1). Such approvals under section 512 of the act must be:

1. An original new animal drug application (NADA),
2. A supplemental NADA, or
3. An abbreviated NADA.

(c) What are the approval requirements under section 512 of the act for new animal drugs intended for use in free-choice feed? An approval under section 512 of the act for a Type A medicated article intended for use in free-choice feed must contain the following information:

1. Data, or reference to data in a master file (MF), showing that the target animal consumes the new animal drug in the Type C free-choice feed in an amount that is safe and effective (consumption/effectiveness data); and
2. Data, or reference to data in an MF, showing the relevant ranges of conditions under which the drug will be chemically and physically stable in the Type C free-choice feed under field conditions.

(d) How are consumption/effectiveness and/or stability data to be submitted? The data must be submitted as follows:

1. Directly in the NADA, by a sponsor; and/or
2. To an MF that a sponsor may then reference in its NADA with written consent of the MF holder.

(e) What will be stated in the published approval for a new animal drug intended for use in free-choice feed? The approval of a new animal drug intended for use in free-choice feed, as published in this subchapter, will include:

1. The formula and/or specifications of the free-choice medicated feed, where the owner of this information requests such publication, or
2. A statement that the approval has been granted for a proprietary formula and/or specifications.

(f) When is a medicated feed mill license required for the manufacture of a free-choice medicated feed? An approved medicated feed mill license is required for the manufacture of the following types of feeds:

1. All free-choice medicated feeds that contain a Category II drug, and
2. Free-choice medicated feeds that contain a Category I drug and use a proprietary formula and/or specifications.


Subpart F [Reserved]

Subpart G—Sponsors of Approved Applications

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

(a) Section 512(i) of the act requires publication of names and addresses of sponsors of approved applications for new animal drugs.

(b) In this section each name and address is identified by a numerical drug labeler code. The labeler codes identify the sponsors of the new animal drug applications associated with the regulations published pursuant to section 512(i) of the act. The codes appear in the appropriate regulations and serve as a reference to the names and addresses listed in this section. The drug labeler code is established pursuant to section 510 of the act.

(c) The names, addresses, and drug labeler codes of sponsors of approved new animal drug applications are as follows:

(1) ALPHABETICAL LISTING OF SPONSORS

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>A &amp; G Pharmaceuticals, Inc., 1030 West Commodore Blvd., Jackson, NJ 08527</td>
<td>057699</td>
</tr>
<tr>
<td>Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B, Durham, NC 27703</td>
<td>016729</td>
</tr>
<tr>
<td>ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62205–3115</td>
<td>012286</td>
</tr>
<tr>
<td>Agri Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO 64503</td>
<td>057561</td>
</tr>
<tr>
<td>Agri-Tech, Inc., 4725 Broadway, Kansas City, MO 64112</td>
<td>017763</td>
</tr>
<tr>
<td>Akorn Animal Health, Inc., 1925 West Field Ct., suite 300, Lake Forest, IL 60045</td>
<td>059393</td>
</tr>
<tr>
<td>Alaco, Inc., 1500 North Wilmet Rd., suite 290-C, Tucson, AZ 85712</td>
<td>064148</td>
</tr>
<tr>
<td>American Pharmaceuticals and Cosmetics, Inc., 1401 Joel East Rd., Fort Worth, TX 76140</td>
<td>065531</td>
</tr>
<tr>
<td>Anika Therapeutics Inc., 236 West Cummings Park, Woburn, MA 01801</td>
<td>060865</td>
</tr>
<tr>
<td>Aquabounty Technologies, Inc., Two Clock Tower Pl., suite 395, Maynard, MA 01754</td>
<td>086053</td>
</tr>
<tr>
<td>Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218</td>
<td>076175</td>
</tr>
<tr>
<td>Aurora Pharmaceutical, LLC, 1196 Highway 3 South, Northfield, MN 55057–3009</td>
<td>051072</td>
</tr>
<tr>
<td>Ascentive SRL, Chemin de Champouse, Quartier Violais, 13320 Buc Bel Air, France</td>
<td>086009</td>
</tr>
<tr>
<td>B.L. Mitchell, Inc., 103 Hwy. 82 E., Leiland, MS 38756</td>
<td>067188</td>
</tr>
<tr>
<td>Baxter Healthcare Corp., One Baxter Pkwy., Deerfield, IL 60015</td>
<td>010019</td>
</tr>
<tr>
<td>Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201</td>
<td>000859</td>
</tr>
<tr>
<td>Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd., Large, FL 33777</td>
<td>062250</td>
</tr>
<tr>
<td>Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt Highway, St. Joseph, MO 64506–2002</td>
<td>000010</td>
</tr>
<tr>
<td>Cephalon Pharma, LLC, 250 East Bonita Ave., Pomona, CA 91767</td>
<td>068330</td>
</tr>
<tr>
<td>Ceva Sante Animale, 10 Avenue de la Ballastiere, 33500 Liebourse, France</td>
<td>013744</td>
</tr>
<tr>
<td>Channelle Pharmaceuticals Manufacturing Ltd., Loughrea, County Galway, Ireland</td>
<td>061651</td>
</tr>
<tr>
<td>ConAgra Pet Products Co., 3902 Lebanon St., Omaha, NE 68110</td>
<td>021091</td>
</tr>
<tr>
<td>Cooperative Research Farms, Box 69, Charlotteville, NY 12036</td>
<td>051267</td>
</tr>
<tr>
<td>Cronus Pharma LLC, 2 Tower Center Blvd., Suite 1101, East Brunswick, NJ 08816</td>
<td>060943</td>
</tr>
<tr>
<td>Cress VetPharm Group Ltd., Brookfield Rd., Tallaght, Dublin 24, Ireland</td>
<td>061223</td>
</tr>
<tr>
<td>Dechra, Ltd., Snapyhill Industrial Estate, Keighley Rd., Skipton, North Yorkshire, BD23 2RW, United Kingdom</td>
<td>043264</td>
</tr>
<tr>
<td>ECO LLC, 344 Nassau St., Princeton, NJ 08540</td>
<td>066916</td>
</tr>
<tr>
<td>Eli Lilly Animal Health, A Division of Eli Lilly &amp; Co., Lilly Corporate Center, Indianapolis, IN 46285</td>
<td>000986</td>
</tr>
<tr>
<td>Eli Lilly US Inc, 2500 Innovation Way, Greenfield, IN 46140</td>
<td>058198</td>
</tr>
<tr>
<td>Farmam Companies, Inc., 301 West Osborn, Phoenix, AZ 85013–3929</td>
<td>017135</td>
</tr>
<tr>
<td>First Priority, Inc., 1590 Todd Farm Dr., Elgin, IL 60123</td>
<td>058829</td>
</tr>
<tr>
<td>Fleming Laboratories, Inc., P.O. Box 34384, Charlotte, NC 28234</td>
<td>015565</td>
</tr>
<tr>
<td>Fougera Pharmaceuticals, Inc., P.O. Box 2006, 69 Baylis Rd., Melville, NY 11747</td>
<td>025445</td>
</tr>
<tr>
<td>G. C. Hanford Manufacturing Co., P.O. Box 1017, Syracuse, NY 13201</td>
<td>010515</td>
</tr>
<tr>
<td>GTC Biotherapeutics, Inc., 175 Crossing Blvd., Framingham, MA 01702</td>
<td>042976</td>
</tr>
<tr>
<td>Halocarbon Products Corp., 887 Kinderkamack Rd., River Edge, NJ 07661</td>
<td>012164</td>
</tr>
<tr>
<td>Happy Jack, Inc., Snow Hill, NC 28580</td>
<td>023851</td>
</tr>
<tr>
<td>Hemoglobin Oxygen Therapeutics, LLC, 674 Souer Rd., Souderton, PA 18964</td>
<td>063075</td>
</tr>
<tr>
<td>Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO 80525</td>
<td>063604</td>
</tr>
<tr>
<td>Hikma International Pharmaceuticals LLC, P.O. Box 182400, Bayader Wadi Seer, Amman, Jordan 11118</td>
<td>059115</td>
</tr>
<tr>
<td>Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045</td>
<td>000409</td>
</tr>
<tr>
<td>HQ Specialty Pharma Corp., 120 Re. 17 North, Suite 130, Paramus, NJ 07652</td>
<td>042791</td>
</tr>
<tr>
<td>Hovopharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sofia, Bulgaria</td>
<td>016592</td>
</tr>
<tr>
<td>IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409</td>
<td>065274</td>
</tr>
<tr>
<td>IMPAX Laboratories, Inc., 38831 Hunter made Ave., Hayward, CA 94544</td>
<td>000115</td>
</tr>
<tr>
<td>Internep, Inc., 2 Giraldia Farms, Madison, NJ 07940</td>
<td>000061</td>
</tr>
<tr>
<td>JBS United Animal Health II LLC, 322 S. Main St., Sheridan, IN 46069</td>
<td>015233</td>
</tr>
<tr>
<td>Jurox Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320, Australia</td>
<td>049480</td>
</tr>
<tr>
<td>LFB USA, Inc., 175 Crossing Blvd., Framingham, MA 01702</td>
<td>086047</td>
</tr>
<tr>
<td>Lloyd, Inc., 604 W. Thomas Ave., Shenandoah, IA 51601</td>
<td>061690</td>
</tr>
<tr>
<td>Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967</td>
<td>010797</td>
</tr>
<tr>
<td>Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767–1861</td>
<td>054925</td>
</tr>
<tr>
<td>Med scape, Inc., 1111 Freedom Dr., Oneida, NY 13421</td>
<td>089463</td>
</tr>
<tr>
<td>Merial, Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640</td>
<td>050604</td>
</tr>
<tr>
<td>Mylan Institutional, Inc., 12720 Daisy Ashford Rd., Sugar Land, TX 77478</td>
<td>051079</td>
</tr>
<tr>
<td>Mylan Institutional, LLC, 4801 Haverlah Dr., Rockford, IL 61103</td>
<td>063031</td>
</tr>
<tr>
<td>Natchez Animal Supply Co., 201 John R. Junkin Dr., Natchez, MS 36280</td>
<td>049965</td>
</tr>
<tr>
<td>NeoGen Corp., 844 Nandino Blvd., Lexington, KY 40511</td>
<td>095051</td>
</tr>
<tr>
<td>Nexcxon Pharmaceuticals, Inc., 644 West Washington Ave., Madison, WI 53719</td>
<td>050529</td>
</tr>
<tr>
<td>Norbrook Laboratories, Ltd., Station Works, Newby BT35 6JG, Northern Ireland</td>
<td>055529</td>
</tr>
<tr>
<td>Osmia Pharmaceutical AB, Vallonsgatan 1, 73258 Upsala, Sweden</td>
<td>052818</td>
</tr>
<tr>
<td>Orion Corp., Orioninrue 1, 02200 Espoo, Finland</td>
<td>052483</td>
</tr>
<tr>
<td>Parmel Technologies Pty. Ltd., unit 4, 476 Gardeners Rd., Alexandria, New South Wales 2015, Australia</td>
<td>068504</td>
</tr>
<tr>
<td>Pegasus Laboratories, Inc., 8809 Elly Rd., Pensacola, FL 32514</td>
<td>059246</td>
</tr>
<tr>
<td>Pharmaceutical Ventures, Ltd., P.O. Box D1400, Pomona, NY 10970</td>
<td>050057</td>
</tr>
<tr>
<td>Pharmacosmos, Inc., 776 Mountain Blvd., Watchung, NJ 07069</td>
<td>042562</td>
</tr>
<tr>
<td>Pharmax AS, Skogmo Industriomrade, N–7863 Overhalla, Norway</td>
<td>015331</td>
</tr>
</tbody>
</table>
### (1) ALPHABETICAL LISTING OF SPONSORS—Continued

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>PharMGate LLC, 1015 Ashes Dr., Suite 102, Wilmington, NC 28405</td>
<td>069254</td>
</tr>
<tr>
<td>Phibro Animal Health Corp., GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666</td>
<td>066104</td>
</tr>
<tr>
<td>Primal Critical Care, Inc., 3850 Schellenberg Circle, Bethlehem, PA 18017</td>
<td>066794</td>
</tr>
<tr>
<td>Piramal Healthcare Ltd., Piramal Tower, Gampatapao Kadam Marg, Lower Parel, Mumbai - 400 013, India</td>
<td>065085</td>
</tr>
<tr>
<td>Planalquimica Industrial Ltda., Rua das Magnolias nr. 2405, Jardim das Bandeiras, CEP 13053-120, Campinas, Sao Paulo, Brazil</td>
<td>060728</td>
</tr>
<tr>
<td>Purina Animal Nutrition LLC, 1080 County Road F West, Shoreview, MN 55126-2910</td>
<td>017800</td>
</tr>
<tr>
<td>Putney, Inc., One Monument Sq., Suite 400, Portland, ME 04101</td>
<td>026637</td>
</tr>
<tr>
<td>Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349</td>
<td>076475</td>
</tr>
<tr>
<td>Ridley Block Operations Inc., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002-8500</td>
<td>068827</td>
</tr>
<tr>
<td>Ridley U.S. Holdings, Inc., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002-8500</td>
<td>067849</td>
</tr>
<tr>
<td>RSIR Laboratories, Inc., 501 Fifth St., Bristol, TN 37620</td>
<td>038106</td>
</tr>
<tr>
<td>Sioux Biochemical, Inc., 204 Third St. NW, Sioux Center, IA 51250</td>
<td>063112</td>
</tr>
<tr>
<td>SmartVet USA, Inc., 22201 West Innovation Dr., Suite 170A, Olathe, KS 66061-1304</td>
<td>086001</td>
</tr>
<tr>
<td>Sogeval S.A., 200 Avenue de Mayenne, 53000 Laval, France</td>
<td>059120</td>
</tr>
<tr>
<td>Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215</td>
<td>058005</td>
</tr>
<tr>
<td>Squire Laboratories, Inc., 100 Mill St., Revere, MA 02151</td>
<td>017153</td>
</tr>
<tr>
<td>Strategic Veterinary Pharmaceuticals, Inc., 100 NW. Airport Rd., St. Joseph, MO 64503</td>
<td>054628</td>
</tr>
<tr>
<td>Summit Hill Laboratories, P.O. Box 535, Navesink, NJ 07752</td>
<td>037990</td>
</tr>
<tr>
<td>Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, NY 10532</td>
<td>051672</td>
</tr>
<tr>
<td>Therio, Inc., 8801 Anderson Ave., Manhattan, KS 66503</td>
<td>052923</td>
</tr>
<tr>
<td>Thorn Bioscience LLC, 1444 East Chestnut St., Louisville, KY 40204</td>
<td>051330</td>
</tr>
<tr>
<td>Vetoquinol N.A., Inc., 2000 chemin Georges, Lavaltrie (PQ), Canada, J5T 3S5</td>
<td>059320</td>
</tr>
<tr>
<td>Vetoquinol USA, Inc., 4250 N. Sylvania Ave., Fort Worth, TX 76137</td>
<td>017038</td>
</tr>
<tr>
<td>Virbac AH, Inc., 3200 Meacham Blvd., Fort Worth, TX 76137</td>
<td>051311</td>
</tr>
<tr>
<td>Walco International, Inc., 15 West Putnam, Port Republic, NJ 08229</td>
<td>049185</td>
</tr>
<tr>
<td>Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA 92880</td>
<td>000402</td>
</tr>
<tr>
<td>Western Biologic Laboratories, Inc., 1369 Lattimore Rd., Ferndale, WA 98248</td>
<td>050378</td>
</tr>
<tr>
<td>Wildlife Laboratories, Inc., 1401 Duff Dr., Suite 600, Fort Collins, CO 80524</td>
<td>053923</td>
</tr>
<tr>
<td>Zoetis Inc., 833 Portage St., Kalamazoo, MI 49007</td>
<td>054771</td>
</tr>
</tbody>
</table>

### (2) NUMERICAL LISTING OF SPONSORS

<table>
<thead>
<tr>
<th>Firm name and address</th>
<th>Drug labeler code</th>
</tr>
</thead>
<tbody>
<tr>
<td>000061</td>
<td>Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940.</td>
</tr>
<tr>
<td>000115</td>
<td>IMPAX Laboratories, Inc., 30831 Hunton Ave., Hayward, CA 94544.</td>
</tr>
<tr>
<td>000402</td>
<td>Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA 92880.</td>
</tr>
<tr>
<td>000409</td>
<td>Hospira Inc., 275 North Field Dr., Lake Forest, IL 60045.</td>
</tr>
<tr>
<td>000859</td>
<td>Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201.</td>
</tr>
<tr>
<td>000966</td>
<td>Elanco Animal Health, A Division of Eli Lilly &amp; Co., Lilly Corporate Center, Indianapolis, IN 46285.</td>
</tr>
<tr>
<td>010109</td>
<td>Baxter Healthcare Corp., One Baxter Plwy., Deerfield, IL 60015.</td>
</tr>
<tr>
<td>010155</td>
<td>G. C. Hrantian Manufacturing Co., P.O. Box 1017, Syracuse, NY 13201.</td>
</tr>
<tr>
<td>010797</td>
<td>Luitpold Pharmaceuticals, Inc., Animal Health Division, Shirley, NY 11967.</td>
</tr>
<tr>
<td>012286</td>
<td>ADM Alliance Nutrition, Inc., 1000 North 30th St., Quincy, IL 62305-3115.</td>
</tr>
<tr>
<td>012578</td>
<td>Janssen Pharmaceutica NV, Turnhoutseweg 30, B–2340 Beerse, Belgium.</td>
</tr>
<tr>
<td>013744</td>
<td>Ceva Sante Animale, 10 Avenue de la Ballastière, 33500 Libourne, France.</td>
</tr>
<tr>
<td>015331</td>
<td>Pharmaq AS, Skogmo Induforomme, N–7863 Overhaug, Norway.</td>
</tr>
<tr>
<td>015569</td>
<td>Fleming Laboratories, Inc., P.O. Box 34384, Charlotte, NC 28234.</td>
</tr>
<tr>
<td>016592</td>
<td>Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sofia, Bulgaria.</td>
</tr>
<tr>
<td>017097</td>
<td>Vetoquinol USA, Inc., 4250 N. Sylvania Ave., Fort Worth, TX 76137.</td>
</tr>
<tr>
<td>017135</td>
<td>Farnam Companies, Inc., 301 West Osborn, Phoenix, AZ 85013-3928.</td>
</tr>
<tr>
<td>017153</td>
<td>Squire Laboratories, Inc., 100 Mill St., Revere, MA 02151.</td>
</tr>
<tr>
<td>017762</td>
<td>Agri-Tech, Inc., 4722 Broadway, Kansas City, MO 64112.</td>
</tr>
<tr>
<td>017800</td>
<td>Purina Animal Nutrition, 1080 County Road F West, Shoreview, MN 55126-2910.</td>
</tr>
<tr>
<td>020191</td>
<td>ConAgra Pet Products Co., 3902 Leavenworth St., Omaha, NE 68105.</td>
</tr>
<tr>
<td>023851</td>
<td>Happy Jack, Inc., Snow Hill, NC 28580.</td>
</tr>
<tr>
<td>025463</td>
<td>Fougera Pharmaceuticals, Inc., P.O. Box 2006, 60 Baylis Rd., Melville, NY 11747.</td>
</tr>
<tr>
<td>026637</td>
<td>Putney, Inc., One Monument Sq., Suite 400, Portland, ME 04101.</td>
</tr>
<tr>
<td>037990</td>
<td>Summit Hill Laboratories, P.O. Box 535, Navesink, NJ 07752.</td>
</tr>
<tr>
<td>042552</td>
<td>Pharmacosmos, Inc., 776 Mountain Blvd., Watchung, NJ 07069.</td>
</tr>
<tr>
<td>042791</td>
<td>HG Specialty Pharm Corp., 120 Rte. 17 North, Suite 130, Paramus, NJ 07652.</td>
</tr>
<tr>
<td>042976</td>
<td>GTC Biotherapeutics, Inc., 175 Crossing Blvd., Framingham, MA 01702.</td>
</tr>
<tr>
<td>Drug labeler code</td>
<td>Firm name and address</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>042264</td>
<td>DeChra, Ltd., Snaygill Industrial Estate, Keighley Rd., Skipton, North Yorkshire, BD23 2RW, United Kingdom.</td>
</tr>
<tr>
<td>045480</td>
<td>Jurca Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320, Australia.</td>
</tr>
<tr>
<td>047026</td>
<td>Natchez Animal Supply Co., 201 John R. Junkin Dr., Natchez, MS 39120.</td>
</tr>
<tr>
<td>050027</td>
<td>Pharmaceutical Ventures, Ltd., P.O. Box D1400, Pomona, NY 10970.</td>
</tr>
<tr>
<td>050378</td>
<td>Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA 98248.</td>
</tr>
<tr>
<td>050504</td>
<td>Inc., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096–4640.</td>
</tr>
<tr>
<td>050329</td>
<td>Nexxyn Pharmaceuticals, Inc., 644 West Washington Ave., Madison, WI 53719.</td>
</tr>
<tr>
<td>050172</td>
<td>Aurora Pharmaceutical, LLC, 1196 Highway 3 South, Northfield, MN 55073–3009.</td>
</tr>
<tr>
<td>050145</td>
<td>Mylan Institutional, Inc., 12720 Dairy Ashford Rd., Sugar Land, TX 77478.</td>
</tr>
<tr>
<td>050123</td>
<td>JBS United Animal Health II LLC, 322 S. Main St., Sheridan, IN 46069.</td>
</tr>
<tr>
<td>050127</td>
<td>Cooperative Research Farms, Box 69, Charlotteville, NY 12036.</td>
</tr>
<tr>
<td>050131</td>
<td>Vetac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137.</td>
</tr>
<tr>
<td>050130</td>
<td>Thom Bioscience LLC, 1044 East Chestnut St., Louisville, KY 40204.</td>
</tr>
<tr>
<td>050136</td>
<td>Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Dr., Hawthorne, NY 10532.</td>
</tr>
<tr>
<td>050143</td>
<td>Orion Corp., Orionnett 1, 02000 Espoo, Finland.</td>
</tr>
<tr>
<td>050114</td>
<td>Oasmos Pharmaceutical AB, Vallgorgatan 1, 75228 Uppsala, Sweden.</td>
</tr>
<tr>
<td>050125</td>
<td>Wildlife Laboratories, Inc., 1401 Duff Dr., Suite 600, Fort Collins, CO 80524.</td>
</tr>
<tr>
<td>050125</td>
<td>Zoetis Inc., 339 Portage St., Kalamazoo, MI 49007.</td>
</tr>
<tr>
<td>050125</td>
<td>Med-Pharmex, Inc., 2727 Scotland Creek Rd., Pomona, CA 91767–1861.</td>
</tr>
<tr>
<td>050125</td>
<td>Northbrook Laboratories, Ltd., Station Works, Nevery BT35 6UP, Northern Ireland.</td>
</tr>
<tr>
<td>050125</td>
<td>Agi Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO 64503.</td>
</tr>
<tr>
<td>050125</td>
<td>Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215.</td>
</tr>
<tr>
<td>050125</td>
<td>RSR Laboratories, Inc., 501 Fifth St., Bristol, TN 37620.</td>
</tr>
<tr>
<td>050125</td>
<td>First Priority, Inc., 1590 Todd Farm Dr., Elgin, IL 60123.</td>
</tr>
<tr>
<td>050125</td>
<td>Neogen Corp., 944 Nandino Blvd., Lexington, KY 40511.</td>
</tr>
<tr>
<td>050125</td>
<td>Hikma International Pharmaceuticals LLC, P.O. Box 182400, Bayyad Wadi Seer, Amman, Jordan 11118.</td>
</tr>
<tr>
<td>050125</td>
<td>Scevala S.A., 200 Avenue de Mayenne, 53000 Laval, France.</td>
</tr>
<tr>
<td>050125</td>
<td>Akorn Animal Health, Inc., 1925 West Field Ct., suite 300, Lake Forest, IL 60045.</td>
</tr>
<tr>
<td>050125</td>
<td>Planalquimica Industrial Ltda., Rua das Magnoalias nr. Jardim das Bandeiras, CEP 13053–120, Campinas, Sao Paulo, Brazil.</td>
</tr>
<tr>
<td>050125</td>
<td>Anika Therapeutics Inc., 236 West Cummings Park, Woburn, MA 01801.</td>
</tr>
<tr>
<td>050125</td>
<td>Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.</td>
</tr>
<tr>
<td>050125</td>
<td>Chanellte Pharmaceuticals Manufacturing Ltd., Loughrhea, County Galway, Ireland.</td>
</tr>
<tr>
<td>060220</td>
<td>Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd., Largo, FL 33777.</td>
</tr>
<tr>
<td>060274</td>
<td>Mylan Bectek Pharmaceuticals, Inc., 12720 Dairy Ashford, Sugar Land, TX 77478.</td>
</tr>
<tr>
<td>060274</td>
<td>Hemoglobin Oxygen Therapeutics, LLC, 674 Souther Rd., Souderton, PA 18964.</td>
</tr>
<tr>
<td>060274</td>
<td>Sioux Biochemical, Inc., 204 Third St. NW, Sioux Center, IA 51250.</td>
</tr>
<tr>
<td>060274</td>
<td>Mylan Institutional, LLC, 4901 Haxathwa Dr., Rockford, IL 61103.</td>
</tr>
<tr>
<td>060274</td>
<td>Heska Corp., 1829 Sharp Point Dr., Fort Collins, CO 80525.</td>
</tr>
<tr>
<td>060274</td>
<td>Piromal Healthcare Ltd., Piromal Tower, Ganpatpato Kadam Marg, Lower Parel, Mumbai - 400 013, India.</td>
</tr>
<tr>
<td>060274</td>
<td>IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd., Greensboro, NC 27409.</td>
</tr>
<tr>
<td>060274</td>
<td>American Pharmaceuticals and Cosmetics, Inc., 1401 Joel East Rd., Fort Worth, TX 76140.</td>
</tr>
<tr>
<td>060274</td>
<td>Primal Critical Care, Inc., 3850 Scheileen Circle, Bethlehem, PA 18017.</td>
</tr>
<tr>
<td>060274</td>
<td>SCOL LLC, 344 Nassau St., Princeton, NJ 08540.</td>
</tr>
<tr>
<td>060274</td>
<td>813 Thompson Creek Rd., Pomona, CA 91767–1861.</td>
</tr>
<tr>
<td>060274</td>
<td>Med-Pharmex, Inc., 2727 Scotland Creek Rd., Pomona, CA 91767.</td>
</tr>
<tr>
<td>060274</td>
<td>Ridley U.S. Holdings, Inc., 424 N. Riverfront Dr., P.O. Box 8500, Mankato, MN 56002–8500.</td>
</tr>
<tr>
<td>060274</td>
<td>Block Operations Inc., 424 North Riverfront Dr., P.O. Box 8500, Mankato, MN 56002–8500.</td>
</tr>
<tr>
<td>060274</td>
<td>Cephalzone Pharma, LLC, 250 East Bonita Ave., Pomona, CA 91767.</td>
</tr>
<tr>
<td>060274</td>
<td>Adionis Pharma LLC, 2 Tower Center Blvd., Suite 1101, East Brunswick, NJ 08816.</td>
</tr>
<tr>
<td>060274</td>
<td>Pharmgate LLC, 1015 Ashes Dr., Suite 102, Wilmington, DE 19808.</td>
</tr>
<tr>
<td>060274</td>
<td>Tek Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218.</td>
</tr>
<tr>
<td>060274</td>
<td>Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville, NC 28349.</td>
</tr>
<tr>
<td>060274</td>
<td>SmartVet USA, Inc., 22201 West Innovation Dr., Suite 170A, Olathe, KS 66061–1304.</td>
</tr>
<tr>
<td>060274</td>
<td>SANL, Chemin de Champoux, Quartier Violesi, 13320 Bouc Bel Air, France.</td>
</tr>
<tr>
<td>060274</td>
<td>LFBI USA, Inc., 175 Crossing Blvd., Framingham, MA 01702.</td>
</tr>
<tr>
<td>060274</td>
<td>Aquabounty Technologies Inc., Two Clock Tower Pl., suite 395, Maynard, MA 01754.</td>
</tr>
</tbody>
</table>
PART 511—NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE

Sec. 511.1 New animal drugs for investigational use exempt from section 512(a) of the act.

511.3 Definitions.


§ 511.1 New animal drugs for investigational use exempt from section 512(a) of the act.

(a) New animal drugs for tests in vitro and in laboratory research animals. (1) A shipment or other delivery of a new animal drug or animal feed containing a new animal drug intended solely for tests in vitro or in animals used only for research purposes shall be exempt from section 512 (a) and (m) of the act if it is labeled as follows:

Caution. Contains a new animal drug for investigational use only in laboratory research animals or for tests in vitro. Not for use in humans.

(2) The person distributing or causing the distribution of new animal drugs for tests in vitro or in animals used only for research purposes under this exemption shall use due diligence to assure that the consignee is regularly engaged in conducting such tests and that the shipment of the new animal drug will actually be used for tests in vitro or in animals used only for research purposes.

(3) The person who introduced such shipment or who delivered the new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the expert or expert organization to whom the new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. Upon the request of a properly authorized employee of the Department at reasonable times, he shall make such records available for inspection and copying.

(4) The exemption allowed in this paragraph shall not apply to any new animal drug intended for in vitro use in the regular course of diagnosing or treating disease, including antibacterial sensitivity discs impregnated with any new animal drug or drugs, which discs are intended for use in determining susceptibility of microorganisms to the new animal drug or drugs.

(b) New animal drugs for clinical investigation in animals. A shipment or other delivery of a new animal drug or an animal feed containing a new animal drug intended for clinical investigative use in animals shall be exempt from section 512(a) and (m) of the act if all the following conditions are met:

(1) The label shall bear the statements:

Caution. Contains a new animal drug for use only in investigational animals in clinical trials. Not for use in humans. Edible products of investigational animals are not to be used for food unless authorization has been granted by the U.S. Food and Drug Administration or by the U.S. Department of Agriculture.

In the case of containers too small or otherwise unable to accommodate a label with sufficient space to bear the caution statements required by paragraph (a) or (b) of this section, the statements may be included on the carton label and other labeling on or within the package from which the new animal drug is to be dispensed.

(2) The person or firm distributing or causing the distribution of the new animal drug or animal feed containing a new animal drug shall use due diligence to assure that the new animal drug or animal feed containing a new
animal drug will actually be used for tests in animals and is not used in humans.

(3) The person who introduced such shipment or who delivered the new animal drug or animal feed containing a new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the investigator to whom the new animal drug or animal feed containing a new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. Upon the request of a properly authorized employee of the Department at reasonable times, such records shall be made available for inspection and copying.

(4) Prior to shipment of the new animal drug for clinical tests in animals, the sponsor of the investigation shall submit in triplicate to FDA a “Notice of Claimed Investigational Exemption for a New Animal Drug” including a signed statement containing the following information:

(i) The identity of the new animal drug.

(ii) All labeling and other pertinent information to be supplied to the investigators. When such pertinent information includes nonclinical laboratory studies, the information shall include, with respect to each nonclinical study, either a statement that the study was conducted in compliance with the requirements set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance.

(iii) The name and address of each clinical investigator.

(iv) The approximate number of animals to be treated (or if not available, the amount of new animal drug to be shipped).

(v) If the new animal drug is given to food-producing animals, the statement shall contain the following additional information:

(a) A commitment that the edible products from such animals shall not be used for food without prior authorization in accordance with the provisions prescribed in this section.

(b) Approximate dates of the beginning and end of the experiment or series of experiments.

(c) The maximum daily dose(s) to be administered to a given species, the size of animal, maximum duration of administration, method(s) of administration, and proposed withdrawal time, if any.

(vi) If a sponsor has transferred any obligations for the conduct of any clinical study to a contract research organization, a statement containing the name and address of the contract research organization, identification of the clinical study, and a listing of the obligations transferred. If all obligations governing the conduct of the study have been transferred, a general statement of this transfer—in lieu of a listing of the specific obligations transferred—may be submitted.

(5) Authorization for use of edible products derived from a treated food-producing animal may be granted under the provisions of this section and when the following specified conditions are met, except that in the case of an animal administered any unlicensed experimental veterinary biological product regulated under the viruses, serums, toxins statute (21 U.S.C., chapter V, sec. 151 et seq.) the product shall be exempt from the requirements of this section when U.S. Department of Agriculture approval has been obtained as provided in 9 CFR 103.2. Conditional authorization may be granted in advance of identification of the name(s) and address(es) of the clinical investigator(s) as required by paragraph (b)(4)(iii) of this section. Information required for authorization shall include, in addition to all other requirements of this section, the following:

(i) Data to show that consumption of food derived from animals treated at the maximum levels with the minimum withdrawal periods, if any, specified in accordance with paragraph (b)(4)(v)(c) of this section, will not be inconsistent with the public health; or

(ii) Data to show that food derived from animals treated at the maximum levels and with the minimum withdrawal periods, if any, specified in accordance with paragraph (b)(4)(v)(c) of this section, does not contain drug residues or metabolites.
(iii) The name and location of the packing plant where the animals will be processed, except that this requirement may be waived, on request, by the terms of the authorization.

Authorizations granted under this paragraph do not exempt investigational animals and their products from compliance with other applicable inspection requirements. Any person who contests a refusal to grant such authorization shall have an opportunity for a regulatory hearing before FDA pursuant to part 16 of this chapter.

(6) On written request of FDA, the sponsor shall submit any additional information reported to or otherwise received by him with respect to the investigation deemed necessary to facilitate a determination whether there are grounds in the interest of public health for terminating the exemption.

(7) The sponsor shall assure himself that the new animal drug is shipped only to investigators who:

(i) Are qualified by scientific training and experience to evaluate the safety and/or effectiveness of the new animal drug.

(ii) Shall maintain complete records of the investigations, including complete records of the receipt and disposition of each shipment or delivery of the new animal drug under investigation. Copies of all records of the investigation shall be retained by the investigator for 2 years after the termination of the investigation or approval of a new animal drug application.

(iii) Shall furnish adequate and timely reports of the investigation to the sponsor.

(8) The sponsor:

(i) Shall retain all reports received from investigators for 2 years after the termination of the investigation or approval of a new animal drug application and make such reports available to a duly authorized employee of the Department for inspection at all reasonable times.

(ii) Shall provide for current monitoring of the investigation by a person qualified by scientific training and experience to evaluate information obtained from the investigation, and shall promptly investigate and report to FDA and to all investigators any findings associated with use of the new animal drug that may suggest significant hazards pertinent to the safety of the new animal drug.

(iii) Shall not unduly prolong distribution of the new animal drug for investigational use.

(iv) Shall not, nor shall any person acting for or on behalf of the sponsor, represent that the new animal drug is safe or effective for the purposes for which it is under investigation. This requirement is not intended to restrict the full exchange of scientific information.

(v) Shall not commercially distribute nor test-market the new animal drug until a new animal drug application is approved pursuant to section 512(c) of the act.

(9) If the shipment or other delivery of the new animal drug is imported or offered for importation into the United States for clinical investigational use in animals, it shall also meet the following conditions:

(i) The importer of all such shipments or deliveries is an agent of the foreign exporter residing in the United States or the ultimate consignee, which person has, prior to such shipments and deliveries, informed FDA of his intention to import the new animal drug as sponsor in compliance with the conditions prescribed in this subdivision; or

(ii) The new animal drug is shipped directly to a scientific institution with adequate facilities and qualified personnel to conduct laboratory or clinical investigations and is intended solely for use in such institutions and which institution has submitted a statement as sponsor of the investigation.

(10) The sponsor shall submit either a claim for categorical exclusion under §25.30 or §25.33 of this chapter or an environmental assessment under §25.40 of this chapter.

(c) Disqualification of a clinical investigator.

(1) If FDA has information indicating that an investigator (including a sponsor-investigator) has repeatedly or deliberately failed to comply with the conditions of these exempting regulations or has repeatedly or deliberately submitted to FDA or to the
Food and Drug Administration, HHS § 511.1

(1) sponsor false information in any required report, the Center for Veterinary Medicine will furnish the investigator written notice of the matter complained of and offer the investigator an opportunity to explain the matter in writing, or, at the option of the investigator, in an informal conference. If an explanation is offered and accepted by the Center for Veterinary Medicine, the Center will discontinue the disqualification proceeding. If an explanation is offered but not accepted by the Center for Veterinary Medicine, the investigator will be given an opportunity for a regulatory hearing under part 16 of this chapter on the question of whether the investigator is eligible to receive test articles under this part and eligible to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA.

(2) After evaluating all available information, including any explanation presented by the investigator, if the Commissioner determines that the investigator has repeatedly or deliberately failed to comply with the conditions of the exempting regulations in this subchapter, or has repeatedly or deliberately submitted to FDA or to the sponsor false information in any required report, the Commissioner will notify the investigator and the sponsor of any investigation in which the investigator has been named as a participant that the investigator is not eligible to receive test articles under this part. The notification to the investigator and sponsor will provide a statement of the basis for such determination. The notification also will explain that an investigator determined to be ineligible to receive test articles under this part will be ineligible to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA, including drugs, biologics, devices, new animal drugs, foods, including dietary supplements, that bear a nutrient content claim or a health claim, infant formulas, food and color additives, and tobacco products.

(3) Each application or submission to FDA under the provisions of this chapter containing data reported by an investigator who has been determined to be ineligible to receive FDA-regulated test articles is subject to examination to determine whether the investigator has submitted unreliable data that are essential to the continuation of an investigation or essential to the approval of a marketing application, or essential to the continued marketing of an FDA-regulated product.

(4) If the Commissioner determines, after the unreliable data submitted by the investigator are eliminated from consideration, that the data remaining are inadequate to support a conclusion that it is reasonably safe to continue the investigation, the Commissioner will notify the sponsor, who shall have an opportunity for a regulatory hearing under part 16 of this chapter. If a danger to the public health exists, however, the Commissioner shall terminate the exemption immediately and notify the sponsor of the termination. In such case, the sponsor shall have an opportunity for a regulatory hearing before FDA under part 16 on the question of whether the exemption should be reinstated. The determination that an investigation may not be considered in support of a research or marketing application or a notification or petition submission does not, however, relieve the sponsor of any obligation under any other applicable regulation to submit to FDA the results of the investigation.

(5) If the Commissioner determines, after the unreliable data submitted by the investigator are eliminated from consideration, that the continued approval of the product for which the data were submitted cannot be justified, the Commissioner will proceed to withdraw approval of the product in accordance with the applicable provisions of the relevant statutes.

(6) An investigator who has been determined to be ineligible under paragraph (c)(2) of this section may be reinstalled as eligible when the Commissioner determines that the investigator has presented adequate assurances that the investigator will employ all test articles, and will conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA, solely in compliance with the applicable provisions of this chapter.
§ 511.3 Definitions.

As used in this part:  
Contract research organization means a person that assumes, as an independent contractor with the sponsor, one or more of the obligations of a sponsor, e.g., design of a protocol, selection or monitoring of investigations, evaluation of reports, and preparation of materials to be submitted to FDA.  
Investigator means an individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. “Sub-investigator” includes any other individual member of that team.  
Sponsor means a person who takes responsibility for and initiates a clinical investigation. The sponsor may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual that uses one or more of its own employees to conduct an investigation that it has
Food and Drug Administration, HHS

initiated is a sponsor, not a sponsor-investigator, and the employees are investigators.

Sponsor-Investigator means an individual who both initiates and conducts an investigation, and under whose immediate direction the investigational drug is administered or dispensed. The term does not include any person other than an individual. The requirements applicable to a sponsor-investigator under this part include both those applicable to an investigator and a sponsor.

[77 FR 25359, Apr. 30, 2012]

PART 514—NEW ANIMAL DRUG APPLICATIONS

Subpart A—General Provisions

Sec.
514.1 Applications.
514.3 Definitions.
514.4 Substantial evidence.
514.5 Presubmission conferences.
514.6 Amended applications.
514.7 Withdrawal of applications without prejudice.
514.8 Supplements and other changes to an approved application.
514.11 Confidentiality of data and information in a new animal drug application file.
514.12 Confidentiality of data and information in an investigational new animal drug notice.
514.15 Untrue statements in applications.

Subpart B—Administrative Actions on Applications

514.80 Records and reports concerning experience with approved new animal drugs.
514.100 Evaluation and comment on applications.
514.106 Approval of applications.
514.110 Reasons for refusing to file applications.
514.111 Refusal to approve an application.
514.115 Withdrawal of approval of applications.
514.116 Notice of withdrawal of approval of application.
514.117 Adequate and well-controlled studies.
514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application.
514.121 Service of notices and orders.

§ 514.1

Subpart C—Hearing Procedures
514.200 Contents of notice of opportunity for a hearing.
514.201 Procedures for hearings.

Subparts D—E [Reserved]

Subpart F—Judicial Review
514.235 Judicial review.


SOURCE: 40 FR 13825, Mar. 27, 1975, unless otherwise noted.

Subpart A—General Provisions

§ 514.1 Applications.

(a) Applications to be filed under section 512(b) of the act shall be submitted in the form and contain the information described in paragraph (b) of this section, as appropriate to support the particular submission. If any part of the application is in a foreign language, an accurate and complete English translation shall be appended to such part. Translations of literature printed in a foreign language shall be accompanied by copies of the original publication. The application must be signed by the applicant or by an authorized attorney, agent, or official. If the applicant or such authorized representative does not reside or have a place of business within the United States, the application must also furnish the name and post office address of, and must be countersigned by, an authorized attorney, agent, or official residing or maintaining a place of business within the United States. Pertinent information may be incorporated in, and will be considered as part of, an application on the basis of specific reference to such information, including information submitted under the provisions of §511.1 of this chapter, in the files of the Food and Drug Administration; however, the reference must be specific in identifying the information. Any reference to information furnished by a person other than the applicant may not be considered unless its use is authorized in a written statement signed by the person who submitted it.

(b) Applications for new animal drugs shall be submitted in triplicate and assembled in the manner prescribed by
paragraph (b)(15) of this section, and shall include the following information, as appropriate to support the particular submission:

(1) Identification. Whether the submission is an original or supplemental application; the name and the address of the applicant; the date of the application; the trade name(s) (if one has been proposed) and chemical name(s) of the new animal drug. Upon receipt, the application will be assigned a number NADA, which shall be used for all correspondence with respect to the application.

(2) Table of contents and summary. The application shall be organized in a cohesive fashion, shall contain a table of contents which identifies the data and other material submitted, and shall contain a well-organized summary and evaluation of the data in the following form:

(a) Chemistry:
   (a) Chemical structural formula or description for any new animal drug substance.
   (b) Relationship to other chemically or pharmacologically related drugs.
   (c) Description of dosage form and quantitative composition.

(b) Scientific rationale and purpose the new animal drug is to serve:
   (a) Clinical purpose.
   (b) Highlights of laboratory studies: The reasons why certain types of studies were done or omitted as related to the proposed conditions of use and to information already known about this class of compounds. Emphasize any unusual or particularly significant pharmacological effects or toxicological findings.
   (c) Highlights of clinical studies: The rationale of the clinical study plan showing why types of studies were done, amended, or omitted as related to laboratory studies and prior clinical experience.
   (d) Conclusions: A short statement of conclusions combining the major points of effectiveness and safety as they relate to the use of the new animal drug.

(3) Labeling. Three copies of each piece of all labeling to be used for the article (total of 9):
   (i) All labeling should be identified to show its position on, or the manner in which it is to accompany the market package.
   (ii) Labeling for nonprescription new animal drugs should include adequate directions for use by the layman under all conditions of use for which the new animal drug is intended, recommended, or suggested in any of the labeling or advertising sponsored by the applicant.
   (iii) Labeling for prescription veterinary drugs should bear adequate information for use under which veterinarians can use the new animal drug safely and for the purposes for which it is intended, including those purposes for which it is to be advertised or represented, in accord with §201.105 of this chapter.
   (iv) All labeling for prescription or nonprescription new animal drugs shall be submitted with any necessary use restrictions prominently and conspicuously displayed.

(v) Labeling for new animal drugs intended for use in the manufacture of medicated feeds shall include:
   (a) Specimens of labeling to be used for such new animal drug with adequate directions for the manufacture and use of finished feeds for all conditions for which the new animal drug is intended, recommended, or suggested in any of the labeling, including advertising, sponsored by the applicant. Ingredient labeling may utilize collective names as provided in §501.110 of this chapter.
   (b) Representative labeling proposed to be used for Type B and Type C medicated feeds containing the new animal drug.

(vi) Draft labeling may be submitted for preliminary consideration of an application. Final printed labeling will ordinarily be required prior to approval of an application. Proposed advertising for veterinary prescription drugs may be submitted for comment or approval.

(4) Components and composition. A complete list of all articles used for production of the new animal drug including a full list of the composition of each article:
   (i) A full list of the articles used as components of the new animal drug. This list should include all substances used in the synthesis, extraction, or other method of preparation of any
new animal drug and in the preparation of the finished dosage form, regardless of whether they undergo chemical change or are removed in the process. Each component should be identified by its established name, if any, or complete chemical name, using structural formulas when necessary for specific identification. If any proprietary name is used, it should be followed by a complete quantitative statement of composition. Reasonable alternatives for any listed component may be specified.

(ii) A full statement of the composition of the new animal drug. The statement shall set forth the name and amount of each ingredient, whether active or not, contained in a stated quantity of the new animal drug in the form in which it is to be distributed (for example, amount per tablet or milliliter) and a batch formula representative of that to be employed for the manufacture of the finished dosage form. All components should be included in the batch formula regardless of whether they appear in the finished product. Any calculated excess of an ingredient over the label declaration should be designated as such and percent excess shown. Reasonable variation may be specified.

(iii) If it is a new animal drug produced by fermentation:
   (a) Source and type of microorganism used to produce the new animal drug.
   (b) Composition of media used to produce the new animal drug.
   (c) Type of precursor used, if any, to guide or enhance production of the antibiotic during fermentation.
   (d) Name and composition of preservative, if any, used in the broth.
   (e) A complete description of the extraction and purification processes including the names and compositions of the solvents, precipitants, ion exchange resins, emulsifiers, and all other agents used.
   (f) If the new animal drug is produced by a catalytic hydrogenation process (such as tetracycline from chlorotetracycline), a complete description of each chemical reaction with graphic formulas used to produce the new animal drug, including the names of the catalyst used, how it is removed, and how the new animal drug is extracted and purified.

(5) Manufacturing methods, facilities, and controls. A full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of the new animal drug. This description should include full information with respect to any new animal drug in sufficient detail to permit evaluation of the adequacy of the described methods of manufacture, processing, and packing, and the described facilities and controls to determine and preserve the identity, strength, quality, and purity of the new animal drug, and the following:
   (i) If the applicant does not himself perform all the manufacturing, processing, packaging, labeling, and control operations for any new animal drug, he shall: Identify each person who will perform any part of such operations and designate the part; and provide a signed statement from each such person fully describing, directly or by reference, the methods, facilities, and controls he will use in his part of the operation. The statement shall include a commitment that no changes will be made without prior approval by the Food and Drug Administration, unless permitted under §514.8.
   (ii) A description of the qualifications, including educational background and experience, of the technical and professional personnel who are responsible for assuring that the new animal drug has the identity, strength, quality, and purity it purports or is represented to possess, and a statement of their responsibilities.
   (iii) A description of the physical facilities including building and equipment used in manufacturing, processing, packaging, labeling, storage, and control operations.
   (iv) The methods used in the synthesis, extraction, isolation, or purification of any new animal drug. When the specifications and controls applied to such new animal drugs are inadequate in themselves to determine its identity, strength, quality, and purity, the methods should be described in sufficient detail, including quantities used, times, temperature, pH, solvents, etc., to determine these characteristics. Alternative methods or variations
in methods within reasonable limits that do not affect such characteristics of the new animal drug may be specified. A flow sheet and indicated equations should be submitted when needed to explain the process.

(v) Precautions to insure proper identity, strength, quality, and purity of the raw materials, whether active or not, including:

(a) The specifications for acceptance and methods of testing for each lot of raw material.

(b) A statement as to whether or not each lot of raw materials is given a serial number to identify it, and the use made of such numbers in subsequent plant operations.

(vi) The instructions used in the manufacturing, processing, packaging, and labeling of each dosage form of the new animal drug, including:

(a) The method of preparation of the master formula records and individual batch records and the manner in which these records are used.

(b) The number of individuals checking weight or volume of each individual ingredient entering into each batch of the new animal drug.

(c) A statement as to whether or not the total weight or volume of each batch is determined at any stage of the manufacturing process subsequent to making up a batch according to the formula card and, if so, at what stage and by whom it is done.

(d) The precautions used in checking the actual package yield produced from a batch of the new animal drug with the theoretical yield. This should include a description of the accounting for such items as discards, breakage, etc., and the criteria used in accepting or rejecting batches of drugs in the event of an unexplained discrepancy.

(e) The precautions used to assure that each lot of the new animal drug is packaged with the proper label and labeling, including provisions for labeling storage and inventory control.

(f) Any special precautions used in the operations.

(vii) The analytical controls used during the various stages of the manufacturing, processing, packaging, and labeling of the new animal drug, including a detailed description of the collection of samples and the analytical procedures to which they are subjected. The analytical procedures should be capable of determining the active components within a reasonable degree of accuracy and of assuring the identity of such components.

(a) A description of practicable methods of analysis of adequate sensitivity to determine the amount of the new animal drug in the final dosage form should be included. The dosage form may be a finished pharmaceutical product, a Type A medicated article, a Type B or a Type C medicated feed, or a product for use in animal drinking water. Where two or more active ingredients are included, methods should be quantitative and specific for each active ingredient.

(b) If the article is one that is represented to be sterile, the same information with regard to the manufacturing, processing, packaging, and the collection of samples of the drug should be given for sterility controls. Include the standards used for acceptance of each lot of the finished drug.

(viii) An explanation of the exact significance of any batch control numbers used in the manufacturing, processing, packaging, and labeling of the new animal drug, including such control numbers that may appear on the label of the finished article. State whether these numbers enable determination of the complete manufacturing history of the product. Describe any methods used to permit determination of the distribution of any batch if its recall is required.

(ix) Adequate information with respect to the characteristics of and the test methods employed for the container, closure, or other component parts of the drug package to assure their suitability for the intended use.

(x) A complete description of, and data derived from, studies of the stability of the new animal drug in the final dosage form, including information showing the suitability of the analytical methods used. A description of any additional stability studies underway or planned. Stability data for the finished dosage form of the new animal drug in the container in which it is to be marketed, including any proposed multiple dose container, and, if it is to
Food and Drug Administration, HHS

§ 514.1

be put into solution at the time of dispensing, for the solution prepared as directed. If the new animal drug is intended for use in the manufacture of Type C medicated feed as defined in §558.3 of this chapter, stability data derived from studies in which representative formulations of the medicated feed articles are used. Similar data may be required for Type B medicated feeds as determined by the Food and Drug Administration on a case-by-case basis. Expiration dates shall be proposed for finished pharmaceutical dosage forms and Type A medicated articles. If the data indicate that an expiration date is needed for Type B or Type C medicated feeds, the applicant shall propose such expiration date. If no expiration date is proposed for Type B or Type C medicated feeds, the applicant shall justify its absence with data.

(x) Additional procedures employed which are designed to prevent contamination and otherwise assure proper control of the product. An application may be refused unless it includes adequate information showing that the methods used in, and the facilities and controls used for, the manufacturing, processing, and packaging of the new animal drug are adequate to preserve its identity, strength, quality, and purity in conformity with good manufacturing practice and identifies each establishment, showing the location of the plant conducting these operations.

(6) Samples. Samples of the new animal drug and articles used as components and information concerning them may be requested by the Center for Veterinary Medicine as follows:

(i) Each sample shall consist of four identical, separately packaged subdivisions, each containing at least three times the amount required to perform the laboratory test procedures described in the application to determine compliance with its control specifications for identity and assays. Each of the samples submitted shall be appropriately packaged and labeled to preserve its characteristics, to identify the material and the quantity in each subdivision of the sample, and to identify each subdivision with the name of the applicant and the new animal drug application to which it relates. Included are:

(a) A sample or samples of any reference standard and blank used in the procedures described in the application for assaying each new animal drug and other assayed components of the finished new animal drug.

(b) A representative sample or samples of each strength of the finished dosage form proposed in the application and employed in the clinical investigations and a representative sample or samples of each new animal drug from the batch(es) employed in the production of such dosage form.

(c) A representative sample or samples of finished market packages of each strength of the dosage form of the new animal drug prepared for initial marketing and, if any such sample is not from a representative commercial-scale production batch, such a sample from a representative commercial-scale production batch, and a representative sample or samples of each new animal drug from the batch(es) employed in the production of such dosage form, provided that in the case of new animal drugs marketed in large packages the sample should contain only three times a sufficient quantity of the new animal drug to allow for performing the control tests for drug identity and assays.

(ii) The following information shall be included for the samples when requested:

(a) For each sample submitted, full information regarding its identity and the origin of any new animal drug contained therein (including a statement whether it was produced on a laboratory, pilot-plant, or full-production scale) and detailed results of all laboratory tests made to determine the identity, strength, quality, and purity of the batch represented by the sample, including assays.

(b) For any reference standard submitted, a complete description of its preparation and the results of all laboratory tests on it. If the test methods used differed from those described in the application, full details of the methods employed in obtaining the reporting results.

(7) Analytical methods for residues. Applications shall include a description of practicable methods for determining the quantity, if any, of the new animal
drug in or on food, and any substance formed in or on food because of its use, and the proposed tolerance or withdrawal period or other use restrictions to ensure that the proposed use of this drug will be safe. When data or other adequate information establish that it is not reasonable to expect the new animal drug to become a component of food at concentrations considered unsafe, a regulatory method is not required.

(i) The kind of information required by this subdivision may include: Complete experimental protocols for determining drug residue levels in the edible products, and the length of time required for residues to be eliminated from such products following the drug’s use; residue studies conducted under appropriate (consistent with the proposed usage) conditions of dosage, time, and route of administration to show levels, if any, of the drug and/or its metabolites in test animals during and upon cessation of treatment and at intervals thereafter in order to establish a disappearance curve; if the drug is to be used in combination with other drugs, possible effects of interaction demonstrated by the appropriate disappearance curve or depletion patterns after drug withdrawal under appropriate (consistent with the proposed usage) conditions of dosage, time, and route of administration; if the drug is given in the feed or water, appropriate consumption records of the medicated feed or water and appropriate performance data in the treated animal; if the drug is to be used in more than one species, drug residue studies or appropriate metabolic studies conducted for each species that is food-producing. To provide these data, a sufficient number of birds or animals should be used at each sample interval. Appropriate use of labeled compounds (e.g. radioactive tracers), may be utilized to establish metabolism and depletion curves. Drug residue levels ordinarily should be determined in muscle, liver, kidney, and fat and where applicable, in skin, milk, and eggs (yolk and egg white). As a part of the metabolic studies, levels of the drug or metabolite should be determined in blood where feasible. Samples may be combined where necessary. Where residues are suspected or known to be present in litter from treated animals, it may be necessary to include data with respect to such residues becoming components of other agricultural commodities because of use of litter from treated animals.

(ii) A new animal drug that has the potential to contaminate human food with residues whose consumption could present a risk of cancer to people must satisfy the requirements of subpart E of part 500 of this chapter.

(b) Evidence to establish safety and effectiveness. (i) An application may be refused unless it contains full reports of adequate tests by all methods reasonably applicable to show whether or not the new animal drug is safe and effective for use as suggested in the proposed labeling.

(ii) An application may be refused unless it includes substantial evidence of the effectiveness of the new animal drug as defined in §514.4.

(iii) An application may be refused unless it contains detailed reports of the investigations, including studies made on laboratory animals, in which the purpose, methods, and results obtained are clearly set forth of acute, subacute, and chronic toxicity, and unless it contains appropriate clinical laboratory results related to safety and efficacy. Such information should include identification of the person who conducted each investigation, a statement of where the investigations were conducted, and where the raw data are available in the application.

(iv) All information pertinent to an evaluation of the safety and effectiveness of the new animal drug received or otherwise obtained by the applicant from any source, including information derived from other investigations or commercial marketing (for example, outside the United States), or reports in the scientific literature, both favorable and unfavorable, involving the new animal drug that is the subject of the application and related new animal drugs shall be submitted. An adequate summary may be acceptable in lieu of a reprint of a published report that only supports other data submitted. Include any evaluation of the safety or effectiveness of the new animal drug that has been made by the applicant’s
Food and Drug Administration, HHS

§ 514.1

veterinary or medical department, expert committee, or consultants.

(v) If the new animal drug is a combination of active ingredients or animal drugs, an application may be refused unless it includes substantial evidence of the effectiveness of the combination new animal drug as required in §514.4.

(vi) An application shall include a complete list of the names and post office addresses of all investigators who received the new animal drug. This may be incorporated in whole or in part by reference to information submitted under the provisions of §511.1 of this chapter.

(vii) Explain any omission of reports from any investigator to whom the investigational new animal drug has been made available. The unexplained omission of any reports of investigations made with the new animal drug by the applicant or submitted to him by an investigator or the unexplained omission of any pertinent reports of investigations or clinical experience received or otherwise obtained by the applicant from published literature or other sources that would bias an evaluation of the safety of the new animal drug or its effectiveness in use, constitutes grounds for the refusal or withdrawal of the approval of an application.

(viii) If a sponsor has transferred any obligations for the conduct of any clinical study to a contract research organization, the application is required to include a statement containing the name and address of the contract research organization, identifying the clinical study, and listing the obligations transferred. If all obligations governing the conduct of the study have been transferred, a general statement of this transfer—in lieu of a listing of the specific obligations transferred—may be submitted.

(ix) If original subject records were audited or reviewed by the sponsor in the course of monitoring any clinical study to verify the accuracy of the case reports submitted to the sponsor, a list identifying each clinical study so audited or reviewed.

9) Veterinary feed directive. Three copies of a veterinary feed directive (VFD) must be submitted in a form that accounts for the information described under §§558.6(b)(3) and 558.6(b)(4) of this chapter.

10) Supplemental applications. If it is a supplemental application, full information shall be submitted on each proposed change concerning any statement made in the approved application.

11) Applicant’s commitment. It is understood that the labeling and advertising for the new animal drug will prescribe, recommend, or suggest its use only under the conditions stated in the labeling which is part of this application and if the article is a prescription new animal drug, it is understood that any labeling which furnishes or purports to furnish information for use or which prescribes, recommends, or suggests a dosage for use of the new animal drug will also contain, in the same language and emphasis, information for its use including indications, effects, dosages, routes, methods, and frequency and duration of administration, any relevant hazards, contraindications, side effects, and precautions contained in the labeling which is part of this application. It is understood that all representations in this application apply to the drug produced until changes are made in conformity with §514.8.

12) Additional commitments. (i) New animal drugs as defined in §510.3 of this chapter, intended for use in the manufacture of animal feeds in any State will be shipped only to persons who may receive such drugs in accordance with §510.7 of this chapter.

(ii) The methods, facilities, and controls described under item 5 of this application conform to the current good manufacturing practice regulations in subchapter C of this chapter.

(iii) With respect to each nonclinical laboratory study contained in the application, either a statement that the study was conducted in compliance with the good laboratory practice regulations set forth in part 56 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance.

13) [Reserved]

14) Environmental assessment. The applicant is required to submit either a claim for categorical exclusion under
§ 514.3

(15) Assembling and binding the application. Assemble and bind an original and two copies of the application as follows:

(i) Bind the original or ribbon copy of the application as copy No. 1.
(ii) Bind two identical copies as copy No. 2 and copy No. 3.
(iii) Identify each front cover with the name of the applicant, new animal drug, and the copy number.
(iv) Number each page of the application sequentially in the upper right hand corner or in another location so that the page numbers remain legible after the application has been bound, and organize the application consistent with paragraphs (b) (1) through (14) of this section. Each copy should bear the same page numbering, whether sequential in each volume or continuous and sequential throughout the application.
(v) Include complete labeling in each of the copies. It is suggested that labeling be identified by date of printing or date of preparation.
(vi) Submit separate applications for each different dosage form of the drug proposed. Repeating basic information pertinent to all dosage forms in each application is unnecessary if reference is made to the application containing such information. Include in each application information applicable to the specific dosage form, such as labeling, composition, stability data, and method of manufacture.
(vii) Submit in folders amendments, supplements, and other correspondence sent after submission of an original application. The front cover of these submissions should be identified with the name of the applicant, new animal drug, copy number, and the new animal drug application number, if known.
(c) When a new animal drug application is submitted for a new animal drug which has a stimulant, depressant, or hallucinogenic effect on the central nervous system, if it appears that the drug has a potential for abuse, the Commissioner shall forward that information to the Attorney General of the United States.

[40 FR 13825, Mar. 27, 1975]
§ 514.4 Substantial evidence.

(a) Definition of substantial evidence. Substantial evidence means evidence consisting of one or more adequate and well-controlled studies, such as a study in a target species, study in laboratory animals, field study, bioequivalence study, or an in vitro study, on the basis of which it could fairly and reasonably be concluded by experts qualified by scientific training and experience to evaluate the effectiveness of the new animal drug involved that the new animal drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof. Substantial evidence shall include such adequate and well-controlled studies that are, as a matter of sound scientific judgment, necessary to establish that a new animal drug will have its intended effect.

(b) Characteristics of substantial evidence—(1) Qualifications of experts. Any study that is intended to be part of substantial evidence of the effectiveness of a new animal drug shall be conducted by experts qualified by scientific training and experience.

(2) Intended uses and conditions of use. Substantial evidence of effectiveness of a new animal drug shall demonstrate that the new animal drug is effective for each intended use and associated conditions of use for and under which approval is sought.

(1) Dose range labeling. Sponsors should, to the extent possible, provide for a dose range because it increases the utility of the new animal drug by...
providing the user flexibility in the selection of a safe and effective dose. In general, substantial evidence to support dose range labeling for a new animal drug intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease must consist of at least one adequate and well-controlled study on the basis of which qualified experts could fairly and reasonably conclude that the new animal drug will be effective for the intended use at the lowest dose of the dose range suggested in the proposed labeling for that intended use. Substantial evidence to support dose range labeling for a new animal drug intended to affect the structure or function of the body of an animal generally must consist of at least one adequate and well-controlled study on the basis of which qualified experts could fairly and reasonably conclude that the new animal drug will be effective for the intended use at all doses within the range suggested in the proposed labeling for the intended use.

(ii) [Reserved]

(3) Studies—(i) Number. Substantial evidence of the effectiveness of a new animal drug for each intended use and associated conditions of use shall consist of a sufficient number of current adequate and well-controlled studies of sufficient quality and persuasiveness to permit qualified experts:

(A) To determine that the parameters selected for measurement and the measured responses reliably reflect the effectiveness of the new animal drug;

(B) To determine that the results obtained are likely to be repeatable, and that valid inferences can be drawn to the target animal population; and

(C) To conclude that the new animal drug is effective for the intended use at the dose or dose range and associated conditions of use prescribed, recommended, or suggested in the proposed labeling.

(ii) Types. Adequate and well-controlled studies that are intended to provide substantial evidence of the effectiveness of a new animal drug may include, but are not limited to, published studies, foreign studies, studies using models, and studies conducted by or on behalf of the sponsor. Studies using models shall be validated to establish an adequate relationship of parameters measured and effects observed in the model with one or more significant effects of treatment.

(c) Substantial evidence for combination new animal drugs—(1) Definitions. The following definitions of terms apply to this section:

(i) Combination new animal drug means a new animal drug that contains more than one active ingredient or animal drug that is applied or administered simultaneously in a single dosage form or simultaneously in or on animal feed or drinking water.

(ii) Dosage form combination new animal drug means a combination new animal drug intended for use other than in animal feed or drinking water.

(iii) Antibacterial with respect to a particular target animal species means an active ingredient or animal drug: That is approved in that species for the diagnosis, cure, mitigation, treatment, or prevention of bacterial disease; or that is approved for use in that species for any other use that is attributable to its antibacterial properties. But, antibacterial does not include ionophores or arsenicals intended for use in combination in animal feed or drinking water.

(iv) Appropriate concurrent use exists when there is credible evidence that the conditions for which the combination new animal drug is intended can occur simultaneously.

(2) Combination new animal drugs that contain only active ingredients or animal drugs that have previously been separately approved. (i) For dosage form combination new animal drugs, except for those that contain a nontopical antibacterial, that contain only active ingredients or animal drugs that have previously been separately approved for the particular uses and conditions of use for which they are intended in combination, a sponsor shall demonstrate:

(A) By substantial evidence, as defined in this section, that any active ingredient or animal drug intended only for the same use as another active ingredient or animal drug in the combination makes a contribution to the effectiveness of the combination new animal drug;

(B) That each active ingredient or animal drug intended for at least one
Food and Drug Administration, HHS

§ 514.5

use that is different from all the other active ingredients or animal drugs used in the combination provides appropriate concurrent use for the intended target animal population; and

(C) That the active ingredients or animal drugs are physically compatible and do not have disparate dosing regimens if FDA, based on scientific information, has reason to believe the active ingredients or animal drugs are physically incompatible or have disparate dosing regimens.

(ii) For combination new animal drugs intended for use in animal feed or drinking water that contain only active ingredients or animal drugs that have previously been separately approved for the particular uses and conditions of use for which they are intended in combination, the sponsor shall demonstrate:

(A) By substantial evidence, as defined in this section, that any active ingredient or animal drug intended only for the same use as another active ingredient or animal drug in the combination makes a contribution to the effectiveness of the combination new animal drug;

(B) For such combination new animal drugs that contain more than one antibacterial ingredient or animal drug, by substantial evidence, as defined in this section, that each antibacterial makes a contribution to labeled effectiveness;

(C) That each active ingredient or animal drug intended for at least one use that is different from all other active ingredients or animal drugs used in the combination provides appropriate concurrent use for the intended target animal population; and

(D) That the active ingredients or animal drugs intended for use in drinking water are physically compatible if FDA, based on scientific information, has reason to believe the active ingredients or animal drugs are physically incompatible.

(iii) Other combination new animal drugs. For all other combination new animal drugs, the sponsor shall demonstrate by substantial evidence, as defined in this section, that the combination new animal drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling and that each active ingredient or animal drug contributes to the effectiveness of the combination new animal drug.

[64 FR 40756, July 28, 1999]

§ 514.5 Presubmission conferences.

(a) General principle underlying the conduct of a presubmission conference. The general principle underlying the conduct of any presubmission conference is that there should be candid, full, and open communication.

(b) Requesting a presubmission conference. A potential applicant is entitled to one or more conferences prior to the submission of an NADA, supplemental NADA, or an ANADA to reach an agreement establishing part or all of a submission or investigational requirement. A potential applicant’s request for a presubmission conference must be submitted to FDA in a signed letter. The letter must include a proposed agenda that clearly outlines the scope, purpose, and objectives of the presubmission conference and must list the names and positions of the representatives who are expected to attend the presubmission conference on behalf of the applicant.

(c) Timing. A potential applicant may request one or more presubmission conferences at any time prior to the filing of a NADA, supplemental NADA, or an ANADA. A request for a presubmission conference must be received by FDA at least 30 calendar days in advance of the requested conference date. FDA will schedule the presubmission conference at a time agreeable to both FDA and the potential applicant.

(d) Advance information. The potential applicant must provide to FDA, at least 30 calendar days before a scheduled presubmission conference, a detailed agenda, a copy of any materials to be presented at the conference, a list of proposed indications and, if available, a copy of the proposed labeling for the product under consideration, and copies of materials evaluated or referenced relative to issues listed in the agenda for the conference. If the materials are not provided or are not sufficient to provide the basis for meaningful discussion, FDA may elect to postpone part or all of the meeting.
§ 514.5 Conduct of a presubmission conference.

The potential applicant and FDA may each bring consultants to the presubmission conference. The presubmission conference(s) will be directed primarily at establishing agreement between FDA and the potential applicant regarding a submission or investigational requirement. The submission or investigational requirement may include, among other things, the number, types, and general design of studies that are necessary to demonstrate the safety and effectiveness of a new animal drug for the intended uses and conditions of use prescribed, recommended, or suggested in the proposed labeling for the new animal drug.

(f) Documentation of a presubmission conference—(1) Memorandum of conference—(i) Preparation. FDA will prepare a memorandum for each presubmission conference that will include, among other things, any background pertinent to the request for meeting; a summary of the key points of discussion; agreements; and action items and assignments of responsibility. That portion of the memorandum of conference that documents any agreements reached regarding all or part of a submission or investigational requirement will be included under the heading “Presubmission Conference Agreement.” If the presubmission conference agreement section of the memorandum is silent on an issue, including one that was discussed in the conference or addressed by materials provided for the conference, such silence does not constitute agreement between FDA and the potential applicant on the issue.

(ii) Sending a copy to the potential applicant. FDA will send a copy of the memorandum to the potential applicant for review no later than 45 calendar days after the date of the conference.

(iii) Requests for changes or clarification. If a potential applicant requests changes to, or clarification of, the substance of the memorandum, the request must be sent to FDA within 30 calendar days from the date a copy of the memorandum is sent to the applicant. If the potential applicant requests changes or clarification, FDA will send the potential applicant a response to their request no later than 45 calendar days after the date of receipt of the request.

(iv) Administrative record. A copy of FDA’s original memorandum of conference and, as appropriate, a copy of an amended memorandum to correct or clarify the content of the original memorandum will be made part of the administrative file.

(2) Field studies. If FDA requires more than one field study to establish by substantial evidence that the new animal drug is effective for its intended uses under the conditions of use prescribed, recommended, or suggested in the proposed labeling, FDA will provide written scientific justification for requiring more than one field study. Such justification must be provided no later than 25 calendar days after the date of the conference at which the requirement for more than one field study is established. If FDA does not believe more than one field study is required but the potential applicant voluntarily proposes to conduct more than one field study, FDA will not provide such written justification. If FDA requires one field study to be conducted at multiple locations, FDA will provide justification for requiring multiple locations verbally during the presubmission conference and in writing as part of the memorandum of conference.

(g) Modification of presubmission conference agreements. An agreement made under a presubmission conference requested under section 512(b)(3) of the act and documented in a memorandum of conference is binding on the potential applicant and FDA and may only be modified if:

(1) FDA and the potential applicant mutually agree to modify, in part or in whole, the agreement and such modification is documented and provided to the potential applicant as described in paragraph (f)(1) of this section; or

(2) FDA by written order determines that a substantiated scientific requirement essential to the determination of safety or effectiveness of the new animal drug appeared after the conference.
(h) When the terms of a presubmission conference agreement are not valid

(1) A presubmission conference agreement will no longer be valid if:
   (i) The potential applicant makes to FDA, before, during, or after the pre-
       submission conference, any untrue statement of material fact; or
   (ii) The potential applicant fails to follow any material term of the agree-
       ment; and

(2) A presubmission conference may no longer be valid if the potential ap-

(i) Dispute resolution. FDA is com-
       mitted to resolving differences between
       a potential applicant and FDA review-
       ing divisions with respect to require-
       ments for the investigation of new ani-
       mal drugs and for NADAs, supple-
       mental NADAs, and ANADAs as quick-
       ly and amicably as possible through a
       cooperative exchange of information
       and views. When administrative or pro-
       cedural disputes arise, a potential ap-
       plicant should first attempt to resolve
       the matter within the appropriate re-
       view division beginning with the indi-
       vidual(s) most directly assigned to the
       review of the application or investiga-
       tional exemption. If the dispute cannot
       be resolved after such attempts, the
       dispute shall be evaluated and adminis-
       tered in accordance with applicable
       regulations (21 CFR 10.75). Dispute res-
       olution procedures may be further ex-
       plained by guidance available from the
       Center for Veterinary Medicine.

(69 FR 51170, Aug. 18, 2004)

§ 514.7 Withdrawal of applications without prejudice.

The sponsor may withdraw his pend-

i ng application from consideration as a

new animal drug application upon writ-

ten notification to the Food and Drug

Administration. Such withdrawal may

be made without prejudice to a future

filing. Upon resubmission, the time

limitation will begin to run from the

date the resubmission is received by the

Food and Drug Administration. The

original application will be re-

tained by the Food and Drug Adminis-

tration although it is considered with-

drawn. The applicant shall be furnished

a copy at cost on request.

§ 514.8 Supplements and other changes
to an approved application.

(a) Definitions. (1) The definitions and

interpretations contained in section 201

of the Federal Food, Drug, and Cos-

metic Act (the act) apply to those
terms when used in this part.

(2) The following definitions of terms
apply to this part:

(i) Assess the effects of the change

means to evaluate the effects of a man-

ufacturing change on the identity,

strength, quality, purity, and potency

of a drug as these factors may relate to

the safety or effectiveness of the drug.

(ii) Drug substance means an active

ingredient as defined under § 210.3(b)(7)

of this chapter.

(iii) Minor changes and stability report

(MCSR) means an annual report that is

submitted to the application once each

year within 60 days before or after the

anniversary date of the application’s

original approval or on a mutually

agreed upon date. The report must in-
clude minor manufacturing and control
changes made according to § 514.8(b)(4)
or state that no changes were made;
and stability data generated on com-
mercial or production batches accord-
ing to an approved stability protocol or
commitment.

(iv) Specification means the quality

standard (i.e., tests, analytical proce-
dures, and acceptance criteria) pro-
vided in an approved application to

confirm the quality of drugs including,
for example, drug substances, Type A
medicated articles, drug products,
intermediates, raw materials, reagents,
components, in-process materials, container closure systems, and other materials used in the production of a drug. For the purpose of this definition, the term “acceptance criteria” means numerical limits, ranges, or other criteria for the tests described.

(b) Manufacturing changes to an approved application—(1) General provisions. (i) The applicant must notify FDA about each change in each condition established in an approved application beyond the variations already provided for in the application. The notice is required to describe the change fully. Depending on the type of change, the applicant must notify FDA about it in a supplement under paragraph (b)(2) or (b)(3) of this section or by inclusion of the information in the annual report to the application under paragraph (b)(4) of this section.

(ii) The holder of an approved application under section 512 of the act must assess the effects of the change before distributing a drug made with a manufacturing change.

(iii) Notwithstanding the requirements of paragraphs (b)(2) and (b)(3) of this section, an applicant must make a change provided for in those paragraphs in accordance with a regulation or guidance that provides for a less burdensome notification of the change (for example, by submission of a supplement that does not require approval prior to distribution of the drug, or by notification in the next annual report described in paragraph (b)(4) of this section).

(iv) In each supplement and amendment to a supplement providing for a change under paragraph (b)(2) or (b)(3) of this section, the applicant must include a statement certifying that a field copy has been provided to the appropriate FDA district office. No field copy is required for a supplement providing for a change made to a drug manufactured outside of the United States.

(v) A supplement or annual report described in paragraph (b)(4) of this section must include a list of all changes contained in the supplement or annual report. For supplements, this list must be provided in the cover letter.

(2) Changes requiring submission and approval of a supplement prior to distribution of the drug made using the change (major changes). (i) A supplement must be submitted for any change in the drug, production process, quality controls, equipment, or facilities that has a substantial potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug as these factors may relate to the safety or effectiveness of the drug.

(ii) These changes include, but are not limited to:

(A) Except those described in paragraphs (b)(3) and (b)(4) of this section, changes in the qualitative or quantitative formulation of the drug, including inactive ingredients, or in the specifications provided in the approved application;

(B) Changes requiring completion of appropriate clinical studies to demonstrate the equivalence of the drug to the drug as manufactured without the change;

(C) Changes that may affect drug substance or drug product sterility assurance, such as changes in drug substance, drug product or component sterilization method(s) or an addition, deletion, or substitution of steps in an aseptic processing operation;

(D) Changes in the synthesis or manufacture of the drug substance that may affect the impurity profile and/or the physical, chemical, or biological properties of the drug substance;

(E) Changes in a drug product container closure system that controls the drug delivered to the animal or changes in the type or composition of a packaging component that may affect the impurity profile of the drug product;

(F) Changes solely affecting a natural product, a recombinant DNA-derived protein/polypeptide, or a complex or conjugate of a drug substance with a monoclonal antibody for the following:

(1) Changes in the virus or adventitious agent removal or inactivation method(s),

(2) Changes in the source material or cell line, and

(3) Establishment of a new master cell bank or seed;
(G) Changes to a drug under an application that is subject to a validity assessment because of significant questions regarding the integrity of the data supporting that application.

(iii) The applicant must obtain approval of a supplement from FDA prior to distribution of a drug made using a change under paragraph (b)(2) of this section. The supplement must be labeled “Prior Approval Supplement.” Except for submissions under paragraph (b)(2)(v) of this section, the following information must be contained in the supplement:

(A) A completed Form FDA 356V;

(B) A detailed description of the proposed change;

(C) The drug(s) involved;

(E) A description of the methods used and studies performed to assess the effects of the change;

(F) The data derived from such studies;

(G) Appropriate documentation (for example, updated master batch records, specification sheets) including previously approved documentation (with the changes highlighted) or references to previously approved documentation;

(H) For a natural product, a recombinant DNA-derived protein/polypeptide, or a complex or conjugate of a drug substance with a monoclonal antibody, relevant validation protocols and standard operating procedures must be provided in addition to the requirements in paragraphs (b)(2)(iii)(E) and (b)(2)(iii)(F) of this section;

(I) For sterilization process and test methodologies related to sterilization process validation, relevant validation protocols and a list of relevant standard operating procedures must be provided in addition to the requirements in paragraphs (b)(2)(iii)(E) and (b)(2)(iii)(F) of this section; and

(J) Any other information as directed by FDA.

(iv) An applicant may ask FDA to expedite its review of a supplement for public health reasons or if a delay in making the change described in it would impose an extraordinary hardship on the applicant. Such a supplement and its mailing cover must be plainly marked: “Prior Approval Supplement—Expedited Review Requested.”

(v) Comparability Protocols. An applicant may submit one or more protocols describing the specific tests and studies and acceptance criteria to be achieved to demonstrate the lack of adverse effect for specified types of manufacturing changes on the identity, strength, quality, purity, and potency of the drug as these factors may relate to the safety or effectiveness of the drug. Any such protocols, if not included in the approved application, or changes to an approved protocol must be submitted as a supplement requiring approval from FDA prior to distribution of the drug produced with the manufacturing change. The supplement, if approved, may subsequently justify a reduced reporting category for the particular change because the use of the protocol for that type of change reduces the potential risk of an adverse effect. A comparability protocol supplement must be labeled “Prior Approval Supplement—Comparability Protocol.”

(3) Changes requiring submission of a supplement at least 30 days prior to distribution of the drug made using the change (moderate changes). (i) A supplement must be submitted for any change in the drug, production process, quality controls, equipment, or facilities that has a moderate potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug as these factors may relate to the safety or effectiveness of the drug.

(ii) These changes include, but are not limited to:

(A) A change in the container closure system that does not affect the quality of the drug except as otherwise described in paragraphs (b)(2) and (b)(4) of this section;

(B) Changes solely affecting a natural protein, a recombinant DNA-derived protein/polypeptide or a complex or conjugate of a drug substance with a monoclonal antibody, including:

(1) An increase or decrease in production scale during finishing steps that involves different equipment, and

(2) Replacement of equipment with that of a different design that does not affect the process methodology or process operating parameters.
(C) Relaxation of an acceptance criterion or deletion of a test to comply with an official compendium that is consistent with FDA statutory and regulatory requirements.

(iii) A supplement submitted under paragraph (b)(3)(i) or (b)(3)(vi) of this section is required to give a full explanation of the basis for the change and identify the date on which the change is made. The supplement submitted under paragraph (b)(3)(i) must be labeled "Supplement-Changes Being Effected in 30 Days."

(iv) Pending approval of the supplement by FDA and except as provided in paragraph (b)(3)(vi) of this section, distribution of the drug made using the change may begin not less than 30 days after receipt of the supplement by FDA. The information listed in paragraphs (b)(2)(iii)(A) through (b)(2)(iii)(J) of this section must be contained in the supplement.

(v) The applicant must not distribute the drug made using the change if within 30 days following FDA’s receipt of the supplement, FDA informs the applicant that either:

(A) The change requires approval prior to distribution of the drug in accordance with paragraph (b)(2) of this section; or

(B) Any of the information required under paragraph (b)(3)(iv) of this section is missing. In this case, the applicant must not distribute the drug made using the change until the supplement has been amended to provide the missing information.

(vi) The agency may designate a category of changes for the purpose of providing that, in the case of a change in such category, the holder of an approved application may commence distribution of the drug involved upon receipt by the agency of a supplement for the change. The information listed in paragraphs (b)(2)(iii)(A) through (b)(2)(iii)(J) of this section must be contained in the supplement. The supplement must be labeled “Supplement-Changes Being Effected.” These changes include, but are not limited to:

(A) Addition to a specification or changes in the methods or controls to provide increased assurance that the drug will have the characteristics of identity, strength, quality, purity, or potency that it purports or is represented to possess; and

(B) A change in the size and/or shape of a container for a nonsterile drug product, except for solid dosage forms, without a change in the labeled amount of drug product or from one container closure system to another.

(vii) If the agency disapproves the supplemental application, it may order the manufacturer to cease distribution of the drug(s) made with the manufacturing change.

(4) Changes and updated stability data to be described and submitted in an annual report (minor changes). (i) Changes in the drug, production process, quality controls, equipment, or facilities that have a minimal potential to have an adverse effect on the identity, strength, quality, purity, or potency of the drug as these factors may relate to the safety or effectiveness of the drug must be documented by the applicant in an annual report to the application as described under paragraph (a)(2)(iii) of this section. The report must be labeled “Minor Changes and Stability Report.”

(1) These changes include but are not limited to:

(A) Any change made to comply with a change to an official compendium, except a change in paragraph (b)(3)(ii)(C) of this section, that is consistent with FDA statutory and regulatory requirements;

(B) The deletion or reduction of an ingredient intended to affect only the color of the drug product;

(C) Replacement of equipment with that of the same design and operating principles except for those equipment changes described in paragraph (b)(3)(i)(B)(2) of this section;

(D) A change in the size and/or shape of a container containing the same number of dosage units for a nonsterile solid dosage form drug product, without a change from one container closure system to another;

(E) A change within the container closure system for a nonsterile drug product, based upon a showing of equivalency to the approved system under a protocol approved in the application or published in an official compendium;
(F) An extension of an expiration dating period based upon full shelf-life data on production batches obtained from a protocol approved in the application;

(G) The addition or revision of an alternative analytical procedure that provides the same or increased assurance of the identity, strength, quality, purity, or potency of the drug being tested as the analytical procedure described in the approved application, or deletion of an alternative analytical procedure; and

(H) The addition by embossing, debossing, or engraving of a code imprint to a solid oral dosage form drug product other than a modified release dosage form, or a minor change in an existing code imprint.

(iii) For changes under this category, the applicant is required to submit in the annual report:

(A) A completed Form FDA 356V;

(B) A statement by the holder of the approved application that the effects of the change have been assessed;

(C) A detailed description of the change(s);

(D) The manufacturing site(s) or area(s) involved;

(E) The date each change was implemented;

(F) Data from studies and tests performed to assess the effects of the change;

(G) For a natural product, recombinant DNA-derived protein/polypeptide, complex or conjugate of a drug substance with a monoclonal antibody, sterilization process or test methodology related to sterilization process validation, relevant validation protocols and/or standard operating procedures;

(H) Appropriate documentation (for example, updated master batch records, specification sheets, etc.) including previously approved documentation (with the changes highlighted) or references to previously approved documentation;

(I) Updated stability data generated on commercial or production batches according to an approved stability protocol or commitment; and

(J) Any other information as directed by FDA.

(c) Labeling and other changes to an approved application—(1) General provisions. The applicant must notify FDA about each change in each condition established in an approved application beyond the variations already provided for in the application. The notice is required to describe the change fully.

(2) Labeling changes requiring the submission and approval of a supplement prior to distribution of the drug made using the change (major changes). (i) Addition of intended uses and changes to package labeling require a supplement. These changes include, but are not limited to:

(A) Revision in labeling, such as updating information pertaining to effects, dosages, adverse reactions, contraindications, which includes information headed "adverse reactions," "warnings," "precautions," and "contraindications," except ones described in (c)(3) of this section;

(B) Addition of an intended use;

(C) If it is a prescription drug, any mailing or promotional piece used after the drug is placed on the market is labeling requiring a supplemental application, unless:

(I) The parts of the labeling furnishing directions, warnings, and information for use of the drug are the same in language and emphasis as labeling approved or permitted; and

(2) Any other parts of the labeling are consistent with and not contrary to such approved or permitted labeling.

(D) Any other changes in labeling, except ones described in paragraph (c)(3) of this section.

(ii) The applicant must obtain approval of the supplement from FDA prior to distribution of the drug. The supplement must contain the following:

(A) A completed Form FDA 356V;

(B) A detailed description of the proposed change;

(C) The drug(s) involved;

(D) The data derived from studies in support of the change; and

(E) Any other information as directed by FDA.
§ 514.11 Confidentiality of data and information in a new animal drug application file.

(a) For purposes of this section the NADA file includes all data and information submitted with or incorporated by reference in the NADA, INAD's incorporated into the NADA, supplemental NADA's, reports under §§ 514.80 and 510.301 of this chapter, master files, and other related submissions. The availability for public disclosure of any record in the NADA file shall be handled in accordance with the provisions of this section.

(b) The existence of an NADA file will not be disclosed by the Food and Drug Administration before the application has been approved, unless it has order withdrawing approval of the application.
Food and Drug Administration, HHS § 514.11

been previously disclosed or acknowledged.

(c) If the existence of an NADA file has not been publicly disclosed or acknowledged, no data or information in the NADA file is available for public disclosure.

(d) If the existence of an NADA file has been publicly disclosed or acknowledged before the application has been approved, no data or information contained in the file is available for public disclosure, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, i.e., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After an application has been approved, the following data and information in the NADA file are immediately available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data and information submitted with or incorporated by reference in the NADA file. Such summaries do not constitute the full reports of investigations under section 512(b)(1) of the act (21 U.S.C. 360b(b)(1)) on which the safety or effectiveness of the drug may be approved. Such summaries shall consist of the following:

(i) For an NADA approved prior to July 1, 1975, internal agency records that describe such data and information, e.g., a summary of basis for approval or internal reviews of the data and information, after deletion of:

(a) Names and any information that would identify the investigators.

(b) Any inappropriate gratuitous comments unnecessary to an objective analysis of the data and information.

(ii) For an NADA approved after July 1, 1975, a summary of such data and information prepared in one of the following two alternative ways shall be publicly released when the application is approved.

(a) The Center for Veterinary Medicine may at an appropriate time prior to approval of the NADA require the applicant to prepare a summary of such data and information, which will be reviewed and, where appropriate, revised by the Center.

(b) The Center for Veterinary Medicine may prepare its own summary of such data and information.

(3) A protocol for a test or study, unless it is shown to fall within the exemption established for trade secrets and confidential commercial information in §20.61 of this chapter.

(4) Adverse reaction reports, product experience reports, consumer complaints, and other similar data and information, after deletion of:

(i) Names and any information that would identify the person using the product.

(ii) Names and any information that would identify any third party involved with the report, such as a physician, hospital, or other institution.

(5) A list of all active ingredients and any inactive ingredients previously disclosed to the public as defined in §20.81 of this chapter.

(6) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and is shown to fall within the exemption established in §20.61 of this chapter.

(7) All correspondence and written summaries of oral discussions relating to the NADA, in accordance with the provisions of part 20 of this chapter.

(f) All safety and effectiveness data and information not previously disclosed to the public are available for public disclosure at the time any one of the following events occurs unless extraordinary circumstances are known:

(1) The NADA has been abandoned and no further work is being undertaken with respect to it.

(2) A final determination is made that the NADA is not approvable, and all legal appeals have been exhausted.

(3) Approval of the NADA is withdrawn, and all legal appeals have been exhausted.

(4) A final determination has been made that the animal drug is not a new animal drug.

(5) A final determination has been made that the animal drug may be
marketed without submission of such safety and/or effectiveness data and information.

(g) The following data and information in an NADA file are not available for public disclosure unless they have been previously disclosed to the public as defined in §20.81 of this chapter or they relate to a product or ingredient that has been abandoned and they no longer represent a trade secret or confidential commercial or financial information as defined in §20.61 of this chapter:

(1) Manufacturing methods or processes, including quality control procedures.

(2) Production, sales, distribution, and similar data and information, except that any compilation of such data and information aggregated and prepared in a way that does not reveal data or information which is not available for public disclosure under this provision is available for public disclosure.

(3) Quantitative or semiquantitative formulas.

(h) For purposes of this regulation, safety and effectiveness data include all studies and tests of an animal drug on animals and all studies and tests on the animal drug for identity, stability, purity, potency, and bioavailability.

§514.12 Confidentiality of data and information in an investigational new animal drug notice.

(a) The existence of an INAD notice will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged.

(b) The availability for public disclosure of all data and information in an INAD file shall be handled in accordance with provisions established in §514.11.

§514.15 Untrue statements in applications.

Among the reasons why an application for a new animal drug or animal feed bearing or containing a new animal drug may contain an untrue statement of a material fact are:

(a) Differences in:

(1) Conditions of use prescribed, recommended, or suggested by the applicant for the product from the conditions of such use stated in the application;

(2) Articles used as components of the product from those listed in the application;

(3) Composition of the product from that stated in the application;

(4) Methods used in or the facilities and controls used for the manufacture, processing, or packing of the product from such methods, facilities, and controls described in the application;

(5) Labeling from the specimens contained in the application; or

(b) The unexplained omission in whole or in part from an application or from an amendment or supplement to an application or from any record or report required under the provisions of section 512 of the act and §514.80 or §510.301 of this chapter of any information obtained from:

(1) Investigations as to the safety, effectiveness, identity, strength, quality, or purity of the drug, made by the applicant on the drug, or

(2) Investigations or experience with the product that is the subject of the application, or any related product, available to the applicant from any source if such information is pertinent to an evaluation of the safety, effectiveness, identity, strength, quality, or purity of the drug, when such omission would bias an evaluation of the safety or effectiveness of the product.

(c) Any nonclinical laboratory study contained in the application was not conducted in compliance with the good laboratory practice regulations as set forth in part 58 of this chapter, and the application fails to include a brief statement of the reason for the noncompliance.

§ 514.80 Records and reports concerning experience with approved new animal drugs.

The following table outlines the purpose for each paragraph of this section:

<table>
<thead>
<tr>
<th>Purpose</th>
<th>21 CFR Paragraph and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>What information must be reported concerning approved NADAs or ANADAs?</td>
<td>§ 514.80(a) Applicability.</td>
</tr>
<tr>
<td>What authority does FDA have for requesting records and reports? Who is required to establish, maintain, and report required information relating to experiences with a new animal drug? Is information from foreign sources required?</td>
<td>§ 514.80(a)(1).</td>
</tr>
<tr>
<td>What records must be established and maintained and what reports filed with FDA?</td>
<td>§ 514.80(a)(2).</td>
</tr>
<tr>
<td>What is FDA’s purpose for requiring reports?</td>
<td>§ 514.80(a)(3).</td>
</tr>
<tr>
<td>Do applicants of Type A medicated articles have to establish, maintain, and report information required under § 514.80?</td>
<td>§ 514.80(a)(4).</td>
</tr>
<tr>
<td>How do the requirements under § 514.80 relate to current good manufacturing practices?</td>
<td>§ 514.80(a)(5).</td>
</tr>
<tr>
<td>What are the requirements for reporting product/manufacturing defects?</td>
<td>§ 514.80(b)(1) Three-day NADA/ANADA field alert report.</td>
</tr>
<tr>
<td>What are the requirements for reporting serious and unexpected adverse drug experiences?</td>
<td>§ 514.80(b)(2) Fifteen-day NADA/ANADA alert report.</td>
</tr>
<tr>
<td>What are the requirements for followup reporting of serious and unexpected adverse drug experiences?</td>
<td>§ 514.80(b)(2)(ii) Followup report.</td>
</tr>
<tr>
<td>What are the requirements for nonapplicants for reporting adverse drug experiences?</td>
<td>§ 514.80(b)(3) Nonapplicant report.</td>
</tr>
<tr>
<td>What are the general requirements for submission of periodic drug experience reports, e.g., forms to be submitted, submission date and frequency, when is it to be submitted, how many copies? How do I petition to change the date of submission or frequency of submissions?</td>
<td>§ 514.80(b)(4) Periodic drug experience report.</td>
</tr>
<tr>
<td>What must be submitted in the periodic drug experience reports?</td>
<td>§ 514.80(b)(4)(i) through (b)(4)(iv).</td>
</tr>
<tr>
<td>What distribution data must be submitted? How should the distribution data be submitted?</td>
<td>§ 514.80(b)(4)(i) Distribution data.</td>
</tr>
<tr>
<td>What labeling materials should be submitted? How do I report changes to the labeling materials since the last report?</td>
<td>§ 514.80(b)(4)(ii) Labeling.</td>
</tr>
<tr>
<td>What are the requirements for submission of nonclinical laboratory studies?</td>
<td>§ 514.80(b)(4)(iii)(A).</td>
</tr>
<tr>
<td>What are the requirements for submission of clinical laboratory data?</td>
<td>§ 514.80(b)(4)(iii)(B).</td>
</tr>
<tr>
<td>When must results of clinical trials conducted by or for the applicant be reported?</td>
<td>§ 514.80(b)(4)(iii)(C).</td>
</tr>
<tr>
<td>How do I report product/manufacturing defects and adverse drug experiences not previously reported to FDA?</td>
<td>§ 514.80(b)(4)(iv) Adverse drug experiences.</td>
</tr>
<tr>
<td>What are the requirements for submitting adverse drug experiences cited in literature?</td>
<td>§ 514.80(b)(4)(iv)(A).</td>
</tr>
<tr>
<td>Purpose</td>
<td>21 CFR Paragraph and Title</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>What are the requirements for submitting adverse drug experiences in postapproval studies and clinical trials?</td>
<td>514.80(b)(iv)(C).</td>
</tr>
<tr>
<td>What are the requirements for reporting increases in the frequency of serious, expected, and unexpected adverse drug experiences?</td>
<td>514.80(b)(v) Summary report of increased frequency of adverse drug experience.</td>
</tr>
<tr>
<td>Can FDA request that an applicant submit information at different times than stated specifically in this regulation?</td>
<td>514.80(b)(5)(i) Special drug experience report.</td>
</tr>
<tr>
<td>What are the requirements for submission of advertisement and promotional labeling to FDA?</td>
<td>514.80(b)(5)(ii) Advertisements and promotional labeling.</td>
</tr>
<tr>
<td>What are the requirements for adding a new distributor to the approved application?</td>
<td>514.80(b)(5)(iii) Distributor's statement.</td>
</tr>
<tr>
<td>What labels and how many labels need to be submitted for review?</td>
<td>514.80(b)(5)(iii)(A).</td>
</tr>
<tr>
<td>What changes are required and allowed to distributor labeling?</td>
<td>514.80(b)(5)(iii)(A)(1).</td>
</tr>
<tr>
<td>What are the requirements for making other changes to the distributor labeling?</td>
<td>514.80(b)(5)(iii)(A)(2).</td>
</tr>
<tr>
<td>What information should be included in each new distributor's signed statement?</td>
<td>514.80(b)(5)(iii)(B)(1) through (b)(5)(iii)(B)(5).</td>
</tr>
<tr>
<td>What are the conditions for submitting information that is common to more than one application? (i.e., can I submit common information to one application?)</td>
<td>514.80(c) Multiple applications.</td>
</tr>
<tr>
<td>What information has to be submitted to the common application and related application?</td>
<td>514.80(c)(1) through (c)(4).</td>
</tr>
<tr>
<td>What forms do I need?</td>
<td>514.80(d) Reporting forms.</td>
</tr>
<tr>
<td>What are Forms FDA 1932 and 2301?</td>
<td>514.80(e) Records to be maintained.</td>
</tr>
<tr>
<td>How can I get them?</td>
<td>514.80(f) Access to records and reports.</td>
</tr>
<tr>
<td>Can I use computer-generated equivalents?</td>
<td>514.80(g) Mailing addresses.</td>
</tr>
<tr>
<td>How long must I maintain Form FDA 1932 and records and reports of other required information, i.e., how long do I need to maintain this information?</td>
<td>514.80(h) Withdrawal of approval.</td>
</tr>
<tr>
<td>What are the requirements for allowing access to these records and reports, and copying by authorized FDA officer or employee?</td>
<td>514.80(i) Disclaimer.</td>
</tr>
<tr>
<td>How do I obtain Forms FDA 1932 and 2301? Where do I mail FDA’s required forms, records, and reports?</td>
<td>514.80(j) Access to records and reports.</td>
</tr>
<tr>
<td>What happens if the applicant fails to establish, maintain, or make the required reports?</td>
<td>514.80(k) Withdrawal of approval.</td>
</tr>
<tr>
<td>What happens if the applicant refuses to allow FDA access to, and/or copying and/or verify records and reports?</td>
<td>514.80(l) Disclaimer.</td>
</tr>
</tbody>
</table>

(a) Applicability. (1) Each applicant must establish and maintain indexed and complete files containing full records of all information pertinent to safety or effectiveness of a new animal drug that has not been previously submitted as part of the NADA or ANADA. Such records must include information from domestic as well as foreign sources. Each nonapplicant must establish and maintain indexed and complete files containing full records of all information pertinent to safety or effectiveness of a new animal drug that is received or otherwise obtained by the nonapplicant. Such records must include information from domestic as well as foreign sources.

(2) Each applicant must submit reports of data, studies, and other information concerning experience with new animal drugs to the Food and Drug...
§ 514.80

Food and Drug Administration, HHS

Administration (FDA) for each approved NADA and ANADA, as required in this section. A nonapplicant must submit data, studies, and other information concerning experience with new animal drugs to the appropriate applicant, as required in this section. The applicant, in turn, must report the nonapplicant’s data, studies, and other information to FDA. Applicants and nonapplicants must submit data, studies, and other information described in this section from domestic, as well as foreign sources.

(3) FDA reviews the records and reports required in this section to facilitate a determination under section 512(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(e)) as to whether there may be grounds for suspending or withdrawing approval of the NADA or ANADA.

(4) The requirements of this section also apply to any approved Type A medicated article. In addition, the requirements contained in §514.80(b)(1), (b)(2), (b)(4)(iv), and (b)(4)(v) apply to any approved Type A medicated article incorporated in animal feeds.

(5) The records and reports referred to in this section are in addition to those required by the current good manufacturing practice regulations in parts 211, 225, and 226 of this chapter.

(b) Reporting requirements—(1) Three-day NADA/ANADA field alert report. This report provides information pertaining to product and manufacturing defects that may result in serious adverse drug events. The applicant (or nonapplicant through the applicant) must submit the report to the appropriate FDA District Office or local FDA resident post within 3 working days of first becoming aware that a defect may exist. The information initially may be provided by telephone or other telecommunication means, with prompt written followup using Form FDA 1932 , "Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report." The mailing cover for these reports must be plainly marked "3-Day NADA/ANADA Field Alert Report."

(2) Fifteen-day NADA/ANADA alert report—(i) Initial report. This report provides information on each serious, unexpected adverse drug event, regardless of the source of the information. The applicant (or nonapplicant through the applicant) must submit the report to FDA within 15 working days of first receiving the information. The report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked "15-Day NADA/ANADA Alert Report."

(ii) Followup report. The applicant must promptly investigate all adverse drug events that are the subject of 15-day NADA/ANADA alert reports. If this investigation reveals significant new information, a followup report must be submitted within 15 working days of receiving such information. A followup report must be submitted on Form FDA 1932, and its mailing cover must be plainly marked "15-Day NADA/ANADA Alert Report Followup." The followup report must state the date of the initial report and provide the additional information. If additional information is sought but not obtained within 3 months of the initial report, a followup report is required describing the steps taken and why additional information was not obtained.

(iii) Nonapplicant report. Nonapplicants must forward reports of adverse drug experiences to the applicant within 3 working days of first receiving the information. The applicant must then submit the report(s) to FDA as required in this section. The nonapplicant must maintain records of all nonapplicant reports, including the date the nonapplicant received the information concerning adverse drug experiences, the name and address of the applicant, and a copy of the adverse drug experience report including the date such report was submitted to the applicant. If the nonapplicant elects to also report directly to FDA, the nonapplicant should submit the report on Form FDA 1932 within 15 working days of first receiving the Information.

(iv) Periodic drug experience report. This report must be accompanied by a completed Form FDA 2301 , "Transmittal of Periodic Reports and Promotional Materials for New Animal Drugs." It must be submitted every 6 months for the first 2 years following approval of an NADA or ANADA and yearly thereafter. Reports required by
§ 514.80  

this section must contain data and information for the full reporting period. The 6-month periodic drug experience reports must be submitted within 30 days following the end of the 6-month reporting period. The yearly periodic drug experience reports must be submitted within 60 days of the anniversary date of the approval of the NADA or ANADA. Any previously submitted information contained in the report must be identified as such. For yearly (annual) periodic drug experience reports, the applicant may petition FDA to change the date of submission or frequency of reporting, and after approval of such petition, file such reports on the new filing date or at the new reporting frequency. Also, FDA may require a report at different times or more frequently. The periodic drug experience report must contain the following:

(i) Distribution data. Information about the distribution of each new animal drug product, including information on any distributor-labeled product. This information must include the total number of distributed units of each size, strength, or potency (e.g., 100,000 bottles of 100 5-milligram tablets; 50,000 10-milliliter vials of 5-percent solution). This information must be presented in two categories: Quantities distributed domestically and quantities exported.

(ii) Labeling. Applicant and distributor current package labeling, including package inserts (if any). For large-size package labeling or large shipping cartons, a representative copy must be submitted (e.g., a photocopy of pertinent areas of large feed bags). A summary of any changes in labeling made since the last report (listed by date of implementation) must be included with the labeling or if there have been no changes, a statement of such fact must be included with the labeling.

(iii) Nonclinical laboratory studies and clinical data not previously reported.

(A) Copies of in vitro studies (e.g., mutagenicity) and other nonclinical laboratory studies conducted by or otherwise obtained by the applicant.

(B) Copies of published clinical trials of the new animal drug (or abstracts of them) including clinical trials on safety and effectiveness, clinical trials on new uses, and reports of clinical experience pertinent to safety conducted by or otherwise obtained by the applicant. Review articles, papers, and abstracts in which the drug is used as a research tool, promotional articles, press clippings, and papers that do not contain tabulations or summaries of original data are not required to be reported.

(C) Descriptions of completed clinical trials conducted by or for the applicant must be submitted no later than 1 year after completion of research. Supporting information is not to be reported.

(iv) Adverse drug experiences. (A) Product/manufacturing defects and adverse drug experiences not previously reported under §514.80(b)(1) and (b)(2) must be reported individually on Form FDA 1932.

(B) Reports of adverse drug experiences in the literature must be noted in the periodic drug experience report. A bibliography of pertinent references must be included with the report. Upon FDA’s request, the applicant must provide a full text copy of these publications.

(C) Reports of previously not reported adverse drug experiences that occur in postapproval studies must be reported separately from other experiences in the periodic drug experience report and clearly marked or highlighted.

(v) Summary report of increased frequency of adverse drug experience. The applicant must periodically review the incidence of reports of adverse drug experiences to determine if there has been an increased frequency of serious (expected and unexpected) adverse drug events. The applicant must evaluate the increased frequency of serious (expected or unexpected) adverse drug events at least as often as reporting of periodic drug experience reports. The applicant must report the increased frequency of serious (expected and unexpected) adverse drug events in the periodic drug experience report. Summaries of reports of increased frequency of adverse drug events must be submitted in narrative form. The summaries must state the time period on which the increased frequency is based,
time period comparisons in determining increased frequency, references to any previously submitted Form FDA 1932, the method of analysis, and the interpretation of the results. The summaries must be submitted in a separate section within the periodic drug experience report.

(5) Other reporting—(1) Special drug experience report. Upon written request, FDA may require that the applicant submit a report required under §514.80 at different times or more frequently than the timeframes stated in §514.80.

(ii) Advertisements and promotional labeling. The applicant must submit at the time of initial dissemination one set of specimens of mailing pieces and other labeling for prescription and over-the-counter new animal drugs. For prescription new animal drugs, the applicant must also submit one set of specimens of any advertisement at the time of initial publication or broadcast. Mailing pieces and labeling designed to contain product samples must be complete except that product samples may be omitted. Each submission of promotional labeling or advertisements must be accompanied by a completed Form FDA 2301.

(iii) Distributor’s statement. At the time of initial distribution of a new animal drug product by a distributor, the applicant must submit a special drug experience report accompanied by a completed Form FDA 2301 containing the following:

(A) The distributor’s current product labeling.

(1) The distributor’s labeling must be identical to that in the approved NADA/ANADA except for a different and suitable proprietary name (if used) and the name and address of the distributor. The name and address of the distributor must be preceded by an appropriate qualifying phrase as permitted by the regulations such as “manufactured for” or “distributed by.”

(2) Other labeling changes must be the subject of a supplemental NADA or ANADA as described under §514.8.

(B) A signed statement by the distributor stating:

(I) The category of the distributor’s operations (e.g., wholesale or retail), (2) That the distributor will distribute the new animal drug only under the approved labeling, (3) That the distributor will promote the product only for use under the conditions stated in the approved labeling, (4) That the distributor will adhere to the records and reports requirements of this section, and (5) That the distributor is regularly and lawfully engaged in the distribution or dispensing of prescription products if the product is a prescription new animal drug.

(c) Multiple applications. Whenever an applicant is required to submit a periodic drug experience report under the provisions of §514.80(b)(4) with respect to more than one approved NADA or ANADA for preparations containing the same new animal drug so that the same information is required to be reported for more than one application, the applicant may elect to submit as a part of the report for one such application (the primary application) all the information common to such applications in lieu of reporting separately and repetitively on each. If the applicant elects to do this, the applicant must do the following:

(1) State when a report applies to multiple applications and identify all related applications for which the report is submitted by NADA or ANADA number.

(2) Ensure that the primary application contains a list of the NADA or ANADA numbers of all related applications.

(3) Submit a completed Form FDA 2301 to the primary application and each related application with reference to the primary application by NADA/ANADA number and submission date for the complete report of the common information.

(4) All other information specific to a particular NADA/ANADA must be included in the report for that particular NADA/ANADA.

(d) Reporting forms. Applicant must report adverse drug experiences and product/manufacturing defects on Form FDA 1932, “Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product Defect Report.” Periodic drug experience reports and special drug experience reports must be accompanied
§ 514.100 Evaluation and comment on applications.

(a) After the filed application has been evaluated, the applicant will be furnished written comment on any apparent deficiencies in the application.

(b) When the description of the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of such new animal drug appears adequate on its face, but it is not feasible to reach a conclusion as to the safety and effectiveness of the new animal drug solely from consideration of this description, the applicant may be notified that an establishment inspection is required to verify their adequacy.

(c) A request for samples of a new animal drug or any edible tissues and byproducts of animals treated with such a drug, shall specify the quantity deemed adequate to permit tests of analytical methods to determine their adequacy for regulatory purposes. The request should be made as early in the 180-day period as possible to assure timely completion. The date used for computing the 180-day limit for the purposes of section 512(c) of the act shall be moved forward 1 day for each day after the mailing date of the request until all of the requested samples are received. If the samples are not received within 90 days after the request, the application will be considered withdrawn without prejudice.
(d) The information contained in an application may be insufficient to determine whether a new animal drug is safe or effective in use if it fails to include (among other things) a statement showing whether such drug is to be limited to prescription sale and exempt under section 502(f) of the act from the requirement that its labeling bear adequate directions for lay use. If such drug is to be exempt, the information may also be insufficient if:

(1) The specimen labeling proposed fails to bear adequate information for professional use including indications, effects, dosages, routes, methods, and frequency and duration of administration and any relevant hazards, contraindications, side effects, and precautions under which practitioners licensed by law to administer such drug can use the drug for the purposes for which it is intended, including all purposes for which it is to be advertised, or represented, in accordance with §201.105 of this chapter, and information concerning hazards, contraindications, side effects, and precautions relevant with respect to any uses for which such drug is to be prescribed.

(2) The application fails to show that the labeling and advertising of such drug will offer the drug for use only under those conditions for which it is offered in the labeling that is part of the application.

(3) The application fails to show that all labeling that furnishes or purports to furnish information for professional use of such drug will contain, in the same language and emphasis, the information for use including indications, effects, dosages, routes, methods, and frequency and duration of administration and any relevant warnings, hazards, contraindications, side effects, and precautions, which is contained in the labeling that is part of the application in accordance with §201.105 of this chapter.

(e) The information contained in an application will be considered insufficient to determine whether a new animal drug is safe and effective for use when there is a refusal or failure upon written notice to furnish inspectors authorized by the Food and Drug Administration an adequate opportunity to inspect the facilities, controls, and records pertinent to the application.

(f) On the basis of preliminary consideration of an application or supplemental application containing typewritten or other draft labeling in lieu of final printed labeling, an applicant may be informed that such application is approvable when satisfactory final printed labeling identical in content to such draft copy is submitted.

(g) When an application has been found incomplete on the basis of a need for the kind of information described in §514.6, such application shall be considered withdrawn without prejudice to future filing on the date of issuance of the letter citing the inadequacies contained in the application, unless within 30 days the sponsor chooses to avail himself of the opportunity for hearing as prescribed by §514.111.

§ 514.106 Approval of applications.

(a) The Commissioner shall forward for publication in the Federal Register a regulation prescribing the conditions under which the new animal drug may be used, including the name and address of the applicant; the conditions and indications for use covered by the application; any tolerance, withdrawal period, or other use restrictions; any tolerance required for the new animal drug substance or its metabolites in edible products of food-producing animals; and, if such new animal drug is intended for use in animal feed, appropriate purposes and conditions of use (including special labeling requirements) applicable to any animal feed; and such other information the Commissioner deems necessary to assure safe and effective use.

(b) He shall notify the applicant by sending him a copy of the proposed publication as described in paragraph (a)(1) of this section.

§ 514.106 Approval of supplemental applications.

(a) Within 180 days after a supplement to an approved application is filed pursuant to §514.8, the Commissioner shall approve the supplemental
application in accordance with procedures set forth in §514.105(a)(1) and (2) if he/she determines that the application satisfies the requirements of applicable statutory provisions and regulations.

(b) The Commissioner will assign a supplemental application to its proper category to ensure processing of the application.

(1) **Category I.** Supplements that ordinarily do not require a reevaluation of any of the safety or effectiveness data in the parent application. Category I supplements include the following:
   (i) A corporate change that alters the identity or address of the sponsor of the new animal drug application (NADA).
   (ii) The sale, purchase, or construction of manufacturing facilities.
   (iii) The sale or purchase of an NADA.
   (iv) A change in container, container style, shape, size, or components.
   (v) A change in approved labeling (color, style, format, addition, deletion, or revision of certain statements, e.g., trade name, storage, expiration dates, etc).
   (vi) A change in promotional material for a prescription new animal drug not exempted by §514.8(c)(2)(i)(C)(1) through (c)(2)(i)(C)(3).
   (vii) Changes in manufacturing processes that do not alter the method of manufacture or change the final dosage form.
   (viii) A change in bulk drug shipments.
   (ix) A change in an analytical method or control procedures that do not alter the approved standards.
   (x) A change in an expiration date.
   (xi) Addition of an alternate manufacturer, repackager, or relabeler of the drug product.
   (xii) Addition of an alternate supplier of the new drug substance.
   (xiii) A change permitted in advance of approval as described under §514.8(b)(3).

(2) **Category II.** Supplements that may require a reevaluation of certain safety or effectiveness data in the parent application. Category II supplements include the following:
   (i) A change in the active ingredient concentration or composition of the final product.
   (ii) A change in quality, purity, strength, and identity specifications of the active or inactive ingredients.
   (iii) A change in dose (amount of drug administered per dose).
   (iv) A change in the treatment regimen (schedule of dosing).
   (v) Addition of a new therapeutic claim to the approved uses of the product.
   (vi) Addition of a new or revised animal production claim.
   (vii) Addition of a new species.
   (viii) A change in the prescription or over-the-counter status of a drug product.
   (ix) A change in statements regarding side effects, warnings, precautions, and contraindications, except the addition of approved statements to container, package, and promotional labeling, and prescription drug advertising.
   (x) A change in the drug withdrawal period prior to slaughter or in the milk discard time.
   (xi) A change in the tolerance for drug residues.
   (xii) A change in analytical methods for drug residues.
   (xiii) A revised method of synthesis or fermentation of the new drug substance.
   (xiv) Updating or changes in the manufacturing process of the new drug substance and/or final dosage form (other than a change in equipment that does not alter the method of manufacture of a new animal drug, or a change from one commercial batch size to another without any change in manufacturing procedure), or changes in the methods, facilities, or controls used for the manufacture, processing, packaging, or holding of the new animal drug (other than use of an establishment not covered by the approval that is in effect) that give increased assurance that the drug will have the characteristics of identity, strength, quality, and purity which it purports or is represented to possess.

§ 514.110 Reasons for refusing to file applications.

(a) The date of receipt of an application for a new animal drug shall be the date on which the application shall be deemed to be filed.

(b) An application for a new animal drug shall not be considered acceptable for filing for any of the following reasons:

1. It does not contain complete and accurate English translations of any pertinent part in a foreign language.
2. Fewer than three copies are submitted.
3. It is incomplete on its face in that it is not properly organized and indexed.
4. On its face the information concerning required matter is so inadequate that the application is clearly not approvable.
5. The new animal drug is to be manufactured, prepared, compounded, or processed in whole or in part in any State in an establishment that has not been registered or exempted from registration under the provisions of section 510 of the act.
6. The sponsor does not reside or maintain a place of business within the United States and the application has not been countersigned by an attorney, agent, or other representative of the applicant, which representative resides in the United States and has been duly authorized to act on behalf of the applicant and to receive communications on all matters pertaining to the application.
7. The new animal drug is a drug subject to licensing under the animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 U.S.C. 151 et seq.). Such applications will be referred to the U.S. Department of Agriculture for action.
8. It fails to include, with respect to each nonclinical laboratory study contained in the application, either a statement that the study was conducted in compliance with the good laboratory practice regulations set forth in part 58 of this chapter, or, if the study was not conducted in compliance with such regulations, a brief statement of the reasons for the noncompliance.
9. [Reserved]
10. The applicant fails to submit a complete environmental assessment under §25.40 of this chapter or fails to provide sufficient information to establish that the requested action is subject to categorical exclusion under §25.30 or §25.33 of this chapter.

(c) If an application is determined not to be acceptable for filing, the applicant shall be notified within 30 days of receipt of the application and shall be given the reasons therefore.

(d) If the applicant disputes the findings that his application is not acceptable for filing, he may make written request that the application be filed over protest, in which case it will be filed as of the day originally received.


§ 514.111 Refusal to approve an application.

(a) The Commissioner shall, within 180 days after the filing of the application, inform the applicant in writing of his intention to issue a notice of opportunity for a hearing on a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the application, or upon the basis of other information before him with respect to a new animal drug, that:

1. The reports of investigations required to be submitted pursuant to section 512(b) of the act do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof; or
2. The results of such tests show that such drug is unsafe for use under such conditions or do not show that such drug is safe for use under such conditions; or
3. The methods used in and the facilities and controls used for the manufacture, processing, and packing of such drug are inadequate to preserve its identity, strength, quality, and purity; or
4. Upon the basis of the information submitted to the Food and Drug Administration as part of the application,
or upon the basis of any other information before it with respect to such drug, it has insufficient information to determine whether such drug is safe for use under such conditions. In making this determination the Commissioner shall consider, among other relevant factors:

(i) The probable consumption of such drug and of any substance formed in or on food because of the use of such drug;

(ii) The cumulative effect on man or animal of such drug, taking into account any chemically or pharmacologically related substances;

(iii) Safety factors which, in the opinion of experts qualified by scientific training and experience to evaluate the safety of such drugs, are appropriate for the use of animal experimentation data; and

(iv) Whether the conditions of use prescribed, recommended, or suggested in the proposed labeling are reasonably certain to be followed in practice;

(5) Evaluated on the basis of information submitted as part of the application and any other information before the Food and Drug Administration with respect to such drug, there is lack of substantial evidence as defined in §514.4.

(6) Failure to include an appropriate proposed tolerance for residues in edible products derived from animals or a withdrawal period or other restrictions for use of such drug if any tolerance or withdrawal period or other restrictions for use are required in order to assure that the edible products derived from animals treated with such drug will be safe.

(7) Based on a fair evaluation of all material facts, the labeling is false or misleading in any particular; or

(8) Such drug induces cancer when ingested by man or animal or, after appropriate tests for evaluation of the safety of such drug, induces cancer in man or animal, except that this subparagraph shall not apply with respect to such drug if the Commissioner finds that, under the conditions of use specified in proposed labeling and reasonably certain to be followed in practice:

(i) Such drug will not adversely affect the animal for which it is intended; and

(ii) No residue of such drug will be found (by methods of examination prescribed or approved by the Commissioner by regulations) in any edible portion of such animal after slaughter or in any food yielded by, or derived from the living animals.

(9) The applicant fails to submit an adequate environmental assessment under §25.40 of this chapter or fails to provide sufficient information to establish that the requested action is subject to categorical exclusion under §25.30 or §25.33 of this chapter.

(10) The drug fails to satisfy the requirements of subpart E of part 500 of this chapter.

(11) Any nonclinical laboratory study that is described in the application and that is essential to show that the drug is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling, was not conducted in compliance with the good laboratory practice regulations as set forth in part 58 of this chapter and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.

(b) The Commissioner, as provided in §514.200 of this chapter, shall expeditiously notify the applicant of an opportunity for a hearing on the question of whether such application is approvable, unless by the 30th day following the date of issuance of the letter informing the applicant:

(1) Withdraws the application; or

(2) Waives the opportunity for a hearing; or

(3) Agrees with the Commissioner on an additional period to precede issuance of such notice of hearing.

§ 514.115 Withdrawal of approval of applications.

(a) The Secretary may suspend approval of an application approved pursuant to section 512(c) of the act and give the applicant prompt notice of his action and afford the applicant the opportunity for an expedited hearing on a finding that there is an imminent hazard to the health of man or of the animals for which such new animal drug or animal feed is intended.

(b) The Commissioner shall notify in writing the person holding an application approved pursuant to section 512(c) of the act and afford an opportunity for a hearing on a proposal to withdraw approval of such application if he finds:

1. That the application contains any untrue statement of a material fact; or
2. That the applicant has made any changes from the standpoint of safety or effectiveness beyond the variations provided for in the application unless he has supplemented the application by filing with the Secretary adequate information respecting all such changes and unless there is in effect an approval of the supplemental application, or such changes are those for which written authorization or approval is not required as provided for in §514.8. The supplemental application shall be treated in the same manner as the original application.

3. That in the case of an application for use of a new animal drug approved or deemed approved pursuant to section 512(c) of the act:
   (i) Experience or scientific data show that such drug is unsafe for use under the conditions of use upon the basis of which the application was approved; or
   (ii) New evidence not contained in such application or not available to the Secretary until after such application was approved, or tests by new methods, or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the evidence available to the Secretary when the application was approved, shows that such drug is not shown to be safe for use under the conditions of use upon the basis of which the application was approved or that section 512(d)(1)(H) of the act applies to such drug; or
   (iii) On the basis of new information before him with respect to such drug, evaluated together with the evidence available to him when the application was approved, there is a lack of substantial evidence that such drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling thereof.

(c) The Commissioner may notify in writing the person holding an application approved pursuant to section 512(c) of the act and afford an opportunity for a hearing on a proposal to withdraw approval of such application if he finds:

1. That the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain such records or to make required reports in accordance with a regulation or order under section 512(l)(1) of the act, or the applicant has refused to permit access to, or copying, or verification of, such records as required by section 512(l)(2) of the act; or
2. That on the basis of new information before him, evaluated together with the evidence before him when the application was approved, the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of such drug or animal feed are inadequate to assure and preserve its identity, strength, quality, and purity and were not made adequate within a reasonable time after receipt of written notice from the Secretary specifying the matter complained of; or
3. That on the basis of new information before him, evaluated together with the evidence before him when the
application was approved, the labeling of such drug, based on a fair evaluation of all material facts, is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the Secretary specifying the matter complained of.

(d) Approval of an application pursuant to section 512(c) of the act will be withdrawn on the basis of a request for its withdrawal submitted in writing by a person holding an approved new animal drug application on the grounds that the drug subject to such application is no longer being marketed and information is included in support of this finding, provided none of the conditions cited in paragraphs (a), (b), and (c) of this section pertain to the subject drug. A written request for such withdrawal shall be construed as a waiver of the opportunity for a hearing as otherwise provided for in this section. Withdrawal of approval of an application under the provisions of this paragraph shall be without prejudice.

(e) On the basis of the withdrawal of approval of an application for a new animal drug approved pursuant to section 512(c) of the act, the regulation published pursuant to section 512(i) of the act covering the conditions of use of such drug as provided for in the application shall be revoked.

[40 FR 13825, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 64 FR 63204, Nov. 19, 1999]

§ 514.116 Notice of withdrawal of approval of application.

When an approval of an application submitted pursuant to section 512 of the act is withdrawn by the Commissioner, he will give appropriate public notice of such action by publication in the FEDERAL REGISTER.

§ 514.117 Adequate and well-controlled studies.

(a) Purpose. The primary purpose of conducting adequate and well-controlled studies of a new animal drug is to distinguish the effect of the new animal drug from other influences, such as spontaneous change in the course of the disease, normal animal production performance, or biased observation. One or more adequate and well-controlled studies are required to establish, by substantial evidence, that a new animal drug is effective. The characteristics described in paragraph (b) of this section have been developed over a period of years and are generally recognized as the essentials of an adequate and well-controlled study. Well controlled, as used in the phrase adequate and well controlled, emphasizes an important aspect of adequacy. The Food and Drug Administration (FDA) considers these characteristics in determining whether a study is adequate and well controlled for purposes of section 512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b). Adequate and well-controlled studies, in addition to providing a basis for determining whether a new animal drug is effective, may also be relied upon to support target animal safety. The report of an adequate and well-controlled study should provide sufficient details of study design, conduct, and analysis to allow critical evaluation and a determination of whether the characteristics of an adequate and well-controlled study are present.

(b) Characteristics. An adequate and well-controlled study has the following characteristics:

1. The protocol for the study (protocol) and the report of the study results (study report) must include a clear statement of the study objective(s).

2. The study is conducted in accordance with an appropriate standard of conduct that addresses, among other issues, study conduct, study personnel, study facilities, and study documentation. The protocol contains a statement acknowledging the applicability of, and intention to follow, a standard of conduct acceptable to FDA. The study report contains a statement describing adherence to the standard.

3. The study is conducted with a new animal drug that is produced in accordance with appropriate manufacturing practices, which include, but are not necessarily limited to, the manufacture, processing, packaging, holding, and labeling of the new animal drug such that the critical characteristics of identity, strength, quality, purity, and physical form of the new animal drug are known, recorded, and reproducible.
Food and Drug Administration, HHS

§514.117

to permit meaningful evaluations of and comparisons with other studies conducted with the new animal drug. The physical form of a new animal drug includes the formulation and physical characterization (including delivery systems thereof, if any) of the new animal drug as presented to the animal. The protocol and study report must include an identification number which can be correlated with the specific formulation and production process used to manufacture the new animal drug used in the study.

(4) The study uses a design that permits a valid comparison with one or more controls to provide a quantitative evaluation of drug effects. The protocol and the study report must describe the precise nature of the study design, e.g., duration of treatment periods, whether treatments are parallel, sequential, or crossover, and the determination of sample size. Within the broad range of studies conducted to support a determination of the effectiveness of a new animal drug, certain of the controls listed below would be appropriate and preferred depending on the study conducted:

(i) Placebo concurrent control. The new animal drug is compared with an inactive preparation designed to resemble the new animal drug as far as possible.

(ii) Untreated concurrent control. The new animal drug is compared with the absence of any treatment. The use of this control may be appropriate when objective measurements of effectiveness, not subject to observer bias, are available.

(iii) Active treatment concurrent control. The new animal drug is compared with known effective therapy. The use of this control is appropriate when the use of a placebo control or of an untreated concurrent control would unreasonably compromise the welfare of the animals. Similarity of the new animal drug and the active control drug can mean either that both drugs were effective or that neither was effective. The study report should assess the ability of the study to have detected a difference between treatments. The evaluation of the study should explain why the new animal drugs should be considered effective in the study, for example, by reference to results in previous placebo-controlled studies of the active control.

(iv) Historical control. The results of treatment with the new animal drug are quantitatively compared with experience historically derived from the adequately documented natural history of the disease or condition, or with a regimen (therapeutic, diagnostic, prophylactic) whose effectiveness is established, in comparable animals. Because historical control populations usually cannot be as well assessed with respect to pertinent variables as can concurrent control populations, historical control designs are usually reserved for special circumstances. Examples include studies in which the effect of the new animal drug is self-evident or studies of diseases with high and predictable mortality, or signs and symptoms of predictable duration or severity, or, in the case of prophylaxis, predictable morbidity.

(5) The study uses a method of selecting animals that provides adequate assurances that the animals are suitable for the purposes of the study. For example, the animals can reasonably be expected to have animal production characteristics typical of the class(es) of animals for which the new animal drug is intended, there is adequate assurance that the animals have the disease or condition being studied, or, in the case of prophylactic agents, evidence of susceptibility and exposure to the condition against which prophylaxis is desired has been provided. The protocol and the study report describe the method of selecting animals for the study.

(6) The study uses a method to assign a treatment or a control to each experimental unit of animals that is random and minimizes bias. Experimental units of animals are groups of animals that are comparable with respect to pertinent variables such as age, sex, class of animal, severity of disease, duration of disease, dietary regimen, level of animal production, and use of drugs or therapy other than the new animal drug. The protocol and the study report describe the method of assignment of animals to an experimental unit to account for pertinent variables and method of assignment of
§514.117
21 CFR Ch. I (4–1–16 Edition)
a treatment or a control to the experimental units. When the effect of such variables is accounted for by an appropriate design, and when, within the same animal, effects due to the test drug can be obtained free of the effects of such variables, the same animal may be used for both the test drug and the control using the controls set forth in paragraph (b)(4) of this section.

(7) The study uses methods to minimize bias on the part of observers and analysts of the data that are adequate to prevent undue influences on the results and interpretation of the study data. The protocol and study report explain the methods of observation and recording of the animal response variables and document the methods, such as “blinding” or “masking,” used in the study for excluding or minimizing bias in the observations.

(8) The study uses methods to assess animal response that are well defined and reliable. The protocol and study report describe the methods for conducting the study, including any appropriate analytical and statistical methods, used to collect and analyze the data resulting from the conduct of the study, describe the criteria used to assess response, and, when appropriate, justify the selection of the methods to assess animal response.

(9) There is an analysis and evaluation of the results of the study in accord with the protocol adequate to assess the effects of the new animal drug. The study report evaluates the methods used to conduct, and presents and evaluates the results of, the study as to their adequacy to assess the effects of the new animal drug. This evaluation of the results of the study assesses, among other items, the comparability of treatment and control groups with respect to pertinent variables and the effects of any interim analyses performed.

(c) Field studies. (1) Field conditions as used in this section refers to conditions which closely approximate the conditions under which the new animal drug, if approved, is intended to be applied or administered.

(2) Studies of a new animal drug conducted under field conditions shall, consistent with generally recognized scientific principles and procedures, use an appropriate control that permits comparison, employ procedures to minimize bias, and have the characteristics generally described in paragraph (b) of this section. However, because field studies are conducted under field conditions, it is recognized that the level of control over some study conditions need not or should not be the same as the level of control in laboratory studies. While not all conditions relating to a field study need to be or should be controlled, observations of the conditions under which the new animal drug is tested shall be recorded in sufficient detail to permit evaluation of the study. Adequate and well-controlled field studies shall balance the need to control study conditions with the need to observe the true effect of the new animal drug under closely approximated actual use conditions.

(d) Waiver. The Director of the Center for Veterinary Medicine (the Director) may, on the Director’s own initiative or on the petition of an interested person, waive in whole or in part any of the criteria in paragraph (b) of this section with respect to a specific study. A petition for a waiver is required to set forth clearly and concisely the specific criteria from which waiver is sought, why the criteria are not reasonably applicable to the particular study, what alternative procedures, if any, are to be, or have been employed, and what results have been obtained. The petition is also required to state why the studies so conducted will yield, or have yielded, substantial evidence of effectiveness, notwithstanding nonconformance with the criteria for which waiver is requested.

(e) Uncontrolled studies. Uncontrolled studies or partially controlled studies are not acceptable as the sole basis for the approval of claims of effectiveness or target animal safety. Such studies, carefully conducted and documented, may provide corroborative support of adequate and well-controlled studies regarding effectiveness and may yield valuable data regarding safety of the new animal drug. Such studies will be considered on their merits in light of the characteristics listed here. Isolated case reports, random experience, and
§ 514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application.

The Commissioner, upon his own initiative or upon request of an applicant stating reasonable grounds therefor and if he finds that the facts so require, may issue an order approving an application that previously has had its approval refused, suspended, or withdrawn.

§ 514.121 Service of notices and orders.

All notices and orders under this subchapter E and section 512 of the act pertaining to new animal drug applications shall be served:

(a) In person by any officer or employee of the Department designated by the Commissioner; or

(b) By mailing the order by certified mail addressed to the applicant or respondent at his last known address in the records of the Food and Drug Administration.

Subpart C—Hearing Procedures

§ 514.200 Contents of notice of opportunity for a hearing.

(a) The notice to the applicant of opportunity for a hearing on a proposal by the Commissioner to refuse to approve an application or to withdraw the approval of an application will specify the grounds upon which he proposes to issue his order. On request of the applicant, the Commissioner will explain the reasons for his action. The notice of opportunity for a hearing will be published in the Federal Register and will specify that the applicant has 30 days after issuance of the notice within which he is required to file a written appearance electing whether:

(1) To avail himself of the opportunity for a hearing; or

(2) Not to avail himself of the opportunity for a hearing.

(b) If the applicant fails to file a written appearance in answer to the notice of opportunity for hearing, his failure will be construed as an election not to avail himself of the opportunity for the hearing, and the Commissioner without further notice may enter a final order.

(c) If the applicant elects to avail himself of the opportunity for a hearing, he is required to file a written appearance requesting the hearing within 30 days after the publication of the notice, giving the reason why the application should not be refused or should not be withdrawn, together with a well-organized and full-factual analysis of the clinical and other investigational data he is prepared to prove in support of his opposition to the Commissioner’s proposal. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing there is a genuine and substantial issue of fact that requires a hearing. When it clearly appears from the data in the application and from the reasons and a factual analysis in the request for the hearing that no genuine and substantial issue of fact precludes the refusal to approve the application or the withdrawal of approval of the application (for example, no adequate and well-controlled clinical investigations to support the claims of effectiveness have been identified), the Commissioner will enter an order on this data, stating his findings and conclusions. If a hearing is requested and is justified by the applicant’s response to the notice of opportunity for a hearing, the issues will be defined, an Administrative Law Judge will be named, and he shall issue a written notice of the time and place at which the hearing will commence. In the case of denial of approval, such time shall be not more than 90 days after the expiration of such 30 days unless the Administrative Law Judge and the applicant otherwise agree; and, in the case of withdrawal of approval, such time shall be as soon as practicable.

(d) The hearing will be open to the public; however, if the Commissioner finds that portions of the application which serve as a basis for the hearing contain information concerning a method or process entitled to protection as a trade secret, the part of the hearing involving such portions will
§ 514.201

not be public, unless the respondent so specifies in his appearance.
[40 FR 13825, Mar. 27, 1975, as amended at 43 FR 1941, Jan. 13, 1978]

§ 514.201 Procedures for hearings.

Hearings relating to new animal drugs under section 512(d) and (e) of the act shall be governed by part 12 of this chapter.
[64 FR 63204, Nov. 19, 1999]

Subparts D–E [Reserved]

Subpart F—Judicial Review

§ 514.235 Judicial review.

(a) The transcript and record shall be certified by the Commissioner. In any case in which the Commissioner enters an order without a hearing pursuant to § 314.200(g) of this chapter, the request(s) for hearing together with the data and information submitted and the Commissioner’s findings and conclusions shall be included in the record certified by the Commissioner.

(b) Judicial review of an order withdrawing approval of a new drug application, whether or not a hearing has been held, may be sought by a manufacturer or distributor of an identical, related, or similar drug product, as defined in § 310.6 of this chapter, in a United States court of appeals pursuant to section 505(h) of the act.
[42 FR 4717, Jan. 25, 1977]

PART 515—MEDICATED FEED MILL LICENSE

Subpart A—Applications

Sec.
515.10 Medicated feed mill license applications.
515.11 Supplemental medicated feed mill license applications.

Subpart B—Administrative Actions on Licenses

515.20 Approval of medicated feed mill license applications.
515.21 Refusal to approve a medicated feed mill license application.
515.22 Suspension and/or revocation of approval of a medicated feed mill license.
21 CFR Ch. 1 (4–1–16 Edition)
515.23 Voluntary revocation of medicated feed mill license.
515.24 Notice of revocation of a medicated feed mill license.
515.25 Revocation of order refusing to approve a medicated feed license application or suspending or revoking a license.
515.26 Services of notices and orders.

Subpart C—Hearing Procedures

515.30 Contents of notice of opportunity for a hearing.
515.31 Procedures for hearings.

Subpart D—Judicial Review

515.40 Judicial review.


SOURCE: 64 FR 63204, Nov. 19, 1999, unless otherwise noted.

Subpart A—Applications

§ 515.10 Medicated feed mill license applications.

(a) Medicated feed mill license applications (Forms FDA 3448) may be obtained from the Public Health Service, Consolidated Forms and Publications Distribution Center, Washington Commerce Center, 3222 Hubbard Rd., Landover, MD 20785, or electronically from the Center for Veterinary Medicine home page at http://www.fda.gov/cvm.

(b) A completed medicated feed mill license must contain the following information:

1. The full business name and address of the facility at which the manufacturing is to take place.

2. The facility’s FDA registration number as required by section 510 of the Federal Food, Drug, and Cosmetic Act (the act).

3. The name, title, and signature of the responsible individual or individuals for that facility.

4. A certification that the animal feeds bearing or containing new animal drugs are manufactured and labeled in accordance with the applicable regulations published under section 512(i) of the act or in accordance with the index listing published under section 572(e)(2) of the act.

5. A certification that the methods used in, and the facilities and controls used for, manufacturing, processing, packaging, and holding such animal feeds are...
feeds conform to current good manufacturing practice as described in section 501(a)(2)(B) of the act and in part 225 of this chapter.

(6) A certification that the facility will establish and maintain all records required by regulation or order issued under sections 512(m)(5)(A) or 504(a)(3)(A) of the act, and will permit access to, or copying or verification of such records.

(7) A commitment that current approved or index listed Type B and/or Type C medicated feed labeling for each Type B and/or Type C medicated feed to be manufactured will be in the possession of the feed manufacturing facility prior to receiving the Type A medicated article containing such drug.

(8) A commitment to renew registration every year with FDA as required in §§207.20 and 207.21 of this chapter.

(c) Applications must be completed, signed, and submitted to the Division of Animal Feeds (HRV–220), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

(d) Applications that are facially deficient will be returned to the applicant. All reasons for the return of the application will be made known to the applicant.

(e) Upon approval, the original copy of the application will be signed by an authorized employee of FDA designated by the Commissioner of Food and Drugs, and a copy will be returned to the applicant.

§515.20 Approval of medicated feed mill license applications.

Within 90 days after an application has been filed under §515.10, if the Commissioner of Food and Drugs (the Commissioner) determines that none of the grounds for denying approval specified in section 512(m)(3) of the Federal Food, Drug, and Cosmetic Act (the act) applies, an authorized employee of the Food and Drug Administration designated by the Commissioner shall notify the applicant that it is approved by signing and mailing to the applicant a copy of the Form FDA 3448. Supplemental applications that do not provide adequate information shall be returned to the applicant and all reasons for the return of the application shall be made known to the applicant.

§515.21 Refusal to approve a medicated feed mill license application.

(a) The Commissioner of Food and Drugs (the Commissioner) shall within 90 days, or such additional period as may be agreed upon by the Commissioner and the applicant, after the filing of an application under §515.10, inform the applicant in writing of his/her intention to issue a notice of opportunity for a hearing on a proposal to refuse to approve the application, if the Commissioner determines upon the basis of the application, on the basis of a preapproval inspection, or upon the basis of any other information before him that:

(1) The application is incomplete, false, or misleading in any particular; or

(2) The methods used in and the facilities and controls used for the manufacturing, processing, and packaging of such animal feed are not adequate to...
§ 515.22 Suspension and/or revocation of approval of a medicated feed mill license.

(a) The Secretary of Health and Human Services may suspend a medicated feed mill license approved under section 512(m)(2) of the Federal Food, Drug, and Cosmetic Act (the act) and give the person holding the medicated feed mill license application prompt notice of this action and afford the applicant the opportunity for an expeditious hearing on a finding that there is an imminent hazard to the health of man or of the animals for which such animal feed is intended.

(b) The Commissioner of Food and Drugs (the Commissioner) shall notify in writing the person holding an application approved under section 512(m)(2) of the act and afford an opportunity for a hearing on a proposal to revoke approval of such application if the Commissioner finds:

(1) That the application contains any untrue statement of a material fact; or
(2) That the applicant has made any changes that would cause the application to contain any untrue statements of material fact or that would affect the safety or effectiveness of the animal feeds manufactured at the facility unless the applicant has supplemented the application by filing a supplemental application under §515.11.

(c) The Commissioner may notify in writing the person holding an application approved under section 512(m)(2) of the act and afford an opportunity for a hearing on a proposal to revoke approval of such application if the Commissioner finds:

(1) That the applicant has failed to establish a system for maintaining required records, or has repeatedly or deliberately failed to maintain such records or to make required reports in accordance with a regulation or order under sections 512(m)(5)(A) or 504(a)(3)(A) of the act, or the applicant has refused to permit access to, or copying, or verification of, such records as required by sections 512(m)(5)(B) or 504(a)(3)(B) of the act; or
(2) That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the methods used in, or the facilities and controls used for, the manufacture, processing, packing, and holding of such animal feed are inadequate to assure and preserve the identity, strength, quality, and purity of the new animal drug therein, and were not made adequate within a reasonable time after receipt of written notice from the Commissioner specifying the matter complained of; or
(3) That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the labeling of any animal feed, based on a fair evaluation of all material facts, is false or misleading in any particular and was not corrected within a reasonable time after receipt of written notice from the Commissioner specifying the matter complained of; or
(4) That on the basis of new information before him, evaluated together with the evidence before him when such license was issued, the facility has manufactured, processed, packed, or held animal feed bearing or containing a new animal drug adulterated under
Food and Drug Administration, HHS

§ 515.30 Contents of notice of opportunity for a hearing.

(a) The notice to the applicant of opportunity for a hearing on a proposal by the Commissioner of Food and Drugs (the Commissioner) to refuse to approve a medicated feed mill license application or to revoke the approval of a medicated feed mill license will specify the grounds upon which the Commissioner proposes to issue this order. On request of the applicant, the Commissioner will explain the reasons for the action. The notice of opportunity for a hearing will be published in the FEDERAL REGISTER and will specify that the applicant has 30 days after issuance of the notice within which the Commissioner is required to file a written appearance electing whether:

(1) To avail himself of the opportunity for a hearing; or
(2) Not to avail himself of the opportunity for a hearing.

(b) If the applicant fails to file a written appearance in answer to the notice of opportunity for hearing, this failure will be construed as an election not to avail himself of the opportunity for the hearing, and the Commissioner without further notice may enter a final order.

(c) If the applicant elects to avail himself of the opportunity for a hearing, the applicant is required to file a written appearance requesting the hearing within 30 days after the publication of the notice, giving the reason why the application should not be refused or the medicated feed mill license should not be revoked, together with a well-organized and full-factual analysis...
of the information the applicant is prepared to prove in support of his opposition to the Commissioner’s proposal. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing there is a genuine and substantial issue of fact that requires a hearing. When it clearly appears from the information in the application and from the reasons and factual analysis in the request for the hearing that no genuine and substantial issue of fact precludes the refusal to approve the application or the revocation of approval of the application, the Commissioner will enter an order on this information, stating his/her findings and conclusions. If a hearing is requested and is justified by the applicant’s response to the notice of opportunity for a hearing, the issues will be defined, an Administrative Law Judge will be named, and the Judge shall issue a written notice of the time and place at which the hearing will commence. In the case of denial of approval, such time shall be not more than 90 days after the expiration of such 30 days unless the Administrative Law Judge and the applicant otherwise agree; and, in the case of withdrawal of approval, such time shall be as soon as practicable.

(d) The hearing will be open to the public; however, if the Commissioner finds that portions of the application which serve as a basis for the hearing contain information concerning a method or process entitled to protection as a trade secret, the part of the hearing involving such portions will not be public, unless the respondent so specifies in the appearance.

§ 515.31 Procedures for hearings.

Hearings relating to new animal drugs under section 512(m)(3) and (m)(4) of the Federal Food, Drug, and Cosmetic Act (the act) shall be governed by part 12 of this chapter.

Subpart D—Judicial Review

§ 515.40 Judicial review.

The transcript and record shall be certified by the Commissioner of Food and Drugs (the Commissioner). In any case in which the Commissioner enters an order without a hearing under § 314.200(g) of this chapter, the request(s) for hearing together with the data and information submitted and the Commissioner’s findings and conclusions shall be included in the record certified by the Commissioner.

PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES

Subpart A—General Provisions

Sec. 516.1 Scope.
516.2 Purpose.
516.3 Definitions.

Subpart B—Designation of a Minor Use or Minor Species New Animal Drug

516.11 Scope of this subpart.
516.12 Purpose.
516.13 Definitions.
516.14 Submission of requests for designation.
516.16 Eligibility to request designation.
516.20 Content and format of a request for MUMS-drug designation.
516.21 Documentation of minor use status.
516.22 Permanent-resident U.S. agent for foreign sponsor.
516.23 Timing of requests for MUMS-drug designation.
516.24 Granting MUMS-drug designation.
516.25 Refusal to grant MUMS-drug designation.
516.26 Amendment to MUMS-drug designation.
516.27 Change in sponsorship.
516.28 Publication of MUMS-drug designations.
516.29 Termination of MUMS-drug designation.
516.30 Annual reports for a MUMS-designated drug.
516.31 Scope of MUMS-drug exclusive marketing rights.
516.32 FDA recognition of exclusive marketing rights.
516.34 Insufficient quantities of MUMS-designated drugs.
516.52 Availability for public disclosure of data and information in requests.

Subpart C—Index of Legally Marketed Unapproved New Animal Drugs for Minor Species

516.11 Scope of this subpart.
516.15 Definitions.
516.17 Submission of correspondence under this subpart.
516.19 Permanent-resident U.S. agent for foreign requestors and holders.
§ 516.121 Meetings.
§ 516.123 Informal conferences regarding agency administrative actions.
§ 516.125 Investigational use of minor species new animal drugs to support indexing.
§ 516.129 Content and format of a request for determination of eligibility for indexing.
§ 516.131 Refuse to file a request for determination of eligibility for indexing.
§ 516.133 Denying a request for determination of eligibility for indexing.
§ 516.135 Granting a request for determination of eligibility for indexing.
§ 516.137 Notification of decision regarding eligibility for indexing.
§ 516.141 Qualified expert panels.
§ 516.143 Written report.
§ 516.145 Content and format of a request for addition to the index.
§ 516.147 Refuse to file a request for addition to the index.
§ 516.149 Denying a request for addition to the index.
§ 516.151 Granting a request for addition to the index.
§ 516.153 Notification of decision regarding index listing.
§ 516.155 Labeling of indexed drugs.
§ 516.157 Publication of the index and content of an index listing.
§ 516.161 Modifications to indexed drugs.
§ 516.163 Change in ownership of an index file.
§ 516.165 Records and reports.
§ 516.167 Removal from the index.
§ 516.171 Confidentiality of data and information in an index file.

Subpart D [Reserved]

Subpart E—Conditionally Approved New Animal Drugs For Minor Use and Minor Species

§ 516.1684 Paclitaxel.

SOURCE: 72 FR 41017, July 26, 2007, unless otherwise noted.

Subpart A—General Provisions

§ 516.1 Scope.
(a) This part implements section 573 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360ccc–2) and contains the following subparts:
(1) Subpart A—General Provisions.
(2) Subpart B—Designation of a Minor Use or Minor Species New Animal Drug.
(3) Subpart C [Reserved]
(4) Subpart D [Reserved]
(b) References in this part to regulatory sections of the Code of Federal Regulations are to Chapter I of Title 21, unless otherwise noted.

§ 516.2 Purpose.
This part establishes standards and procedures for implementing section 573 of the act, including designation of minor use or minor species new animal drugs and associated exclusive marketing rights.

§ 516.3 Definitions.
(a) The definitions and interpretations contained in section 201 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321) apply to those terms when used in this part.
(b) The following definitions of terms apply to all subparts of part 516:
Active moiety means the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the pharmacological action of the drug substance.
Functionally superior means that a drug has been shown to provide a significant therapeutic or physiologic advantage over that provided by a conditionally-approved or approved MUMS drug, that is otherwise the same drug, in one or more of the following ways:
(i) The drug has been shown to be more effective, as assessed by effect on a clinically meaningful endpoint in adequate and well-controlled clinical trials, than a conditionally approved or approved MUMS drug, that is otherwise the same drug.
(ii) The drug has been shown to be safer than a conditionally-approved or approved MUMS drug, that is otherwise the same drug, in a substantial portion of the target population, for example, by the elimination of an ingredient or contaminant that is associated with relatively frequent adverse effects. In some cases, direct comparative clinical trials will be necessary.
§ 516.3

Infrequently, as used in the minor use definition, means a disease or condition that is uncommon or that occurs only sporadically on an annualized basis.

Limited geographical areas, as used in the minor use definition, means regions of the United States distinguished by physical, chemical, or biological factors that limit the distribution of a disease or condition.

Major species means cattle, horses, swine, chickens, turkeys, dogs, and cats.

Minor species means animals, other than humans, that are not major species.

Minor use means the intended use of a drug in a major species for an indication that occurs infrequently and in only a small number of animals or in limited geographical areas and in only a small number of animals annually.

MUMS drug means a new animal drug, as defined in section 201 of the act, intended for a minor use or for use in a minor species.

Same dosage form means the same as one of the dosage form categories specified in the following parts of this chapter:

(i) Part 520: Oral dosage form new animal drugs (excluding use in animal feeds as specified in part 558 of this chapter).

(ii) Part 522: Implantation or injectable dosage form new animal drugs.

(iii) Part 524: Ophthalmic and topical dosage form new animal drugs.

(iv) Part 526: Intramammary dosage forms.

(v) Part 529: Certain other dosage form new animal drugs.


Same drug means a MUMS drug for which designation, indexing, or conditional approval is sought that meets the following criteria:

(i) If it is a MUMS drug composed of small molecules and contains the same active moiety as a prior designated, conditionally-approved, or approved MUMS drug, even if the particular ester or salt (including a salt with hydrogen or coordination bonds) or other noncovalent derivative such as a complex, chelate or clathrate is not the same, it is considered the same drug; except that, if the prior MUMS drug is conditionally approved or approved and the second MUMS drug is shown to be functionally superior to the conditionally approved or approved MUMS drug for the same intended use, it is not considered the same drug.

(ii) If it is a MUMS drug composed of large molecules (macromolecules) and contains the same principal molecular structural features (but not necessarily all of the same structural features) as a prior designated, conditionally approved, or approved MUMS drug, it is considered the same drug; except that, if the prior MUMS drug is conditionally approved or approved and the second MUMS drug is shown to be functionally superior to the conditionally approved or approved MUMS drug for the same intended use, it is not considered the same drug. This criterion will be applied as follows to different kinds of macromolecules:

(A) Two protein drugs would be considered the same if the only differences in structure between them were due to post-translational events or infidelity of translation or transcription or were minor differences in amino acid sequence; other potentially important differences, such as different glycosylation patterns or different tertiary structures, would not cause the drugs to be considered different unless the subsequent drug is shown to be functionally superior.

(B) Two polysaccharide drugs would be considered the same if they had identical saccharide repeating units, even if the number of units were to vary and even if there were postpolymerization modifications, unless the subsequent drug is shown to be functionally superior.

(C) Two polynucleotide drugs consisting of two or more distinct nucleotides would be considered the same if they had identical nucleotide repeating units, even if the number of units were to vary and even if there were postpolymerization modifications, unless the subsequent drug is shown to be functionally superior.

(D) Closely related, complex partly definable drugs with similar pharmacologic intent would be considered the
same unless the subsequent drug is shown to be functionally superior.

Same intended use means an intended use of a MUMS drug, for which designation, indexing, or conditional approval is sought, that is determined to be the same as (or not different from) a previously designated, conditionally approved, or approved intended use of a MUMS drug. Same intended use is established by comparing two intended uses and not by simply comparing the specific language by means of which the intent is established in labeling in accordance with the following criteria:

(i) Two intended uses are considered the same if one of the intended uses falls completely within the scope of the other.

(ii) For intended uses associated with diseases or conditions with multiple causative organisms, two intended uses are not considered the same when they involve different causative organisms or different subsets of causative organisms of that disease or condition when the causative organisms involved can reliably be shown to be clinically significant causes of the disease or condition.

(iii) Two intended uses of a drug are not considered the same if they involve different intended species or different definable subpopulations (including "production classes") of a species.

Small number of animals means equal to or less than 50,000 horses; 70,000 dogs; 120,000 cats; 310,000 cattle; 1,450,000 pigs; 14,000,000 turkeys; and 72,000,000 chickens.

Sponsor means the person requesting designation for a MUMS drug who must be the real party in interest of the development and the intended or actual production and sales of such drug (in this context, the sponsor may be an individual, partnership, organization, or association). Sponsor also means the person responsible for an investigation of a new animal drug (in this context, the sponsor may be an individual, partnership, corporation, or Government agency or may be a manufacturer, scientific institution, or an investigator regularly and lawfully engaged in the investigation of new animal drugs). Sponsor also means the person submitting or receiving approval for a new animal drug application (in this context, the sponsor may be an individual, partnership, organization, or association). In all contexts, the sponsor is responsible for compliance with applicable provisions of the act and regulations.

Subpart B—Designation of a Minor Use or Minor Species New Animal Drug

§516.11 Scope of this subpart.

This subpart implements section 573 of the act. Specifically, this subpart sets forth the procedures and requirements for submissions to FDA of requests for designation of a new animal drug for a minor use or a minor species.

§516.12 Purpose.

This subpart establishes standards and procedures for determining eligibility for designation and the associated incentives and benefits described in section 573 of the act, including a 7-year period of exclusive marketing rights.

§516.13 Definitions.

The following definitions of terms apply only in the context of subpart B of this part:

Director means the Director of the Office of Minor Use and Minor Species Animal Drug Development of the FDA Center for Veterinary Medicine.

Intended use means the intended treatment, control or prevention of a disease or condition, or the intention to affect the structure or function of the body of animals within an identified species, subpopulation of a species, or collection of species.

MUMS-designated drug means a new animal drug, as defined in section 201 of the act, intended for a minor use or for use in a minor species that has been designated under section 573 of the act.

MUMS-drug exclusive marketing rights or exclusive marketing rights means that, effective on the date of FDA conditional approval or approval as stated in the approval letter of an application.
for a MUMS-designated drug, no conditional approval or approval will be given to a subsequent application for the same drug, in the same dosage form, for the same intended use for 7 years, except as otherwise provided by law or in this subpart.

§516.14 Submission of requests for designation.

All correspondence relating to a request for designation of a MUMS drug must be addressed to the Director of the Office of Minor Use and Minor Species Animal Drug Development. Submissions not including all elements specified in §516.20 will be returned to the sponsor without review.

§516.16 Eligibility to request designation.

The person requesting designation must be the sponsor and the real party in interest of the development and the intended or actual production and sales of the drug or the permanent-resident U.S. agent for such a sponsor.

§516.20 Content and format of a request for MUMS-drug designation.

(a) A sponsor that submits a request for designation of a new animal drug intended for a minor use or minor species must submit each request in the form and containing the information required in paragraph (b) of this section. While a request for designation may involve multiple intended uses, each request for designation must constitute a separate submission. A sponsor may request MUMS-drug designation of a previously unapproved drug, or a new intended use or dosage form for an already conditionally approved or approved drug. Only one sponsor may receive MUMS-drug designation of the same drug, in the same dosage form, for the same intended use.

(b) A sponsor must submit two copies of a completed, dated, and signed request for designation that contains the following information:

(1) A request for designation of a new animal drug for a minor use or use in a minor species, which must be specific.

(2) The name and address of the sponsor; the name of the sponsor’s primary contact person and/or permanent-resident U.S. agent including title, address, and telephone number; the established name (and proprietary name, if any) of the active pharmaceutical ingredient of the drug; and the name and address of the source of the active pharmaceutical ingredient of the drug.

(3) A description of the proposed intended use for which the drug is being or will be investigated.

(4) A description of the drug and dosage form.

(5) A discussion of the scientific rationale for the intended use of the drug; specific reference, including date(s) of submission, to all data from nonclinical laboratory studies, clinical investigations, copies of pertinent unpublished and published papers, and other relevant data that are available to the sponsor, whether positive, negative, or inconclusive.

(6) A specific description of the product development plan for the drug, its dosage form, and its intended use.

(7) If the drug is intended for a minor use in a major species, documentation in accordance with §516.21, with appended authoritative references, to demonstrate that such use is a minor use.

(8) A statement that the sponsor submitting the request is the real party in interest of the development and the intended or actual production and sales of the product.

(9) A statement that the sponsor acknowledges that, upon granting a request for MUMS designation, FDA will make information regarding the designation publicly available as specified in §516.28.

§516.21 Documentation of minor use status.

So that FDA can determine whether a drug qualifies for MUMS-drug designation as a minor use in a major species under section 573 of the act, the sponsor shall include in its request to FDA for MUMS-drug designation under §516.20 documentation demonstrating that the use is limited to a small number of animals (annualized). This documentation must include the following information:
(a) The estimated total number of animals to which the drug could potentially be administered on an annual basis for the treatment, control, or prevention of the disease or condition for which the drug is being developed, including animals administered the drug as part of herd or flock treatment, together with a list of the sources (including dates of information provided and literature citations) for the estimate.

(b) The estimated total number of animals referred to in paragraph (a) of this section may be further reduced to only a subset of the estimated total number of animals if administration of the drug is only medically justified for this subset. To establish this, requestors must demonstrate that administration of the drug to animals subject to the disease or condition for which the drug is being developed other than the subset is not medically justified. The sponsor must also include a list of the sources (including dates of information provided and literature citations) for the justification that administration of the drug to animals other than the targeted subset is medically inappropriate.

§ 516.23 Timing of requests for MUMS-drug designation.

A sponsor may request MUMS-drug designation at any time in the drug development process prior to the submission of an application for either conditional approval or approval of the MUMS drug for which designation is being requested.

§ 516.24 Granting MUMS-drug designation.

(a) FDA may grant the request for MUMS-drug designation if none of the reasons described in §516.25 for refusal to grant such a request apply.

(b) When a request for MUMS-drug designation is granted, FDA will notify the sponsor in writing and will give public notice of the MUMS-drug designation in accordance with §516.28.

§ 516.25 Refusal to grant MUMS-drug designation.

(a) FDA will refuse to grant a request for MUMS-drug designation if any of the following reasons apply:

1. The drug is not intended for use in a minor species or FDA determines that there is insufficient evidence to demonstrate that the drug is intended for a minor use in a major species.

2. The drug is the same drug in the same dosage form for the same intended use as one that already has a MUMS-drug designation but has not yet been conditionally approved or approved.

3. The drug is the same drug in the same dosage form for the same intended use as one that already has a MUMS-drug designation but has not yet been conditionally approved or approved.

4. The drug is the same drug in the same dosage form for the same intended use as one that already has a MUMS-drug designation but has not yet been conditionally approved or approved. A drug that FDA has found to be functionally superior is not considered the same drug as an already conditionally approved or approved drug even if it is otherwise the same drug in the same dosage form for the same intended use.

(b) The sponsor has failed to provide:

1. A credible scientific rationale in support of the intended use.

2. Sufficient information about the product development plan for the drug, its dosage form, and its intended use to establish that adherence to the plan can lead to successful drug development in a timely manner, and

3. Any other information required under §516.20.

§ 516.22 Permanent-resident U.S. agent for foreign sponsor.

Every foreign sponsor that seeks MUMS-drug designation shall name a permanent resident of the United States as the sponsor’s agent upon whom service of all processes, notices, orders, decisions, requirements, and other communications may be made on behalf of the sponsor. Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes. The permanent-resident U.S. agent may be an individual, firm, or domestic corporation and may represent any number of sponsors. The name and address of the permanent-resident U.S. agent shall be provided to the Director of the Office of Minor Use and Minor Species Animal Drug Development.
§ 516.26 Amendment to MUMS-drug designation.

(a) At any time prior to conditional approval or approval of an application for a MUMS-designated drug, the sponsor may apply for an amendment to the designated intended use if the proposed change is due to new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments.

(b) FDA will grant the amendment if it finds:

1. That the initial designation request was made in good faith;
2. That the amendment is intended to make the MUMS-drug designated intended use conform to the results of new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments; and
3. In the case of a minor use, that as of the date of the submission of the amendment request, the amendment would not result in the intended use of the drug no longer being considered a minor use.

§ 516.27 Change in sponsorship.

(a) A sponsor may transfer sponsorship of a MUMS-designated drug to another person. A change of sponsorship will also transfer the designation status of the drug which will remain in effect for the new sponsor subject to the same conditions applicable to the former sponsor provided that at the time of a potential transfer, the new and former sponsors submit the following information in writing and obtain permission from FDA:

1. The former sponsor shall submit a letter to FDA that documents the transfer of sponsorship of the MUMS-designated drug. This letter shall specify the date of the transfer. The former sponsor shall also certify in writing to FDA that a complete copy of the request for MUMS-drug designation, including any amendments to the request, and correspondence relevant to the MUMS-drug designation, has been provided to the new sponsor.
2. The new sponsor shall submit a letter or other document containing the following information:
   (i) A statement accepting the MUMS-drug designated file or application;
   (ii) The date that the change in sponsorship is intended to be effective;
   (iii) A statement that the new sponsor has a complete copy of the request for MUMS-drug designation, including any amendments to the request and any correspondence relevant to the MUMS-drug designation;
   (iv) A statement that the new sponsor understands and accepts the responsibilities of a sponsor of a MUMS-designated drug established elsewhere in this subpart;
   (v) The name and address of a new primary contact person or permanent resident U.S. agent; and
   (vi) Evidence that the new sponsor is capable of actively pursuing approval with due diligence.
3. No sponsor may relieve itself of responsibilities under the act or under this subpart by assigning rights to another person without:
   (1) Assuring that the new sponsor will carry out such responsibilities; and
   (2) Obtaining prior permission from FDA.

§ 516.28 Publication of MUMS-drug designations.

FDA will periodically update a publicly available list of MUMS-designated drugs. This list will be placed on file at the FDA Division of Dockets Management, and will contain the following information for each MUMS-designated drug:

(a) The name and address of the sponsor;
(b) The established name and trade name, if any, of the drug;
(c) The dosage form of the drug;
(d) The species and the proposed intended use for which MUMS-drug designation was granted; and
(e) The date designation was granted.

§ 516.29 Termination of MUMS-drug designation.

(a) The sponsor of a MUMS-designated drug must notify FDA of any
§ 516.30 Annual reports for a MUMS-designated drug.

Within 14 months after the date on which a MUMS drug is granted designation and annually thereafter until approval, the sponsor of a MUMS-designated drug shall submit a brief progress report on the drug to the investigational new animal drug file addressed to the Director of the Office of Minor Use and Minor Species Animal Drug Development that includes the following information:

(a) A short account of the progress of drug development including a description of studies initiated, ongoing, and completed, and a short summary of the status or results of such studies;

(b) A description of the investigational plan for the coming year, as well as any anticipated difficulties in development, testing, and marketing; and

(c) A brief discussion of any changes that may affect the MUMS-designated drug status of the product. For example, situations in which testing data demonstrate that the proposed intended use is inappropriate due to unexpected issues of safety or effectiveness.

§ 516.31 Scope of MUMS-drug exclusive marketing rights.

(a) After conditional approval or approval of an application for a MUMS-designated drug in the dosage form and for the intended use for which MUMS-

Food and Drug Administration, HHS

decision to discontinue active pursuit of conditional approval or approval of such MUMS drug. FDA must terminate the designation upon such notification.

(b) A conditionally-approved or approved MUMS-designated drug sponsor must notify FDA at least 1 year before it intends to discontinue the manufacture of such MUMS drug. FDA must terminate designation upon such notification.

(c) MUMS designation shall terminate upon the expiration of any applicable period of exclusive marketing rights under this subpart.

(d) FDA may terminate designation if it independently determines that the sponsor is not actively pursuing conditional approval or approval with due diligence. At a minimum, due diligence must be demonstrated by:

(1) Submission of annual progress reports in a timely manner in accordance with §516.30 that demonstrate that the sponsor is progressing in accordance with the drug development plan submitted to the agency under §516.20 and

(2) Compliance with all applicable requirements of part 511 of this chapter.

(e) Designation of a conditionally approved or approved MUMS-designated drug and the associated exclusive marketing rights may be terminated if the sponsor is unable to provide sufficient quantities of the drug to meet the needs for which it is designated.

(f) FDA may also terminate MUMS-drug designation for any drug if the agency finds that:

(1) The request for designation contained an untrue statement of material fact; or

(2) The request for designation omitted material information required by this subpart; or

(3) FDA subsequently finds that the drug in fact had not been eligible for MUMS-drug designation at the time of submission of the request;

(4) The same drug, in the same dosage form, for the same intended use becomes conditionally approved or approved for another sponsor; or

(5) FDA withdraws the conditional approval or approval of the application for the new animal drug.

(g) For a conditionally approved or approved drug, termination of MUMS-drug designation also terminates the sponsor’s exclusive marketing rights for the drug but does not withdraw the conditional approval or approval of the drug’s application.

(h) Where a drug has been MUMS-designated for a minor use in a major species, its designation will not be terminated on the grounds that the number of animals to which the drug could potentially be administered on an annual basis for the treatment, control, or prevention of the disease or condition for which the drug is being developed, including animals administered the drug as part of herd or flock treatment, subsequently increases.

(i) When a MUMS-drug designation is terminated, FDA will notify the sponsor in writing and will give public notice of the termination of the MUMS-drug designation.
drug designation has been granted, FDA will not conditionally approve or approve another application or abbreviated application for the same drug in the same dosage form for the same intended use before the expiration of 7 years after the date of conditional approval or approval as stated in the approval letter from FDA, except that such an application can be conditionally approved or approved sooner if, and at such time as, any of the following occurs:

(1) FDA terminates the MUMS-drug designation and associated exclusive marketing rights under § 516.29; or
(2) FDA withdraws the conditional approval or approval of the application for the drug for any reason; or
(3) The sponsor with exclusive marketing rights provides written consent to FDA to conditionally approve or approve another application before the expiration of 7 years; or
(4) The sponsor fails to assure a sufficient quantity of the drug in accordance with section 573 of the act and § 516.36.

(b) If an application for a MUMS drug cannot be approved until the expiration of the period of exclusive marketing of a MUMS-designated drug, FDA will so notify the sponsor in writing.

§ 516.34 FDA recognition of exclusive marketing rights.

(a) FDA will send the sponsor (or the permanent-resident U.S. agent, if applicable) timely written notice recognizing exclusive marketing rights when an application for a MUMS-designated drug has been conditionally approved or approved. The written notice will inform the sponsor of the requirements for maintaining MUMS-designated drug exclusive marketing rights for the full 7-year term. This notice will generally be contained in the notice of conditional approval or approval of the application.

§ 516.36 Insufficient quantities of MUMS-designated drugs.

(a) Under section 573 of the act, whenever FDA has reason to believe that sufficient quantities of a conditionally-approved or approved, MUMS-designated drug to meet the needs for which the drug was designated cannot be assured by the sponsor, FDA will so notify the sponsor of this possible insufficiency and will offer the sponsor the following options, one of which must be exercised by a time that FDA specifies:

(1) Provide FDA information and data regarding how the sponsor can assure the availability of sufficient quantities of the MUMS-designated drug within a reasonable time to meet the needs for which the drug was designated; or
(2) Provide FDA in writing the sponsor’s consent for the conditional approval or approval of other applications for the same drug before the expiration of the 7-year period of exclusive marketing rights.

(b) If, within the time that FDA specifies, the sponsor fails to consent to the conditional approval or approval of other applications and if FDA finds that the sponsor has not shown that it can assure the availability of sufficient quantities of the MUMS-designated drug to meet the needs for which the drug was designated, FDA will issue a written order terminating designation of the MUMS drug and the associated exclusive marketing rights. This order will state FDA’s findings and conclusions and will constitute final agency action. An order terminating designation and associated exclusive marketing rights may issue whether or not there are other sponsors that can assure the availability of alternative sources of supply. Such an order will not withdraw the conditional approval or approval of an application. Once terminated under this section, neither designation, nor exclusive marketing rights may be reinstated.
§ 516.52 Availability for public disclosure of data and information in requests.
(a) FDA will not publicly disclose the existence of a request for MUMS-drug designation under section 573 of the act prior to final FDA action on the request unless the existence of the request has been previously publicly disclosed or acknowledged.
(b) Whether or not the existence of a pending request for designation has been publicly disclosed or acknowledged, no data or information in the request are available for public disclosure prior to final FDA action on the request.
(c) Except as provided in paragraph (d) of this section, upon final FDA action on a request for designation, the public availability of data and information in the request will be determined in accordance with part 20 of this chapter and other applicable statutes and regulations.
(d) In accordance with § 516.28, FDA will make a cumulative list of all MUMS-drug designations available to the public and update such list periodically. In accordance with § 516.29, FDA will give public notice of the termination of all MUMS-drug designations.

Subpart C—Index of Legally Marketed Unapproved New Animal Drugs for Minor Species

Source: 72 FR 69121, Dec. 6, 2007, unless otherwise noted.

§ 516.111 Scope of this subpart.
This subpart implements section 572 of the act and provides standards and procedures to establish an index of legally marketed unapproved new animal drugs. This subpart applies only to minor species and not to minor use in major species. This index is only available for new animal drugs intended for use in a minor species for which there is a reasonable certainty that the animal or edible products from the animal will not be consumed by humans or food-producing animals and for new animal drugs intended for use only in a hatchery, tank, pond, or other similar contained man-made structure in an early, nonfood life stage of a food-producing minor species, where safety for humans is demonstrated in accordance with the standard of section 512(d) of the act (including, for an antimicrobial new animal drug, with respect to antimicrobial resistance). The index shall not include a new animal drug that is contained in, or a product of, a transgenic animal. Among its topics, this subpart sets forth the standards and procedures for:
(a) Investigational exemptions for indexing purposes;
(b) Submissions to FDA of requests for determination of eligibility of a new animal drug for indexing;
(c) Establishment and operation of expert panels;
(d) Submissions to FDA of requests for addition of a new animal drug to the index;
(e) Modifications to index listings;
(f) Publication of the index; and
(g) Records and reports.

§ 516.115 Definitions.
(a) The following definitions of terms apply only in the context of subpart C of this part:
Director OMUMS means the Director of the Office of Minor Use and Minor Species Animal Drug Development of the FDA Center for Veterinary Medicine.
Holder means the requestor of an index listing after the request is granted and the new animal drug is added to the index.
Index means FDA’s list of legally marketed unapproved new animal drugs for minor species.
Intended use has the same meaning as that given in § 516.13 of this chapter.
Qualified expert panel means a panel that is composed of experts qualified by scientific training and experience to evaluate the target animal safety and effectiveness of a new animal drug under consideration for indexing.
Requestor means the person making a request for determination of eligibility for indexing or a request for addition to the index.
Transgenic animal means an animal whose genome contains a nucleotide sequence that has been intentionally modified in vitro, and the progeny of such an animal, provided that the term ‘transgenic animal’ does not include an
§ 516.117 Submission of correspondence under this subpart.

Unless directed otherwise by FDA, all correspondence relating to any aspect of the new animal drug indexing process described in this subpart must be addressed to the Director, OMUMS. The initial correspondence for a particular index listing should include the name and address of the authorized contact person. Notifications of changes in such person or changes of address of such person should be provided in a timely manner.

§ 516.119 Permanent-resident U.S. agent for foreign requestors and holders.

Every foreign requestor and holder shall name a permanent resident of the United States as their agent upon whom service of all processes, notices, orders, decisions, requirements, and other communications may be made on behalf of the requestor or holder. Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes. The permanent resident U.S. agent may be an individual, firm, or domestic corporation and may represent any number of requestors or holders. The name and address of the permanent-resident U.S. agent shall be submitted to the Director, OMUMS, and included in the index file.

§ 516.121 Meetings.

(a) A requestor or potential requestor is entitled to one or more meetings to discuss the requirements for indexing a new animal drug.

(b) Requests for such meetings should be in writing, be addressed to the Director, OMUMS, specify the participants attending on behalf of the requestor or potential requestor, and contain a proposed agenda for the meeting.

(c) Within 30 days of receiving a request for a meeting, FDA will attempt to schedule the meeting at a time agreeable to both FDA and the person making the request.

§ 516.123 Informal conferences regarding agency administrative actions.

(a) Should FDA make an initial decision denying a request for determination of eligibility for indexing, terminating an investigational exemption, determining that a qualified expert panel does not meet the selection criteria, denying a request for addition to the index, or removing a new animal drug from the index, FDA will give written notice that specifies the grounds for the initial decision and provides an opportunity for an informal conference for review of the decision.

(b) The written notice will include information for scheduling the informal conference and state that a written request for a conference must be made within 60 days of the date FDA sends its notice.

(c) Within 45 days of receiving a request for an informal conference, FDA will schedule and hold the informal conference at a time agreeable to both FDA and the person making the request.

(d) Such an informal conference will be conducted by a presiding officer who will be the Director of the Center for Veterinary Medicine or his or her designee, excluding the Director of the Office of Minor Use and Minor Species Animal Drug Development and other persons significantly involved in the initial decision.

(e) The person requesting an informal conference must provide a written response to FDA’s initial decision at least 2 weeks prior to the date of the scheduled meeting. Generally, this written response would be attached to the request for an informal conference.
At the option of the person requesting an informal conference, such written response to FDA's initial decision may act in lieu of a face-to-face meeting. In this case, the informal conference will consist of a review by the presiding officer of the submitted written response.

(f) The purpose of an informal conference is to discuss scientific and factual issues. It will involve a discussion of FDA's initial decision and any written response to that decision.

(g) Internal agency review of a decision must be based on the information in the administrative file. If the person requesting an informal conference presents new information not in the file, the matter will be returned to the appropriate lower level in the agency for reevaluation based on the new information.

(h) Informal conferences under this part are not subject to the separation of functions rules in §10.55 of this chapter.

(i) The rules of evidence do not apply to informal conferences. No motions or objections relating to the admissibility of information and views will be made or considered, but any party to the conference may comment upon or rebut all such data, information and views.

(j) [Reserved]

(k) The presiding officer will prepare a written report regarding the subject of the informal conference that states and describes the basis for his or her findings. Whenever time permits, the parties to the informal conference will have 30 days to review and comment on the report.

(l) The administrative record of the informal conference will consist of:

1. The notice providing an opportunity for an informal conference and the written response to the notice.

2. All written information and views submitted to the presiding officer at the conference or, at the discretion of the presiding officer, thereafter.

3. The presiding officer's written report.

4. All correspondence and memoranda of any and all meetings between the participants and the presiding officer.

(m) The administrative record of the informal conference is closed to the submission of information at the close of the conference, unless the presiding officer specifically permits additional time for further submission.

(n) The administrative record of the informal conference specified herein constitutes the exclusive record for decision.

§516.125 Investigational use of minor species new animal drugs to support indexing.

(a) The investigational use of a new animal drug or animal feed bearing or containing a new animal drug intended solely for investigational use in minor species shall meet the requirements of part 511 of this chapter if the investigational use is for the purpose of:

1. Demonstrating human food safety under section 572(a)(1)(B) of the act;

2. Demonstrating safety with respect to individuals exposed to the new animal drug through its manufacture and use under section 572(c)(1)(F) of the act;

3. Conducting an environmental assessment under section 572(c)(1)(E) of the act;

4. Obtaining approval of a new animal drug application or abbreviated new animal drug application under section 512(b) of the act.

(b) Correspondence and information associated with investigations described in paragraph (a) of this section shall not be sent to the Director, OMUMS, but shall be submitted to FDA in accordance with the provisions of part 511 of this chapter.

(c) The investigational use of a new animal drug or animal feed bearing or containing a new animal drug intended solely for investigational use in minor species, other than for an investigational use described in paragraph (a) of this section, shall meet the requirements of this section. For such investigations, all provisions of part 511 of this chapter apply with the following modifications:

1. Under §511.1(a)(1) of this chapter, the label statement is as follows:

"Caution. Contains a new animal drug for investigational use only in laboratory animals or for tests in vitro in support of index listing. Not for use in humans."
(2) Under §511.1(b)(1) of this chapter, the label statement is as follows:

"Caution. Contains a new animal drug for use only in investigational animals in clinical trials in support of index listing. Not for use in humans. Edible products of investigational animals are not to be used for food for humans or other animals unless authorization has been granted by the U.S. Food and Drug Administration or by the U.S. Department of Agriculture."

(3) Under §511.1(b)(4) of this chapter, the notice is titled “Notice of Claimed Investigational Exemption for a New Animal Drug for Index Listing” and is submitted in duplicate to the Director, OMUMS.

(4) Under §511.1(c)(3) of this chapter, if an investigator is determined to be ineligible to receive new animal drugs, each “Notice of Claimed Investigational Exemption for a New Animal Drug for Index Listing” and each request for indexing shall be examined with respect to the reliability of information submitted by the investigator.

(5) Under §511.1(c)(4) and (d)(2) of this chapter, with respect to termination of exemptions, the sponsor of an investigation shall not be granted an opportunity for a regulatory hearing before FDA pursuant to part 16 of this chapter. Instead, the sponsor shall have an opportunity for an informal conference as described in §516.123.

(6) Under §511.1(c)(5) of this chapter, if the Commissioner of Food and Drugs determines, after the unreliable data submitted by the investigator are eliminated from consideration, that the data remaining are such that a request for addition to the index would have been denied, FDA will remove the new animal drug from the index in accordance with §516.167.

(d) The investigational use of a new animal drug or animal feed bearing or containing a new animal drug subject to paragraph (c) of this section shall not be subject to the good laboratory practice requirements in part 86 of this chapter.

(e) Correspondence and information associated with investigations described in paragraph (c) of this section shall be sent to the Director, OMUMS, in accordance with the provisions of this section.

§516.129 Content and format of a request for determination of eligibility for indexing.

(a) Each request for determination of eligibility:

(1) May involve only one drug (or one combination of drugs) in one dosage form;

(2) May not involve a new animal drug that is contained in or a product of a transgenic animal;

(3) May not involve the same drug in the same dosage form for the same intended use as a drug that is already approved or conditionally approved; and

(4) Must be submitted separately.

(b) A request for determination of eligibility for indexing may involve multiple intended uses and/or multiple minor species. However, if a request for determination of eligibility for indexing that contains multiple intended uses and/or multiple minor species cannot be granted in any part, the entire request will be denied.

(c) A requestor must submit two copies of a dated request signed by the authorized contact person for determination of eligibility for indexing that contains the following:

(1) Identification of the minor species or groups of minor species for which the new animal drug is intended;

(2) Information regarding drug components and composition;

(3) A statement of the intended use(s) of the new animal drug in the identified minor species or groups of minor species;

(4) A statement of the proposed conditions of use associated with the stated intended use(s) of the new animal drug, including the proposed dosage, route of administration, contraindications, warnings, and any other significant limitations associated with the intended use(s) of the new animal drug;

(5) A brief discussion of the need for the new animal drug for the intended use(s);

(6) An estimate of the anticipated annual distribution of the new animal drug, in terms of the total quantity of active ingredient, after indexing;

(7) Information to establish that the new animal drug is intended for use:

(i) In a minor species for which there is a reasonable certainty that the animal or edible products from the animal
Food and Drug Administration, HHS

§ 516.133 Denying a request for determination of eligibility for indexing.

(a) FDA will deny a request for determination of eligibility for indexing if it determines upon the basis of the request evaluated together with any other information before it with respect to the new animal drug that:

(1) The same drug in the same dosage form for the same intended use is already approved or conditionally approved;

(2) There is insufficient information to demonstrate that the new animal drug is intended for use:

   (i) In a minor species for which there is a reasonable certainty that the animal or edible products from the animal will not be consumed by humans or food-producing animals, or

   (ii) In a hatchery, tank, pond, or other similar contained man-made structure in (which includes on) an early, non-food life stage of a food-producing minor species, and there is insufficient evidence to demonstrate safety for humans in accordance with the standard of section 512(d) of the act and §514.111 of this chapter (including, for an antimicrobial new animal drug, with respect to antimicrobial resistance);

(3) The new animal drug is contained in or is a product of a transgenic animal;

(4) There is insufficient information to demonstrate that the requestor has established appropriate specifications for the manufacture and control of the new animal drug and that the requestor has an understanding of current good manufacturing practices;

(5) The requester fails to submit an adequate environmental assessment under §25.40 of this chapter or fails to provide sufficient information to establish that the requested action is subject to categorical exclusion under §25.30 or §25.33 of this chapter;

(6) There is insufficient information to determine that the new animal drug is safe with respect to individuals exposed to the new animal drug through its manufacture or use; or

(7) The request for determination of eligibility for indexing fails to contain any other information required under the provisions of §516.129.

(b) FDA may deny a request for determination of eligibility for indexing if it contains any untrue statement of a material fact or omits material information.
§ 516.135  Granting a request for determination of eligibility for indexing.

(a) FDA will grant the request for determination of eligibility for indexing if none of the reasons described in §516.133 for denying such a request applies.

(b) When a request for determination of eligibility for indexing is granted, FDA will notify the requestor in accordance with §516.137.

§ 516.137  Notification of decision regarding eligibility for indexing.

(a) Within 90 days after the filing of a request for a determination of eligibility for indexing based on §516.129(c)(7)(i), or 180 days for a request based on §516.129(c)(7)(ii), FDA shall grant or deny the request, and notify the requestor of FDA’s decision in writing.

(b) If FDA denies the request, FDA shall provide due notice and an opportunity for an informal conference as described in §516.123 regarding its decision. A decision of FDA to deny a request for determination of eligibility for indexing following an informal conference shall constitute final agency action subject to judicial review.

§ 516.141  Qualified expert panels.

(a) Establishment of a qualified expert panel. Establishing a qualified expert panel is the first step in the process of requesting the addition of a new animal drug to the index. A qualified expert panel may not be established until FDA has determined that the new animal drug is eligible for indexing. The requestor must choose members for the qualified expert panel in accordance with selection criteria listed in paragraph (b) of this section and submit information about these proposed members to FDA. FDA must determine whether the proposed qualified expert panel meets the selection criteria prior to the panel beginning its work. Qualified expert panels operate external to FDA and are not subject to the Federal Advisory Committee Act, as amended, 5 U.S.C. App.

(b) Criteria for the selection of a qualified expert panel. (1) A qualified expert panel member must be an expert qualified by training and experience to evaluate a significant aspect of target animal safety or effectiveness of the new animal drug under consideration.

(2) A qualified expert panel member must certify that he or she has a working knowledge of section 572 of the act (the indexing provisions of the statute) and this subpart, and that he or she has also read and understood a clear written statement provided by the requestor stating his or her duties and responsibilities with respect to reviewing the new animal drug proposed for addition to the index.

(3) A qualified expert panel member may not be an FDA employee.

(4) A qualified expert panel must have at least three members.

(5) A qualified expert panel must have members with a range of expertise such that the panel, as a whole, is qualified by training and experience to evaluate the target animal safety and effectiveness of the new animal drug under consideration.

(6) Unless FDA makes a determination to allow participation notwithstanding an otherwise disqualifying financial interest, a qualified expert panel member must not have a conflict of interest or the appearance of a conflict of interest, as described in paragraph (g) of this section.

(c) Requestor responsibilities. (1) The requestor must:

(i) Choose members for the qualified expert panel in accordance with selection criteria listed in paragraph (b) of this section.

(ii) Provide each potential expert panel member a copy of section 572 of the act (the indexing provisions of the statute) and this subpart and obtain certification that he or she has a working knowledge of the information.

(iii) Provide each potential expert panel member a written statement describing the purpose and scope of his or her participation on the qualified expert panel and obtain certification that he or she has read and understood the information. The written statement should describe the duties and responsibilities of qualified expert panels and...
their members established by paragraphs (e) and (f) of this section, including the need to prepare a written report under §516.143.

(iv) Obtain information from each potential expert panel member demonstrating that he or she is qualified by training and experience to evaluate the target animal safety and effectiveness of the new animal drug under consideration. This information can be obtained from a comprehensive curriculum vitae or similar document.

(v) Notify each potential expert panel member that he or she must submit information relating to potential conflict of interest directly to FDA in a timely manner, as required in paragraph (e)(6) of this section.

(2) The requestor must submit, in writing, the names and addresses of the proposed qualified expert panel members and sufficient information about each proposed member for FDA to determine whether the panel meets the selection criteria listed in paragraphs (b)(1) through (b)(5) of this section.

(3) After FDA has determined that the qualified expert panel meets the selection criteria, the requestor must provide to the panel all information known by the requestor that is relevant to a determination of the target animal safety and the effectiveness of the new animal drug at issue. In addition, the requestor must notify FDA of the name of the qualified expert panel leader.

(4) The requestor must immediately notify FDA if it believes a qualified expert panel member no longer meets the selection criteria listed in paragraph (b) of this section or is otherwise not in compliance with the requirements of this section.

(5) If a qualified expert panel member cannot complete the review for which he or she was selected, the requestor must either choose a replacement or justify the continued work of the panel in the absence of the lost panelist. In either case, the requestor must submit sufficient information for FDA to determine whether the proposed revised qualified expert panel meets the selection criteria listed in paragraphs (b)(1) through (b)(5) of this section.

(6) The requestor must keep copies of all information provided to, or received from, qualified expert panel members, including the written report, for 2 years after the completion of the report, or the product is added to the index, whichever occurs later, and make them available to a duly authorized employee of the agency at all reasonable times.

(d) FDA responsibilities. (1) FDA will determine whether the requestor’s proposed qualified expert panel meets the selection criteria listed in paragraph (b) of this section. FDA will expeditiously inform the requestor, in writing, of its determination. If FDA determines that the qualified expert panel does not meet the selection criteria, FDA will provide due notice and an opportunity for an informal conference as described in §516.123. A determination by FDA that a proposed qualified expert panel does not meet the selection criteria following an informal conference shall constitute final agency action subject to judicial review.

(2) If FDA determines that a qualified expert panel no longer meets the selection criteria listed in paragraph (b) of this section or that the panel or its members are not in compliance with the requirements of this section, the agency will expeditiously inform the requestor, in writing, of this determination and provide due notice and an opportunity for an informal conference as described in §516.123. A determination by FDA, following an informal conference, that a qualified expert panel no longer meets the selection criteria listed in paragraph (b) of this section or that the panel or its members are not in compliance with the requirements of this section shall constitute final agency action subject to judicial review.

(e) Responsibilities of a qualified expert panel member. A qualified expert panel member must do the following:

(1) Continue to meet all selection criteria described in paragraph (b) of this section.

(2) Act in accordance with generally accepted professional and ethical business practices.

(3) Review all information relevant to a determination of the target animal safety and effectiveness of the new animal drug provided by the requestor.
§ 516.141  21 CFR Ch. I (4–1–16 Edition)

The panel should also consider all relevant information otherwise known by the panel members, including anecdotal information.

(4) Participate in the preparation of the written report of the findings of the qualified expert panel, described in §516.143.

(5) Sign, or otherwise approve in writing, the written report. Such signature or other written approval will serve as certification that the written report meets the requirements of the written report in §516.143.

(6) Provide the information relating to potential conflict of interest described in paragraph (g) of this section to FDA for its consideration. Such information should be submitted directly to the Director, OMUMS, when notified by the requestor.

(7) Immediately notify the requestor and FDA of any change in conflict of interest status.

(8) Certify at the time of submission of the written report that there has been no change in conflict of interest status, or identify and document to FDA any such change.

(f) Additional responsibilities of a qualified expert panel leader. (1) The qualified expert panel leader must ensure that the activities of the panel are performed efficiently and in accordance with generally accepted professional and ethical business practices.

(2) The qualified expert panel leader serves as the principal point of contact between representatives of the agency and the panel.

(3) The qualified expert panel leader is responsible for submitting the written report and all notes or minutes relating to panel deliberations to the requestor.

(4) The qualified expert panel leader must maintain a copy of the written report and all notes or minutes relating to panel deliberations that are submitted to the requestor for 2 years after the report is submitted. Such records must be made available to a duly authorized employee of the agency for inspection at all reasonable times.

(g) Prevention of conflicts of interest. (1) For the purposes of this subpart, FDA will consider a conflict of interest to be any financial or other interest that could impair a person’s objectivity in serving on the qualified expert panel or could create an unfair competitive advantage for a person or organization.

(2) Factors relevant to whether there is a conflict of interest or the appearance of a conflict of interest include whether the qualified expert panel member, their spouse, their minor children, their general partners, or any organizations in which they serve as an officer, director, trustee, general partner or employee:

(i) Is currently receiving or seeking funding from the requestor through a contract or research grant (either directly or indirectly through another entity, such as a university).

(ii) Has any employment, contractual, or other financial arrangement with the requestor other than receiving a reasonable fee for serving as a member of the qualified expert panel.

(iii) Has any ownership or financial interest in any drug, drug manufacturer, or drug distributor which will benefit from either a favorable or unfavorable evaluation or opinion.

(iv) Has any ownership or financial interest in the new animal drug being reviewed by the qualified expert panel.

(v) Has participated in the design, manufacture, or distribution of any drug that will benefit from either a favorable or unfavorable opinion of the qualified expert panel.

(vi) Has provided within 1 year any consultative services regarding the new animal drug being reviewed by the qualified expert panel.

(vii) Has entered into an agreement in which fees charged or accepted are contingent upon the panel member making a favorable evaluation or opinion.

(viii) Receives payment for services related to preparing information the requestor presents to the qualified expert panel, other than for services related to the written report described in §516.143.

(3) To permit FDA to make a decision regarding potential conflict of interest, a potential qualified expert panel member must submit to the Director, OMUMS, the following information relating to themselves, their spouse, their minor children, their general...
partners, or any organizations in which they serve as an officer, director, trustee, general partner or employee, regarding the following issues to the extent that they are, in any way, relevant to the subject of the review of the qualified expert panel:

(i) Investments (for example, stocks, bonds, retirement plans, trusts, partnerships, sector funds, etc.), including for each the following: Name of the firm, type of investment, owner (self, spouse, etc.), number of shares / current value.

(ii) Employment (full or part time, current or under negotiation), including for each the following: Name of the firm, relationship (self, spouse, etc.), position in firm, date employment or negotiation began.

(iii) Consultant/advisor (current or under negotiation), including for each the following: Name of the firm, topic/issue, amount received, date initiated.

(iv) Contracts, grants, Cooperation Research and Development Agreement (CRADAs) (current or under negotiation), including for each the following: Type of agreement, product under study and indications, amount of remuneration (institution/self), time period, sponsor (government, firm, institution, individual), role of the person (site investigator, principal investigator, co-investigator, partner, no involvement, other), awardee.

(v) Patents/royalties/trademarks, including for each the following: Description, name of firm involved, income received.

(vi) Expert witness (last 12 months or under negotiation), including for each the following: For or against, name of firm, issue, amount received.

(vii) Speaking/writing (last 12 months or under negotiation), including for each the following: Firm, topic/issue, amount received (honorarium/travel), date.

(viii) Whether the potential qualified expert panel member, their spouse, their minor children, their general partners or any organizations in which they serve as an officer, director, trustee, general partner or employee, have had, at any time in the past, involvement of the kind noted in paragraph (g)(3)(i) through (g)(3)(vii) of this section with respect to the animal drug that is the subject of the qualified expert panel review.

(ix) Whether there are any other involvements (other kinds of relationships) that would give the appearance of a conflict of interest which have not been described in paragraph (g)(3)(i) through (g)(3)(vii) of this section.

(x) In all cases, a response of “no,” “none,” or “not applicable” is satisfactory when there is no relevant information to submit.

(xi) A certification statement signed by the potential qualified expert panel member to the effect that all information submitted is true and complete to the best of their knowledge, that they have read and understood their obligations as an expert panel member, and that they will notify FDA and the requester of any change in their conflict of interest status.

(4) The fact that a qualified expert panel member receives a reasonable fee for services as a member of the qualified expert panel, provided that the fee is no more than commensurate with the value of the time that the member devotes to the review process, does not constitute a conflict of interest or the appearance of a conflict of interest.

§516.143 Written report.

The written report required in §516.145(b)(3) shall:

(a) Be written in English by a qualified expert panel meeting the requirements of §516.141;

(b) Describe the panel’s evaluation of all available target animal safety and effectiveness information relevant to the proposed use of the new animal drug, including anecdotal information;

(c) For all information considered, including anecdotal information, include either a citation to published literature or a summary of the information;

(d) State the panel’s opinion regarding whether the benefits of using the new animal drug for the proposed use in a minor species outweigh its risks to the target animal, taking into account the harm being caused by the absence of an approved or conditionally-approved new animal drug for the minor species in question;
§ 516.145
Content and format of a request for addition to the index.

(a) A requestor may request addition of a new animal drug to the index only after the new animal drug has been granted eligibility for indexing.

(b) A requestor shall submit two copies of a dated request signed by the authorized contact for addition of a new animal drug to the index that contains the following:

1. A copy of FDA’s determination of eligibility issued under §516.137;
2. A copy of FDA’s written determination that the proposed qualified expert panel meets the selection criteria provided for in §516.141(b);
3. A written report that meets the requirements of §516.143;
4. A proposed index entry that contains the information described in §516.157;
5. Proposed labeling, including representative labeling proposed to be used for Type B and Type C medicated feeds if the drug is intended for use in the manufacture of medicated feeds;
6. Anticipated annual distribution of the new animal drug, in terms of the total quantity of active ingredient, after indexing;
7. A written commitment to manufacture the new animal drug and animal feeds bearing or containing such new animal drug according to current good manufacturing practices;
8. A written commitment to label, distribute, and promote the new animal drug only in accordance with the index entry;
9. The name and address of the contact person or permanent-resident U.S. agent; and
10. A draft Freedom of Information summary which includes the following information:
   1. A general information section that contains the name and address of the requestor and a description of the drug, route of administration, indications, and recommended dosage.
   2. A list of the names and affiliations of the members of the qualified expert panel, not including their addresses or other contact information.
   3. A summary of the findings of the qualified expert panel concerning the target animal safety and effectiveness of the drug.
   4. Citations of all publicly-available literature considered by the qualified expert panel.
   5. For an early life stage of a food-producing minor species animal, a human food safety summary.
   6. Upon specific request by FDA, the requestor shall submit the information described in §516.141 that it submitted to the qualified expert panel. Any such information not in English should be accompanied by an English translation.

§ 516.147 Refuse to file a request for addition to the index.

(a) If a request for addition to the index contains all of the information required by §516.145(b), FDA shall file it, and the filing date shall be the date FDA receives the request.

(b) If a request for addition to the index lacks any of the information required by §516.145, FDA will not file it, but will inform the requestor in writing within 30 days of receiving the request as to what information is lacking.
§ 516.149 Denying a request for addition to the index.

(a) FDA will deny a request for addition to the index if it finds the following:

(1) The same drug in the same dosage form for the same intended use is already approved or conditionally approved;

(2) On the basis of new information, the new animal drug no longer meets the conditions for eligibility for indexing;

(3) The request for indexing fails to contain information required under the provisions of § 516.145;

(4) The qualified expert panel fails to meet any of the selection criteria listed in § 516.141(b);

(5) The written report of the qualified expert panel and other information available to FDA is insufficient to permit FDA to determine that the benefits of using the new animal drug for the proposed use in a minor species outweigh its risks to the target animal, taking into account the harm caused by the absence of an approved or conditionally-approved new animal drug for the minor species in question;

(6) On the basis of the report of the qualified expert panel and other information available to FDA, the benefits of using the new animal drug for the proposed use in a minor species do not outweigh its risks to the target animal, taking into account the harm caused by the absence of an approved or conditionally-approved new animal drug for the minor species in question; or

(7) The request contains any untrue statement of a material fact or omits material information.

(b) When a request for addition to the index is denied, FDA will notify the requestor in accordance with § 516.153.

§ 516.151 Granting a request for addition to the index.

(a) FDA will grant the request for addition of a new animal drug to the index if none of the reasons described in § 516.149 for denying such a request applies.

(b) When a request for addition of a new animal drug to the index is granted, FDA will notify the requestor in accordance with § 516.153.

§ 516.153 Notification of decision regarding index listing.

(a) Within 180 days after the filing of a request for addition of a new animal drug to the index, FDA shall grant or deny the request and notify the requestor of FDA’s decision in writing.

(b) If FDA denies the request for addition of a new animal drug to the index, FDA shall provide due notice and an opportunity for an informal conference as described in § 516.123. A decision of FDA to deny a request to index a new animal drug following an informal conference shall constitute final agency action subject to judicial review.

§ 516.155 Labeling of indexed drugs.

(a) The labeling of an indexed drug that is found to be eligible for indexing under § 516.129(c)(7)(i) shall state, prominently and conspicuously: “NOT APPROVED BY FDA.—Legally marketed as an FDA indexed product. Extra-label use is prohibited.” “This product is not to be used in animals intended for use as food for humans or other animals.”

(b) The labeling of an indexed drug that was found to be eligible for indexing for use in an early, non-food life stage of a food-producing minor species animal, under § 516.129(c)(7)(ii), shall state, prominently and conspicuously: “NOT APPROVED BY FDA.—Legally marketed as an FDA indexed product. Extra-label use is prohibited.”

(c) The labeling of an indexed drug shall contain such other information as may be prescribed in the index listing.

§ 516.157 Publication of the index and content of an index listing.

(a) FDA will make the list of indexed drugs available through the FDA Web site at http://www.fda.gov. A printed copy can be obtained by writing to the Freedom of Information Staff or by visiting FDA’s Freedom of Information Staff’s Public Reading Room at the address listed on the Agency’s Web site at http://www.fda.gov.

(b) The list will contain the following information for each indexed drug:

(1) The name and address of the person who holds the index listing;

(2) The name of the drug and the intended use and conditions of use for which it is indexed;
§ 516.161 Modifications to indexed drugs.

(a) After a drug is listed in the index, certain modifications to the index listing may be requested. Any modification of an index listing may not cause an indexed drug to be a different drug (on a different combination of drugs) or a different dosage form. If such modification is requested, FDA will notify the holder that a new index listing is required for the new drug or dosage form.

(b) Modifications to the indexed drug will fall under one of three categories and must be submitted as follows:

(1) Urgent changes. (i) The following modifications to an indexed drug or its labeling should be made as soon as possible, and a request to modify the indexed drug should be concurrently submitted:

(A) The addition to package labeling, promotional labeling, or prescription drug advertising of additional warning, contraindication, side effect, or cautionary information.

(B) The deletion from package labeling, promotional labeling, and drug advertising of false, misleading, or unsupported indications for use or claims for effectiveness.

(C) Changes in manufacturing methods or controls required to correct product or manufacturing defects that may result in serious adverse drug events.

(ii) The modifications described in paragraph (b)(1)(i) of this section must be submitted to the Director, OMUMS, in the form of a request for modification of an indexed drug, and must contain sufficient information to permit FDA to determine the need for the modification and whether the modification appropriately addresses the need.

(iii) FDA will take no action against an indexed drug or index holder solely because modifications of the kinds described in paragraph (b)(1)(i) of this section are placed into effect by the holder prior to receipt of a written notice granting the request if all the following conditions are met:

(A) A request to modify the indexed drug providing a full explanation of the basis for the modifications has been submitted, plainly marked on the mailing cover and on the request as follows: ‘‘Special indexing request— modifications being effected;’’

(B) The holder specifically informs FDA of the date on which such modifications are to be placed in use, and

(C) All promotional labeling and all drug advertising are promptly revised consistent with modifications made in the labeling on or within the indexed drug package.

(2) Significant changes. (i) The following modifications to an indexed drug or its labeling may be made only after a request has been submitted to and subsequently granted by FDA:

(A) Addition of an intended use.

(B) Addition of a species.

(C) Addition or alteration of an active ingredient.

(D) Alteration of the concentration of an active ingredient.

(E) Alteration of dose or dosage regimen.

(F) Alteration of prescription or over-the-counter status.

(ii) Each modification described in paragraph (b)(2)(i) of this section must go through the same review process as an original index listing and is subject to the same standards for review.

(iii) Each submission of a request for a modification described in paragraph (b)(2)(i) of this section should contain only one type of modification unless one modification is actually necessitated by another, such as a modification of dose necessitated by a modification of the concentration of an active ingredient. Submissions relating to addition of an intended use for an existing species or addition of a species should be submitted separately, but each such submission may include multiple additional intended uses and/or multiple additional species.

(3) Minor changes. All modifications other than those described in paragraphs (b)(1) and (b)(2) of this section including, but not limited to, formulation, labeling, and manufacturing
§516.165 Records and reports.

(a) Scope and purpose. (1) The recordkeeping and reporting requirements of this section apply to all holders of indexed drugs, including indexed drugs intended for use in medicated feeds.

(2) A holder is not required to report information under this section if the holder has reported the same information under §514.80 of this chapter.

(3) The records and reports referred to in this section are in addition to those required by the current good manufacturing practice regulations in parts 211, 225, and 226 of this chapter.

(4) FDA will review the records and reports required in this section to determine, or facilitate a determination, whether there may be grounds for removing a drug from the index under section 572(f) of the act.

(b) Recordkeeping requirements. (1) Each holder of an indexed drug must establish and maintain complete files containing full records of all information pertinent to the safety or effectiveness of the indexed drug. Such records must include information from foreign and domestic sources.

(2) The holder must, upon request from any authorized FDA officer or employee, at all reasonable times, permit such officer or employee to have access to copy and to verify all such records.

(c) Reporting requirements—(1) Three-day indexed drug field alert report. The holder must inform the appropriate FDA District Office or local FDA resident post of any product or manufacturing defects that may result in serious adverse drug events within 3 working days of first becoming aware that such a defect may exist. The holder may initially provide this information by telephone or other electronic communication means, with prompt written followup. The mailing cover must be plainly marked “3-Day Indexed Drug Field Alert Report.”

(2) Fifteen-day indexed drug alert report. The holder must submit a report on each serious, unexpected adverse

§516.163 Change in ownership of an index file.

(a) A holder may transfer ownership of a drug’s index file to another person.

(1) The former owner shall submit in writing to FDA a statement that all rights in the index file have been transferred, giving the name and address of the new owner and the date of the transfer. The former owner shall also certify that a complete copy of the following, to the extent that they exist at the time of the transfer of ownership, has been provided to the new owner:

(i) The request for determination of eligibility;

(ii) The request for addition to the index;

(iii) Any modifications to the index listing;

(iv) Any records and reports under §516.165; and

(v) All correspondence with FDA relevant to the indexed drug and its index listing.

(2) The new owner shall submit the following information in writing to FDA:

(i) The date that the change in ownership is effective;

(ii) A statement that the new owner has a complete copy of all documents listed in paragraph (a)(1) of this section to the extent that they exist at the time of the transfer of ownership;

(iii) A statement that the new owner understands and accepts the responsibilities of a holder of an indexed drug;

(iv) The name and address of a new primary contact person or permanent resident U.S. agent; and

(v) A list of labeling changes associated with the change of ownership (e.g., a new trade name) as draft labeling, with complete final printed labeling to be submitted in the indexed drug annual report in accordance with §§516.161 and 516.165.
drug event, regardless of the source of the information. The holder must submit the report within 15 working days of first receiving the information. The mailing cover must be plainly marked “15-Day Indexed Drug Alert Report.”

(3) Annual indexed drug experience report. The holder must submit this report every year on the anniversary date of the letter granting the request for addition of the new animal drug to the index, or within 60 days thereafter. The report must contain data and information for the full reporting period. Any previously submitted information contained in the report must be identified as such. The holder may ask FDA to change the date of submission and, after approval of such request, file such reports by the new filing date. The report must contain the following:

(i) The number of distributed units of each size, strength, or potency (e.g., 100,000 bottles of 100 5-milligram tablets; 50,000 10-milliliter vials of 5-percent solution) distributed during the reporting period. This information must be presented in two categories: Quantities distributed domestically and quantities exported. This information must include any distributor-labeled product.

(ii) If the labeling has changed since the last report, include a summary of those changes and the holder’s and distributor’s current package labeling, including any package inserts. For large-size package labeling or large shipping cartons, submit a representative copy (e.g., a photocopy of pertinent areas of large feed bags). If the labeling has not changed since the last report, include a statement of such fact.

(iii) A summary of any changes made during the reporting period in the methods used in, and facilities and controls used for, manufacture, processing, and packing. This information must be presented in the same level of detail that it was presented in the request for determination of eligibility for indexing. Do not include changes that have already been submitted under §516.161.

(iv) Nonclinical laboratory studies and clinical data not previously reported under this section.

(vi) Any other information pertinent to safety or effectiveness of the indexed drug not previously reported under this section.

(4) Distributor’s statement. At the time of initial distribution of an indexed drug by a distributor, the holder must submit a report containing the following:

(i) The distributor’s current product labeling. This must be identical to that in the index listing except for a different and suitable proprietary name (if used) and the name and address of the distributor. The name and address of the distributor must be preceded by an appropriate qualifying phrase such as “manufactured for” or “distributed by.”

(ii) A signed statement by the distributor stating:

(A) The category of the distributor’s operations (e.g., wholesale or retail);

(B) That the distributor will distribute the drug only under the indexed drug labeling;

(C) That the distributor will promote the indexed drug only for use under the conditions stated in the index listing; and

(D) If the indexed drug is a prescription new animal drug, that the distributor is regularly and lawfully engaged in the distribution or dispensing of prescription products.

(5) Other reporting. FDA may by order require that a holder submit information in addition to that required by this section or that the holder submit the same information but at different times or reporting periods.

§516.167 Removal from the index.

(a) After due notice to the holder of the index listing and an opportunity for an informal conference as described in §516.123, FDA shall remove a new animal drug from the index if FDA finds that:

(1) The same drug in the same dosage form for the same intended use has been approved or conditionally approved;

(2) The expert panel failed to meet the requirements in §516.141;

(3) On the basis of new information before FDA, evaluated together with the evidence available to FDA when the new animal drug was listed in the
Food and Drug Administration, HHS

§ 516.171 Confidentiality of data and information in an index file.

(a) For purposes of this section, the index file includes all data and information submitted to or incorporated by reference into the index file, such as data and information related to investigational use exemptions under §516.125, requests for determination of eligibility for indexing, requests for addition to the index, modifications to indexed drugs, changes in ownership, reports submitted under §516.165, and master files. The availability for public disclosure of any record in the index file shall be handled in accordance with the provisions of this section.

(b) The existence of an index file will not be disclosed by FDA before an index listing has been made public by FDA, unless it has previously been publicly disclosed or acknowledged by the requestor.

(c) If the existence of an index file has not been publicly disclosed or acknowledged, no data or information in the index file are available for public disclosure.

(d) If the existence of an index file has been publicly disclosed or acknowledged before an index listing has been made public by FDA, no data or information contained in the file will be available for public disclosure before such index listing is made public, but the agency may, at its discretion, disclose a brief summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.

(e) After FDA sends a written notice to the requestor granting a request for addition to the index, the following data and information in the index file are available for public disclosure unless extraordinary circumstances are shown:

(1) All safety and effectiveness data and information previously disclosed to the public, as defined in §20.81 of this chapter.

(2) A summary or summaries of the safety and effectiveness data and information submitted with or incorporated by reference in the index file. Such summaries do not constitute the full information described under section 572(c) and (d) of the act on which the safety or effectiveness of the drug may be determined. Such summaries will be based on the draft Freedom of Information summary submitted under §516.145, which will be reviewed and, where appropriate, revised by FDA.

(3) A protocol for a test or study, unless it is shown to fall within the exemption established for trade secrets and confidential commercial information in §20.61 of this chapter.
§ 516.1684 21 CFR Ch. I (4–1–16 Edition)

(4) Adverse reaction reports, product experience reports, consumer complaints, and other similar data and information, after deletion of the following:
   (i) Names and any information that would identify the person using the product.
   (ii) Names and any information that would identify any third party involved with the report, such as a veterinarian.
(5) A list of all active ingredients and any inactive ingredients previously disclosed to the public as defined in § 20.81 of this chapter.
(6) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and is shown to fall within the exemption established in § 20.61 of this chapter.
(7) All correspondence and written summaries of oral discussions relating to the index file, in accordance with the provisions of part 20 of this chapter.
(f) The following data and information in an index file are not available for public disclosure unless they have been previously disclosed to the public as defined in § 20.81 of this chapter:
   (1) Manufacturing methods or processes, including quality control procedures.
   (2) Production, sales, distribution, and similar data and information, except that any compilation of such data and information aggregated and prepared in a way that does not reveal data or information which is not available for public disclosure under this provision is available for public disclosure.
   (3) Quantitative or semiquantitative formulas.
   (g) Subject to the disclosure provisions of this section, the agency shall regard the contents of an index file as confidential information unless specifically notified in writing by the holder of the right to disclose, to reference, or otherwise utilize such information on behalf of another named person.

(h) For purposes of this regulation, safety and effectiveness data include all studies and tests of an animal drug on animals and all studies and tests on the animal drug for identity, stability, purity, potency, and bioavailability.
   (i) Safety and effectiveness data and information that have not been previously disclosed to the public are available for public disclosure at the time any of the following events occurs unless extraordinary circumstances are shown:
      (1) No work is being or will be undertaken to have the drug indexed in accordance with the request.
      (2) A final determination is made that the drug cannot be indexed and all legal appeals have been exhausted.
      (3) The drug has been removed from the index and all legal appeals have been exhausted.
      (4) A final determination has been made that the animal drug is not a new animal drug.

Subpart D [Reserved]

Subpart E—Conditionally Approved New Animal Drugs For Minor Use and Minor Species

SOURCE: 72 FR 57200, Oct. 9, 2007, unless otherwise noted.

§ 516.1684 Paclitaxel.
   (a) Specifications. Each vial of powder contains 60 milligrams (mg) paclitaxel. Each milliliter of constituted solution contains 1 mg paclitaxel.
   (b) Sponsor. See No. 052818 in 510.600(c) of this chapter.
   (c) Conditions of use in dogs—(1) Amount. Administer 150 mg per square meter of body surface area intravenously over 15 to 30 minutes, once every 3 weeks, for up to 4 doses.
      (2) Indications for use. For the treatment of nonresectable stage III, IV, or V mammary carcinoma in dogs that have not received previous chemotherapy or radiotherapy. For the treatment of resectable and nonresectable squamous cell carcinoma in dogs that have not received previous chemotherapy or radiotherapy.
      (3) Limitations. Federal law restricts this drug to use by or on the order of a
Food and Drug Administration, HHS

licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.

[79 FR 18158, Apr. 1, 2014]

**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**

<table>
<thead>
<tr>
<th>Sec.</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.23</td>
<td>Acepromazine.</td>
</tr>
<tr>
<td>520.28</td>
<td>Acetazolamide.</td>
</tr>
<tr>
<td>520.38</td>
<td>Albendazole oral dosage forms.</td>
</tr>
<tr>
<td>520.38a</td>
<td>Albendazole suspension.</td>
</tr>
<tr>
<td>520.38b</td>
<td>Albendazole paste.</td>
</tr>
<tr>
<td>520.43</td>
<td>Afoxolaner.</td>
</tr>
<tr>
<td>520.48</td>
<td>Altrenogest.</td>
</tr>
<tr>
<td>520.62</td>
<td>Aminopentamide.</td>
</tr>
<tr>
<td>520.82</td>
<td>Aminopropazine oral dosage forms.</td>
</tr>
<tr>
<td>520.82a</td>
<td>Aminopropazine.</td>
</tr>
<tr>
<td>520.82b</td>
<td>Aminopropazine and neomycin.</td>
</tr>
<tr>
<td>520.88</td>
<td>Amoxicillin oral dosage forms.</td>
</tr>
<tr>
<td>520.88a</td>
<td>Amoxicillin trihydrate film-coated tablets.</td>
</tr>
<tr>
<td>520.88b</td>
<td>Amoxicillin trihydrate for oral suspension.</td>
</tr>
<tr>
<td>520.88c</td>
<td>Amoxicillin trihydrate suspension.</td>
</tr>
<tr>
<td>520.88d</td>
<td>Amoxicillin trihydrate soluble powder.</td>
</tr>
<tr>
<td>520.88e</td>
<td>Amoxicillin trihydrate boluses.</td>
</tr>
<tr>
<td>520.88f</td>
<td>Amoxicillin trihydrate tablets.</td>
</tr>
<tr>
<td>520.88g</td>
<td>Amoxicillin trihydrate and clavulinate potassium film-coated tablets.</td>
</tr>
<tr>
<td>520.88h</td>
<td>Amoxicillin trihydrate and clavulinate potassium for oral suspension.</td>
</tr>
<tr>
<td>520.90</td>
<td>Ampicillin oral dosage forms.</td>
</tr>
<tr>
<td>520.90a</td>
<td>[Reserved]</td>
</tr>
<tr>
<td>520.90b</td>
<td>Ampicillin tablets.</td>
</tr>
<tr>
<td>520.90c</td>
<td>Ampicillin capsules.</td>
</tr>
<tr>
<td>520.90d</td>
<td>Ampicillin for oral suspension.</td>
</tr>
<tr>
<td>520.90e</td>
<td>Ampicillin for soluble powder.</td>
</tr>
<tr>
<td>520.90f</td>
<td>Ampicillin boluses.</td>
</tr>
<tr>
<td>520.100</td>
<td>Ampromilium.</td>
</tr>
<tr>
<td>520.110</td>
<td>Apramycin sulfate soluble powder.</td>
</tr>
<tr>
<td>520.154</td>
<td>Bacitracin oral dosage forms.</td>
</tr>
<tr>
<td>520.154a</td>
<td>Bacitracin methylene disalicylate.</td>
</tr>
<tr>
<td>520.154b</td>
<td>Bacitracin methylene disalicylate and streptomycin sulfate powder.</td>
</tr>
<tr>
<td>520.154c</td>
<td>Bacitracin zinc soluble powder.</td>
</tr>
<tr>
<td>520.222</td>
<td>Bunamidine hydrochloride.</td>
</tr>
<tr>
<td>520.246</td>
<td>Butorphanol tablets.</td>
</tr>
<tr>
<td>520.269</td>
<td>n-Butyl chloride.</td>
</tr>
<tr>
<td>520.300</td>
<td>Cam bendazole oral dosage forms.</td>
</tr>
<tr>
<td>520.300a</td>
<td>Cambendazole suspension.</td>
</tr>
<tr>
<td>520.300b</td>
<td>Cambendazole pellets.</td>
</tr>
<tr>
<td>520.300c</td>
<td>Cambendazole paste.</td>
</tr>
<tr>
<td>520.301</td>
<td>Carbamphen ethanedisulfonate and ammonium chloride tablets.</td>
</tr>
<tr>
<td>520.302</td>
<td>Caridazolates tablets.</td>
</tr>
<tr>
<td>520.304</td>
<td>Carprofen.</td>
</tr>
<tr>
<td>520.314</td>
<td>Cefadroxil.</td>
</tr>
<tr>
<td>520.370</td>
<td>Cefpodoxime tablets.</td>
</tr>
<tr>
<td>520.376</td>
<td>Cephalxin.</td>
</tr>
</tbody>
</table>

151
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>520.905b</td>
<td>Fenbendazole granules.</td>
</tr>
<tr>
<td>520.905c</td>
<td>Fenbendazole paste.</td>
</tr>
<tr>
<td>520.905d</td>
<td>Fenbendazole powder.</td>
</tr>
<tr>
<td>520.905e</td>
<td>Fenbendazole blocks.</td>
</tr>
<tr>
<td>520.928</td>
<td>Fluroxicib tablets.</td>
</tr>
<tr>
<td>520.930</td>
<td>Fluoroxyb paste.</td>
</tr>
<tr>
<td>520.935</td>
<td>Fiornenicol.</td>
</tr>
<tr>
<td>520.960</td>
<td>Flumetasone.</td>
</tr>
<tr>
<td>520.970</td>
<td>Fluoxetine.</td>
</tr>
<tr>
<td>520.980</td>
<td>Fluralaner.</td>
</tr>
<tr>
<td>520.998</td>
<td>Furosemide.</td>
</tr>
<tr>
<td>520.1044</td>
<td>Gentamicin sulfate oral dosage forms.</td>
</tr>
<tr>
<td>520.1044a</td>
<td>Gentamicin sulfate oral solution.</td>
</tr>
<tr>
<td>520.1044b</td>
<td>Gentamicin sulfate pig pump oral solution.</td>
</tr>
<tr>
<td>520.1044c</td>
<td>Gentamicin sulfate powder.</td>
</tr>
<tr>
<td>520.1044d</td>
<td>Gentamicin sulfate oral forms.</td>
</tr>
<tr>
<td>520.1044e</td>
<td>Gentamicin sulfate oral suspension.</td>
</tr>
<tr>
<td>520.1060</td>
<td>Glucose and glycine.</td>
</tr>
<tr>
<td>520.1100</td>
<td>Griseofulvin.</td>
</tr>
<tr>
<td>520.1120</td>
<td>Haloxon oral dosage forms.</td>
</tr>
<tr>
<td>520.1120a</td>
<td>Haloxon drench.</td>
</tr>
<tr>
<td>520.1120b</td>
<td>Haloxon boluses.</td>
</tr>
<tr>
<td>520.1130</td>
<td>Hetacillin.</td>
</tr>
<tr>
<td>520.1156</td>
<td>Imidacloprid.</td>
</tr>
<tr>
<td>520.1157</td>
<td>Iodinated casein.</td>
</tr>
<tr>
<td>520.1158</td>
<td>Iodochlorhydroxyquin.</td>
</tr>
<tr>
<td>520.1182</td>
<td>Iron dextran suspension.</td>
</tr>
<tr>
<td>520.1192</td>
<td>Ivermectin paste.</td>
</tr>
<tr>
<td>520.1193</td>
<td>Ivermectin tablets and chewables.</td>
</tr>
<tr>
<td>520.1194</td>
<td>Ivermectin meal.</td>
</tr>
<tr>
<td>520.1195</td>
<td>Ivermectin liquid.</td>
</tr>
<tr>
<td>520.1196</td>
<td>Ivermectin and pyrantel tablets.</td>
</tr>
<tr>
<td>520.1197</td>
<td>Ivermectin sustained-release bolus.</td>
</tr>
<tr>
<td>520.1198</td>
<td>Ivermectin and praziquantel paste.</td>
</tr>
<tr>
<td>520.1200</td>
<td>Ivermectin, fenbendazole, and praziquantel tablets.</td>
</tr>
<tr>
<td>520.1204</td>
<td>Ivermectin, bismuth subcarbonate, activated attapulgite.</td>
</tr>
<tr>
<td>520.1242</td>
<td>Levamisole.</td>
</tr>
<tr>
<td>520.1242a</td>
<td>Levamisole powder.</td>
</tr>
<tr>
<td>520.1242b</td>
<td>Levamisole boluses or oblets.</td>
</tr>
<tr>
<td>520.1242c</td>
<td>Levamisole and piperazine.</td>
</tr>
<tr>
<td>520.1242d</td>
<td>Levamisole resinate.</td>
</tr>
<tr>
<td>520.1242e</td>
<td>Levamisole hydrochloride effervescent tablets.</td>
</tr>
<tr>
<td>520.1242f</td>
<td>Levamisole gel.</td>
</tr>
<tr>
<td>520.1242g</td>
<td>Levamisole resinate and famphur paste.</td>
</tr>
<tr>
<td>520.1263</td>
<td>Lincomycin.</td>
</tr>
<tr>
<td>520.1263a</td>
<td>Lincomycin tablets and sup.</td>
</tr>
<tr>
<td>520.1263b</td>
<td>Lincomycin powder.</td>
</tr>
<tr>
<td>520.1265</td>
<td>Lincomycin and spectinomycin powder.</td>
</tr>
<tr>
<td>520.1284</td>
<td>Liothyronine.</td>
</tr>
<tr>
<td>520.1288</td>
<td>Lufenuron tablets.</td>
</tr>
<tr>
<td>520.1289</td>
<td>Lufenuron suspension.</td>
</tr>
<tr>
<td>520.1310</td>
<td>Marbofloxacin.</td>
</tr>
<tr>
<td>520.1315</td>
<td>Maropitant.</td>
</tr>
<tr>
<td>520.1320</td>
<td>Mebendazole.</td>
</tr>
<tr>
<td>520.1326</td>
<td>Mebendazole and trichlorfon oral dosage forms.</td>
</tr>
<tr>
<td>520.1326a</td>
<td>Mebendazole and trichlorfon powder.</td>
</tr>
<tr>
<td>520.1330</td>
<td>Meloxicam.</td>
</tr>
<tr>
<td>520.1331</td>
<td>Methimazole.</td>
</tr>
<tr>
<td>520.1338</td>
<td>Methocarbamol.</td>
</tr>
<tr>
<td>520.1340</td>
<td>Meflofenic acid.</td>
</tr>
<tr>
<td>520.1408</td>
<td>Meprobamate and aspirin.</td>
</tr>
<tr>
<td>520.1422</td>
<td>Metadoxine.</td>
</tr>
<tr>
<td>520.1430</td>
<td>Megestrol acetate tablets.</td>
</tr>
<tr>
<td>520.1441</td>
<td>Milbemycin oxime.</td>
</tr>
<tr>
<td>520.1443</td>
<td>Milbemycin oxime and lufenuron.</td>
</tr>
<tr>
<td>520.1445</td>
<td>Milbemycin oxime and praziquantel.</td>
</tr>
<tr>
<td>520.1450</td>
<td>Morantel tartrate oral dosage forms.</td>
</tr>
<tr>
<td>520.1450a</td>
<td>Morantel tartrate bolus.</td>
</tr>
<tr>
<td>520.1450b</td>
<td>Morantel tartrate cartridge.</td>
</tr>
<tr>
<td>520.1450c</td>
<td>Morantel tartrate sustained-release trilaminate cylindersheet.</td>
</tr>
<tr>
<td>520.1451</td>
<td>Moxidectin tablets.</td>
</tr>
<tr>
<td>520.1452</td>
<td>Moxidectin gel.</td>
</tr>
<tr>
<td>520.1453</td>
<td>Moxidectin and praziquantel gel.</td>
</tr>
<tr>
<td>520.1454</td>
<td>Moxidectin solution.</td>
</tr>
<tr>
<td>520.1458</td>
<td>Naproxen.</td>
</tr>
<tr>
<td>520.1494</td>
<td>Neomycin.</td>
</tr>
<tr>
<td>520.1510</td>
<td>Nitrofurazone.</td>
</tr>
<tr>
<td>520.1510a</td>
<td>Oclacitinib.</td>
</tr>
<tr>
<td>520.1615</td>
<td>Omeprazole.</td>
</tr>
<tr>
<td>520.1616</td>
<td>Oxytetracycline.</td>
</tr>
<tr>
<td>520.1618</td>
<td>Oxytetracycline and carbomycin in combination.</td>
</tr>
<tr>
<td>520.1619</td>
<td>Oxytetracycline hydrochloride capsules.</td>
</tr>
<tr>
<td>520.1619c</td>
<td>Oxytetracycline hydrochloride tablets/boluses.</td>
</tr>
<tr>
<td>520.1660d</td>
<td>Oxytetracycline powder.</td>
</tr>
<tr>
<td>520.1696</td>
<td>Penicillin.</td>
</tr>
<tr>
<td>520.1696a</td>
<td>Penicillin G powder.</td>
</tr>
<tr>
<td>520.1696b</td>
<td>Penicillin V powder.</td>
</tr>
<tr>
<td>520.1696c</td>
<td>Penicillin V tablets.</td>
</tr>
<tr>
<td>520.1705</td>
<td>Pergolide.</td>
</tr>
<tr>
<td>520.1720</td>
<td>Phenylbutazone oral dosage forms.</td>
</tr>
<tr>
<td>520.1720a</td>
<td>Phenylbutazone tablets and boluses.</td>
</tr>
<tr>
<td>520.1720b</td>
<td>Phenylbutazone granules.</td>
</tr>
<tr>
<td>520.1720c</td>
<td>Phenylbutazone paste.</td>
</tr>
<tr>
<td>520.1720d</td>
<td>Phenylbutazone gel.</td>
</tr>
<tr>
<td>520.1720e</td>
<td>Phenylbutazone powder.</td>
</tr>
<tr>
<td>520.1760</td>
<td>Phenytoin.</td>
</tr>
<tr>
<td>520.1802</td>
<td>Piperazine-carbon disulfide complex oral dosage forms.</td>
</tr>
</tbody>
</table>
520.1802b Piperazine-carbon disulfide complex boluses.
520.1802c Piperazine-carbon disulfide complex with phenothiazine suspension.
520.1803 Piperazine citrate capsules.
520.1804 Piperazine phosphate capsules.
520.1805 Piperazine phosphate with thenium closylate tablets.
520.1806 Piperazine suspension.
520.1807 Piperazine.
520.1840 Poloxalene.
520.1846 Polyoxyethylene (23) lauryl ether blocks.
520.1855 Ponazuril.
520.1860 Pradofloxacin.
520.1870 Praziquantel tablets.
520.1871 Praziquantel and pyrantel.
520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.
520.1880 Prednisolone.
520.1900 Primidone.
520.1920 Prochlorperazine and isopropamide.
520.1921 Prochlorperazine, isopropamide, and neomycin.
520.1962 Promazine.
520.2002 Propiomazine.
520.2041 Pyrantel pamoate chewable tablets.
520.2042 Pyrantel pamoate tablets.
520.2043 Pyrantel pamoate suspension.
520.2044 Pyrantel pamoate paste.
520.2045 Pyrantel tartrate powder.
520.2046 Pyrantel tartrate pellets.
520.2075 Robenacoxib.
520.2098 Selegiline.
520.2100 Selenium and vitamin E.
520.2123 Spectinomycin oral dosage forms.
520.2123a Spectinomycin tablets.
520.2123b Spectinomycin powder.
520.2123c Spectinomycin solution.
520.2130 Spinosad.
520.2134 Spinosad and milbemycin.
520.2150 Stanazolol.
520.2158 Streptomycin.
520.2170 Sulfabromomethazine.
520.2184 Sulfachloropyrazine.
520.2200 Sulfachloropyridazine.
520.2215 Sulfaethoxypyridazine.
520.2218 Sulfamerazine, sulfamethazine, and sulfaquinoxaline powder.
520.2220 Sulfamethoxine oral dosage forms.
520.2220a Sulfamethoxine solution and soluble powder.
520.2220b Sulfadimethoxine suspension.
520.2220c Sulfadimethoxine tablet.
520.2220d Sulfadimethoxine bolus.
520.2220e Sulfadimethoxine extended-release bolus.
520.2220f Sulfadimethoxine and ormetoprim tablet.
520.2240a Sulfathoxypridazine.
520.2240b Sulfathoxypridazine solution.
520.2240c Sulfathoxypridazine tablets.
520.2250a Sulfamethazine oral dosage forms.
520.2250b Sulfamethazine sustained-release boluses.
520.2250c Sulfamethazine sustained-release tablets.
520.2261 Sulfamethazine sodium oral dosage forms.
520.2261a Sulfamethazine solution.
520.2261b Sulfamethazine powder.
520.2270 Sulfamethizole and methenamine.
520.2275 Sulfamethoxazole oral dosage forms.
520.2275a Sulfamethoxazole powder and solution.
520.2275b Sulfamethoxazole drench.
520.2275c Sulfisoxazole tablets.
520.2275d Tepoxalin.
520.2280 Tetracycline.
520.2280a Tetracycline capsules.
520.2280b Tetracycline tablets.
520.2280c Tetracycline boluses.
520.2280d Tetracycline powder.
520.2280e Tetracycline solution.
520.2280f Tetracycline phosphate complex and sodium novobiocin capsules.
520.2280g Tetracycline hydrochloride and sodium novobiocin tablets.
520.2280h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets.
520.2280i Thiambendazole oral dosage forms.
520.2280j Thiambendazole top dressing and mineral protein block.
520.2280k Thiambendazole drench or paste.
520.2280l Thiambendazole and piperazine citrate.
520.2280m Thiambendazole and trichlorfon.
520.2280n Thiambendazole and piperazine phosphate.
520.2280o Tiamulin.
520.2280p Tilmicosin.
520.2280q Tioxidazole oral dosage forms.
520.2280r Tioxidazole granules.
520.2280s Tioxidazole paste.
520.2280t Toceranib.
520.2280u Triamcinolone acetonide tablets.
520.2280v Triamcinolone acetonide oral powder.
520.2280w Triamcinolone.
520.2280x Trichlorofon oral dosage forms.
520.2280y Trichlorofon and atropine.
520.2280z Trichlorofon boluses.
520.2281 Trichlorofon granules.
520.2281a Trichlorofon, phenothiazine, and piperazine dihydrochloride powder.
520.2281b Triflupromazine.
520.2281c Tripeprazine and prednisolone tablets.
520.2281d Trimethiazole and prednisolone capsules.
520.2281e Trimeprazine and sulfadiazine paste.
520.2281f Tripeprazine and sulfadiazine suspension.
§ 520.23 Acepromazine.

(a) Specifications. Each tablet contains 5, 10, or 25 milligrams (mg) acepromazine maleate.

(b) Sponsors. See No. 000010 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 0.25 to 1.0 mg per pound (/lb) body weight orally.

(ii) Indications for use. As an aid in tranquilization and as a preanesthetic agent.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. 0.5 to 1.0 mg/lb body weight orally.

(ii) Indications for use. As a tranquilizer.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]

§ 520.28 Acetazolamide.

(a) Specifications. A powder containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally at a dosage of 5 to 15 milligrams per pound of body weight daily.

(ii) Indications for use. As an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.

(iii) Limitations. Do not use in female dairy cattle of breeding age: Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls.

(2) Sheep. Administer 4.45 or 11.36 percent suspension:

(i) Amount. 3.4 mg/lb body weight (7.5 mg/kg) as a single oral dose using dosing gun or dosing syringe.

(ii) Indications for use. For removal and control of adult liver flukes (Fasciola hepatica) and segments of tapeworms (Moniezia benedeni and M. expansa); adult and fourth stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (Ostertagia ostertagi), barberpole worm (Haemonchus contortus and H. placei), small stomach worm (Trichostrongylus axei)); adult stages of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger and N. helveticus), small intestinal worm (Cooperia punctata and C. oncophora)); adult stages of intestinal worms (hookworm (Bunostomum phlebotomum), bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum radiatum)); and adult and fourth stage larvae of lungworms (Dictyocaulus viviparus).

(iii) Limitations. Do not slaughter within 27 days of last treatment. Do not use in female dairy cattle of breeding age: Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls.

§ 520.38 Albendazole oral dosage forms.

§ 520.38a Albendazole suspension.

(a) Specifications. Each milliliter of suspension contains 45.5 milligrams (mg) (4.55 percent) or 113.6 mg (11.36 percent) albendazole.

(b) Sponsor. See No. 054771 in § 510.600 of this chapter.

(c) Related tolerances. See § 556.34 of this chapter.

(d) Special considerations. See § 500.25 of this chapter.

(e) Conditions of use—(1) Cattle. Administer 11.36 percent suspension:

(i) Amount. 4.54 mg/pound (lb) body weight (10 mg/kilogram (kg)) as a single oral dose using dosing gun or dosing syringe.

(ii) Indications for use. For removal and control of adult liver flukes (Fasciola hepatica); heads and segments of tapeworms (Moniezia benedeni and M. expansa); adult and fourth stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (Ostertagia ostertagi), barberpole worm (Haemonchus contortus and H. placei), small stomach worm (Trichostrongylus axei)); and adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger and N. helveticus), small intestinal worm (Cooperia punctata and C. oncophora)); adult stages of intestinal worms (hookworm (Bunostomum phlebotomum), bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum radiatum)); and adult and fourth stage larvae of lungworms (Dictyocaulus viviparus).

(2) Sheep. Administer 4.45 or 11.36 percent suspension:

(i) Amount. 3.4 mg/lb body weight (7.5 mg/kg) as a single oral dose using dosing gun or dosing syringe.

(ii) Indications for use. For removal and control of adult liver flukes (Fasciola hepatica and Fascioloides magna); heads and segments of common tapeworms (Moniezia expansa) and fringed tapeworm (Thysanosoma actinioides); and adult and fourth stage larvae of stomach worms (brown stomach worm (Ostertagia circumcinta and Marshallagia marshalli), barberpole worm (Haemonchus contortus), small stomach worm (Trichostrongylus axei)).
adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger and N. filicollis), Cooper’s worm (Cooperia oncophora), bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum columbianum), and large-mouth bowel worm (Chabertia ovina)); adult and larval stages of lungworms (Dictyocaulus filicollis).

(iii) Limitations. Do not slaughter within 7 days of last treatment. Do not administer to does during the first 30 days of pregnancy or for 30 days after removal of rams.

(3) Goats. Administer 11.36 percent suspension:

(i) Amount. 4.54 mg/lb body weight (10 mg/kg) as a single oral dose using dosing gun or dosing syringe.

(ii) Indications for use. For the treatment of adult liver flukes (Fasciola hepatica) in nonlactating goats.

(iii) Limitations. Do not slaughter within 7 days of last treatment. Do not administer to does during the first 30 days of pregnancy or for 30 days after removal of rams.

§ 520.48 Altrenogest.

(a) Specifications. Each milliliter (mL) of solution contains 2.2 milligrams (mg) altrenogest.

(b) Sponsors. See Nos. 000061 and 013744 in §510.600(c) of this chapter.

(c) Tolerances. See §556.36 of this chapter.

§ 520.43 Afoxolaner.

(a) Specifications. Each chewable tablet contains 11.3, 28.3, 68, or 136 milligrams (mg) afoxolaner.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer orally once a month at a minimum dosage of 1.14 mg/pound (lb) (2.5 mg/kg) for larger or greater, for 1 month.

(2) Indications for use. Kills adult fleas; for the treatment and prevention of flea infestations (Ctenocephalides felis); for the treatment and control of black-legged tick (Ixodes scapularis), American dog tick (Dermacentor variabilis), lone star tick (Amblyomma americanum), and brown dog tick (Rhipicephalus sanguineus) infestations in dogs and puppies 8 weeks of age and older, weighing 4 lb of body weight or greater, for 1 month.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.38b Albendazole paste.

(a) Specifications. The product contains 30 percent albendazole.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.34 of this chapter.

(d) Conditions of use in cattle—(1) Amount. Equivalent to 4.54 milligrams per 1 pound of body weight (10 milligrams per kilogram).

(2) Indications for use. For removal and control of the following internal parasites of cattle: adult liver flukes (Fasciola hepatica); heads and segments of tapeworms (Moniezia benedeni, M. expansa); adult and fourth stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (Ostertagia ostertagi); barberpole worm (Haemonchus contortus, H. placei); small stomach worm (Trichostrongylus axei)); adult and fourth stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger, N. helvetianus); small intestinal worm (Cooperia punctata and C. oncophora)); adult stages of intestinal worms (hookworm (Bunostomum phlebotomum); bankrupt worm (Trichostrongylus colubriformis), nodular worm (Oesophagostomum radiatum)); adult and fourth stage larvae of lungworms (Dictyocaulus viviparus).

(iii) Limitations. Do not administer to female dairy cattle of breeding age. Do not use in female dairy cattle during first 45 days of pregnancy or for 45 days after removal of bulls. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(d) Conditions of use—(1) Horses—(i) Amount. 1.0 mL per 110 pounds body weight (0.044 mg/kg) daily for 15 consecutive days.

(ii) Indications for use. For suppression of estrus in mares.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Swine—(i) Amount. Administer 6.8 mL (15 mg altrenogest) per gilt once daily for 14 consecutive days by top-dressing on a portion of each gilt’s daily feed.

(ii) Indications for use. For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle.

(iii) Limitations. Do not use in gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis). Gilts must not be slaughtered for human consumption for 21 days after the last treatment.

§ 520.62 Aminopentamide.

(a) Specifications. Each tablet contains 0.2 milligram (mg) aminopentamide hydrogen sulphate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer orally every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; for animals weighing 11 to 20 lbs: 0.2 mg; for animals weighing 21 to 50 lbs: 0.3 mg; for animals weighing 51 to 100 lbs: 0.4 mg; for animal weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Oral administration of tablets may be preceded by subcutaneous or intramuscular use of the injectable form of the drug.

(2) Indications for use. For the treatment of vomiting and/or diarrhea, nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.82 Aminopropazine oral dosage forms.

§ 520.82a Aminopropazine.

(a) Specifications. Each tablet contains aminopropazine fumarate equivalent to 25 percent aminopropazine base.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer orally at a dosage of 1 to 2 milligrams per pound of body weight, repeated every 12 hours as indicated.

(2) Indications for use. For reducing excessive smooth muscle contractions, such as occur in urethral spasms associated with urolithiasis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.82b Aminopropazine and neomycin.

(a) Specifications. Each tablet contains aminopropazine fumarate equivalent to 25 percent aminopropazine base and neomycin sulfate equivalent to 50 milligrams (mg) of neomycin base.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally at a dosage of 1 to 2 mg per pound of body weight, repeated every 12 hours as indicated.

(2) Indications for use. For control of bacterial diarrhea caused by organisms susceptible to neomycin and to reduce smooth muscle contractions.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.88 Amoxicillin oral dosage forms.

§ 520.88a Amoxicillin trihydrate film-coated tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate equivalent to 50, 100, 150, 200, or 400 milligrams (mg) amoxicillin.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use.—(1) Dogs—(i) Amount. Administer orally 5 mg per pound (/lb) of body weight, twice a day for 5 to 7 days.

(ii) Indications for use. Treatment of infections of the respiratory tract (tonsillitis, tracheobronchitis), genitourinary tract (cystitis), gastrointestinal tract (bacterial gastroenteritis), and soft tissues (abscesses, lacerations, wounds), caused by susceptible strains of *Staphylococcus aureus*, *Streptococcus spp.*, *Escherichia coli*, *Proteus mirabilis*, and bacterial dermatitis caused by *S. aureus*, *Streptococcus spp.*, and *P. mirabilis*.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(B) Oral Suspension.

(C) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c) Amoxicillin trihydrate for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(C) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.88b Amoxicillin trihydrate for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(i) Conditions of use.—(A) Amount. Administer orally 5 mg/lb of body weight, once daily for 5 to 7 days.

(ii) Indications for use. Treatment of infections caused by susceptible strains of organisms as follows: upper respiratory tract due to *Escherichia coli*, *Pasteurella multocida*, and *Haemophilus spp.*; gastrointestinal tract due to *E. coli*; and skin and soft tissue (abscesses, lacerations, and wounds) due to *S. aureus*, *Streptococcus spp.*, and *Pasteurella multocida*.

(C) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c) Amoxicillin trihydrate for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(C) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.88c Amoxicillin trihydrate oral suspension.

(a) Specifications. Each 0.8-milliliter dose contains amoxicillin trihydrate equivalent to 40 milligrams (mg) amoxicillin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.510 of this chapter.

(d) Conditions of use in swine—(1) Amount. Administer 40 mg orally twice a day using a dosing pump. Treat animals for 48 hours after all symptoms have subsided but not beyond 5 days.

(2) Indications for use. Treatment of baby pigs under 10 pounds for porcine colibacillosis caused by Escherichia coli susceptible to amoxicillin.

(3) Limitations. Do not slaughter during treatment or for 15 days after latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.88d Amoxicillin trihydrate soluble powder.

(a) Specifications. Each gram of powder contains amoxicillin trihydrate equivalent to 115.4 milligrams (mg) amoxicillin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.38 of this chapter.

(d) Conditions of use in preruminating calves including veal calves—(1) Amount. Administer 400 mg per 100 pounds of body weight twice daily. Treatment should be continued for 48 hours after all symptoms have subsided but not to exceed 5 days.

(2) Indications for use. Treatment of bacterial enteritis when due to susceptible Escherichia coli in preruminating calves including veal calves.

(3) Limitations. Do not slaughter animals during treatment or for 20 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.88f Amoxicillin trihydrate tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate equivalent to 50, 100, 200, or 400 milligrams (mg) amoxicillin.

(b) Sponsors. See Nos. 051311 and 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 5 mg per pound of body weight twice daily for 5 to 7 days or 48 hours after all symptoms have subsided.

(2) Indications for use. For treatment of bacterial dermatitis due to Staphylococcus aureus, Streptococcus spp., Staphylococcus spp., and Escherichia coli; and soft tissue infections (abscesses, wounds, lacerations) due to S. aureus, Streptococcus spp., E. coli, Proteus mirabilis, and Staphylococcus spp.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28817, May 20, 2014]

§ 520.88g Amoxicillin trihydrate and clavulanate potassium film-coated tablets.

(a) Specifications. Each tablet contains amoxicillin trihydrate and clavulanate potassium, equivalent to either 50 milligrams of amoxicillin and 12.5 milligrams clavulanic acid, or 100 milligrams of amoxicillin and 25 milligrams clavulanic acid, or 200 milligrams amoxicillin and 50 milligrams clavulanic acid or 300 milligrams amoxicillin and 75 milligrams clavulanic acid.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 6.25 milligrams (equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic acid) per pound of body weight twice daily for 5 to 7 days or for 48 hours after all signs have subsided. Deep pyoderma may require treatment for 21 days; do not treat for more than 30 days.

(ii) Indications for use. Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of beta-lactamase (penicillinase) Staphylococcus aureus, nonbeta-lactamase producing S. aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Also, treatment of urinary tract infections (cystitis) due to susceptible strains of E. coli.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.88h Amoxicillin trihydrate and clavulanate potassium for oral suspension.

(a) Specifications. When reconstituted, each milliliter contains amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin with clavulanate potassium equivalent to 12.5 milligrams of clavulanic acid.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 6.25 milligrams (equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic acid) per pound of body weight twice daily for 5 to 7 days or for 48 hours after all signs have subsided. Deep pyoderma may require treatment for 21 days; do not treat for more than 30 days.

(ii) Indications for use. Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of beta-lactamase (penicillinase) producing Staphylococcus aureus, nonbeta-lactamase producing S. aureus, Staphylococcus spp., Streptococcus spp., and Escherichia coli. Treatment of periodontal infections due to susceptible strains of aerobic and anaerobic bacteria.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. 62.5 milligrams (50 milligrams amoxicillin and 12.5 milligrams clavulanic acid) twice daily for 5 to 7 days or for 48 hours after all signs have subsided. Urinary tract infections may require treatment for 10 to 14 days or longer. The maximum duration of treatment should not exceed 30 days.

(ii) Indications for use. Treatment of skin and soft tissue infections, such as wounds, abscesses and cellulitis/dermatitis due to susceptible strains of beta-lactamase (penicillinase) producing S. aureus, nonbeta-lactamase producing S. aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Also, treatment of urinary tract infections (cystitis) due to susceptible strains of E. coli.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

such as wounds, abscesses and cellulitis/dermatitis due to susceptible strains of beta-lactamase (penicillinase) producing *S. aureus*, nonbeta-lactamase *S. aureus*, *Staphylococcus* spp., *Streptococcus* spp., *E. coli*, *Pasteurella multocida*, and *Pasteurella* spp.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.90 Ampicillin oral dosage forms.

§ 520.90a [Reserved]

§ 520.90b Ampicillin tablets.

(a) Specifications. Each tablet contains ampicillin trihydrate equivalent to 50 or 100 milligrams of ampicillin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 5 milligrams per pound of body weight, at 8-hour intervals, 1 to 2 hours prior to feeding, to be continued 36 to 48 hours after all symptoms have subsided. If no improvement is seen within 5 days, stop treatment, reevaluate diagnosis, and change therapy.

(2) Indications for use. Oral treatment of infections caused by susceptible organisms as follows: Upper respiratory infections, tonsillitis, and bronchitis due to *Streptococcus* spp., *Escherichia coli*, *Proteus mirabilis*, and *Pasteurella* spp., urinary tract infections (cystitis) due to *Staphylococcus* spp., *Streptococcus* spp., *Escherichia coli*, *P. mirabilis*, and *Enterococcus* spp.; gastrointestinal infections due to *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., and *E. coli*; infections associated with abscesses, lacerations, and wounds caused by *Staphylococcus* spp., and *Streptococcus* spp.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.90c Ampicillin capsules.

(a) Specifications. Each capsule contains ampicillin trihydrate equivalent to 125, 250, or 500 milligrams of ampicillin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(1) Amount. 5 to 10 milligrams per pound of body weight two or three times daily. In severe or acute conditions, 10 milligrams per pound of body weight, three times daily. Administer 1 to 2 hours prior to feeding.

(2) Cats—(i) Amount. 10 to 30 milligrams per pound of body weight or three times daily. Administer 1 to 2 hours prior to feeding.

(3) Indications for use. Treatment against strains of gram-negative and gram-positive organisms sensitive to ampicillin and associated with respiratory tract infections (tracheobronchitis and tonsillitis); urinary tract infections (cystitis); bacterial gastroenteritis; generalized infections (septicemia) associated with abscesses, lacerations, and wounds; and bacterial dermatitis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.90d Ampicillin for oral suspension.

(a) Specifications. When reconstituted as directed, each milliliter contains ampicillin trihydrate equivalent to 25 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(1) Amount. Administer to 10 milligrams per pound of body weight orally, 2 or 3 times daily, 1 to 2 hours prior to feeding. In severe or acute conditions, 10 milligrams per pound of body weight 3
§ 510.600(c) of this chapter.


(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. Administer 10 to 30 milligrams per pound of body weight orally, 2 or 3 times daily, 1 to 2 hours prior to feeding. Duration of treatment is usually 3 to 5 days. Continue treatment 48 hours after the animal’s temperature has returned to normal and all other signs of infection have subsided.


(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.90f Ampicillin boluses.

(a) Specifications. Each bolus contains ampicillin trihydrate equivalent to 400 milligrams of ampicillin.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) No. 055529 for use as in paragraph (d)(1) of this section;

(2) No. 054771 for use as in paragraph (d)(2) of this section.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Swine—(1) Amount. 5 milligrams of ampicillin per pound of body weight twice daily, orally by gavage or in drinking water for up to 5 days.

(2) Related tolerances. See §556.40 of this chapter.

§ 520.90e Ampicillin for soluble powder.

(a) Specifications. Each gram contains ampicillin trihydrate equivalent to 88.2 milligrams of ampicillin.

(b) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Nonruminating calves—(1) Amount. 5 milligrams per pound of body weight twice daily for up to 5 days.


(ii) Limitations. Treated calves must not be slaughtered for food during treatment and for 15 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Amount. 5 milligrams per pound of body weight twice daily not to exceed 4 days.

(i) Indications for use. Oral treatment of bacterial enteritis (colibacillosis) caused by E. coli.
§ 520.100 Amprolium.

(a) Specifications. (1) Each milliliter of solution contains 96 milligrams (mg) amprolium (9.6 percent solution).
(2) Each gram of powder contains 200 mg amprolium (20 percent).
(3) Each ounce (28.4 grams) of crumbles contains 355 mg amprolium (1.25 percent).
(b) Sponsors. See sponsors in 510.600(c) of this chapter.
(1) No. 016592 for use of products described in paragraph (a) of this section as in paragraph (d) of this section.
(2) No. 066104 for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section.
(3) No. 000859 for use of product described in paragraph (a)(1) of this section as in paragraph (d) of this section.
(4) No. 061623 for use of products described in paragraphs (a)(1) and (a)(2) of this section as in paragraph (d) of this section.
(c) Related tolerances. See § 556.50 of this chapter.
(d) Conditions of use—(1) Growing chickens, turkeys, and laying hens. It is used in drinking water as follows:
(i) Amount. Administer at the 0.012 percent level in drinking water as soon as coccidiosis is diagnosed and continue for 3 to 5 days (in severe outbreaks, give amprolium at the 0.024 percent level); continue with 0.006 percent amprolium-mediated water for an additional 1 to 2 weeks.
(ii) Indications for use. For the treatment of coccidiosis.
(iii) Limitations. Use as the sole source of amprolium.
(2) Calves. Administer crumbles top-dressed on or thoroughly mixed in the daily feed ration; administer concentrate solution or soluble powder as a drench or in drinking water as follows:
(i) Indications for use and amounts—(A) As an aid in the prevention of coccidiosis caused by Eimeria bovis and E. zurnii, administer 5 mg per kilogram (mg/kg) body weight for 21 days during periods of exposure or when experience indicates that coccidiosis is likely to be a hazard.
(B) As an aid in the treatment of coccidiosis caused by E. bovis and E. zurnii, administer 10 mg/kg body weight for 5 days.
(ii) Limitations. Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Use as the sole source of amprolium.

§ 520.110 Apramycin sulfate soluble powder.

(a) Specifications. A water soluble powder used to make a medicated drinking water containing apramycin sulfate equivalent to 0.375 gram of apramycin activity per gallon of drinking water.
(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.52 of this chapter.
(d) Conditions of use in swine—(1) Amount. Administer in drinking water at the rate of 12.5 milligrams of apramycin per kilogram (5.7 milligrams per pound) of body weight per day for 7 days.
(2) Indications for use. For the control of porcine colibacillosis (weanling pig scours) caused by strains of Escherichia coli sensitive to apramycin.
(3) Limitations. Prepare fresh medicated water daily. Do not slaughter treated swine for 28 days following treatment.

§ 520.154 Bacitracin oral dosage forms.

§ 520.154a Bacitracin methylenedisalicylate.

(a) Specifications. Each pound of soluble powder contains the equivalent of
§ 520.154c Bacitracin zinc soluble powder.

(a) Specifications. Each pound contains the equivalent of not less than 5 grams of bacitracin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use—(1) Broiler chickens—(i) Amount. 100 milligrams per gallon in drinking water.

(A) Indications for use. Prevention of necrotic enteritis caused by Clostridium perfringens susceptible to bacitracin zinc.

(B) Limitations. Prepare a fresh solution daily. Use as sole source of drinking water.


§ 520.154b Bacitracin methylenedisalicylate and streptomycin sulfate powder.

(a) Specifications. Each gram of powder contains 200 units bacitracin methylenedisalicylate and streptomycin sulfate equivalent to 20 milligrams of streptomycin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 1 level teaspoonful per 10 pounds of body weight three times daily, mixed in a small quantity of liquid or feed.

(2) Indications for use. For the treatment of bacterial enteritis caused by pathogens susceptible to bacitracin and streptomycin such as Escherichia coli, Proteus spp., Staphylococcus spp., and Streptococcus spp., and for the symptomatic treatment of associated diarrhea.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.154c Bacitracin zinc soluble powder.

(a) Specifications. Each pound contains the equivalent of not less than 5 grams of bacitracin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.70 of this chapter.

(d) Conditions of use—(1) Broiler chickens—(i) Amount. 100 milligrams per gallon in drinking water.

(A) Indications for use. Prevention of necrotic enteritis caused by Clostridium perfringens susceptible to bacitracin zinc.

(B) Limitations. Prepare a fresh solution daily.

(ii) Amount. 200 to 400 milligrams per gallon in drinking water.
§ 520.222 Bunamidine hydrochloride.  

(a) Chemical name. N,N-Dibutyl-4-(hexyloxy)-1-naphthamidine hydrochloride.  

(b) Specifications. The drug is an oral tablet containing 100, 200, or 400 milligrams of bunamidine hydrochloride.  

(c) Sponsor. See No. 000061 in § 510.600(c) of this chapter.  

(d) Conditions of use. (1) The drug is intended for oral administration to dogs for the treatment of the tapeworms Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus, and to cats for the treatment of the tapeworms Dipylidium caninum and Taenia taeniaeformis.  

(2) It is administered to cats and dogs at the rate of 25 to 50 milligrams per kilogram of body weight. The drug should be given on an empty stomach and food should not be given for 9 hours following treatment.  

(3) Tablets should not be crushed, mixed with food, or dissolved in liquid. Repeat treatments should not be given within 14 days. The drug should not be given to male dogs within 28 days prior to their use for breeding. Do not administer to dogs or cats having known heart conditions.  

(4) For use only by or on the order of a licensed veterinarian.  

§ 520.300a Cambendazole oral dosage forms.

(a) Specifications. Each fluid ounce contains 0.9 gram of cambendazole.

(b) Sponsor. No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer by stomach tube or as a drench at a dose of 0.3 gram of cambendazole per 100 pounds of body weight (20 milligrams per kilogram).

(2) Indications for use. For the control of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles (Trichonema, Poteriostomum, Cylicobrachytus, Craterostomum, Oesophagodontus); roundworms...
(Parascaris); pinworms (Oxyuris); and threadworms (Strongyloides).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.300b Cambendazole pellets.

(a) Specifications. The drug is in feed pellets containing 5.3 percent cambendazole.

(b) Sponsor. No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 20 milligrams cambendazole per kilogram body weight (6 ounces per 1,000 pounds) by mixing with normal grain ration given at one feeding. Doses for individual horses should be mixed and fed separately to assure that each horse will consume the correct amount. For animals maintained on premises where reinfection is likely to occur, re-treatments may be necessary. For most effective results, re-treat in 6 to 8 weeks.

(2) Indications for use. For the control of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles (Trichonema, Poteriostomum, Cyclicobrachytus, Craterostomum, Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and threadworms (Strongyloides).

(3) Limitations. Do not administer to pregnant mares during first 3 months of pregnancy. Do not use in horses intended for human consumption. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.300c Cambendazole paste.

(a) Specifications. The drug is a paste containing 45 percent cambendazole.

(b) Sponsor. No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 20 milligrams cambendazole per kilogram body weight (5 grams per 550 pounds (250 kilograms)) by depositing the paste on the back of the tongue using a dosing gun. For animals maintained on premises where reinfection is likely to occur, re-treatments may be necessary. For most effective results, re-treat in 6 to 8 weeks.

(2) Indications for use. For the control of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles (Trichonema, Poteriostomum, Cyclicobrachytus, Craterostomum, Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and threadworms (Strongyloides).

(3) Limitations. Do not administer to pregnant mares during first 3 months of pregnancy. Do not use in horses intended for human consumption. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.301 Caramiphen ethanedisulfonate and ammonium chloride tablets.

(a) Specifications. Each tablet contains 10 milligrams of 5st caramiphen ethanedisulfonate and 80 milligrams of ammonium chloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. One tablet per 15 to 30 pounds of body weight every 4 to 6 hours.

(2) Indications for use. For relief of cough.


§ 520.302 Carnidazole tablets.

(a) Specifications. Each tablet contains 10 milligrams of carnidazole.

(b) Sponsor. See 053923 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Adult pigeons: 1 tablet (10 milligrams); newly weaned pigeons: ½ tablet (5 milligrams).

(2) Indications for use. For treating trichomoniasis (canker) in ornamental and homing pigeons.


Food and Drug Administration, HHS

§ 520.304 Carprofen.

(a) Specifications. (1) Each caplet contains 25, 75, or 100 milligrams (mg) carprofen.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as follows:

(1) No. 054771 for use of products described in paragraph (a) of this section as in paragraph (d) of this section.

(2) Nos. 000859, 026637, 055529, and 062250 for use of product described in paragraph (a)(1) as in paragraph (d) of this section.

(3) Nos. 026637 and 062250 for use of product described in paragraph (a)(2) of this section as in paragraph (d) of this section.

(c) [Reserved]

(d) Conditions of use in dogs—(1) Amount. 2 mg per pound (/lb) of body weight once daily or 1 mg/lb twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure.

(2) Indications for use. For the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries.

(3) Limitations. Federal Law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.370 Cefpodoxime tablets.

(a) Specifications. (1) Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.

(2) Each chewable tablet contains cefpodoxime proxetil equivalent to 100 or 200 mg cefpodoxime.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as follows:

(1) No. 026637 for use of product in paragraph (a)(1) of this section as in paragraph (c) of this section.

(2) No. 054771 for use of products in paragraph (a) of this section as in paragraph (c) of this section.

(c) Conditions of use in dogs—(1) Amount. 5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) caused by susceptible strains...
§ 520.376 Cephalexin.

(a) Specifications. Each chewable tablet contains 75, 150, 300, or 600 milligrams (mg) cephalexin.

(b) Sponsor. See No. 051311 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Administer 22 mg per kilogram of body weight twice daily for 28 days.

(ii) Indications for use. For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.390 Chloramphenicol oral dosage forms.

§ 520.390a Chloramphenicol tablets.

(a) Specifications. Each tablet contains 50, 100, 250, or 500 milligrams (mg); 1 or 2.5 grams (g) of chloramphenicol.

(b) Sponsors. See Nos. 050057 and 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 25 mg per pound of body weight every 6 hours.

(ii) Indications for use. For treatment of bacterial pulmonary infections, bacterial infections of the urinary tract, bacterial enteritis, and bacterial infections associated with canine distemper caused by susceptible organisms.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.390b Chloramphenicol capsules.

(a) Specifications. Each capsule contains 50, 100, 250, or 500 milligrams (mg) chloramphenicol.

(b) Sponsors. See Nos. 050057 and 054771 in §510.600(c) of this chapter.

(c) Special considerations. Federal law prohibits the extralabel use of this product in food-producing animals.

(d) Conditions of use in dogs—(1) Amount. 25 mg per pound of body weight every 6 hours.

(ii) Indications for use. For treatment of bacterial pulmonary infections, bacterial infections of the urinary tract, bacterial enteritis, and bacterial infections associated with canine distemper caused by susceptible organisms.

§ 520.390c Chloramphenicol palmitate oral suspension.

(a) Specifications. Each milliliter contains chloramphenicol palmitate equivalent to 30 milligrams of chloramphenicol.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight every 6 hours. If no response is obtained in 3 to 5 days, discontinue use and reevaluate diagnosis.
(2) **Indications for use.** Treatment of bacterial pulmonary infections, infections of the urinary tract, enteritis, and infections associated with canine distemper that are caused by organisms susceptible to chloramphenicol.

(3) **Limitations.** Not for use in animals that are raised for food production. Must not be used in meat-, egg-, or milk-producing animals. The length of time that residues persist in milk or tissues has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.420 Chlorothiazide tablets and boluses.

(a)(1) **Specifications.** Each tablet contains 0.25 gram of chlorothiazide.

(2) **Sponsor.** See No. 050604 in § 510.600(c) of this chapter.

(3) **Conditions of use—(i) Amount.** Usual dosage is 5 to 10 milligrams per pound of body weight two or three times daily.

(ii) **Indications for use.** For use in dogs for treatment of congestive heart failure and renal edema.

(iii) **Limitations.** (a) Dosage must be adjusted to meet the changing needs of the individual animal. In mild and responsive cases, it is suggested that a dose of 5 milligrams per pound of body weight be administered two or three times daily. In moderately edematous and moderately responsive animals, a dose of 7.5 to 10 milligrams per pound of body weight may be administered three times daily. Severe conditions may require higher doses. Certain animals may respond adequately to intermittent therapy; in these cases, the drug may be administered every other day or for 3 to 5 days each week.

(b) Animals should be regularly and carefully observed for early signs of fluid and electrolyte imbalance. Take appropriate countermeasures if this should occur. In some dogs, hypochloremic alkalosis may occur (that is, excretion of chloride in relation to sodium is excessive; the plasma bicarbonate level increases and alkalosis results). Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.434 Chlorophenesin carbamate tablets.

(a) **Specifications.** Each tablet contains 400 milligrams of chlorophenesin carbamate.

(b) **Sponsor.** See No. 054771 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs—(1) Amount.** 50 milligrams per pound of body weight on first day; 25 milligrams per pound of body weight each following day. Divide total daily dose into 2 or 3 equal doses—administer at 12- or 8-hour intervals.

(2) **Indications for use.** For use as an adjunct to therapy of acute inflammatory and traumatic conditions of skeletal muscles. The drug provides relief of the signs of discomfort associated with myositis, muscle sprains, traumatic injuries, stifle injuries—especially when administered before or after surgery—and invertebral disc syndrome (can be used concurrently with adrenal corticosteroids).

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(44 FR 16009, Mar. 16, 1979, as amended at 79 FR 28819, May 20, 2014)
§ 520.441 Chlortetracycline powder.

(a) Specifications. Chlortetracycline powder contains not less than 15 milligrams per gram chlortetracycline hydrochloride, or chlortetracycline bisulfate equivalent to 25.6, 64 or 102.4 grams per pound (56.4, 141 or 225.6 milligrams per gram) chlortetracycline hydrochloride.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

1) No. 069254 for use as in paragraph (d) of this section.

2) Nos. 016592 and 054771 for use as in paragraph (d) of this section.

3) No. 054628 for use as in paragraphs (d)(4)(i)(A), (d)(4)(i)(B), and (d)(4)(ii) through (d)(4)(iv) of this section.

4) Nos. 069254 and 076475 for use as in paragraphs (d)(4)(i)(A), (d)(4)(i)(B), (d)(4)(ii), and (d)(4)(iii) of this section.

(c) Related tolerances. See §556.150 of this chapter.

(d) Conditions of use. (1) Use as chlortetracycline hydrochloride in drinking water as follows:

(i) Swine—(A) Amount. Ten milligrams per pound of body weight daily in divided doses.


(B) Limitations. Prepare fresh solution twice daily; as sole source of chlortetracycline; administer for not more than 5 days.

(ii) [Reserved]

(2) Use as chlortetracycline hydrochloride in a drench or drinking water as follows:

(i) Calves—(A) Amount. Ten milligrams per pound of body weight daily in divided doses.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; administer for not more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.

(i) [Reserved]

(ii) [Reserved]

(3) [Reserved]

(4) The following uses of chlortetracycline hydrochloride or chlortetracycline bisulfate in drinking water or drench were reviewed by the National Academy of Sciences/National Research Council (NAS/NRC) and found effective:

1) Chickens—(A) Amount. 200 to 400 milligrams per gallon.

(1) Indications for use. Control of infectious synovitis caused by Mycoplasma synoviae.

(B) Amount. 400 to 800 milligrams per gallon.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment; do not use in laying chickens.

(3) Amount. One thousand milligrams per gallon.

(1) Indications for use. Control of chronic respiratory disease and air-sac infections caused by M. gallisepticum and E. coli.

(C) Amount. One thousand milligrams per gallon.

(1) Indications for use. Control of mortality due to fowl cholera caused by Pasteurella multocida susceptible to chlortetracycline.

(B) Limitations. See paragraph (d)(4)(i)(A)(2) of this section.

(ii) Growing turkeys—(A) Amount. 400 milligrams per gallon.

(1) Indications for use. Control of infectious synovitis caused by M. synoviae.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; control and treatment of bacterial enteritis (scours) caused by E. coli and bacterial pneumonia (shipping fever) associated with Pasteurella spp., A. pleuropneumoniae (Haemophilus spp.), and Klebsiella spp.

(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; administer for not more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal. (B) [Reserved]

(ii) [Reserved]

(3) [Reserved]
days; do not slaughter animals for food within 24 hours of treatment.
(B) Amount. 25 milligrams per pound of body weight daily.

(1) Indications for use. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis).
(2) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 14 days; do not slaughter animals for food within 24 hours of treatment.

(1) Swine—(A) Amount. 10 milligrams per pound body weight daily in divided doses.
(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp. and bacterial pneumonia associated with Pasteurella spp., Actinobacillus pleuropneumoniae (Haemophilus spp.), and Klebsiella spp.
(C) Limitations. Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 5 days. For Nos. 016592 and 021930, do not slaughter animals for food within 5 days of treatment. For No. 016592, do not slaughter animals for food within 24 hours of treatment.
(iv) Calves, beef cattle, and nonlactating dairy cattle—(A) Amount. 10 milligrams per pound daily in divided doses.
(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp. and bacterial pneumonia (shipping fever complex) associated with Pasteurella spp., A. pleuropneumoniae (Haemophilus spp.), and Klebsiella spp.
(C) Limitations. Prepare fresh solution daily; use as a drench; as sole source of chlortetracycline; do not use for more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not use in lactating cattle; do not administer this product with milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.
(5) Use in a drench or drinking water as follows:
(i) Chickens—(A) Amount. 200 to 400 mg/gal, for 7 to 14 days.

(1) Indications for use. Control of infectious synovitis caused by M. synoviae susceptible to chlortetracycline.
(2) Limitations. Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 14 consecutive days; do not use in laying chickens; do not administer to chickens within 24 hours of slaughter.
(B) Amount. 400 to 800 mg/gal, for 7 to 14 days.

(1) Indications for use. Control of chronic respiratory disease (CRD) and air-sac infections caused by M. gallisepticum and E. coli susceptible to chlortetracycline.
(2) Limitations. As in paragraph (d)(5)(1)(A)(2) of this section.
(C) Amount. One thousand mg/gal, for 7 to 14 days.

(1) Indications for use. Control of mortality due to fowl cholera caused by Pasteurella multocida susceptible to chlortetracycline.
(2) Limitations. As in paragraph (d)(5)(1)(A)(2) of this section.
(ii) Growing Turkeys—(A) Amount. 400 mg/gal, for 7 to 14 days.

(1) Indications for use. Control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.
(2) Limitations. Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 14 consecutive days; do not administer to growing turkeys within 24 hours of slaughter.
(B) Amount. 25 mg/lb body weight daily, for 7 to 14 days.

(1) Indications for use. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to chlortetracycline.
(2) Limitations. As in paragraph (d)(5)(1)(A)(2) of this section.
(iii) Swine—(A) Amount. 10 mg/lb body weight daily, for 3 to 5 days.
(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by E. coli and Salmonella spp., and bacterial pneumonia associated with Pasteurella spp., A. pleuropneumoniae, and Klebsiella spp. susceptible to chlortetracycline.
§ 520.443

(C) Limitations. Prepare fresh solution daily; use as the sole source of chlortetracycline; do not use for more than 5 days; do not administer to swine within 24 hours of slaughter.

(iv) Calves, beef cattle, and nonlactating dairy cattle—(A) Amount. 10 mg/lb body weight daily in divided doses, for 3 to 5 days.

(B) Indications for use. Control and treatment of bacterial enteritis (scours) caused by Escherichia coli and Salmonella spp., and bacterial pneumonia associated with Pasteurella spp., Histophilus spp., and Klebsiella spp. susceptible to chlortetracycline.

(C) Limitations. Prepare fresh solution daily; use as a drench; use as the sole source of chlortetracycline; do not use for more than 5 days; do not administer to cattle within 24 hours of slaughter; do not use in lactating dairy cattle; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.

57 FR 37324, Aug. 18, 1992

EDITORIAL NOTE: For Federal Register citations affecting § 520.441, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

§ 520.443 Chlortetracycline tablets and boluses.

(a) Specifications. Each tablet/bolus contains 25, 250, or 500 milligrams (mg) chlortetracycline hydrochloride.

(b) Sponsor. See Nos. 016592 and 054628 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.150 of this chapter.

(d) Conditions of use in calves—(1) Amount. One 250 milligram bolus per 100 pounds of body weight twice a day for 3 to 5 days.

(i) Indications for use. Treatment of bacterial enteritis (scours) caused by Escherichia coli and Pasteurella spp., Klebsiella spp., and Haemophilus spp.

(ii) Limitations. Administer bolus directly by mouth or crush and dissolve in milk or water for drenching or bucket feeding; if no improvement is noted after 3 days of treatment, consult a veterinarian; do not use for more than 5 days; do not administer within 24 hours of slaughter.


§ 520.445 Chlortetracycline and sulfamethazine powder.

(a) Specifications. Each pound of soluble powder contains chlortetracycline bisulfate equivalent to 102.4 grams (g) of chlortetracycline hydrochloride and sulfamethazine bisulfate equivalent to 102.4 g of sulfamethazine.

(b) Sponsor. See No. 016592 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.150 and 556.670 of this chapter.

(d) Conditions of use in swine. Administer in drinking water as follows:
§ 520.447 Clindamycin solution.

(a) Specifications. Each milliliter of solution contains the equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.

(b) Sponsors. See Nos. 051311, 054771, 068829, 061623, and 069043 in § 510.600(c) of this chapter as follows:

(1) Each capsule contains the equivalent of 25, 75, 150, or 300 milligrams (mg) clindamycin as the hydrochloride salt.

(2) Each tablet contains the equivalent of 25, 75, or 150 mg clindamycin as the hydrochloride salt.

(3) Each capsule contains the equivalent of 25, 75, or 150 mg clindamycin as the hydrochloride salt.

(c) Conditions of use—(1) Dogs—(1) Amount. Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenica, Fusobacterium necrophorum, and Clostridium perfringens; dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens; and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Conditions of use—(1) Cats—(1) Amount. 5.0 to 15.0 mg/lb body weight every 24 hours for a maximum of 14 days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Staphylococcus aureus, S. intermedius, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens; osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens; and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Conditions of use—(1) Pigs—(1) Amount. Wounds, abscesses, and dental infections: 2.5 to 15 mg per pound (lb) body weight every 12 hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body weight every 12 hours for a minimum of 28 days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenica, Fusobacterium necrophorum, and Clostridium perfringens; dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens; and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Conditions of use—(1) Sheep—(1) Amount. 0.5 to 2.5 mg/lb body weight every 12 hours for a maximum of 28 days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) due to susceptible strains of Bacteroides fragilis, Prevotella melaninogenica, Fusobacterium necrophorum, and Clostridium perfringens; dental infections due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens; and osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. melaninogenica, F. necrophorum, and C. perfringens.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Streptococcus spp.; deep wounds and abscesses due to susceptible strains of Clostridium perfringens and Bacteroides fragilis; and dental infections due to susceptible strains of S. aureus, S. intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

§ 520.452 Clenbuterol syrup.

(a) Specifications. Each milliliter contains 72.5 micrograms of clenbuterol hydrochloride.

(b) Sponsor. See 000010 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Horses—(i) Amount. Administer orally twice a day (b.i.d.). Initial dose is 0.5 milliliter per 100 pounds body weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2 milliliters per 100 pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 2.5 milliliters per 100 pounds (4.0 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 3 milliliters per 100 pounds (4.8 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 3.5 milliliters per 100 pounds (5.6 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 4 milliliters per 100 pounds (6.4 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 4.5 milliliters per 100 pounds (7.2 micrograms per kilogram) for 3 days (6 treatments). If no improvement, administer 5 milliliters per 100 pounds (8.0 micrograms per kilogram) for 3 days (6 treatments). If no improvement, horse is non-responder to clenbuterol and treatment should be discontinued.

(ii) Indications for use. Indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

(iii) Limitations. Treat at effective dose for 30 days. At the end of the 30-day treatment period, drug should be withdrawn. If signs return, the 30-day treatment period may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated. The effect of this drug on breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended. Federal law prohibits the extralabel use of this drug in food animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[63 FR 41419, Aug. 4, 1998]

§ 520.455 Clomipramine tablets.

(a) Specifications. Each tablet contains 5, 20, 40, or 80 milligrams (mg) clomipramine hydrochloride.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 2 to 4 milligrams of clomipramine hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body weight per day, administered as a single daily dose or divided twice daily.

(2) Indications for use. For use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[64 FR 1762, Jan. 12, 1999, as amended at 72 FR 262, Jan. 4, 2007]

§ 520.462 Clorsulon drench.

(a) Specifications. The drug is a suspension containing 8.5 percent clorsulon (85 milligrams per milliliter).

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use. Cattle—(1) Amount. One-quarter fluid ounce per 200 pounds of body weight (7 milligrams per kilogram or 3.2 milligrams per pound of body weight).

(2) Indications for use. For the treatment of immature and adult liver fluke (Fasciola hepatica) infestations in cattle.

(3) Limitations. Using dose syringe, deposit drench over back of tongue. Do not treat cattle within 8 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.522 Cyclosporine.

(a) Specifications. (1) Each cyclosporine capsule, USP (MODIFIED)
contains 10, 25, 50, or 100 milligrams (mg) cyclosporine.
(2) Each milliliter of cyclosporine oral solution, USP (MODIFIED) contains 100 mg cyclosporine.
(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use—(1) Dogs. Use capsules described in paragraph (a)(1) of this section as follow:
   (i) Amount. Administer 5 mg per kilogram (mg/kg) of body weight given orally as a single daily dose for 30 days.
   Following this initial daily treatment period, the dosage may be tapered by decreasing the frequency of administration to every other day or two times a week, until a minimum frequency is reached which will maintain the desired therapeutic effect.
   (ii) Indications for use. For the control of atopic dermatitis in dogs weighing at least 4 pounds.
   (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats. Use the solution described in paragraph (a)(2) of this section as follow:
   (i) Amount. Administer 7 mg/kg of body weight orally as a single daily dose for a minimum of 4 to 6 weeks or until resolution of clinical signs. Following this initial daily treatment period, the dosage may be tapered by decreasing the frequency of administration to every other day or twice weekly to maintain the desired therapeutic effect.
   (ii) Indications for use. For the control of feline allergic dermatitis in cats at least 6 months of age and weighing at least 3 pounds.
   (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.531 Cythioate tablets.
(a) Specifications. Each tablet contains 30 or 90 milligrams (mg) cythioate.
(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:
   (1) No. 000859 for use of 30- and 90-mg tablets;
   (2) No. 054771 for use of the 30-mg tablet.
(c) Conditions of use—(1) Amount. 30 milligrams cythioate per 20 pounds of body weight every third day or twice a week.
(2) Indications for use. Dogs, for control of fleas.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.532 Cythioate oral liquid.
(a) Specifications. Each milliliter contains 15 milligrams of cythioate.
(b) Sponsor. See Nos. 000859 and 054771 in §510.600(c) of this chapter.
(c) Special considerations. Cythioate is a cholinesterase inhibitor. Do not use this product in animals simultaneously with or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, insecticides, pesticides, or chemicals.
(d) Conditions of use—(1) Amount. 15 milligrams cythioate per 10 pounds of body weight every third day or twice a week.
(2) Indications for use. Dogs, for control of fleas.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.533 Decoquinate.
(a) Specifications. Each gram of powder contains 8 milligrams (0.8 percent) decoquinate.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.170 of this chapter.
(d) Conditions of use. Calves—(1) Amount. Feed 22.7 milligrams per 100 pounds of body weight (0.5 milligram per kilogram) per day.
(2) Indications for use. For the prevention of coccidiosis in ruminating and nonruminating calves, including veal calves, caused by Eimeria bovis and E. zuernii.
(3) Limitations. Feed in whole milk at the rate of 22.7 milligrams per 100
§ 520.538 Deracoxib.

(a) Specifications. Each tablet contains 12, 25, 50, 75, or 100 milligrams (mg) deracoxib.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use in dogs—

(1) Amount. Administer orally as needed, as a single daily dose based on body weight:
   (i) 1 to 2 mg/kilogram (kg) (0.45 to 0.91 mg/pound (lb)), for use as in paragraph (d)(2)(i) of this section.
   (ii) 1 to 2 mg/kg (0.45 to 0.91 mg/lb) for 3 days, for use as in paragraph (d)(2)(ii) of this section.
   (iii) 3 to 4 mg/kg (1.4 to 1.8 mg/lb) for up to 7 days, for use as in paragraph (d)(2)(iii) of this section.

(2) Indications for use. (i) For the control of pain and inflammation associated with osteoarthritis.
   (ii) For the control of postoperative pain and inflammation associated with dental surgery.
   (iii) For the control of postoperative pain and inflammation associated with orthopedic surgery.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.540b Dexamethasone tablets and boluses.

(a)(1) Specifications. Each bolus is half-scored and contains 10 milligrams of dexamethasone.

(b) Sponsor. See Nos. 000061 and 061623 in § 510.600(c) of this chapter.

(1) Amount. Administer orally 5 to 10 milligrams on the first day, then 5 milligrams per day as required.

(2) Indications for use. As supportive therapy following parenteral steroid administration for management or inflammatory conditions such as acute arthritic lameness, and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Do not use in horses intended for human consumption.

[79 FR 28819, May 20, 2014]
Food and Drug Administration, HHS

§ 520.581  Dichlorophene tablets.

(a) Specifications. Each tablet contains 1 gram of dichlorophene.

(b) Sponsor. See 023851 in § 510.600(c) of this chapter.

§ 520.580  Dichlorophene and toluene.

(a) Specifications. Each capsule contains 50 milligrams (mg) of dichlorophene and 60 mg of toluene, or multiples thereof.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) Nos. 017135, 025851, 053111, and 058670 for use only as a single dose.

(2) Nos. 000061 and 054771 for use in a single dose or divided-dosage regimen.

(c) Required statement. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism, and before administering to weak or debilitated animals.

(d) Conditions of use—

(i) Amount. Administer orally as follows:

(1) Single dose: Administer 100 mg of dichlorophene and 120 mg of toluene per pound of body weight.

(ii) Divided dose: Administer 100 mg of dichlorophene and 120 mg of toluene per 5 pounds of body weight (20 and 24 mg per pound) daily for 6 days.

(2) Indications for use. For the removal of ascarids (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala); and as an aid in removing tape worms (Taenia pisiformis, Dipylidium caninum, and Echinococcus granulosus) from dogs and cats.

(3) Limitations. Withhold solid foods and milk for at least 12 hours prior to medication and for 4 hours afterward. Repeat treatment in 2 to 4 weeks in animals subject to reinfection.

[45 FR 10332, Feb. 15, 1980]
§ 520.600 Dichlorvos.

(a) Chemical name. 2,2-Dichlorvinyl dimethyl phosphate.

(b) [Reserved]

(c) Sponsor. See No. 054628 in § 510.600(c) of this chapter.

(d) Related tolerances. See § 556.180 of this chapter.

(e) Conditions of use in swine. (1) It is recommended for the removal and control of sexually mature (adult), sexually immature and/or 4th stage larvae of the whipworm (Trichuris suis), nodular worms (Oesophagostomum spp.), large round-worm (Ascaris suum), and the mature thick stomach worm (Ascarops strongylina) occurring in the lumen of the gastrointestinal tract of pigs, boars, and open or bred gilts and sows.

(2) The preparation should be added to the indicated amount of feed as set forth in paragraph (e)(2) of this section and administered shortly after mixing, as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Pounds of feed to be mixed with each 0.08 ounce of dichlorvos</th>
<th>Pounds of mixed feed to be administered to each pig as a single treatment</th>
<th>Number of pigs to be treated per 0.08 ounce of dichlorvos</th>
</tr>
</thead>
<tbody>
<tr>
<td>20–30</td>
<td>4</td>
<td>0.33</td>
<td>12</td>
</tr>
<tr>
<td>31–40</td>
<td>5</td>
<td>0.56</td>
<td>9</td>
</tr>
<tr>
<td>41–60</td>
<td>6</td>
<td>1.00</td>
<td>6</td>
</tr>
<tr>
<td>61–80</td>
<td>5</td>
<td>1.00</td>
<td>5</td>
</tr>
<tr>
<td>81–100</td>
<td>4</td>
<td>1.00</td>
<td>4</td>
</tr>
<tr>
<td>Adult Gilts, Sows, and Boars</td>
<td>16</td>
<td>4.00</td>
<td>4</td>
</tr>
</tbody>
</table>

(3) Do not use this product on animals either simultaneously or within a few days before or after treatment with or exposure to cholinesterase inhibiting drugs, pesticides, or chemicals. The preparation should be mixed thoroughly with the feed on a clean, impermeable surface. Do not allow swine access to feed other than that containing the preparation until treatment is complete. Do not treat pigs with signs of scour until these signs subside or are alleviated by proper medication. Resume normal feeding schedule afterwards. Swine may be retreated in 4 to 5 weeks.

(f) Conditions of use in dogs. (1) For removal of Toxocara canis and Toxascaris leonina (roundworms), Ancylostoma caninum and Uncinaria stenocephala (hookworms), and Trichuris vulpis (whipworm) residing in the lumen of the gastrointestinal tract.

(2) The drug is in capsule form for direct administration and in pellet form for administration in about one-third of the regular canned dog food ration or in ground meat. Dogs may be treated with any combination of capsules and/or pellets so that the animal receives a single dose equaling 12 to 15 milligrams of the active ingredient per pound of body weight. One-half of the single recommended dosage may be given, and the other half may be administered 8 to 24 hours later. This split dosage schedule should be used in animals which are very old, heavily parasitized, anemic, or otherwise debilitated. The drug should not be used in dogs weighing less than 2 pounds.

(3) In some dogs, efficacy against Trichurias vulpis (whipworm) may be erratic. Dogs that do not develop a negative stool for Trichuris vulpis ova 10 to 14 days following initial treatment should be re-treated. If a negative stool is not obtained in 10 to 14 days following re-treatment, alternate means of therapy should be considered.

(4) Do not use in dogs infected with Dirofilaria immitis.

(5) Do not use with other anthelmintics, taeniacides, antifilarial agents, muscle relaxants, or tranquilizers.

(6) The drug is a cholinesterase inhibitor. Not for use simultaneously or
within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(7) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(g) Conditions of use in horses when administered in grain. (1) It is recommended for the removal and control of bots (Gastrophilus intestinalis, G. nasalis), large strongyles (Strongylus vulgaris, S. equinus, S. edentatus), small strongyles (of the genera Cyathostomum, Cylicocercus, Cylicocyclus, Cylicodontophorus, Triodontophorus, Poteriostomum, Gyalocephalus), pinworms (Oxyuris equi), and large roundworm (Parascaris equorum) in horses including ponies and mules. Not for use in foals (sucklings and young weanlings).

(2) For a satisfactory diagnosis, a microscopic fecal examination should be performed by a veterinarian or a diagnostic laboratory prior to worming.

(3) It is administered in the grain portion of the ration at a dosage of 14.2 milligrams to 18.5 milligrams per pound of body weight as a single dose. It may be administered at one-half of the single recommended dosage and repeated 8 to 12 hours later in the treatment of very aged, emaciated or debilitated subjects or those reluctant to consume medicated feed. In suspected cases of severe ascarid infection sufficient to cause concern over mechanical blockage of the intestinal tract, the split dosage should be utilized.

(4) Do not use in horses which are severely debilitated, suffering from diarrhea or severe constipation, infectious disease, toxemia or colic. Do not administer in conjunction with or within 1 week of administration of muscle relaxant drugs, phenothiazine derived tranquilizers or central nervous system depressant drugs. Do not administer to horses affected with chronic alveolar emphysema (heaves) or related respiratory conditions. The product is a cholinesterase inhibitor and should not be used simultaneously or within a few days before or after treatment with or exposure to cholinesterase inhibiting drugs, pesticides or chemicals.

(5) Do not use in animals other than horses, ponies, and mules. Do not use in horses, ponies, and mules intended for food purposes. Do not allow fowl access to feed containing this preparation or to fecal excrement from treated animals.

(h) Conditions of use in horses when administered orally by syringe. (1) It is recommended for the removal and control of first, second, and third instar bots (Gastrophilus intestinalis and G. nasalis), sexually mature and sexually immature (4th stage) ascarids (Parascaris equorum) in horses and foals.

(2) The product is in the form of a gel which is administered directly from a syringe onto the horse’s tongue. The product is administered at a dosage level of 20 milligrams of dichlorvos per kilogram of body weight for the removal of bots and ascarids. The same dosage level is repeated every 21 to 28 days for the control of bots and ascarids. For the control of bots only, the repeat dosage is 10 milligrams per kilogram of body weight every 21 to 28 days during bot fly season.

(3) Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides or chemicals. Do not administer in conjunction with or within 1 week of administration of muscle-relaxant drugs, phenothiazine derived tranquilizers, or central nervous system depressants.

(4) Do not use in horses which are severely debilitated or suffering from diarrhea or severe constipation, infectious disease, toxemia, or colic. Do not administer to horses affected with chronic alveolar emphysema (heaves) or other respiratory conditions.

(5) Do not use in horses intended for food purposes.

(6) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(i) Conditions of use in dogs, cats, puppies, and kittens. (1) Each tablet contains 2, 5, 10, or 20 milligrams of dichlorvos.
(3) Dogs and puppies: Removal and control of intestinal roundworms (*Toxocara canis* and *Toxascaris leonina*) and hookworms (*Ancylostoma caninum* and *Uncinaria stenocephala*).

(4) Cats and kittens: Removal and control of intestinal roundworms (*Toxocara cati* and *Toxascaris leonina*) and hookworms (*Ancylostoma tubaeforme* and *Uncinaria stenocephala*).

(5) Dichlorvos is a cholinesterase inhibitor. Do not use simultaneously with or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(6) Do not use in animals under 10 days of age or 1 pound of body weight.

(7) Do not administer to animals showing signs of constipation, mechanical blockage of the intestinal tract, impaired liver function, or recently exposed to or showing signs of infectious disease.

(8) Do not use in dogs or puppies infected with *Dirofilaria immitis*.

(9) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.606 Diclazuril.

(a) **Specifications.** Each 100 grams (g) of pellets contain 1.56 g diclazuril.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use in horses—(1) Amount.** Administer orally 1 milligram (mg) per kilogram (0.45 mg per pound) of body weight in the daily grain ration for 28 days.

(2) **Indications for use.** For the treatment of equine protozoal myeloencephalitis (EPM) caused by *Sarcocystis neurona*.

(3) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.608 Dicloxacillin.

(a) **Specifications.** Each capsule contains dicloxacillin sodium monohydrate equivalent to 50, 100, 200, or 500 milligrams of dicloxacillin.

(b) **Sponsor.** See No. 054771 in §510.600(c) of this chapter.

(c) **Conditions of use in dogs—(1) Amount.** Administer orally 5 to 10 milligrams per pound of body weight, three times daily. In severe cases, up to 25 milligrams per pound of body weight three times daily.

(2) **Indications for use.** For the treatment of pyoderma (pyogenic dermatitis) due to penicillinase-producing staphylococci sensitive to dicloxacillin.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.620 Diethylcarbamazine oral dosage forms.

§ 520.622 Diethylcarbamazine citrate oral dosage forms.

§ 520.622a Diethylcarbamazine citrate tablets.

(a) **Sponsors.** (1) [Reserved]

(2) See No. 054771 in §510.600(c) of this chapter for use of 100, 200, and 300 milligram tablets for prevention of heartworm disease in dogs and as an aid in the treatment of ascarid infections in dogs.

(3) See No. 061623 in §510.600(c) of this chapter for use of 50, 100, 200, 300, or 400 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(4) [Reserved]

(5) See No. 000061 in §510.600(c) of this chapter for use of 60, 120, or 180 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(6) See No. 054628 in §510.600(c) of this chapter for use of 50, 100, 200, 300, or 400 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(7) See No. 000061 in §510.600(c) of this chapter for use of 60, 120, or 180 milligram tablets for prevention of heartworm disease in dogs, as an aid in the control of ascarid infections in dogs, and as an aid in the treatment of ascarid infections in dogs and cats.

(8) [Reserved]

(9) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.624 Doxycycline oral dosage forms.

§ 520.626 Doxycycline oral solution.

§ 520.628 Doxycycline intravenous powder for injection.

§ 520.630 Doxycycline injectable.
§ 520.622b Diethylcarbamazine citrate syrup.

(a)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is indicated for use in dogs for the prevention of infection with Dirofilaria immitis and T. canis and T. leonina. It is also indicated for treatment of ascarid infections of T. canis and T. leonina in dogs and T. cati in cats.

(ii) For prevention of heartworm and ascarid infections in dogs, the drug may be added to the daily diet at a dosage rate of 3.0 milligrams per pound of body weight per day or given directly by mouth at the same dosage rate. For treatment of ascarid infections in dogs and cats, the drug is administered at a dosage level of 25 to 50 milligrams per pound of body weight preferably administered immediately after feeding.

(iii) Older dogs should be proven negative for the presence of Dirofilaria immitis infection before administration of the drug. Those with proven infection of Dirofilaria immitis should be rendered negative using adulticidal and microfilaricidal drugs before administration of this drug.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b) [Reserved]

(c)(1) Specifications. Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.

(2) Sponsor. See No. 054628 in §510.600(c) of this chapter.

(3) Conditions of use. (i) The drug is used in dogs between 4 weeks and 8 months of age for the removal of ascarids (Toxocara canis) and in animals over 4 weeks of age for the prevention of heartworm disease (Dirofilaria immitis).

(ii) The drug is administered (a) for removal of ascarids at a dosage of 50 milligrams per pound of body weight divided into two equal doses and administered 8 to 12 hours apart (morning and night), orally or mixed with either dry or wet food, and (b) for prevention of heartworm disease at a dosage of 3 milligrams per pound of body weight daily, orally or in food, in heartworm endemic areas, from the beginning of mosquito activity, during the mosquito season, and for 2 months following the end thereof.

(iii) Dogs older than 8 months of age may be infected with Dirofilaria immitis. Use of the drug is contraindicated in dogs with active D. immitis infections.

(iv) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.622c Diethylcarbamazine citrate chewable tablets.

(a) Specifications. Each chewable tablet contains 30, 45, 60, 120, 150, or 180 milligrams of diethylcarbamazine citrate.

(b) Sponsors. See drug listing nos. in §510.600(c) of this chapter for identification of sponsors as follows:

(1) [Reserved]
§ 520.623 Diethylcarbamazine and oxibendazole chewable tablets.

(a) Specifications. Each tablet contains 60, 120, or 180 milligrams of diethylcarbamazine citrate with 45, 91, or 136 milligrams of oxibendazole, respectively.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally to dogs at a dosage level of 6.6 milligrams of diethylcarbamazine citrate per kilogram of body weight (3 milligrams per pound of body weight) and 5.0 milligrams of oxibendazole per kilogram of body weight (2.27 milligrams per pound of body weight).

(2) Indications for use. For prevention of infection with Dirofilaria immitis (heartworm disease) and Ancylostoma caninum (hookworm infection) and for removal and control of Trichuris vulpis (whipworm infection) and mature and immature stages of intestinal Toxocara canis (ascarid infection).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.645 Difloxacin.

(a) Specifications. Each tablet contains 11.4, 45.4, or 136 milligrams (mg) of difloxacin hydrochloride.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Reserved

(d) Conditions of use—(1) Amount. Administer 5 to 10 mg per kilogram (2.3 to 4.6 mg per pound) of body weight orally once a day for 2 to 3 days beyond cessation of clinical signs of disease up to a maximum of 30 days.

(2) Indications for use. For management of diseases in dogs associated with bacteria susceptible to difloxacin.

(iii) Limitations. Federal law prohibits the extra-label use of this drug in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.666 Dirlotapide.

(a) Specifications. Each milliliter (mL) of solution contains 5 milligrams (mg) dirlotapide.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. The initial dosage is 0.01 mL/kg (0.0045 mL/lb) body weight for the first 14 days. After the first 14 days of treatment, the dose volume is doubled to 0.02 mL/kg (0.009 mL/lb) body weight per day.
for the next 14 days (days 15 to 28 of treatment). Dogs should be weighed monthly and the dose volume adjusted every month, as necessary, to maintain a target percent weight loss until the desired weight is achieved.
(2) Indications for use. For the management of obesity.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.763 Dithiazanine oral dosage forms.

§ 520.763a Dithiazanine tablets.
(a) Specifications. Each tablet contains 10, 50, 100, or 200 milligrams (mg) dithiazanine iodide.
(b) Sponsor. See No. 054628 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Indications for use and amount. Administer orally immediately after feeding as follows:
(i) For large roundworms (Toxocara canis, Toxascaris leonina): 10 mg per pound (/lb) of body weight for 3 to 5 days;
(ii) For hookworms (Ancylostoma caninum, Uncinaria stenocephala) and whipworms (Trichuris vulpis): 10 mg/lb of body weight for 7 days;
(iii) For Strongyloides (Strongyloides canis, Strongyloides stercoralis): 10 mg/lb of body weight for 10 to 12 days;
(iv) For heartworm microfilariae (Dirofilaria immitus): 3 to 5 mg/lb of body weight for 7 to 10 days. Treatment for heartworm microfilariae should follow 6 weeks after therapy for adult worms.
(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28820, May 20, 2014]

§ 520.763b Dithiazanine powder.
(a) Specifications. Each tablespoon of powder contains 200 milligrams (mg) dithiazanine iodide.
(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Indications for use and amount. Administer orally by mixing in food as follows:
(i) For large roundworms (Toxocara canis, Toxascaris leonina): 10 mg per pound (/lb) of body weight for 3 to 5 days;
(ii) For hookworms (Ancylostoma caninum, Uncinaria stenocephala) and whipworms (Trichuris vulpis): 10 mg/lb of body weight for 7 days;
(iii) For Strongyloides (Strongyloides canis, Strongyloides stercoralis): 10 mg/lb of body weight for 10 to 12 days;
(iv) For heartworm microfilariae (Dirofilaria immitus): 3 to 5 mg/lb of body weight for 7 to 10 days. Treatment for heartworm microfilariae should follow 6 weeks after therapy for adult worms.
(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28820, May 20, 2014]

§ 520.763c Dithiazanine iodide and piperazine citrate suspension.
(a) Specifications. Each milliliter of suspension contains 69 milligrams (mg) dithiazanine iodide and 83 mg piperazine base (as piperazine citrate).
(b) Sponsor. See No. 054628 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. 1 ounce (30 milliliters) per 100 pounds of body weight for the first 500 pounds; ¾ ounce for each 100 pounds thereafter, up to 1,200 pounds; 10¼ ounces to animals over 1,200 pounds.
(2) Indications for use. For control of large roundworms, Parascaris equorum; small strongyles; large strongyles, Strongylus vulgaris; and pinworms, Oxyuris equi.
(3) Limitations. Administer by drench or mixed with the daily ration as a single dose. Treatment is recommended in spring and fall. In a heavily infested environment, treatment may be repeated every 30 days. Not for use in horses intended for food purposes. Severely debilitated animals should not be wormed except on the advice of a veterinarian. If the drug is for administration by stomach tube, it shall be labeled: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”

[79 FR 28820, May 20, 2014]
§ 520.766 Domperidone.

(a) Specifications. Each milliliter of gel contains 110 milligrams (mg) domperidone.

(b) Sponsor. See No. 043264 in § 510.600 of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 0.5 mg per pound (mg/lb) (1.1 mg/kilogram (kg)) by mouth once daily starting 10 to 15 days prior to the expected foaling date. Treatment may be continued for up to 5 days after foaling if mares are not producing adequate milk.

(2) Indications for use. For prevention of fescue toxicosis in periparturient mares.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 67031, Nov. 1, 2010]

§ 520.784 Doxylamine.

(a) Specifications. The drug is in tablet form and contains doxylamine succinate as the active drug ingredient.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Horses: Administer orally 1 to 2 milligrams (mg) per pound (lb) of body weight per day divided into 3 or 4 equal doses. Dogs and cats: Administer orally 2 to 3 mg/lb of body weight per day divided into 3 or 4 equal doses.

(2) Indications for use. For use when antihistaminic therapy may be expected to alleviate some signs of disease in horses, dogs, and cats.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.804 Enalapril.

(a) Specifications. Each tablet contains 1.0, 2.5, 5.0, 10, or 20 milligrams (mg) of enalapril maleate per kilogram of body weight per day.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally 0.5 to 1.0 mg of enalapril maleate per kilogram of body weight per day.

(2) Indications for use. For the treatment of mild, moderate, and severe (modified New York Heart Association Class II, III, IV) heart failure in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.812 Enrofloxacin.

(a) Specifications. Each tablet contains:

(1) 22.7, 68.0, or 136.0 milligrams (mg) enrofloxacin; or

(2) 22.7, 68.0, 136.0, or 272 mg enrofloxacin.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (c) of this section.

(1) Nos. 000859 and 026637 for use of product described in paragraph (a)(1) of this section.

(2) No. 058198 for use of product described in paragraph (a)(2) of this section.

(1) Amount. Administer orally as a single, daily dose or divided into two equal doses at 12-hour intervals.

(i) Dogs. 5 to 20 mg per kilogram (kg) (2.27 to 9.07 mg per pound (lb)) of body weight.

(ii) Cats. 5 mg/kg (2.27 mg/lb) of body weight.

(2) Indications for use. For the management of diseases associated with bacteria susceptible to enrofloxacin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

[78 FR 30197, May 22, 2013, as amended at 78 FR 52853, Aug. 27, 2013]

§ 520.816 Epsiprantel.

(a) Specifications. Each tablet contains either 12.5, 25, 50, or 100 milligrams of epsiprantel.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. 2.5 milligrams per pound of body weight.
(1) **Indications for use.** Removal of canine cestodes *Dipylidium caninum* and *Taenia pisiformis*.

(2) **Cats**—(1) **Amount.** 1.25 milligrams per pound of body weight.

(ii) **Indications for use.** Removal of feline cestodes *D. caninum* and *T. taeniaeformis*.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.823 Erythromycin.

(a) **Specifications.** Each gram of powder contains erythromycin phosphate equivalent to 0.89 gram of erythromycin master standard.

(b) **Sponsor.** See No. 061623 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.230 of this chapter.

(d) **Conditions of use.** It is used in drinking water as follows:

(i) **Broiler and replacement chickens**—(1) **Amount.** 0.500 gram per gallon.

(ii) **Indications for use.** As an aid in the control of chronic respiratory disease due to *Mycoplasma gallisepticum* susceptible to erythromycin.

(iii) **Limitations.** Administer for 5 days; do not use in replacement pullets over 16 weeks of age; do not use in chickens producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

(ii) **Replacement chickens and chicken breeders**—(i) **Amount.** 0.500 gram per gallon.

(ii) **Indications for use.** As an aid in the control of infectious coryza due to *Haemophilus gallinarum* susceptible to erythromycin.

(iii) **Limitations.** Administer for 7 days; do not use in turkeys producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

(3) **Growing turkeys**—(1) **Amount.** 0.500 gram per gallon.

(ii) **Indications for use.** As an aid in the control of blue comb (nonspecific infectious enteritis) caused by organisms susceptible to erythromycin.

(iii) **Limitations.** Administer for 7 days; do not use in turkeys producing eggs for human consumption; to assure effectiveness, treated birds must consume enough medicated water to provide a therapeutic dosage; solutions older than 3 days should not be used; withdraw 1 day before slaughter.

§ 520.852 Estriol.

(a) **Specifications.** Each tablet contains 1 milligram (mg) estriol.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs**—(1) **Amount.** Administer at an initial dose of 2 mg per dog per day. The dosage may be titrated to as low as 0.5 mg per dog every second day, depending on response.

(ii) **Indications for use.** For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.

(iii) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.863 Ethylisobutrazine.

(a) **Specifications.** Each tablet contains either 10 milligrams or 50 milligrams of ethylisobutrazine hydrochloride.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs**—(1) **Amount.** Administer orally 2 to 5 milligrams per pound of body weight once daily.

(ii) **Indications for use.** As a tranquilizer.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.870

Etodolac.

(a) Specifications. Each tablet contains 150, 300, or 500 milligrams (mg) of etodolac.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 10 to 15 mg per kilogram (4.5 to 6.8 mg per pound) of body weight per day orally.

(2) Indications for use. For the management of pain and inflammation associated with osteoarthritis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.903

Febantel oral dosage forms.

§ 520.903a Febantel oral paste.

(a) Specifications. Each gram of paste contains 455 milligrams (45.5 percent) of febantel.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer paste orally at 6 milligrams per kilogram (2.73 milligrams per pound) of body weight on the base of the tongue or well mixed into a portion of the normal grain ration. For animals maintained on premises where reinfection is likely to occur, retreatment may be necessary. For most effective results, retreat in 6 to 8 weeks.

(2) Indications for use. For removal of ascarids (Parascaris equorum—adult and sexually immature), pinworms (Oxyuris equi—adult and 4th stage larvae), large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), and various small strongyles in horses, breeding stallions and mares, pregnant mares, foals, and ponies.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.903b Febantel suspension.

(a) Specifications. Each ounce of suspension contains 2.75 grams (9.3 percent ounce) of febantel.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 3 milliliters per 100 pounds body weight or 1 fluid ounce per 1000 pounds (6 milligrams per kilogram body weight). Administer by stomach tube or drench, or by mixing well into a portion of the normal grain ration. For animals maintained on premises where reinfection is likely to occur, retreatment may be necessary. For most effective results, retreat in 6 to 8 weeks.

(2) Indications for use. For removal of ascarids (Parascaris equorum—adult and sexually immature), pinworms (Oxyuris equi—adult and 4th stage larvae), large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), and various small strongyles in horses, breeding stallions and mares, pregnant mares, foals, and ponies.

(d) Special considerations. Febantel suspension may be used in combination with trichlorfon oral liquid in accordance with the provisions of § 520.2520c, this section, and the following conditions:

(1) Combine 1 part febantel suspension with 5 parts trichlorfon liquid.

(2) Allow animal to consume a portion of daily grain ration; administer mixture by stomach tube at rate of 18 milliliters per 100 pounds of body weight.

§ 520.903c [Reserved]

§ 520.903d Febantel and praziquantel paste.

(a) Specifications. Each gram of paste contains 34 milligrams of febantel and 3.4 milligrams of praziquantel.
§ 520.905 Fenbendazole oral dosage forms.

(a) Specifications. Each milliliter of suspension contains 100 milligrams (mg) fenbendazole for use as in paragraphs (e)(1), (2), (3), and (4) of this section; or 200 mg fenbendazole for use as in paragraph (e)(5) of this section.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

§ 520.905a Fenbendazole suspension.

(a) Specifications. Each milliliter of suspension contains 100 milligrams (mg) fenbendazole for use as in paragraphs (e)(1), (2), (3), and (4) of this section; or 200 mg fenbendazole for use as in paragraph (e)(5) of this section.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

§ 520.903e Febantel tablets.

(a) Specifications. Each scored tablet contains 27.2 milligrams of febantel for use in dogs, puppies, cats, and kittens or 163.3 milligrams of febantel for use in dogs, puppies, and cats. (b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount—(i) Dogs and cats (over 6 months of age): 10 milligrams of febantel and 1 milligram of praziquantel per kilogram of body weight (1 gram of paste per 7.5 pounds body weight) administered by mouth or in the food once daily for 3 days.

(ii) Puppies and kittens (less than 6 months of age): 15 milligrams of febantel and 1.5 milligrams of praziquantel per kilogram of body weight (1 gram of paste per 5 pounds body weight) administered by mouth on a full stomach once daily for 3 days.

(2) Indications for use. (i) Dogs and puppies: For removal of hookworms (Ancylostoma caninum and Uncinaria stenocephala), whipworms (Trichuris vulpis), ascarsids (Toxocara canis and Toxascaris leonina), and tapeworms (Dipylidium canum and Taenia pisiformis).

(ii) Cats and kittens: For removal of hookworms (Ancylostoma tubaeforme), ascarsids (Toxocara cati) and tapeworms (Dipylidium canum and Taenia taeniaeformis).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2520, have been shown to be compatible and not to interfere with one another.

(e) Conditions of use—(1) Horses—(i) Amount. Administer orally 5 mg per kilogram (5/kg) (2.3 mg per pound (lb)) for the control of large strongyles, small strongyles, and pinworms; 10 mg/kg for the control of ascarsids.

(ii) Indications for use. For the control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles (Cystocotyloides spp., Cysticola spp., Cylicostephanus spp., Triodontophorus spp., pinworms (Oxyuris equi), and ascarsids (Parascaris equorum) in horses.

(iii) Limitations. Administer by dose syringe or suitable plastic syringe. Do not use in horses intended for human consumption.

(2) Cattle including dairy cows of breeding age—(i) Amount. Administer orally 5 mg/kg of body weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.

(ii) Indications for use. For the removal and control of lungworm...
(Dictyocaulus viviparus); stomach worm (adults)—brown stomach worm (Ostertagia ostertagi); stomach worms (adults and 4th-stage larvae)—barberpole worm (Haemonchus contortus and H. placei) and small stomach worm (Trichostongylus axei); intestinal worms (adults and 4th-stage larvae)—hookworm (Bunostomum phlebotomum), threadnecked intestinal worm (Nematodirus helvetianus), small intestinal worm (Cooperia punctata and C. oncophora), bankrupt worm (Trichostrongylus colubriformis), and nodular worm (Oesophagostomum radiatum).

(iii) Limitations. Cattle must not be slaughtered within 8 days following last treatment. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(3) Beef cattle—(i) Amount. Administer orally 10 mg/kg body weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.

(ii) Indications for use. For the removal and control of stomach worm (4th stage inhibited larvae/type II ostertagiasis), Ostertagia ostertagi, and tapeworm, Moniezia benedeni.

(iii) Limitations. Cattle must not be slaughtered within 8 days following last treatment. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Goats—(i) Amount. Administer orally 5 mg/kg body weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.

(ii) Indications for use. For the removal and control of stomach worms (adults) Haemonchus contortus and Teladorsagia circumcincta.

(iii) Limitations. Goats must not be slaughtered for food within 6 days following last treatment. Do not use in lactating goats.

(5) Chickens—(i) Amount. Administer orally via drinking water at a daily dose of 1 mg/kg body weight (0.454 mg/lb) for 5 consecutive days.

(ii) Indications for use. For the treatment and control of adult Ascaridia galli in broiler chickens and replacement chickens intended to become breeding chickens, and for the treatment and control of adult A. galli and Heterakis gallinarum in breeding chickens.

(iii) Limitations. Not for use in laying hens and replacement chickens intended to become laying hens.
(3) Zoo and wildlife animals—(i) Amount. 10 mg/kg per day for 3 days.

(ii) Indications for use. For control of internal parasites of Felidae and Ursidae as follows:

(A) Lion (Panthera leo) and Tiger (Panthera tigris): Ascarid (Toxocara cati, Toxascaris leonina), Hookworm (Ancylostoma spp.).
(B) Cheetah (Acinonyx jubatus): Ascarid (Toxocara cati, Toxascaris leonina).
(C) Puma (Felis concolor), Panther (Panthera spp.), Leopard (Panthera pardus), Jaguar (Panthera onca): Ascarid (Toxocara cati, Toxascaris leonina), Hookworm (Ancylostoma spp.), Tapeworm (Taenia hydatigena, T. krabbei, T. taeniaeformis).
(D) Black Bear (Ursus americanus): Ascarid (Baylisascaris transfuga, Toxascaris leonina), Hookworm (Ancylostoma caninum), Tapeworm (Taenia hydatigena, T. krabbei).
(E) Polar Bear (Ursus maritimus) and Grizzly Bear (Ursus horribilis): Ascarid (Baylisascaris transfuga, Toxascaris leonina).

(iii) Limitations. Top dress or mix with a small portion of food. Must be fully consumed prior to feeding. Do not use 14 days before or during the hunting season.

§ 520.905c Fenbendazole paste.

(a) Specifications. Each gram of paste contains 100 milligrams (mg) fenbendazole (10 percent).
(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.275 of this chapter.
(d) Special considerations. See §500.25 of this chapter.
(e) Conditions of use—(1) Horses—(i) Indications for use and amounts—(A) For control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, pinworms (Oxyuris equi), and ascarids (Parascaris equorum): 2.3 mg per pound /lb) of body weight, or for foals and weanlings (less than 18 months of age), 4.6 mg/lb of body weight. Treatment at intervals of 6 to 8 weeks may be required.
(B) For control of arteritis caused by the fourth-stage larvae of S. vulgaris: 4.6 mg/lb of body weight daily for 5 days. Treatment should be initiated in the spring and repeated in 6 months.
(C) For treatment of encysted mucosal cyathostome (small strongyle) larvae including early third-stage (hypobiotic), late third-stage, and fourth-stage larvae: 4.6 mg/lb of body weight daily for 5 consecutive days.

 §520.905d Fenbendazole powder.

(a) Specifications. (1) Each 2-ounce packet contains 2.27 grams (4 percent) of fenbendazole plus other inert ingredients.

(b) Sponsor. (1) See No. 000061 in §510.600(c) of this chapter for use of the 4-percent product.
§ 520.905e Fenbendazole blocks.

(a) Specifications. (1) Each pound of molasses block contains 750 milligrams of fenbendazole.

(2) Each pound of protein block contains 750 milligrams of fenbendazole.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.275 of this chapter.

(d) Conditions of use—(1) Amount. 0.1 pound of block per 100 pounds of body weight per day for up to 14 days. Total dose for the 3-day period is 2.27 milligrams of fenbendazole per pound of body weight for mature cattle.

(2) Indications for use. For removal and control of infections of lungworms (Dictyocaulus viviparus) and gastrointestinal roundworms (Haemonchus contortus, Ostertagia ostertagi, Trichostrongylus axei, Bunostomum phlebotomum, Nemato dolorus helvetianus, Cooperia oncophora and C. punctata, Trichostrongylus colubriformis, and Oesophagostomum radiatum) in beef cattle.

(3) Limitations. Administer free choice of beef cattle on pasture that have become accustomed to nonmedicated block feeding during an adaptation period of 12 to 19 days. Molasses block: Cattle must not be slaughtered within 11 days following last treatment. Protein block: Cattle must not be slaughtered within 16 days following last treatment; do not use in dairy cattle of breeding age. Animals maintained under conditions of constant worm exposure may require retreatment within 6 to 8 weeks. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.928 Firocoxib tablets.

(a) Specifications. Each chewable tablet contains 57 or 227 milligrams (mg) firocoxib.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 5 mg/kg (2.27 mg/lb) body weight. Administer once daily for osteoarthritis. Administer approximately 2 hours before soft-tissue or orthopedic surgery.

(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis; and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.930 Firocoxib paste.

(a) Specifications. Each milligram (mg) of paste contains 0.82 mg firocoxib.

(b) Sponsors. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 0.1 mg per kilogram (0.045 mg per pound) body weight daily for up to 14 days.

(2) **Indications for use.** For the control of pain and inflammation associated with osteoarthritis.

(3) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[71 FR 5788, Feb. 3, 2006]

§ 520.955 Florfenicol.

(a) **Specifications.** Each milliliter (mL) contains 23 milligrams (mg) florfenicol.

(b) **Sponsor.** See Nos. 000061 and 058198 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §556.283 of this chapter.

(d) **Conditions of use in swine—(1) Amount.** Administer in drinking water ad libitum at 400 mg per gallon (100 parts per million (ppm)) for 5 consecutive days.

(2) **Indications for use.** For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis.

(3) **Limitations.** Do not slaughter within 16 days of last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.960 Flumethasone.

(a) **Specifications.** Each tablet contains 0.0625 milligram of flumethasone.

(b) **Sponsor.** See No. 054771 in §510.600(c) of this chapter.

(c) **Conditions of use—(1) Dogs: Amount—(i) Administer orally from 0.0625 to 0.25 milligram daily in divided doses. (ii) Cats: Administer orally from 0.03125 to 0.125 milligram daily in divided doses. (2) Indications for use—(i) Dogs: It is used for musculoskeletal conditions due to inflammation of muscles or joints and accessory structures, where permanent structural changes do not exist, such as arthritis, the disc syndrome, and myositis. (ii) Dogs and cats: It is used in certain acute and chronic dermatoses of varying etiology to help control the pruritus, irritation, and inflammation associated with these conditions.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.970 Flunixin.

(a) **Specifications.** (1) Each 10-gram (g) packet of granules contains flunixin meglumine equivalent to 250 milligrams (mg) of flunixin.

(2) Each 30-g syringe of paste contains flunixin meglumine equivalent to 1,500 mg of flunixin.

(b) **Sponsors.** See sponsors in §510.600(c) of this chapter for use as in paragraph (c) of this section.

(1) No. 000061 for use of products described in paragraph (a).

(2) No. 061623 for use of the product described in paragraph (a)(2).

(c) **Conditions of use in horses—(1) Amount.** 0.5 mg per pound of body weight per day for up to 5 days.

(2) **Indications for use.** For alleviation of inflammation and pain associated with musculoskeletal disorders.

(3) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.980 Fluoxetine.

(a) **Specifications.** Each chewable tablet contains 8, 16, 32, or 64 milligrams (mg) fluoxetine hydrochloride.

(b) **Sponsor.** See No. 050929 in §510.600 of this chapter.

(c) **Conditions of use in dogs—(1) Amount—(1) Dogs: Administer orally from 0.0625 to 0.25 milligram per kilogram body weight once daily.

(2) **Indications for use.** For the treatment of canine separation anxiety in conjunction with a behavior modification plan.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.998 Fluralaner.

(a) **Specifications.** Each chewable tablet contains 112.5, 250, 500, 1000, or 1400 milligrams (mg) fluralaner.
§ 520.1010 Furosemide.

(a) Specifications. (1) Each tablet contains 12.5 or 50 milligrams (mg) furosemide.
(2) Each bolus contains 2 grams (g) furosemide.
(3) Each packet of powder contains 2 g furosemide.
(4) Each milliliter of syrup contains 10 mg furosemide.

(b) Sponsors. See Nos. 000061 and 054925 in § 510.600(c) of this chapter.

§ 520.1044 Gentamicin sulfate oral dosage forms.

§ 520.1044a Gentamicin sulfate oral solution.

(a) Specifications. Each milliliter of aqueous solution contains gentamicin sulfate equivalent to 50 milligrams of gentamicin.
Food and Drug Administration, HHS

§ 520.1044c

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use—(1) Amount. Colibacillosis: 1 milliliter per 2 gallons of drinking water for 3 consecutive days, to provide 0.5 milligram/pound/day; swine dysentery: 1 milliliter per 1 gallon of drinking water for 3 consecutive days, to provide 1.0 milligram/pound/day.

(2) Indications for use. In weanling swine for control and treatment of colibacillosis caused by strains of E. coli sensitive to gentamicin, and in swine for control and treatment of swine dysentery associated with Treponema hyodysenteriae.

(3) Limitations. For use in swine drinking water only. Do not store or offer medicated drinking water in rusty containers since the drug is quickly destroyed in such containers. Medicated drinking water should be prepared daily and be the sole source of drinking water for 3 consecutive days. Treatment may be repeated if dysentery recurs. Do not slaughter treated swine for food for at least 3 days following treatment.

§ 520.1044b Gentamicin sulfate pig pump oral solution.

(a) Specifications. Each milliliter of pig pump oral solution contains gentamicin sulfate equivalent to 4.35 milligrams of gentamicin.

(b) Sponsor. See Nos. 000061 and 000859 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use—(1) Amount. Administer 1.15 milliliters of pig pump oral solution (5 milligrams of gentamicin) orally per pig one time.

(2) Indications for use. In neonatal swine 1 to 3 days of age for control and treatment of colibacillosis caused by strains of E. coli sensitive to gentamicin.

(3) Limitations. For use in neonatal swine only. Do not slaughter treated swine for food for at least 14 days following treatment.

§ 520.1044c Gentamicin sulfate powder.

(a) Specifications. Each gram of powder contains gentamicin sulfate equivalent to:

(1) 16.7, 66.7, or 333.3 milligrams (mg) gentamicin.

(2) 333.3 mg gentamicin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section as follows:

(1) No. 000061 for products described in paragraph (a)(1) of this section.

(2) Nos. 057561 and 061623 for product described in paragraph (a)(2) of this section.

(c) Related tolerances. See §556.300 of this chapter.

(d) Conditions of use in swine—(1) Amount. Administer in drinking water for 3 consecutive days as follows:

(i) For colibacillosis: Gentamicin sulfate equivalent to 25 mg of gentamicin per gallon of drinking water to provide 0.5 mg per pound of body weight per day;

(ii) For swine dysentery: Gentamicin sulfate equivalent to 50 mg of gentamicin per gallon of drinking water to provide 1 mg per pound of body weight per day. Treatment may be repeated if dysentery recurs.

(2) Indications for use. For control and treatment of colibacillosis in weanling swine caused by strains of Escherichia coli sensitive to gentamicin, and for control and treatment of swine dysentery associated with Treponema hyodysenteriae.

(3) Limitations. For use in swine drinking water only. Do not store or offer medicated drinking water in rusty containers since the drug is quickly destroyed in such containers. Medicated drinking water should be prepared daily and be the sole source of drinking water.

(4) Withdrawal period. 10 days.

[77 FR 4226, Jan. 27, 2012]
§ 520.1060 Glucose and glycine.

(a) Specifications. Each packet of powder contains 8.82 grams sodium chloride, 4.20 grams potassium phosphate, 0.5 gram citric acid anhydrous, 0.12 gram potassium citrate, 6.36 grams aminoacetic acid (glycine), and 44.0 grams glucose.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in calves—

(1) Amount. Dissolve each packet in 2 quarts of warm water and administer to each calf as follows:

(i) Scouring and/or dehydrated calves. Feed 2 quarts of solution, twice daily for 2 days (four feedings). No milk or milk replacer should be fed during this period. For the next four feedings (days 3 and 4), use 1 quart of solution together with 1 quart of milk replacer. Thereafter, feed as normal.

(ii) Newly purchased calves. Feed 2 quarts of solution instead of milk as the first feed upon arrival. For the next scheduled feeding, use 1 quart of solution mixed together with 1 quart of milk or milk replacer. Thereafter, feed as normal.

(2) Indications for use. For control of dehydration associated with diarrhea (scours); and as an early treatment at the first signs of scouring. It may also be used as a followup treatment following intravenous fluid therapy.

(3) Limitations. The product should not be used in animals with severe dehydration (down, comatose, or in a state of shock). Such animals need intravenous therapy. A veterinarian should be consulted in severely scouring calves. The product is not nutritionally complete if administered by itself for long periods of time. It should not be administered beyond the recommended treatment period without the addition of milk or milk replacer.

[79 FR 28821, May 20, 2014]

§ 520.1100 Griseofulvin.

(a) Specifications—

(1) The powder complies with U.S.P. for griseofulvin, microsize.

(2) Each bolus contains 2.5 grams griseofulvin.

(3) Each tablet contains 125 or 500 milligrams griseofulvin.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter.

(1) No. 000061 for use of products described in paragraph (a) for use as in paragraph (d) of this section.

(2) No. 061623 for use of the powder described in paragraph (a)(1) for use as in paragraphs (d)(1)(i)(A) and (d)(1)(i) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—

(1) Horses—

(A) Amount and indications for use—For equine ringworm infection caused by Trichophyton equinum or Microsporum gypseum, administer soluble powder described in paragraph (a)(1) of this section daily as a drench or as a top dressing on feed for not less than 10 days as follows: adults, 2.5 grams; yearlings, 1.25 to 2.5 grams; and foals, 1.25 grams.

(B) For treating ringworm infection caused by T. equinum, administer boluses described in paragraph (a)(2) of this section daily for not less than 10 days as follows: adults, 1 bolus; yearlings, one-half to 1 bolus; and foals, one-half bolus.

(ii) Limitations. Do not use in horses intended for human consumption.

(2) Dogs and cats: (i) Amount. 125- and 500-milligram tablets administered orally as follows:

(A) Daily (single or divided) dose as follows: For animals weighing up to 6 pounds: 62.5 milligrams; for animals weighing 6 to 18 pounds: 125 milligrams; for animals weighing 18 to 36 pounds: 250 milligrams; for animals weighing 36 to 48 pounds: 375 milligrams; for animal weighing 48 to 75 pounds: 500 milligrams.

(B) Weekly (single) dose: If experience indicates that treatment is more effective for the drug given in large doses, administer at intervals of 7 to 10 days, a dose equal to 10 milligrams/pound of body weight × body weight × number of days between treatments. Dosage should be adjusted according to response. Administer additional dose after the animal is free of infection.

(ii) Indications for use. For treatment of fungal infections of the skin, hair, and claws caused by Trichophyton mentagrophytes, T. rubrum, T. schoenleini, T. sulphureum, T. verrucosum, T. interdigitale, Epidermophyton
floccosum, Microsporum gypseum, M. canis, M. audouini.

§ 520.1120 Haloxon oral dosage forms.

(a) Specifications. Each packet contains 141.5 grams haloxon.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Special considerations. Do not use any drug, insecticide, pesticide, or other chemical having cholinesterase-inhibiting activity either simultaneously or within a few days before or after treatment with haloxon.

(d) Related tolerances. See §556.310 of this chapter.

§ 520.1120b Haloxon boluses.

(a) Specifications. Each bolus contains 10.1 grams of haloxon.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

§ 520.1130 Hetacillin.

(a) Specifications. Each capsule or tablet contains hetacillin potassium equivalent to 50, 100, or 200 milligrams (mg) of ampicillin.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount—(i) Dogs. Administer 5 mg per pound (lb) of body weight orally, twice daily. In severe infections, administer 5 mg/lb three times daily, or up to 10 mg/lb twice daily. For staphylococcal urinary tract infections, administer up to 20 mg/lb twice daily.

(ii) Cats. Administer 50 mg twice daily.

(2) Indications for use. For the treatment of respiratory tract infections, urinary tract infections, gastrointestinal infections, skin infections, soft tissue infections, and postoperative infections associated with strains of organisms susceptible to hetacillin potassium.

(d) Conditions of use in cattle—(1) Amount. Administer one bolus per 500 pounds body weight (35 to 50 milligrams per kilogram of body weight). Retreat in 3 to 4 weeks.

(2) Indications for use. For control of gastrointestinal roundworms of the genera Haemonchus, Ostertagia, Trichostrongylus, and Cooperia.

(3) Limitations. Do not treat dairy animals of breeding age or older. Do not treat within 3 weeks of slaughter.

§ 520.1156 Imidacloprid.

(a) Specifications. Each chewable tablet contains 7.5 or 37.5 milligrams (mg) imidacloprid.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.
§ 520.1157 Iodinated casein.

(a) Specifications. Each 1-gram tablet contains 25 milligrams of iodinated casein.

(b) Sponsor. See No. 017762 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. ¼ to 1 tablet per 10 pounds of body weight (equivalent to 0.5 to 2.5 milligrams of iodinated casein per pound of body weight).

(2) Indications for use. For dogs for apparent decreased thyroid activity where the signs are alopecia, scaliness of the skin surface, loss of hair, seborrhea, thickening of the skin, hyperpigmentation, and lethargy.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1158 Iodochlorhydroxyquin.

(a) Specifications. Each bolus contains 10 grams of iodochlorhydroxyquin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 1 bolus (10 grams) daily for a 1,000-pound horse.

(2) Indications for use. For treatment of equine diarrhea.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1182 Iron dextran suspension.

(a) Specifications. Each milliliter (mL) of suspension contains 55.56 milligrams (mg) iron as ferric hydroxide in complex with a low molecular weight dextran.

(b) Sponsor. See No. 051311 in §510.600(c) of this chapter.

(c) Conditions of use in swine—(1) Amount. Administer 100 mg (1.8 mL) orally by automatic dose dispenser.

(2) Indications for use. For the prevention of iron deficiency anemia in baby pigs.

(3) Limitations. Treat each pig within 24 hours of farrowing.

[70 FR 32489, June 3, 2005]

§ 520.1192 Ivermectin paste.

(a) Specifications. Each milligram (mg) of paste contains 0.0187 mg (1.87 percent) or 0.00153 mg (0.153 percent) of ivermectin.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (e) of this section:

(1) No. 050604 for use of a 1.87 percent paste as in (e)(1) of this section and a 0.153 percent paste for use as in paragraph (e)(2) of this section.

(2) Nos. 000859, 051311, 054925, and 061623 for use of a 1.87 percent paste for use as in paragraph (e)(1) of this section.

(c) Related tolerances. See § 556.344 of this chapter.

(d) Special considerations. See § 500.25 of this chapter.

(e) Conditions of use—(1) Horses—(i) Amount. 200 micrograms per kilogram (91 micrograms per pound) of body weight.

(ii) Indications for use. For treatment and control of Large Strongyles (adults): Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp. including T. brevicauda and T. serratus, and Craterostomum acuticaudatum; Small Strongyles (adults, including those resistant to some benzimidazole class compounds): Coronocyclus spp. including C. coronatus, C. labiatus, and C. labratus, Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus, and C.
§ 520.1193 Ivermectin tablets and chewables.

(a) Specifications. (1) Each tablet or chewable contains 68, 136, or 272 micrograms (mcg) ivermectin.

(2) Each chewable contains 55 or 165 mcg ivermectin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 050604 for use of tablets or chewables described in paragraph (a)(1) as in paragraph (d)(1) and chewables described in paragraph (a)(2) as in paragraph (d)(2) of this section.

(2) Nos. 065111 and 069043 for use of tablets described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs. For use in dogs 6 weeks of age and older as follows:

(i) Amount. 6.0 mcg per kilogram (kg) of body weight (2.72 mcg per pound (lb)), minimum. Up to 25 lb, 68 mcg; 26 to 50 lb, 136 mcg; 51 to 100 lb, 272 mcg; over 100 lb, a combination of the appropriate tablets. Administer at monthly dosing intervals.

(ii) Indications for use. To prevent canine heartworm disease by eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) for 1 month (30 days) after infection.

(2) Cats. For use in cats 6 weeks of age and older as follows:

(i) Amount. Up to 2.3 kilograms (up to 5 lb), 55 mcg; 2.3 to 6.8 kilograms (5 to 15 lb), 165 mcg; over 6.8 kilograms (15 lb), a combination of the appropriate chewables (recommended minimum dose of 24 mcg/kg of body weight (10.9 mcg/lb)). Administer once a month.

(ii) Indications for use. To prevent feline heartworm disease by eliminating the tissue stage of heartworm larvae Dirofilaria immitis for a month (30 days) after infection, and for removal and control of adult and immature (L4) hookworms Ancylostoma tubaeforme and A. braziliense.
§ 520.1194 Ivermectin meal.

(a) Specifications. Each gram of meal contains 6 milligrams ivermectin (0.6 percent).

(b) Sponsor. See No. 017135 in §510.600(c) of this chapter.

(c) Special considerations. See §500.25 of this chapter.

(d) Conditions of use in horses—(1) Amount. Administer 136 micrograms (mcg) ivermectin per pound (lb) body weight (300 mcg/kilogram) as a single dose on approximately 2 lb grain or sweet feed.

(2) Indications for use. For treatment and control of Large Strongyles (adults): Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp. including T. brevicauda and T. serratus, and Craterostomum acuticaudatum: Small Strongyles (adults, including those resistant to some benzimidazole class compounds): Coronocyclus spp. including C. coronatus, C. labiatus, and C. labratus, Cyathostomum spp. including C. catinatum and C. pateratum, Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus spp., Cylicostephanus spp. including C. calicatus, C. goldi, C. longibursatus, and C. minutus, and Petrovinema poculatum; Blood Vessels Worms (adults, including those resistant to some benzimidazole class compounds): Coronocyclus spp. including C. catinatum and C. pateratum; Small Strongyles (fourth-stage larvae); Pinworms (adults and fourth stage larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus axei; Large Mouth Stomach Worms (adults): Habronema muscae; Bots (oral and gastric stages): Gasterophilus spp. including G. intestinalis and G. nasalis; Lungworms (adults and fourth stage larvae): Dictyocaulus arnfieldi; Intestinal Threadworms (adults): Strongyloids westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca sp.

Limitations. Do not use in horses intended for human consumption.

[70 FR 1817, Jan. 11, 2005, as amended at 70 FR 19262, Apr. 13, 2005]

§ 520.1195 Ivermectin liquid.

(a) Specifications—(1) Each milliliter (mL) contains 10 milligrams (mg) ivermectin.

(2) Each mL of micellar solution contains 0.8 mg ivermectin.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter.

(1) Nos. 050604, 058829, 054925, and 068005 for use of product described in paragraph (a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) of this section.

(2) No. 058829 for use of product described in paragraph (a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(ii)(B), and (e)(1)(iii) of this section.

(3) Nos. 050604 and 058829 for use of product described in paragraph (a)(2) of this section as in paragraph (e)(2) of this section.

(c) Related tolerances. See §556.344 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use—(1) Horses—(i) Amount. 200 micrograms (mcg) per kilogram (kg) of body weight as a single dose by stomach tube or as an oral drench.

(ii) Indications for use. For treatment and control of:

(A) Large Strongyles (adults): Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp. including T. brevicauda and T. serratus, and Craterostomum acuticaudatum: Small Strongyles (adults, including those resistant to some benzimidazole class compounds): Coronocyclus spp. including C. coronatus, C. labiatus, and C. labratus, Cyathostomum spp. including C. catinatum and C. pateratum, Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus spp., Cylicostephanus spp. including C. calicatus, C. goldi, C. longibursatus, and C. minutus, and Petrovinema poculatum; Blood Vessels Worms (adults, including those resistant to some benzimidazole class compounds): Coronocyclus spp. including C. catinatum and C. pateratum; Small Strongyles (fourth-stage larvae); Pinworms (adults and fourth stage larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus axei; Large Mouth Stomach Worms (adults): Habronema muscae; Bots (oral and gastric stages):
Food and Drug Administration, HHS

§ 520.1197

Gasterophilus spp. including G. intestinalis and G. nasalis; Lungworms (adults and fourth-stage larvae); Dictyocaulus arnfieldi; Intestinal Threadworms (adults), Strongyloides westeri; Summer Sores caused by Habronema and Drasia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca sp.

(B) Large Strongyles (Strongylus equinus (adult), S. vulgaris (adult and arterial larval stages), S. endentatus (adult and migrating tissue stages), Triodontophorus spp. (adult)); Small Strongyles including those resistant to some benzimidazole class compounds (Clyathostomum spp. (adult and fourth-stage larvae), Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp.); Pinworms (Oxyuris equi (adult and fourth-stage larvae)); Ascarids (Parasarcis equorum (adult and third- and fourth-stage larvae)); Ascariids (Parasarcis equorum (adult and third- and fourth-stage larvae)); Hairworms (Trichostongylus axei (adult)); Large mouth Stomach Worms (Habronema muscae (adult)); Stomach Bots (Gastrophilus spp. (oral and gastric stages)); Lungworms (Dictyocaulus arnfieldi (adult and fourth-stage larvae)); intestinal threadworms (Strongyloides westeri (adult)); Summer Sores caused by Habronema and Drasia spp. cutaneous third-stage larvae; and Dermatitis caused by neck threadworm microfilariae (Onchocerca spp.).

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Sheep—(i) Amount. 200 mcg/kg (3 mL/26 pounds) of body weight as a single dose oral drench.

(ii) Indications for use. For treatment and control of the adult and fourth-stage larvae of gastrointestinal roundworms (Haemonchus contortus, H. placei (adults only), Ostertagia circumcincta, Trichostrongylus axei, T. colubriformis, Cooperia oncophora (adults only), C. curticei, Oesophagostomum columbianum, O. venulosum (adults only), Nematodirus battus, N. spathiger, S. papillosus (adults only), Chabertia ovina (adult only), Trichuris ovis (adults only)); lungworms (D. filaria); and all larval stages of the nasal bot Oestrus ovis.

(3) [Reserved]

§ 520.1196 Ivermectin and pyrantel tablets.

(a) Specifications. Each chewable tablet contains either 68 micrograms (μg) of ivermectin and 57 milligrams (mg) of pyrantel (as pamoate salt), or 136 μg and 114 mg, or 272 μg and 227 mg, respectively.

(b) Sponsors. See Nos. 050604, 051311, and 063604 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Administer a minimum of 6 μg of ivermectin and 5 mg of pyrantel per kilogram (2.72 μg and 2.27 mg per pound) of body weight monthly.

(ii) Indications for use. To prevent canine heartworm disease by eliminating the tissue larval stages of Dirofilaria immitis for up to a month (30 days) after infection and treatment and control of adult ascarids Toxocara canis and Toxascaris leonina, and adult hookworms Ankylostoma caninum, A. braziliense, and Uncinaria stenocephala.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

§ 520.1197 Ivermectin sustained-release bolus.

(a) Specifications. Each sustained-release bolus contains 1.72 grams of ivermectin.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.344 of this chapter.

(d) Conditions of use in ruminating calves—(1) Amount. Administer one bolus per calf weighing at least 275 pounds (lb) (125 kilograms (kg)) and not...
more than 660 lb (300 kg) on the day of administration.

(2) Indications. For treatment and control, throughout the grazing season (approximately 130 days), of gastrointestinal roundworms *Haemonchus placei*, *Ostertagia ostertagi* (including inhibited fourth-stage larvae), *Trichostrongylus axei*, *T. colubriformis*, *Cooperia spp.*, *Nematodirus helvetianus*, *Bunostomum phlebotomum*, *Oesophagostomum radiatum*; lungworms *Dictyocaulus viviparus*; grubs *Hypoderma spp.*; sucking lice *Linognathus vituli*, *Solenopotes capillatus*; mange mites *Psoroptes ovis*, *Sarcoptes scabiei*, and ticks *Amblyomma americanum*.

(3) Limitations. The bolus was specifically designed for use in cattle; do not use in other animal species. Calves must be ruminating and older than 12 weeks of age. Do not administer to calves weighing less than 275 lb (125 kg). Do not administer a damaged bolus. Because a milk withdrawal time has not been established, do not use in female dairy cattle of breeding age. Do not slaughter cattle within 180 days of treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1198 Ivermectin and praziquantel paste.

(a) Specifications. Each milligram (mg) of paste contains:

(1) 0.0155 mg (1.55 percent) ivermectin and 0.0775 mg (7.75 percent) praziquantel.

(2) 0.0187 mg (1.87 percent) ivermectin and 0.1403 mg (14.03 percent) praziquantel.

(3) 0.0187 mg (1.87 percent) ivermectin and 0.2338 mg (23.38 percent) praziquantel.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) No. 050604 for use of products described in paragraph (a)(3) of this section as in paragraphs (d)(1)(ii), (d)(2)(iii) and (d)(3) of this section.

(2) No. 051311 for use of product described in paragraph (a)(2) of this section as in paragraphs (d)(1)(ii), (d)(2)(ii), and (d)(3) of this section.

(3) No. 050604 for use of products described in paragraph (a)(3) of this section as in paragraphs (d)(1)(ii), (d)(2)(iii) and (d)(3) of this section.

(c) Special considerations. See § 500.25 of this chapter.

(d) Conditions of use in horses—(1) Amount—(i) 200 micrograms (mcg) per kilogram (/kg) ivermectin (91 mcg per pound (/lb)) and 1 mg/kg praziquantel (454 mcg/lb) body weight.

(ii) 200 mcg/kg ivermectin (91 mcg/lb) and 1.5 mg/kg praziquantel (681 mcg/lb) body weight.

(iii) 200 mcg/kg ivermectin (91 mcg/lb) and 2.5 mg/kg praziquantel (1.14 mg/lb).

(2) Indications for use—(i) For treatment and control of the following parasites: Tapeworms—*Anoplocephala perfoliata*; Large Strongyles (adults)—*Strongylus vulgaris* (also early forms in blood vessels), *S. edentatus* (also tissue stages), *S. equinus*, *Triodontophorus* spp. including *T. brevicauda* and *T. serrata*, and *Craterostomum acuticaudatum*; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Coronocyclus spp. including *C. coronatus*, *C. labratus*, and *C. latratus*; *Cystodotomum* spp. including *C. catinatum* and *C. pateratum*; *Cyclocoelum* spp. including *C. insignis*, *C. leptostomum*, *C. nassatus*, and *C. brevicaudatus*; *Cyclocoelidophorus* spp.; *Cyclicostephanus* spp. including *C. calicatus*, *C. goldi*, *C. longibursatus*, and *C. minutus*, and *Petrovinema poculatum*; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—*Oxyuris equi*; *Ascarids* (adults and third- and fourth-stage larvae)—*Parascaris equorum*; Hairworms (adults)—*Trichostrongylus axei*; Large-mouth Stomach Worms (adults)—*Habronema muscae*; Bots (oral and gastric stages)—*Gasterophilus* spp. including *G. intestinalis* and *G. nasalis*; Lungworms (adults and fourth-stage larvae)—*Dictyocaulus arnfieldi*; Intestinal *Threadworms* (adults)—*Strongyloides westeri*; Summer Sores caused by *Habronema* and *Draschia* spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of *Onchocerca sp.*

(ii) For treatment and control of the following parasites: Tapeworms—*Anoplocephala perfoliata*; Large Strongyles (adults)—*Strongylus vulgaris*
(also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp. (iii) For treatment and control of the following parasites in horses over 5 months of age: Tapeworms—Anoplocephala perfoliata; Large Strongyles (adults)—Strongylus vulgaris (also early forms in blood vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus spp.; Small Strongyles (adults, including those resistant to some benzimidazole class compounds)—Cyathostomum spp.; Cyllicocyclus spp.; Cylcogonophorus spp.; Small Strongyles—fourth-stage larvae; Pinworms (adults and fourth-stage larvae)—Oxyuris equi; Ascarids (adults and third- and fourth-stage larvae)—Parascaris equorum; Hairworms (adults)—Trichostrongylus axei; Large-mouth Stomach Worms (adults)—Habronema muscae; Bots (oral and gastric stages)—Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)—Dictyocaulus arnfieldi; Intestinal Threadworms (adults)—Strongyloides westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage larvae; Dermatitis caused by neck threadworm microfilariae of Onchocerca sp.
§ 520.1200  Ivermectin, fenbendazole, and praziquantel tablets.

(a) Specifications. Each chewable tablet contains either:

(1) 68 micrograms (μg) ivermectin, 1.134 grams fenbendazole, and 57 milligrams (mg) praziquantel; or

(2) 27 μg ivermectin, 454 mg fenbendazole, and 23 mg praziquantel.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount. Administer tablets to provide 6 μg per kilogram (kg) ivermectin, 100 mg/kg fenbendazole, and 5 mg/kg praziquantel.

(2) Indications for use. For the treatment and control of adult Toxocara canis (roundworm), Ancylostoma caninum (hookworm), Trichuris vulpis (whipworm), and Dipylidium caninum (tapeworm), and for the prevention of heartworm disease caused by Dirofilaria immitis in adult dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1204  Kanamycin, bismuth subcarbonate, activated attapulgite.

(a) Specifications. Each package of powder contains 9.075, 11.7, 18.15, 46.8, 362.7, or 544.5 grams (g) levamisole hydrochloride.

(b) Sponsors. See sponsors in § 510.600(c) for use as follows:

(1) No. 000061 for use of 46.8- and 544.5-g packages as in paragraph (e)(1)(i), (e)(1)(ii)(B), and (e)(1)(iii) of this section; for 11.7-, 46.8-, and 544.5-g packages as in paragraph (e)(2)(i), (e)(2)(ii)(B), and (e)(2)(iii) of this section; and for an 18.15-g package as in paragraph (e)(3) of this section.

(2) No. 054771 for use of a 46.8-g package as in paragraph (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) of this section; for 11.7- and 46.8-g packages as in paragraph (e)(2)(i), (e)(2)(ii)(A), and (e)(2)(iii) of this section; and for use of an 18.15-g package as in paragraph (e)(3) of this section.

(3) No. 057561 for use of 46.8- and 544.5-g packages as in paragraphs (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) and (e)(2)(i), (e)(2)(ii)(A), and (e)(2)(iii) of this section; for 9.075- and 18.15-g packages as in paragraph (e)(3) of this section.

(4) No. 059130 for use of 46.8-, 362.7-, and 544.5-g packages as in paragraphs (e)(1)(i), (e)(1)(ii)(B), (e)(1)(iii), (e)(2)(i), (e)(2)(ii)(B), and (e)(2)(iii) of this section; and for use of an 18.15-g package as in paragraph (e)(3) of this section.

(c) Related tolerances. See § 556.350 of this chapter.

(d) Special considerations. See § 500.25 of this chapter.

(e) Conditions of use. It is used as an anthelmintic as follows:

(1) Cattle—(i) Amount. 8 milligrams per kilogram (mg/kg) body weight as a drench.
(ii) Indications for use—(A) Effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia); intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum); and lungworms (Dictyocaulus).

(B) Effective against the following adult nematode infections: Stomach worms (Haemonchus placei, Ostertagia ostertagi, Trichostrongylus axei); intestinal worms (T. longispicularis, Cooperia oncophora, C. punctata, Nematodirus spathiger, Bunostomum phlebotomum, Oesophagostomum radiatum); and lungworms (Dictyocaulus viviparous).

(iii) Limitations. Do not slaughter for food within 48 hours of treatment. Not for use in dairy animals of breeding age. Conditions of constant helminth exposure may require retreatment 2 to 4 weeks after the first treatment. Consult your veterinarian before using in severely debilitated animals. 

(2) Sheep—(i) Amount. 8 mg/kg body weight as a drench.

(ii) Indications for use—(A) Effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia); intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia); and lungworms (Dictyocaulus).

(B) Effective against the following adult nematode infections: Stomach worms (Haemonchus contortus, Trichostrongylus axei, Teladorsagia circumcincta); intestinal worms (Trichostrongylus colubriformis, Cooperia curticei, Nematodirus spathiger, Bunostomum trigonocephalum, Oesophagostomum columbognum, Chabertia ovina), and lungworms (Dictyocaulus). 

(iii) Limitations. Do not slaughter for food within 72 hours of treatment. Conditions of constant helminth exposure may require retreatment 2 to 4 weeks after the first treatment. Consult veterinarian before using in severely debilitated animals.

(3) Swine—(i) Amount. 8 mg/kg body weight in drinking water.

(ii) Indications for use—Effective against the following nematode infections: Large roundworms (Ascaris suum), nodular worms (Oesophagostomum spp.), intestinal thread worms (Strongyloides ransomi) and lungworms (Metastrongylus spp.).

(iii) Limitations. Do not administer within 72 hours of slaughter for food. Pigs maintained under conditions of constant exposure to worms may require retreatment within 4 to 5 weeks after the first treatment. Consult your veterinarian before administering to sick swine.


§ 520.1242b Levamisol boluses or oblets.

(a) Specifications. Each bolus contains 2.19 grams levamisol hydrochloride. Each oblet contains 0.184 grams levamisol hydrochloride.

(b) Sponsors. See Nos. 000061 and 054771 in §510.600(c) of this chapter.

(c) Required labeling. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(d) Related tolerances. See §556.350 of this chapter.

(e) Conditions of use.—(1) Cattle—(i) Amount. Administer orally 2.19-gram boluses as a single dose as follows: 250 to 450 pounds, ½ bolus; 450 to 750 pounds, 1 bolus; and 750 to 1,050 pounds, 1½ boluses.

(ii) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms (Dictyocaulus).

(iii) Limitations. Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment. Do not slaughter for food within 48 hours of treatment. Not for use in dairy animals of breeding age. Consult veterinarian before using in severely debilitated animals.

(2) Sheep—(i) Amount. Administer orally one 0.184-gram oblet for each 50 pounds of body weight.

(ii) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms...
§ 520.1242c Levamisole and piperazine.

(a) Specifications. (1) Each ounce of solution contains 0.36 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 3.98 grams of piperazine base.

(2) A soluble powder which when constituted with water contains in each fluid ounce 0.45 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 5.0 grams of piperazine base.

(b) Sponsor. See No. 047711 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Aqueous solution: administer by stomach tube or drench 1 fluid ounce per 100 pounds of body weight. Reconstituted soluble powder: administer by stomach tube 1 fluid ounce per 125 pounds of body weight. If reinfestation occurs, re-treat animals at 6- to 8-week intervals.

(2) Indications for use. An anthelmintic effective against infections of large strongyles (Strongylus vulgaris, S. edentatus), small strongyles (Cylicocercus spp., Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp.), ascarids (Parascaris equorum), and pinworms (Ozyurus equi).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1242e Levamisole hydrochloride effervescent tablets.

(a) Specifications. Each tablet contains 907 milligrams of levamisole hydrochloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.350 of this chapter.

§ 520.1242d Levamisole resinate.

(a) Specifications. The drug is levamisole adsorbed on a resin, in a concentration equivalent to 10 percent levamisole hydrochloride. Each 2.05-ounce (58.1 gram) packet contains levamisole equivalent to 5.806 grams of levamisole hydrochloride.

(b) Sponsor. See No. 047781 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.350 of this chapter.

§ 520.1242c Limitations. Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment. Do not slaughter for food within 72 hours of treatment. Consult a veterinarian before using in severely debilitated animals.

[78 FR 28822, May 20, 2014]
(d) Conditions of use. It is used for swine as follows:
(1) Amount. The equivalent of 8 milligrams of levamisole hydrochloride per kilogram of body weight, as a single dose.
(2) Indications for use. See §520.1242g(f)(11).
(3) Limitations. Withholding water from pigs before treatment is not necessary. Add one tablet for each 2 1/2 gallons of water; mix thoroughly. Allow 1 gallon of medicated water for each 100 pounds body weight of pigs to be treated. No other source of water should be offered. After pigs have consumed medicated water, resume use of regular water. Pigs maintained under conditions of constant worm exposure may require re-treatment within 4 to 5 weeks. Consult your veterinarian before administering to sick swine. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Do not administer within 72 hours of slaughter for food.


§520.1242f Levamisol gel.

(a) Specifications. Each gram of gel contains 115 milligrams (11.5 percent) levamisol hydrochloride.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.350 of this chapter.
(d) Conditions of use—(1) Cattle—(i) Amount. Eight milligrams of levamisol hydrochloride per kilogram of body weight, as a single oral dose.
(2) Indications for use. Anthelmintic effective against the following nematode infections: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms (Dictyocaulus).
(3) Limitations. Conditions of constant helminth exposure may require re-treatment within 2 to 4 weeks after the first treatment; do not administer to cattle within 6 days of slaughter for food; do not administer to dairy animals of breeding age; consult veterinarian before using in severely debilitated animals.


§520.1242g Levamisole resinate and famphur paste.

(a) Specifications. The drug is a paste containing 11.6 percent levamisole resinate (50 percent potency) and 23.6 percent famphur.
(b) Sponsor. See 000061 in §510.600(c) of this chapter.
(c) Special considerations. Do not use any cholinesterase-inhibiting drugs, pesticides, insecticides, or chemicals on cattle simultaneously or within a few days before or after treatment with this product.
(d) Related tolerances. See §§556.273 and 556.350 of this chapter.
(e) Conditions of use in cattle—(1) Amount. 8 milligrams of levamisole hydrochloride (equivalent) and 30 milligrams of famphur activity per kilogram of body weight.
(2) Indications for use. For treatment of cattle infected with the following parasites: Stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum), lungworms (Dictyocaulus), cattle grubs (Hypoderma), biting lice (Bovicola), and sucking lice (Linognathus, Solenoptes).
§ 520.1263 Lincomycin.

§ 520.1263a Lincomycin tablets and syrup.

(a) Specifications. (1) Each ounce of syrup contains lincomycin hydrochloride equivalent to either 25 or 50 milligrams (mg) lincomycin.

(2) Each tablet contains lincomycin hydrochloride equivalent to either 25 or 50 mg lincomycin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. Administer orally 10 mg per pound of body weight every 12 hours, or 7 mg per pound of body weight every 8 hours, for up to 12 days.

(2) Indications for use. For infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1263b [Reserved]

§ 520.1263c Lincomycin powder.

(a) Specifications. Each gram of soluble powder contains lincomycin hydrochloride equivalent to 0.4 grams of lincomycin.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraphs (d)(1) and (d)(2) of this section.

(1) No. 054771 for use as in paragraph (d) of this section.

(2) Nos. 054771, 054925, 061623, and 076475 for use as in paragraphs (d)(1) and (d)(2) of this section.

(c) Tolerances. See § 516.306 of this chapter.

(d) Conditions of use—(1) Swine—(i) Amount. 250 milligrams per gallon of drinking water to provide 3.8 milligrams per pound of body weight per day.

(ii) Indications for use. For the treatment of swine dysentery (bloody scours).

(iii) Limitations. Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Do not use for more than 10 days. If clinical signs of disease have not improved within 6 days, discontinue treatment and reevaluate diagnosis.

The safety of lincomycin has not been demonstrated in pregnant swine or swine intended for breeding. For No. 051259: Do not slaughter swine for 6 days following last treatment.

(2) Chickens—(i) Amount. 64 milligrams per gallon of drinking water.

(ii) Indications for use. For the control of necrotic enteritis caused by Clostridium perfringens susceptible to lincomycin in broiler chickens.

(iii) Limitations. Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Administer for 7 consecutive days. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to water containing lincomycin. Not for use in layer and breeder chickens.

(3) Honey bees—(i) Amount. Mix 100 milligrams lincomycin with 20 grams confectioners’/powdered sugar and dust over the top bars of the brood chamber once weekly for 3 weeks.

(ii) Indications for use. For the control of American foulbrood (Paenibacillus larvae).

(iii) Limitations. The drug should be fed early in the spring or late in the fall and consumed by the bees before the main honey flow begins to avoid contamination of production honey.
§ 520.1265 Lincosycin and spectinomycin powder.

(a) Specifications. The following salts of lincosycin and spectinomycin are present in a soluble powder in the ratio of 1 to 2 on the basis of equivalency of lincosycin base to equivalency of spectinomycin base:

1. Lincomycin hydrochloride monohydrate and spectinomycin sulfate tetrahydrate.
2. Lincomycin hydrochloride monohydrate and spectinomycin dihydrochloride pentahydrate.

(b) Sponsors. See sponsors in §510.600(c) of this chapter.

(c) Tolerances. See §§556.360 and 556.600 of this chapter.

(d) Conditions of use in chickens—(1) Amount. 2 grams of antibiotic activity per gallon of drinking water; administer as the sole source of water for the first 5 to 7 days of life.

(2) Indications for use. As an aid in the control of airsacculitis caused by either Mycoplasma synoviae or M. gallisepticum susceptible to lincosycin-spectinomycin and complicated chronic respiratory disease (air sac infection) caused by Escherichia coli and M. gallisepticum susceptible to lincosycin-spectinomycin.

§ 520.1284 Liothyronine.

(a) Specifications. Each tablet contains 60 or 120 micrograms (μg) liothyronine as the sodium salt.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally to dogs at levels up to 12.8 μg per kilogram (kg) of body weight per day. Dosage should be adjusted according to the severity of the condition and the response of the patient. Dosage at the total replacement level (12.8 μg/kg of body weight) should be considered for initiating therapy and then titrated downward for optimum maintenance effect. Twice daily administration is recommended.

(2) Indications for use. For treatment of hypothyroidism in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1288 Lufenuron tablets.

(a) Specifications—(1) Tablets containing 45, 90, 204.9, or 409.8 milligrams (mg) lufenuron for use as in paragraphs (c)(1)(i), (c)(1)(ii)(A), (c)(1)(iii), (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of this section.

(2) Flavored tablets containing 45, 90, 204.9, or 409.8 milligrams (mg) lufenuron for use as in paragraphs (c)(1)(i), (c)(1)(ii)(A) or (c)(1)(ii)(B), and (c)(1)(iii) of this section.

(3) Flavored tablets containing 90 or 204.9 mg lufenuron for use as in paragraphs (c)(2)(i), (c)(2)(ii)(A) or (c)(2)(ii)(B), and (c)(2)(iii) of this section.

(4) Flavored tablets containing 135 or 270 mg lufenuron for use as in paragraphs (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of this section.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Minimum of 10 mg lufenuron per kilogram (4.5 mg per pound [lb]) of body weight, once a month.

(II) Indications for use—(A) For the prevention and control of flea populations.
(B) The concurrent use of flavored lufenuron tablets described in paragraph (a)(2) of this section as in paragraph (c)(1)(ii)(A) of this section with nitenzpyram tablets as in §520.1510(d)(1) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

(iii) Limitations. For use in dogs and puppies 4 weeks of age and older.

(2) Cats—(1) Amount. Minimum of 30 mg lufenuron per kilogram (13.6 mg/lb) of body weight, once a month.

(ii) Indications for use—(A) For the control of flea populations.

(B) The concurrent use of flavored lufenuron tablets described in paragraph (a)(3) of this section as in paragraph (c)(2)(ii)(A) of this section with nitenzpyram tablets as in §520.1510(d)(2) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

(iii) Limitations. For use in cats and kittens 4 weeks of age and older.

§ 520.1289 Lufenuron suspension.

(a) Specifications. Each individual dose pack contains either 135 or 270 milligrams of lufenuron.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Indications for use and amount. (A) For prevention of acute vomiting in dogs 2 to 7 months of age, administer a minimum dose of 2.0 mg per kilogram (4.4 mg/lb) of body weight once daily for up to 5 consecutive days.

(B) For prevention of acute vomiting in dogs 7 months of age and older, administer a minimum dose of 2.0 mg/kg body weight once daily until resolution of acute vomiting.

(C) For prevention of vomiting due to motion sickness in dogs 4 months of age and older, administer a minimum dose of 2.0 mg/kg body weight once daily for up to 2 consecutive days.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.


§ 520.1310 Marbofloxacin.

(a) Specifications. Each tablet contains 25, 50, 100, or 200 milligrams (mg) marbofloxacin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 1.25 mg per pound (lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

(2) Indications for use. For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

[64 FR 46369, Sept. 5, 2001; 78 FR 28823, May 20, 2014]

§ 520.1315 Maropitant.

(a) Specifications. Each tablet contains 16, 24, 60, or 160 milligrams (mg) maropitant as maropitant citrate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Indications for use and amount. (i) For prevention of acute vomiting in dogs 2 to 7 months of age, administer a minimum dose of 2.0 mg per kilogram (4.4 mg/lb) of body weight once daily for up to 5 consecutive days.

(ii) For prevention of acute vomiting in dogs 7 months of age and older, administer a minimum dose of 2.0 mg/kg body weight once daily until resolution of acute vomiting.

(iii) For prevention of vomiting due to motion sickness in dogs 4 months of age and older, administer a minimum dose of 2.0 mg/kg body weight once daily for up to 2 consecutive days.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1320 Mebendazole.

(a) Specifications. (1) Each gram of powder contains either 40 or 166.7 milligrams of mebendazole.
Food and Drug Administration, HHS

§ 520.1330

(2) Each gram of paste contains 200 milligrams of mebendazole.
(3) Each milliliter of suspension contains 33.3 milligrams of mebendazole.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Horses—(i) Amount. 1 gram of mebendazole per 250 pounds of body weight per dose, as an oral powder, paste or suspension.
(ii) Indications for use. For treatment of infections caused by large roundworms (Parascaris equorum); large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles; and mature and immature (4th larval stage) pinworms (Oxyuris equi).
(iii) Limitations. The drug is compatible with carbon disulfide. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Dogs—(i) Amount. Administer 100 milligrams of mebendazole per 10 pounds of body weight, once daily for 3 days, as an oral powder by mixing with a small quantity of food, preferably before the regular meal.
(ii) Indications for use. The drug is used for treatment of infections of roundworms (Toxocara canis), hookworms (Ancylostoma caninum, Uncinaria stenocephala), whipworms (Trichuris vulpis), and tapeworms (Taenia pisiformis).
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1330b Mebendazole and trichlorfon paste.

(a) Specifications. Each gram of paste contains 100 milligrams of mebendazole and 454 milligrams of trichlorfon.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. 8.8 milligrams of mebendazole and 40 milligrams of trichlorfon per kilogram of body weight.
(2) Indications for use. It is used in horses for treatment of infections of bots (Gastrophilus intestinalis and G. nasalis), large roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small strongyles, and pinworms (Oxyuris equi).
(3) Limitations. Do not administer more than once every 30 days. Do not treat sick or debilitated animals, foals under 4 months of age, or mares in the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not administer simultaneously or within a few days before or after treatment with, or exposure to, cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not administer intravenous anesthetics, especially muscle relaxants, concurrently. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1330 Meclofenamic acid granules.

(a) Specifications. Each gram of granules contains 5 milligrams (5 percent) meclofenamic acid.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 1 milligram per pound of body weight (1 gram per 1000 pounds) once daily for 5 to 7 days by addition to the daily grain ration.

(2) Indications for use. For the treatment of acute or chronic inflammatory diseases involving the musculoskeletal system.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1331 Meclofenamic acid tablets.

(a) Specifications. Each tablet contains either 10 or 20 milligrams of meclofenamic acid.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 1.1 milligrams per kilogram (0.5 milligram per pound) daily for 5 to 7 days.

(2) Indications for use. For the relief of signs and symptoms of chronic inflammatory disease involving the musculoskeletal system.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1341 Megestrol.

(a) Specifications. Each tablet contains 5 or 20 milligrams of megestrol acetate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally, intact, or crushed and mixed with food as follows:

(i) For the postponement of estrus by proestrus treatment: 1 milligram per pound of body weight per day for 8 days.

(ii) For the postponement of estrus by anestrus treatment: 0.25 milligram per pound of body weight per day for 32 days.

(iii) For alleviation of false pregnancy: 1 milligram per pound of body weight per day for 8 days.

(2) Indications for use. For the postponement of estrus and the alleviation of false pregnancy in female dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1367 Meloxicam.

(a) Specifications—(1) Each milliliter of suspension contains 0.5 milligrams (mg) meloxicam.

(2) Each milliliter of suspension contains 1.5 mg meloxicam.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (c) of this section:

(1) No. 000010 for use of the products described in paragraph (a) of this section; and

(2) Nos. 013744 and 055529 for use of the product described in paragraph (a)(2) of this section.

(c) Conditions of use in dogs—(1) Amount. Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatment after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.

(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1372 Methimazole.

(a) Specifications. Each tablet contains 2.5 or 5 milligrams (mg) methimazole.

(b) Sponsor. See No. 043264 in §510.600 of this chapter.

(c) Conditions of use in cats—(1) Amount. The starting dose is 2.5 mg every 12 hours. Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 levels and clinical response.

(2) Indications for use. For the treatment of hyperthyroidism.
§ 520.1380 Methocarbamol.

(a) Specifications. Each tablet contains 500 milligrams (mg) of methocarbamol.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. Administer 60 mg per pound of body weight in two or three equally divided doses, followed each following day by 30 to 60 mg per pound of body weight, usually not to exceed 14 to 21 days.

(2) Indications for use. As an adjunct to therapy for acute inflammatory and traumatic conditions of the skeletal muscles in order to reduce muscular spasms.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[78 FR 28824, May 20, 2014]

§ 520.1408 Methylprednisolone.

(a) Specifications. Each tablet contains 1, 2, or 4 milligrams (mg) of methylprednisolone.

(b) Sponsors. See No. 054628 for use of 1- and 2-mg tablets.

(2) Conditions of use in dogs and cats—

(1) Amount. Under 15 pounds, 1⁄4 to 1 tablet daily; 15 to 40 pounds, 1 to 2 tablets daily; 40 pounds and over, 2 tablets daily. Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved.

(2) Indications for use. As an anti-inflammatory and analgesic agent.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1409 Methylprednisolone and aspirin.

(a) Specifications. Each tablet contains 0.5 milligram of methylprednisolone and 300 milligrams of aspirin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount. Under 15 pounds, 1⁄4 to 1 tablet daily; 15 to 60 pounds, 1 to 2 tablets daily; 60 pounds and over, 2 tablets daily. Administer total daily dose in divided doses 6 to 10 hours apart, with a light feeding. When response is attained, dosage should be gradually reduced until maintenance level is achieved.

(2) Indications for use. As an anti-inflammatory and analgesic agent.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[78 FR 28824, May 20, 2014]
§ 520.1430 Megestrol acetate tablets.

(a) Specifications. Each milliliter contains 100 micrograms of mibolerone.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 30 micrograms for animals weighing 1 to 25 pounds; 60 micrograms for animals weighing 26 to 50 pounds; 120 micrograms for animals weighing over 50 pounds, German Shepherds, or German Shepherd mix. Administer daily, orally or in a small amount of food, at least 30 days before expected initiation of heat, and continue daily as long as desired, but not for more than 24 months.

(2) Indications for use. For the prevention of estrus (heat) in adult female dogs not intended primarily for breeding purposes.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1441 Milbemycin oxime.

(a) Specifications—(1) Dogs. Each tablet contains 2.3, 5.75, 11.5, or 23.0 milligrams of milbemycin oxime.

(2) Cats. Each tablet contains 5.75, 11.5, or 23.0 milligrams of milbemycin oxime.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs and puppies—(i) Amount. For hookworm, roundworm, and whipworm, use 0.23 milligram per pound of body weight (0.5 milligram per kilogram). For heartworm, use 0.05 milligram per pound of body weight (0.1 milligram per kilogram).

(ii) Indications for use. For prevention of heartworm disease caused by Dirofilaria immitis and the removal of adult Toxocara cati (roundworm) and Ancylostoma tubaeforme (hookworm) infections in cats 6 weeks of age or greater and 1.5 pounds body weight or greater.

(iii) Limitations. Do not use in kittens less than 6 weeks of age or 1.5 pounds body weight. Administer once a month. Follow the manufacturer’s instructions for use.

§ 520.1443 Milbemycin oxime and lufenuron.

(a) Specifications—(1) Tablets containing: 2.3 milligrams (mg) milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460 mg lufenuron.

(2) Flavored tablets containing: 2.3 mg milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460 mg lufenuron.

(b) Sponsor. See No. 051311 in § 510.600(c) of this chapter.
(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount. 0.5 mg milbemycin oxime and 10 mg lufenuron per kilogram of body weight, once a month.

(ii) Indications for use—(A) For use in dogs and puppies for the prevention of heartworm disease caused by *Dirofilaria immitis*, for prevention and control of flea populations, for control of adult *Ancylostoma caninum* (hookworm), and for removal and control of adult *Toxocara canis*, *Toxascaris leonina* (roundworm), and *Trichuris vulpis* (whipworm) infections.

(B) The concurrent use of flavored milbemycin oxime and lufenuron tablets described in paragraph (a)(2) of this section as in paragraph (d)(1)(ii)(A) of this section with nitenpyram tablets as in §520.1510(d)(1) of this chapter is indicated to kill adult fleas and prevent flea eggs from hatching.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

VerDate Sep<11>2014 10:06 Apr 14, 2016 Jkt 238075 PO 00000 Frm 00223 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31lpowell on DSK54DXVN1OFR with $$_JOB
§ 520.1450 Morantel tartrate oral dosage forms.

§ 520.1450a Morantel tartrate bolus.

(a) Specifications. Each bolus contains 2.2 grams morantel tartrate equivalent to 1.3 grams of morantel base.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.425 of this chapter.

(d) Conditions of use—(1) Amount. One bolus per 500 pounds of body weight (4.4 milligrams per pound of body weight) as a single oral dose. Boluses may be divided in half for more accurate dosing as follows: up to 325 pounds, ½ bolus; 326 to 600 pounds, 1 bolus; 601 to 900 pounds, 1½ boluses; and 901 to 1,200 pounds, 2 boluses.

(2) Indications for use. For removal and control of mature gastrointestinal nematode infections of cattle including stomach worms (Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms of the small intestine (Cooperia spp., Trichostrongylus spp., Nematodirus spp.), and worms of the large intestine (Oesophagostomum radiatum).

(3) Limitations. Administer orally with the dosing gun to all cattle that will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 106 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1450b Morantel tartrate cartridge.

(a) Specifications. The drug product consists of a stainless-steel cylinder having both ends closed with polyethylene diffusing discs and containing a morantel tartrate paste. The paste contains 22.7 grams of morantel tartrate equivalent to 13.5 grams of morantel base.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.425 of this chapter.

(d) Conditions of use—(1) Amount. Grazing cattle: Administer 1 cartridge to each animal at the start of the grazing season.

(2) Indications for use. For control of the adult stage of the following gastrointestinal nematode infections in weaned calves and yearling cattle weighing a minimum of 200 pounds: Ostertagia spp., Trichostrongylus axei, Cooperia spp., and Oesophagostomum radiatum.

(3) Limitations. Administer orally with the dosing gun to all cattle that will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 106 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1450c Morantel tartrate sustained-release trilaminate cylinder/sheet.

(a) Specifications. The drug product consists of a trilaminated, perforated, plastic sheet formed into a cylinder having plastic plugs in its ends. The core lamina contains 19.8 grams of morantel tartrate equivalent to 11.8 grams of morantel base.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.425 of this chapter.

(d) Conditions of use—(1) Amount. Grazing cattle: Administer 1 cartridge to each animal at the start of the grazing season.

(2) Indications for use. For control of the adult stage of the following gastrointestinal nematode infections in weaned calves and yearling cattle weighing a minimum of 200 pounds: Ostertagia spp., Trichostrongylus axei, Cooperia spp., and Oesophagostomum radiatum.

(3) Limitations. Administer orally with the dosing gun to all cattle that
will be grazing the same pasture. Effectiveness of the drug product is dependent upon continuous control of the gastrointestinal parasites for approximately 90 days following administration. Therefore, treated cattle should not be moved to pastures grazed in the same grazing season/calendar year by untreated cattle. Do not administer to cattle within 102 days of slaughter. Consult your veterinarian before administering to severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1451 Moxidectin tablets.
(a) Specifications. Each tablet contains 30, 68, or 136 micrograms of moxidectin.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. 3 micrograms per kilogram (1.36 micrograms per pound) of body weight.
(2) Indications for use. To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1452 Moxidectin gel.
(a) Specifications. Each milliliter of gel contains 20 milligrams (mg) (2.0 percent) moxidectin and 125 mg (12.5 percent) praziquantel.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Special considerations. See §500.25 of this chapter.
(d) Conditions of use in horses and ponies—(1) Amount. 0.4 milligram moxidectin per kilogram (2.2 pounds) of body weight.
(2) Indications for use. For the treatment and control of large strongyles: Strongylus vulgaris (adults and L4/L5 larval stages), S. edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), and T. serratus (adults); small strongyles (adults): Cyathostomum spp., including C. cuniculatum and C. pateratum; Cylicocyclus spp., including C. insignis, C. leptostomum, C. nassatus, and C. radiatus; Cylicostephanus spp., including C. calicatus, C. goldi, C. longibursatus, and C. minutus; Coronocycalus spp., including C. coronatus, C. labiatus, and C. labratus; Gyalocephalus capillatus; and Petrovinema pectinulum; small strongyles: undifferentiated luminal larvae; encysted cyathostomes (late L3 and L4 mucosal cyathostome larvae); ascarids: Parasascaris equorum (adults and L4 larval stages); pinworms: Oxyuris equi (adults and L4 larval stages); hairworms: Trichostrongylus axei (adults); large-mouth stomach worms: Habronema muscae (adults); and horse stomach bots: Gasterophilus intestinalis (2nd and 3rd instars) and G. nasalis (3rd instars). One dose also suppresses strongyle egg production for 84 days.
(3) Limitations. Do not use in horses intended for human consumption.


§ 520.1453 Moxidectin and praziquantel gel.
(a) Specifications. Each milliliter of gel contains 2 milligrams (mg) (2.0 percent) moxidectin and 125 mg (12.5 percent) praziquantel.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Special considerations. See §500.25 of this chapter.
(d) Conditions of use in horses and ponies—(1) Amount. Administer by mouth as a single dose: 0.4 mg moxidectin per kilogram and 2.5 mg praziquantel per kilogram (2.2 pounds) body weight.
(2) Indications for use. For the treatment and control of large strongyles: Strongylus vulgaris (adults and L4/L5 arterial stages), S. edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), and T. serratus (adults); small strongyles (adults): Cyathostomum spp., including C. cuniculatum and C. pateratum; Cylicocyclus spp., including C. insignis, C. leptostomum, C. nassatus, and C. radiatus; Cylicostephanus spp., including C. calicatus, C. goldi, C. longibursatus,
and C. minutus; Coronocyculus spp., including C. coronatus, C. labiatus, and C. labratus; Gyalcephalus capitatus; and Petrovinema pocuslatus; small strongyles: undifferentiated luminal larvae; encysted cyathostomes (late L3 and L4 mucosal cyathostome larvae); ascarids: Parascaris equorum (adults and L4 larval stages); pinworms: Oxyuris equi (adults and L4 larval stages); Oxyuris equi (adults and L4 larval stages); hairworms: Trichostrongylus axei (adults); large-mouth stomach worms: Habronema muscae (adults); horse stomach bots: Gasterophilus intestinalis (2nd and 3rd instars) and G. nasalis (3rd instars); and tapeworms: Anoplocephala perfoliata (adults). One dose also suppresses strongyle egg production for 84 days.

Limitations. Do not use in horses intended for human consumption.

§ 520.1454 Moxidectin solution.

(a) Specifications. Each milliliter (mL) of solution contains 1 milligram (mg) moxidectin.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.426 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(3) Limitations. Do not use in horses intended for human consumption.

§ 520.1468 Naproxen.

(a) Specifications. Each gram of granules contains 500 milligrams (mg) (50 percent) naproxen.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 10 mg per kilogram of body weight twice daily top dressed on feed for up to 14 consecutive days.

(2) Indications for use. For the relief of inflammation and associated pain and lameness exhibited with arthritis, as well as myositis and other soft tissue diseases of the musculoskeletal system.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1484 Neomycin.

(a) Specifications—(1) Each ounce of powder contains 20.3 grams (g) neomycin sulfate (equivalent to 14.2 g neomycin base).

(2) Each milliliter of solution contains 200 milligrams (mg) neomycin sulfate (equivalent to 140 mg neomycin base).

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) Nos. 054771 and 054925 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section.

(2) Nos. 054771, 058005, and 061623 for use of product described in paragraph (a)(1) as in paragraphs (e)(1) and (e)(2) of this section.

(3) Nos. 000859, 054771, 054925, and 058005 for use of product described in paragraph (a)(2) as in paragraph (e)(1) of this section.

(c) Related tolerances. See §556.430 of this chapter.

(d) Special labeling considerations. Labeling shall bear the following warning statements: "A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. Use of more than one product containing neomycin or failure to follow withdrawal times may result in illegal drug residues."
§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.

§ 520.1604 Oclacitinib.

(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) oclacitinib as oclacitinib maleate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) Amount. Administer orally 0.18 to 0.27 mg/pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administer once daily for maintenance therapy.
(2) **Indications for use.** For control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[78 FR 42007, July 15, 2013]

§ 520.1615 Omeprazole.

(a) **Specifications.** Each gram of paste contains 0.37 gram omeprazole.

(b) **Sponsor.** See No. 050604 in § 510.600(c) of this chapter.

(c) **Special considerations.** When labeled for use as in paragraph (d)(2)(i) of this section, product labeling shall bear: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”

(d) **Conditions of use in horses**—(1) **Amount**—(i) For treatment of gastric ulcers, 1.8 milligrams per pound (mg/lb) of body weight (4 milligrams per kilogram (mg/kg)) once daily for 4 weeks. For prevention of recurrence of gastric ulcers, 0.9 mg/lb of body weight (2 mg/kg) once daily for at least an additional 4 weeks.

(ii) For prevention of gastric ulcers using the premarked syringe, one dose per day for 8 or 28 days. Each dose delivers at least 1 mg/kg of body weight. Horses over 1,200 lb body weight should receive two doses per day.

(2) **Indications for use.** (i) For treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older.

(ii) For prevention of gastric ulcers in horses.

(3) **Limitations.** Do not use in horses intended for human consumption.


§ 520.1616 Orbifloxacin tablets.

(a) **Specifications.** Each tablet contains 5.7, 22.7, or 68 milligrams (mg) orbifloxacin.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs and cats**—(1) **Amount.** 2.5 to 7.5 mg per kilogram body weight once daily.

(2) **Indications for use.** For management of diseases associated with bacteria susceptible to orbifloxacin.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food producing animals.

[71 FR 14643, Mar. 23, 2006, as amended at 75 FR 26646, May 12, 2010]

§ 520.1618 Orbifloxacin suspension.

(a) **Specifications.** Each milliliter of suspension contains 30 milligrams (mg) orbifloxacin.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Special considerations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

(d) **Conditions of use**—(1) **Dogs**—(i) **Amount.** 1.1 to 3.4 mg/lb (2.5 to 7.5 mg/kg) of body weight once daily.

(ii) **Indications for use.** For the treatment of urinary tract infections (cystitis) in dogs caused by susceptible strains of *Staphylococcus pseudintermedius*, *Staphylococcus aureus*, coagulase-positive *staphylococci*, *Pasteurella multocida*, *Proteus mirabilis*, *Escherichia coli*, and *Enterococcus faecalis*.

(ii) **Cats**—(i) **Amount.** 3.4 mg/lb (7.5 mg/kg) of body weight once daily.

(2) **Indications for use.** For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of *S. aureus*, *E. coli*, and *P. multocida*.

[75 FR 26646, May 12, 2010]

§ 520.1628 Oxfendazole powder and pellets.

(a) **Specifications**—(1) **Powder for suspension.** Each gram of powder contains 7.57 percent oxfendazole.

(2) **Pellets.** Each gram of pellets contains 6.49 percent oxfendazole.

(b) **Sponsor.** See No. 054771 in § 510.600(c) of this chapter.
§ 520.1630 Oxfendazole paste.

(a)(1) Specifications. Each gram of paste contains 0.375 gram oxfendazole (37.5 percent).

(2) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. 10 milligrams per kilogram of body weight.

(ii) Indications for use. The drug is used in horses for removal of the following gastrointestinal worms: Large roundworms (Parascaris equorum), mature and immature pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, Strongylus vulgaris, and Strongylus equinus), and small strongyles.

(iii) Limitations. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(b)(1) Specifications. Each gram of paste contains 185 milligrams of oxfendazole (18.5 percent).

(2) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(3) Related tolerances. See § 556.495 of this chapter.

(4) Conditions of use—(i) Amount. 4.5 milligrams per kilogram of body weight (2.05 milligrams per pound),

(ii) Indications for use. The drug is used in cattle for the removal and control of the following worms: lungworms (Dictyocaulus viviparus—adult, L4); stomach worms: barberpole worms (Haemonchus contortus and H. placei—adult), small stomach worms (Trichostrongylus axei—adult); brown stomach worms (Ostertagia ostertagi—adult, L4, inhibited L4); intestinal worms; nodular worms (Oesophagostomum radiatum—adult), hookworms (Bunostomum phlebotomum—adult), small intestinal worms (Cooperia punctata, C. oncophora, and C. mcmasteri—adult, L4); and tapeworms (Moniezia benedeni—adult).

(iii) Limitations. For use in cattle only. Treatment may be repeated in 4 to 6 weeks. Cattle must not be slaughtered until 11 days after treatment. Do not use in female dairy cattle of breeding age. Consult a veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1629 Oxfendazole suspension.

(a) Specifications. Each milliliter of suspension contains 0.375 gram oxfendazole (37.5 percent).

(2) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. 10 milligrams per kilogram (2.2 pounds) of body weight.

(ii) Indications for use. The drug is used in horses for removal of the following gastrointestinal worms: Large roundworms (Parascaris equorum), mature and 4th stage larvae pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus), and small strongyles.

(iii) Limitations. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Not for use in horses intended for food. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

restricts this drug to use by or on the order of a licensed veterinarian.

(e) Conditions of use—(1) Horses. Use the product described in paragraph (a)(1) of this section as follows:

(i) Amount. 10 mg per kilogram (/kg) of body weight by stomach tube or dose syringe. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks.

(ii) Indications for use. For removal of large roundworms (Parascaris equorum), mature and 4th stage larvae pinworms (Oxyuris equi), large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus), and small strongyles.

(iii) Limitations. Withholding feed or water prior to use is unnecessary. Administer drug with caution to sick or debilitated horses. Do not use in horses intended for human consumption.

(2) Cattle. Use the products described in paragraphs (a)(1) and (a)(2) of this section as follows:

(i) Amount. 4.5 mg/kg of body weight by dose syringe. Treatment may be repeated in 4 to 6 weeks.

(ii) Indications for use. For the removal and control of: lungworms (Dictyocaulus viviparus—adult, L4); stomach worms: barberpole worms (Haemonchus contortus and H. placei—adult), small stomach worms (Trichostrongylus axei—adult), brown stomach worms (Ostertagia ostertagi—adult, L4, inhibited L4); intestinal worms: nodular worms (Oesophagostomum radiatum—adult), hookworms (Bunostomum phlebotomum—adult), small intestinal worms (Cooperia punctata, C. oncophora, and C. surinamensis—adult, L4), and tape worms (Moniezia benedeni—adult).

(iii) Limitations. Cattle must not be slaughtered until 7 days after treatment. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age.


§ 520.1631 Oxfendazole and trichlorfon paste.

(a) Specifications. Each gram of paste contains 28.5 milligrams oxfendazole and 454.5 milligrams trichlorfon.

(b) Sponsor. See 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 2.5 milligrams of oxfendazole and 40 milligrams of trichlorfon per kilogram of body weight.

(2) Indications for use. The drug is used in horses for removal of bots (Gasterophilus intestinalis, 2nd and 3rd instars; G. nasalis, 3rd instar) and the following gastrointestinal worms: Large roundworms (Parascaris equorum), pinworms (Oxyuris equi), adult and 4th stage larvae; large strongyles (Strongylus edentatus, S. vulgaris, and S. equinus); and small strongyles.

(3) Limitations. Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water before use is unnecessary. Administer with caution to sick or debilitated horses. Not for use in horses intended for food. Do not administer to mares during the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not use this product in animals simultaneously with, or within a few days before or after treatment with or exposure to, cholinesterase-inhibiting drugs, pesticides, or chemicals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1638 Oxibendazole.

(a) Specifications—(1) Each gram of paste contains 227 milligrams (mg) (22.7 percent) oxibendazole.

(2) Each milliliter of suspension contains 100 mg (10 percent) oxibendazole.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Special considerations—(1) See §500.25 of this chapter.

(2) Suspension product described in paragraph (a)(2) of this section shall be labeled: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”
Food and Drug Administration, HHS

§ 520.1660b  Oxytetracycline hydrochloride capsules.

(a) Specifications. The drug is in capsule form with each capsule containing 125 or 250 milligrams of oxytetracycline hydrochloride. Oxytetracycline is the antibiotic substance produced by growth of Streptomyces rimosus or the same antibiotic substance produced by any other means.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use. (1) It is used in dogs and cats for the treatment of bacterial pneumonia caused by Brucella bronchiseptica, tonsillitis caused by Streptococcus hemolyticus, bacterial enteritis caused by Escherichia coli, urinary tract infections caused by Escherichia coli, and wound infections caused by Staphylococcus aureus.

(2) The drug is administered orally to dogs and cats at a dosage level of 25–50 milligrams per pound of body weight per day in divided doses at 12-hour intervals. The drug can be used for continuation of compatible antibiotic therapy following parenteral oxytetracycline administration where rapidly attained, sustained antibiotic blood levels are required. The duration of treatment required to obtain favorable response will depend to some extent on the severity and degree of involvement and the susceptibility of the infectious agent. Clinical response to antibiotic therapy usually occurs within 48 to 72 hours. If improvement is not observed within that period, the diagnosis and course of treatment should be reconsidered. To assure adequate treatment,
administration of the drug should continue for at least 48 hours following favorable clinical response.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 78 FR 28825, May 20, 2014]

§ 520.1660c Oxytetracycline hydrochloride tablets/boluses.

(a) Specifications. Each tablet or bolus contains 250, 500, or 1,000 milligrams of oxytetracycline hydrochloride.

(b) Sponsors. For sponsors in §510.600(c) of this chapter: See 000010 for use of 500 and 1,000 milligram boluses. See No. 054771 for use of 250 and 500 milligram tablets.

(c) Tolerances. See §556.500 of this chapter.

(d) Conditions of use in beef and dairy cattle—(1)(i) Amount. 250 milligrams per 100 pounds of body weight every 12 hours (5 milligrams per pound of body weight daily in two doses).

(ii) Indications for use. For treatment of bacterial enteritis caused by Salmonella typhimurium and Escherichia coli (coli bacillosis) and bacterial pneumonia (shipping fever complex, pasteurellosis) caused by Pasteurella multocida.

(2)(i) Amount. 500 milligrams per 100 pound of body weight every 12 hours (10 milligrams per pound of body weight daily in two doses).

(ii) Indications for use. For treatment of bacterial enteritis caused by Salmonella typhimurium and Escherichia coli (coli bacillosis) and bacterial pneumonia (shipping fever complex, pasteurellosis) caused by Pasteurella multocida.

(3) Limitations. Dosage should continue until the animal returns to normal and for 24 hours to 48 hours after symptoms have subsided. Treatment should not exceed 4 consecutive days. Do not exceed 500 milligrams per 100 pounds of body weight every 12 hours (10 milligrams per pound daily). For sponsor No. 054771: Discontinue treatment 7 days prior to slaughter. Not for use in lactating dairy cattle. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.


§ 520.1660d Oxytetracycline powder.

(a) Specifications. The drug is a soluble powder distributed in packets or pails having several concentrations of oxytetracycline hydrochloride (independent of the various net weights) as follows:

(1) Each 18.14 grams of powder contains 1 gram of oxytetracycline hydrochloride (OTC HCl) (packets: 4, 6.4, and 16 oz.).

(2) Each 4.43 grams of powder contains 1 gram of OTC HCl (packets: 4 and 16 oz.).

(3) Each 1.32 grams of powder contains 1 gram of OTC HCl (packets: 4.78 and 9.55 oz.; jars: 2.25 lbs.; and pails: 4.5 lbs.).

(4) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 2.39, 4.78, and 9.55 oz.; jars: 2.25 lbs.; and pails: 4.5 lbs.).

(5) Each 4.2 grams of powder contains 1 gram of OTC HCl (packets: 3.8 and 16.2 oz; pails: 4.74 and 23.7 lbs.).

(6) Each 1.32 grams of powder contains 1 gram of OTC HCl (packets: 2.39 oz.; pail: 5 lb). Each 2.73 grams of powder contains 1 gram of OTC HCl (packet: 9.87 oz.).

(7) Each 1.32 grams of powder contains 1 gram of OTC HCl (packet: 4.78 oz.; pails: 5 lb). Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 9.87 oz.).

(8) Each 135.5-gram packet (4.78 ounce) contains 102.4 grams of OTC HCl. Each 677.5-gram packet (23.9 ounce) contains 512 grams of OTC HCl.

(9) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 9.87 and, 19.75 oz., and 3.91 lb; pails: 3.09 and 5 lb).

(10) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 9.87 and 19.74 oz.; pails: 5 lb).

(b) Sponsor. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) No. 054771 for use of OTC HCl concentrations in paragraphs (a)(1), (a)(2), and (a)(3) of this section in chickens,
Food and Drug Administration, HHS

§ 520.1660d

(2) No. 054771 for use of OTC HCl concentration in paragraph (a)(4) of this section in chickens, turkeys, and swine.

(3) No. 054628 for use of OTC HCl concentration in paragraph (a)(5) of this section in turkeys and chickens.

(4) No. 057561 for use of OTC HCl concentration in paragraph (a)(6) of this section in chickens, turkeys, and swine.

(5) No. 061623 for use of OTC HCl concentration in paragraph (a)(7) of this section in chickens, turkeys, swine, cattle, sheep, and honey bees.

(6) No. 069254 for use of OTC HCl concentration in paragraph (a)(8) of this section in chickens, turkeys, swine, cattle, sheep, and honey bees.

(7) No. 061623 for use of OTC HCl concentration in paragraph (a)(9) of this section in chickens, turkeys, and swine.

c) Related tolerances. See § 556.500 of this chapter.

d) Conditions of use. (1) It is used in drinking water as follows:

(i) Chickens—(A)(1) Amount per gallon. 200 to 400 milligrams.

(2) Indications for use. Control of infectious synovitis caused by *Mycoplasma synoviae* susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(B)(1) Amount per gallon. 400 milligrams.

(2) Indications for use. Control of infectious synovitis caused by *Mycoplasma synoviae* susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(C)(1) Amount. 25 milligrams per pound of body weight.

(2) Indications for use. Growing turkeys. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(ii) Turkeys—(A)(1) Amount per gallon. 200 to 400 milligrams.

(2) Indications for use. Control of hexamitiasis caused by *Hexamita meleagridis* susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(B)(1) Amount per gallon. 400 milligrams.

(2) Indications for use. Control of infectious synovitis caused by *Mycoplasma synoviae* susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.

(C)(1) Amount. 25 milligrams per pound of body weight.

(2) Indications for use. Growing turkeys. Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to oxytetracycline.

(3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 days. Not to be used for more than 14 consecutive days. Use as sole source of drinking water. Do not use in birds producing eggs for human consumption. With draw 5 days prior to slaughter those products sponsored by Nos. 054771, and 061623 in § 510.600(c) of this chapter. Withdraw 4 days prior to slaughter those products sponsored by No. 054628. Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.
§ 520.1696 Penicillin.
§ 520.1696a [Reserved]
§ 520.1696b Penicillin G powder.

(a) Specifications. Each gram of powder contains penicillin G potassium equivalent to 1.54 million units of penicillin G.

(b) Sponsors. See Nos. 010515, 054771, 059320, 061623 and 076475 in § 510.600(c) of this chapter.

(c) Conditions of use in turkeys—(1) Amount. 1,500,000 units per gallon drinking water for 5 days.

(2) Indications for use. Treatment of erysipelas caused by *Erysipelothrix rhusiopathiae*.

(3) Limitations. Prepare concentrated stock solution for use with medication proportioners fresh every 24 hours. Prepare recommended use levels for gravity flow watering system fresh every 12 hours. For best results, treatment should be started at the first sign of infection. Discontinue treatment at least 1 day prior to slaughter. Not for use in...
§ 520.1720a Phenylbutazone oral dosage forms.

§ 520.1720a Phenylbutazone tablets and boluses.

(a) Specifications. Each tablet contains 100, 200, or 400 milligrams (mg), or 1 gram (g) of phenylbutazone. Each bolus contains 1, 2, or 4 gram g of phenylbutazone.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter, as follows:

(1) No. 000061 for use of 100- or 400-mg or 1-g tablets, or 2- or 4-g boluses, in dogs and horses.
(2) Nos. 054628 and 069043 for use of 100- or 200-mg or 1-g tablets in dogs and horses.
(3) Nos. 054771 and 061623 for use of 100-mg or 1-g tablets in dogs and horses.
(4) [Reserved]
(5) No. 000143 for use of 1-g tablets in horses.
(6) No. 058829 for use of 100-mg or 1-g tablets in dogs and horses.

(c) Conditions of use—

(i) Dogs—

(1) Amount. 20 mg per pound of body weight daily.

(ii) Indications for use. For the relief of inflammatory conditions associated with the musculoskeletal system.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—

(1) Amount. 1 to 2 g per 500 pounds of body weight daily.
§ 520.1720b Phenylbutazone granules.

(a) Specifications. Each package of granules contains 1 or 8 grams of phenylbutazone.

(b) Sponsors. See sponsors in §510.600(c) of this chapter.

(ii) Indications for use. For the relief of inflammatory conditions associated with the musculoskeletal system.

(ii) Limitations. Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1720d Phenylbutazone gel.

(a) Specifications. Each 30 grams of gel contains 4 grams of phenylbutazone.

(b) Sponsor. See No. 061623 in §510.600(c) of this chapter. Require bioequivalency and safety information.

(c) Conditions of use in horses—(1) Amount. 1 to 2 grams of phenylbutazone per 500 pounds of body weight, not to exceed 4 grams daily.

(2) Indications for use. For treatment of inflammatory conditions associated with the musculoskeletal system.

(3) Limitations. Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1720e Phenylbutazone powder.

(a) Specifications—(1) Each 1.15 grams (g) of powder contains 1 g phenylbutazone.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter.

(1) No. 027053 for use of product described in paragraph (a)(1) of this section.

(2) No. 057699 for use of product described in paragraph (a)(2) of this section.

(c) Conditions of use in horses—(1) Amount. 1 to 2 grams of phenylbutazone per 500 pounds of body weight, not to exceed 4 grams daily.

(2) Indications for use. For relief of inflammatory conditions associated with the musculoskeletal system.

(3) Limitations. Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Food and Drug Administration, HHS

(c) Conditions of use in horses—(1) Amount. Administer 1 to 2 g (1 to 2 level scoops, using the scoop provided) per 500 pounds of body weight on a small amount of palatable feed, not exceed 4 g per animal daily.

(2) Indications for use. For the relief of inflammatory conditions associated with the musculoskeletal system.

(3) Limitations. Do not use in horses intended for human consumption. Federal law prohibits the extralabel use of this product in female cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1760 Phenylpropanolamine.

(a) Specifications. Each chewable tablet contains 25, 50, or 75 milligram (mg) phenylpropanolamine hydrochloride.

(b) Sponsors. See No. 055246 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 2 mg/kg of body weight twice daily.

(2) Indications for use. For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1780 Pimobendan.

(a) Specifications. Each chewable tablet contains 1.25, 2.5, 5, or 10 milligrams (mg) pimobendan.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Conditions of use in horses and ponies—(1) Amount. Administer orally at a total daily dose of 0.23 mg per pound (0.5 mg per kilogram) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into two portions administered approximately 12 hours apart.

(2) Indications for use. For the management of the signs of mild, moderate, or severe (modified New York Heart Association Class II, III, or IV) congestive heart failure due to atrioventricular valvular insufficiency or dilated cardiomyopathy; for use with concurrent therapy for congestive heart failure as appropriate on a case-by-case basis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1802 Piperazine-carbon disulfide complex oral dosage forms.

§ 520.1802a Piperazine-carbon disulfide complex suspension.

(a) Specifications. Each fluid ounce of suspension contains 7.5 grams of piperazine-carbon disulfide complex. The piperazine-carbon disulfide complex contains equimolar parts of piperazine and carbon disulfide (1 gram contains 530 mgs of piperazine and 470 mgs of carbon disulfide).

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses and ponies—(1) Amount. Administer 1 fluid ounce per 100 pounds of body weight by stomach tube or dose syringe after withholding feed overnight or for 8 to 10 hours.

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), bots (Gastrophilus spp.), small strongyles, large strongyles (Strongyles spp.), and pinworms (Oxyuris equi).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1802b Piperazine-carbon disulfide complex boluses.

(a) Specifications. Each bulus contains 20 grams of piperazine-carbon disulfide complex.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses and ponies—(1) Amount. For removal of ascarids and small strongyles, 1 bolus (20 grams) per 500 pounds body weight; removal of large strongyles, pinworms, and bots, 1 bolus per 250 pounds body weight.

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), large strongyles (Strongyles spp.) bots (Gastrophilus spp.), small
§ 520.1802c Piperazine-carbon disulfide complex with phenothiazine suspension.

(a) Specifications. Each fluid ounce contains 5 grams of piperazine-carbon disulfide complex and 0.83 gram of phenothiazine.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses and ponies—(1) Amount. Administer 1 fluid ounce per 100 pounds of body weight by stomach tube or dose syringe after withholding feed overnight or for 8 to 10 hours.

(2) Indications for use. For removing ascarids (large roundworms, Parascaris equorum), bots (Gastrophilus spp.), small strongyles, and large strongyles (Strongylus spp.).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.1804 Piperazine phosphate capsules.

(a) Specifications. Each capsule contains 120, 300, or 600 milligrams of piperazine phosphate monohydrate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 60 milligrams of piperazine phosphate monohydrate per pound of body weight.

(2) Indications for use—(i) Dogs. It is used for the removal of large roundworms (ascarids) Toxocara canis and Toxascaris leonina.

(ii) Cats. It is used for the removal of large roundworms (ascarids) Toxocara mystax and Toxacaris leonina.

(3) Limitations. Administer in animal’s food or milk. For animals up to 1 year of age administer every 2 or 3 months; for animals over 1 year old, administer periodically as necessary. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1805 Piperazine phosphate with thenium closylate tablets.

(a) Specifications. Each scored tablet contains the equivalent of 250 milligrams piperazine hexahydrate (as piperazine phosphate) and 125 milligrams thenium (as thenium closylate) or 250 milligrams thenium (as thenium closylate) and 250 milligrams thenium (as thenium closylate).

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer orally to dogs as follows:

<table>
<thead>
<tr>
<th>Animal weight (lb)</th>
<th>375 mg</th>
<th>750 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 but less than 5</td>
<td>1⁄2</td>
<td>1</td>
</tr>
<tr>
<td>5 but less than 10</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>10 or heavier</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

(2) Indications for use. For removal of immature (fourth stage larvae) and adult hookworms (Ancylostoma caninum, A. braziliense, and Uncinaria stenocephala) and ascarids (Toxocara canis) from weaned pups and adult dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1806 Piperazine suspension.

(a) Specifications. Each milliliter of suspension contains piperazine monohydrochloride equivalent to 33.5 milligrams (mg) piperazine base.

(b) Sponsor. See No. 017135 in § 510.600(c) of this chapter.

(c) Special considerations. See § 50.025(c) of this chapter.

(d) Conditions of use in dogs—(1) Indications for use. For the removal of roundworms (Toxocara canis and Toxascaris leonina).

(2) Dosage. Administer 20 to 30 mg piperazine base per pound body weight as a single dose.

(3) Limitations. Administer by mixing into the animal’s ration to be consumed at one feeding. For animals in heavily contaminated areas, reworm at monthly intervals. Not for use in unweaned pups or animals less than 3 weeks of age.

§ 520.1807 Piperazine.

(a) Specifications. A soluble powder or liquid containing piperazine dihydrochloride or dipiperazine sulfate, equivalent to 17, 34, or 230 grams of piperazine per pound or 100 milliliters.

(b) Sponsor. See No. 015565 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.513 of this chapter.

(d) Conditions of use—(1) Chickens—(i) Amount. 50 milligrams per bird under 6 weeks, 100 milligrams per bird over 6 weeks.

(ii) Indications for use. For removal of large roundworm (Ascaridia spp.).

(iii) Limitations. For use in drinking water or feed. Use as sole source of drinking water. Prepare fresh solution daily. Use as 1-day single treatment. Withdraw 14 days prior to slaughter. Do not use for chickens producing eggs for human consumption. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(2) Turkeys—(i) Amount. 100 milligrams per bird up to 12 weeks and 200 milligrams per bird over 12 weeks.

(ii) Indications for use. For removal of large roundworm (Ascaridia spp.).

(iii) Limitations. For use in drinking water or feed. Use as sole source of drinking water. Prepare fresh solution daily. Use as 1-day single treatment. Withdraw 14 days prior to slaughter. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

(3) Swine—(i) Amount. 50 milligrams per pound of body weight.

(ii) Indications for use. For removal of large roundworm (Ascaris suum) and nodular worms (Oesophagostomum spp.).

(iii) Limitations. For use in drinking water or feed. Use as sole source of drinking water. Prepare fresh solution daily. Use as 1-day single treatment. Withdraw 21 days prior to slaughter. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.1840 Poloxalene.

(a) Specifications. Polyoxypropylene-polyoxyethylene glycol nonionic block polymer.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 054771 for use as in paragraphs (d)(1) and (d)(3) of this section.

(2) No. 651311 for use as in paragraph (d)(4) of this section.

(3) No. 067949 for use as in paragraph (d)(2) of this section.

(4) No. 066104 for use as in paragraph (d)(3) of this section.

(c) [Reserved]

(d) Conditions of use. (1) For treatment of legume (alfalfa, clover) bloat in cattle. Administer as a drench at the rate of 25 grams for animals up to 500 pounds and 50 grams for animals over 500 pounds of body weight.

(2) For control of legume (alfalfa, clover) bloat in cattle. Administer, in molasses block containing 6.6 percent poloxalene, at the rate of 0.8 oz. of block (1.5 grams poloxalene) per 100 lbs. of body weight per day.

(3) For prevention of legume (alfalfa, clover) and wheat pasture bloat in cattle. A 53-percent poloxalene top dressing on individual rations of ground feed. Dosage is 1 gram of poloxalene per 100 pounds of body weight daily. If bloating conditions are severe, the dose is doubled. Treatment should be started 2 to 3 days before exposure to bloat-producing conditions. Do not exceed the double dose in any 24-hour period.

(4) For control of legume (alfalfa, clover) and wheat pasture bloat in cattle. Administer in molasses block containing 6.6 percent poloxalene, at the rate of 0.8 ounce of block (1.5 grams of poloxalene) per 100 pounds of body weight per day. Provide access to blocks at least 7 days before exposure to bloat-producing conditions.


§ 520.1846 Polyoxyethylene (23) lauryl ether blocks.

(a) Specifications. Each molasses-based block contains 2.2 percent polyoxyethylene (23) lauryl ether.

(b) Sponsor. See No. 067949 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 2 grams of polyoxyethylene (23) lauryl ether per 100 kilograms of body weight per day (1 pound of block per 500 kilogram (1,100 pound) animal per day).

(2) Indications for use. For reduction of the incidence of bloat (alfalfa and clover) in pastured cattle.

(3) Limitations. Administer free-choice to beef cattle and nonlactating dairy cattle only. Initially, provide one block per five head of cattle. Start treatment 10 to 14 days before exposure to bloat-producing pastures. Do not allow cattle access to other sources of salt while being fed this product. Do not feed this product to animals without adequate forage/roughage consumption.


§ 520.1855 Ponazuril.

(a) Specifications. Each gram of paste contains 150 milligrams (mg) ponazuril.

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer orally 15 mg per kilogram (kg) (6.81 mg per pound (lb)) body weight as the first dose, followed by 5 mg/kg (2.27 mg/lb) body weight once daily for a period of 27 additional days.

(2) Indications for use. For the treatment of equine protozoal myeloencephalitis caused by Sarcocystis neurona.

§ 520.1860 Pradofloxacin.

(a) Specifications. Each milliliter of suspension contains 25 milligrams (mg) pradofloxacin.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in cats—(1) Amount. Administer 3.4 mg/lb (7.5 mg/kg) body weight once daily for 7 consecutive days.

(2) Indications for use. For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis, and Staphylococcus pseudintermedius.

(3) Limitations. Federal law prohibits the extralabel use of this drug in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. [77 FR 76863, Dec. 31, 2012, as amended at 79 FR 28827, May 20, 2014]

§ 520.1870 Praziquantel tablets.

(a) Specifications. Each tablet contains:

(1) 34 milligrams (mg) praziquantel.

(2) 11.5 or 23 mg praziquantel.

(b) Sponsor. See No. 069043 in § 510.600(c) of this chapter for use as in paragraph (d) of this chapter.

(1) See No. 000859 for use of tablets described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.

(2) Cats—(i) Indications for use. For removal of feline cestodes Dipylidium caninum and Taenia taeniaeformis.

(ii) Dosage. Cats 4 pounds and under, 11.5 mg; 5 to 11 pounds, 23 mg; over 11 pounds, 34.5 mg.

(iii) Limitations. Administer directly by mouth or crumbled and in feed. Not intended for use in kittens less than 6 weeks of age. For OTC use: Consult your veterinarian before administering tablets to weak or debilitated animals, and for assistance in the diagnosis, treatment, and control of parasitism.


§ 520.1871 Praziquantel and pyrantel.

(a) Specifications. (1) Each tablet contains 13.6 milligrams (mg) praziquantel and 54.3 mg pyrantel base (as pyrantel pamoate), 18.2 mg praziquantel and 72.6 mg pyrantel base (as pyrantel pamoate), or 27.2 mg praziquantel and 108.6 mg pyrantel base (as pyrantel pamoate).

(2) Each chewable tablet contains 30 mg praziquantel and 30 mg pyrantel pamoate or 114 mg praziquantel and 114 mg pyrantel pamoate.

(b) Sponsors. See sponsors in § 510.600(c) for use as in paragraph (d) of this chapter.

(1) See No. 000859 for use of tablets described in paragraph (a)(1) of this section for use as in paragraph (d)(1) of this section.

(B) For removal of the canine cestode Echinococcus granulosus, and for removal and control of the canine cestode Echinococcus multilocularis.

(iii) Limitations—(A) If labeled only for use as in paragraph (c)(i)(ii)(A) of this section: Not intended for use in puppies less than 4 weeks of age. Consult your veterinarian before administering tablets to weak or debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(B) If labeled for use as in paragraph (c)(i)(ii)(B) of this section: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.

(a) Specifications. Each tablet or chewable tablet contains either:

(1) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams pyrantel pamoate per pound of body weight according to the dosing tables on labeling. May be given directly by mouth or in a small amount of food. Do not withhold food prior to or after treatment. If reinfection occurs, treatment may be repeated.

(ii) Indications for use. For the removal of tapeworms (Dipylidium caninum and Taenia taeniaeformis), hookworms (Ancylostoma tubaeforme), and large roundworms (Toxocara cati) in cats and kittens.

(iii) Limitations. Not for use in kittens less than 2 months of age or weighing less than 2.0 pounds. Consult your veterinarian before giving to sick or pregnant animals.

(2) Dogs—(i) Amount. Administer a minimum dose of 5 mg praziquantel and 5 mg pyrantel pamoate per kilogram body weight (2.27 mg praziquantel and 2.27 mg pyrantel pamoate per pound body weight) according to the dosing tables on labeling.

(ii) Indications for use. For the treatment and control of roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala), and tapeworms (Dipylidium caninum and Taenia pisiformis) in dogs and puppies.

(b) Sponsor. See 000859 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Administer as a single dose directly by mouth or in a small amount of food as follows:

<table>
<thead>
<tr>
<th>Weight of animal (Kilograms)</th>
<th>Number of tablets per dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tablet no. 1</td>
</tr>
<tr>
<td>0.9 to 1.8</td>
<td>2 to 4</td>
</tr>
<tr>
<td>2.3 to 3.2</td>
<td>5 to 7</td>
</tr>
<tr>
<td>3.6 to 5.4</td>
<td>8 to 12</td>
</tr>
<tr>
<td>5.9 to 8.2</td>
<td>13 to 18</td>
</tr>
<tr>
<td>8.6 to 11.4</td>
<td>19 to 25</td>
</tr>
<tr>
<td>11.8 to 13.6</td>
<td>26 to 30</td>
</tr>
<tr>
<td>14.1 to 20.0</td>
<td>31 to 44</td>
</tr>
<tr>
<td>20.4 to 27.2</td>
<td>45 to 69</td>
</tr>
<tr>
<td>27.7 to 40.9</td>
<td>61 to 90</td>
</tr>
<tr>
<td>41.3 to 54.5</td>
<td>91 to 120</td>
</tr>
</tbody>
</table>

(ii) Indications for use. For the removal of tapeworms (Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus); hookworms (Ancylostoma caninum, Uncinaria stenocephala); ascarids (Toxocara canis, Toxascaris leonina); and whipworms (Trichuris vulpis) and for the removal and control of tapeworm Echinococcus multilocularis in dogs.

(iii) Limitations. Do not use in pregnant animals. Do not use in dogs weighing less than 0.9 kilogram (2 pounds) or puppies less than 3 weeks of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1880 Prednisolone.

(a) Specifications. Each tablet contains 5 or 20 milligrams prednisolone.

(b) Sponsor. See 000859 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 2.5 milligrams per 4.5 kilograms (10 pounds) body weight per day. Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved.

(2) Indications for use. For use as an anti-inflammatory agent.
Food and Drug Administration, HHS

§ 520.1900 Primidone.

(a) Specifications. Each tablet contains 50 or 250 milligrams of primidone.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter.

(1) No. 054628 for use of 250 milligram tablets.

(2) No. 054771 for use of 50 and 250 milligram tablets.

(c) Conditions of use in dogs—(1) Amount. Twenty-five milligrams of primidone per pound of body weight (55 milligrams per kilogram of body weight) daily.

(2) Indications for use. For the control of convulsions associated with idiopathic epilepsy, epileptiform convulsions, viral encephalitis, distemper, and hardpad disease that occurs as a clinically recognizable lesion in certain entities in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1920 Prochlorperazine and isopropamide.

(a) Specifications. Each capsule contains either:

(1) 3.33 milligrams of prochlorperazine (as the dimaleate) and 1.67 milligrams of isopropamide (as the iodide); or

(2) 10 milligrams of prochlorperazine (as the dimaleate) and 5 milligrams of isopropamide (as the iodide).

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer capsules orally twice daily to dogs as follows:

<table>
<thead>
<tr>
<th>Animal weight (pounds)</th>
<th>Capsule No. 1</th>
<th>Capsule No. 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 to 20</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>20 to 30</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Over 30</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Over 60</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

(2) Indications for use. For the treatment of infectious bacterial gastroenteritis associated with emotional stress.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.1962 Promazine.

(a) Specifications. Conforms to N.F. XII for promazine hydrochloride.
§ 520.2002 Propiopromazine.

(a) Specifications. Each chewable tablet contains 10 or 20 milligrams of propiopromazine hydrochloride.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Administer 0.45 to 0.9 milligrams per pound of body weight mixed with an amount of feed that will be readily consumed.

(2) Indications for use. For quieting excitable, unruly, or intractable horses.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28827, May 20, 2014]

§ 520.2004 Pyrantel pamoate chewable tablets.

(a) Specifications. Each tablet contains pyrantel pamoate equivalent to 22.7 or 113.5 milligrams pyrantel base.

(b) Sponsor. See Nos. 017135 and 051311 in §510.600(c) of this chapter.

(c) Conditions of use—

(1) Amount. Provides at least 2.27 milligrams pyrantel base per pound body weight for dogs weighing more than 5 pounds, and at least 4.54 milligrams of pyrantel base per pound body weight for dogs weighing 5 pounds or less.

(2) Indications for use—

(i) In dogs and puppies. For removal of ascarids (Toxocara canis; Toxascaris leonina) and hookworms (Ancylostoma caninum; Uncinia stenocephala).

(ii) In puppies and adult dogs and in lactating bitches after whelping. To prevent reinfection of Toxocara canis.

(iii) In puppies and adult dogs and in lactating bitches after whelping. To prevent reinfection of T. canis in puppies, lactating bitches after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 weeks of age; treat lactating bitches 2 to 3 weeks after whelping; routinely treat adult dogs monthly. Do not withhold food prior to or after treatment. The presence of these parasites should be confirmed by laboratory fecal examination. A followup fecal examination should be conducted...
2 to 4 weeks after first treatment regimen to determine the need for re-treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

§ 520.2043 Pyrantel pamoate suspension.

(a) Specifications. (1) Each milliliter (mL) contains pyrantel pamoate equivalent to 50 milligrams (mg) pyrantel base.

(2) Each mL contains pyrantel pamoate equivalent to 2.27 or 4.54 mg pyrantel base.

(3) Each mL contains pyrantel pamoate equivalent to 4.54 mg pyrantel base.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) Nos. 054771, 058829, and 069043 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(2) Nos. 000859, 054771, and 058829 for use of the products described in paragraph (a)(2) as in paragraph (d)(2) of this section.

(3) No. 023851 for use of the product described in paragraph (a)(3) as in paragraph (d)(2) of this section.

(c) Special considerations. See §500.25 of this chapter.

(d) Conditions of use—(1) Horses and ponies. It is used as follows:

(i) Amount. 3 mg per pound (lb) body weight as a single dose mixed with the usual grain ration, or by stomach tube or dose syringe.

(ii) Indications for use. For the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); pinworms (Oxyurus equi); large roundworms (Parascaris equorum); and small strongyles.

(iii) Limitations. Do not use in horses intended for human consumption. When the drug is for administration by stomach tube, it shall be labeled: "Federal law restricts this drug to use by or on the order of a licensed veterinarian."

(2) Dogs. It is used as follows:

(i) Dogs and puppies—(A) Amount. 2.27 mg/lb body weight as a single dose in the animal’s feed bowl by itself or mixed in a small quantity of food.

(B) Indications for use. For the removal of large roundworms (Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).

(C) Limitations. Additional treatment may be required and should be confirmed by fecal examination within 2 to 4 weeks.

(ii) Dogs, puppies, and lactating bitches after whelping—(A) Amount. 2.27 mg/lb body weight.

(B) Indications for use. To prevent re-infections of T. canis.

(C) Limitations. Administer to puppies at 2, 3, 4, 6, 8, and 10 weeks of age. Administer to lactating bitches 2 to 3 weeks after whelping. Adult dogs kept in heavily contaminated quarters may be treated at monthly intervals.

§ 520.2044 Pyrantel pamoate paste.

(a) Specifications—(1) Each milliliter (mL) contains 180 milligrams (mg) pyrantel base (as pyrantel pamoate).

(2) Each mL contains 226 mg pyrantel base (as pyrantel pamoate).

(3) Each mL contains 171 mg pyrantel base (as pyrantel pamoate).

(b) Sponsors. See sponsors in §510.600(c) of this chapter.

(1) No. 054771 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1)(i) and (d)(2) of this section.

(2) No. 017135 for use of product described in paragraph (a)(2) of this section as in paragraph (d) of this section.

(3) No. 061623 for use of product described in paragraph (a)(3) of this section as in paragraph (d)(1)(i) and (d)(2) of this section.

(c) Special considerations. See §500.25 of this chapter.

(d) Conditions of use. It is used in horses and ponies as follows:
§ 520.2045 Pyrantel tartrate powder.

(a) Specifications. Each gram of powder contains 106 milligrams (10.6 percent) or 113 milligrams (11.3 percent) pyrantel tartrate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter for use of products described in paragraph (a) as in paragraph (c) of this section.

(2) Conditions of use in horses—(1) Amount. Administer as a single dose at 0.57 gram of pyrantel tartrate per 100 pounds of body weight mixed with the usual grain ration. Do not administer by stomach tube or dose syringe.

(2) Indications for use. For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), small strongyles (Trichonema spp., Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris equorum).

(ii) 6 mg/lb body weight as single oral dose for the removal and control of mature infections of tapeworms (Anoplocephala perfoliata).

(2) Limitations. Do not use in horses intended for human consumption.


§ 520.2046 Pyrantel tartrate pellets.

(a) Specifications. (1) Each gram of pellets contains 12.5 milligrams (mg) (1.25 percent) pyrantel tartrate; or (2) Each gram of pellets contains 21.1 mg (2.11 percent) pyrantel tartrate.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter:

(1) No. 054771 for use of products described in paragraph (a) as in paragraph (c) of this section.

(2) No. 061623 for use of product described in paragraph (a)(1) as in paragraph (c) of this section.

(2) Indications for use. For the removal and control of infections from the following mature parasites: Large strongyles (Strongylus vulgaris, S. edentatus, S. equinus), small strongyles (Trichonema spp., Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).

(3) Limitations. Do not treat severely debilitated animals with this drug. Do not use in horses intended for human consumption.

[79 FR 28827, May 20, 2014]

§ 520.2075 Robenacoxib.

(a) Specifications. Each tablet contains 6 milligrams (mg) robenacoxib.

(b) Sponsors. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use in cats—(1) Amount. Administer 0.45 mg per pound (1lb) (1 mg/kilogram (kg)) once daily.

(2) Indications for use. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats weighing at least 5.5 lb (2.5 kg) and at least 4 months of age; for up to a maximum of 3 days.
§ 520.2123b Spectinomycin oral dosage forms.

§ 520.2123a Spectinomycin tablets.

§ 520.2123b Spectinomycin powder.

Food and Drug Administration, HHS

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2098 Selegiline.

(a) Specifications. Each tablet contains 2, 5, 10, 15, or 30 milligrams (mg) selegiline hydrochloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount and indications for use. (i) Administer 1 mg per kilogram (0.45 mg per pound) of body weight once daily for control of clinical signs associated with uncomplicated pituitary-dependent hyperadrenocorticism in dogs.

(ii) Administer 0.5 to 1.0 mg per kilogram of body weight once daily for the control of clinical signs associated with canine cognitive dysfunction syndrome.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28828, May 20, 2014]

§ 520.2100 Selenium and vitamin E.

(a) Specifications. Each capsule contains:

(1) 2.19 milligrams (mg) sodium selenite (equivalent to 1 mg selenium) and 56.2 mg (68 IU) vitamin E as d-alpha tocopheryl acid succinate; or

(2) 0.548 mg sodium selenite (equivalent to 0.25 mg selenium) and 14 mg (17 IU) vitamin E as d-alpha tocopheryl acid succinate.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally to provide 10 mg per pound (lb) of body weight twice daily. Dosage may be continued for 4 consecutive days.

(2) Indications for use. For the treatment of infectious diarrhea and gastroenteritis caused by organisms susceptible to spectinomycin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28828, May 20, 2014]
synoviae in broiler chickens, administer 1 g per gallon of water as the only source of drinking water for the first 3 to 5 days of life.

(iii) As an aid in the prevention or control of losses due to CRD associated with M. gallisepticum (PPLO) in growing chickens, administer 2 g per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination.

(2) Limitations. Do not administer to laying chickens. Do not administer within 5 days of slaughter.

[73 FR 6607, Feb. 5, 2008]

§ 520.2123c Spectinomycin solution.

(a) Specifications. Each milliliter of solution contains spectinomycin dihydrochloride pentahydrate equivalent to 50 milligrams (mg) spectinomycin.

(b) Sponsors. See Nos. 000859, 054771, and 061623 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.600 of this chapter.

(d) Conditions of use in swine—(1) Amount. Administer 5 mg per pound (lb) of body weight orally twice daily for 3 to 5 days.

(2) Indications for use. For the treatment and control of porcine enteric colibacillosis (scours) caused by E. coli susceptible to spectinomycin in pigs under 4 weeks of age.

(3) Limitations. Do not administer to pigs over 15 lb body weight or over 4 weeks of age. Do not administer within 21 days of slaughter.


§ 520.2130 Spinosad.

(a) Specifications. Each chewable tablet contains 90, 140, 270, 560, 810, or 1620 milligrams (mg) spinosad.

(b) Sponsor. See No. 000986 in § 510.600 of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs—(i) Amount. Administer tablets once a month at a minimum dosage of 13.5 mg/pound (30 mg/kg) of body weight.

(ii) Indications for use. To kill fleas and for the prevention and treatment of flea infestations (Ctenocephalides felis) for 1 month on dogs and puppies 8 weeks of age and older and 3.3 pounds of body weight or greater.

(2) Cats—(i) Amount. Administer tablets once a month at a minimum dosage of 22.5 mg per pound (50 mg per kilogram) of body weight.

(ii) Indications for use. To kill fleas and for the prevention and treatment of flea infestations (C. felis) for 1 month on cats and kittens 14 weeks of age and older and 2 pounds of body weight or greater.

[77 FR 60623, Oct. 4, 2012]

§ 520.2134 Spinosad and milbemycin.

(a) Specifications. Each chewable tablet contains 140 milligrams (mg) spinosad and 2.3 mg milbemycin oxime, 270 mg spinosad and 4.5 mg milbemycin oxime, 560 mg spinosad and 9.3 mg milbemycin oxime, 810 mg spinosad and 13.5 mg milbemycin oxime, or 1,620 mg spinosad and 27 mg milbemycin oxime.

(b) Sponsor. See No. 000986 in § 510.600 of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer once a month at a minimum dosage of 13.5 mg/pound (lb) (30 mg/kg) of body weight spinosad and 0.2 mg/lb (0.5 mg/kg) of body weight milbemycin oxime.

(2) Indications for use. To kill fleas; for the prevention and treatment of flea infestations (Ctenocephalides felis); for the prevention of heartworm disease (Dirofilaria immitis); and for the treatment and control of adult hookworm (Ancylostoma caninum), adult roundworm (Toxocara canis) and Toxascaris leonina), and adult whipworm (Trichuris vulpis) infections in dogs and puppies 8 weeks of age or older and 5 lbs of body weight or greater.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[76 FR 12563, Mar. 8, 2011]

§ 520.2150 Stanozolol.

(a) Specifications. Each tablet or chewable tablet contains 2 milligrams stanozolol.

(b) Sponsor. No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—

(1) Amount—

(i) Dogs: Administered orally to small breeds, ½ to 1 tablet twice daily for several weeks; to large breeds, 1 to 2 tablets twice daily for several weeks. The tablets may be crushed and administered in feed.

(ii) Cats: Administered orally ½ to 1 tablet twice daily for several weeks.

(2) Indications for use. As an anabolic steroid treatment.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2158 Streptomycin.

(a) Specifications. Each milliliter of solution contains 250 milligrams (25 percent) streptomycin sulfate.

(b) Sponsor. See No. 016592 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.610 of this chapter.

(d) Conditions of use. Use in drinking water as follows:

(1) Calves—

(i) Amount. 10 to 15 milligrams per pound (mg/pound) of body weight (1.0 to 1.5 grams per gallon) for up to 5 days.

(ii) Indications for use. For the treatment of bacterial enteritis caused by Escherichia coli and Salmonella spp. susceptible to streptomycin.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Swine—

(i) Amount. 10 to 15 mg/pound of body weight (0.6 to 0.9 grams per gallon) for up to 4 days.

(ii) Indications for use. For the treatment of bacterial enteritis caused by Escherichia coli and Salmonella spp. susceptible to streptomycin.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Chickens—

(i) Amount. 10 to 15 mg/pound of body weight (0.6 to 0.9 grams per gallon) for up to 5 days.

(ii) Indications for use. For the treatment of nonspecific infectious enteritis caused by organisms susceptible to streptomycin.

(iii) Limitations. Withdraw 4 days before slaughter. Do not administer to chickens producing eggs for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2170 Sulfabromomethazine.

(a) Specifications. Each bolus contains 15 grams of sulfabromomethazine sodium.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Related tolerance. See § 556.620 of this chapter.

(d) Conditions of use in cattle—

(1) Amount. Administer 90 milligrams per pound body weight orally. Repeat in 48 hours if necessary.

(2) Indications for use. Treatment of necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum; colibacillosis (scours) caused by Escherichia coli; bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) associated with Pasteurella spp.; acute metritis and acute mastitis caused by Streptococcus spp.

(3) Limitations. Milk taken from animals within 96 hours (8 milkings) of latest treatment must not be used for food. Do not administer within 18 days of slaughter.

§ 520.2184 Sulfachloropyrazine.

(a) Specifications. Each gram of powder contains 476 milligrams of sodium sulfachloropyrazine monohydrate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerance. See § 556.625 of this chapter.

(d) Conditions of use in chickens. It is used in the drinking water of broilers, breeder flocks, and replacement chickens as follows:

(1) Amount. Administer in drinking water at 0.03 percent solution for 3 days.

(2) Indications for use. For the treatment of coccidiosis.
§ 520.2200 Sulfachlorpyridazine.

(a) Specifications. (1) Sodium sulfachlorpyridazine powder.
   (2) Each bolus contains 2 grams sulfachlorpyridazine.
   (3) Each tablet contains 250 milligrams (mg) sulfachlorpyridazine.

(b) Sponsor. See No. 016592 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.630 of this chapter.

(d) Conditions of use. It is used as follows:
   (1) Calves—(i) Amount. Administer 30 to 45 mg sulfachlorpyridazine powder per pound (lb) of body weight per day in milk or milk replacer, or in a bolus, in divided doses twice daily for 1 to 5 days.
      (ii) Indications for use. For the treatment of diarrhea caused or complicated by Escherichia coli (coli bacillosis).
      (iii) Limitations. Treated ruminating calves must not be slaughtered for food during treatment or for 7 days after the last treatment. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
   (2) Swine—(i) Amount. Administer 20 to 35 mg/lb body weight per day, in divided doses twice daily for 1 to 5 days:
      (A) In drinking water or
      (B) For individual treatment, in an oral suspension containing 50 mg per milliliter.
   (ii) Indications for use. For the treatment of diarrhea caused or complicated by E. coli (coli bacillosis).
   (iii) Limitations. Treated swine must not be slaughtered for food during treatment or for 4 days after the last treatment.
   (3) Dogs—(i) Amount. Administer tablets orally at 500 mg per 10 to 15 lb of body weight daily, in two or three divided doses.
   (ii) Indications for use. As an aid in the treatment of infectious tracheobronchitis and infections caused by E. coli, and in the treatment of infections caused by other Gram-positive and Gram-negative organisms that are susceptible to sulfonamide therapy.
      (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2215 Sulfadiazine/pyrimethamine suspension.

(a) Specifications. Each milliliter (mL) of suspension contains 250 milligrams (mg) sulfadiazine (as the sodium salt) and 12.5 mg pyrimethamine.

(b) Sponsor. See No. 055246 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer orally 20 mg sulfadiazine per kilogram (kg) body weight and 1 mg/kg pyrimethamine daily.
   (2) Indications for use. For the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona.
   (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2218 Sulfamerazine, sulfamethazine, and sulfadiazine powder.

(a) Specifications. Each 195-gram (g) packet of powder contains 78 g sulfamerazine, 78 g sulfamethazine, and 39 g sulfadiazine.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.670 and 556.685 of this chapter.

(d) Conditions of use—(1) Chickens—(i) Amounts and indications for use—(A) As an aid in the control of coccidiosis caused by Eimeria tenella and E. necatrix susceptible to sulfamerazine, sulfamethazine, and sulfadiazine: Provide medicated water (0.04 percent solution) for 2 to 3 days, then plain water for 3 days, then medicated water (0.025 percent solution) for 2 days. If bloody droppings appear, repeat at 0.025...
percent level for 2 more days. Do not change litter.

(B) As an aid in the control of acute fowl cholera caused by *Pasteurella multocida* susceptible to sulfamerazine, sulfamethazine, and sulfaquinoxaline: Provide medicated water (0.04 percent solution) for 2 to 3 days. If disease recurs, repeat treatment.

(ii) Limitations. Make fresh solution daily. Do not treat chickens within 14 days of slaughter for food. Do not medicate chickens producing eggs for human consumption.

(2) Turkeys—(i) Amounts and indications for use—(A) As an aid in the control of coccidiosis caused by *Eimeria* meleagrimitis and *E. adenoeides* susceptible to sulfamerazine, sulfamethazine, and sulfaquinoxaline: Provide medicated water (0.025 percent solution) for 2 days, then plain water for 3 days, then medicated water (0.025 percent solution) for 2 days, then plain water for 3 days, then medicated water (0.025 percent solution) for 2 days. Repeat if necessary. Do not change litter.

(B) As an aid in the control of acute fowl cholera caused by *Pasteurella multocida* susceptible to sulfamerazine, sulfamethazine, and sulfaquinoxaline: Provide medicated water (0.04 percent solution) for 2 to 3 days. If disease recurs, repeat treatment.

(ii) Limitations. Make fresh solution daily. Do not treat turkeys within 14 days of slaughter for food. Do not medicate turkeys producing eggs for human consumption.

(3) Cattle—(i) Amount. 1.18 to 2.36 grams per gallon (0.031 to 0.062 percent) of drinking water. As a drench, administer 2.5 grams per 100 pounds of body weight for first day, then 1.25 grams per 100 pounds of body weight per day for the next 4 consecutive days. If no improvement within 2 to 3 days, re-evaluate diagnosis. Do not treat beyond 5 days.

(ii) Indications for use. Dairy calves, dairy heifers, and beef cattle: For the treatment of shipping fever complex and bacterial pneumonia associated with *Pasteurella* spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with *Fusobacterium necrophorum* (*Sphaerophorus necrophorus*) sensitive to sulfadimethoxine.

(iii) Limitations. Withdraw 7 days before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal...
law prohibits the extralabel use of this product in lactating dairy cattle.
[79 FR 28829, May 20, 2014]

§ 520.2220b Sulfadimethoxine suspension.
(a) Specifications. Each milliliter of suspension contains 50 milligrams (mg) sulfadimethoxine.
(b) Sponsors. See Nos. 000061 and 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—
(1) Amount. Administer orally 25 mg per pound of body weight, followed by 12.5 mg per pound of body weight daily.
(2) Indications for use. For the treatment of sulfonamide susceptible bacterial infections in dogs and cats and enteritis associated with coccidiosis in dogs.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28829, May 20, 2014]

§ 520.2220c Sulfadimethoxine tablet.
(a) Specifications. Each tablet contains 125, 250, or 500 milligrams (mg) sulfadimethoxine.
(b) Sponsors. See Nos. 000061 and 054771 in § 510.600(c) of this chapter.
(c) [Reserved]
(d) Conditions of use in dogs and cats—
(1) Amount. Administer 25 milligrams (mg) per pound of body weight on the first day followed by 12.5 milligrams (mg) per pound of body weight per day until the animal is free of symptoms for 48 hours.
(2) Indications for use. Treatment of sulfadimethoxine-susceptible bacterial infections.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28829, May 20, 2014]

§ 520.2220d Sulfadimethoxine bolus.
(a) Specifications. Each bolus contains 2.5, 5, or 15 grams sulfadimethoxine.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.640 of this chapter.
(d) Conditions of use in cattle—
(1) Amount. Administer 2.5 grams per 100 pounds body weight for 1 day followed by 1.25 grams per 100 pounds body weight per day; treat for 4 to 5 days.
(2) Indications for use. For the treatment of shipping fever complex and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with Fusobacterium necrophorum sensitive to sulfadimethoxine.
(3) Limitations. Do not administer within 7 days of slaughter; milk that has been taken from animals during treatment and 60 hours (5 milkings) after the latest treatment must not be used for food. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
[79 FR 28829, May 20, 2014]

§ 520.2220e Sulfadimethoxine extended-release bolus.
(a) Specifications. Each extended-release bolus contains 12.5 grams sulfadimethoxine.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Related tolerances. See § 556.640 of this chapter.
(d) Conditions of use in beef cattle and non-lactating dairy cattle—
(1) Amount. Administer one 12.5-gram-sustained-release bolus for the nearest 200 pounds of body weight, i.e., 62.5 milligrams per pound of body weight. Do not repeat treatment for 7 days.
(2) Indications for use. For the treatment of shipping fever complex and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; and calf diphtheria and foot rot associated with Fusobacterium necrophorum sensitive to sulfadimethoxine.
(3) Limitations. Do not use in female dairy cattle 20 months of age or older. Do not administer within 12 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28830, May 20, 2014]

§ 520.2220f Sulfadimethoxine and ormetoprim tablet.
(a) Specifications. Each tablet contains 120 milligrams (mg) (100 mg sulfadimethoxine and 20 mg
ormetoprim), 240 mg (200 mg sulfadimethoxine and 40 mg ormetoprim), 600 mg (500 mg sulfadimethoxine and 100 mg ormetoprim), or 1200 mg (1000 mg sulfadimethoxine and 200 mg ormetoprim).

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. On the first day of treatment, administer 25 mg per pound (55 mg per kilogram) of body weight. Then follow with a daily dosage of 12.5 mg per pound (27.5 mg per kilogram) of body weight. Do not exceed a total of 21 consecutive days.

(2) Indications of use. Treatment of skin and soft tissue infections (wounds and abscesses) in dogs caused by strains of *Staphylococcus aureus* and *Escherichia coli* and urinary tract infections caused by *E. coli*, *Staphylococcus* spp., and *Proteus mirabilis* susceptible to ormetoprim-potentiated sulfadimethoxine.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28830, May 20, 2014]

§520.2240b Sulfaethoxypyridazine tablets.

(a) Specifications—(1) Each tablet contains 2.5 or 15 grams sulfaethoxypyridazine.

(2) Each extended-release tablet contains 5 grams sulfaethoxypyridazine.

(b) Sponsor. See No. 054771 §510.600(c) of this chapter.

(c) Related tolerances. See §556.650 of this chapter.

(d) Conditions of use in cattle—(1) 2.5- or 15-gram tablets—(i) Amount. Administer 25 milligrams per pound of body weight per day for 4 days. Use as the sole source of sulfonamide.

(ii) Indications for use. For treatment of respiratory infections (pneumonia, shipping fever), foot rot, calf scours; and as adjunctive therapy in septicemia accompanying mastitis and metritis.

(iii) Limitations. Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) 15-gram extended-release tablets—(i) Amount. Administer 100 milligrams per pound of body weight. Use as the sole source of sulfonamide.

(ii) Indications for use. For treatment of foot rot and respiratory infections (shipping fever and pneumonia) caused by sulfonamide-susceptible pathogens (*E. coli*, *Streptococci*, *Staphylococci*, *Sphaerophorus necrophorus* and Gram-negative rods including *Pasteurella*);
and for use prophylactically during periods of stress for reducing losses due to sulfonamide sensitive disease conditions.

(iii) Limitations. Do not treat within 16 days of slaughter. Not for use in lactating dairy cows. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28830, May 20, 2014]

§ 520.2260 Sulfamethazine oral dosage forms.

§ 520.2260a Sulfamethazine oblet, tablet, and bolus.

(a)(1) Sponsor. See No. 016592 in § 510.600(c) of this chapter for use of 2.5-, 5-, and 15-gram sulfamethazine oblet in beef cattle, nonlactating dairy cattle, and horses. See No. 061690 in § 510.600(c) of this chapter for use of 5-, 15-, and 25-gram tablet in beef and nonlactating dairy cattle.

(2) Related tolerances in edible products. See § 556.670 of this chapter.

(i) Indications for use. For treatment of diseases caused by organisms susceptible to sulfamethazine:

(A) Beef cattle and nonlactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.), acute encephalitis (Streptococcus spp.), coccidiosis (Eimeria bovis and Eimeria zurnii).

(B) Horses. Treatment of bacterial pneumonia (secondary infections associated with Pasteurella spp.), strangles (Streptococcus equi), and bacterial enteritis (Escherichia coli).

(iii) Limitations. Administer daily until animal’s temperature and appearance are normal. If symptoms persist after using for 2 or 3 days consult a veterinarian. Fluid intake must be adequate. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed 5 consecutive days. Follow dosages carefully. Do not treat cattle within 10 days of slaughter. Do not use in female dairy cattle 20 months of age or older. Use of sulfamethazine in this class of cattle may cause milk residues. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Do not use in horses intended for human consumption.

(b)(1) Sponsor. See No. 054771 in § 510.600(c) of this chapter for use of 5-gram sulfamethazine bolus.

(2) Related tolerances in edible products. See § 556.670 of this chapter.

(i) Indications for use. Ruminating beef and dairy calves. For treatment of the following diseases caused by organisms susceptible to sulfamethazine: bacterial scours (colibacillosis) caused by E. coli; necrotic pododermatitis (foot rot) and calf diphtheria caused by F. necrophorum; bacterial pneumonia associated with Pasteurella spp.; and coccidiosis caused by E. bovis and E. zurnii.

(ii) Limitations. Do not administer for more than 5 consecutive days. Do not treat calves within 11 days of slaughter. Do not use in calves to be slaughtered under 1 month of age or in calves being fed an all milk diet. Do not use in female dairy cattle 20 months of age or older; such use may cause drug residues in milk. Administer with adequate supervision. Follows recomended dosages carefully. Fluid intake must be adequate. If symptoms persist after 2 or 3 days, consult a veterinarian.

§ 520.2260b Sulfamethazine sustained-release boluses.

(a)(1) Sponsor. See No. 000859 in §510.600(c) of this chapter for use of a 22.5-gram sulfamethazine prolonged-release bolus.

(2) Conditions of use—(i) Amount. Depending on the duration of therapeutic levels desired, administer boluses as a single dose as follows: 3½ days—1 bolus (22.5 grams) per 200 pounds of body weight; 5 days—1 bolus per 100 pounds of body weight.

(ii) Indications for use. For beef and nonlactating cattle for sustained treatment of shipping fever pneumonia caused or complicated by Pasteurella multocida; as an aid in the treatment of foot rot, mastitis, pneumonia, metritis, bacterial enteritis, calf diphtheria, and septicemia when caused or complicated by bacteria susceptible to sulfamethazine.

(iii) Limitations. Cattle that are acutely ill should be treated parenterally with a suitable antibacterial product to obtain immediate therapeutic blood levels; do not slaughter animals for food within 16 days of treatment; do not use in lactating dairy cattle; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Sponsor. See No. 054771 in §510.600(c) of this chapter for use of a 27-gram sulfamethazine sustained-release bolus.

(2) Conditions of use—(i) Amount. 27 grams (1 bolus) for each 150 pounds of body weight as a single dose.

(ii) Indications for use. For nonlactating cattle for the treatment of infections caused by organisms sensitive to sulfamethazine such as hemorrhagic septicemia (shipping fever complex), bacterial pneumonia, foot rot, and calf diphtheria and as an aid in the control of bacterial diseases usually associated with shipping and handling of cattle.

(iii) Limitations. If no response within 2 to 3 days, reevaluate therapy; do not crush tablets; treated animals must not be slaughtered for food within 28 days after the latest treatment; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Sponsor. See No. 061623 in §510.600(c) of this chapter for use of a 32.1-gram sustained-release bolus.

(2) Conditions of use—(i) Amount. 32.1 grams (1 bolus) per 200 pounds of body weight.

(ii) Indications for use. For beef and nonlactating dairy cattle for the treatment of diseases caused by sulfamethazine-sensitive organisms as follows; bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) caused by Pasteurella spp., colibacillosis (bacterial scours) caused by E. coli, necrotic pododermatitis (foot rot) and calf diphtheria caused by Pasteurella multocida, colibacillosis (bacterial scours) caused by Streptococcus spp.

(iii) Limitations. After 72 hours, all animals should be reexamined for persistence of observable disease signs. If signs are present, consult a veterinarian. It is strongly recommended that a second dose be given to provide for an additional 72 hours of therapy, particularly in more severe cases. The dosage schedule should be used at each 72-hour interval. Animals should not receive more than 2 doses because of the possibility of incurring residue violations. This drug, like all sulfonamides, may cause toxic reactions and irreparable injury unless administered with adequate and continuous supervision; follow dosage carefully. Fluid intake must be adequate at all times throughout the 3-day therapy. Do not use in female dairy cattle 20 months of age or older. Use of sulfamethazine in this class of cattle may cause milk residues. Do not treat animals within 12 days of slaughter.

(d)(1) Sponsor. See 000859 in §510.600(c) of this chapter for use of a 22.5-gram sulfamethazine sustained release bolus.

(2) Conditions of use—(i) Amount. Administer 1 bolus (22.5 grams) per 200 pounds of body weight, as a single dose.

(ii) Indications for use. For beef and nonlactating dairy cattle for the prolonged treatment of the following diseases when caused by one or more of the listed pathogenic organisms sensitive to sulfamethazine: bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), bacterial pneumonia (Pasteurella spp.), necrotic pododermatitis (foot rot) (Pasteurella multocida), colibacillosis (bacterial scours)
(Escherichia coli), calf diphtheria
(Fusobacterium necrophorum), acute
mastitis (Streptococcus spp.) and acute
metritis (Streptococcus spp.).

(iii) Limitations. Cattle that are
acutely ill should be treated by injec-
tion with a suitable antibacterial prod-
cuct to obtain immediate therapeutic
blood levels; do not slaughter animals
for food within 16 days of treatment; do
not use in lactating dairy cattle; if
treated animals do not respond within
2 to 3 days, consult a veterinarian.

(e)(1) Sponsor. See No. 061623 in
§ 510.600(c) of this chapter for use of an
8.02-gram sulfamethazine sustained-re-
lease bolus.

(ii) Indications for use. Administer or-
ally to ruminating calves for the pro-
longed treatment of the following dis-
eases when caused by one or more of
the listed pathogenic organisms sen-
sitive to sulfamethazine: bacterial
pneumonia (Pasteurella spp.),
colibacillosis (bacterial scours) (E.
coli), and calf diphtheria (Fusobacterium
necrophorum).

(iii) Limitations. For use in rumi-
nating replacement calves only; 72
hours after dosing all animals should
be reexamined for persistence of dis-
ease signs; if signs are present, consult
a veterinarian; do not slaughter ani-
mals for food for at least 8 days after
the last dose; do not use in lactating
dairy cattle; do not administer
more than two consecutive doses.

(g) Related tolerances. See § 556.670 of
this chapter.

(h)(1) Sponsor. See No. 000010 in
§ 510.600(c) of this chapter for use of an
8.25-gram sulfamethazine sustained-re-
lease bolus.

(ii) Indications for use. Administer or-
ally to beef cattle and nonlactating
cattle for treatment of the following
diseases when caused by one or more of
the listed pathogenic organisms sus-
ceptible to sulfamethazine: bo-
vine respiratory disease complex (ship-
ning fever complex) associated with
Pasteurella spp.; bacterial pneumonia
associated with Pasteurella spp.; necrotic
pododermatitis (foot rot) and calf diph-
theria caused by Fusobacterium
necrophorum; colibacillosis (bacterial
scours) caused by Escherichia coli; coc-
cidiosis caused by Eimeria bovis and E.
zurnii; acute mastitis and metritis
caused by Streptococcus spp.

(iii) Limitations. Do not use in calves
to be slaughtered under 1 month of age
or calves being fed an all milk diet. Do
not use in female dairy cattle 20
months of age or older. If symptoms
persist after 3 days, consult a veteri-
narian. Do not administer more than 2
consecutive doses. Do not slaughter

§ 520.2260c Sulfamethazine sustained-release tablets.

(a) Specifications. Each extended-release tablet contains 8 grams sulfamethazine.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.670 of this chapter.

(d) Conditions of use—(1) Amount. 8 grams (1 tablet) per 45 pounds of body weight as a single dose.

(2) Indications for use. In calves for sustained treatment of pneumonia caused by Pasteurella spp., colibacillosis (bacterial scours) caused by Escherichia coli, and calf diphtheria caused by Fusobacterium necrophorum.

(3) Limitations. Treated animals must not be slaughtered for food within 18 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2261 Sulfamethazine sodium oral dosage forms.

§ 520.2261a Sulfamethazine solution.

(a) Specifications. Each milliliter of solution contains 125 milligrams (12.5 percent) sulfamethazine sodium.

(b) Sponsors. See Nos. 016592 and 061623 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.670 of this chapter.

(d) Conditions of use—(1) Amount. Administer in drinking water to provide: Cattle and swine 112.5 milligrams of sulfamethazine sodium per pound of body weight per day on the first day and 56.25 milligrams per pound of body weight on subsequent days; Chickens, 61 to 89 milligrams of sulfamethazine sodium per pound of body weight per day, and turkeys 53 to 130 milligrams of sulfamethazine sodium per pound of body weight per day, depending upon the dosage, age, and class of chickens or turkeys, ambient temperature, and other factors.

(2) Indications for use. For treatment and control of diseases caused by organisms sensitive to sulfamethazine.

(i) Beef and nonlactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial scours) (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis (Streptococcus spp.), and acute metritis (Streptococcus spp.).

(ii) Swine. Treatment of porcine colibacillosis (bacterial scours) (Escherichia coli), and bacterial pneumonia (Pasteurella spp.).

(iii) Chickens and turkeys. In chickens for control of infectious coryza (Avibacterium paragallinarum), coccidiosis (Eimeria tenella, Eimeria necatrix), acute fowl cholera (Pasteurella multocida), and pullorum disease (Salmonella Pullorum). In turkeys for control of coccidiosis (Eimeria meleagrimitis, Eimeria adenoeides). Medicate as follows: Infectious coryza in chickens, medicate for 2 consecutive days; acute fowl cholera and pullorum disease, in chickens, medicate for 6 consecutive days; coccidiosis, in chickens and turkeys, medicate as in paragraph (c) of this section, then reduce amount of medication to one-half for 4 additional days.

(3) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication from cattle, chickens, and turkeys 10 days prior to slaughter for food. Withdraw medication from swine 15 days before slaughter for food. Do not medicate chickens or turkeys producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease...
§ 520.2261b Sulfamethazine powder.

(a) Specifications. A soluble powder composed of 100 percent sulfamethazine sodium.

(b) Sponsors. See Nos. 016592 and 061623 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.670 of this chapter.

(d) Conditions of use—(1) Chickens—(i) Amount. Administer in drinking water to provide 58 to 85 milligrams (mg) per pound (lb) of body weight per day.

(ii) Indications for use. For control of infectious coryza (Avibacterium paragallinarum), coccidiosis (Eimeria tenella, E. necatrix), acute fowl cholera (Pasteurella multocida), and pullorum disease (Salmonella Pullorum).

(iii) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 15 days prior to slaughter for food. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms. Medicated chickens must actually consume enough medicated water which provides the recommended dosages.

(2) Turkeys—(i) Amount. Administer in drinking water to provide 50 to 124 mg/lb of body weight per day

(ii) Indications for use. For control of coccidiosis (E. meleagrimitis, E. adenoeides).

(iii) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 10 days prior to slaughter for food. Do not medicate turkeys producing eggs for human consumption. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms. Medicated turkeys must actually consume enough medicated water which provides the recommended dosages.

(3) Swine—(i) Amount. Administer in drinking water, or as a drench, to provide 108 mg/lb of body weight on the first day and 54 mg/lb of body weight per day on the second, third, and fourth days of administration.

(ii) Indications for use. For treatment of porcine colibacillosis (bacterial scour) (E. coli), and bacterial pneumonia (Pasteurella spp.).

(iii) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 15 days prior to slaughter for food. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days. Medicated swine must actually consume enough medicated water which provides the recommended dosages.

(4) Cattle—(i) Amount. Administer in drinking water, or as a drench, to provide 108 mg/lb of body weight on the first day and 54 mg/lb of body weight per day on the second, third, and fourth days of administration.

(ii) Indications for use in beef and non-lactating dairy cattle. Treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial scour) (E. coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (F. necrophorum), acute mastitis
(Streptococcus spp.), and acute metritis (Streptococcus spp.)

(iii) Limitations. Add the required dose to that amount of water that will be consumed in 1 day. Consumption should be carefully checked. Have only medicated water available during treatment. Withdraw medication 10 days prior to slaughter for food. Treatment of all diseases should be instituted early. Treatment should continue 24 to 48 hours beyond the remission of disease symptoms, but not to exceed a total of 5 consecutive days. Medicated cattle must actually consume enough medicated water which provides the recommended dosages. Do not use in female dairy cattle 20 months of age or older. Use of sulfamethazine in this class of cattle may cause milk residues. Do not use in calves under one (1) month of age or calves being fed an all-milk diet. Use in these classes of calves may cause violative residues to remain beyond the withdrawal time.


§ 520.2325 Sulfaquinoxaline oral dosage forms.

§ 520.2325a Sulfaquinoxaline powder and solution.

(a) Sponsor. See §510.600(c) of this chapter for identification of the sponsors.

(1) To No. 000859 for use of a 25-percent sulfaquinoxaline soluble powder and a 20-percent sulfaquinoxaline sodium solution as provided for in paragraph (c) of this section.

(2) To No. 061623 for use of 3.44- and 12.85-percent sulfaquinoxaline sodium solutions as provided for in paragraphs (c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.

(3) To No. 054771 for use of a 31.92-percent sulfaquinoxaline solution (sodium and potassium salts) as provided for in paragraphs (c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.

(4) No. 053501 for use of a 28.62-percent sulfaquinoxaline sodium solution as provided in paragraphs (c)(1), (c)(2), and (c)(3) of this section.

(b) Related tolerances. See §556.685 of this chapter.

(c) Conditions of use. It is used in drinking water as follows:

(1) Chickens. (i) As an aid in the control of outbreaks of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, and E. brunetti.

(ii) Administer at the 0.04 percent level for 2 or 3 days, skip 3 days then administer at the 0.025 percent level for 2 more days. If bloody droppings appear, repeat treatment at the 0.025 percent level for 2 more days. Do not change litter unless absolutely necessary. Do not give flushing mashes.

(2) Turkeys. (i) As an aid in the control of outbreaks of coccidiosis caused by Eimeria meleagrimitis and E. adenoeides.

(ii) Administer at the 0.025 percent level for 2 days, skip 3 days, give for 2 more days, skip 3 days and give for 2 more days. Repeat if necessary. Do not
change litter unless absolutely necessary. Do not give flushing mashes.

(3) **Chickens and turkeys.** (i) As an aid in the control of acute fowl cholera caused by *Pasteurella multocida* susceptible to sulfaquinoxaline and fowl typhoid caused by *Salmonella gallinarum* susceptible to sulfaquinoxaline.

(ii) Administer at the 0.04 percent level for 2 or 3 days. Move birds to clean ground. If disease recurs, repeat treatment. If cholera has become established as the respiratory or chronic form, use feed medicated with sulfaquinoxaline. Poultry which have survived typhoid outbreaks should not be kept for laying house replacements or breeders unless tests show they are not carriers.

(4) **Cattle and calves.** (i) For the control and treatment of outbreaks of coccidiosis caused by *Eimeria bovis* or *E. zuernii*.

(ii) Administer at the 0.015-percent level for 3 to 5 days in drinking water medicated with sulfaquinoxaline solution.

(iii) In lieu of treatment as provided in paragraph (e)(4)(ii) of this section, administer 1 teaspoon of 25-percent sulfaquinoxaline soluble powder per day for each 125 pounds of body weight in drinking water.

(d) **Limitations.** Consult a veterinarian or poultry pathologist for diagnosis. May cause toxic reactions unless the drug is evenly mixed in water at dosages indicated and used according to directions. For control of outbreaks of disease, medication should be initiated as soon as the diagnosis is determined. Medicated chickens, turkeys, cattle, and calves must actually consume enough medicated water which provides a recommended dosage of approximately 10 to 45 milligrams per pound per day in chickens, 3.5 to 55 milligrams per pound per day in turkeys, and approximately 6 milligrams per pound per day in cattle and calves depending on the age, class of animal, ambient temperature, and other factors. A withdrawal period has not been established for sulfaquinoxaline in preruminating calves. Do not use in calves to be processed for veal. Not for use in lactating dairy cattle. Do not medicate chickens or turkeys producing eggs for human consumption. Make fresh drinking water daily.

§ 520.2340 Tepoxalin.

(a) Specifications. Each tablet contains 30, 50, 100, or 200 milligrams (mg) tepoxalin.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 10 mg per kilogram (/kg) daily; or 20 mg/kg on the initial day of treatment, followed by 10 mg/kg daily.

(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[68 FR 34795, June 11, 2003]

§ 520.2345 Tetracycline.

§ 520.2345a Tetracycline capsules.

(a) Specifications. Each capsule contains 50, 100, 125, 250, or 500 milligrams (mg) tetracycline hydrochloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 25 mg per pound of body weight per day in divided doses every 6 hours.

(2) Indications for use. For treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E. coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli*.

(3) Limitations. Administer orally; continue treatment until symptoms of the disease have subsided and temperature is normal for 48 hours; not for use in animals raised for food production; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28831, May 20, 2014]

§ 520.2345b Tetracycline tablets.

(a) Specifications. Each tablet contains 100, 250, or 500 milligrams of tetracycline (as the hydrochloride).

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. Dogs—(1) Amount. 25 milligrams per pound of body weight per day in divided doses every 6 hours.

(2) Indications for use. Treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E. coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli*.

(3) Limitations. Administer orally; continue treatment until symptoms of the disease have subsided and temperature is normal for 48 hours; not for use in animals raised for food production; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2345c Tetracycline boluses.

(a) Specifications. Each bolus contains 500 milligrams of tetracycline (as the hydrochloride).

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.720 of this chapter.

(d) Conditions of use. Calves—(1) Amount. 10 milligrams per pound of body weight per day in divided doses.

(i) Indications for use. Control and treatment of bacterial enteritis (scours) caused by *E. coli* and bacterial pneumonia caused by *Pasteurella* spp., *Hemophilus* spp., and *Klebsiella* spp.

(ii) Limitations. Administer orally for 3 to 5 days; do not slaughter animals for food within 14 days of treatment; use as sole source of tetracycline.

(iii) National Academy of Sciences/National Research Council (NAS/NRC) status. The conditions of use specified in paragraph (d)(1)(i) of this section were NAS/NRC reviewed and found effective. Applications for these uses need not include effectiveness data as specified in § 514.111 of this chapter, but may require bioequivalency and safety information.

(ii) Amount. 10 milligrams per pound of body weight per day in two divided doses.

(i) Indications for use. Treatment of bacterial pneumonia caused by organisms susceptible to tetracycline, bacterial enteritis caused by *E. coli*, and salmonella organisms susceptible to tetracycline.

(ii) Limitations. Administer orally for not more than 5 days; do not slaughter animals for food within 12 days of...
§ 520.2345d Tetracycline powder.

(a) Specifications. Each pound of powder contains 25, 102.4, or 324 grams tetracycline hydrochloride.

(b) Sponsors. See sponsors listed in §510.600(c) of this chapter for conditions of use as in paragraph (d) of this section:

1. No. 054771: 25 grams per pound as in paragraphs (d)(3) and (d)(4) of this section.
2. No. 054628: 25, 102.4, and 324 grams per pound as in paragraph (d) of this section.
3. No. 054771: 25, 102.4, and 324 grams per pound as in paragraph (d) of this section.
4. Nos. 054925, 057561, 061623, and 076475: 324 grams per pound as in paragraph (d) of this section.
5. No. 016592: 25 grams per pound as in paragraphs (d)(1) and (d)(2) of this section.

(c) Related tolerances. See §556.720 of this chapter.

(d) Conditions of use. It is administered in drinking water as follows:

1. Calves—(i) Amount. 10 milligrams per pound of body weight per day in divided doses.
3. Limitations. Administer for 3 to 5 days; do not slaughter animals for food within 7 days of treatment for Nos. 054771, 054925, 057561, 059130, and 061623; prepare a fresh solution daily; use as the sole source of tetracycline.

2. Swine—(i) Amount. 10 milligrams per pound of body weight per day in divided doses.
4. Limitations. Administer for 3 to 5 days; do not slaughter animals for food within 4 days of treatment for Nos. 054771, 054925, 057561, 059130, and 061623; prepare a fresh solution daily; use as the sole source of tetracycline.

3. Chickens—(i) Amount. Chronic respiratory disease: 400 to 800 milligrams per gallon. Infectious synovitis: 200 to 400 milligrams per gallon.
2. Indications for use. Control of chronic respiratory disease (CRD or air-sac disease) caused by Mycoplasma gallisepticum and E. coli; control of infectious synovitis caused by M. synoviae susceptible to tetracycline.
3. Limitations. Administer for 7 to 14 days; do not slaughter for food within 4 days of treatment; not for use in chickens producing eggs for human consumption; prepare a fresh solution daily; use as the sole source of tetracycline.

4. Turkeys—(i) Amount. For infectious synovitis: 400 milligrams per gallon. For complicating bacterial organisms associated with bluecomb (transmissible enteritis or coronaviral enteritis): 25 milligrams per pound of body weight per day.
2. Indications for use. Control of infectious synovitis caused by M. synoviae; control of bluecomb complicated by organisms sensitive to tetracycline.
3. Limitations. Administer for 7 to 14 days; do not slaughter for food within 4 days of treatment; not for use in turkeys producing eggs for human consumption; prepare a fresh solution daily; use as the sole source of tetracycline.
daily; use as the sole source of tetracycline.

§ 520.2345e Tetracycline solution.

(a) Specifications. Each milliliter contains the equivalent of either 25 or 100 milligrams of tetracycline hydrochloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 25 milligrams per pound of body weight per day in divided doses every 6 hours.

(2) Indications for use. Treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to Escherichia coli and urinary tract infections due to Staphylococcus spp. and E. coli.

(iii) Limitations. Administer orally; continue treatment until symptoms have subsided and the temperature is normal for 48 hours; not for use in food-producing animals; Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2345f Tetracycline phosphate complex and sodium novobiocin capsules.

(a) Specifications. Each capsule contains the equivalent of 60 milligrams of tetracycline hydrochloride and 60 milligrams of novobiocin.

(b) Sponsor. No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 10 milligrams of each antibiotic per pound of body weight (1 capsule for each 6 pounds) every 12 hours.

(2) Indications for use. Treatment of acute or chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as Staphylococcus spp. and Escherichia coli.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets.

(a) Specifications. Each tablet contains the equivalent of 60 milligrams of tetracycline hydrochloride and 60 milligrams of novobiocin, or 180 milligrams of tetracycline hydrochloride and 180 milligrams of novobiocin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 10 milligrams of each antibiotic per pound of body weight (one single-strength tablet for each 6 pounds or one triple-strength tablet for each 18 pounds).

(2) Indications for use. Treatment of acute or chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as Staphylococcus spp. and Escherichia coli.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.2345h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets.

(a) Specifications. Each tablet contains the equivalent of 60 milligrams of tetracycline hydrochloride, 60 milligrams of novobiocin, and 1.5 milligrams of prednisolone or 180 milligrams of tetracycline hydrochloride, 180 milligrams of novobiocin, and 4.5 milligrams of prednisolone.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount. 10 milligrams of each antibiotic and 0.25 milligram of prednisolone per pound of body weight (one single-strength tablet for each 6 pounds or one triple-strength tablet for each 18 pounds) every 12 hours for 48 hours. Treatment is to be continued with novobiocin and tetracycline alone at the same dose schedule for an additional 3 days or longer as needed.

(2) Indications for use. Treatment of acute and chronic canine respiratory infections such as tonsillitis, bronchitis, and tracheobronchitis when caused by pathogens susceptible to tetracycline and/or novobiocin, such as Staphylococcus spp. and Escherichia coli, when it is necessary to initially reduce the severity of associated clinical signs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2380 Thiabendazole oral dosage forms.

§ 520.2380a Thiabendazole top dressing and mineral protein block.

(a) Specifications. Conforms to N.F. XII.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 051311 for use as in paragraph (d)(1)(i) of this section.

(2) No. 050604 for use as in paragraph (d)(1)(ii) of this section.

(3) No. 012286 for use as in paragraph (d)(2) of this section.

(c) Related tolerances. See § 556.730 of this chapter.

(d) Conditions of use. It is used as follows:

(1) Horses—

(i) Route of administration. In feed, as a top dressing. (a) Amount. 2 grams per 100 pounds of body weight.

(b) Indications for use. For control of large strongyles, small strongyles, pinworms, and threadworms (including members of the genera Strongylus, Cyathostomum, Cylicobrachytus, and related genera, Craterostomum, Oesophagodontus, Poteriostomum, Oxyuris, and Strongyloides).

(c) Limitations. Add to the usual feed of horses mixed into that amount of the feed normally consumed at one feeding. Warning: Not for use in horses intended for food.

(ii) Route of administration. In feed. (a) Amount. 2 grams per 100 pounds of body weight.

(b) Indications for use. For control of large and small strongyles, Strongyloides, and pinworms of the genera Strongylus, Cyathostomum, Cylicobrachytus and related genera, Craterostomum, Oesophagodontus, Poteriostomum, Oxyuris, and Strongyloides.


§ 520.2382 Thienium closylate.

(a) Specifications. Each tablet contains thienium closylate equivalent to 500 milligrams thienium base.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount. Dogs weighing over 10 pounds: Administer 1 tablet as a single dose. Dogs weighing 5 to 10 pounds: Administered one-half tablet twice during a single day. Repeat treatment after 2 or 3 weeks.

(2) Indications for use. For treatment of canine ancylostomiasis by the removal from the intestines of the adult forms of the species Ancylostoma caninum and Uncinaria stenocephala (hookworms).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2380b Thiabendazole drench or paste.

(a) Specifications. Conforms to N.F. XII.

(b) Sponsor. See No. 050604 in § 556.730 of this chapter.

(c) Related tolerances. See § 556.730 of this chapter.

(d) Conditions of use. It is used as follows:

(1) Horses. As a single liquid oral dose, administered as a drench or by stomach tube; or as an oral paste.

(i) Amount. 2 grams per 100 pounds of body weight.

(2) Limitations. Administer in a single dosage mixed with the normal grain ration given at one feeding. Warning: Not for use in horses intended for food.

(b) Amount. 4 grams per 100 pounds of body weight.

(1) Indications for use. For control of ascarids of the genus Parascaris.

(2) Limitations. Administer in a single dosage mixed with the normal grain ration given at one feeding. Warning: Not for use in horses intended for food.

(2) Cattle—(i) Route of administration. In feed block.

(ii) Amount. 3.3 percent block consumed at the recommended level of 0.11 pound per 100 pounds of body weight per day.

(iii) Indications for use. For control of infections of gastrointestinal roundworms (Trichostrongylus, Haemonchus, Ostertagia and Cooperia).

(iv) Limitations. Administer to cattle on pasture or range accustomed to mineral protein block feeding for 3 days. Milk taken from animals during treatment and within 96 hours (8 milkings) after the latest treatment must not be used for food. Do not treat cattle within 3 days of slaughter. For a satisfactory diagnosis, a microscopic fecal examination should be performed by a veterinarian or diagnostic laboratory prior to worming. Animals maintained under conditions of constant worm exposure may require re-treatment within 2 to 3 weeks. Animals that are severely parasitized, sick, or off feed should be isolated and a veterinarian consulted for advice concerning treatment.

(3) Pigs. As an oral paste.

(i) Amount. 200 milligrams for each 5 to 7 pounds of body weight per dose.

(ii) Indications for use. For control of infections with Strongyloides ransomi.

These infections are commonly found in Southeastern United States.

(iii) Limitations. Administer to baby pigs (1 to 8 weeks of age). Treatment may be repeated in 5 to 7 days if necessary. Before treatment, obtain an accurate diagnosis from a veterinarian or diagnostic laboratory. Do not treat within 30 days of slaughter.

(3) Cattle. Orally as a drench and in paste form using a dosing gun designed for the product.

(i) Amount. 3 grams per 100 pounds of body weight.

(a) Indications for use. Control of infections of gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., Nematodirus spp., Ostertagia spp., and Oesophagostomum radiatum).
§ 520.2380c Thiabendazole bolus.

(a) Specifications. Conforms to N.F. XII.

(b) Sponsor. See No. 050604 in 21 CFR Ch. I (4–1–16 Edition).

(c) Related tolerances. See §556.730 of this chapter.

(d) Conditions of use. It is used as follows:

(1) Cattle. In a bolus.

(i) Amount. 3 grams per 100 pounds of body weight.


(iii) Limitations. As a single oral dose; may repeat once in 2 to 3 weeks; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; treatment should be repeated in 2 to 3 weeks.

(2) Sheep and goats. Orally, as a drench.

(i) Amount. 2 grams per 100 pounds of body weight.

(ii) Indications for use. Control of infections of gastrointestinal roundworms in sheep and goats. (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., Strongyloides spp., Chabertia spp., and Oesophagostomum spp.); also active from 3 hours to 3 days following treatment against ova and larvae passed by sheep. Good activity against Trichostrongylus colubriformis and axei, Ostertagia spp., Bunostomum spp., Nematodirus spp., and Strongyloides spp.; less effective against Haemonchus contortus and Oesophagostomum spp.

(iii) Limitations. As a single oral dose; may repeat once in 2 to 3 weeks; do not treat animals within 30 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; in severe infections in sheep, treatment should be repeated in 2 to 3 weeks.

(3) Goats. Orally, as a drench.

(i) Amount. 3 grams per 100 pounds of body weight.


(iii) Limitations. As a single oral dose; do not treat animals within 3 days of slaughter; milk taken from treated animals within 96 hours (8 milkings) after the latest treatment must not be used for food; treatment should be repeated in 2 to 3 weeks.

(4) Pigs. Orally, as a drench or bolus.

(i) Amount. 3 grams per 100 pounds of body weight.


(b) Limitations. As a single oral dose; as a drench or bolus; may repeat once in 2 to 3 weeks; do not treat animals
Food and Drug Administration, HHS

§ 520.2380d Thiabendazole and piperazine citrate.

(a) Specifications. Each fluid ounce of suspension contains 2 grams of thiabendazole and 2.5 grams of piperazine (from piperazine citrate).

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Administer 1 ounce of suspension per 100 pounds of body weight by stomach tube or as a drench.

(2) Indications for use. For the control of large strongyles, small strongyles, pinworms, Strongyloides and ascarids (including members of the genera Strongylus spp., Cyathostomum spp., Cylicobrachytus spp. and related genera Craterostomum spp., Oesophagodontus spp., Poteriostomum spp., Oxyuris spp., Strongyloides spp., and Parasascaris spp.).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2380e Thiabendazole and triclorfon.

(a) Specifications. The drug contains 5 grams of thiabendazole with 4.5 grams of trichlorfon, or 20 grams of thiabendazole with 18 grams of trichlorfon.

(b) Sponsor. See No. 017135 in §510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Administer 0.1 gram of thiabendazole with 0.12 gram of trichlorfon per 100 pounds of body weight sprinkled on the animals’ usual daily ration of feed, or may be mixed in 5 to 10 fluid ounces of water and administered by stomach tube or drench.

(2) Indications for use. For the treatment and control of bots (Gasterophilus spp.), large strongyles (Strongylus spp.), small strongyles (genera Cyathostomum, Cylicobrachytus, Craterostomum, Oesophagodontus, Poteriostomum), pinworms (Oxyuris spp., Strongyloides spp.), and ascarids (Parascaris spp.).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 520.2380f Thiabendazole and piperazine phosphate.

(a) Specifications. Each ounce of water dispersible powder contains 6.67 grams of thiabendazole and 8.33 grams of piperazine (as piperazine phosphate).

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 2 grams of thiabendazole and 2.5 grams of piperazine (0.3 ounce of powder) per 100 pounds of body weight. Use a single oral dose. Administer as a drench or by stomach tube suspended in 1 pint of warm water; by dose syringe suspended in 1/2 ounce of water for each 100 pounds of body weight; or sprinkled over a small amount of daily feed.

(2) Indications for use. Treatment of infections of large strongyles (genus Strongylus), small strongyles (genera Cyathostomum, Cyclicobrachytus, and related genera Craterostomum, Oesophagodontus, Potoriodontus), pinworms (Oxyuris), threadworms (Strongyloides), and ascarids (Parascaris) in horses.

(3) Limitations. Do not use in horses intended for human consumption. If the label bears directions for administration by stomach tube or drench, it shall also bear the statement “Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.”; if not labeled for use by stomach tube or drench, the label shall bear the statement, “Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.”


§ 520.2455 Tiamulin.

(a) Specifications. (1) Each gram of soluble powder contains 450 milligrams (mg) tiamulin hydrogen fumarate.

(2) Each milliliter (mL) of solution contains 125 mg (12.5 percent) tiamulin hydrogen fumarate.

(3) Each mL of solution contains 123 mg (12.3 percent) tiamulin hydrogen fumarate.

(b) Sponsor. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 058198 for products described in paragraphs (a)(1) and (a)(2) of this section.

(2) No. 066104 for the product described in paragraph (a)(1) of this section.

(3) No. 054771 for the product described in paragraph (a)(3) of this section.

(c) Related tolerances. See § 556.732 of this chapter.

(d) Conditions of use in swine—(1) Amounts and indications for use. Administer in drinking water for 5 consecutive days:

(i) 3.5 mg per (/) lb of body weight daily for treatment of swine dysentery associated with Brachyspira hyodysenteriae susceptible to tiamulin.

(ii) 10.5 mg/lb of body weight daily for treatment of swine pneumonia due to Actinobacillus pleuropneumoniae susceptible to tiamulin.

(2) Limitations. Use as only source of drinking water. Prepare fresh medicated water daily. Withdraw medication 3 days before slaughter following treatment at 3.5 mg/lb and 7 days before slaughter following treatment at 10.5 mg/lb of body weight. Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse reactions may occur. The effects of tiamulin on swine reproductive performance, pregnancy, and lactation have not been determined.


§ 520.2471 Tilmicosin.

(a) Specifications. Each milliliter of concentrate solution contains 250 milligrams (mg) tilmicosin as tilmicosin phosphate.

(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.

(c) Tolerances. See § 556.735 of this chapter.

(d) Conditions of use in swine—(1) Amount. Administer in drinking water at a concentration of 200 mg per liter for 5 consecutive days.
(2) **Indications for use**—(i) For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

(ii) For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

(3) **Limitations.** Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2473 **Tioxidazole oral dosage forms.**

§ 520.2473a **Tioxidazole granules.**

(a) **Specifications.** Each gram of granules contains 200 milligrams of tioxidazole.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Horses**—(i) **Amount.** 5 milligrams per pound of body weight as a single dose.

(ii) **Indications for use.** Removal of mature large strongyles (*Strongylus edentatus, S. equinus, and S. vulgaris*), mature ascarids (*Parascaris equorum*), mature and immature (4th larval stage) pinworms (*Oxyuris equi*), and mature small strongyles (*Triodontophorus spp.*).

(iii) **Limitations.** For administration with feed: Sprinkle required amount of granules on a small amount of the usual grain ration and mix. Prepare for each horse individually. Withholding of feed or water not necessary. For use in horses intended for food. The reproductive safety of tioxidazole in breeding animals has not been determined. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. It is recommended that this drug be administered with caution to sick or debilitated horses.

(2) [Reserved]


§ 520.2473b **Tioxidazole paste.**

(a) **Specifications.** Each plastic syringe contains 6.25 grams of tioxidazole.

(b) **Sponsor.** See No. 000061 in §510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Horses**—(i) **Amount.** 5 milligrams of tioxidazole per pound of body weight as a single dose.

(ii) **Indications for use.** Removal of mature large strongyles (*Strongylus edentatus, S. equinus, and S. vulgaris*), mature ascarids (*Parascaris equorum*), mature and immature (4th larval stage) pinworms (*Oxyuris equi*), and mature small strongyles (*Triodontophorus spp.*).

(iii) **Limitations.** Administer orally by inserting the nozzle of the syringe through the space between front and back teeth and deposit the required dose on the base of the tongue. Before dosing, make sure the horse’s mouth contains no feed. Not for use in horses intended for food. The reproductive safety of tioxidazole in breeding animals has not been determined. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. It is recommended that this drug be administered with caution to sick or debilitated horses.

(2) [Reserved]

[52 FR 43059, Nov. 9, 1987]

§ 520.2475 **Toceranib.**

(a) **Specifications.** Each tablet contains 10, 15, or 50 milligrams (mg) toceranib as toceranib phosphate.

(b) **Sponsor.** See No. 054771 in §510.600 of this chapter.

(c) **Conditions of use**—(1) **Dogs**—(i) **Amount.** Administer an initial dose of 3.25 mg per kilogram (1.48 mg per pound) body weight, orally every other day.

(ii) **Indications for use.** For the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement.

(iii) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 520.2483  Triamcinolone.

(a) Specifications. (1) Each tablet contains 0.5 milligram (mg) or 1.5 mg triamcinolone acetonide.
(2) Each 15 grams of powder contains 10 mg triamcinolone acetonide.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Special considerations. See § 510.410 of this chapter.

(d) Conditions of use—(1) Dogs and cats. Use tablets described in paragraph (a)(1) of this section as follows:
   (i) Amount. Administer 0.05 mg per pound (/lb) of body weight daily by mouth; up to 0.1 mg per pound (/lb) of body weight daily, if response to the smaller dose is inadequate. Therapy may be initiated with a single injection of triamcinolone acetonide suspension as in § 522.2483 of this chapter, in which case triamcinolone acetonide tablets should be administered beginning 5 to 7 days after the injection.
   (ii) Indications for use. As an anti-inflammatory agent.
   (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses. Use oral powder described in paragraph (a)(2) of this section as follows:
   (i) Amount. Administer 0.005 to 0.01 mg/lb of body weight twice daily, sprinkled (top-dressed) on a small portion of feed. Therapy may be initiated with a single injection of triamcinolone acetonide suspension as in § 522.2483 of this chapter, in which case triamcinolone acetonide oral powder should be administered beginning 3 or 4 days after the injection.
   (ii) Indications for use. As an anti-inflammatory agent.
   (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28832, May 20, 2014]

§ 520.2520 Trichlorfon oral dosage forms.

§ 520.2520a Trichlorfon and atropine.

(a) Specifications. (1) For trichlorfon: O,O-Dimethyl 2,2,2-trichloro-1-hydroxyethyl phosphonate.
(2) For atropine: Atropine N.F.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in mice—(1) Amount. Administer 1.67 grams of trichlorfon and 7.7 milligrams of atropine per liter continuously for 7 to 14 days as the sole source of drinking water.
(2) Indications for use. For the treatment of Syphacia obvelata (pinworm) in laboratory mice.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28832, May 20, 2014]

§ 520.2520b Trichlorfon boluses.

(a) Specifications. Each bolus contains either 7.3, 10.9, 14.6, or 18.2 g of trichlorfon.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 18.2 milligrams per pound of body weight, except for strongyles use 36.4 milligrams per pound of body weight.
(2) Indications for use. For horses for removal of bots (Gastrophilus nasalis, Gastrophilus intestinalis), large strongyles (Strongylus vulgaris), small strongyles, large roundworms (ascarids, Parascaris equorum), and pinworms (Oxyuris equi).
(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2520c Trichlorfon granules.

(a) Specifications. Each package contains either 18.2 or 36.4 g of trichlorfon.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. 18.2 milligrams per pound of body weight.
(2) Indications for use. For horses for removal of bots (Gastrophilus nasalis, Gastrophilus intestinalis), large roundworms (ascarids, Parascaris equorum), and pinworms (Oxyuris equi).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2520d Trichlorfon, phenothiazine, and piperazine dihydrochloride powder.

(a) Specifications. Each 54.10 grams (1.91 ounces) of water dispersible powder contains 9.10 grams of trichlorfon, 6.25 grams of phenothiazine, and the equivalent of 20.0 grams of piperazine base (as piperazine dihydrochloride).

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.


EDITORIAL NOTE: At 79 FR 28833, May 20, 2014, §520.2520d was amended in part by redesignating paragraph (e) as (c). This action could not be performed because paragraph (e) did not exist.

§ 520.2582 Triflupromazine.

(a) Specifications. Each tablet contains 10 or 25 milligrams (mg) triflupromazine hydrochloride.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

[79 FR 28833, May 20, 2014]

§ 520.2598 Trilostane.

(a) Specifications. Each capsule contains 5, 10, 30, 60, or 120 milligrams (mg) trilostane.

(b) Sponsor. See No. 043264 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. The starting dose is 1.0 to 3.0 milligrams per pound (2.2 to 6.7 milligrams per kilogram) once a day.

(2) Indications for use. For treatment of pituitary-dependent hyperadrenocorticism. For treatment of hyperadrenocorticism due to adrenocortical tumor.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 520.2604 Trimeprazine and prednisolone tablets.

(a) Specifications. Each tablet contains 5 milligrams (mg) trimeprazine tartrate and 2 mg prednisolone.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

[79 FR 28833, May 20, 2014]
§ 520.2605 Trimeprazine and prednisolone capsules.

(a) Specifications. Each capsule contains:
(1) 3.75 milligrams (mg) trimeprazine in sustained release form (as trimeprazine tartrate) and 1 mg prednisolone (Capsule No. 1); or
(2) 7.5 mg trimeprazine in sustained release form (as trimeprazine tartrate) and 2 mg prednisolone (Capsule No. 2).

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer orally once daily an initial dosage:
(i) For dogs weighing up to 10 pounds: one Capsule No. 1;
(ii) For dogs weighing 11 to 20 pounds, one Capsule No. 2 or two Capsule No. 1;
(iii) For dogs weighing 21 to 40 pounds, two Capsule No. 2 or four Capsule No. 1; and
(iv) For dogs weighing over 40 pounds, three Capsule No. 2 or six Capsule No. 1. After 4 days, the dosage is reduced to approximately ½ the initial dosage or to an amount just sufficient to maintain remission of symptoms.

(2) Indications for use. For the relief of itching regardless of cause; and for reduction of inflammation commonly associated with most skin disorders of dogs such as eczema, caused by internal disorders, otitis, and dermatitis, allergic, parasitic, pustular and nonspecific. As adjunctive therapy in various cough conditions including treatment of “kennel cough” or tracheobronchitis, bronchitis including allergic bronchitis, in tonsillitis, acute upper respiratory infections and coughs of nonspecific origin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 28833, May 20, 2014]

§ 520.2610 Trimethoprim and sulfadiazine paste.

(a) Specifications. Each gram (g) of paste contains 67 milligrams (mg) trimethoprim and 333 mg sulfadiazine.

(b) Sponsors. See sponsors in §510.600(c) of this chapter:
(1) No. 054771 for product administered as in paragraph (c)(1)(1) of this section.
(2) No. 000061 for product administered as in paragraph (c)(1)(ii) of this section.

(c) Conditions of use in horses—(1) Amount. Administer orally as a single daily dose for 5 to 7 days:
(i) 5 g of paste (335 mg trimethoprim and 1,665 mg sulfadiazine) per 150 pounds (68 kilograms) of body weight per day.
(ii) 3.75 g of paste (250 mg trimethoprim and 1,250 mg sulfadiazine) per 110 pounds (50 kilograms) of body weight per day.

(2) Indications for use. For use where systemic antibacterial action against sensitive organisms is required during treatment of acute strangles, respiratory infections, acute urogenital...
Food and Drug Administration, HHS

§ 520.2640

Tylosin.

(a) Specifications. Each container of soluble powder contains tylosin tartrate equivalent to either 100 or 256 grams tylosin base.

(b) Sponsors—(1) No. 000986 for use as in paragraph (e) of this section.

(2) Nos. 016592 and 061623 for use as in paragraphs (e)(1)(i)(A), (e)(1)(ii), (e)(2), (e)(3), and (e)(4) of this section.

(c) Related tolerances. See § 556.740 of this chapter.

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(1) Conditions of use—(i) Chickens—(1) Amounts and indications for use. (A) Administer 2 grams per gallon (528 parts per million (ppm)) for 1 to 5 days as an aid in the treatment of chronic respiratory disease (CRD) associated with Mycoplasma gallisepticum in broiler and replacement chickens. For the control of CRD associated with M. gallisepticum at time of vaccination or other stress

VerDate Sep<11>2014 10:06 Apr 14, 2016 Jkt 238075 PO 00000 Frm 00273 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31lpowell on DSK54DXVN1OFR with $$_JOB
in chickens. For the control of CRD associated with *Mycoplasma synoviae* in broiler chickens. Treated chickens should consume enough medicated drinking water to provide 50 milligrams (mg) tylosin per pound of body weight per day.

(B) Administer 851 to 1,419 mg/gallon (225 to 375 ppm) for 5 days for the control of mortality caused by necrotic enteritis associated with *Clostridium perfringens* in broiler chickens.

(ii) *Limitations.* Do not use in layers producing eggs for human consumption. Do not administer within 24 hours of slaughter.

(2) *Turkeys*—(i) **Amount.** 2 grams per gallon for 2 to 5 days as the sole source of drinking water. Treated turkeys should consume enough medicated drinking water to provide 60 mg tylosin per pound of body weight per day.

(ii) **Indications for use.** For the reduction in severity of effects of infectious sinusitis associated with *Mycoplasma gallisepticum*.

(iii) **Limitations.** Do not use in layers producing eggs for human consumption. Do not administer within 5 days of slaughter.

(3) *Swine*—(i) **Amount.** 250 mg per gallon as the only source of drinking water for 3 to 10 days, depending on the severity of the condition being treated.

(ii) **Indications for use.** (A) For the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* when followed immediately by tylosin phosphate medicated feed; and for the control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis* when followed immediately by tylosin phosphate medicated feed.

(B) For the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae*.

(iii) **Limitations.** Do not administer within 48 hours of slaughter. As indicated in paragraph (d)(3)(ii)(A) of this section, follow with tylosin phosphate medicated feed as in §538.625(d)(1)(vi)(c) of this chapter.

(4) *Honey bees*—(i) **Amount.** Mix 200 milligrams tylosin in 20 grams confectioners’/powdered sugar. Use immediately. Apply (dust) this mixture over the top bars of the brood chamber once weekly for 3 weeks.

(ii) **Indications for use.** For the control of American foulbrood (*Paenibacillus larvae*).

(iii) **Limitations.** The drug should be fed early in the spring or fall and consumed by the bees before the main honey flow begins, to avoid contamination of production honey. Complete treatments at least 4 weeks before main honey flow.


§ 520.2645 *Tylvalosin.*

(a) **Specifications.** Granules containing 62.5 percent tylvalosin (w/w) as tylvalosin tartrate.

(b) **Sponsor.** See No. 066916 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §556.748 of this chapter.

(d) **Conditions of use in swine**—(1) **Amount.** Administer 50 parts per million tylvalosin in drinking water for 5 consecutive days.

(2) **Indications for use.** For the control of porcine proliferative enteropathy (PPE) associated with *Lawsonia intracellularis* infection in groups of swine in buildings experiencing an outbreak of PPE.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[77 FR 55415, Sept. 10, 2012]

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

Sec. 522.23 Acepromazine.

522.52 Alfaxalone.

522.56 Amikacin.

522.62 Aminopentamide.

522.82 Aminopropamide.

522.84 Beta-aminopropionitrile.

522.88 Amoxicillin.

522.90 Ampicillin injectable dosage forms.

522.90a Ampicillin trihydrate suspension.

522.90b Ampicillin trihydrate powder for injection.

522.90c Ampicillin sodium.
522.144 Arsenamide.
522.147 Atipamezole.
522.150 Azaperone.
522.161 Betamethasone.
522.163 Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension.
522.167 Betamethasone sodium phosphate and betamethasone acetate.
522.204 Boldenone.
522.230 Buprenorphine.
522.234 Butamisole.
522.246 Butorphanol.
522.275 N-Butylscopolammonium.
522.300 Carfentanil.
522.304 Carprofen.
522.311 Cefovecin.
522.313 Ceftiofur injectable dosage forms.
522.313a Ceftiofur crystalline free acid.
522.313b Ceftiofur hydrochloride.
522.313c Ceftiofur sodium.
522.380 Chloral hydrate, pentobarbital, and magnesium sulfate.
522.390 Chloramphenicol.
522.454 Clodronate.
522.460 Cloprostenol.
522.468 Colistimethate sodium powder for injection.
522.480 Corticotropin.
522.518 Cupric glycinate injection.
522.522 Danofloxacin.
522.533 Deslorelin.
522.535 Desoxycorticosterone.
522.536 Detomidine.
522.540 Dexamethasone solution.
522.542 Dexamethasone suspension.
522.558 Dexmedetomidine.
522.563 Diatrizoate.
522.650 Dihydrostreptomycin sulfate injection.
522.690 Dinoprost.
522.723 Diprenorphine.
522.770 Doramectin.
522.775 Doxapram.
522.784 Doxylamine.
522.800 Droperidol and fentanyl.
522.810 Embutramide, chloroquine, and lidocaine solution.
522.812 Enrofloxacin.
522.820 Erythromycin.
522.840 Estradiol.
522.842 Estradiol benzoate and testosterone propionate.
522.850 Estradiol valerate and norgestomet in combination.
522.863 Ethylisobutrazine.
522.870 Endotec.
522.880 Etorphine.
522.900 Euthanasia solution.
522.914 Fenprostalene.
522.930 Flirociclib.
522.956 Florfenicol.
522.960 Flumethasone injectable dosage forms.
522.960a Flumethasone acetate solution.
522.960b Flumethasone solution.
522.970 Flunixin.
522.995 Fluprostol.
522.1002 Follitropin stimulating hormone.
522.1010 Furosemide.
522.1014 Gelatin.
522.1044 Gentamicin.
522.1066 Glycopyrrolate.
522.1077 Gonadorelin.
522.1079 Serum gonadotropin and choric gonadotropin.
522.1081 Chorionic gonadotropin for injection; choric gonadotropin suspension.
522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate.
522.1085 Guaifenesin powder for injection.
522.1086 Guaifenesin solution.
522.1125 Hemoglobin glutamer-200 (bovine).
522.1145 Hyaluronate.
522.1150 Hydrochlorothiazide.
522.1155 Imidocarb powder for injection.
522.1156 Imidocarb solution.
522.1158 Insulin.
522.1182 Iron injection.
522.1185 Isofuripredone.
522.1192 Ivermectin.
522.1193 Ivermectin and clorsulon.
522.1194 Kanamycin.
522.1222 Ketamine.
522.1223 Ketamine, promazine, and aminoglutethimide.
522.1225 Ketoprofen.
522.1242 Levamisole.
522.1250 Lincomycin.
522.1289 Lufenuron.
522.1290 Luprostioli.
522.1315 Maropitant.
522.1335 Medetomidine.
522.1350 Melatonin implant.
522.1362 Melarsomine powder for injection.
522.1367 Meloxicam.
522.1372 Mepivacaine.
522.1380 Methocarbamol.
522.1410 Metyrapone.
522.1450 Moxidectin solution.
522.1451 Moxidectin microspheres for injection.
522.1452 Nalorphine.
522.1465 Naltrexone.
522.1468 Naproxen for injection.
522.1484 Neomycin.
522.1503 Neostigmine.
522.1610 Olate sodium.
522.1620 Orgotein for injection.
522.1660 Oxytetracycline injectable dosage forms.
522.1660a Oxytetracycline solution, 200 milligrams/milliliter.
522.1660b Oxytetracycline solution, 300 milligrams/milliliter.
522.1662 Oxytetracycline hydrochloride implantation or injectable dosage forms.
522.1662a Oxytetracycline hydrochloride injection.
§ 522.23 Acepromazine.

(a) Specifications. Each milliliter of solution contains 10 milligrams (mg) acepromazine maleate.

(b) Sponsors. See Nos. 000010 and 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs, cats, and horses—(1) Amount. Dogs: 0.25 to 0.5 mg per pound (/lb) of body weight; Cats: 0.5 to 1.0 mg/lb of body weight; Horses: 2.0 to 4.0 mg per 100 lbs of body weight.

(2) Indications for use. For use as a tranquilizer and as a preanesthetic agent.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.52 Alfaxalone.

(a) Specifications. Each milliliter contains 10 milligrams (mg) alfaxalone.

(b) Sponsor. See No. 049480 in § 510.600(c) of this chapter.

(c) Conditions of use in cats and dogs—(1) Amount—(i) Cats—(A) Induction of general anesthesia. Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 2.2 to 9.7 mg/kilogram (kg) for cats that did not receive a preanesthetic or 1.0 to 10.8 mg/kg for cats that received a preanesthetic.

(B) Maintenance of general anesthesia following induction. Administer an intravenous bolus containing 1.1 to 1.3 mg/kg to provide an additional 7 to 8 minutes of anesthesia in preanesthetized cats; a dose containing 1.4 to 1.5 mg/kg provides an additional 3 to 5 minutes anesthesia in unpreanesthetized cats.

(ii) Dogs—(A) Induction of general anesthesia. Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 1.5 to 4.5 mg/kg for dogs that did not receive a preanesthetic or...
Food and Drug Administration, HHS

0.2 to 3.5 mg/kg for dogs that received a preanesthetic.

(B) Maintenance of general anesthesia following induction. Administer an intravenous bolus containing 1.2 to 1.4 mg/kg to provide an additional 6 to 8 minutes of anesthesia in preanesthetized dogs; a dose of 1.5 to 2.2 mg/kg provides an additional 6 to 8 minutes of anesthesia in unpreanesthetized dogs.

(2) Indications for use. For the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in dogs and cats.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Alfaxalone is a Class IV controlled substance.


§ 522.56 Amikacin.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of amikacin as amikacin sulfate.

(b) Sponsor. See No. 069043 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. 5 mg/pound (lb) of body weight twice daily by intramuscular or subcutaneous injection.

(2) Indications for use. For treatment of genitourinary tract infections (cystitis) caused by susceptible strains of Escherichia coli and Proteus spp. and skin and soft tissue infections caused by susceptible strains of Pseudomonas spp. and E. coli.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.62 Aminopentamide.

(a) Specifications. Each milliliter of solution contains 0.5 milligram (mg) aminopentamide hydrogen sulfate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer by subcutaneous or intramuscular injection every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; for animals weighing 11 to 20 lbs: 0.2 mg; for animals weighing 21 to 50 lbs: 0.3 mg; for animals weighing 51 to 100 lbs: 0.4 mg; for animals weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Following parenteral use, dosage may be continued by oral administration of tablets.

(2) Indications for use. For the treatment of vomiting and/or diarrhea, nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16183, Mar. 25, 2014]

§ 522.82 Aminopropazine.

(a) Specifications. Each milliliter of solution contains aminopropazine fumarate equivalent to 25 milligrams (mg) aminopropazine base.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs and cats—(i) Amount. 1 to 2 mg per pound of body weight, repeated every 12 hours as indicated, by intramuscular or intravenous injection.

(ii) Indications for use. For reducing excessive smooth muscle contractions, such as occur in urethral spasms associated with urolithiasis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—(i) Amount. Administer 0.25 mg per pound of body weight, repeated every 12 hours as indicated, by intramuscular or intravenous injection.

(ii) Indications for use. For reducing excessive smooth muscle contractions, such as occur in colic spasms.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16183, Mar. 25, 2014]

§ 522.84 Beta-aminopropionitrile.

(a) Specifications. The drug is a sterile powder. Each milliliter of constituted solution contains 0.7 milligrams (mg) beta-aminopropionitrile fumarate.

(b) Sponsor. See No. 064146 in § 510.600(c) of this chapter.
§ 522.88 Amoxicillin.

(a) Specifications.—(1) Each vial contains 3 grams (g) of amoxicillin trihydrate. Each milliliter of constituted suspension contains 100 or 250 milligrams (mg) amoxicillin trihydrate for use as in paragraph (d)(1) of this section.

(2) Each vial contains 25 g of amoxicillin trihydrate. Each milliliter of constituted suspension contains 250 mg amoxicillin trihydrate for use as in paragraph (d)(2) of this section.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerance. See §556.38 of this chapter.

(d) Conditions of use.—(1) Dogs and cats.—(i) Amount. Administer 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.

(ii) Indications for use.—(A) Dogs. For treatment of infections caused by susceptible strains of organisms as follows: Respiratory infections (tonsillitis, tracheobronchitis) due to *Staphylococcus aureus*, *Streptococcus spp.*, *Escherichia coli*, and *Proteus mirabilis*; gastrointestinal infections (cystitis) due to *S. aureus*, *Streptococcus spp.*, *E. coli*, and *P. mirabilis*; gastrointestinal infections (bacterial gastroenteritis) due to *S. aureus*, *Streptococcus spp.*, *E. coli*, and *P. mirabilis*; soft tissue infections (abscesses, lacerations, and wounds), due to *S. aureus*, *Streptococcus spp.*, *E. coli*, and *P. mirabilis*.

(B) Cats. For treatment of infections caused by susceptible strains of organisms as follows: Upper respiratory infections due to *S. aureus*, *Staphylococcus spp.*, *Streptococcus spp.*, *Haemophilus spp.*, *E. coli*, *Pasteurella spp.*, and *P. mirabilis*; genitourinary infections (cystitis) due to *S. aureus*, *Streptococcus spp.*, *E. coli*, *P. mirabilis*, and *Corynebacterium spp.*; gastrointestinal infections due to *E. coli*, *Proteus spp.*, *Staphylococcus spp.*, and *Streptococcus spp.*; skin and soft tissue infections (abscesses, lacerations, and wounds) due to *S. aureus*, *Staphylococcus spp.*, *Streptococcus spp.*, *E. coli*, and *Pasteurella multocida*.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(ii) Cattle.—(1) Amount. Administer 3 to 5 mg per pound of body weight daily for up to 5 days by intramuscular or subcutaneous injection.

(ii) Indications for use. For treatment of diseases due to amoxicillin-susceptible organisms as follows: Respiratory tract infections (shipping fever, pneumonia) due to *P. multocida*, *P. hemolytica*, *Haemophilus spp.*, *Staphylococcus spp.*, and *Streptococcus spp.* and acute necrotic pododermatitis (foot rot) due to *Fusobacterium necrophorum*.

(iii) Limitations. Treated animals must not be slaughtered for food during treatment and for 25 days after the last treatment. Milk from treated cows must not be used for human consumption during treatment or for 96 hours (8 milkings) after last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16183, Mar. 25, 2014]

§ 522.90 Ampicillin injectable dosage forms.

[79 FR 16183, Mar. 25, 2014]

§ 522.90a Ampicillin trihydrate suspension.

(a) Specifications. (1) Each milliliter contains ampicillin trihydrate equivalent to 200 milligrams (mg) of ampicillin.

(2) Each milliliter contains ampicillin trihydrate equivalent to 150 mg of ampicillin.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter.
(1) No. 054771 for use of product described in paragraph (a)(1) as in paragraphs (d)(1), (d)(2), (d)(3)(i)(A), (d)(3)(ii)(A), (d)(3)(iii), and (d)(4) of this section.

(2) No. 054771 for use of product described in paragraph (a)(2) as in paragraphs (d)(3)(i)(B), (d)(3)(ii)(B), and (d)(3)(iii) of this section.

(c) Related tolerances. See §556.40 of this chapter.

(d) Amount. For enteritis: 3 mg per pound of body weight, intramuscularly, once or twice daily, for up to 3 days. For pneumonia: 3 mg per pound of body weight, intramuscularly, twice daily, for up to 3 days.

(2) Swine—(i) Amount. 3 mg per pound of body weight by intramuscular injection, once or twice daily, for up to 3 days.

(3) Cattle—(i) Amount.—(A) 3 to 6 mg per pound of body weight twice daily by subcutaneous or intramuscular injection, once or twice daily.

(2) Cattle—(i) Amount. 5 to 10 mg per pound of body weight by intramuscular or subcutaneous injection, once or twice daily. Usual treatment is 3 to 5 days.

(1) Indications for use. Treatment of generalized infections (septicemia) associated with abscesses, lacerations, and wounds due to Pasteurella spp., Staphylococcus spp., and Streptococcus spp.

§522.90b Amoxicillin trihydrate powder for injection.

(a) Specifications. Each milliliter of aqueous suspension constituted from amoxicillin trihydrate powder contains 50, 100, or 250 milligrams (mg) amoxicillin equivalents.

(b) Sponsors. See Nos. 000010 and 010515 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Treatment of bacterial enteritis in calves caused by Escherichia coli and bacterial pneumonia caused by Pasteurella spp. susceptible to ampicillin. Treated animals must not be slaughtered for food use or on the order of a licensed veterinarian.

§522.90b Amoxicillin trihydrate powder for injection.

(a) Specfications. Each milliliter of aqueous suspension constituted from amoxicillin trihydrate powder contains 50, 100, or 250 milligrams (mg) amoxicillin equivalents.

(b) Sponsors. See Nos. 000010 and 010515 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.40 of this chapter.

(d) Conditions of use. Treatment of enteritis caused by susceptible organisms.
(ii) Indications for use. For treatment of respiratory tract infections caused by organisms susceptible to ampicillin, bacterial pneumonia (shipping fever, calf pneumonia, and bovine pneumonia) caused by *Aerobacter* spp., *Klebsiella* spp., *Staphylococcus* spp., *Streptococcus* spp., *Pasteurella multocida*, and *Escherichia coli*.

(iii) Limitations. Do not treat cattle for more than 7 days. Milk from treated cows must not be used for food during treatment and for 48 hours (4 milkings) after the last treatment. Cattle must not be slaughtered for food during treatment and for 144 hours (6 days) after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.90c Ampicillin sodium.

(a) Specifications. Each milliliter of aqueous solution constituted from ampicillin sodium powder contains 300 milligrams (mg) ampicillin equivalents.

(b) Sponsors. See Nos. 010515 and 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 0.1 milliliter (mL) per pound of body weight (1.0 mL for every 10 pounds) by intravenous injection twice a day for 2 days.

(2) Indications for use. For the treatment and prevention of canine heartworm disease caused by *Dirofilaria immitis*.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 16184, Mar. 25, 2014]

§ 522.144 Atipamezole.

(a) Specifications. Each milliliter of solution contains 5.0 milligrams atipamezole hydrochloride.

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Inject intramuscularly the same volume as that of dexmedetomidine or medetomidine used.

(2) Indications for use. For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.150 Azaperone.

(a) Specifications. Each milliliter of solution contains 40 milligrams (mg) azaperone.

(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For control of aggressiveness when mixing or regrouping weanling or feeder pigs weighing up to 80 pounds.

(2) Dosage. 2.2 mg per kilogram (1 mg per pound) by deep intramuscular injection.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[74 FR 65689, Dec. 11, 2009, as amended at 77 FR 46613, Aug. 6, 2012]

§ 522.161 Betamethasone.

(a) Specifications. Each milliliter of suspension contains:
§ 522.167  Betamethasone sodium phosphate and betamethasone acetate.

(a) Specifications. Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension is a sterile aqueous suspension. Each milliliter of the suspension contains the equivalent of 5 milligrams of betamethasone as betamethasone dipropionate and 2 milligrams of betamethasone as betamethasone sodium phosphate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs. (i) It is used as an aid in the control of pruritus associated with dermatoses.
(ii) It is administered by intramuscular injection at a dosage of 0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of 4 injections.
(2) Horses. (i) It is used as an aid in the control of inflammation associated with various arthropathies.
(ii) It is administered aseptically by intraarticular injection at a dosage of 2.5 to 5 milliliters per joint, depending on the severity of the condition and the joint size. Dosage may be repeated upon recurrence of clinical signs. Injection into the joint cavity should be preceded by withdrawal of synovial fluid.
(iii) Not for use in horses intended for food.
(3) Clinical and experimental data. It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
(4) Restrictions. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 27316, July 2, 1976; 52 FR 7832, Mar. 13, 1987]
§ 522.204  Boldenone.

(a) Specifications. Each milliliter of solution contains 25 or 50 milligrams (mg) boldenone undecylenate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 0.5 mg per pound body weight by intramuscular injection. Treatment may be repeated at 3-week intervals.

(2) Indications for use. As an aid for treating debilitated horses when an improvement in weight, hair coat, or general physical condition is desired.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16184, Mar. 25, 2014]

§ 522.230  Buprenorphine.

(a) Specifications. Each milliliter of solution contains 1.8 milligrams (mg) buprenorphine.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in cats—(1) Amount. Administer 0.24 mg per kilogram (0.11 mg per pound) by subcutaneous injection once daily, for up to 3 days. Administer the first dose approximately 1 hour prior to surgery.

(2) Indications for use. For the control of postoperative pain associated with surgical procedures in cats.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 53136, Sept. 8, 2014, as amended at 80 FR 18776, Apr. 8, 2015]
Food and Drug Administration, HHS

§ 522.304

(d) Conditions of use—(1) Dogs—(i) Amount. Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days. (ii) Indications for use. For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.

(2) Cats—(i) Amount. Administer 0.2 mg per pound of body weight by subcutaneous injection. Dose may be repeated up to 4 times per day. Do not treat for more than 2 days. (ii) Indications for use. For the relief of pain in cats caused by major or minor trauma, or pain associated with surgical procedures.

(3) Horses—(i) Amount. Administer 0.05 mg per pound of body weight by intravenous injection. Dose may be repeated within 3 to 4 hours. Treatment should not exceed 48 hours. (ii) Indications for use. For the relief of pain associated with colic and postpartum pain in adult horses and yearlings. (iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.300 Carfentanil.

(a) Specifications. Each milliliter of solution contains 3 milligrams (mg) carfentanil citrate. (b) Sponsor. See No. 053923 in §510.600(c) of this chapter. (c) Conditions of use—(1) Amount. Administer 5 to 20 micrograms per kilogram (0.005 to 0.020 mg per kilogram) of body weight into large muscle of the neck, shoulder, back, or hindquarter. (2) Indications for use. For immobilizing free ranging and confined members of the family Cervidae (deer, elk, and moose). (3) Limitations. Do not use in domestic animals intended for food. Do not use 30 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian. The licensed veterinarian shall be a veterinarian engaged in zoo and exotic animal practice, wildlife management programs, or research.

§ 522.304 Carprofen.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) carprofen. (b) Sponsors. See Nos. 026637, 054771, and 055529 in §510.600(c) of this chapter. (c) [Reserved] (d) Conditions of use in dogs—(1) Amount. 2 mg/lb (4.4 mg/kg) body weight once daily or 1 mg/lb (2.2 mg/kg) twice daily, by subcutaneous injection. For the control of postoperative pain, administer approximately 2 hours before the procedure. (2) Conditions of use. For the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.311 Cefovecin.

(a) Specifications. Each milliliter of constituted solution contains 80 milligrams (mg) cefovecin as the sodium salt.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs—(i) Amount. Administer 3.6 mg/pound (lb) (8 mg/kg) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.

(ii) Indications for use. For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

(2) Cats—(i) Amount. Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

(ii) Indications for use. For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.


§ 522.313 Ceftiofur injectable dosage forms.

§ 522.313a Ceftiofur crystalline free acid.

(a) Specifications. The product is a suspension of ceftiofur crystalline free acid.

(1) Each milliliter (mL) contains 100 milligrams (mg) ceftiofur equivalents.

(2) Each mL contains 200 mg ceftiofur equivalents.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.113 of this chapter.

(d) Conditions of use—(1) Swine. The formulation described in paragraph (a)(1) of this section is used as follows:

(i) Amount. 5.0 mg CE per kilogram (kg) of body weight by intramuscular injection in the postauricular region of the neck.

(ii) Indications for use. For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuroneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis. For the control of SRD associated with A. pleuroneumoniae, P. multocida, H. parasuis, and S. suis in groups of pigs where SRD has been diagnosed.

(iii) Limitations. Following label use as a single treatment, a 14-day pre-slaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in swine for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved, major food-producing species/production classes.

(2) Cattle. The formulation described in paragraph (a)(2) of this section is used as follows:

(1) Amount. For subcutaneous (SC) injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle. For SC injection in the middle third of the posterior aspect of the ear or in the base of the ear in beef and non-lactating dairy cattle.

(A) Single-dose regimen: 6.6 mg ceftiofur equivalents per kg of body weight as a single injection.

(B) Two-dose regimen: 6.6 mg ceftiofur equivalents per kg of body weight given as two injections in the base of the ear approximately 72 hours apart.

(ii) Indications for use—(A) Single-dose regimen: For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle. For the control of respiratory disease in beef and non-lactating dairy cattle which are at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.

(B) Two-dose regimen: For the treatment of acute metritis (0-to 10-days postpartum) associated with bacterial
organisms susceptible to ceftiofur in lactating dairy cattle.

(iii) Limitations. Following label use as either a single-dose or 2-dose regimen, a 13-day pre-slaughter withdrawal period is required after the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in cattle for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved, major food-producing species/production classes.

(3) Horses. The formulation described in paragraph (a)(2) of this section is used as follows:

(i) Amount. Two intramuscular injections, 4 days apart, at a dose of 3.0 mg/lb (6.6 mg/kg) body weight.

(ii) Indications for use. For the treatment of lower respiratory tract infections in horses caused by susceptible strains of *Streptococcus equi* subspp. *zooepidemicus*.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.313b Ceftiofur hydrochloride.

(a) Specifications. Each milliliter of ceftiofur hydrochloride suspension contains 50 milligrams (mg) ceftiofur equivalents.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.113 of this chapter.

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in cattle and swine for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved major food-producing species/production classes.

(e) Conditions of use—(1) Swine—(1) Amount. 3 to 5 mg per kilogram (kg) of body weight by intramuscular injection. Treatment should be repeated at 24-hour intervals for a total of 3 consecutive days.

(ii) Indications for use. For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Salmonella Choleraesuis*, and *Streptococcus suis*.

(iii) Limitations. Treated swine must not be slaughtered for 4 days following the last treatment.

(2) Cattle—(1) Amount. Administer by subcutaneous or intramuscular injection as follows:

(A) For bovine respiratory disease and acute bovine interdigital necrobacillosis: 1.1 to 2.2 mg/kg of body weight at 24-hour intervals for 3 to 5 consecutive days.

(B) For bovine respiratory disease: 2.2 mg/kg of body weight administered twice at a 48 hour interval.

(C) For acute metritis: 2.2 mg/kg of body weight at 24-hour intervals for 5 consecutive days.

(ii) Indications for use. For treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with *Mannheimia haemolytica*, *P. multocida*, and *Histophilus somni*; acute bovine interdigital necrobacillosis (foot rot, pododermatitis) associated with *Fusobacterium necrophorum* and *Bacteroides melaninigenicus*; and acute metritis (0 to 14 days post-partum) associated with bacteria susceptible to ceftiofur.

(iii) Limitations. Treated cattle must not be slaughtered for 4 days following the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.

§ 522.313c Ceftiofur sodium.

(a) Specifications. Each milliliter of aqueous solution constituted from ceftiofur sodium powder contains 50 milligrams (mg) ceftiofur equivalents.

(b) Sponsors. See Nos. 000409, 054771, and 068330 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.113 of this chapter.

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in cattle, swine, chickens, and turkeys for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved major food-producing species/production classes.

(e) Conditions of use—(1) Swine—(i) Amount. 3 to 5 mg per kilogram (/kg) body weight by intramuscular injection for 3 consecutive days.

(ii) Indications for use. For treatment and control of swine bacterial respiratory disease (swine bacterial pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.

(3) Cattle—(i) Amount. 0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

(ii) Indications for use. For treatment of caprine respiratory disease (goat pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.

(4) Dogs—(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

(ii) Indications for use. For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.

(iii) Limitations. Do not use in horses intended for human consumption.

(8) Horses—(i) Amount. 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.

(ii) Indications for use. For treatment of early mortality associated with E. coli organisms susceptible to ceftiofur in day-old poults.

(7) Horses—(i) Amount. 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.

(ii) Indications for use. For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.

(iii) Limitations. Do not use in horses intended for human consumption.

(8) Dogs—(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

(ii) Indications for use. For treatment of sheep respiratory disease (sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida.

(4) Goats—(i) Amount. 0.5 to 1.0 mg/lb body weight by intramuscular injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

(ii) Indications for use. For treatment of early mortality associated with Escherichia coli organisms susceptible to ceftiofur in day-old chicks.

(5) Chickens—(i) Amount. 0.08 to 0.20 mg as a single subcutaneous injection in the neck.

(ii) Indications for use. For control of early mortality associated with Escherichia coli organisms susceptible to ceftiofur in day-old poults.

(6) Turkeys—(i) Amount. 0.17 to 0.5 mg as a single subcutaneous injection in the neck.

(7) Horses—(i) Amount. 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.

(ii) Indications for use. For treatment of respiratory infections in horses associated with Streptococcus zooepidemicus.

(iii) Limitations. Do not use in horses intended for human consumption.

(8) Dogs—(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.

(ii) Indications for use. For treatment of early mortality associated with E. coli organisms susceptible to ceftiofur in day-old poults.

(7) Horses—(i) Amount. 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body weight by intramuscular injection. Treatment should be repeated every 24 hours, continued for 48 hours after clinical signs have disappeared, and should not exceed 10 days. A maximum of 10 mL should be administered per injection site.

(ii) Indications for use. For treatment of early mortality associated with E. coli organisms susceptible to ceftiofur in day-old poults.

(8) Dogs—(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by subcutaneous injection for 3 days. Additional treatments may be given on days 4 and 5 for animals which do not show satisfactory response.
(i) Indications for use. For treatment of canine urinary tract infections associated with E. coli and Proteus mirabilis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extralabel use of this drug in food-producing animals.

§ 522.454 Clodronate.

(a) Specifications. Each milliliter of solution contains 60 milligrams (mg) clodronate disodium.

(b) Sponsor. See No. 043264 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 1.8 mg per kilogram of body weight by intramuscular injection up to a maximum dose of 900 mg per horse.

(2) Indications for use. For the control of clinical signs associated with navicular syndrome.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.460 Cloprostenol.

(a) Specifications. Each milliliter of solution contains 60 milligrams (mg) clodronate disodium equivalent to:

(1) 125 micrograms (µg) of cloprostenol; or

(2) 250 µg of cloprostenol.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter.

(1) No. 000061 for use of product described in paragraph (a)(1) of this section as in paragraphs (c)(1)(i) and (c)(2) of this section.

(2) Nos. 000061 and 068504 for use of product described in paragraph (a)(2) as in paragraphs (c)(1)(ii), (c)(1)(iii), and (c)(2) of this section.

(c) Conditions of use in cattle—(1) Amount and indications for use—(i) Administer 375 µg by intramuscular injection to induce abortion in pregnant feedlot heifers from 1 week after mating until 4 1/2 months of gestation.

(ii) Administer 500 µg by intramuscular injection for terminating unwanted pregnancies from mismatings from 1 week after mating.
§ 522.468 Colistimethate sodium powder for injection.

(a) Specifications. Each vial contains colistimethate sodium equivalent to 10 grams colistin activity and mannitol to be reconstituted with 62.5 milliliters sterile saline or sterile water for injection. The resulting solution contains colistimethate sodium equivalent to 133 milligrams per milliliter colistin activity.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use. (1) 1- to 3-day-old chickens.

(i) Dosage. 0.2 milligram colistin activity per chicken.

(ii) Indications for use. Control of early mortality associated with Escherichia coli organisms susceptible to colistin.

(iii) Limitations. For subcutaneous injection in the neck of 1- to 3-day-old chickens. Not for use in laying hens producing eggs for human consumption. Do not use in turkeys. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]


§ 522.480 Corticotropin.

(a) Specifications. Each milliliter (mL) of sterile aqueous solution contains 40 or 80 U.S.P. (I.U.) units of repository corticotropin.

(b) Sponsor. See sponsors in § 510.600(c) of this chapter.

(1) No. 061623 for use as in paragraphs (c)(1) and (2) of this section.

(2) No. 026637 for use as in paragraph (c)(2) and (3) of this section.

(c) Conditions of use. (1) Dogs—(i) Amount. Administer one unit per pound of body weight by intramuscular injection.

(ii) Indications for use. As a diagnostic aid to test for adrenal dysfunction.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs and cats—(i) Amount. Administer one unit per pound of body weight by intramuscular or subcutaneous injection, to be repeated as indicated.

(ii) Indications for use. For stimulation of the adrenal cortex where there is a general deficiency of corticotropin (ACTH).

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Cattle—(i) Amount. Administer 200 to 600 units by intramuscular or subcutaneous injection as an initial dose, followed by a dose daily or every other day of 200 to 300 units.

(ii) Indications for use. For stimulation of the adrenal cortex where there is a general deficiency of ACTH.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16185, Mar. 25, 2014]

§ 522.518 Cupric glycinate injection.

(a) Specifications. Each milliliter (mL) of sterile aqueous suspension contains 200 milligrams of cupric glycinate (equivalent to 60 milligrams of copper).

(b) Sponsor. See No. 049185 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. 200 milligrams (1 mL) for calves 300 pounds and under; 400 milligrams (2 mL) for calves over 300 pounds and adult cattle.

(2) Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.

(3) Limitations. For subcutaneous use only; repeat dose in 3 months in young
Food and Drug Administration, HHS

§ 522.522 Danofloxacin.

(a) Specifications. Each milliliter of solution contains 180 milligrams (mg) danofloxacin as the mesylate salt.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.169 of this chapter.

(d) Conditions of use in cattle—(1) Amount and indications for use. Administer by subcutaneous injection either:

(i) 6 mg per kilogram (kg) of body weight, repeated in 48 hours, for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida; or

(ii) 8 mg/kg of body weight as a single dose for the treatment of BRD associated with M. haemolytica and P. multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with M. haemolytica and P. multocida.

(2) Limitations. Animals intended for human consumption should not be slaughtered within 4 days from the last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.


§ 522.533 Deslorelin.

(a) Specifications—(1) Each implant contains 2.1 milligrams (mg) deslorelin acetate.

(2) Each milliliter (mL) of suspension contains 1.8 mg deslorelin acetate.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) No. 051311 for use of product described in paragraph (a)(1) as in paragraph (c)(1) of this section.

(2) No. 051330 for use of product described in paragraph (a)(2) as in paragraph (c)(2) of this section.

(c) Conditions of use—(1) Horses and ponies—(i) Amount. One implant per mare subcutaneously in the neck.

(ii) Indications for use. For inducing ovulation within 48 hours in estrous mares with an ovarian follicle greater than 30 mL in diameter.

(iii) Limitations. Do not use in horses or ponies intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—(i) Amount. Administer 1.8 mg (1 mL) by intramuscular injection in the neck.

(ii) Indications for use. For inducing ovulation within 48 hours in cyclic estrous mares with an ovarian follicle between 30 and 40 mL in diameter.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.535 Desoxycorticosterone.

(a) Specifications. Each milliliter of suspension contains 25 milligrams of desoxycorticosterone pivalate.

(b) Sponsor. See No. 058198 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.

(ii) Indications for use. For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]


279
§ 522.536 Detomidine.

(a) Specification. Each milliliter of solution contains 10 milligrams of detomidine hydrochloride.

(b) Sponsor. See No. 052483 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. For sedation, analgesia, or sedation and analgesia: 20 or 40 micrograms per kilogram (0.2 or 0.4 milliliter per 100 kilogram or 220 pounds) by body weight, depending on depth and duration required. For sedation, administer by intravenous (IV) or intramuscular (IM) injection; for analgesia, administer by IV injection; for both sedation and analgesia, administer by IV injection.

(2) Indication for use. As a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16186, Mar. 25, 2014]

§ 522.540 Dexamethasone solution.

(a)(1) Specifications. Each milliliter of solution contains 2 milligrams (mg) dexamethasone.

(2) Sponsors. See sponsors in §510.600(c) of this chapter:

(i) Nos. 000061, 000859, and 061623 for use as in paragraph (a)(3) of this section.


(3) Conditions of use—(i) Amount. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary, as follows:

(A) Dogs. 0.25 to 1 mg.

(B) Cats. 0.125 to 0.5 mg.

(C) Horses. 2.5 to 5 mg.

(D) Cattle. 5 to 20 mg, depending on the severity of the condition.

(ii) Indications for use. The drug is indicated:

(A) For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses;

(B) As an anti-inflammatory agent in dogs and cats.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).

(2) Sponsor. See number in §510.600(c) of this chapter as follows:

(i) No. 061623 for use of 2.0 milligrams dexamethasone or 4.0 milligrams dexamethasone sodium phosphate injections.

(ii) No. 000402 for use of 2.0 milligrams dexamethasone or 4.0 milligrams dexamethasone sodium phosphate injections.

(3) Conditions of use—(i) Amount. Administer 0.25 to 1 mg by intravenous injection, repeated for 3 to 5 days or until a response is noted.

(ii) Indications for use. For use in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis, as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).

(2) Sponsor. See Nos. 000402 and 061623 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Administer 2.5 to 5.0 mg by intravenous injection.

(4) Indications for use. For use in horses as a rapid adrenal glucocorticoid and/or anti-inflammatory agent.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)(1) Specifications. Each milliliter of solution contains 2.0 mg of dexamethasone or 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg of dexamethasone).

(2) Sponsors. See the following numbers in §510.600(c) of this chapter:
Food and Drug Administration, HHS

(i) Nos. 000859 and 054771 for intravenous or intramuscular use of 2.0 milligrams dexamethasone injection.
(ii) No. 054771 for intravenous use of 2.0 milligrams dexamethasone injection.

(3) Conditions of use—(i) Amount. Administer by intravenous or intramuscular injection as follows:
(A) Dogs: 0.25 to 1 mg.
(B) Cats: 0.125 to 0.5 mg.
(C) Horses: 2.5 to 5 mg.
(ii) Indications for use. For use in dogs, cats, and horses as an anti-inflammatory agent.
(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e)(1) Specifications. Each milliliter of solution contains 4.0 mg of dexamethasone sodium phosphate (equivalent to 3.0 mg dexamethasone).
(2) Sponsor. See No. 069043 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Administer by intravenous injection as follows:
(A) Dogs: 0.25 to 1 mg; may be repeated for 3 to 5 days.
(B) Horses: 2.5 to 5 mg.
(ii) Indications for use. For use in dogs and horses for glucocorticoid and anti-inflammatory effect.
(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§522.542 Dexamethasone suspension.

(a) Specifications. Each milliliter of suspension contains 1 milligram (mg) of dexamethasone-21-isonicotinate.
(b) Sponsor. No. 000010 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount. Administer by intramuscular injection as follows: Dogs: 0.25 to 1 mg; cats: 0.125 to 0.5 mg; horses: 5 to 20 mg. Dosage may be repeated.
(2) Indications for use. For the treatment of various inflammatory conditions associated with the musculoskeletal system in dogs, cats, and horses.
(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16186, Mar. 25, 2014]

§522.558 Dexmedetomidine.

(a) Specifications. Each milliliter of solution contains:
(1) 0.1 milligrams (mg) dexmedetomidine hydrochloride; or
(2) 0.5 mg dexmedetomidine hydrochloride.
(b) Sponsors. See sponsors in in §510.600(c) of this chapter for use as in paragraph (c) of this section:
(1) No. 026637 for use of product described in paragraph (a)(2) of this section;
(2) No. 052483 for use of products described in paragraph (a) of this section.
(c) Conditions of use—(1) Dogs—(i) Indications for use and amount. (A) For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures, administer 375 micrograms (μg) per square meter (m²) of body surface area by intravenous injection or 500 μg/m² of body surface area by intramuscular injection.
(B) For use as a preanesthetic to general anesthesia, administer 125 μg/m² of body surface area or 375 μg/m² of body surface area by intramuscular injection.
(ii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats—(i) Amount. 40 μg/kilogram by intramuscular injection.
(ii) Indications for use. For use as a sedative and analgesic to facilitate clinical examinations, clinical procedures, minor surgical procedures, and minor dental procedures, and as a preanesthetic to general anesthesia.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.563 Diatrizoate.

(a) Specifications. Each milliliter of solution contains 34.3 percent diatrizoate meglumine and 35 percent diatrizoate sodium, or 66 percent diatrizoate meglumine and 10 percent diatrizoate sodium.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—
(1) Amount. For excretion urography, administer 0.5 to 1.0 milliliter (mL) per pound of body weight to a maximum of 30 mL intravenously. For cystography, remove urine, administer 5 to 25 mL directly into the bladder via catheter. For urethrography, administer 1.0 to 5 mL via catheter into the urethra to provide desired contrasts delineation. For cerebral angiography, rapid injection of 3 to 10 mL via carotid artery. For peripheral arteriography and/or venography and selective coronary arteriography, rapidly inject 3 to 10 mL intravascularly into the vascular bed to be delineated. For lymphography, slowly inject 1.0 to 10 mL directly into the lymph vessel to be delineated. For arthrogram, slowly inject 1.0 to 5 mL directly into the joint to be delineated. For discography, slowly inject 0.5 to 1.0 mL directly into the disc to be delineated. For delineation of fistulous tracts, slowly inject quantity necessary to fill the tract. For delineation of peritoneal hernias, inject 0.5 to 1.0 mL per pound of body weight directly into the peritoneal cavity.

(2) Indications for use. For visualization in excretion urography, including renal angiography, urethrography, cystography, and ureterography; aortography; angiocardiology, peripheral arteriography, and venography; selective coronary arteriography; cerebral angiography; lymphography; arthrogram; discography; and sialography; and as an aid in delineating peritoneal hernias and fistulous tracts.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16186, Mar. 25, 2014]

§ 522.650 Dihydrostreptomycin sulfate injection.

(a) Specifications. Each milliliter contains dihydrostreptomycin sulfate equivalent to 500 milligrams of dihydrostreptomycin.

(b) Sponsors. See Nos. 054771 and 055529 in §510.600(c) of this chapter.

(c) Related tolerance. See §556.200 of this chapter.

(d) Conditions of use— (1) Amount. Administer 5 milligrams per pound of body weight by deep intramuscular injection every 12 hours, for 3 to 5 days or until the urine is free of leptospira for at least 72 hours as measured by darkfield microscopic examination.

(2) Indications for use. Treatment of leptospirosis in dogs and horses due to Leptospira canicola, L. icterohemorrhagiae, and L. pomona; in cattle due to L. pomona; and in swine due to L. pomona; and L. grippotyphosa.

(3) Limitations. Discontinue use 30 days before slaughter for food. Not for use in animals producing milk because use of the drug will contaminate the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.690 Dinoprost.

(a) Specifications. Each milliliter (mL) of solution contains dinoprost tromethamine equivalent to 5 milligrams (mg) or 12.5 mg dinoprost.

(b) Sponsors. See sponsors in §510.600(c) of this chapter.

(1) No. 054771 for use of the 12.5 mg/mL product as in paragraph (d)(1) of this section.

(2) No. 054771 for use of the 5 mg/mL product as in paragraphs (d)(1), (2), and (3) of this section.

(3) No. 000859 for use of the 5 mg/mL product as in paragraphs (d)(2), (3), and (4) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Food and Drug Administration, HHS

§ 522.723 Diprenorphine.

(a) Specifications. Each milliliter of solution contains 2 milligrams of diprenorphine hydrochloride.

(b) Sponsors. See No. 053923 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. It is administered intramuscularly or intravenously at a suitable dosage level depending upon the species.

(2) Indications for use. The drug is used for reversing the effects of etorphine hydrochloride injection, veterinary, the use of which is provided for in §522.883, in wild and exotic animals.

(3) Limitations. For use in wild or exotic animals only. Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.723 Diprenorphine.

(a) Specifications. Each milliliter of solution contains 2 milligrams of diprenorphine hydrochloride.

(b) Sponsors. See No. 053923 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. It is administered intramuscularly or intravenously at a suitable dosage level depending upon the species.

(2) Indications for use. The drug is used for reversing the effects of etorphine hydrochloride injection, veterinary, the use of which is provided for in §522.883, in wild and exotic animals.

(3) Limitations. For use in wild or exotic animals only. Do not use in domestic food-producing animals. Do not use 30 days before, or during, the hunting season in free-ranging wild animals that might be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Distribution is restricted to veterinarians engaged in zoo and exotic animal practice, wildlife management programs, and researchers.

[79 FR 16187, Mar. 25, 2014]

§ 522.770 Doramectin.

(a) Specifications. Each milliliter of solution contains 10 milligrams of doramectin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.225 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. 200 micrograms per kilogram (10 milligrams per 110 pounds).

(ii) Indications for use. For treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice, and mange mites. To control infections and to protect from reinfection with Cooperia oncophora and Haemonchus placei for 14 days, Ostertagia ostertagi for 21 days, and C. punctata, Oesophagostomum radiatum, and Dictyocaulus viviparus for 28 days after treatment.

(iii) Limitations. Administer as a single subcutaneous or intramuscular injection. Do not slaughter cattle within 35 days of treatment. Not for use in female dairy cattle 20 months of age or older. Do not use in calves to be processed for veal.

(2) Swine—(i) Amount. 300 micrograms per kilogram (10 milligrams per 75 pounds).

(ii) Indications for use. For treatment and control of gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and mange mites.

(iii) Limitations. Administer as a single intramuscular injection. Do not slaughter swine within 24 days of treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.


§ 522.775 Doxapram.

(a) Specifications. Each milliliter contains 20 milligrams (mg) doxapram hydrochloride.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For intravenous use in dogs and cats at a dose of 2½ to 5 mg per pound (/lb) body weight in barbiturate anesthesia, 0.5 mg/lb in inhalation anesthesia; for intravenous use in horses at 0.25 mg/lb body weight in barbiturate anesthesia, 0.2 mg/lb in inhalation anesthesia, 0.25 mg/lb with chloral hydrate with or without magnesium sulfate; for subcutaneous, sublingual, or umbilical vein administration in neonate puppies at a dose rate of 1 to 5 mg; for subcutaneous or sublingual use in neonate kittens at 1 to 2 mg. Dosage may be repeated in 15 to 20 minutes if necessary.

(2) Indications for use. Administer to dogs, cats, and horses to stimulate respiration during and after general anesthesia; or to speed awakening and return of reflexes after anesthesia. Administer to neonate dogs and cats to initiate respiration following dystocia or cesarean section; or to stimulate respiration following dystocia or cesarean section.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.784 Doxylamine.

(a) Specifications. Each milliliter contains 11.36 milligrams (mg) of doxylamine succinate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Horses: Administer 25 mg per hundred pounds of body weight by intramuscular, subcutaneous, or slow intravenous injection.

(ii) Dogs and cats: Administer 0.5 to 1 mg per pound of body weight by intramuscular or subcutaneous injection. Doses may be repeated at 8 to 12 hours, if necessary, to produce desired effect.

(2) Indications for use. For use in conditions in which antihistaminic therapy may be expected to alleviate some signs of disease in horses, dogs, and cats.
Food and Drug Administration, HHS  

§ 522.800 Droperidol and fentanyl.  

(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of droperidol and 0.4 mg of fentanyl citrate.  

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.  

(c) Conditions of use—(1) Amount. For analgesia and tranquilization, administer as follows:  

(A) 1 milliliter (mL) per 15 to 20 pounds (lbs) of body weight by intramuscular injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight; or  

(B) 1 mL per 25 to 60 lbs of body weight by intravenous injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight.  

(ii) For general anesthesia, administer as follows:  

(A) Administer 1 mL per 40 lbs of body weight by intramuscular injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight and followed in 10 minutes by an intravenous administration of sodium pentobarbital at the rate of 3 mg per pound of body weight; or  

(B) Administer 1 mL per 25 to 60 lbs of body weight by intravenous injection in conjunction with atropine sulfate administered at the rate of 0.02 mg per pound of body weight and followed within 15 seconds by an intravenous administration of sodium pentobarbital at the rate of 3 mg per pound of body weight.  

(2) Indications for use. As an analgesic and tranquilizer and for general anesthesia.  

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.  


§ 522.810 Embutramide, chloroquine, and lidocaine solution.  

(a) Specifications. Each milliliter (mL) of solution contains 135 milligrams (mg) embutramide; 45 mg chloroquine phosphate, U.S.P.; and 1.9 mg lidocaine, U.S.P.  

(b) Sponsor. See No. 069043 in § 510.600(c) of this chapter.  

(c) Conditions of use in dogs—(1) Amount. One mL per 5 pounds of body weight.  

(2) Indications for use. For euthanasia.  

(3) Limitations. Not for use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.  

§ 522.812 Enrofloxacin.  

(a) Specifications. Each milliliter (mL) of solution contains:  

(1) 22.7 milligrams (mg) enrofloxacin or  

(2) 100 mg enrofloxacin.  

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter:  

(1) No. 000859 for use of products described in paragraph (a) as in paragraph (e) of this section; and  

(2) No. 055529 for use of product described in paragraph (a)(1) of this section as in paragraph (e)(1) of this section, and use of product described in paragraph (a)(2) in this section as in paragraphs (e)(2), (e)(3)(i)(B), and (e)(3)(ii) of this section.  

(3) No. 026637 for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section.  

(c) Related tolerance. See §556.226 of this chapter.  

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.  

(e) Conditions of use—(1) Dogs. Use the product described in paragraph (a)(1) of this section as follows:  

(1) Amount. 2.5 mg per kilogram (/kg) of body weight (1.13 mg per pound) as a single, intramuscular, initial dose followed by use of tablets twice daily for 2 to 3 days beyond cessation of clinical signs to a maximum of 10 days.
(ii) Indications for use. For the management of diseases associated with bacteria susceptible to enrofloxacin.

(2) Cattle. Use the product described in paragraph (a)(2) of this section as follows:

(A) Single-dose therapy: For treatment of bovine respiratory disease (BRD), administer 7.5 to 12.5 mg/kg of body weight (3.4 to 5.7 mL per 100 pounds (100 lb)) once by subcutaneous injection. For control of BRD, administer 7.5 mg/kg of body weight (3.4 mL/100 lb) once by subcutaneous injection.

(B) Multiple-day therapy: For treatment of BRD, administer 2.5 to 5.0 mg/kg of body weight (1.1 to 2.3 mL/100 lb) by subcutaneous injection. Treatment should be repeated at 24-hour intervals for 3 days. Additional treatments may be given on days 4 and 5 to animals that have shown clinical improvement but not total recovery.

(ii) Indications for use—(A) Single-dose therapy: For the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle; for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.

(B) Multiple-day therapy: For the treatment of bovine respiratory disease (BRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis.

(C) Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed.

(ii) Limitations. Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.

§ 522.814 Eprinomectin.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) eprinomectin.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 500.1410 and 556.227 of this chapter.

(d) Conditions of use in cattle on pasture—(1) Amount. Administer 1 mg/kilogram of body weight by subcutaneous injection.

(2) Indications for use. For the treatment and control of the following internal and external parasites: Gastrointestinal roundworms (adults and fourth-stage larvae) Bunostomum phlebotomum, Cooperia oncophora, C. punctata, C. surnabada, Trichostrongylus axei, Ostertagia ostertagi (including inhibited stage); (adults) Haemonchus placei, Oesophagostomum radiatum, O. lyrata, T. colubriformis; lungworms
Food and Drug Administration, HHS

§ 522.840 Estradiol.

(a) Specifications. Each silicone rubber implant contains 25.7 or 43.9 milligrams (mg) estradiol and is coated with not less than 0.5 mg oxytetracycline powder.

(b) Sponsor. See No. 000986 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.240 of this chapter.

(d) Conditions of use. For implantation in steers and heifers as follows:

(1) Amount. Insert one 25.7-mg implant every 200 days; insert one 43.9-mg implant every 400 days.

(2) Indications for use. For increased rate of weight gain in suckling and pastured growing steers; for improved feed efficiency and increased rate of weight gain in confined steers and heifers. No additional effectiveness may be
expected from reimplanting in less than 200 days for the 25.7-mg implant or 400 days for the 43.9-mg implant.

(3) Limitations. For subcutaneous ear implantation in steers and heifers only. Safety and effectiveness have not been established in veal calves. Do not use in calves to be processed for veal.

§ 522.842 Estradiol benzoate and testosterone propionate.

(a) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section.

(1) No. 054771 for use as in paragraph (c)(1)(i), (c)(2), and (c)(3) of this section.

(2) No. 000986 for use as in paragraph (c) of this section.

(b) Related tolerances. See §§ 556.240 and 556.710 of this chapter.

(c) Conditions of use.

(1) Amount. One implant and 2 milliliters of injection at time of implantation.

(2) Indications for use. For synchronization of estrus/ovulation in cycling beef cattle and non-lactating dairy heifers.

(3) Limitations. Insert implant subcutaneously in the ear only; then immediately inject solution intramuscularly only. Counting the day of implantation as day 1, remove the implant on day 10. Collect all implants as they are removed and burn them. While animals are restrained for artificial insemination, avoid other treatments such as vaccinations, dipping, pour-on grub and louse prevention, spraying, etc. When inseminating without estrus detection, the entire treated group should be started at 48 hours after the last implant has been removed and should be completed within 6 hours. Where estrus detection is preferred, insemination should be approximately 12 hours after first detection of estrus. Those that do not conceive can be re-bred when they return to estrus approximately 17 to 25 days after implant removal. Do not use in cows producing milk for human consumption.

§ 522.863 Ethylisobutrazine.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of ethylisobutrazine hydrochloride.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 2 to 5 mg per pound of body weight by intramuscular injection for profound tranquilization.
§ 522.940 Euthanasia solution.
(a) Specifications. Each milliliter (mL) of solution contains:
(1) 390 milligrams (mg) of pentobarbital sodium and 50 mg phenytoin sodium.
(2) 400 mg secobarbital sodium and 25 mg dibucaine hydrochloride.
(b) Sponsors. See sponsors in § 510.600(c) of this chapter:
(1) Nos. 000061, 051311, and 054925 for use of product described in paragraph (a)(1) of this section.
(2) No. 054771 for use of product described in paragraph (a)(2) of this section.
(c) Special considerations. Product labeling shall bear the following warning statements: “ENVIRONMENTAL HAZARD: This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife.”
(d) Conditions of use in dogs—(1) Indications for use. For humane, painless, and rapid euthanasia.
(2) Amount. One mL per 10 pounds of body weight.
(3) Limitations. Do not use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.914 Fenprostalene.
(a) Specifications. (1) Each milliliter of solution contains 0.5 milligram (mg) fenprostalene.
(2) Each milliliter of solution contains 0.25 mg fenprostalene.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section; and for use of product described in paragraph (a)(2) as in paragraph (e)(2) of this section.
(c) Related tolerances. See § 556.277 of this chapter.
(d) Special considerations. Labeling shall bear the following statements:
Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. It is readily absorbed through the skin and may cause abortion and/or bronchospasms. Accidental spillage on the skin should be washed off immediately with soap and water.

(e) Conditions of use—(1) Cattle—(i) Indications for use and amount—(A) For feedlot heifers to induce abortion when pregnant 150 days or less, administer 1 mg (2 milliliter (mL)) subcutaneously. (B) For beef or nonlactating dairy cattle for estrus synchronization, administer a single or two 1-mg (2-mL) doses subcutaneously, 11 to 13 days apart. (ii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Swine—(i) Amount. Administer a single injection of 0.25 mg (1 mL) subcutaneously. (ii) Indications for use. For the induction of parturition in sows and gilts pregnant at least 112 days. (iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16188, Mar. 25, 2014]

§ 522.930  Firocoxib.

(a) Specifications. Each milliliter of solution contains: 20 milligrams (mg) firocoxib. (b) Sponsors. See No. 050604 in § 510.600(c) of this chapter. (c) Conditions of use in horses—(1) Amount. Administer 0.04 mg/pound (lb) (0.09 mg/kilogram (kg)) of body weight (BW) intravenously, once daily, for up to 5 days. If further treatment is needed, firocoxib oral paste can be administered at a dosage of 0.045 mg/lb (0.1 mg/kg) of BW for up to an additional 9 days of treatment. (2) Indications for use. For the control of pain and inflammation associated with osteoarthritis. (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 59611, Sept. 28, 2010]
of body weight as a single subcutaneous injection may be used.

(2) Indications for use. For treatment of BRD associated with Mannheimia (Pasteurella) haemolytica, P. multocida, and Haemophilus somnus. For treatment of bovine interdigital phlegmon (foot rot, acute interdigital necrobacillosis, infectious pododermitatis) associated with Fusobacterium necrophorum and Bacteroides melaninogenicus.

(B)(1) Amount. 40 mg/kg of body weight as a single subcutaneous injection.

(2) Indications for use. For control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica, P. multocida, and Haemophilus somnus.

(C) Limitations. Animals intended for human consumption must not be slaughtered within 38 days of treatment. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.960a Flumethasone suspension.

(a) Specifications. Each milliliter of suspension contains 2 milligrams (mg) of flumethasone.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 6 to 10 mg by intra-articular injection. Dosage is limited to a single injection per week in any one synovial structure.

(2) Indications for use. For use in the various disease states involving synovial structures (joints) of horses where excessive synovial fluid of inflammatory origin is present and where permanent structural changes do not exist. Such conditions include arthritis, carpitis, and osselets.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.960b Flumethasone acetate solution.

(a) Specifications. Each milliliter of solution contains 2 milligrams (mg) of flumethasone acetate.
§ 522.960c Flumethasone solution.

(a) Specifications. Each milliliter of solution contains 0.5 milligrams (mg) of flumethasone.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use.

Horses—(1) Amount. Administer 1.25 to 2.5 milligrams (mg) daily by intravenous, intramuscular, or intra-articular injection.

(ii) Indications for use. For use in the treatment of musculoskeletal conditions due to inflammation of muscles or joints and accessory structures where permanent structural changes do not exist, e.g., arthritis, osteoarthritis, disc syndrome, and myositis; and allergic states, e.g., hives, urticaria, and insect bites.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dogs—(1) Amount. Administer 0.0625 to 0.25 mg daily by intravenous, intramuscular, or subcutaneous injection; 0.125 to 1.0 mg daily by intraleisonal injection, depending on the size and location of the lesion; or 0.106 to 1.0 mg daily by intra-articular injection, depending on the severity of the condition and the size of the involved joint.

(ii) Indications for use. For use in the treatment of musculoskeletal conditions due to inflammation of muscles or joints and accessory structures where permanent structural changes do not exist, e.g., arthritis, osteoarthritis, disc syndrome, and myositis; and allergic states, e.g., hives, urticaria, and insect bites; and shock and shock-like states by intravenous administration.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Cats—(1) Amount. Administer 0.03125 to 0.125 mg daily by intravenous, intramuscular, or subcutaneous injection.

(ii) Indications for use. For use in the treatment of certain acute and chronic dermatoses of varying etiology to help control associated pruritus, irritation, and inflammation.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.970 Flunixin.

(a) Specifications. Each milliliter of solution contains flunixin meglumine equivalent to 50 milligrams (mg) flunixin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

1. See Nos. 000061, 055529, and 061623 for use as in paragraph (e) of this section.

2. See No. 054771 for use as in paragraph (e)(1) of this section.

3. See Nos. 057561 and 059130 for use as in paragraphs (e)(1) and (2) of this section.

(c) Related tolerances. See §556.286 of this chapter.

(d) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Food and Drug Administration, HHS

§ 522.1002

(e) Conditions of use—(1) Horses—(i) Amount. 0.5 mg per pound (/lb) of body weight per day, intravenously or intramuscularly, for up to 5 days.

(ii) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders, and alleviation of visceral pain associated with colic.

(iii) Limitations. Do not use in horses intended for human consumption.

(2) Cattle—(i) Amounts and indications for use—(A) Administer 1.1 to 2.2 mg/kg (0.5 to 1.0 mg/lb) of body weight per day intravenously, as a single dose or divided into two doses administered at 12-hour intervals, for up to 3 days for control of pyrexia associated with bovine respiratory disease and endotoxemia or for control of inflammation in endotoxemia.

(B) Administer 2.2 mg/kg (1.0 mg/lb) of body weight once intravenously for control of pyrexia associated with acute bovine mastitis.

(ii) Limitations. Cattle must not be slaughtered for human consumption within 4 days of last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Do not use in dry dairy cows. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal.

(B) For control of pyrexia associated with acute bovine mastitis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.995 Fluprostenol.

(a) Specifications. Each milliliter of solution contains fluprostenol sodium equivalent to 50 micrograms (μg) of fluprostenol.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 0.55 μg fluprostenol per kilogram of body weight by intramuscular injection.

(ii) Indications for use. For use in mares for its luteolytic effect to control the timing of estrus in estrous cycling and in clinically anestrous mares that have a corpus luteum.

(iii) Limitations. Swine must not be slaughtered for human consumption within 12 days of last treatment.

§ 522.1002 Follicle stimulating hormone.

(a)(1) Specifications. Each package contains 2 vials. One vial contains dry, powdered, porcine pituitary gland equivalent to 75 units (NIH-FSH-S1) of follicle stimulating hormone. The other vial contains 10 milliliters of aqueous diluent.

(2) Sponsor. See No. 052923 in § 510.600(c) of this chapter.

(3) Conditions of use. (i) Dosage. 12.5 units of follicle stimulating hormone twice a day for 3 days (a total of 75 units). To effect regression of the corpus luteum, prostaglandin should be given with the 5th dose.

(ii) Indications for use. For the control of pyrexia associated with swine respiratory disease.
(iii) Limitations. For intramuscular use in cows that are not pregnant and have a normal corpus luteum. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. The drug is a lyophilized pituitary extract material. Each 10-milliliter vial contains an amount equivalent to 50 milligrams of standard porcine follicle stimulating hormone and is reconstituted for use by addition of 10 milliliters of 0.9 percent aqueous sodium chloride solution.

(2) Sponsor. See 063112 in § 510.600(c) of this chapter.


(ii) Indications for use. The drug is used as a supplemental source of follicle stimulating hormone where there is a general deficiency in cattle, horses, sheep, swine, and dogs.

(iii) Limitations. Administer intramuscularly, subcutaneously, or intravenously. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each package contains 2 vials. One vial contains 700 international units (IU) porcine-pituitary derived follicle stimulating hormone (FSH) equivalent to 400 milligrams NIH–FSH–P1, as a dry powder. The other vial contains 20 milliliters (mL) of bacteriostatic sodium chloride injection. When reconstituted, each milliliter of constituted solution contains 35 IU FSH.

(2) Sponsor. See No. 017030 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Dosage. Administer 2.5 mL (87.5 IU) intramuscularly, twice daily at 12-hour intervals, for 4 consecutive days. In conjunction with the 6th dose, administer an approved prostaglandin product for cattle (cloprostenol sodium or dinoprost tromethamine), using the labeled dosage and administration instructions to cause luteolysis and induce estrus. See § 522.460 for use of cloprostenol sodium or § 522.690 for use of dinoprost tromethamine.

(ii) Indications for use. For the induction of superovulation in beef and dairy heifers and cows.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(i) **Amount.** 0.5 mg/lb body weight once or twice daily, intramuscularly or intravenously.

(A) **Indications for use.** For treatment of acute noninflammatory tissue edema.

(B) **Limitations.** Do not use in horses intended for human consumption.

(iii) **Amount.** 250 to 500 mg/animal once or twice daily, intramuscularly or intravenously.

(A) **Indications for use.** For the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency, and acute noninflammatory tissue edema.

(B) **Limitations.** Do not use in horses intended for human consumption.

(3) **Cattle**—(i) **Amount.** Administer 6 mg/kilogram of body weight (2 mL per 110 pounds) one time by subcutaneous injection in the neck.

(ii) **Indications for use.** For the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, *Histophilus somni*, and *Mycoplasma bovis* in beef and non-lactating dairy cattle; and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica* and *P. multocida*.

(iii) **Limitations.** Cattle intended for human consumption must not be slaughtered within 35 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]


§ 522.1020 Gelatin.

(a) **Specifications.** Each 100 milliliters contains 8 grams of gelatin in a 0.85 percent sodium chloride solution.

(b) **Sponsor.** See No. 054771 in §510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Amount.** The exact dosage to be administered must be determined after evaluating the animal’s condition and will vary according to the size of the animal and the degree of shock. A suggested dosage range for small animals such as dogs is 4 to 8 cubic centimeters per pound body weight. The suggested dosage range for large animals such as sheep, calves, cows, or horses is 2 to 4 cubic centimeters per pound body weight.

(2) **Indications for use.** For use to restore circulatory volume and maintain blood pressure in animals being treated for shock.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16189, Mar. 25, 2014]

§ 522.1044 Gentamicin.

(a) **Specifications.** Each milliliter of solution contains gentamicin sulfate equivalent to 5, 50, or 100 milligrams (mg) gentamicin.

(b) **Sponsors.** See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.
§ 522.1044

(1) No. 000061 for use of 5 mg per milliliter (mL) solution in swine as in paragraph (d)(4), 50 mg/mL solution in dogs and cats as in paragraph (d)(1), 50 mg/mL and 100 mg/mL solution in chickens and turkeys as in paragraphs (d)(2) and (d)(3) of this section.

(2) No. 058005 for use of 5 mg/mL solution in swine as in paragraph (d)(4) of this section.

(3) No. 054628 for use of 50 mg/mL solution in dogs as in paragraph (d)(5) of this section.

(4) Nos. 000859 and 061623 for use of 100 mg/mL solution in turkeys as in paragraph (d)(2) and in chickens as in paragraph (d)(3) of this section.

(c) Related tolerances. See § 556.300 of this chapter.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. Two milligrams of gentamicin per pound of body weight, twice daily on the first day, once daily thereafter, using a 50 milligram-per-milliliter solution.

(ii) Indications for use—(a) Dogs. For the treatment of infections of urinary tract (cystitis, nephritis), respiratory tract (tonsillitis, pneumonia, tracheobronchitis), skin and soft tissue (pyodermatitis, wounds, lacerations, peritonitis).

(b) Cats. For the treatment of infections of urinary tract (cystitis, nephritis), respiratory tract (pneumonitis, pneumonia, upper respiratory tract infections), skin and soft tissue (wounds, lacerations, peritonitis), and as supportive therapy for secondary bacterial infections associated with panleucopenia.

(iii) Limitations. Administer intramuscularly or subcutaneously. If response is not noted after 7 days, the antibiotic sensitivity of the infecting organism should be retested. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Turkeys—(i) Amount. One milligram of gentamicin per 0.2 milliliter dose, using the 50- or 100-milligram-per-milliliter product diluted with sterile saline to a concentration of 1.0 milligram-per-milliliter.

(ii) Indications for use. As an aid in the prevention of early mortality due to Arizona paracolon infections susceptible to gentamicin.

(iii) Limitations. For 1- to 3-day old turkey poults. Administer subcutaneously in the neck. Injected poults must not be slaughtered for food for at least 9 weeks after treatment.

(3) Chickens—(i) Amount. 0.2 milligram of gentamicin per 0.2 milliliter dose, using the 50- or 100-milligram-per-milliliter product diluted with sterile saline to a concentration of 1.0 milligram-per-milliliter.

(ii) Indications for use. In day-old chickens, for prevention of early mortality caused by Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa that are susceptible to gentamicin.

(iii) Limitations. For use in day-old chickens only. Administer aseptically, injecting the diluted product subcutaneously in the neck. Do not slaughter treated animals for food for at least 5 weeks after treatment.

(4) Swine—(i) Amount. 5 milligrams of gentamicin as a single intramuscular dose using 5 milligram-per-milliliter solution.

(ii) Indications for use. In piglets up to 3 days old for treatment of porcine colibacillosis caused by strains of E. coli sensitive to gentamicin.

(iii) Limitations. For single intramuscular dose in pigs up to 3 days of age only. Do not slaughter treated animals for food for at least 40 days following treatment.

(5) Dogs—(i) Amount. 2 milligrams of gentamicin per pound of body weight, twice daily on the first day, then once daily.


(iii) Limitations. Administer intramuscularly or subcutaneously. If no improvement is seen after 3 days, treatment should be discontinued and the diagnosis reevaluated. Treatment
§ 522.1077 Gonadorelin.

(a) Specifications. Each milliliter (mL) of solution contains:

(1) 43 micrograms (μg) of gonadorelin as gonadorelin acetate;

(2) 100 μg of gonadorelin as gonadorelin acetate;

(3) 50 μg of gonadorelin as gonadorelin diacetate tetrahydrate; or

(4) 50 μg of gonadorelin as gonadorelin hydrochloride.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter:

(1) No. 000061 for use of the 43-μg/mL product described in paragraph (a)(1) as in paragraphs (d)(1)(i), (d)(1)(iv), and (d)(2) of this section.

(2) No. 068504 for use of the 100-μg/mL product described in paragraph (a)(2) as in paragraphs (d)(1)(ii), (d)(1)(v), and (d)(2) of this section.

(3) Nos. 000859 and 050604 for use of the 50-μg/mL product described in paragraph (a)(3) as in paragraphs (d)(1)(ii) and (d)(2) of this section.

(4) No. 054771 for use of the 50-μg/mL product described in paragraph (a)(4) as in paragraphs (d)(1)(iii), (d)(1)(vi), and (d)(2) of this section.

(c) Special considerations. Concurrent luteolytic drug use is approved as follows:

(1) Cloprostenol injection for use as in paragraph (d)(1)(iv) of this section as provided by No. 000061 in §510.600(c) of this chapter.

(2) Cloprostenol injection for use as in paragraph (d)(1)(v) of this section as provided by No. 000061 or No. 068504 in §510.600(c) of this chapter.

(3) Dinoprost injection for use as in paragraph (d)(1)(vi) of this section as provided by No. 054771 in §510.600(c) of this chapter.

(d) Conditions of use in cattle—

(1) Indications for use and amounts—

(i) For the treatment of ovarian follicular cysts in dairy cattle: Administer 86 μg gonadorelin by intramuscular or intravenous injection.

(ii) For the treatment of ovarian follicular cysts in dairy cattle: Administer 100 μg gonadorelin by intramuscular injection.

(iii) For the treatment of ovarian follicular cysts in cattle: Administer 100 μg gonadorelin by intramuscular injection.

(iv) For use with cloprostenol injection to synchronize estrous cycles to allow for fixed-time artificial insemination (PTAI) in lactating dairy cows: Administer to each cow 86 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 86 μg gonadorelin by intramuscular injection.

(v) For use with cloprostenol injection to synchronize estrous cycles to allow for fixed-time artificial insemination (PTAI) in lactating dairy cows and beef cows: Administer to each cow 100 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 μg gonadorelin by intramuscular injection.

§ 522.1066 Glycopyrrolate.

(a) Specifications. Each milliliter of solution contains 0.2 milligram glycopyrrolate.

(b) Sponsors. See Nos. 054771 and 069043 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. 5 micrograms per pound of body weight (0.25 milliliter per 10 pounds of body weight) by intravenous, intramuscular, or subcutaneous injection in dogs or by intramuscular injection in cats.

(2) Indications for use. As a preanesthetic agent.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1077 Gonadorelin.

(a) Specifications. Each milliliter (mL) of solution contains:

(1) 43 micrograms (μg) of gonadorelin as gonadorelin acetate;

(2) 100 μg of gonadorelin as gonadorelin acetate;

(3) 50 μg of gonadorelin as gonadorelin diacetate tetrahydrate; or

(4) 50 μg of gonadorelin as gonadorelin hydrochloride.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter:

(1) No. 000061 for use of the 43-μg/mL product described in paragraph (a)(1) as in paragraphs (d)(1)(i), (d)(1)(iv), and (d)(2) of this section.

(2) No. 068504 for use of the 100-μg/mL product described in paragraph (a)(2) as in paragraphs (d)(1)(ii), (d)(1)(v), and (d)(2) of this section.

(3) Nos. 000859 and 050604 for use of the 50-μg/mL product described in paragraph (a)(3) as in paragraphs (d)(1)(ii) and (d)(2) of this section.

(4) No. 054771 for use of the 50-μg/mL product described in paragraph (a)(4) as in paragraphs (d)(1)(iii), (d)(1)(vi), and (d)(2) of this section.

(c) Special considerations. Concurrent luteolytic drug use is approved as follows:

(1) Cloprostenol injection for use as in paragraph (d)(1)(iv) of this section as provided by No. 000061 in §510.600(c) of this chapter.

(2) Cloprostenol injection for use as in paragraph (d)(1)(v) of this section as provided by No. 000061 or No. 068504 in §510.600(c) of this chapter.

(3) Dinoprost injection for use as in paragraph (d)(1)(vi) of this section as provided by No. 054771 in §510.600(c) of this chapter.

(d) Conditions of use in cattle—

(1) Indications for use and amounts—

(i) For the treatment of ovarian follicular cysts in dairy cattle: Administer 86 μg gonadorelin by intramuscular or intravenous injection.

(ii) For the treatment of ovarian follicular cysts in dairy cattle: Administer 100 μg gonadorelin by intramuscular injection.

(iii) For the treatment of ovarian follicular cysts in cattle: Administer 100 μg gonadorelin by intramuscular injection.

(iv) For use with cloprostenol injection to synchronize estrous cycles to allow for fixed-time artificial insemination (PTAI) in lactating dairy cows: Administer to each cow 86 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 86 μg gonadorelin by intramuscular injection.

(v) For use with cloprostenol injection to synchronize estrous cycles to allow for fixed-time artificial insemination (PTAI) in lactating dairy cows and beef cows: Administer to each cow 100 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 500 μg cloprostenol by intramuscular injection, followed 30 to 72 hours later by 100 μg gonadorelin by intramuscular injection.
(vi) For use with dinoprost injection to synchronize estrous cycles to allow fixed-time artificial insemination (FTAI) in lactating dairy cows: Administer to each cow 100 to 200 μg gonadorelin by intramuscular injection, followed 6 to 8 days later by 25 mg dinoprost by intramuscular injection, followed 30 to 72 hours later by 100 to 200 μg gonadorelin by intramuscular injection.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[80 FR 34279, June 16, 2015]

§ 522.1079 Serum gonadotropin and chorionic gonadotropin.

(a) Specifications. Each dose consists of 400 international units (I.U.) serum gonadotropin and 200 I.U. chorionic gonadotropin as a freeze-dried powder to be reconstituted with 5 milliliters of sterile aqueous diluent.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in swine—(1) Amount. 400 I.U. serum gonadotropin with 200 I.U. chorionic gonadotropin per 5 milliliters dose per animal.

(ii) Indications for use. (i) Gilts. For induction of fertile estrus (heat) in healthy prepuberal (noncycling) gilts.

(ii) Sows. For induction of estrus in healthy weaned sows experiencing delayed return to estrus.

(3) Limitations. For subcutaneous use only.

(i) Gilts. For use only in gilts over 5 1⁄2 months of age and weighing at least 85 kilograms (187 pounds).

(ii) Sows. Delayed return to estrus is most prevalent after the first litter. The effectiveness has not been established after later litters. Delayed return to estrus often occurs during periods of adverse environmental conditions, and sows mated under such conditions may farrow smaller than normal litters.


§ 522.1081 Chorionic gonadotropin.

(a) Specifications. Each vial contains 5,000, 10,000 or 20,000 USP units of lyophilized powder for constitution with accompanying diluent to a 10-milliliter solution.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) Nos. 000402 and 054771 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B) and (d)(1)(i)(C) of this section.

(2) [Reserved]

(3) No. 000061 for use as in paragraphs (d)(1)(i)(A) and (d)(2) of this section.

(c) Related tolerances. See § 556.304 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. As a single dose. Dosage may be repeated in 14 days if the animal’s behavior or examination of the ovaries per rectum indicates retreatment.

(A) 10,000 USP units by intramuscular injection.

(B) 500 to 2,500 USP units by intrafollicular injection.

(C) 2,500 to 5,000 USP units by intravenous injection.

(ii) Indications for use. For parenteral use in cows for treatment of nymphomania (frequent or constant heat) due to cystic ovaries.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Finfish—(i) Amount. 50 to 510 IU per pound of body weight for males, 67 to 1,816 IU per pound of body weight for females, by intramuscular injection. Up to three doses may be administered.

(ii) Indications for use. An aid in improving spawning function in male and female brood finfish.

(iii) Limitations. In fish intended for human consumption, the total dose administered per fish (all injections combined) should not exceed 25,000 IU chorionic gonadotropin. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1083 Gonadotropin releasing factor analog-diphtheria toxoid conjugate.

(a) Specifications. Each milliliter of solution contains 0.2 milligrams (mg) gonadotropin releasing factor analog-diphtheria toxoid conjugate.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use in swine—(1) Amount. Administer 0.4 mg (2 milliliter (mL)) by subcutaneous injection no earlier than 9 weeks of age. A second subcutaneous injection of 0.4 mg (2 mL) should be administered at least 4 weeks after the first dose.

(2) Indications for use. For the temporary immunological castration (suppression of testicular function) and reduction of boar taint in intact male pigs intended for slaughter.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Pigs should be slaughtered no earlier than 3 weeks and no later than 10 weeks after the second dose.

§ 522.1085 Guaifenesin powder for injection.

(a) Specifications. The product is a sterile powder containing guaifenesin. A solution is prepared by dissolving the drug in sterile water for injection to make a solution containing 50 milligrams of guaifenesin per milliliter of solution.

(b) Sponsors. See Nos. 037990 and 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 1 milliliter of prepared solution per pound of body weight by rapid intravenous infusion.

(2) Indications for use. For use as a muscle relaxant.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1086 Guaifenesin solution.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of guaifenesin and 50 mg of dextrose.

(b) Sponsors. See Nos. 000859 and 037990 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 1 milliliter per pound of body weight by rapid intravenous infusion.

(2) Indications for use. For use as a skeletal muscle relaxant.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1125 Hemoglobin glutamer-200 (bovine).

(a) Specifications. Each 125 milliliter bag contains 13 grams per deciliter of polymerized hemoglobin of bovine origin in modified Lactated Ringer’s Solution. It is a sterile, clear, dark purple solution.

(b) Sponsor. See No. 063075 in §510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. One-time dose of 10 to 30 milliliters per kilogram of body weight administered intravenously at a rate of up to 10 milliliters per kilogram per hour.

(2) Indications for use. For the treatment of anemia in dogs by increasing systemic oxygen content (plasma hemoglobin concentration) and improving the clinical signs associated with anemia, regardless of the cause of anemia (hemolysis, blood loss, or ineffective erythropoiesis).

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1145 Hyaluronate.

(a)(1) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.

(2) Sponsor. See 034771 in §510.600(c).

(3) Conditions of use—(1) Amount. Small and medium-size joints (carpal, fetlock): 20 mg; larger joint (hock): 40 mg. Treatment may be repeated at weekly intervals for a total of three treatments.

(ii) Indications for use. Treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. Each milliliter of sterile aqueous solution contains 5 milligrams of hyaluronate sodium.

(2) Sponsor. See 034771 in §510.600(c) of this chapter.
§ 522.1150

(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock): 10 mg; larger joint (hock): 20 mg. Treatment may be repeated at weekly intervals for a total of four treatments.

(ii) Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.

(2) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock): 20 mg. Treatment may be repeated at weekly intervals for a total of three treatments.

(ii) Indications for use. For the intraarticular treatment of carpal or fetlock joint dysfunction in horses due to acute or chronic, noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d)(1) Specifications. Each milliliter of sterile aqueous solution contains 10 milligrams of hyaluronate sodium.

(2) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. 50 milligrams in carpal and fetlock joints.

(ii) Indications for use. For treatment of equine carpal and fetlock joint dysfunction caused by traumatic and/or degenerative joint disease of mild to moderate severity.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e)(1) Specifications. Each milliliter of solution contains:

(i) 10 milligrams (mg) hyaluronate sodium; or

(ii) 10 mg hyaluronate sodium with benzyl alcohol as a preservative.

(2) Sponsor. See sponsors in § 510.600(c) of this chapter:

(i) No. 050604 for use of products described in paragraph (e)(1) as in paragraph (e)(3) of this section.

(ii) No. 017030 for use of product described in paragraph (e)(1)(i) as in paragraph (e)(3) of this section.

(iii) No. 050604 for use of product described in paragraph (e)(1)(ii) as in paragraph (e)(3) of this section.

(3) Conditions of use—(i) Amount. 20 mg of the product described in paragraph (e)(1)(i) of this section by intraarticular injection into the carpus or fetlock; or 40 mg of the product described in paragraph (e)(1)(i) or (e)(1)(ii) of this section by slow intravenous injection into the jugular vein. Treatment may be repeated at weekly intervals for a total of three treatments.

(ii) Indications for use. For treatment of carpal or fetlock joint dysfunction due to noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


(2) Sponsor. See No. 060865 in § 510.600(c).

(3) Conditions of use—(i) Amount. Small and medium-size joints (carpal, fetlock): 22 mg; larger joint (hock): 44 mg. Treatment may be repeated at weekly intervals for a total of three treatments.

(ii) Indications for use. Treatment of joint dysfunction in horses due to noninfectious synovitis associated with equine osteoarthritis.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1150 Hydrochlorothiazide.

(a) Specifications. Each milliliter of solution contains 25 milligrams of hydrochlorothiazide.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.
§ 522.1155 Imidocarb powder for injection.

(a) Specifications. The product is a sterile powder containing imidocarb dipropionate. Each milliliter of constituted solution contains 100 milligrams (mg) of imidocarb base.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Special considerations. Imidocarb dipropionate is sold only under permit issued by the Director of the National Program Planning Staff, Veterinary Services, Animal and Plant Health Inspection Service, U.S. Department of Agriculture, to licensed or full-time State, Federal, or military veterinarians.

(d) Conditions of use in horses and zebras—(1) Amount. For Babesia caballi infections, administer 2 mg of imidocarb base per kilogram of body weight by intramuscular injection in the neck region, repeating dosage once after 24 hours. For Babesia equi infections, administer 4 mg of imidocarb base per kilogram of body weight by intramuscular injection in the neck region, repeating dosage four times at 72-hour intervals.

(2) Indications for use. For the treatment of babesiosis (piroplasmosis) caused by Babesia caballi and Babesia equi.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1156 Imidocarb solution.

(a) Specifications. Each milliliter of solution contains 120 milligrams (mg) of imidocarb dipropionate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer 6.6 mg per kilogram (3 mg per pound) of body weight by intramuscular injection. Repeat the dose after 2 weeks for a total of two treatments.

(2) Indications for use. For the treatment of clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1160 Insulin.

(a) Specifications—(1) Each milliliter (mL) of porcine insulin zinc suspension contains 40 international units (IU) of insulin.

(2) Each mL of protamine zinc recombinant human insulin suspension contains 40 IU of insulin.

(b) Sponsors. See sponsors in §510.600 of this chapter for use as in paragraph (c) of this section.

(1) No. 000061 for use of product described in paragraph (a)(1) of this section as in paragraphs (c)(1), (c)(2)(1)(A), (c)(2)(ii), and (c)(2)(iii) of this section.

(2) No. 000010 for use of product described in paragraph (a)(2) of this section as in paragraphs (c)(2)(1)(B), (c)(2)(ii), and (c)(2)(iii) of this section.

(c) Conditions of use—(1) Dogs—(1) Amount. Administer an initial once-daily dose of 0.5 IU per kilogram of body weight by subcutaneous injection concurrently with or right after a meal. Adjust this once-daily dose at appropriate intervals based on clinical signs, urinalysis results, and glucose curve values until adequate glycemic control has been attained. Twice-daily therapy should be initiated if the duration of insulin action is determined to be inadequate. If twice-daily treatment is initiated, the two doses should be 25 percent less than the once daily dose required to attain an acceptable nadir.
(ii) Indications for use. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount—(A) Porcine insulin zinc. Administer an initial dose of 1 to 2 IU by subcutaneous injection. Injections should be given twice daily at approximately 12-hour intervals. For cats fed twice daily, the injections should be concurrent with or right after a meal. For cats fed ad libitum, no change in feeding is needed. Adjust the dose at appropriate intervals based on clinical signs, urinalysis results, and glucose curve values until adequate glycemic control has been attained.

(B) Protamine zinc recombinant human insulin. Administer an initial dose of 0.1 to 0.3 IU/pound of body weight (0.2 to 0.7 IU/kilogram) every 12 hours. The dose should be given concurrently with or right after a meal. Re-evaluate the cat at appropriate intervals and adjust the dose based on both clinical signs and glucose nadirs until adequate glycemic control has been attained.

(ii) Indications for use. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1182 Iron injection.

(a) Specifications. See §510.440 of this chapter. Each milliliter (mL) of solution contains the equivalent of:

(1) 100 milligrams (mg) of elemental iron derived from:

(i) Ferric hydroxide;

(ii) Ferric oxide; or

(iii) Elemental iron.

(2) 200 mg of elemental iron derived from ferric hydroxide.

(b) Sponsors and conditions of use. It is used in baby pigs by sponsors in §510.600(c) of this chapter as follows:

(1) Nos. 000839 and 042552 for use of product described in paragraph (a)(1)(i) of this section as follows:

(i) For prevention of iron deficiency anemia, inject 100 mg (1 mL) by intramuscular injection at 2 to 4 days of age.

(ii) For treatment of iron deficiency anemia, inject 100 mg (1 mL) by intramuscular injection. Dosage may be repeated in approximately 10 days.

(2) No. 054771 for use of product described in paragraph (a)(1)(i) of this section as follows:

(i) For the prevention of anemia due to iron deficiency, administer an initial intramuscular injection of 100 mg at 2 to 4 days of age. Dosage may be repeated in 14 to 21 days.

(ii) For the treatment of anemia due to iron deficiency, administer an intramuscular injection of 200 mg.

(3) Nos. 000661 and 059120 for use of product described in paragraph (a)(1)(i) of this section as follows:

(i) For the prevention of anemia due to iron deficiency, administer an initial intramuscular injection of 100 mg at 2 to 3 days of age.

(ii) For the treatment of anemia due to iron deficiency, administer an intramuscular injection of 200 mg.

(4) Nos. 051311 and 054771 for use of product described in paragraph (a)(1)(ii) of this section as follows:

(i) For prevention of iron deficiency anemia, administer 1 mL by intramuscularly an amount of drug containing 100 to 200 mg of elemental iron to animals from 1 to 3 days of age.

(ii) For the treatment of iron deficiency anemia, administer intramuscularly an amount of drug containing 100 to 200 mg of elemental iron per animal. Dosage may be repeated in 10 days to 2 weeks.

(5) No. 054771 for use of product described in paragraph (a)(1)(ii) of this section as follows:

(i) For prevention of anemia due to iron deficiency, administer 100 mg by intramuscular injection at 2 to 5 days of age. Dosage may be repeated at 2 weeks of age.

(ii) For treatment of iron deficiency anemia, administer 1 to 2 mL by intramuscular injection at 5 to 28 days of age.

(6) Nos. 000659 and 058005 for use of product described in paragraph (a)(1)(iii) of this section as follows:

(i) For prevention of anemia due to iron deficiency, administer 100 mg by intramuscular or subcutaneous injection at 2 to 4 days of age.

(ii) For treatment of anemia due to iron deficiency, administer 100 mg by intramuscular or subcutaneous injection up to 4 weeks of age.

(7) Nos. 000659 and 058005 for use of product described in paragraph (a)(1)(iii) of this section as follows:
Food and Drug Administration, HHS

§ 522.1192 Ivermectin.

(a) Specifications—(1) Each milliliter (mL) of solution contains 20 milligrams (mg) ivermectin.

(2) Each mL of solution contains 10 mg ivermectin.

(3) Each mL of solution contains 2.7 mg ivermectin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) No. 050604 for use of the product described in paragraph (a)(1) of this section as in paragraph (e)(1) of this section; the product described in paragraph (a)(2) of this section as in paragraphs (e)(2), (e)(3), (e)(4), and (e)(5) of this section; and the product described in paragraph (a)(3) of this section as in paragraphs (e)(3) and (e)(6) of this section.

(2) Nos. 000859 055529, 058005, and 061623 for use of the product described in paragraph (a)(2) of this section as in paragraphs (e)(2), (e)(3), (e)(4), and (e)(5) of this section.

(d) Special considerations—(1) See §500.25 of this chapter.

(2) Labeling shall bear the following precaution: “This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.”
§ 522.1193

(1) Horses—(i) Amount. 200 micrograms per kilogram (µg/kg) of body weight by intramuscular injection.

(ii) Indications for use. For the treatment and control of large strongyles (adult) (*Strongylus vulgaris*, *S. edentatus*, *Trichostrongylus spp.*), small strongyles (adult and fourth-stage larvae) (*Cyathostomum spp.*, *Cylicocyclus spp.*, *Cylicostephanus spp.*), pinworms (adult and fourth-stage larvae) (*Oxyuris equi*), large roundworms (adult) (*Parascaris equorum*), hairworms (adult) (*Trichostrongylus axei*), large mouth stomach worms (adult) (*Habronema muscae*), neck threadworms (microfilariae) (*Onchocerca spp.*), and stomach bots (*Gastrophilus spp.*).

(iii) Limitations. Not for use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. 200 µg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (*Haemonchus placei*, *Ostertagia ostertagi* (including inhibited larvae), *O. lyrata*, *Trichostrongylus axei*, *T. colubriformis*, *Cooperia oncophora*, *C. punctata*, *C. pectinata*, *Oesophagostomum radiatum*, *Nematodirus helvetianus* (adults only), *N. spathiger* (adults only), *Bunostomum phlebotomum*); lungworms (adults and fourth-stage larvae) (*Dictyocaulus viviparus*); grubs (parasitic stages) (*Hypoderma bovis*, *H. lineatum*); sucking lice (*Linognathus vituli*, *Haematopinus eurysternus*, *Solenopotes capillatus*); mites (scabies) (*Psoroptes ovis* (syn. *P. communis var. bovis*), *Sarcopes scabiei var. bovis*). For control of infections and to protect from reinfection with *D. viviparus* and *O. radiatum* for 28 days after treatment; *O. ostertagi*, *T. axei*, and *C. punctata* for 21 days after treatment; *H. placei* and *C. oncophora* for 14 days after treatment.

(iii) Limitations. Do not treat cattle within 35 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(3) Swine—(i) Amount. 300 µg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of gastrointestinal roundworms (adults and fourth-stage larvae) (large roundworm, *Ascaris suum*; red stomach worm, *Hyostrongylus rubidus*; nodular worm, *Oesophagostomum spp.*; threadworm, *Strongyloides ransomi* (adults only)); somatic roundworm larvae (threadworm, *S. ransomi* (somatic larvae)); lungworms (*Metastrongylus spp.* (adults only)); lice (*H. suis*); and mites (*S. scabiei var. suis*).

(iii) Limitations. Do not treat swine within 18 days of slaughter.

(4) American bison—(1) Amount. 200 µg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of grubs (*H. bovis*).

(iii) Limitations. Do not slaughter within 56 days of last treatment.

(5) Reindeer—(1) Amount. 200 µg/kg of body weight by subcutaneous injection.

(ii) Indications for use. For the treatment and control of ear mites (*Oedemagena tarandi*).

(iii) Limitations. Do not treat reindeer within 56 days of slaughter.

(6) Ranch-raised foxes—(i) Amount. 200 µg/kg of body weight by subcutaneous injection. Repeat in 3 weeks.

(ii) Indications for use. For treatment and control of ear mites (*Otodectes cynotis*).

§ 522.1193 Ivermectin and clorsulon.

(a) Specifications. Each milliliter (mL) of solution contains 10 milligrams (mg) (1 percent) ivermectin and 100 mg (10 percent) clorsulon.

(b) Sponsors. See Nos. 050604, 055529, and 058005 in § 510.600(c) of this chapter.

(c) Related tolerances. See §§ 556.163 and 556.344 of this chapter.

(d) Special considerations. See § 500.25 of this chapter.

(e) Conditions of use in cattle—(1) Amount. Administer 1 mL (10 mg ivermectin and 100 mg clorsulon) per 50 kilograms (110 pounds) by subcutaneous injection.
(2) **Indications for use.** For the treatment and control of gastrointestinal nematodes (adults and fourth-stage larvae) (*Haemonchus placei*, *Ostertagia ostertagi* (including inhibited larvae), *O. lyrata*, *Trichostrongylus axei*, *T. colubriformis*, *Cooperia oncophora*, *C. punctata*, *C. pectinata*, *Oesophagostomum radiatum*, *Nematodirus helvetianus* (adults only), *N. spathiger* (adults only), *Bunostomum phlebotomum*; lungworms (adults and fourth-stage larvae) (*Dictyocaulus viviparus*); liver flukes (adults only) (*Fasciola hepatica*); grubs (parasitic stages) (*Hypoderma bovis*, *H. lineatum*); lice (*Linognathus vituli*, *Haematopinus eurysternus*, *Solenopotes capillatus*); mites (*Psoroptes ovis* (syn. *P. communis* var. *bovis*), *Sarcoptes scabiei* var. *bovis*); and for control of infections of *D. viviparus* and *O. radiatum* for 28 days after treatment; *O. ostertagi*, *T. axei*, and *C. punctata* for 21 days after treatment; and *H. placei* and *C. oncophora* for 14 days after treatment.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian. [79 FR 16190, Mar. 25, 2014]

§ 522.1222 Ketamine.

(a) **Specifications.** Each milliliter contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity.

(b) **Sponsors.** See Nos. 000859, 026637, 054628, 054771, 059399, and 063286 in §510.600(c) of this chapter.

(c) **Special considerations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) **Conditions of use—**

(i) **Cats**—

(A) **Amount.** 5 to 15 mg/pound body weight intramuscularly, depending on the effect desired.

(ii) **Indications for use.** For restraint or as the sole anesthetic agent in diagnostic or minor, brief surgical procedures that do not require skeletal muscle relaxation.

(ii) **Subhuman primates**—

(A) **Amount.** 3 to 15 mg/kilogram body weight intramuscularly, depending upon the species, general condition, and age of the subject.

(ii) **Indications for use.** For restraint.


§ 522.1223 Ketamine, promazine, and aminopentamide.

(a) **Specifications.** Each milliliter of solution contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity, 7.5 (mg) of promazine hydrochloride, and 0.0625 mg of aminopentamide hydrogen sulfate.

(b) **Sponsor.** See No. 054771 in §510.600(c) of this chapter.

(c) **Conditions of use in cats—**

(i) **Amount.** Administer by intramuscular injection 5 mg per pound of body weight per day in equally divided doses at 12-hour intervals.

(ii) **Indications for use.** For the treatment of bacterial infections due to kanamycin-sensitive organisms in dogs and cats.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian. [79 FR 16190, Mar. 25, 2014]
§ 522.1225 Ketoprofen.

(a) Specifications. Each milliliter of solution contains 100 milligrams (mg) of ketoprofen.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer by intravenous injection 1.0 mg per pound of body weight once daily for up to 5 days.

(2) Indications for use. For alleviation of inflammation and pain associated with musculoskeletal disorders in horses.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16191, Mar. 25, 2014]

§ 522.1242 Levamisole.

(a) Specifications. Each milliliter of solution contains levamisole phosphate equivalent to 136.5 or 182 milligrams of levamisole hydrochloride (13.65 or 18.2 percent).

(b) Sponsor. See Nos. 000061 and 057561 in §510.600 of this chapter for use of 13.65 percent injection, and see No. 054771 for use of 13.65 and 18.2 percent injection.

(c) Conditions of use—(1) Amount. 2 milliliters per 100 pounds of body weight, subcutaneously in the neck.

(2) Indications for use. (i) The 13.65 percent injection is used as an anthelmintic in cattle for treatment of the following parasites: stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia), and lungworms (Dictyocaulus).

(ii) The 18.2 percent injection is used as an anthelmintic in cattle for treatment of the following parasites: stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum) and lungworms (Dictyocaulus).

(3) Limitations. Do not administer more than 10 milliliters per site. Cattle that are severely parasitized or maintained under conditions of constant helmith exposure may require re-treatment within 2 to 4 weeks after first treatment. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism. Consult your veterinarian before using in severely debilitated animals or animals under severe stress. Do not administer to dairy animals of breeding age.


§ 522.1260 Lincomycin.

(a) Specifications. Each milliliter of solution contains lincomycin hydrochloride monohydrate equivalent to:

(1) 25, 50, 100, or 300 milligrams (mg) lincomycin.

(2) 25, 100, or 300 mg lincomycin.

(3) 300 mg lincomycin.

(4) 100 or 300 mg lincomycin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) No. 054771 for use of concentrations in paragraph (a)(1) of this section as in paragraph (e) of this section.

(2) Nos. 000859 and 058005 for use of concentrations in paragraph (a)(2) of this section as in paragraph (e)(2) of this section.

(3) No. 054771 for use of concentration in paragraph (a)(3) of this section as in paragraph (e)(2) of this section.

(4) No. 061623 for use of concentrations in paragraph (a)(4) of this section as in paragraph (e)(2) of this section.

(c) Special considerations. When common labeling for use of the drug in dogs, cats, and swine is included with the drug, all such uses are subject to the labeling requirements of §201.105 of this chapter.

(d) Related tolerances. See §556.360 of this chapter.

(e) Conditions of use. It is used for animals as follows:

(1) Dogs and cats—(i) Amount. 5 mg per pound (lb) of body weight twice
daily or 10 mg/lb body weight once daily by intramuscular injection; 5 to 10 mg/lb body weight one or two times daily by slow intravenous injection.

(ii) **Indications for use.** Infections caused by Gram-positive organisms, particularly streptococci and staphylococci.

(iii) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) **Swine**—(i) **Amount.** 5 mg/lb body weight once daily by intramuscular injection for 3 to 7 days.

(ii) **Indications for use.** Treatment of infectious arthritis and mycoplasma pneumonia.

(iii) **Limitations.** Do not treat within 48 hours of slaughter.


§ 522.1289 Lufenuron.

(a) **Specifications.** Each milliliter of suspension contains 100 milligrams (mg) of lufenuron.

(b) **Sponsor.** See No. 058198 in § 510.600(c) of this chapter.

(c) **Conditions of use in cats**—(1) **Amount.** 10 mg per kilogram (4.5 mg per pound) of body weight every 6 months, by subcutaneous injection.

(ii) **Indications for use.** For control of flea populations in cats 6 weeks of age and older.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16191, Mar. 25, 2014]

§ 522.1290 Luprostiol.

(a) **Specifications.** Each milliliter of solution contains 7.5 milligrams (mg) luprostiol.

(b) **Sponsor.** See No. 051311 in § 510.600(c) of this chapter.

(c) **Special considerations.** Labeling shall bear the following statements: Warning: Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. Luprostiol is readily absorbed through the skin and can cause abortion and/or bronchospasms. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

(d) **Conditions of use in horses**—(1) **Amount.** 7.5 mg by intramuscular injection.

(ii) **Indications for use.** For estrus control and termination of pregnancy in mares.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.


§ 522.1315 Maropitant.

(a) **Specifications.** Each milliliter of solution contains 10 milligrams (mg) maropitant as maropitant citrate.

(b) **Sponsor.** See No. 054771 in § 510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Dogs**—(i) **Amount.** Administer 1.0 mg per kilogram (mg/kg) of body weight by subcutaneous injection once daily for up to 5 consecutive days.

(ii) **Indications for use.** For the prevention and treatment of acute vomiting.

(iii) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) **Cats**—(i) **Amount.** Administer 1.0 mg/kg of body weight by subcutaneous injection once daily for up to 5 consecutive days.

(ii) **Indications for use.** For the treatment of vomiting.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1335 Medetomidine.

(a) **Specifications.** Each milliliter of solution contains 1.0 milligrams of medetomidine hydrochloride.

(b) **Sponsor.** See 052483 in § 510.600(c) of this chapter.
§ 522.1350  
(c) Conditions of use—(1) Amount.  750 micrograms intravenously (IV) or 1,000 micrograms intramuscularly per square meter of body surface. The IV route is more efficacious for dental care.
(2) Indications for use.  As a sedative and analgesic in dogs over 12 weeks of age to facilitate clinical examinations, clinical procedures, minor surgical procedures not requiring muscle relaxation, and minor dental procedures not requiring intubation.  The intravenous route of administration is more efficacious for dental care.
(3) Limitations.  Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1367  
(a) Specifications.  Each milliliter of solution contains 5.0 milligrams (mg) meloxicam.
(b) Sponsors.  See Nos. 000010, 016729, 026637, and 055529 in § 510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount.  Administer 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) by intravenous or subcutaneous injection on the first day of treatment.  For treatment after day 1, administer meloxicam suspension orally at 0.045 mg/lb (0.1 mg/kg) body weight once daily as in §520.1350(c) of this chapter.
(ii) Indications for use.  For the control of pain and inflammation associated with osteoarthritis.
(iii) Limitations.  Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats—(i) Amount.  Administer 0.14 mg/lb (0.3 mg/kg) body weight as a single, one-time subcutaneous injection.
(ii) Indications for use.  For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration when administered prior to surgery.
(iii) Limitations.  Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1372  
(a) Specifications.  Each milliliter (mL) of solution contains 20 milligrams mepivacaine hydrochloride.
(b) Sponsors.  See No. 054771 in §510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount.  For nerve block, 3 to 5 mL; for epidural anesthesia, 5 to 20 mL; for intra-articular anesthesia, 10 to 15 mL; for infiltration, as required; for anesthesia of the laryngeal mucosa prior to...
ventriculectomy, by topical spray, 25 to 40 mL, by infiltration, 20 to 50 mL.

(2) Indications for use. For use as a local anesthetic for infiltration, nerve block, intra-articular and epidural anesthesia, and topical and/or infiltration anesthesia of the laryngeal mucosa prior to ventriculectomy.

(3) Limitations. Not for use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1380 Methocarbamol.

(a) Specifications. Each milliliter of solution contains 100 milligrams (mg) of methocarbamol.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount—(i) Dogs and cats. Administer by intravenous injection 20 mg per pound of body weight for moderate conditions or 25 to 100 mg per pound of body weight for severe conditions (tetanus and strychnine poisoning). The total cumulative dose should not exceed 150 mg per pound of body weight.

(ii) Horses. Administer by intravenous injection 2 to 10 mg per pound of body weight for moderate conditions or 10 to 25 mg per pound of body weight for severe conditions (tetanus). Additional amounts may be needed to relieve residual effects and to prevent recurrence of symptoms.

(2) Indications for use. As an adjunct for treating acute inflammatory and traumatic conditions of the skeletal muscles and to reduce muscular spasms.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1410 Methylprednisolone.

(a) Specifications. Each milliliter of suspension contains 20 or 40 milligrams (mg) of methylprednisolone acetate.

(b) Sponsors. See Nos. 054628 and 054771 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Dogs—(i) Amount. Administer 2 to 40 mg (up to 120 mg in extremely large breeds or dogs with severe involvement) by intramuscular injection or up to 20 mg by intrasynovial injection.

(ii) Indications for use. For treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. Administer 10 to 20 mg by intramuscular injection.

(ii) Indications for use. For treatment of inflammation and related disorders; treatment of allergic and dermatologic disorders; and as supportive therapy to antibacterial treatment of severe infections.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1450 Moxidectin solution.

(a) Specifications. Each milliliter of solution contains 10 milligrams (mg) moxidectin.

(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.426 of this chapter.

(d) Special considerations. See § 500.25 of this chapter.

(e) Conditions of use in beef and non-lactating dairy cattle—(1) Amount. Administer 0.2 mg/kg of body weight (0.2 mg/2.2 pound) as a single, subcutaneous injection.

(2) Indications for use. For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage larvae, and inhibited larvae), Haemonchus placei.
(adults), *Trichostrongylus axei* (adults and fourth-stage larvae), *Trichostrongylus colubriformis* (adults and fourth-stage larvae), *Cooperia oncophora* (adults), *Cooperia pectinata* (adults and fourth-stage larvae), *Cooperia spatulata* (adults), *Cooperia surinamensis* (adults and fourth-stage larvae), *Nematodirus helvetianus* (adults), *Oesophagostomum radiatum* (adults and fourth-stage larvae), *Trichuris spp.* (adults); lungworms: *Dictyocaulus viviparus* (adults and fourth-stage larvae); grubs: *Hypoderma bovis* and *Hypoderma lineatum*; mites: *Psoroptes ovis* (*Psoroptes communis var. bovis*); lice: *Linognathus vituli* and *Solenopotes capillatus*; for protection of cattle from reinfection with *D. viviparus* and *O. radiatum* for 42 days after treatment, with *H. placei* for 35 days after treatment, and with *O. ostertagi* and *T. axei* for 14 days after treatment.

(3) Limitations. Do not slaughter cattle within 21 days of treatment. Because a withholding time for milk has not been established, do not use in female dairy cattle 20 months of age and older. A withdrawal period has not been established for pre-ruminating calves. Do not use in calves to be processed for veal.


§ 522.1451 Moxidectin microspheres for injection.

(a) Specifications. The drug product consists of two separate vials. One contains 10 percent moxidectin microspheres, and the other contains a vehicle for constitution of the moxidectin microspheres. Each milliliter of constituted, sustained-release suspension contains 7.4 milligrams (mg) of moxidectin.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use: dogs—(1) Amount. 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.

(2) Indications for use. For prevention of heartworm disease caused by *Dirofilaria immitis*; for treatment of existing larval and adult hookworm (Ancylostoma caninum) and Uncinaria stenocephala infections.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1452 Nalorphine.

(a) Specifications. Each milliliter of solution contains 5 milligrams of nalorphine hydrochloride.

(b) Sponsor. See No. 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. One milligram per 5 pounds; intravenously, intramuscularly, or subcutaneously.

(2) Indications for use. Respiratory and circulatory depression in dogs resulting from overdosage of, or unusual sensitivity to, morphine and certain other narcotics. Not for depression due to any other cause.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1465 Naltrexone.

(a) Specifications. Each milliliter of solution contains 50 milligrams of naltrexone hydrochloride.

(b) Sponsor. See 053923 in § 510.600(c) of this chapter.

(c) Conditions of use in elk and moose—(1) Amount. 100 milligrams of naltrexone hydrochloride for each milligram of carfentanil citrate administered. One-quarter of the dose should be administered intravenously and three-quarters of the dose should be administered subcutaneously.

(2) Indications for use. As an antagonist to carfentanil citrate immobilization in free-ranging or confined elk and moose (*Cervidae*).

(3) Limitations. Do not use in domestic food-producing animals. Do not use in free-ranging animals for 45 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.1468 Naproxen for injection.

(a) Specifications. The drug is a lyophilized powder which is reconstituted with sterile water for injection to form a 10 percent sterile aqueous solution (100 milligrams per milliliter).

(b) Sponsor. See 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Dosage. Five milligrams per kilogram of body weight intravenously followed by maintenance oral therapy of 10 milligrams per kilogram of body weight twice daily for up to 14 consecutive days.

(2) Indications for use. For the relief of inflammation and associated pain and lameness exhibited with arthritis, as well as myositis and other soft tissue diseases of the musculoskeletal system of the horse.

(3) Limitations. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1484 Neomycin.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of neomycin sulfate (equivalent to 35 mg of neomycin base).

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer 5 mg per pound of body weight daily by intramuscular or intravenous injection, divided into portions administered every 6 to 8 hours for 3 to 5 days.

(2) Indications for use. For the treatment of acute and chronic bacterial infections due to organisms susceptible to neomycin.

(3) Limitations. Not for parenteral use in food-producing animals because of prolonged residues in edible tissues. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16192, Mar. 25, 2014]

§ 522.1503 Neostigmine.

(a) Specifications. Each milliliter of solution contains 2 milligrams (mg) neostigmine methylsulfate.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer to cattle and horses at a dosage level of 1 mg per (/) 100 pounds (lbs) of body weight subcutaneously. Administer to sheep at a dosage level of 1 to 11⁄2 mg/100 lbs body weight subcutaneously. Administer to swine at a dosage level of 2 to 3 mg/100 lbs body weight intramuscularly. These doses may be repeated as indicated.

(2) Indications for use. For treating rumen atony; initiating peristalsis which causes evacuation of the bowel; emptying the urinary bladder; and stimulating skeletal muscle contractions.

(3) Limitations. Not for use in animals producing milk, since this use will result in contamination of the milk. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1610 Oleate sodium.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) of sodium oleate.

(b) Sponsor. See No. 037990 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer by parenteral injection depending on the area of response desired. An injection of 1 milliliter (mL) will produce a response of approximately 15 square centimeters. Do not inject more than 2 mL per injection site. Regardless of the number of injection sites, the total volume used should not exceed 10 mL.

(2) Indications for use. It is used in horses to stimulate infiltration of cellular blood components that subsequently differentiate into fibrous and/or fibrocartilagenous tissue.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1620 Orgotein for injection.

(a) Specifications. Orgotein for injection is packaged in a vial containing 5
§ 522.1660 Oxytetracycline injectable dosage forms.

§ 522.1660a Oxytetracycline solution, 200 milligrams/milliliter.

(a) Specifications. Each milliliter of sterile solution contains 200 milligrams of oxytetracycline base.

(b) Sponsors. See Nos. 000010, 000859, 046164, 054771, 055529, 057561, and 061623 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.500 of this chapter.

(d) Special considerations. When labeled for the treatment of anaplasmosis or anthrax, labeling shall also bear the following: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”

(e) Conditions of use—(1) Beef cattle, dairy cattle, and calves including prerumenative (veal) calves—(A) Amount and indications for use—(1) 3 to 5 mg per pound of body weight (mg/lb BW) per day (2/day) intramuscularly, subcutaneously, or intravenously for treatment of pneumonia and shipping fever complex associated with Pasteurella spp. and Haemophilus spp., foot-rot and diphtheria caused by Fusobacterium necrophorum, bacterial enteritis (scours) caused by Escherichia coli, wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, wound infections and acute metritis caused by Staphylococcus spp. and Streptococcus spp., and anthrax caused by Bacillus anthracis.

(B) 5 mg/lb BW/day intramuscularly or intravenously for treatment of anaplasmosis caused by Anaplasma marginale, severe foot-rot, and advanced cases of other indicated diseases.

(C) 9 mg/lb BW intramuscularly or subcutaneously as single dosage where retreatment of calves and yearlings for bacterial pneumonia is impractical, for treatment of infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis, or where retreatment for anaplasmosis is impractical.

(ii) Limitations. Exceeding the highest recommended level of drug per pound of bodyweight per day, administering more than the recommended number of treatments, and/or exceeding 10 mL intramuscularly or subcutaneously per injection site may result in antibiotic residues beyond the withdrawal time. Rapid intravenous administration in cattle may result in animal collapse. Oxytetracycline should be administered intravenously slowly over a period of at least 5 minutes. Discontinue treatment at least 28 days prior to slaughter. Milk taken from animals during treatment and for 96 hours after the last treatment must not be used for food.
Food and Drug Administration, HHS

§ 522.1660b

(2) Swine—(i) Amounts and indications for use—(A) Sows: 3 mg/lb BW intramuscularly once, approximately 8 hours before farrowing or immediately after completion of farrowing, as an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by E. coli.

(B) 3 to 5 mg/lb BW/day intramuscularly for treatment of bacterial enteritis (scours, colibacillosis) caused by E. coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona.

(C) 9 mg/lb BW as a single dosage where retreatment for pneumonia is impractical.

(ii) Limitations. Administer intramuscularly. Do not inject more than 5 mL per site in adult swine. Discontinue treatment at least 28 days prior to slaughter.


EDITORIAL NOTE: For Federal Register citations affecting § 522.1660a, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

§ 522.1660b Oxytetracycline solution, 300 milligrams/milliliter.

(a) Specifications. Each milliliter (mL) of solution contains 300 milligrams (mg) oxytetracycline base.

(b) Sponsor. See No. 055529 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.500 of this chapter.

(d) Special considerations. When labeled for use as in paragraph (e)(1)(i)(D) or (e)(1)(i)(E) of this section, labeling shall also bear the following: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.”

(e) Conditions of use—(1) Beef cattle, nonlactating dairy cattle, and calves including preruminating (veal) calves—(i) Amounts and indications for use—(A) 3 to 5 mg per pound of bodyweight (mg/lb BW) per day (d) intramuscularly, subcutaneously, or intravenously for treatment of pneumonia and shipping fever complex associated with Pasteurella spp. and Histophilus spp., foot-rot and diphtheria caused by Fusobacterium necrophorum, bacterial enteritis (scours) caused by Escherichia coli, wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, wound infections and acute metritis caused by Staphylococcus spp. and Streptococcus spp.

(B) 5 mg/lb BW/day intramuscularly, subcutaneously, or intravenously for treatment of severe foot-rot, and advanced cases of other indicated diseases.

(C) 9 mg/lb BW intramuscularly or subcutaneously as single dosage where retreatment of calves and yearlings for bacterial pneumonia is impractical or for treatment of infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis.

(D) 9 to 13.6 mg/lb BW intramuscularly or subcutaneously as single dosage where retreatment of calves and yearlings for bacterial pneumonia is impractical or for treatment of infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis.

(E) 13.6 mg/lb BW intramuscularly or subcutaneously as a single dosage for control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia (Pasteurella) haemolytica.

(ii) Limitations. Treatment should be continued 24 to 48 hours following remission of disease signs, however, not to exceed a total of four consecutive days. Do not inject more than 10 mL per site in adult cattle, reducing the volume according to age and body size to 1 to 2 mL in small calves. Exceeding the highest recommended level of drug/lb BW/day, administering more than the recommended number of treatments, and/or exceeding 10 mL intramuscularly or subcutaneously per injection site may result in antibiotic residues beyond the withdrawal time. Rapid intravenous administration may result in animal collapse. Oxytetracycline should be administered intravenously slowly over a period of at least 5 minutes. Discontinue treatment at least 28 days prior to slaughter. Not for use in lactating dairy animals.

(2) Swine—(i) Amounts and indications for use—(A) Sows: 3 mg/lb BW intramuscularly once, approximately 8 hours before farrowing or immediately after completion of farrowing, as an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by E. coli.
pig scours, colibacillosis) in suckling pigs caused by E. coli.

(B) 3 to 5 mg/lb BW/day intramuscularly for treatment of bacterial enteritis (scours, colibacillosis) caused by E. coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona.

(C) 9 mg/lb BW as a single dosage where retreatment for pneumonia is impractical.

(ii) Limitations. Administer intramuscularly. Treatment should be continued 24 to 48 hours beyond remission of disease signs, however, not to exceed a total of 4 consecutive days. Exceeding the highest recommended level of drug/lb BW/day, administering more than the recommended number of treatments, and/or exceeding 5 mL intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 28 days prior to slaughter.


§522.1662 Oxytetracycline hydrochloride implantation or injectable dosage forms.

§522.1662a Oxytetracycline hydrochloride injection.

(b)(1) Specifications. Each milliliter of sterile solution contains 50 or 100 milligrams of oxytetracycline (as oxytetracycline hydrochloride).

(2) Sponsor. See 054628 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Beef cattle and nonlactating dairy cattle—(a) Amount. Three to 5 milligrams of oxytetracycline per pound of body weight per day; 5 milligrams per pound of body weight per day for the treatment of anaplasmosis, severe foot-rot, and severe cases of other indicated diseases.

(b) Indications for use. Treatment of diseases due to oxytetracycline-susceptible organisms as follows: Pneumonia and shipping fever complex associated with Pasteurella spp., Haemophilus spp., and Klebsiella spp.; foot-rot and diphtheria caused by Spherophorus necrophorus; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, and wound infections; acute metritis; traumatic injury (caused by a variety of bacterial organisms (such as streptococcal and staphylococcal organisms)).
Food and Drug Administration, HHS

§ 522.1662a

be used for the treatment of anaplasmosis caused by *Anaplasma marginale*.

(c) Limitations. For 50-milligram-per-milliliter solution, administer intramuscularly or intravenously; for 100-milligram-per-milliliter solution, administer intramuscularly only. Treatment of all diseases should be instituted early and continue for 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 4 consecutive days. Consult your veterinarian if no improvement is noted within 48 hours. Do not inject more than 10 milliliters per site in adult cattle, reducing the volume according to age and body size to 0.5 to 2 milliliters in small calves. Exceeding the highest recommended dose of 5 milligrams per pound of body weight, administering at recommended levels for more than 4 consecutive days, and/or exceeding 10 milliliters intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 18 days prior to slaughter. Not for use in lactating dairy cattle.

(ii) Swine—(a) Amount. Three to 5 milligrams of oxytetracycline per pound of body weight per day. Sows: 3 milligrams of oxytetracycline per pound of body weight, approximately 8 hours before farrowing or immediately after completion of farrowing.

(b) Indications for use. For treatment of bacterial enteritis (scours, colibacillosis) caused by *Escherichia coli*, pneumonia caused by *Pasteurella multocida*, and leptospirosis caused by *Leptospira pomona*. Sows: as an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by *Escherichia coli*.

(c) Limitations. Administer intramuscularly. Do not inject more than 5 milliliters per site. Do not use for more than 4 consecutive days. Discontinue treatment at least 26 days before slaughter.

(c)(1) Specifications. The drug contains 50 or 100 milligrams of oxytetracycline hydrochloride in each milliliter of sterile solution.

(2) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(3) Conditions of use. (i) In beef cattle and nonlactating dairy cattle as follows:

(a) It is used for the treatment of pneumonia and shipping fever complex associated with *Pasteurella spp., Haemophilus spp., Klebsiella spp., foot-rot and diphtheria caused by Spherophorus necrophorus*, bacterial enteritis (scours) caused by *Escherichia coli*, wooden tongue caused by *Actinobacillus lignieresi*, acute metritis, and wound infections caused by staphylococcal and streptococcal organisms.

(ii) It is administered to cattle at a dosage level of 3 to 5 milligrams per pound of body weight per day. It may be administered intramuscularly or intravenously from a 50 milligram per milliliter solution. It is administered intravenously from a 100 milligram per milliliter solution. Severe foot-rot and the severe forms of the indicated diseases should be treated with 5 milligrams per pound of body weight. Treatment should be continued 24 to 48 hours following remission of disease symptoms, however, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 hours, consult a veterinarian. When injecting the drug intramuscularly, do not inject more than 10 milliliters per site in adult cattle. Reduce the amount injected at each site according to the size of the animal. For very small calves do not use more than 2 milliliters per injection site.

(iii) Not for use in lactating dairy cattle. Discontinue treatment at least 19 days prior to slaughter. When administered intramuscularly within 30 days of slaughter, muscle discoloration may necessitate trimming of the injection site and surrounding tissues.

(d)(1) Specifications. The drug contains 50 milligrams of oxytetracycline hydrochloride in each milliliter of sterile solution.

(2) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(3) Conditions of use. (i) In beef cattle and nonlactating dairy cattle as follows:

(a) It is used for the treatment of pneumonia and shipping fever complex associated with *Pasteurella spp. and Haemophilus spp.; foot-rot and diphtheria caused by Spherophorus necrophorus*.
necrophorus; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; leptospirosis caused by Leptospira pomona; wound infections and acute metritis caused by staphylococcal and streptococcal organisms.

(b) Administer by intravenous or intramuscular injection at 3 to 5 milligrams of oxytetracycline per pound of body weight per day. In the treatment of severe foot-rot and severe forms of the indicated diseases, a dosage level of 5 milligrams per pound of body weight per day is recommended.

(c) If the labeling of the drug bears the statement “Federal law restricts this drug to use by or on the order of a licensed veterinarian.” it may include additional directions for use in beef cattle and non lactating dairy cattle for the treatment of anaplasmosis caused by Anaplasma marginale, and anthrax caused by Bacillus anthracis in which case the drug is given at 3 to 5 milligrams of oxytetracycline per pound of body weight per day for anthrax, and at 5 milligrams per pound of body weight per day for anaplasmosis.

(ii) In swine as follows:

(a) It is used for the treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli; pneumonia caused by Pasteurella multocida; and leptospirosis caused by Leptospira pomona. Administered to sows as an aid in the control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(b) Administer by intramuscular injection at 3 to 5 milligrams of oxytetracycline per pound of body weight per day to swine. Administered to sows at 3 milligrams of oxytetracycline per pound of body weight approximately 8 hours before farrowing or immediately after farrowing.

(iii) In poultry (broilers, turkeys, and breeding chickens) as follows:

(a) It is used for the treatment of air sacculitis (air-sac disease, chronic respiratory disease) caused by Mycoplasma gallisepticum and Escherichia coli; fowl cholera caused by Pasteurella multocida; infectious sinusitis caused by Mycoplasma synovitidis and infectious synovitis caused by Mycoplasma synoviae.

(b) Administered subcutaneously to chickens 1 day to 2 weeks of age at 6.25 milligrams of oxytetracycline per bird per day diluted with 1 part of the drug to 3 parts of sterile water; to chickens 2 to 4 weeks of age using the same diluted product at 12.5 milligrams of oxytetracycline per bird; to chickens 4 to 8 weeks of age without dilution at 25 milligrams of oxytetracycline per bird; to chickens 8 weeks of age (broilers and light pullets) at 50 milligrams of oxytetracycline per bird; to adult chickens at 100 milligrams of oxytetracycline per bird.

(c) Administered subcutaneously to turkeys 1 day to 2 weeks of age and 2 to 4 weeks of age at the same dosage as chickens; to turkeys 4 to 6 weeks of age at 50 milligrams of oxytetracycline as the undiluted product per bird; to turkeys 6 to 9 weeks of age at 100 milligrams of oxytetracycline per bird; to turkeys 9 to 12 weeks of age at 150 milligrams of oxytetracycline per bird; to turkeys 12 weeks of age and older at 200 milligrams of oxytetracycline per bird. In light turkey breeds, no more than 25 milligrams per pound of body weight is administered. For the treatment of infectious sinusitis in turkeys, ¼ to ½ milliliter of the drug is injected directly into each swollen sinus depending upon the age of the bird and the severity of the condition. At the time that the sinuses are treated, the drug should also be administered subcutaneously to the birds according to the dosage schedule given in paragraph (d)(3)(iii)(c) of this section. If re-filling of the sinuses occurs, the treatment may be repeated in 5 to 7 days.

(iv) Treatment of all diseases should be instituted early. Treatment should continue for 24 to 48 hours beyond the remission of disease symptoms, but not exceed a total of 4 consecutive days. If no improvement is noted within 24 to 48 hours, diagnosis and therapy should be reevaluated.

(v) When injecting intramuscularly in adult livestock, do not inject more than 10 milliliters at any one site. The volume administered per injection site should be reduced according to age and body size so that 1 or 2 milliliters are injected in smaller animals such as small calves and young pigs. Intravenous administration is recommended...
Food and Drug Administration, HHS

§ 522.1662a

in cattle when daily dosage exceeds 50 milliliters.

(vi) Treatment must be discontinued at least 5 days prior to slaughter for chickens and turkeys and at least 22 days prior to slaughter for cattle and swine. When administered intramuscularly to animals within 30 days of slaughter, muscle discoloration may necessitate trimming of the injection site(s) and surrounding tissues during the dressing procedure.

(vii) Not for use in lactating dairy animals. Do not administer to laying hens unless the eggs are used for hatching only.

(e)(1) Specifications. Each milliliter of sterile solution contains 100 milligrams of oxytetracycline hydrochloride.

(2) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(3) Conditions of use—(i) Beef cattle and nonlactating dairy cattle—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day; 5 milligrams per pound of body weight per day for treatment of anaplasmosis, severe foot-rot, and severe cases of other indicated diseases.

(b) Indications for use. Treatment of diseases due to oxytetracycline-susceptible organisms as follows: Pneumonia and shipping fever complex associated with Pasteurella spp. and Haemophilus spp., foot-rot and diphtheria caused by Fusobacterium necrophorum, bacterial enteritis (scours) caused by Escherichia coli, wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, and wound infections and acute metritis caused by Staphylococcus spp. and Streptococcus spp. If labeled for use by or on the order of a licensed veterinarian, it may be used for the treatment of anaplasmosis caused by Anaplasma marginale and anthrax caused by Bacillus anthracis.

(c) Limitations. Administer intramuscularly. Treatment of all diseases should be initiated early and continue for 24 to 48 hours beyond remission of disease symptoms, but not to exceed a total of 4 consecutive days. Consult your veterinarian if no improvement is noted within 48 hours. Do not inject more than 10 milliliters per site in adult cattle, reducing the volume according to age and body size to 1 to 2 milliliters in small calves. Exceeding the highest recommended dose of 5 milligrams per pound of body weight, administering at recommended levels for more than 4 consecutive days, and/or exceeding 10 milliliters intramuscularly per injection site may result in antibiotic residues beyond the withdrawal time. Discontinue treatment at least 15 days prior to slaughter. Not for use in lactating dairy cattle.

(ii) Swine—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day. Sows: 3 milligrams of oxytetracycline per pound of body weight, administered once, approximately 8 hours before farrowing or immediately after completion of farrowing.

(b) Indications for use. For treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona. Sows: as an aid in control of infections enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. Do not inject more than 5 milliliters per site in adult swine, reducing the volume according to age and body size to 1 to 2 milliliters in young pigs. Discontinue treatment at least 22 days prior to slaughter.

(f) [Reserved]

(g)(1) Specifications. Each milliliter of sterile solution contains 100 milligrams of oxytetracycline as oxytetracycline hydrochloride.

(2) Sponsor. See No. 054628 in § 510.600(c) of this chapter.

(3) Conditions of use. The drug is used for the treatment of diseases due to oxytetracycline-susceptible organisms as follows:

(i) Beef cattle, beef calves, nonlactating dairy cattle, and dairy calves—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day.

(b) Indications for use. For the treatment of pneumonia and shipping fever complex associated with Pasteurella spp., Haemophilus spp., or Klebsiella spp.

(c) Limitations. Administer by intramuscular, intravenous, or subcutaneous injection. In severe forms of...
the indicated diseases, administer 5 milligrams of oxytetracycline per pound of body weight per day. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 48 hours, consult a veterinarian. Do not inject more than 10 milliliters per injection site in calves weighing 100 pounds or less. Do not slaughter cattle for 13 days after intramuscular or intravenous treatment, or 2 days after subcutaneous treatment. Exceeding the highest recommended dosage or duration of treatment (not more than 4 consecutive days) may result in residues beyond the withdrawal period. A withdrawal period has not been established for use of this product in preruminating calves. Do not use in calves to be processed for veal.

(ii) Swine—(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of body weight per day. Sows: Administer once 3 milligrams of oxytetracycline per pound of body weight, approximately 8 hours before farrowing or immediately after completion of farrowing.

(b) Indications for use. For treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli, pneumonia caused by Pasteurella multocida, and leptospirosis caused by Leptospira pomona. Sows: As an aid in control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

(c) Limitations. Administer intramuscularly. If no improvement is noted within 24 hours, consult a veterinarian. Do not inject more than 5 milliliters per site. Discontinue treatment at least 22 days prior to slaughter.

(h)(1) Specifications. Each milliliter of sterile solution contains 50 milligrams of oxytetracycline hydrochloride.

(2) Sponsors. See No. 054628 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 to 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day; 5 milligrams per pound of body weight per day for treatment of severe forms of the indicated diseases.

(i) Indications for use. The drug is used for treatment of bacterial pneumonia and shipping fever complex associated with Pasteurella spp.; foot-rot and calf diphtheria caused by Spherophorus necrophorus; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; wound infections, acute metrities, and traumatic injury caused by staphylococcal and streptococcal organisms.

(iii) Limitations. Administer 50-milligram-per-milliliter solution intramuscularly; administer 100-milligram-per-milliliter solution intravenously. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement is noted within 24 to 48 hours, consult a veterinarian for diagnosis and therapy. When injecting the drug intramuscularly, do no inject more than 10 milliliters per site in adult cattle. Reduce the volume administered per injection site according to age and body size. In calves weighing 100 pounds or less, do no inject more than 2 milliliters intramuscularly per site. Discontinue treatment at least 22 days before slaughter. Not for use in lactating dairy animals.

(i)(1) Specifications. Each milliliter of sterile solution contains 50 milligrams of oxytetracycline hydrochloride.

(2) Sponsors. See No. 000859 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Amount. The drug is used in beef cattle, beef calves, nonlactating dairy cattle, and dairy calves as follows: Administer 3 to 5 milligrams of the oxytetracycline hydrochloride intramuscularly per pound of body weight per day.

(ii) Indications for use. The drug is used for treatment of bacterial pneumonia and shipping fever complex associated with Pasteurella spp.; foot-rot and diphtheria caused by Spherophorus necrophorus; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; wound infections, acute metrities, and traumatic injury caused by staphylococcal and streptococcal organisms.
Food and Drug Administration, HHS

§ 522.1664 Oxytetracycline and flunixin.

(a) Specifications. Each milliliter (mL) of solution contains 300 milligrams (mg) oxytetracycline base as

tongue caused by Actinobacillus lignieresii; wound infections and acute metritis caused by staphylococcal and streptococcal organisms susceptible to oxytetracycline.

(iii) Limitations. In severe forms of the indicated diseases, administer the equivalent of 5 milligrams of oxytetracycline hydrochloride per pound of body weight per day. Continue treatment 24 to 48 hours following remission of disease symptoms, not to exceed a total of 4 consecutive days. If no improvement occurs within 24 to 48 hours, consult a veterinarian for diagnosis and therapy. In adult livestock, do not inject more than 10 milliliters at any one site. Reduce the volume administered per injection site according to age and body size. In calves weighing 100 pounds or less inject only 2 milliliters per site. Discontinue treatment at least 18 days before slaughter. Not for use in lactating dairy cattle.

{[40 FR 13858, Mar. 27, 1975]}

EDITORIAL NOTE: For Federal Register citations affecting §522.1662a, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

§ 522.1662b Oxytetracycline hydrochloride with lidocaine injection.

(a) Specifications. The drug contains 50 or 100 milligrams of oxytetracycline hydrochloride and 2 percent lidocaine in each milliliter of sterile aqueous solution.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is indicated for use in the treatment of diseases of dogs caused by pathogens sensitive to oxytetracycline hydrochloride including treatment for the following conditions in dogs caused by susceptible microorganisms: Bacterial infections of the urinary tract caused by Hemolytic staphylococcus, Streptococcus spp., Bacterial pulmonary infections caused by Brucella bronchiseptica, Streptococcus pyogenes, Staphylococcus aureus, secondary bacterial infections caused by Micrococcus pyogenes var. albus, Brucella bronchiseptica, Streptococcus spp.

(2) The drug is administered intramuscularly at a recommended daily dosage to dogs at 5 milligrams per pound of body weight administered in divided doses at 6 to 12 hour intervals. Therapy should be continued for at least 24 hours after all symptoms have subsided.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

amphoteric oxytetracycline and 20 mg flunixin base as flunixin meglumine.

(b) **Sponsor.** See No. 055529 in §510.600(c) of this chapter.

(c) **Related tolerances.** See §§556.286 and 556.500 of this chapter.

(d) **Conditions of use—cattle**—(1) **Amount.** Administer once as an intramuscular or subcutaneous injection of 1 mL per 22 pounds (lb) body weight (BW) (13.6 mg oxytetracycline and 0.9 mg flunixin per lb BW) where retreatment of calves and yearlings for bacterial pneumonia is impractical due to husbandry conditions, such as cattle on range, or where their repeated restraint is inadvisable.

(2) **Indications for use.** For the treatment of bacterial pneumonia associated with *Pasteurella* spp. and for the control of associated pyrexia in beef and nonlactating dairy cattle.

(3) **Limitations.** Discontinue treatment at least 21 days prior to slaughter of cattle. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1680 Oxytocin.

(a) **Specifications.** Each milliliter (mL) of solution contains 20 USP units oxytocin.

(b) **Sponsors.** See Nos., 000859, 054628, 054771 and 061623 in §510.600(c) of this chapter.

(c) **Conditions of use—(1) Amount—(i) Obstetrical.** Administer drug intravenously, intramuscularly, or subcutaneously under aseptic conditions as indicated. The following dosages are recommended and may be repeated as conditions require:

<table>
<thead>
<tr>
<th>Animal</th>
<th>mL</th>
<th>U.S.P. units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cats</td>
<td>0.25 to 0.5</td>
<td>5 to 10.</td>
</tr>
<tr>
<td>Dogs</td>
<td>0.25 to 1.5</td>
<td>5 to 30.</td>
</tr>
<tr>
<td>Ewes, Cows</td>
<td>1.5 to 2.5</td>
<td>30 to 50.</td>
</tr>
<tr>
<td>Cows, Horses</td>
<td>5.0</td>
<td>100.</td>
</tr>
</tbody>
</table>

(ii) **Milk letdown.** Intravenous administration is desirable. The following dosage is recommended and may be repeated as conditions require:

<table>
<thead>
<tr>
<th>Animal</th>
<th>mL</th>
<th>U.S.P. units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cows</td>
<td>0.5 to 1.0</td>
<td>10 to 20.</td>
</tr>
<tr>
<td>Sows</td>
<td>0.25 to 1.0</td>
<td>5 to 20.</td>
</tr>
</tbody>
</table>

(2) **Indications for use.** Oxytocin may be used as a uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris. In surgery it may be used postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood. It will contract smooth muscle cells of the mammary gland for milk letdown if the udder is in proper physiological state.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1696 Penicillin G procaine injectable dosage forms.

§ 522.1696a Penicillin G benzathine and penicillin G procaine suspension.

(a) **Specifications.** Each milliliter of aqueous suspension contains penicillin G benzathine and penicillin G procaine, each equivalent to 150,000 units of penicillin G.

(b) **Sponsors.** See sponsors in §510.600(c) of this chapter for the conditions of use in paragraphs (d)(1) of this section as follows:

(1) Nos. 054771, 055529, and 061623 for use as in paragraph (d)(1) of this section.

(2) Nos. 000859, 055529, and 061623 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(2)(iii) of this section.
Food and Drug Administration, HHS

§ 522.1696b Penicillin G procaine aqueous suspension

(a) Specifications. Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) Nos. 000859, 054771, and 055529 for use as in paragraph (d) of this section.

(2) No. 061623 for use as in paragraph (d)(2) of this section.

(c) Related tolerances. See §556.510 of this chapter.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. 10,000 units per pound body weight daily by intramuscular injection at 24-hour intervals. Continue treatment at least 48 hours after symptoms disappear.

(ii) Indications for use. Treatment of infections caused by penicillin-sensitive organisms.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle, sheep, swine, and horses—(i) Amount. 3,000 units per pound body weight (1 milliliter per 100 pounds body weight) daily by intramuscular injection.

(A) For Nos. 000859, 054771, 055529, and 061623: Continue treatment at least 48 hours after symptoms disappear.

(B) For No. 055529: Continue treatment at least 1 day after symptoms disappear (usually 2 or 3 days).

(ii) Indications for use. Treatment of cattle and sheep for bacterial pneumonia (shipping fever) caused by Pasteurella multocida; swine for erysipelas caused by Erysipelothrix rhusiopathiae; and horses for strangles caused by Streptococcus equi.

(iii) Limitations. Not for use in horses intended for food. Milk that has been taken during treatment and for 48 hours after the last treatment must not be used for food.

(A) For Nos. 000859 and 055529: Do not exceed 7 days of treatment in nonlactating dairy and beef cattle, sheep, and swine, or 5 days in lactating cattle. Discontinue treatment for the following number of days before slaughter: Nonruminating cattle (calves)—7; all other cattle—4; sheep—8; and swine—6.

(B) For Nos. 000859 and 055529: Continue treatment at least 1 day after

§ 522.1696c Penicillin G procaine in oil.

(a) Specifications. Each milliliter contains penicillin G procaine equivalent to 300,000 units of penicillin G.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Dogs and cats—10,000 units per pound of body weight once daily. Horses—3,000 units per pound of body weight once daily.

(2) Indications for use. Treatment of infections of dogs, cats, and horses caused by penicillin-susceptible organisms such as Streptococci, Staphylococci, and Corynebacteria.

(3) Limitations. Not for use in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1704 Pentobarbital.

(a) Specifications. Each milliliter of solution contains 64.8 milligrams (mg) of sodium pentobarbital.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. The drug is administered intravenously “to effect”. For general surgical anesthesia, the usual dose is 11 to 13 mg per pound of body weight. For sedation, the usual dose is approximately 2 mg per pound of body weight. For relieving convulsive seizures caused by strychnine in dogs, the injection should be administered intravenously “to effect”. The drug may be administered intraperitoneally. When given intraperitoneally, it is administered at the same dosage level as for intravenous administration.

(2) Indications for use. The drug is indicated for use as a general anesthetic in dogs and cats. Although it may be used as a general surgical anesthetic for horses, it is usually given at a lower dose to cause sedation and hypnosis and may be supplemented with a local anesthetic. It may also be used in dogs for the symptomatic treatment of strychnine poisoning.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16193, Mar. 25, 2014]

§ 522.1720 Phenylbutazone.

(a) Specifications—(1) Each milliliter of solution contains 100 milligrams (mg) of phenylbutazone.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter for use as in paragraph (c) of this section:
Food and Drug Administration, HHS

§522.1862 Pralidoxime powder for injection.

(a) Specifications. Each vial contains 1 gram (g) of pralidoxime chloride powder for mixing with 20 cubic centimeters of sterile water for injection.

(b) Sponsor. No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Cattle and horses: 25 milligrams; swine: 5 milligrams; sheep: 2.5 milligrams; and dogs: 1.0 milligram. Preferably given by intravenous injection, it may be administered subcutaneously. Treatment may be repeated in 1 to 4 weeks, or as indicated.

(2) Indications for use. As an aid in the treatment of botulism in cattle, swine, sheep, and horses.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 67816, Dec. 21, 2009]
§ 522.1870

Each milliliter of constituted solution contains 50 milligrams (mg) pralidoxime chloride.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer as soon as possible after exposure to the poison. Before administration of the sterile pralidoxime chloride, atropine is administered intravenously at a dosage rate of 0.05 mg per pound of body weight, followed by administration of an additional 0.15 mg of atropine per pound of body weight administered intramuscularly. Then the appropriate dosage of sterile pralidoxime chloride is administered slowly intravenously. The dosage rate for sterile pralidoxime chloride when administered to horses is 2 g per horse. When administered to dogs and cats, it is 25 mg per pound of body weight. For small dogs and cats, sterile pralidoxime chloride may be administered either intraperitoneally or intramuscularly. A mild degree of atropinization should be maintained for at least 48 hours. Following severe poisoning, a second dose of sterile pralidoxime chloride may be given after 1 hour if muscle weakness has not been relieved.

(2) Indications for use. It is used in horses, dogs, and cats as an antidote in the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity in horses, dogs, and cats.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16193, Mar. 25, 2014]

§ 522.1870 Praziquantel.

(a) Specification. Each milliliter contains 56.8 milligrams (mg) praziquantel.

(b) Sponsors. See Nos. 000061 and 000059 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. For dogs 5 pounds and under, 0.3 milliliter (17.0 milligrams); for 6 to 10 pounds, 0.5 milliliter (28.4 milligrams); for 11 to 25 pounds, 1.0 milliliter (56.8 milligrams); if over 25 Pounds, 0.2 milliliter (11.4 milligrams) per 5 pounds body weight to a maximum of 3 milliliters (170.4 milligrams).

(ii) Indications for use. For removal of canine cestodes Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus, and removal and control of canine cestode Echinococcus multilocularis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cats—(i) Amount. For cats under 5 pounds, 0.2 milliliter (11.4 milligrams); for 6 to 10 pounds, 0.4 milliliter (22.7 milligrams); 11 pounds and over, 0.6 milliliter (34.1 milligrams) maximum.

(ii) Indications for use. For removal of feline cestodes Dipylidium caninum and Taenia taeniaeformis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.1881 Prednisolone acetate.

(a) Specifications. Each milliliter of suspension contains 25 milligrams (mg) of prednisolone acetate.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. The drug is administered to horses intra-articularly at a dosage level of 50 to 100 mg. The dose may be repeated when necessary. The drug is administered to dogs and cats intramuscularly at a dosage level of 10 to 50 mg. The dosage may be repeated when necessary. If the condition is of a chronic nature, an oral corticosteroid may be given as a maintenance dosage. The drug may be given intra-articularly to dogs and cats at a dosage level of 5 to 25 mg. The dose may be repeated when necessary after 7 days for two or three doses.

(2) Indications for use. The drug is indicated in the treatment of dogs, cats, and horses for conditions requiring an anti-inflammatory agent. The drug is indicated for the treatment of acute musculoskeletal inflammations such as bursitis, carpitis, and spondylitis. The drug is indicated as supportive therapy in nonspecific dermatosis such as summer eczema and atopy. The drug may be used as supportive therapy pre- and postoperatively and for various stress conditions.
conditions when corticosteroids are required while the animal is being treated for a specific condition.

(3) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16194, Mar. 25, 2014]

§ 522.1883 Prednisolone sodium phosphate.

(a) **Specifications.** Each milliliter of solution contains 20 milligrams (mg) prednisolone sodium phosphate (equivalent to 14.88 mg of prednisolone).

(b) **Sponsor.** See No. 061623 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs**—(1) **Amount.** Administer intravenously in a dosage of 2½ to 5 mg per pound of body weight, initially for shock and shock-like states, followed by equal maintenance doses at 1-, 3-, 6-, or 10-hour intervals as determined by the condition of the animal.

(2) **Indications for use.** Administer when a rapid adrenal glucocorticoid and/or anti-inflammatory effect is necessary.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[68 FR 59881, Oct. 20, 2003]

§ 522.1884 Prednisolone sodium succinate.

(a) **Specifications.** Each milliliter of prednisolone sodium succinate injection contains: Prednisolone sodium succinate equivalent in activity to 10, 20, or 50 milligrams (mg) of prednisolone.

(b) **Sponsor.** See No. 054771 in § 510.600(c) of this chapter for products containing 10, 20, and 50 mg equivalent prednisolone activity per milliliter for use in horses, dogs, and cats as provided in paragraphs (c)(1)(i), (ii), and (iii) of this section.

(c) **Conditions of use**—(1) **Amount and indications for use**—(i) **Horses:** Administer by intramuscular injection 100 to 300 mg or by intrasynovial injection at a dosage level of 50 to 100 mg. Retreatment of horses in 24 to 48 hours may be necessary, depending on the general condition of the animal and the severity and duration of the disease.

(ii) **Dogs and cats:** Administer by intramuscular injection 1 mg per 5 pounds of body weight or intrasynovially at a dosage level of 10 to 20 mg.

(2) **Indications for use.** It is used as an anti-inflammatory agent in horses, dogs, and cats.

(3) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16194, Mar. 25, 2014]

§ 522.1885 Prednisolone tertiary butylacetate.

(a) **Specifications.** Each milliliter of suspension contains 20 milligrams (mg) of prednisolone tertiary butylacetate.

(b) **Sponsor.** See No. 050604 in § 510.600(c) of this chapter.

(c) **Conditions of use**—(1) **Amount**—(i) **Horses:** Administer by intramuscular injection 50 to 100 mg as an initial dose by intravenous injection over a period of one-half to 1 minute, or by intramuscular injection, and may be repeated in inflammatory, allergic, or other stress conditions at intervals of 12, 24, or 48 hours, depending upon the size of the animal, the severity of the condition and the response to treatment.

(ii) **Dogs.** Administer by intravenous injection at a range of 2.5 to 5 mg per pound of body weight as an initial dose followed by maintenance doses at 1, 3, 6, or 10 hour intervals, as determined by the condition of the animal, for treatment of shock.

(iii) **Dogs and cats.** Administer by intramuscular injection for treatment of inflammatory, allergic, and less severe stress conditions, where immediate effect is not required, at 1 to 5 mg ranging upward to 30 to 50 mg in large breeds of dogs. Dosage may be repeated in 12 to 24 hours and continued for 3 to 5 days if necessary. If permanent corticosteroid effect is required, oral therapy with prednisolone tablets may be substituted.

(2) **Limitations.** Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16194, Mar. 25, 2014]
§ 522.1890 Sterile prednisone suspension.

(a) Specifications. Each milliliter of suspension contains 10 to 40 milligrams (mg) of prednisone.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount—(i) Horses. Administer 100 to 400 mg by intramuscular injection, repeating if necessary.

(ii) Dogs and cats. Administer 0.25 to 1.0 mg per pound of body weight by intramuscular injection for 3 to 5 days or until a response is noted. Treatment may be continued with an orally administered dose.

(2) Indications for use. It is used for conditions requiring an anti-inflammatory agent.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16194, Mar. 25, 2014]

§ 522.1920 Prochlorperazine and isopropamide.

(a) Specifications. Each milliliter of solution contains prochlorperazine edisylate equivalent to 4 milligrams (mg) prochlorperazine and isopropamide iodide equivalent to 0.28 mg of isopropamide.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. (i) Dosage is administered by subcutaneous injection twice daily as follows:

<table>
<thead>
<tr>
<th>Weight of animal in pounds</th>
<th>Dosage in milliliters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 4</td>
<td>0.25</td>
</tr>
<tr>
<td>5 to 14</td>
<td>0.5–1</td>
</tr>
<tr>
<td>15 to 30</td>
<td>2–3</td>
</tr>
<tr>
<td>30 to 45</td>
<td>3–4</td>
</tr>
<tr>
<td>45 to 60</td>
<td>4–6</td>
</tr>
<tr>
<td>Over 60</td>
<td>6</td>
</tr>
</tbody>
</table>

(ii) Following the last injection, administer prochlorperazine and isopropamide sustained release capsules as indicated.

(2) Indications for use. For use in dogs and cats in which gastrointestinal disturbances are associated with emotional stress.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16194, Mar. 25, 2014]

§ 522.1940 Progesterone and estradiol benzoate.

(a) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) No. 054771 for use in paragraphs (c)(1)(i)(A), (c)(1)(ii), (c)(1)(iii), (c)(2)(i)(A), (c)(2)(ii), (c)(2)(iii), and (c)(3) of this section.

(2) No. 000986 for use as in paragraphs (c)(1) and (c)(2) of this section.

(b) Related tolerances. See §§ 556.240 and 556.540 of this chapter.

(c) Conditions of use in cattle. It is used for implantation as follows:

(1) Suckling beef calves—(i) Amount—(A) 100 milligrams (mg) progesterone and 10 mg estradiol benzoate (one implant consisting of 4 pellets, each pellet containing 25 mg progesterone and 2.5 mg estradiol benzoate) per implant dose.

(B) 100 mg progesterone and 10 mg estradiol benzoate (one implant consisting of 5 pellets, each of 4 pellets containing 25 mg progesterone and 2.5 mg estradiol benzoate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain.

(iii) Limitations. For use in suckling beef calves (at least 45 days of age) up to 400 pounds (lb) of body weight. For subcutaneous ear implantation, one dose per animal. Do not use in bull calves intended for reproduction. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(2) Steers—(i) Amount—(A) 200 mg progesterone and 20 mg estradiol benzoate (one implant consisting of 8 pellets, each pellet containing 25 mg progesterone and 2.5 mg estradiol benzoate) per implant dose.

(B) 200 mg progesterone and 20 mg estradiol benzoate (one implant consisting of 9 pellets, each of 8 pellets containing 25 mg progesterone and 2.5
mg estradiol benzoate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. For animals weighing 400 lb or more; for subcutaneous ear implantation, one dose per animal. Safety and effectiveness have not been established in veal calves. Do not use in calves to be processed for veal.

(3) Steers fed in confinement for slaughter—(i) Amount. Reimplant 200 mg progesterone and 20 mg estradiol benzoate on approximately day 70 following an initial implant of 100 mg progesterone and 10 mg estradiol benzoate or 200 mg progesterone and 20 mg estradiol benzoate.

(ii) Indications for use. For additional improvement in rate of weight gain.

(iii) Limitations. For subcutaneous ear implantation. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

§ 522.1962 Promazine.

(a) Specifications. Each milliliter of solution contains 50 milligrams (mg) promazine hydrochloride.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) No. 054771 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii)(A), (c)(1)(iii), and (c)(2) of this section.

(2) No. 061623 for use as in paragraphs (c)(1)(i)(B), (c)(1)(ii)(B), and (c)(1)(iii) of this section.

(c) Conditions of use in dogs and cats—

(1) Amounts and indications for use. Administer 0.05 to 0.5 mg per pound of body weight by intravenous or intramuscular injection for tranquilization. Administer 0.25 mg per pound of body weight by intravenous injection as a preanesthetic.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2002 Propiopromazine.

(a) Specifications. Each milliliter of solution contains 5 or 10 milligrams (mg) propiopromazine hydrochloride.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amounts and indications for use. Administer 0.05 to 0.5 mg per pound of body weight by intravenous or intramuscular injection for tranquilization. Administer 0.25 mg per pound of body weight by intravenous injection as a preanesthetic.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2005 Propofol.

(a) Specifications. Each milliliter of emulsion contains 10 milligrams (mg) propofol.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter.

(1) No. 000859 for use as in paragraphs (c)(1), (c)(2)(i), and (c)(3) of this section.

(2) No. 054771 for use as in paragraph (c) of this section.

(c) Conditions of use in dogs and cats—

(1) Amount. Administer by intravenous injection according to label directions.
The use of preanesthetic medication reduces propofol dose requirements. (2) Indications for use—(i) As a single injection to provide general anesthesia for short procedures; for induction and maintenance of general anesthesia using incremental doses to effect; for induction of general anesthesia where maintenance is provided by inhalant anesthetics. (ii) For the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. 


(a) Specifications. Each milliliter of solution contains 1 milligram of prostalene. 
(b) Sponsor. No. 054771 in § 510.600(c) of this chapter. 
(c) Conditions of use in horses—(1) Amount. Administer 5 micrograms per kilogram of body weight as a single subcutaneous injection. (2) Indications for use. For the control of estrus in mares. (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. 

§ 522.2063 Pyrilamine. 

(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) pyrilamine maleate. 
(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter. 
(c) Conditions of use in cats—(1) Amount. Administer 0.91 mg per pound (2 mg/kilogram) by subcutaneous injection, once daily, for a maximum of 3 days. (2) Indications for use. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats at least 4 months of age for a maximum of 3 days. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. 

§ 522.2075 Robenacoxib. 

(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) robenacoxib. 
(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter. 
(c) Conditions of use in cats—(1) Amount. Administer 0.91 mg per pound (2 mg/kilogram) by subcutaneous injection, once daily, for a maximum of 3 days. (2) Indications for use. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration in cats at least 4 months of age for a maximum of 3 days. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. 

§ 522.2076 Romifidine. 

(a) Specifications. Each milliliter of solution contains 10 milligrams (mg) romifidine hydrochloride. 
(b) Sponsor. See No. 000010 in § 510.600(c) of this chapter. 
(c) Conditions of use in horses—(1) Amount. 40 to 120 micrograms per kilogram of body weight (mcg/kg BW) intravenously for sedation and analgesia; 100 mcg/kg BW intravenously as a preanesthetic. (2) Indications for use. For use as a sedative and analgesic to facilitate handling, clinical examinations, clinical procedures, and minor surgical procedures in adult horses; and for use as a preanesthetic prior to the induction of general anesthesia in adult horses.
§ 522.2100 Selenium and vitamin E.

(a)(1) Specifications. Each milliliter of emulsion contains 5.48 milligrams (mg) sodium selenite (equivalent to 2.5 mg selenium) and 50 mg of vitamin E (68 I.U.) (as d-alpha tocopheryl acetate).

(2) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(3) Conditions of use in horses—(i) Amount. Administer 1 milliliter (mL) per 100 pounds (lbs) of body weight by intravenous injection or by deep intramuscular injection in divided doses in two or more sites in the gluteal or cervical muscles. Administration may be repeated at 5 to 10 day intervals.

(ii) Indications for use. For the prevention and treatment of selenium-tocopherol deficiency syndrome in horses.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(b)(1) Specifications. Each milliliter contains 2.19 mg of sodium selenite (equivalent to 1 mg of selenium), 50 mg of vitamin E (68 U.S.P. units).

(2) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(3) Conditions of use in dogs—(i) Amount. Administer by subcutaneous or intramuscular injection in divided doses in two or more sites at 1 mL/20 lbs of body weight with a minimum dosage of 1/4 mL and a maximum dosage of 5 mL. The dose is repeated at 3-day intervals until a satisfactory therapeutic response is observed. A maintenance regimen is then initiated which consists of 1 mL per 40 lbs of body weight with a minimum dosage of 1/4 mL which is repeated every 3 days or 7 days, or longer, as required to maintain continued improvement or an asymptomatic condition; or the drug may be used in capsule form for oral maintenance therapy.

(ii) Indications for use. As an aid in alleviating and controlling inflammation, pain, and lameness associated with certain arthropathies in dogs.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c)(1) Specifications. Each milliliter contains 2.19 milligrams of selenite sodium (equivalent to 1 milligram selenium), 50 milligrams vitamin E (68 U.S.P. units).

(2) Sponsor. See Nos. 000061 and 054771 in §510.600(c) of this chapter.

(3) Conditions of use—(i) Dosage. Breeding beef cows: 1 milliliter per 200 pounds of body weight during the middle third of gestation, and 30 days before calving. Weanling calves: 1 milliliter per 200 pounds of body weight.

(ii) Indications for use. Weanling calves and breeding beef cows: For the prevention and treatment of selenium-tocopherol deficiency syndrome.

(iii) Limitations. For subcutaneous or intramuscular use. Discontinue use 30 days before treated calves are slaughtered for human consumption. Discontinue use 14 days before treated lambs, ewes, sows, or pigs are slaughtered for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 522.2112 21 CFR Ch. I (4–1–16 Edition)

days before treated cattle are slaughtered for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(e)(1) Specifications. Each milliliter contains 0.55 milligram selenite sodium (equivalent to 0.25 milligram selenium), 50 milligrams (68 U.S.P. units) vitamin E.

(2) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(3) Conditions of use—(1) Dosage. Newborn lambs: 1 milliliter. Lambs 2 weeks of age or older: 4 milliliters. Baby pigs: 1 milliliter (or treat the sow during the last week of pregnancy).


(iii) Limitations. For subcutaneous or intramuscular use only. Discontinue use 14 days before treated animals are slaughtered for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2112 Sometribove zinc suspension.

(a) Specifications. Each single-dose syringe contains 500 milligrams (mg) sometribove zinc in a prolonged-release suspension.

(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Inject 500 mg every 14 days starting during the 9th or 10th week (57 to 70 days) after calving and continue until the end of lactation.

(2) Indications for use. To increase production of marketable milk in healthy lactating dairy cows.

(3) Limitations. Use in lactating dairy cows only. Safety to replacement bulls born to treated dairy cows has not been established. Inject subcutaneously. Avoid injections within 2 weeks of expected slaughter to minimize injection site hematomas on carcass. There is no milk discard or preslaughter withdrawal period. Use may reduce pregnancy rates and increase days open. Treated cows are at an increased risk for mastitis and higher milk somatic cell counts. Use care to differentiate increased body temperature due to use of this product from an increased body temperature that may occur due to illness. Cows treated with this product may have more enlarged hocks and disorders of the foot region. Use may reduce hemoglobin and hematocrit values during treatment. Human warning: Avoid prolonged or repeated contact with eyes and skin.


§ 522.2120 Spectinomycin dihydrochloride injection.

(a) Specifications. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by the growth of Streptomyces flavopersicus (var. Abbott) or the same antibiotic substance produced by any other means. Each milliliter of the drug contains the following amount of spectinomycin activity from spectinomycin dihydrochloride pentahydrate:

1. 5 milligrams when used as provided in paragraph (d)(1) of this section.

2. [Reserved]

3. 100 milligrams when used as provided in paragraphs (d)(2), (3), and (4) of this section.

(b) Sponsor. In § 510.600 of this chapter, see No. 000859 for conditions of use as in paragraph (d) of this section, and see No. 054771 for conditions of use as in paragraph (d)(2) and (d)(4) of this section.

(c) Special considerations. The quantity of spectinomycin referred to in this section refers to the equivalent weight of base activity for the drug.

(d) Conditions of use. It is administered as spectinomycin dihydrochloride pentahydrate as follows:

1. Subcutaneously in the treatment of 1-to-3-day-old turkey poults at the rate of 1 to 2 milligrams per poult as an aid in the prevention of mortality associated with Arizona group infection.
(2) Subcutaneously in the treatment of 1-to-3-day old:
(i) Turkey poults at the rate of 5 milligrams per poult as an aid in the control of chronic respiratory disease (CRD) associated with E. coli.
(ii) Baby chicks at the rate of 2.5 to 5 milligrams per chick as an aid in the control of mortality and to lessen severity of infections caused by M. synoviae, S. typhimurium, S. infantis, and E. coli.

(3) Intramuscularly in the treatment of dogs:
(i) At a dosage level of 2.5 milligrams to 5.0 milligrams per pound of body weight twice daily. Treatment may be continued for 4 days. For treatment of infections caused by gram-negative and gram-positive organisms susceptible to spectinomycin.
(ii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Administer single injection of 0.1 milliliter (10 milligrams) subcutaneously in nape of neck of 1- to 3-day-old turkey poults as an aid in control of airsacculitis associated with M. meleagridis sensitive to spectinomycin.

§ 522.2121 Spectinomycin sulfate.
(a) Specifications. Each milliliter of solution contains spectinomycin sulfate tetrahydrate equivalent to 100 milligrams (mg) spectinomycin.
(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.600 of this chapter.
(d) Conditions of use in cattle—(1) Amount. 10 to 15 mg per kilogram of body weight at 24-hour intervals for 3 to 5 consecutive days.
(2) Indications for use. For the treatment of bovine respiratory disease (pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.
(3) Limitations. Do not use in female dairy cattle 20 months of age or older. Use in this class of cattle may cause residues in milk. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2150 Stanozolol.
(a) Specifications. Each milliliter of suspension contains 50 milligrams (mg) of stanozolol.
(b) Sponsor. No. 054771 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Amount—(i) Dogs and cats. For cats and small breeds of dogs: 25 mg. For larger dogs: 50 mg. Administer by deep intramuscular injection in the thigh at weekly intervals, for several weeks.
(ii) Horses. Administer 25 mg per 100 pounds of body weight by deep intramuscular injection in the gluteal region at weekly intervals, for not more than 4 weeks.
(2) Indications for use. For use as an anabolic steroid treatment.
(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2200 Sulfachlorpyridazine.
(a) Specifications. Each milliliter of solution contains sulfachlorpyridazine tetrahydrate equivalent to 100 milligrams (mg) sulfachlorpyridazine.
(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.630 of this chapter.
(d) Conditions of use in calves. It is used as follows:
(1) Amount. Administer 30 to 45 mg per pound (lb) of body weight in divided doses by twice daily injection for 1 to 5 days.
(2) Indications for use. For the treatment of diarrhea caused or complicated by Escherichia coli (colibacillosis).
(3) Limitations. Treated calves must not be slaughtered for food during treatment or for 5 days after the last treatment. A withdrawal period has
§ 522.2220 Sulfadimethoxine.

(a) Specifications. Each milliliter of solution contains:

(1) 100 milligrams (mg) of sulfadimethoxine sodium.

(2) 400 mg of sulfadimethoxine sodium.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 054628 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(2) No. 054771 for use of the product described in paragraph (a)(2) as in paragraphs (d)(2), (3), and (4) of this section.

(3) Nos. 000859, 057561, and 061623 for use of the product described in paragraph (a)(2) as in paragraph (d)(4) of this section.

(c) Related tolerances. See §556.640 of this chapter.

(d) Conditions of use—(1) Dogs—(i) Amount. Administer by subcutaneous, intramuscular, or intravenous injection at an initial dose of 25 mg per pound of body weight followed by 12.5 mg per pound of body weight every 24 hours thereafter. Continue treatment until the animal is free from symptoms for 48 hours.

(ii) Indications for use. For the treatment of sulfadimethoxine-susceptible bacterial infections in dogs.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Dogs and cats—(i) Amount. Administer by intravenous or subcutaneous injection at an initial dose of 55 mg per kilogram of body weight followed by 27.5 mg per kilogram of body weight every 24 hours.

(ii) Indications for use. For the treatment of respiratory, genitourinary tract, enteric, and soft tissue infections when caused by Streptococci, Staphylococci, Escherichia, Salmonella, Klebsiella, Proteus, or Shigella organisms sensitive to sulfadimethoxine, and in the treatment of canine bacterial enteritis associated with coccidiosis and canine Salmonellosis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Horses—(1) Amount. Administer by intravenous injection at an initial dose of 55 mg per kilogram of body weight followed by 27.5 mg per kilogram of body weight every 24 hours until the patient is asymptomatic for 48 hours.

(ii) Indications for use. For the treatment of respiratory disease caused by Streptococcus equi (strangles).

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Cattle—(1) Amount. Administer an initial dose of 25 mg per pound of body weight by intravenous injection followed by 12.5 mg per pound of body weight every 24 hours until the animal is asymptomatic for 48 hours.

(ii) Indications for use. For the treatment of bovine respiratory disease complex (shipping fever complex) and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum sensitive to sulfadimethoxine.

(iii) Limitations. Milk taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Do not administer within 5 days of slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

§ 522.2240 Sulfaethoxypyridazine.

(a) Specifications. The drug is an aqueous solution of sulfaethoxypyridazine.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.650 of this chapter.

(d) Conditions of use in cattle—(1) Amount. Administer 2.5 grams per 100 pounds of body weight per day by intravenous injection for not more than 4 days; or first treatment may be followed by 3 days of treatment with sulfaethoxypyridazine in drinking water or tablets in accordance with
§ 522.2240a (e) and § 520.2240b (e) of this chapter.

(2) Indications for use. For treatment of respiratory infection (pneumonia, shipping fever), foot rot, calf scour; as adjunctive therapy in septicemia accompanying mastitis and metritis.

(3) Limitations. Do not treat within 16 days of slaughter. Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16196, Mar. 25, 2014]

§ 522.2260 Sulfamethazine.

(a) Specifications. Each milliliter (mL) of solution contains 250 milligrams (mg) sulfamethazine sodium.

(b) Sponsor. See No. 016592 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.670 of this chapter.

(d) Conditions of use in cattle — (1) Amount. Initially administer 20 mL for each 50 pounds (lb) of body weight (100 mg/lb) by intravenous injection, followed by 20 mL per 100 lb of body weight (50 mg/lb) by intravenous injection, daily thereafter. Treatment should not exceed a total of 5 consecutive days.

(2) Indications for use. For cattle for treatment of bacterial pneumonia and bovine respiratory disease complex (shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial scour) (Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium necrophorum), calf diphtheria (Fusobacterium necrophorum), acute mastitis and acute metritis (Streptococcus spp.) when caused by one or more pathogenic organisms sensitive to sulfamethazine.

(3) Limitations. Withdraw medication from cattle 10 days prior to slaughter. Do not use in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2340 Sulfomycin.

(a) Specifications. Sulfomycin for injection is sterile. It is derived from the antibiotic substance produced by the growth of Bacillus polymyxa or is the same substance produced by any other means.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Special considerations. The quantities of antibiotic in paragraph (e) of this section refer to the activity of the appropriate standard.

(d) Related tolerances. See § 556.700 of this chapter.

(e) Conditions of use. (1) It is used or intended for use in chickens and turkeys as an aid in the treatment of disease caused or complicated by E. coli, such as colibacillosis and complicated chronic respiratory disease.

(2) It is administered by subcutaneous injection as follows:

<table>
<thead>
<tr>
<th>Age of birds in days</th>
<th>Antibiotic activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chickens (units)</td>
</tr>
<tr>
<td></td>
<td>Turkeys (units)</td>
</tr>
<tr>
<td>1 to 14</td>
<td>12,500</td>
</tr>
<tr>
<td>15 to 28</td>
<td>25,000</td>
</tr>
<tr>
<td>29 to 63</td>
<td>50,000</td>
</tr>
<tr>
<td>Over 63</td>
<td>50,000</td>
</tr>
<tr>
<td></td>
<td>100,000</td>
</tr>
</tbody>
</table>

(3) A second injection may be given 3 days later if symptoms persist.

(4) Not for use in laying hens; do not treat chickens within 5 days of slaughter; do not treat turkeys within 7 days of slaughter.

[40 FR 13858, Mar. 27, 1975, as amended at 79 FR 16196, Mar. 25, 2014]

§ 522.2404 Thialbarbitone sodium for injection.

(a) Specifications. Thialbarbitone sodium for injection when reconstituted with sterile distilled water provides 94 milligrams of thialbarbitone sodium per milliliter of solution.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use. (1) The drug is administered as a general anesthetic in surgical procedures on dogs, cats, swine, sheep, cattle, and horses. The drug is used for procedures of relatively short duration. However, the period of anesthesia can be lengthened by slower initial injection and supplemental administration during surgery.

§ 522.2424 Thiamyral.

(a) Specifications. The drug is a sterile powder. It is reconstituted with sterile distilled water, water for injection, or sodium chloride injection, to a desired concentration of 0.5 to 4 percent sodium thiamylal.

(b) Sponsors. See Nos. 054628 and 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer by intravenous injection to effect. The average single dose is:

(i) Dogs and cats: 8 milligrams (mg) per pound of body weight (when used with a preanesthetic, generally one-half the normal dose).

(ii) Swine: 40 mg per 5 pounds (lbs) of body weight.

(iii) Horses: Light anesthesia, 1 gram per 500 lbs to 1,100 lbs of body weight; deep anesthesia, 1 gram per 300 lbs of body weight (40 mg/12 lbs of body weight).

(iv) Cattle: Short duration, 20 mg/5 lbs of body weight; longer duration, 40 mg/7 lbs of body weight.

(2) Indications for use. It is used as an ultra-short-acting anesthetic in dogs, cats, swine, horses, and cattle.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16196, Mar. 25, 2014]

§ 522.2444 Thiopental injectable dosage forms.

§ 522.2444a Thiopental powder for injection.

(a) Specifications. The drug contains sodium thiopental powder for constitution with sterile water for injection.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Administer by intravenous injection as follows:

(i) 6 to 9 milligrams (mg) per pound of body weight for brief anesthesia (6 to 10 minutes).

(ii) 10 to 12 mg per pound of body weight for anesthesia of 15 to 25 minutes duration.

(2) Indications for use. It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical and other procedures. It is also used to induce anesthesia in dogs and cats which then have surgical anesthesia maintained by use of a volatile anesthetic.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16196, Mar. 25, 2014]

§ 522.2444b Thiopental and pentobarbital powder for injection.

(a) Specifications. Each gram of powder contains 750 milligrams (mg) of sodium thiopental and 250 mg of sodium pentobarbital powder for dilution with sterile water for injection.

(b) Sponsor. See No. 061623 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For total anesthesia, it is given at approximately 10 to 12 mg per pound of body weight over a period of 3.5 to 5 minutes. When preanesthetic medication is used, wait at least an hour before administering thiopental and sodium pentobarbital for injection, and the dosage necessary for anesthesia is reduced. Usually ½ to ⅔ the normal amount is adequate.
(2) **Indications for use.** It is used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16197, Mar. 25, 2014]

§ 522.2460 Tildipirosin.

(a) **Specifications.** Each milliliter of solution contains:

(1) 180 milligrams (mg) tildipirosin.

(2) [Reserved]

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.733 of this chapter.

(d) **Conditions of use—(1) Cattle—(i) Amount.** Administer 4 mg/kg of body weight one time by subcutaneous injection in the neck.

(ii) **Indications for use.** For the treatment of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni* in beef and non-lactating dairy cattle; and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, and *H. somni*.

(iii) **Limitations.** Cattle intended for human consumption must not be slaughtered within 21 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) [Reserved]

[77 FR 38991, July 3, 2012]

§ 522.2470 Tiletamine and zolazepam for injection.

(a) **Specifications.** The drug is a sterile powder. Each milliliter of constituted solution contains tiletamine hydrochloride equivalent to 50 milligrams (mg) of tiletamine base and zolazepam hydrochloride equivalent to 50 mg of zolazepam base.

(b) **Sponsors.** See Nos. 026637 and 054771 in § 510.600(c) of this chapter.

(c) **Conditions of use in dogs and cats—(1) Amount.** Expressed as milligrams of the drug combination:

(i) **Healthy dogs:** An initial intramuscular dosage of 3 to 4.5 mg per pound of body weight for diagnostic purposes; 4.5 to 6 mg per pound of body weight for minor procedures of short duration such as repair of lacerations and wounds, castrations, and other procedures requiring mild to moderate analgesia. Supplemental doses when required should be less than the initial dose and the total dose given should not exceed 12 mg per pound of body weight. The maximum total safe dose is 13.6 milligrams per pound of body weight.

(ii) **Healthy cats:** An initial intramuscular dosage of 4.4 to 5.4 mg per pound of body weight for such procedures as dentistry, treatment of abscesses, foreign body removal, and related types of surgery; 4.8 to 5.7 mg per pound of body weight for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations, and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg per pound of body weight are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg per pound of body weight.

(2) **Indications for use.** For restraint or for anesthesia combined with muscle relaxation in cats and in dogs for restraint and minor procedures of short duration (30 minutes) requiring mild to moderate analgesia.

(3) **Limitations.** Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2471 Tilmicosin.

(a) **Specifications.** Each milliliter of solution contains 300 milligrams (mg) tilmicosin base as tilmicosin phosphate.

(b) **Sponsor.** See No. 000986 in § 510.600(c) of this chapter.
§ 522.2473  
(c) Related tolerances. See §556.735 of this chapter.
(d) Special considerations. (1) Not for human use. Use of this antibiotic in humans may prove fatal. Do not use in automatically powered syringes.
(2) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(e) Conditions of use—(1) Cattle—(i) Amount. 10 to 20 milligrams per kilograms (mg/kg) of body weight as a single subcutaneous injection.
(ii) Indications for use. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. For the control of respiratory disease in cattle at high risk of developing BRD associated with M. haemolytica.
(iii) Limitations. Do not use in female dairy cattle 20 months of age or older. Use of this antibiotic in this class of cattle may cause milk residues. Do not slaughter within 42 days of last treatment.
(2) Sheep—(1) Amount. 10 mg/kg body weight as a single subcutaneous injection.
(ii) Indications for use. For the treatment of ovine respiratory disease (ORD) associated with Mannheimia (P.) haemolytica.
(iii) Limitations. Do not slaughter within 28 days of last treatment.

§ 522.2474  Tolazoline.
(a) Specifications. Each milliliter of solution contains tolazoline hydrochloride equivalent to 100 milligrams (mg) of base activity.
(b) Sponsor. See No. 059399 in §510.600(c) of this chapter.
(c) Conditions of use in horses—(1) Amount. Administer slowly by intravenous injection 4 mg per kilogram of body weight or 1.8 mg per pound (4 milliliters (mL) per 100 kilograms or 4 mL per 220 pounds).
(ii) Indications for use. For use in horses when it is desirable to reverse the effects of sedation and analgesia caused by xylazine.
(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 522.2476  Trenbolone acetate.
(a) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (d) of this section.
(1) No. 021641 for use as in paragraph (c) of this section.
(2) No. 000061 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii), (c)(1)(iii), (c)(2)(i)(A), (c)(2)(ii), and (c)(2)(iii) of this section.
(b) Related tolerances. See §556.739 of this chapter.
(c) Conditions of use—(1) Steers fed in confinement for slaughter—(1) Amount. Use 126 days prior to slaughter; should be reimplemented once after 63 days.
(A) 140 milligrams (mg) trenbolone acetate (one implant consisting of 7 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.
(B) 140 mg trenbolone acetate (one implant consisting of 8 pellets, each of 7 pellets containing 20 milligrams trenbolone acetate, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.
(ii) Indications for use. For improved feed efficiency.
(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(2) Heifers fed in confinement for slaughter—(i) Amount. Use last 63 days prior to slaughter.

(A) 200 mg trenbolone acetate (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate) per implant dose.

(B) 200 mg of trenbolone acetate (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg trenbolone acetate, and 1 pellet containing 29 mg of tylosin tartrate) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

§522.2477 Trenbolone acetate and estradiol.

(a) [Reserved]

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (d) of this section.


(c) Conditions of use—(1) Steers fed in confinement for slaughter—(i) Amount. Use 120 milligrams (mg) trenbolone acetate and 24 mg estradiol (one implant consisting of 6 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.

(B) 120 mg trenbolone acetate and 24 mg estradiol (one implant consisting of 7 pellets, each of 6 pellets containing 20 mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(C) 200 mg trenbolone acetate and 40 mg estradiol (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose.

(D) 80 mg trenbolone acetate and 16 mg estradiol (one implant consisting of 4 pellets, each pellet containing 20 mg trenbolone acetate and 4 mg estradiol) per implant dose.

(E) 200 mg trenbolone acetate and 20 mg estradiol (one implant consisting of 11 pellets, each of 10 pellets containing 20 mg trenbolone acetate and 2 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(F) 80 mg trenbolone acetate and 16 mg estradiol (one implant consisting of 5 pellets, each of 4 pellets containing 20 mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant dose.

(G) 200 milligram (mg) trenbolone acetate and 40 mg estradiol (one implant consisting of 10 pellets, each pellet containing 20 mg trenbolone acetate and 2 mg estradiol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in animals intended for subsequent breeding or in dairy animals. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.


Editorial Note: At 77 FR 31723, May 30, 2012, §522.2476 was amended in paragraph (b)(1) by removing “021641” and in its place adding “000986”; however, the amendment could not be incorporated because (b)(1) didn’t exist.
§ 522.2478  Trenbolone acetate and estradiol benzoate.

(a) Specifications—(1) Each implant consists of:

(i) 8 pellets, each pellet containing 25 milligrams (mg) trenbolone acetate and 3.5 mg estradiol benzoate.

(ii) 4 pellets, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.

(2) Each extended release implant consists of:

(i) 8 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.

(ii) 6 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.240 and 556.739 of this chapter.
(d) Conditions of use—(1) Steers fed in confinement for slaughter—(i) For an implant as described in paragraph (a)(1)(i) of this section:
   (A) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate.
   (B) Indications for use. For increased rate of weight gain and improved feed efficiency.
   (C) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(ii) For an implant as described in paragraph (a)(1)(ii) of this section:
   (A) Amount. 100 mg trenbolone acetate and 14 mg estradiol benzoate.
   (B) Indications for use. For increased rate of weight gain.
   (C) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(iii) For an implant as described in paragraph (a)(2)(i) of this section:
   (A) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant.
   (B) Indications for use. For increased rate of weight gain and improved feed efficiency for up to 200 days.
   (C) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(2) Heifers fed in confinement for slaughter—(i) For an implant as described in paragraph (a)(1)(i) of this section:
   (A) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate.
   (B) Indications for use. For increased rate of weight gain.
   (C) Limitations. Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(ii) For an implant as described in paragraph (a)(1)(ii) of this section:
   (A) Amount. 100 mg trenbolone acetate and 14 mg estradiol benzoate.
   (B) Indications for use. For increased rate of weight gain.
   (C) Limitations. Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(iii) For an implant as described in paragraph (a)(2)(i) of this section:
   (A) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant.
   (B) Indications for use. For increased rate of weight gain and improved feed efficiency for up to 200 days.
   (C) Limitations. Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(3) Pasture steers and heifers (slaughter, stocker, and feeder)—(i) For an implant as described in paragraph (a)(2)(ii) of this section:
   (A) Amount. 150 mg trenbolone acetate and 21 mg estradiol benzoate in an extended release implant.
   (B) Indications for use. For increased rate of weight gain for up to 200 days.
   (C) Limitations. Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(ii) [Reserved]
§ 522.2483 Triamcinolone.

(a) Specifications. Each milliliter of suspension contains 2 or 6 milligrams (mg) triamcinolone acetonide.

(b) Sponsors. See Nos. 000010 and 054628 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs and cats—(i) Amount—(A) Intramuscular or subcutaneous. For inflammatory, arthritic, or allergic disorders, administer 0.05 to 0.1 mg per pound (lb) of body weight as a single injection. For dermatologic disorders, administer 0.1 mg per pound (lb) of body weight as a single injection. If symptoms recur, the dose may be repeated, or oral corticosteroid therapy may be instituted.

(B) Intralesional. Administer 1.2 to 1.8 mg, divided in several injections around the lesion, spaced 0.5 to 2.5 centimeters apart, depending on lesion size. At any one site, the dose injected should not exceed 0.6 mg and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 mg.

(C) Intra-articular and intrasynovial. Administer 1 to 3 mg as a single injection, depending on the size of the joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased, not to exceed 3 mg.

(ii) Indications for use. For the treatment of inflammation and related disorders.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2582 Triflupromazine.

(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of triflupromazine hydrochloride.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs. Administer by intravenous injection at a dosage of 0.5 to 1 mg per pound of body weight daily, or by intramuscular injection at a dosage of 1 to 2 mg per pound of body weight daily.

(ii) Cats. Administer by intramuscular injection at a dosage of 2 to 4 mg per pound of body weight daily.

(iii) Horses. Administer by intravenous or intramuscular injection at a dosage of 10 to 15 mg per 100 pounds of body weight daily to a maximum dose of 100 mg.

(2) Indications for use. For use in dogs, cats, and horses to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus. The drug is indicated in various office and clinical procedures which require the aid of a tranquilizer, antiemetic, or preanesthetic.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 16197, Mar. 25, 2014]

§ 522.2610 Trimethoprim and sulfadiazine.

(a) Specifications. Each milliliter (mL) contains:

(1) 40 milligrams (mg) trimethoprim suspended in a solution containing 200 mg sulfadiazine; or

(2) 80 mg trimethoprim suspended in a solution containing 400 mg sulfadiazine (as the sodium salt).
Food and Drug Administration, HHS

§ 522.2630 Tulathromycin.

(a) Specifications. Each milliliter of solution contains 20 milligrams (mg) of tulathromycin hydrochloride.

(b) Sponsor. See Nos. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.741 of this chapter.

(d) Conditions of use—(1) Dogs and cats—(i) Amount. Administer 0.5 mg per pound of body weight by intramuscular injection.

(ii) Indications for use. For use in treating conditions in which antibacterial therapy is expected to lead to alleviation of some signs of disease.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Horses—(i) Amount. Administer 0.5 mg per pound of body weight by intramuscular injection.

(ii) Indications for use. For use in treating conditions in which antibacterial therapy is expected to lead to alleviation of some signs of disease.

(iii) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(3) Cattle—(i) Amount. Administer 0.5 mg per pound of body weight by intravenous or intramuscular injection.

(ii) Indications for use. For use in treating conditions in which antibacterial therapy is expected to lead to alleviation of some signs of disease.

(iii) Limitations. Treated cattle must not be slaughtered for food during treatment and for 4 days following the last treatment. Milk that has been taken during treatment and for 24 hours (two milkings) after the last treatment must not be used for food. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(c) Related tolerances. See §556.745 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. 2.5 mg per kilogram (kg) body weight as a single subcutaneous injection in the neck.

(ii) Indications for use—(A) Beef and non-lactating dairy cattle. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. For the control of respiratory disease in cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis. For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.

(B) Suckling calves, dairy calves, and veal calves. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.

(iii) Limitations. (A) Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(B) Calves intended for human consumption must not be slaughtered within 22 days from the last treatment. Not for use in ruminating cattle. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Swine—(1) Amount. 2.5 mg/kg body weight as a single intramuscular injection in the neck.

(ii) Indications for use. For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, P. multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with A. pleuropneumoniae, P. multocida, and M. hyopneumoniae in groups of pigs where SRD has been diagnosed.

(iii) Limitations. Swine intended for human consumption must not be slaughtered within 5 days from the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§522.2640 Tylosin.

(a) Specifications. Each milliliter of solution contains 50 or 200 milligrams of tylosin activity (as tylosin base).

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter for use as in paragraphs (d)(1), (2), and (3) of this section.

(1) No. 000986 for use in paragraphs (d)(1), (2), and (3) of this section.

(2) No. 000010 for use as in paragraphs (d)(1) and (2) of this section.

(c) Related tolerances. See §556.740 of this chapter.

(d) Conditions of use—(1) Beef cattle and nonlactating dairy cattle—(i) Amount. 8 milligrams per pound of body weight once daily.

(ii) Indications for use. Treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Arcanobacterium pyogenes; foot rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Arcanobacterium pyogenes.

(iii) Limitations. Administer intramuscularly for not more than 5 consecutive days. Continue treatment 24 hours after symptoms disappear. Use a 50-milligram-per-milliliter solution for calves weighing less than 200 pounds. Do not inject more than 10 milliliters per site. Do not administer within 21 days of slaughter. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(2) Swine—(i) Amount. 4 milligrams per pound of body weight twice daily.

(ii) Indications for use. Treatment of swine arthritis caused by Mycoplasma
hyosynoviae; swine pneumonia caused by Pasteurella spp.; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.

(iii) Limitations. Administer intramuscularly for not more than 3 consecutive days. Continue treatment 24 hours after symptoms disappear. Do not inject more than 5 milliliters per site. Do not administer within 14 days of slaughter. If tylosin medicated drinking water is used as followup treatment for swine dysentery, the animal should thereafter receive feed containing 40 to 100 grams of tylosin per ton for 2 weeks to assure depletion of tissue residues.

(3) Dogs and cats—(i) Amount. Administer 3 to 5 milligrams per pound of body weight by intramuscular injection at 12- to 24-hour intervals. Use 50 milligram per milliliter solution only.

(ii) Indications for use—(a) Dogs. Treatment of upper respiratory infections such as bronchitis, tracheobronchitis, tracheitis, laryngitis, tonsillitis, and pneumonia caused by Staphylococci spp., hemolytic Streptococci spp., and Pasteurella multocida.

(b) Cats. Treatment of upper respiratory infections caused by Staphylococci spp. and hemolytic Streptococci spp. and for feline pneumonitis caused by tylosin susceptible organisms.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

食物和药物管理署，HHS

§ 522.2662 Xylazine.

(a) Specifications. Each milliliter (mL) of solution contains xylazine hydrochloride equivalent to:

(1) 20 milligrams (mg) xylazine.

(2) 100 mg xylazine.

(3) 300 mg xylazine.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(1) No. 054628 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.

(2) Nos. 000010 and 061623 for use of product described in paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), (d)(3)(ii)(A), and (d)(3)(iii) of this section.

(3) Nos. 000859 and 061651 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1); and product described in paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), (d)(3)(ii)(A), and (d)(3)(iii) of this section.

(4) No. 059399 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section; product described in paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), (d)(3)(ii)(A), and (d)(3)(iii) of this section; and product described in paragraph (a)(3) of this section as in paragraphs (d)(3)(i), (d)(3)(ii)(B), and (d)(3)(iii) of this section.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(1) Horses—(i) Amount. 0.5 mg/pound (lb) intravenously or 1.0 mg/lb subcutaneously.

(ii) Indications for use. To produce sedation, as an analgesic, and as a preanesthetic to local or general anesthesia.

(2) Dogs and cats—(i) Amount. 0.5 mg/lb intravenously or 1.0 mg/lb intramuscularly.

(ii) Indications for use. To produce sedation, as an analgesic, and as a preanesthetic to local or general anesthesia.

(3) Elk and deer—(i) Amount. Administer intramuscularly, by hand syringe, or by syringe dart, in the heavy muscles of the croup or shoulder as follows:

(A) Elk (Cervus canadensis): 0.25 to 0.5 mg/lb.

(B) Mule deer (Odocoileus hemionus), sika deer (Cervus nippon), and white-tailed deer (Odocoileus virginianus): 1 to 2 mg/lb.
§ 522.2670 Yohimbine.

(a) Specifications. Each milliliter (mL) of solution contains 2 or 5 milligrams (mg) of yohimbine (as hydrochloride).

(b) Sponsors. See sponsors in §510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs—(i) Amount. Administer 0.05 mg per pound (0.11 mg per kilogram) of body weight by intravenous injection.

(ii) Indications for use. To reverse the effects of xylazine in dogs.

(iii) Limitations. Not for use in food-producing animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Deer and elk—(i) Amount. Administer 0.2 to 0.3 mg per kilogram of body weight by intravenous injection.

(ii) Indications for use. A s an antagonist to xylazine sedation in free ranging or confined members of the family Cervidae (deer and elk).

(iii) Limitations. Do not use in domestic food-producing animals. Do not use for 30 days before or during hunting season. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 522.2680 Zeranol.

(a) Specifications. Each pellet contains 12, 18, or 20 milligrams (mg) zeranol.

(b) Sponsor. See 000061 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.760 of this chapter.

(d) Conditions of use—(1) Beef cattle—(i) Amount. 36 mg zeranol (one implant consisting of 3 pellets, each pellet containing 12 mg zeranol) per implant dose.

(ii) Indications for use—(A) For increased rate of weight gain and improved feed conversion in weaned beef calves, growing beef cattle, feedlot steers, and feedlot heifers.

(B) For increased rate of weight gain in suckling calves.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in bulls intended for reproduction or in dairy animals. Do not use before 1 month of age or after weaning in heifers intended for reproduction. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(2) Feedlot lambs—(i) Amount. 12 mg zeranol (one implant consisting of 1 pellet containing 12 mg zeranol) per implant dose.

(ii) Indications for use. For increased rate of weight gain and improved feed conversion.

(iii) Limitations. Implant subcutaneously in ear only. Do not use in breeding animals. Do not implant animals within 40 days of slaughter. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(3) Steers fed in confinement for slaughter—
   (i) Amount. 72 mg zeranol (one implant consisting of 6 pellets, each pellet containing 12 mg zeranol) per implant dose.
   (ii) Indications for use. For increased rate of weight gain and improved feed efficiency.
   (iii) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(4) Pasture cattle (slaughter, stocker, feeder steers, and heifers)—
   (i) Amount. 138 mg zeranol (one implant consisting of 7 pellets, each of 6 pellets containing 20 mg zeranol and a seventh pellet containing 18 mg zeranol) per implant dose.
   (ii) Indications for use. For increased rate of weight gain.
   (iii) Limitations. Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

§ 522.2690 Zinc gluconate.
(a) Specifications. Each milliliter of solution contains 13.1 milligrams zinc as zinc gluconate neutralized to pH 7.0 with L-arginine.
(b) Sponsor. See No. 076175 in §510.600(c) of this chapter.
(c) Conditions of use in dogs—
   (1) Amount. The volume injected into each testicle is based on testicular width as determined by measuring each testicle at its widest point using a metric scale (millimeter) caliper.
   (2) Indications for use. Intratesticular injection for chemical sterilization of 3- to 10-month-old male dogs.
   (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

Sec.
524.86 Amitraz.
524.154 Bacitracin, neomycin, and polymyxin B ophthalmic ointment.
524.155 Bacitracin, neomycin, polymyxin B, and hydrocortisone ophthalmic ointment.
524.900 Chloramphenicol ophthalmic ointment.
524.402 Chlorhexidine.
524.450 Clotrimazole.
524.463 Copper naphthenate.
524.575 Cyclosporine ophthalmic ointment.
524.590 Diclofenac.
524.660 Dimethyl sulfoxide.
524.770 Doramectin.
524.775 Emodepside and praziquantel.
524.802 Enrofloxacin and silver sulfadiazine otic emulsion.
524.814 Eprinomectin.
524.900 Famphur.
524.920 Fenthion.
524.916 Fenpyroximate.
524.955 Florfenicol, terbinafine, and betamethasone acetate oint gel.
524.957 Florfenicol, terbinafine, and mometasone otic solution.
524.960 Flumethasone, neomycin, and polymyxin B ophthalmic solution.
524.981 (Reserved)
524.981a Fluocinolone ointment.
524.981b Fluocinolone and betamethasone ointment.
524.981c Fluocinolone and neomycin cream.
524.981d Fluocinolone and dimethyl sulfoxide solution.
524.981e Fluocinolone and dimethyl sulfoxide ointment.
524.1005 Furazolidone powder.
524.104 Gentamicin ophthalmic and topical dosage forms.
524.104a Gentamicin ophthalmic solution.
524.104b Gentamicin and betamethasone ointment.
524.104c Gentamicin ophthalmic ointment.
524.104d Gentamicin and betamethasone ointment.
524.104e Gentamicin spray.
524.104f Gentamicin and betamethasone spray.
524.104g Gentamicin, betamethasone, and clotrimazole ointment.
524.104h Gentamicin, mometasone, and clotrimazole ointment.
524.104i Gentamicin and betamethasone ophthalmic solution.
524.1132 Hydrocortisone, miconazole, and gentamicin ophthalmic suspension.
524.1140 Imidacloprid and ivermectin.
524.1146 Imidacloprid and moxidectin.
524.1193 Ivermectin topical solution.
524.1195 Ivermectin oint.

345
§ 524.86  Amitraz.

(a) Specifications. Amitraz liquid contains 19.9 percent amitraz in an organic solvent.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For dogs for the treatment of generalized demodicosis (Demodex canis).

(2) Amount. One 10.6 milliliter bottle per 2 gallons of warm water (250 parts per million) for each treatment, for a total of 3 to 6 treatments, 14 days apart.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.154 Bacitracin, neomycin, and polymyxin B ophthalmic ointment.

(a) Specifications. Each gram of ointment contains:

1) 500 units bacitracin, 3.5 milligrams (mg) neomycin sulfate (equivalent to 3.5 mg neomycin base), and 10,000 units polymyxin B sulfate.

2) 400 units bacitracin zinc, 5 mg neomycin sulfate (equivalent to 3.5 mg neomycin base), and 10,000 units polymyxin B sulfate.

(b) Sponsors. See sponsor numbers in §510.600(c) of this chapter as follows:

(1) No. 054771 for use of product described in paragraph (a)(1) as in paragraph (c) of this section.

(2) Nos. 000061, 043264, and 059399 for use of product described in paragraph (a)(2) as in paragraph (c) of this section.

(c) Conditions of use in dogs and cats—

1) Amount. Apply a thin film over the cornea 3 or 4 times daily.

2) Indications for use. Treatment of superficial bacterial infections of the eyelid and conjunctiva of dogs and cats when due to susceptible organisms.
§ 524.575 Cyclosporine ophthalmic ointment.

(a) Specifications. Each gram of ointment contains 2 milligrams of cyclosporine.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.
§ 524.590  
(c) Conditions of use—(1) Amount. Apply a ¼-inch strip of ointment directly on the cornea or into the conjunctival sac of the affected eye(s) every 12 hours.

(2) Indications for use. For management of chronic keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.590 Di clofenac.

(a) Specifications. Each gram of cream contains 10 milligrams diclofenac sodium.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Apply a 5-inch (5") ribbon of cream twice daily over the affected joint for up to 10 days and rub thoroughly into the hair covering the joint until it disappears.

(2) Indications for use in horses. For the control of pain and inflammation associated with osteoarthritis in tar-sal, carpal, metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal (hock, knee, fetlock and pastern) joints.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.660 Dimethyl sulfoxide.

(a) Specifications—(1) Each milliliter (mL) of solution contains 90 percent dimethyl sulfoxide and 10 percent water.

(2) Each milliliter (mL) of gel product contains 90 percent dimethyl sulfoxide.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses and dogs—(1) Amount—(1) Horses. Apply topically two to three times daily in an amount not to exceed 100 mL per day. Total duration of therapy should not exceed 30 days.

(2) Dogs. Apply topically three to four times daily in an amount not to exceed 20 mL per day. Total duration of therapy should not exceed 14 days.

(2) Indications for use. To reduce acute swelling due to trauma.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10967, Feb. 27, 2014]

§ 524.770 Doramectin.

(a) Specifications. Each milliliter (mL) of solution contains 5 milligrams (mg) doramectin.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.225 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use in cattle—(1) Amount. Administer topically as a single dose 0.5 mg (1 mL) per kilogram (1 mL per 22 pounds) body weight.

(2) Indications for use. For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults and fourth-stage larvae), Ostertagia ostertagi (inhibited fourth-stage larvae), Ostertagia lyrata (adults), Haemonchus placei (adults and fourth-stage larvae), Trichostrongylus axei (adults and fourth-stage larvae), Trichostrongylus colubriformis (adults and fourth-stage larvae), Cooperia oncophora (adults and fourth-stage larvae), Cooperia pectinata (adults and fourth-stage larvae), Cooperia sarcophora (adults), Cooperia surnabada (adults), Bunostomum phlebotomum (adults), Oesophagostomum radiatum (adults and fourth-stage larvae), Tricharis spp. (adults); lungworms: Dictyocaulus viviparous (adults and fourth-stage larvae); eyeworms: Thelazia gulosae (adults), Thelazia skrjabini (adults); grubs: Hypoderma bovis and Hypoderma lineatum; sucking lice: Linognathus vituli, Haematopinus eurysternus, and Solenopotes capillatus; biting lice: Bovicola (Damalinia) bovis; mange mites: Chorioptes bovis and Sarcoptes scabiei; horn flies: Haematobia irritans; and to control infections and to protect from reinfection with Cooperia oncophora, Dictyocaulus viviparous, Ostertagia ostertagi, and...
§ 510.600(c) of this chapter.

and 10 mg silver sulfadiazine.

contains 5 milligrams (mg) enrofloxacin

§ 524.775 Emodepside and praziquantel.

(ac) Specifications. Each milliliter of solution contains 21.4 milligrams (mg) emodepside and 85.7 mg praziquantel.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.

(c) Conditions of use in cattle—(1) Amount. The recommended minimum dose is 1.36 mg/pound (lb) (3 mg/kilogram (kg)) emodepside and 5.45 mg/lb (12 mg/kg) praziquantel applied as a single topical dose.

(2) Indications for use. For the treatment and control of hookworm infections caused by *Ancylostoma tubaeforme* (adults, immature adults, and fourth stage larvae), roundworm infections caused by *Toxocara cati* (adults and fourth stage larvae), and tapeworm infections caused by *Dipylidium caninum* (adults) and *Taenia taeniaeformis* (adults).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.802 Enrofloxacin and silver sulfadiazine otic emulsion.

(a) Specifications. Each milliliter contains 5 milligrams (mg) enrofloxacin and 10 mg silver sulfadiazine.

(b) Sponsor. See No. 000859 in §510.600(c) of this chapter.
§ 524.900 Famphur.

(a) Specifications. The drug is in liquid form containing 13.2 percent famphur.

(b) Sponsor. See Nos. 000061 and 051311 in §510.600(c) of this chapter.

(c) Special considerations. Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(d) Related tolerances. See §556.273 of this chapter.

(e) Conditions of use—(1) Amount. Apply 1 ounce per 200 pounds body weight, not to exceed a total dosage of 4 ounces, from the shoulder to the tail head as a single treatment. Apply as soon as possible after heel fly activity ceases.

(2) Indications for use in beef and non-lactating dairy cattle. For control of cattle grubs and to reduce cattle lice infestations.

(3) Limitations. Do not slaughter within 35 days after treatment. Do not use on lactating dairy cows or dry dairy cows within 21 days of freshening, calves less than 3 months old, animals stressed from castration, overexcitement or dehorning, sick or convalescent animals. Animals may become dehydrated and under stress following shipment. Do not treat until they are in good condition. Brahman and Brahman crossbreeds are less tolerant of cholinesterase-inhibiting insecticides than other breeds. Do not treat Brahman bulls. Swine should be eliminated from area where runoff occurs.

[76 FR 72619, Nov. 25, 2011]

§ 524.920 Fenthion.

(a) Specifications. (1) The drug is a liquid containing:
   (i) 3 percent of fenthion; or
   (ii) 20 percent fenthion.

(d) Conditions of use—(1) Beef cattle and nonlactating dairy cattle—(i) Amount. It is used at the rate of one-half fluid ounce per 100 pounds of body weight applied topically on the backline of the animal. Only one application per season should be made for grub control and this will also provide initial control of lice. A second application for lice control may be made if animals become reinfested, but no sooner than 35 days after the first treatment. Proper timing of treatment is important for grub control; cattle should be treated as soon as possible after heel-fly activity ceases.

(2) Indications for use. For the control of postoperative pain associated with surgical procedures in dogs.

(3) Limitations. Fentanyl is a Class II controlled substance. Observe all “black-box warnings” on product labeling. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[77 FR 47512, Aug. 9, 2012, as amended at 79 FR 44433, July 24, 2013]
drugs, pesticides, or chemicals. Cattle should not be slaughtered within 35 days following a single treatment. If a second application is made for lice control, cattle should not be slaughtered within 45 days of the second treatment. The drug must not be used within 28 days of freshening of dairy cattle. If freshening should occur within 28 days after treatment, do not use milk as human food for the balance of the 28-day interval. Do not treat lactating dairy cattle; calves less than 3 months old; sick, convalescent, or stressed livestock. Do not treat cattle for 10 days before or after shipping, weaning, dehorning, or after exposure to contagious or infectious diseases.

(2) Beef cattle and dairy cattle not of breeding age—(i) Amount. It is administered as a single, topical application placed on the backline of animals as follows: For animals weighing 150 to 300 pounds, apply 4 milliliters (mL); for animals weighing 301 to 600 pounds, apply 8 mL; for animals weighing 601 to 900 pounds, apply 12 mL; for animals weighing 901 to 1,200 pounds, apply 16 mL; and for animals weighing over 1,200 pounds, apply 20 mL. For most effective results, cattle should be treated as soon as possible after heel-fly activity ceases. A second application is required for animals heavily infested with lice or for those which become reinfested. A second application should be made no sooner than 35 days after the first treatment.

(ii) Indications for use. For control of cattle grubs and as an aid in controlling lice on beef cattle and on dairy cattle not of breeding age.

(iii) Limitations. Do not use on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Host-parasite reactions such as bloat, salivation, staggering and paralysis may sometimes occur when cattle are treated while the common cattle grub (Hypoderma lineatum) is in the gullet, or while the northern cattle grub (H. bovis) is in the area of the spinal cord. Cattle should be treated before these stages of grub development. Consult your veterinarian, extension livestock specialist, or extension entomologist regarding the timing of treatment. If it is impossible to determine the area from which the cattle came and/or exact stage of the grubs, it is recommended that the cattle receive only a maintenance ration of low-energy feed during the treatment period. This lessens the likelihood of severe bloat which may occur in cattle on full feed when the common grub is killed while in the gullet. Do not treat dairy cattle of breeding age; calves less than 3 months old; sick, convalescent, or severely stressed livestock. Do not treat cattle for 10 days before or after shipping, weaning, dehorning, or after exposure to contagious or infectious diseases. Do not slaughter within 45 days of treatment.

(3) Dogs—(i) Amount. Four to 8 milligrams per kilogram of body weight. Apply the contents of the proper size, single-dose tube directly to one spot on the dog’s skin.

(ii) Indications for use. For flea control on dogs only.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(79 FR 10968, Feb. 27, 2014)

§ 524.955 Florfenicol, terbinafine, and betamethasone acetate otic gel.

(a) Specifications. Each milliliter of gel contains 10 milligrams (mg) florfenicol, 10 mg terbinafine, and 1 mg betamethasone acetate.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days.

(2) Indications for use. For the treatment of otitis externa in dogs associated with susceptible strains of bacteria (Staphylococcus pseudintermedius) and yeast (Malassezia pachydermatis).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[80 FR 13230, Mar. 13, 2015]

§ 524.957 Florfenicol, terbinafine, and mometasone otic solution.

(a) Specifications. Each single-dose, prefilled dropperette contains 1 milliliter (mL) of a solution containing 15 milligrams (mg) florfenicol, 13.3 mg terbinafine, and 1 mg mometasone fumerate.
§ 524.960 Flumethasone, neomycin, and polymyxin B ophthalmic solution.

(a) Specifications. Each milliliter of ophthalmic preparation contains 0.10 milligrams flumethasone, 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), and 10,000 units of polymyxin B sulfate, with or without hydroxypropyl methylcellulose.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—

(1) Preparation containing hydroxypropyl methylcellulose. Dogs: 1 to 2 drops per eye, every 6 hours.

(2) Preparation without hydroxypropyl methylcellulose. Dogs and cats: 2 to 3 drops per eye, every 4 hours.

(2) Indications for use. Treatment of the inflammation, edema, and secondary bacterial infections associated with topical ophthalmological conditions of the eye such as corneal injuries, incipient pannus, superficial keratitis, conjunctivitis, acute nongranulomatous anterior uveitis, keratoconjunctivitis, and blepharitis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.961 Fluocinolone solution.

(a) Specifications. The drug contains 0.01 percent fluocinolone acetonide.

(b) Sponsor. See No. 099207 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount—A small amount of solution is applied to the affected area two or three times daily.

(2) Indications for use. For the relief of pruritis and inflammation associated with certain superficial acute and chronic dermatoses.

(3) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.961a Fluocinolone and neomycin cream.

(a) Specifications. The drug contains 0.25 percent fluocinolone acetonide and 0.5 percent neomycin sulfate (0.35 percent neomycin base).

(b) Sponsor. See No. 099207 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—

(1) Amount—A small amount is applied to the affected area two or three times daily.

(2) Indications for use. For the relief of pruritis and inflammation associated with superficial acute and chronic dermatoses.
Food and Drug Administration, HHS

§ 524.1005 Furazolidone powder.

(a) Specifications. The product contains either 4 or 10 percent furazolidone in inert dispersing agent and propel-

(b) Sponsors. (1) See No. 054771 in §510.600(c) of this chapter for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii), and (c)(3) of this section.

(2) See No. 054771 in §510.600(c) of this chapter for use as in paragraph (c)(2)(iv) of this section.

(c) Conditions of use—(1) Amount. Hold container about 6 to 12 inches from the eye or affected area and apply only enough powder to impart a light yellow color.

(2) Indications of use—(i) Dogs. For treatment or prevention of bacterial infection of superficial wounds, abrasions, lacerations, and pyogenic dermatitis.

(ii) Horses. For treatment or prevention of bacterial infection of superficial wounds, abrasions, lacerations, and following firing (heat or electrocautery).

(iii) [Reserved]

(iv) Horses and ponies. For treatment or prevention of bacterial infection of superficial wounds, abrasions, and lacerations caused by Staphylococcus aureus, Streptococcus spp. and Proteus spp. sensitive to furazolidone.

(3) Limitations. For topical application in horses, ponies, and dogs: Clean affected area thoroughly, apply drug once or twice daily, and repeat treatment as required. Use only as recom-

§ 524.981d Fluocinolone and dimethyl sulfoxide solution.

(a) Specifications. Each milliliter of solution contains 0.01 percent fluocinolone acetonide and 20 percent dimethyl sulfoxide.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount—Instill 1 to 2 milliliters into each anal sac following expression of anal sac contents.

(2) Indications for use. For the relief of impaction commonly present in apparently normal anal sacs, for the reversal of inflammatory changes associated with abnormal anal sacs, and to counteract the offensive odor of anal sac se-

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.981e Fluocinolone and dimethyl sulfoxide otic solution.

(a) Specifications. Each milliliter of solution contains 0.01 percent fluocinolone acetonide and 60 percent dimethyl sulfoxide.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount—Instill 4 to 6 drops (0.2 milli-

(2) Indications for use. For the relief of pruritus and inflammation associated with acute and chronic otitis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

353
§ 524.1044 Gentamicin ophthalmic and topical dosage forms.

§ 524.1044a Gentamicin ophthalmic solution.
(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.
(b) Sponsors. See Nos. 000061 and 059399 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—
(1) Amount. Administer 1 or 2 drops into the conjunctival sac 2 to 4 times a day.
(2) Indications for use. For the topical treatment of conjunctivitis caused by susceptible bacteria.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[80 FR 18776, Apr. 8, 2015]

§ 524.1044b Gentamicin and betamethasone otic solution.
(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams (mg) gentamicin base and betamethasone valerate equivalent to 1 mg betamethasone alcohol.
(b) Sponsors. See Nos. 000061 and 054925 in § 510.600(c) of this chapter.
(c) Conditions of use—
(1) Amount—(i) Otis externa. Instill 3 to 8 drops into the ear canal twice daily for 7 days.
(ii) Infected superficial lesions. Apply to cover the treatment area twice daily for 7 to 14 days.
(2) Indications for use. For the treatment of acute and chronic otitis externa and infected superficial lesions caused by bacteria sensitive to gentamicin.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 13542, Mar. 16, 2006]

§ 524.1044c Gentamicin ophthalmic ointment.
(a) Specifications. Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.
(b) Sponsors. See Nos. 000061 and 043264 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs and cats—
(1) Amount. Apply approximately a 1/2-inch strip to the affected eye 2 to 4 times a day.
(2) Indications for use. For treatment of conjunctivitis caused by susceptible bacteria.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1044d Gentamicin and betamethasone ointment.
(a) Specifications. Each gram of ointment contains gentamicin sulfate equivalent to 3 milligrams of gentamicin base and betamethasone valerate equivalent to 1 milligram of betamethasone.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—
(1) Amount—(i) Otitis externa. Instill 3 to 8 drops into the ear canal twice daily for 7 days.
(ii) Infected superficial lesions. Apply to cover the treatment area twice daily for 7 to 14 days.
(2) Indications for use. For the treatment of acute and chronic otitis externa and infected superficial lesions caused by bacteria sensitive to gentamicin.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1044e Gentamicin spray.
(a) Specification. Each milliliter of sterile aqueous solution contains gentamicin sulfate equivalent to 1.07 milligrams of gentamicin.
(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.
(c) Conditions of use in cattle—
(1) Amount. Hold the sprayer upright 3 to 6 inches from the affected eye, with the opening directed towards the eye, and pump once. Treat once daily for up to 3 days.
(2) Indications for use. For the treatment of pinkeye in cattle (infectious
bovine keratoconjunctivitis) caused by Moraxella bovis.

(3) Limitations. Conditions other than bacterial infections of the bovine eye and infectious keratoconjunctivitis caused by Moraxella bovis may produce similar signs. If conditions persist or increases, discontinue use and consult a veterinarian.


§ 524.1044f Gentamicin and betamethasone spray.

(a) Specifications. Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram (mg) gentamicin base and betamethasone valerate equivalent to 0.284 mg betamethasone.

(b) Sponsors. See Nos. 000061, 054925, 058005, 058829, and 065531 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer two spray actuations two to four times daily for 7 days.

(2) Indications for use. For the treatment of infected superficial lesions caused by bacteria susceptible to gentamicin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1044g Gentamicin, betamethasone, and clotrimazole ointment.

(a) Specifications. Each gram (g) of ointment contains gentamicin sulfate equivalent to 3 milligrams (mg) gentamicin base, betamethasone valerate equivalent to 1 mg betamethasone, and 10 mg clotrimazole.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for uses as in paragraph (c) of this section.

(1) No. 000061 for use of 7.5- or 15-gram (g) tubes, 12.5-, 30-, or 215-g bottles.

(2) No. 054925 for use of 7.5- or 15-g tubes; 10-, 15-, 25-, or 215-g bottles.

(3) No. 00593 for use of 10-, 20-, 40-, or 215-g bottles.

(4) No. 025463 for use of 7.5- or 15-g tubes, or 215-g bottles.

(c) Conditions of use in dogs—(1) Amount. Instill ointment twice daily into the ear canal for 7 consecutive days.

(i) From 7.5- or 15-g tubes: 10-, 12.5-, 15-, 25-, or 30-g bottles: 4 drops for dogs weighing less than 30 pounds (lb) or 8 drops for dogs weighing 30 lb or more.

(ii) From 20-, 40-, or 215-g bottles: 2 drops for dogs weighing less than 30 lb or 4 drops for dogs weighing 30 lb or more.

(2) Indications for use. For the treatment of acute and chronic canine otitis externa associated with yeast (Malassezia pachydermatis, formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1044h Gentamicin, mometasone, and clotrimazole otic suspension.

(a) Specifications. Each gram contains gentamicin sulfate, United States Pharmacopeia (USP) equivalent to 3 milligram (mg) gentamicin base, mometasone furoate monohydrate equivalent to 1 mg mometasone, and 10 mg clotrimazole, USP.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. For dogs weighing less than 30 pounds (lb), instill 4 drops from the 7.5-, 15-, or 30-gram (g) bottle into the ear canal (2 drops from the 215-g bottle) or, for dogs weighing 30 lb or more, instill 8 drops from the 7.5-, 15-, or 30-g bottle into the ear canal (4 drops from the 215-g bottle), once or twice daily for 7 days.

(2) Indications for use. For the treatment of otitis externa caused by susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Pseudomonas spp. [including P. aeruginosa]), coagulase-positive.
staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-hemolytic streptococci).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1044i Gentamicin and betamethasone ophthalmic solution.

(a) Specifications. Each milliliter (mL) of solution contains gentamicin sulfate equivalent to 3 milligrams (mg) of gentamicin base and 1 mg betamethasone acetate equivalent to 0.89 mg betamethasone alcohol.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Instill one or two drops of solution in the conjunctival sac three or four times a day.

(2) Indications for use. For treatment of external eye infections and inflammation.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1132 Hydrocortisone, miconazole, and gentamicin otic suspension.

(a) Specifications. Each milliliter (mL) of suspension contains 1.11 milligrams (mg) of hydrocortisone aceponate, 15.1 mg of miconazole nitrate, and 1,505 micrograms of gentamicin sulfate.

(b) Sponsor. See No.051311 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Instill 1.0 mL in the affected ear once daily for 5 days.

(2) Indications for use. For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1140 Imidacloprid and ivermectin.

(a) Specifications. The product is available in unit applicator tubes containing 0.4, 1.0, 2.5, or 4.0 milliliters (mL). Each mL of solution contains 100 milligrams (mg) imidacloprid and 800 micrograms (μg) ivermectin.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Conditions of Use in Dogs—(1) Amount. The recommended minimum dosage is 4.5 mg/pound (lb) (10 mg/kilogram (kg)) of imidacloprid and 96.4 μg/lb (80 μg/kg) of ivermectin, topically once a month.

(2) Indications for Use. For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1146 Imidacloprid and moxidectin.

(a) Specifications—(1) Each milliliter of solution contains 100 milligrams (mg) imidacloprid and 25 mg moxidectin for use as in paragraph (d)(1) of this section.

(2) Each milliliter of solution contains 100 mg imidacloprid and 10 mg moxidectin for use as in paragraphs (d)(2) and (d)(3) of this section.

(b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs—(i) Amount. Topically apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month.

(ii) Indications for use—(A) For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis).

(B) For treatment of Dirofilaria immitis circulating microfilariae in
§ 524.1195 Ivermectin topical solution.

(a) Specifications. Each milliliter (mL) of solution contains 5 milligrams of ivermectin.

(b) Sponsors. See sponsors in §510.600(c) of this chapter for use as in paragraph (e) of this section.

(c) Related tolerances. See §556.344 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

§ 524.1195 Ivermectin otic suspension.

(a) Specifications. Each tube contains 0.5 milliliter (mL) of a 0.01 percent suspension of ivermectin.

(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer the contents of one 0.5-mL tube topically into each external ear canal.

(2) Indications for use. For the treatment of adult ear mite (Otodectes cynotis) infestations in cats and kittens 4 weeks of age and older. Effectiveness against eggs and immature stages has not been proven.
§ 524.1200 Kanamycin ophthalmic and topical dosage forms.

§ 524.1200a Kanamycin ophthalmic ointment.

(a) Specifications. Each gram of ointment contains 3.5 milligrams kanamycin activity as kanamycin sulfate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Apply a thin film to the affected eye three or four times daily or more frequently if deemed advisable. Treatment should be continued for at least 48 hours after the eye appears normal.

(2) Indications for use. For the treatment of various eye infections (conjunctivitis, blepharitis, dacryocystitis, keratitis, and corneal ulcerations) due to bacteria sensitive to kanamycin. For prophylaxis in traumatic conditions, removal of foreign bodies, and intraocular surgery.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10970, Feb. 27, 2014]

§ 524.1200b Kanamycin ophthalmic solution.

(a) Specifications. Each milliliter of solution contains 10 milligrams kanamycin activity as kanamycin sulfate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Instill a few drops into the affected eye every 3 hours or more frequently if deemed advisable. Administer as frequently as possible for the first 48 hours, after which the frequency of applications may be decreased. Treatment should be continued for at least 48 hours after the eye appears normal.

(2) Indications for use. For the treatment of various eye infections (conjunctivitis, blepharitis, dacryocystitis, keratitis, and corneal ulcerations) due to bacteria sensitive to kanamycin. For prophylaxis in traumatic conditions, removal of foreign bodies, and intraocular surgery.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10970, Feb. 27, 2014]

§ 524.1204 Kanamycin, amphomycin, and hydrocortisone ointment.

(a) Specifications. Each gram of ointment contains 5 milligrams kanamycin activity as kanamycin sulfate, 5 milligrams of amphomycin activity as the calcium salt, and 10 milligrams of hydrocortisone acetate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Apply to the affected areas of the skin at least twice daily. In severe or widespread lesions it may be desirable to apply the ointment more than twice daily. After some improvement is observed, treatment can usually be reduced to once daily.

(2) Indications for use. For the treatment of acute otitis externa, furunculosis, folliculitis, pruritus, anal gland infections, erythema, decubital ulcers, superficial wounds, and superficial abscesses associated with bacterial infections caused by organisms susceptible to one or both antibiotics.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10970, Feb. 27, 2014]

§ 524.1240 Levamisole.

(a) Specifications. The drug contains 200 milligrams of levamisole per milliliter of diethylene glycol monobutyl ether (DGME) solution.

(b) Sponsors. See Nos. 000061 and 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.350 of this chapter.

(d) Conditions of use. Cattle—(1) Amount. 2.5 milliliters per 110 pounds (10 milligrams of levamisole per kilogram) of body weight as a single dose topically to the back of the animal.

(2) Indications for use. Anthelmintic effective against stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms
Food and Drug Administration, HHS § 524.1446

(Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia), and lungworms (Dictyocaulus).

(3) Limitations. Conditions of constant helminth exposure may require retreatment within 2 to 4 weeks after the first treatment. Cattle must not be slaughtered within 9 days following last treatment. Do not administer to dairy animals of breeding age. Do not treat animals before dipping or prior to exposure to heavy rain. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism, and before using in severely debilitated animals.


§ 524.1376 2-Mercaptobenzothiazole solution.

(a) Specifications. The drug contains 1.3 percent 2-mercaptobenzothiazole in a suitable solvent.

(b) Sponsor. See 017135 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply twice daily to affected area.

(2) Indications for use. For dogs as an aid in the treatment of hot spots (moist dermatitis) and as first aid for scrapes and abrasions.

(3) Limitations. Clip hair from affected area before applying. If no improvement is seen within 1 week, consult a veterinarian.


§ 524.1443 Miconazole.

(a) Specifications—(1) Each gram of cream contains miconazole nitrate equivalent to 20 milligrams miconazole base.

(2) Each gram of lotion or spray contains miconazole nitrate equivalent to 1 percent miconazole base.

(b) Sponsors. See § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) No. 000061 for use of cream, lotion, and spray.

(2) Nos. 054925 and 058829 for use of lotion and spray.

(c) Conditions of use in dogs and cats—(1) Amount. Apply once daily by rubbing into or spraying a light covering on the infected site and the immediate surrounding vicinity. Continue treatment for 2 to 4 weeks until infection is completely eradicated as determined by appropriate laboratory examination.

(2) Indications for use. For topical treatment of infections caused by Microsporum canis, Microsporum gypseum, and Trichophyton mentagrophytes.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[71 FR 13542, Mar. 16, 2006]

§ 524.1445 Miconazole, polymixin B, and prednisolone suspension.

(a) Specifications. Each milliliter of suspension contains 23 milligrams (mg) miconazole nitrate, 0.5293 mg polymixin B sulfate, and 5 mg prednisolone acetate.

(b) Sponsor. See No. 000986 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Instill five drops in the ear canal twice daily for 7 consecutive days.

(2) Indications for use. For the treatment of canine otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 524.1446 Milbemycin otic solution.

(a) Specifications. Each tube contains 0.25 millimeter of suspension contains 0.1 percent solution of milbemycin oxime.

(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. One tube administered topically into each external ear canal.

(2) Indications for use. For the treatment of ear mite (Otodectes cynotis) infestations in cats and kittens 4 weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.
§ 524.1450 Moxidectin.

(a) Specifications. Each milliliter of solution contains:

(1) 5 milligrams (mg) moxidectin (0.5 percent solution).

(2) 25 mg moxidectin (2.5 percent solution).

(b) Sponsors. See sponsor numbers in §510.600 of this chapter:

(1) No. 000010 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section;

(2) No. 000859 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section;

(c) Related tolerances. See §556.426 of this chapter.

(d) Conditions of use—(1) Cattle—(i) Amount. Administer topically 0.5 mg per kilogram (kg) of body weight.

(ii) Indications for use. Beef and dairy cattle: For treatment and control of internal and external parasites; gastrointestinal roundworms (Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult and L4), C. punctata (adult and L4), C. spatulata (adult), C. surinabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)), lungworms (Dictyocaulus viviparus (adult and L4)); cattle grubs (Hypoderma bovis, H. lineatum); mites (Choriotes bovis, Psoroptes ovis (P. communis var. bovis)); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, Bovicola (Damalina) bovis); and horn flies (Haematobia irritans). To control infestations and to protect from reinfestation with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparos for 42 days after treatment.

(iii) Limitations. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal. See §500.25 of this chapter.

(2) Dogs—(i) Amount. Administer topically a minimum of 1.1 mg per pound (lb) (2.5 mg/kg) of body weight, once monthly using the appropriate pre-loaded applicator tube.

(ii) Indications for use. For the prevention of heartworm disease caused by Dirofilaria immitis, as well as the treatment and control of intestinal hookworm (Ancylostoma caninum (adult, immature adult, and L4 larvae) and Uncinia stenocephala (adult, immature adult, and L4 larvae)), roundworm (Toxocara canis (adult and L4 larvae) and Toxascaris leonina (adult)), and whipworm (Trichuris vulpis (adult)) infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

equivalent to 3.5 milligrams of neomycin base, 1 milligram of isoflupredone acetate, 5 milligrams of tetracaine hydrochloride and 2 milligrams of myristyl-gamma-picolinium chloride in each gram of the product in a special adherent powder base.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses, dogs, and cats—(1) Amount. Apply to affected areas as a dusting powder.

(2) Indications for use. For the treatment or as adjunctive therapy of certain ear and skin conditions caused by or associated with neomycin-susceptible organisms and/or allergy; as a superficial dressing applied to minor cuts, wounds, lacerations, abrasions, and for postsurgical application where reduction of pain and inflammatory response is deemed desirable; as a dusting powder following amputation of tails, claws, and dewclaws and following ear trimming, castrating, and such surgical procedures as ovariohysterectomies. For the treatment of acute otitis externa, acute moist dermatitis, and interdigital dermatitis in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978; 79 FR 10970, Feb. 27, 2014]

§ 524.1484d Neomycin, hydrocortisone, and tetracaine otic ointment.

(a) Specifications. The product contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, 5 milligrams of hydrocortisone acetate, and 5 milligrams of tetracaine hydrochloride in each gram of ointment.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—(1) Amount. Instill a quantity of ointment sufficient to fill the external ear canal; may be applied one to three times daily.

(2) Indications for use. For the treatment of ear canker and other inflammatory conditions of the external ear canal, acute otitis externa and, to a lesser degree, chronic otitis externa.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 49 FR 21922, May 24, 1984; 79 FR 10970, Feb. 27, 2014]

§ 524.1484e Neomycin and polymyxin B ophthalmic solution.

(a) Specifications. Each milliliter of the ophthalmic preparation contains 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), and 10,000 Units of polymyxin B sulfate.
§ 524.1484f Neomycin, prednisolone, and tetracaine otic suspension.

(a) Specifications. The product contains 5 milligrams of neomycin sulfate equivalent to 3.5 milligrams of neomycin base, 2.5 milligrams of prednisolone acetate, and 5 milligrams of tetracaine hydrochloride in each milliliter of sterile suspension.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. Instill 2 to 6 drops in the external ear canal 2 or 3 times daily.

(2) Indications for use. For the treatment of acute otitis externa and, to a lesser degree, chronic otitis externa; as treatment or adjunctive therapy of certain ear conditions caused by or associated with neomycin-susceptible organisms and/or allergy.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 79 FR 10971, Feb. 27, 2014]

§ 524.1484g Neomycin, thiabendazole, and dexamethasone solution.

(a) Specifications. Each milliliter of solution contains 40 milligrams (mg) thiabendazole, 3.2 mg neomycin (from neomycin sulfate), and 1 mg dexamethasone.

(b) Sponsors. See Nos. 026637 and 050604 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. In treating dermatoses affecting areas other than the ear, the surface of the lesions should be well moistened (2 to 4 drops per square inch) twice daily. In treating otitis externa, instill 5 to 15 drops in the ear twice daily. Treat for up to 7 days.

(2) Indications for use. As an aid in the treatment of bacterial, mycotic, and inflammatory dermatoses and otitis externa.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1484i Neomycin and hydrocortisone ointment.

(a) Specifications. The drug contains 5 milligrams of neomycin sulfate, equivalent to 3.5 milligrams of neomycin base, and 5 milligrams of hydrocortisone acetate in each gram of ointment.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. Apply 3 or 4 times daily into the conjunctival sac. With improvement, frequency may be reduced to 2 or 3 times daily. For treatment of ear canker and other inflammatory conditions of the external ear canal, fill external ear canal 1 to 3 times daily.

(2) Indications for use. For the treatment of infections, allergic and traumatic keratitis, conjunctivitis, acute otitis externa and, to a lesser degree, chronic otitis externa.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1484j Neomycin and prednisolone ophthalmic ointment.

(a) Specifications. Each gram of ointment contains prednisolone sodium phosphate equivalent to 2.5 milligrams prednisolone 21-phosphate and 5 milligrams neomycin sulfate equivalent to 3.5 milligrams neomycin base.

(b) Sponsor. See No. 050694 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. A small quantity of the ointment should be expressed into the conjunctival sac 4 times a day (at intervals of 1 to 8 hours) for a few days until there is a favorable response, then the frequency of application may be reduced to twice daily as long as the condition remains under control. Treatment may require from a few days to several weeks.

(2) Indications for use. For use in superficial ocular inflammations or infections limited to the conjunctiva or the anterior segment of the eye, such as those associated with allergic reactions or gross irritants.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1484k Prednisolone and neomycin suspension.

(a) Specifications. Each milliliter of suspension contains 2.5 milligrams of prednisolone acetate and 5 milligrams of neomycin sulfate equivalent to 3.5 milligrams of neomycin base.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. For beginning treatment of acute ocular inflammations place 1 or 2 drops in the conjunctival sac 3 to 6 times during a 24 hour period. When improvement occurs, reduce the dosage to 1 drop 2 to 4 times daily. For otitis externa, place 2 to 6 drops in the external ear canal 2 or 3 times daily.

(2) Indications for use. For the treatment of treating infectious, allergic and traumatic keratitis and conjunctivitis, acute otitis externa, and chronic otitis externa.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
§ 524.1580b Nitrofurazone soluble powder.

(a) Specifications. The drug contains 0.2 percent nitrofurazone in a water-soluble base.

(b) Sponsor. See No. 054628 and 059051 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount.

(i) For topical dermatological use: Clean affected areas and remove any encrusted discharge or exudate, and apply sparingly either ointment or an aqueous solution to the lesion with a sterile swab or applicator. For otic use: Clean ear canal of impacted cerumen, remove any foreign bodies such as grass awns and ticks, and instill three to five drops of nitrofurazone soluble powder on a piece of gauze. Use of a bandage is optional. The preparation should remain on the lesion for at least 24 hours. The dressing may be changed several times daily or left on the lesion for a longer period. For use only on dogs, cats, and horses (not for food use). In case of deep or puncture wounds or serious burns, use only as recommended by a veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian.

(2) Indications for use. For prevention or treatment of surface bacterial infections of ears, wounds, burns, and cutaneous ulcers of dogs, cats, and horses.

(iii) For infected anal glands and cystic areas: Drain gland or cyst and fill with petrolatum base ointment.

(2) Indications for use. (i) Topically: Use either ointment in dogs and cats for anti-inflammatory, antipruritic, antifungal, and antibacterial treatment of superficial bacterial infections, and for dermatologic disorders characterized by inflammation and dry or exudative dermatitis, particularly associated with bacterial or candidal (Candida albicans) infections.

(ii) Otitis, cysts, and anal gland infections: Use petrolatum base ointment in dogs and cats for the treatment of acute and chronic otitis and interdigital cysts, and in dogs for anal gland infections.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1600b Nystatin, neomycin, thiostrepton, and triamcinolone ophthalmic ointment.

(a) Specifications. Each cubic centimeter of ointment contains: 100,000 units of nystatin, neomycin sulfate equivalent to 2.5 milligrams of neomycin base, 2,500 units of thiostrepton, and 1.0 milligram of triamcinolone acetonide.

(b) Sponsor. See No. 053501 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Dogs and cats—(i) Amount. Apply 1 drop of ointment to the affected eye(s) 2 or 3 times daily. Treatment may be continued for up to 2 weeks if necessary.

(ii) Indications for use. For use as an anti-inflammatory, antipruritic, antifungal (Candida albicans), and antibacterial ointment for local therapy in keratitis and conjunctivitis.

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) Cattle—(i) Amount. Apply small line of ointment to the affected eye(s) once daily. Treatment may be continued for up to 2 weeks if necessary.

(ii) Indications for use. For infectious kerato-conjunctivitis (pinkeye).

(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1610 Orbifloxacin, mometasone furoate monohydrate, and posaconazole suspension.

(a) Specifications. Each gram of suspension contains 10 milligrams (mg) orbifloxacin, mometasone furoate monohydrate equivalent to 1 mg mometasone furoate, and 1 mg posaconazole.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. For dogs weighing less than 30 lbs. instill 4 drops once daily into the ear canal. For dogs weighing 30 lbs. or more, instill 8 drops into the ear canal. Therapy should continue for 7 consecutive days.

(2) Indications for use. For the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase-positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 524.1662 Oxytetracycline ophthalmic and topical dosage forms.

§ 524.1662a Oxytetracycline and hydrocortisone spray.

(a) Specifications. Each 3-ounce unit of oxytetracycline hydrochloride and hydrocortisone spray contains 300 milligrams of oxytetracycline hydrochloride and 180 milligrams of hydrocortisone with an inert freon propellant such that a 1-second spray treatment will deliver approximately 2.5 milligrams of oxytetracycline hydrochloride and 0.8 milligram of hydrocortisone.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
§524.1662b  Oxytetracycline and polymyxin B ophthalmic ointment.

(a) Specifications. Each gram of the ointment contains oxytetracycline hydrochloride equivalent to 5 milligrams of oxytetracycline and 10,000 units of polymyxin B sulfate.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Indications for use. For the relief of many allergic, infectious, and traumatic skin conditions; for the prevention of bacterial infections in superficial wounds, cuts, and abrasions, treatment of allergic dermatoses, including urticaria, eczemas, insect bites, and cutaneous drug reactions, infections associated with minor burns and wounds, and nonspecific pruritus.

(2) Limitations. Keep away from eyes or other mucous membranes; avoid inhaling; use with adequate ventilation; in case of deep or puncture wounds or serious burns, consult a veterinarian.

§524.1742  N-(Mercaptomethyl) phthalimide S-(O,O-dimethyl phosphorodithioate) emulsifiable liquid.

(a) Specifications. The emulsifiable liquid contains 11.6 percent N-(mercaptopethyl) phthalimide S-(O,O-dimethyl phosphorodithioate).

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Methods of application. Methods of application to control the following conditions on beef cattle:

<table>
<thead>
<tr>
<th>Condition</th>
<th>To control/method of use</th>
<th>Dilution rate (gal. drug: gal. of water)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grubs</td>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td></td>
<td>Pour-on</td>
<td>1:2</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49</td>
</tr>
<tr>
<td>Lice</td>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td></td>
<td>Pour-on</td>
<td>1:2 or 1:5</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49 or 1:100</td>
</tr>
<tr>
<td>Hornflies</td>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49 or 1:100</td>
</tr>
<tr>
<td>Cattle Ticks</td>
<td>Dip</td>
<td>1:60 or 1:240</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49 or 1:100</td>
</tr>
<tr>
<td>Southern cattle ticks</td>
<td>Dip</td>
<td>1:60 or 1:240</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49</td>
</tr>
<tr>
<td>Scabies mites:</td>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49 or 1:100</td>
</tr>
<tr>
<td>Lone Star Ticks</td>
<td>Dip</td>
<td>1:60</td>
</tr>
<tr>
<td></td>
<td>Spray</td>
<td>1:49 or 1:100</td>
</tr>
</tbody>
</table>

(i) Dip vat procedure. (a) Prior to charging vat, empty old contents and thoroughly clean the vat. Dip vats should be calibrated to maintain an accurate dilution. Add water, then drug to the vat according to the dilution
rate indicated in the table. Add super phosphate at a rate of 100 pounds per 1,000 gallons of vat solution. Super phosphate is added to control the pH of the solution and ensure vat stability. Super phosphate is usually available at most fertilizer dealers as 0–45–0 or 0–46–0. Stir the dip thoroughly, preferably with a compressed air device; however, any form of thorough mixing is adequate. Re-stir vat contents prior to each use. During the dipping operation, each time the dip’s volume is reduced by \( \frac{1}{8} \) to \( \frac{1}{4} \) of its initial volume, replenish with water and add the drug at a rate of 1 gallon for each 50 or 200 gallons water added—depending on dilution rate 1:60 or 1:240. Also add super phosphate as necessary to maintain pH between 4.5 and 6.5. Stir well and resume dipping. Repeat replenishment process as necessary. For evaporation, add additional water accordingly. For added water due to rainfall, merely replenish dip with the product according to directions. If overflow occurs, either analyze for drug concentration and adjust accordingly or dispose of vat contents and recharge. Check pH after each addition of water or super phosphate to assure proper pH controls.

(b) Dip maintenance. (1) With use of dip vat tester, dipping may continue as long as the drug concentration is maintained between 0.15 and 0.25 percent, and the dip is not too foul for satisfactory use as indicated by foul odor or excessive darkening (i.e., color changes from beige to very dark brown). (2) Without use of dip vat tester, vat should be emptied, cleaned, and recharged each time one of the following occurs: When the dip has been charged for 120 days; when the dip becomes too foul for satisfactory use, within the 120-day limit; if the number of animals dipped equals twice the number of gallons of the initial dip volume, within the 120-day limit.

(ii) Spray method. To prepare the spray, mix drug with water according to table and stir thoroughly. Apply the fresh mixture as a high-pressure spray, taking care to wet the skin, not just the hair. Apply to the point of “run-off,” about 1 gallon of diluted spray per adult animal. Lesser amounts will permit runoff for younger animals.

(iii) Pour-on method. Dilute the drug with water according to table by slowly adding water to the product while stirring. Apply 1 ounce of the diluted mixture per 100 pounds of body weight (to a maximum of 8 ounces per head) down the center line of the back.

(2) Timing of applications for cattle grub control. For optimum cattle grub control, it is important to treat as soon as possible after the heel fly season, before the grub larvae reach the gullet or spinal canal, as the rapid kill of large numbers of larvae in these tissues may cause toxic side effects, such as bloat, salivation, staggering, and paralysis.

(3) Treatment regimens. (1) Control of scabies mites requires two treatments, 10 to 14 days apart. (ii) Control of Lone Star Ticks and hornflies requires two treatments, 7 days apart.

(4) Warnings. The drug is a cholinesterase inhibitor. Do not use this drug on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. Do not apply within 21 days of slaughter. For use on beef cattle only. Do not treat sick, convalescent, or stressed cattle, or calves less than 3 months old except in Federal or State eradication programs where immediate treatment of all animals in an infested herd is mandatory. Be sure free access to drinking water is available to cattle prior to dipping. Do not dip excessively thirsty animals. Do not dip animals when overheated. Repeat treatment as necessary but not more often than every 7 to 10 days. Treatment for lice, ticks, hornflies, and scabies mites may be made any time of the year except when cattle grub larvae are in the gullet or spinal canal. Treatment for lice, ticks, and scabies mites may be made any time 7 to 10 days following treatment for grubs. Do not treat grubs when the grub larvae are in the gullet or spinal canal. Do not get in eyes, on skin, or on clothing. Do not breathe spray mist. Wear rubber gloves, goggles, and protective clothing. In case of skin contact, wash immediately with soap and water; for eyes, flush with water. Wash all contaminated clothing with soap and hot water before re-use.
§ 524.1982 Proparacaine ophthalmic solution.

(a) Specifications. The drug is an aqueous solution containing 0.5 percent proparacaine hydrochloride, 2.45 percent glycerin as a stabilizer, and 0.2 percent chlorobutanol (choral derivative) and 1:10,000 benzalkonium chloride as preservatives.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs and cats—

(1) Amount. It is administered as follows:
   (i) For removal of sutures: Instill one to two drops 2 or 3 minutes before removal of stitches.
   (ii) For removal of foreign bodies from eye, ear, and nose: For ophthalmic use, instill three to five drops in the eye prior to examination; for otic use, instill five to ten drops in the ear; for nasal use, instill five to ten drops in each nostril every 3 minutes for three doses.
   (iii) For tonometry: Instill one to two drops immediately before measurement.
   (iv) As an aid in treatment of otitis: Instill two drops into the ear every 5 minutes for three doses.
   (v) For minor surgery: Instill one or more drops as required.
   (vi) For catheterization: Instill two to three drops with a blunt 20-gauge needle immediately before inserting catheter.

(2) Indications for use. For use as a topical ophthalmic anesthetic. It is used as an anesthetic in cauterization of corneal ulcers, removal of foreign bodies and sutures from the cornea, and measurement of intraocular pressure (tonometry) when glaucoma is suspected. Local applications may also be used as an aid in the removal of foreign bodies from the nose and ear canal, as an accessory in the examination and treatment of painful otitis, in minor surgery, and prior to catheterization.

(3) Limitations. Keep away from eyes or other mucous membranes; avoid inhaling; use with adequate ventilation; in case of deep or puncture wounds or serious burns, consult a veterinarian.

(d) Conditions of use. (1) The drug is indicated for use as a topical ophthalmic anesthetic in animals. It is used as an anesthetic in cauterization of corneal ulcers, removal of foreign bodies and sutures from the cornea, and measurement of intraocular pressure (tonometry) when glaucoma is suspected. Local applications may also be used as an aid in the removal of foreign bodies from the nose and ear canal, as an accessory in the examination and treatment of painful otitis, in minor surgery, and prior to catheterization.

(2) It is administered as follows:
   (i) For removal of sutures: Instill one to two drops 2 or 3 minutes before removal of stitches.
   (ii) For removal of foreign bodies from eye, ear, and nose: For ophthalmic use, instill three to five drops in the eye prior to examination; for otic use, instill five to 10 drops in the ear; for nasal use, instill five to 10 drops in each nostril every 3 minutes for three doses.
   (iii) For tonometry: Instill one to two drops immediately before measurement.
   (iv) As an aid in treatment of otitis: Instill two drops into the ear every 5 minutes for three doses.
   (v) For minor surgery: Instill one or more drops as required.
   (vi) For catheterization: Instill two to three drops with a blunt 20-gauge needle immediately before inserting catheter.

(3) For use only by or on the order of a licensed veterinarian.

§ 524.2098 Selamectin.

(a) Specifications. Each milliliter contains 60 or 120 milligrams of selamectin.

(b) Sponsor. See 054771 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use—(1) Amount. 2.7 milligrams of selamectin, topically,
Food and Drug Administration, HHS

§ 524.2482 Triamcinolone spray.

(a) Specifications. Each milliliter of solution contains 0.15 milligrams triamcinolone acetonide.

(b) Sponsor. See No. 051311 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Apply sufficient pump sprays to uniformly and thoroughly wet the affected areas while avoiding run off of excess product. Administer twice daily for 7 days, then once daily for 7 days, then every other day for an additional 14 days (28 days total).

(2) Indications for use. For the control of pruritus associated with allergic dermatitis.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[78 FR 17868, Mar. 25, 2013]

§ 524.2483 Triamcinolone cream.

(a) Specifications. The vanishing cream contains 0.1 percent triamcinolone acetonide.

(b) Sponsor. See Nos. 000010 and 054925 in §510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Rub into affected areas two to four times daily for 4 to 10 days.

(2) Indications for use. For topical treatment of allergic dermatitis and summer eczema.
§ 524.2620  Liquid crystalline trypsin, Peru balsam, castor oil.

(a) Specifications—(1) Each gram of liquid or aerosol contains 0.12 milligram of crystalline trypsin, 87.0 milligrams of Peru balsam, and 788.0 milligrams of castor oil.

(2) Each gram of liquid or aerosol contains 0.1 milligram of crystalline trypsin, 72.5 milligrams of Peru balsam, and 800 milligrams of castor oil.

(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (c) in this section:

(1) No. 051079 for use of product described in paragraph (a)(1).

(2) No. 017135 for use of product described in paragraph (a)(2).

(c) Conditions of use—(1) Amount. Apply directly to the wound site.

(2) Indications for use. As an aid in the treatment of external wounds and assists healing by facilitating the removal of necrotic tissue, exudate, and organic debris.

§ 526.88 Amoxicillin trihydrate for intramammary infusion.

(a) Specifications. Each single dose syringe contains amoxicillin trihydrate equivalent to 62.5 milligrams of amoxicillin.

(b) Sponsor. See No. 000061 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.38 of this chapter.

(d) Conditions of use—Lactating cows—(1) Amount. One syringe (equivalent to 62.5 milligrams amoxicillin) per quarter.

(2) Indications for use. For the treatment of subclinical infectious bovine mastitis due to Streptococcus agalactiae and Staphylococcus aureus (penicillin sensitive).

(3) Limitations. Administer after milking. Clean and disinfect the teat. Use one syringe per infected quarter every 12 hours for a maximum of 3 doses. Do not use milk taken from treated animals for food purposes within 60 hours (5 milkings) after last treatment. Do not slaughter treated animals for food purposes within 12 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10973, Feb. 27, 2014]
(ii) Indications for use. For use in lactating dairy cattle:
(A) For the treatment of clinical mastitis associated with coagulase-negative staphylococci, *Streptococcus dysgalactiae*, and *Escherichia coli*; and
(B) For the treatment of diagnosed subclinical mastitis associated with coagulase-negative staphylococci and *S. dysgalactiae*.

(iii) Limitations. Milk taken from cows during treatment (a maximum of eight daily infusions) and for 72 hours after the last treatment must not be used for human consumption. Following label use for up to 8 consecutive days, a 2-day preslaughter withdrawal period is required. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in lactating dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species-production classes.

(2) Dry cows—(i) Amount. Infuse 500 mg per affected quarter at the time of dry off.

(ii) Indications for use. For the treatment of subclinical mastitis in dairy cattle at the time of dry off associated with *Staphylococcus aureus*, *Streptococcus dysgalactiae*, and *Streptococcus uberis*.

(iii) Limitations. Milk taken from cows completing a 30-day dry-off period may be used for food with no milk discard due to ceftiofur residues. Following intramammary infusion, a 16-day preslaughter withdrawal period is required for treated cows. Following label use, no preslaughter withdrawal period is required for neonatal calves from treated cows regardless of colostrum consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in dry dairy cattle for disease prevention purposes; at unapproved doses; frequencies, durations, or routes of administration; and in unapproved major food producing species-production classes.

§ 526.363 Cephapirin benzathine.

(a) Specifications. Each 10 milliliter disposable syringe contains 300 milligrams of cephapirin activity (as cephapirin benzathine) in a peanut-oil gel.
(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.115 of this chapter.

(2) Conditions of use—(1) Amount. Infuse the contents of one syringe into each quarter.

(2) Indications for use. Use in dry cows for treatment of mastitis caused by susceptible strains of *Streptococcus agalactiae* and *Staphylococcus aureus*, including penicillin-resistant strains.

(3) Limitations. Infuse each quarter following last milking, but no later than 30 days before calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Animals infused with this product must not be slaughtered for food until 42 days after the latest infusion. For use in dry cows only.

§ 526.365 Cephapirin sodium.

(a) Specifications. Each 10-milliliter dose contains 200 milligrams of cephapirin sodium activity in a peanut-oil gel.
(b) Sponsor. See No. 000010 in §510.600(c) of this chapter.
(c) Related tolerances. See §556.115 of this chapter.

(d) Conditions of use in lactating cows—(1) Amount. Infuse one dose into each infected quarter immediately after the quarter has been completely milked out. Do not milk out for 12 hours. Repeat once only in 12 hours.

(2) Indications for use. For the treatment of mastitis in lactating cows caused by susceptible strains of *Streptococcus agalactiae* and *Staphylococcus*
§ 526.464 Cloxacillin intramammary dosage forms.

§ 526.464a Cloxacillin benzathine.

(a) Specifications. Each dose contains cloxacillin benzathine equivalent to 500 milligrams of cloxacillin.

(b) Related tolerances. See §556.165 of this chapter.

(c) Sponsor. See No. 000010 in §510.600(c) of this chapter.

(1) Amount. Administer aseptically into each quarter immediately after last milking.

(2) Indications for use. For the treatment of mastitis caused by Staphylococcus aureus and Streptococcus agalactiae including penicillin resistant strains in dairy cows during the dry period.

(3) Limitations. For use in dry cows only. Not to be used within 30 days of calving. Animals infused with this product must not be slaughtered for food from the time of infusion until 72 hours after calving. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 526.464b Cloxacillin benzathine for intramammary infusion, sterile.

(a) Specifications. Each 6 milliliter dose contains cloxacillin benzathine equivalent to 500 milligrams of cloxacillin.

(b) Related tolerances. See §556.165 of this chapter.

(c) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(1) Amount. One dose per infected quarter immediately after last milking.

(2) Indications for use. Treatment and prophylaxis of bovine mastitis in non-lactating cows due to Streptococcus agalactiae and Staphylococcus aureus.

(3) Limitations. For use in dry cows only. Not to be used within 4 weeks (28 days) of calving. Animals infused with this product must not be slaughtered for food for 4 weeks (28 days) after the latest infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 526.464c Cloxacillin sodium for intramammary infusion, sterile.

(a) Specifications. Each milliliter contains cloxacillin sodium equivalent to 20.0 milligrams of cloxacillin.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.165 of this chapter.

(d) Conditions of use. Lactating cows—

(1) Amount. 10 milliliters (one dose of 200 milligrams) per infected quarter.

(2) Indications for use. Treatment of mastitis in lactating cows due to Streptococcus agalactiae and Staphylococcus aureus including strains resistant to penicillin.

(3) Limitations. If improvement is not noted within 48 hours after treatment, consult your veterinarian. Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food. Treated animals must not be slaughtered for food until 4 days after the last treatment.


§ 526.464b Cloxacillin benzathine for intramammary infusion, sterile.

(a) Specifications. Each milliliter contains cloxacillin benzathine equivalent to 500 milligrams of cloxacillin.

(b) Related tolerances. See §556.165 of this chapter.

(c) Sponsor. See No. 055529 in §510.600(c) of this chapter.

(1) Amount. 6 milliliters per infected quarter aseptically immediately after last milking at the time of drying-off of the cow.

(2) Indications for use. Treatment of mastitis caused by Staphylococcus aureus and Streptococcus agalactiae in dairy cows at the time of drying-off of the cow.

(3) Limitations. For use in dry cows only. Not to be used within 30 days of calving. Milk taken from treated cows prior to 72 hours (6 milkings) after calving must not be used for human food. Animals infused with this product must not be slaughtered for food from the time of infusion until 72 hours after calving. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(1) Amount. One dose per infected quarter immediately after last milking.

(2) Indications for use. Treatment and prophylaxis of bovine mastitis in non-lactating cows due to Streptococcus agalactiae and Staphylococcus aureus.

(3) Limitations. For use in dry cows only. Not to be used within 30 days of calving. Milk taken from treated cows prior to 72 hours (6 milkings) after calving must not be used for food. Treated animals must not be slaughtered for food until 4 days after the last treatment.

§ 526.464c Cloxacillin sodium for intramammary infusion, sterile.

(a) Specifications. Each milliliter contains cloxacillin sodium equivalent to 20.0 milligrams of cloxacillin.

(b) Sponsor. See No. 000061 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.165 of this chapter.

(d) Conditions of use. Lactating cows—

(1) Amount. 10 milliliters (one dose of 200 milligrams) per infected quarter.

(2) Indications for use. Treatment of mastitis in lactating cows due to Streptococcus agalactiae and Staphylococcus aureus including strains resistant to penicillin.

(3) Limitations. If improvement is not noted within 48 hours after treatment, consult your veterinarian. Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food. Treated animals must not be slaughtered for food until 4 days after the last treatment.

aureus, nonpenicillinase-producing strains.

(3) **Limitations.** Administer after milking, cleaning, and disinfecting, and as early as possible after detection. Treatment should be repeated at 12-hour intervals for a total of three doses. Milk taken from treated animals within 48 hours (four milkings) after the latest treatment should not be used for food. Treated animals should not be slaughtered for food within 10 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 526.1130 Hetacillin infusion.

(a) **Specifications.** Each 10 milliliter syringe contains hetacillin potassium equivalent of 62.5 milligrams of ampicillin.

(b) **Sponsor.** See No. 000010 in § 510.600(c) of this chapter.

(c) **Conditions of use.** Lactating cows—

(1) **Amount.** 10 milliliters of hetacillin potassium equivalent to 62.5 milligrams ampicillin into each infected quarter. Repeat at 24-hour intervals until a maximum of three treatments has been given.

(2) **Indications for use.** Treating acute, chronic, or subclinical bovine mastitis in lactating cows caused by susceptible strains of *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Staphylococcus aureus*, and *Escherichia coli*.

(3) **Limitations.** Milk that has been taken from animals during treatment and for 72 hours (6 milkings) after the latest treatment must not be used for food. Treated animals must not be slaughtered for food until 10 days after the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 75 FR 10168, Mar. 5, 2010]

§ 526.1590 Novobiocin infusion.

(a) **Specifications.** Each 10 milliliters of oil suspension contains the equivalent of 400 milligrams of novobiocin (present as sodium novobiocin).

(b) **Sponsor.** See No. 054771 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.460 of this chapter.

(d) **Conditions of use.** Treatment of mastitis due to *Staphylococcus aureus*, *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, and *Streptococcus uberis* in lactating or dry cows.

(ii) **Limitations.** Milk taken from animals during treatment and for 36 hours (3 milkings) after the latest treatment must not be used for food.

than 30 days prior to calving. Do not slaughter treated animals for food use for 30 days following udder infusion. For udder installation for the treatment of mastitis in dry cows only.

(b)(1) Specifications. Each 10 milliliters of oil suspension contains the equivalent of 150 milligrams of novobiocin (present as sodium novobiocin).

(2) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(3) Related tolerances. See §556.460 of this chapter.

(4) Conditions of use—(i) Amount. Infuse 10 milliliters (equivalent to 150 milligrams of novobiocin) in each quarter after milking. Repeat treatment once after 24 hours.

(ii) Indications for use. Use in lactating cows for treatment of mastitis caused by susceptible strains of <i>Staphylococcus aureus</i>.

(iii) Limitations. Do not milk for at least 6 hours after treatment; afterwards, milk at regular intervals. Milk taken from treated animals within 72 hours (6 milkings) after latest treatment must not be used for food. Do not slaughter treated animals for food for 15 days following latest treatment. If redness, swelling, or abnormal milk persists or increases after treatment, discontinue use and consult a veterinarian. Discard all milk for 72 hours (6 milkings) following calving, or later as indicated by the marketable quality of the milk. Animals must not be slaughtered for food within 14 days postinfusion.

[73 FR 18442, Apr. 4, 2008, as amended at 74 FR 16990, Apr. 27, 2009]

§526.1696b Penicillin G procaine-dihydrostreptomycin in soybean oil for intramammary infusion (dry cows).

(a) Specifications. Each 10 milliliters of suspension contains penicillin G procaine equivalent to 200,000 units of penicillin G and dihydrostreptomycin sulfate equivalent to 300 milligrams of dihydrostreptomycin.

(b) Sponsor. See No. 054628 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.200 and 556.510 of this chapter.

(d) Conditions of use. Dairy cows—(1) Amount. One syringe into each quarter at the last milking prior to drying off. (2) Indications for use. Intramammary treatment of subclinical mastitis in dairy cows at the time of drying off, specifically against infections caused by <i>Staphylococcus aureus</i> and <i>Streptococcus agalactiae</i>.

(3) Limitations. Not to be used within 6 weeks of calving. For use in dry cows only. Milk taken from cows within 24 hours (2 milkings) after calving must not be used for food. Animals infused with this drug must not be slaughtered for food within 60 days of treatment nor within 24 hours after calving.

[57 FR 37236, Aug. 18, 1992, as amended at 78 FR 21060, Apr. 9, 2013]
§ 526.1696c Penicillin G procaine-dihydrostreptomycin sulfate for intramammary infusion (dry cows).

(a) Specifications. Each 10 milliliters of suspension contains penicillin G procaine equivalent to 1 million units of penicillin G and dihydrostreptomycin sulfate equivalent to 1 gram of dihydrostreptomycin.

(b) Sponsor. See No. 042791 in §510.600(c) of this chapter.

(c) Related tolerances. See §§556.200 and 556.510 of this chapter.

(d) Conditions of use. Dairy cows—(1) Amount. One syringe per quarter at the last milking prior to drying off.

(2) Indications for use. Intramammary use to reduce the frequency of existing infection and to prevent new infections with Staphylococcus aureus in dry cows.

(3) Limitations. Not to be used within 6 weeks of freshening. Not for use in lactating cows. Milk taken from animals within 96 hours (8 milkings) after calving must not be used for feed. Animals infused with this drug must not be slaughtered for food within 60 days from the time of infusion nor within 96 hours after calving. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 526.1696d Penicillin G procaine-novobiocin for intramammary infusion.

(a) Specifications. For lactating cattle: each 10-milliliter dose contains 100,000 units of penicillin G procaine and 150 milligrams of novobiocin as novobiocin sodium. For dry cows: 200,000 units of penicillin G procaine and 400 milligrams of novobiocin as novobiocin sodium.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.515 of this chapter.

(d) Conditions of use in cattle—(1) Amount. Infuse 50 mg into each infected quarter. Repeat treatment after 24 hours. Daily treatment may be repeated at 24-hour intervals for up to 8 consecutive days.

(2) Indications for use. For the treatment of clinical and subclinical mastitis in lactating dairy cattle associated with Staphylococcus species such as Staphylococcus aureus and Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.

(3) Limitations. Milk taken from animals during treatment and for 36 hours following the last treatment must not be used. Following infusion twice at a 24-hour interval, treated animals must not be slaughtered for food for 90 days following the last treatment.


§ 526.1810 Pirlimycin.

(a) Specifications. Each 10-milliliter syringe contains 50 milligrams (mg) pirlimycin (as pirlimycin hydrochloride).

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.515 of this chapter.

(d) Conditions of use in cattle—(1) Amount. Infuse 50 mg into each infected quarter. Repeat treatment after 24 hours. Daily treatment may be repeated at 24-hour intervals for up to 8 consecutive days.

(2) Indications for use. For the treatment of clinical and subclinical mastitis in lactating dairy cattle associated with Staphylococcus species such as Staphylococcus aureus and Streptococcus species such as Streptococcus agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.

(3) Limitations. Milk taken from animals during treatment and for 36 hours following the last treatment must not be used. Following infusion twice at a 24-hour interval, treated animals must not be slaughtered for food for 90 days following the last treatment.

days. Following any extended duration of therapy (infusion longer than twice at a 24-hour interval, up to 8 consecutive days), animals must not be slaughtered for 21 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


PART 528—NEW ANIMAL DRUGS IN GENETICALLY ENGINEERED ANIMALS

Sec.

528.1070 Bc6 recombinant deoxyribonucleic acid construct.

528.1092 opAFP–GHc2 recombinant deoxyribonucleic acid construct.

528.2010 Human lysosomal acid lipase recombinant deoxyribonucleic acid construct.


SOURCE: 74 FR 6823, Feb. 11, 2009, unless otherwise noted.

§ 528.1070 Bc6 recombinant deoxyribonucleic acid construct.

(a) Specifications and indications for use. Five copies of a human Bc6 recombinant deoxyribonucleic acid (rDNA) construct located at the GTC 155–92 site in a specific hemizygous diploid line of dairy breeds of domestic goats (Capra aegagrus hircus) directing the expression of the human gene for antithrombin (which is intended for the treatment of humans) in the mammary gland of goats derived from lineage progenitor 155–92.

(b) Sponsor. See No. 086047 in § 510.600 of this chapter.

(c) Limitations. Food or feed from GTC–155–92 goats is not permitted in the food or feed supply.

[74 FR 6823, Feb. 11, 2009, as amended at 80 FR 34279, June 16, 2015]

§ 528.1092 opAFP–GHc2 recombinant deoxyribonucleic acid construct.

(a) Specifications. A single copy of the human lysosomal acid lipase (hLAL) recombinant deoxyribonucleic acid (rDNA) gene construct located at the SYN LAL–C site in chromosome 6 in a specific, diploid line (SBC LAL–C) of hemizygous and homozygous domestic chickens (Gallus gallus), derived from the lineage progenitor XLL 109.

(b) Sponsor. See No. 069334 in § 510.600 of this chapter.

(c) Conditions of use—(1) Intended use. The gene construct directs the expression of that encoding gene such that recombinant, human lysosomal acid lipase (rhLAL) protein intended for the treatment of human disease is present in SBC LAL–C chicken egg whites.

(2) Limitations. Food or feed from XLL 109 chickens is not permitted in the food or feed supply.

[81 FR 17608, Mar. 30, 2016]

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

Sec.

529.10 Albuterol.

529.56 Amikacin.

529.382 Chloramine-T.

529.400 Chlorhexidine tablets and suspension.

529.536 Detomidine.

529.539 Dexametomidine.

529.778 Doxycycline.

529.1030 Formalin.

529.1044 Gentamicin in certain other dosage forms.

529.1044a Gentamicin solution for infusion.

529.1044b Gentamicin solution for dipping eggs.

529.1115 Halothane.

529.1150 Hydrogen peroxide.

529.1186 Isoflurane.
§ 529.400 Chlorhexidine tablets and suspension.

(a) Specification. Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.\footnote{These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may be submitted to the Agency for review.}

Food and Drug Administration, HHS

529.1350 Meloxicam.
529.1660 Oxytetracycline.
529.1940 Progesterone intravaginal inserts.
529.2150 Sevoflurane.
529.2464 Ticarcillin.
529.2503 Tricaine methanesulfonate.
529.2620 Triptorelin.

SOURCE: 40 FR 13881, Mar. 27, 1975, unless otherwise noted.

§ 529.40 Albuterol.

(a) Specifications. A net weight of 6.7 grams of formulated albuterol sulfate is supplied in a pressurized aluminum canister within an actuator system equipped with a detachable nasal delivery bulb.

(b) Approvals. See No. 000010 in §510.600(c) of this chapter for uses as in paragraph (d) of this section.

(c) Conditions of use—(1) Amount. Each valve actuation (puff) of the device delivers 120 micrograms (mcg) of albuterol sulfate. One dose is three (3) puffs, totaling 360 mcg.

(2) Indications for use. For the immediate relief of bronchospasm and bronchoconstriction associated with reversible airway obstruction in horses.

(3) Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 529.56 Amikacin.

(a) Specifications. Each milliliter (mL) of solution contains 250 milligrams of amikacin as amikacin sulfate.

(b) Sponsors. See Nos. 000859 and 054771 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Administer 2 grams (8 mL) diluted with 200 mL of sterile physiological saline by intrauterine infusion daily for 3 consecutive days.

(2) Indications for use. For treating genital tract infections (endometritis, metritis, and pyometra) in mares caused by susceptible organisms including Escherichia coli, Pseudomonas spp., and Klebsiella spp.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 37621, July 2, 2014]

§ 529.400 Chlorhexidine tablets and suspension.

(a) Specification. Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.\footnote{These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may be submitted to the Agency for review.}
§ 529.536 Detomidine.

(a) Specifications. Each milliliter of gel contains 7.6 milligrams (mg) of detomidine hydrochloride.

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet dissolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.

(2) Indications for use. For prevention or treatment of metritis and vaginitis in cows and mares when caused by pathogens sensitive to chlorhexidine dihydrochloride.

(3) Limitations. Prior to administration, remove any unattached placental membranes, any excess uterine fluid or debris, and carefully clean external genitalia. Use a clean, sterile inseminating pipette for administering solutions and suspensions. Treatment may be repeated in 48 to 72 hours.


EDITORIAL NOTE: At 79 FR 10973, Feb. 27, 2014, § 529.400 was amended by revising the section heading, however, the section heading was not provided, therefore, the amendment could not be incorporated because of an inaccurate amendatory instruction.

§ 529.539 Dexmedetomidine.

(a) Specifications. Each milliliter of gel contains 0.09 milligrams (mg) dexmedetomidine (equivalent to 0.1 mg dexmedetomidine hydrochloride).

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer onto the oral mucosa between the dog’s cheek and gum at a dose of 125 micrograms per square meter.

(2) Indications for use. For the treatment of noise aversion in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[81 FR 17608, Mar. 30, 2016]

§ 529.778 Doxycycline.

(a) Specifications. Doxycycline hyclate solution contains 8.5 percent doxycycline activity. A syringe of N-methyl-2-pyrroldione and poly (DL-lactide) mixed with a syringe of doxycycline produces 0.5 milliliter of solution.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer subgingivally to periodontal pocket(s) of affected teeth.

(2) Indications for use. For treatment and control of periodontal disease.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[79 FR 10973, Feb. 27, 2014]

§ 529.1030 Formalin.

(a) Specifications. Formalin is an aqueous solution containing approximately 37 percent by weight of formaldehyde gas, U.S.P.

(b) Sponsors. See Nos. 049968, 050378, and 067188 in § 510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Add 0.018 mg per pound (mg/lb) (0.040 mg/kilogram (kg)) sublingually.

(2) Indications for use. For sedation and restraint.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.


§ 529.539 Doxycycline.

(a) Specifications. Each milliliter of gel contains 0.09 milligrams (mg) doxycycline (equivalent to 0.1 mg doxycycline hydrochloride).

(b) Sponsor. See No. 052483 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Administer onto the oral mucosa between the dog’s cheek and gum at a dose of 125 micrograms per square meter.

(2) Indications for use. For the treatment of noise aversion in dogs.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[81 FR 17608, Mar. 30, 2016]
(i) For control of external protozoan parasites on shrimp:

<table>
<thead>
<tr>
<th>Shrimp</th>
<th>Concentration of formalin (microliters per liter)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shrimp</td>
<td>Tanks and raceways (up to 4 hours daily)</td>
</tr>
<tr>
<td></td>
<td>Earthen ponds (single treatment)</td>
</tr>
<tr>
<td>Penaeid Shrimp</td>
<td>50 to 100 °</td>
</tr>
</tbody>
</table>

1 Treat for up to 4 hours daily. Treatment may be repeated daily until parasite control is achieved. Use the lower concentration when the tanks and raceways are heavily loaded.

2 Although the indicated concentrations are considered safe for cold and warm water finfish, a small number of each lot or allowed to freeze. Do not treat ponds subjected to temperatures below 40 °F, or allowed to freeze. Do not treat ponds containing striped bass. Treatments in tanks should never exceed 1 hour even if fish show no signs of stress. Do not apply formalin to ponds with water warmer than 27 °C (80 °F), when a heavy bloom of phytoplankton is present, or when the concentration of dissolved oxygen is less than 5 milligrams per liter.

(ii) For control of external parasites on finfish:

<table>
<thead>
<tr>
<th>Aquatic species</th>
<th>Concentration of formalin (microliters per liter or ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salmon and trout:</td>
<td>Up to 170 (micro liter or part per million)</td>
</tr>
<tr>
<td>Above 50 ° F</td>
<td>Up to 250</td>
</tr>
<tr>
<td>Below 50 ° F</td>
<td>Up to 250</td>
</tr>
</tbody>
</table>

1 Use the lower concentration when ponds, tanks, or raceways are heavily loaded.

2 Although the indicated concentrations are considered safe for cold and warm water finfish, a small number of each lot or allowed to freeze. Do not treat ponds subjected to temperatures below 40 °F, or allowed to freeze. Do not treat ponds containing striped bass. Treatments in tanks should never exceed 1 hour even if fish show no signs of stress. Do not apply formalin to ponds with water warmer than 27 °C (80 °F), when a heavy bloom of phytoplankton is present, or when the concentration of dissolved oxygen is less than 5 milligrams per liter.

(iii) For control of fungi of the family Saprolegniaceae on finfish eggs:

Eggs of all finfish except Acipenseriformes, 1,000 to 2,000 μL/L (ppm) for 15 minutes; eggs of Acipenseriformes, up to 1,500 μL/L (ppm) for 15 minutes.

(3) Limitations. Fish tanks and raceways may be treated daily until parasite control is achieved. Pond treatment may be repeated in 5 to 10 days if needed. However, pond treatments for Ichthyophthirius should be made at 2-day intervals until control is achieved. Egg tanks may be treated as often as necessary to prevent growth of fungi. Do not use formalin which has been subjected to temperatures below 40 °F, or allowed to freeze. Do not treat ponds containing striped bass. Treatments in tanks should never exceed 1 hour even if fish show no signs of stress. Do not apply formalin to ponds with water warmer than 27 °C (80 °F), when a heavy bloom of phytoplankton is present, or when the concentration of dissolved oxygen is less than 5 milligrams per liter.

§ 529.1044b Gentamicin in certain other dosage forms.

(a) Specifications. Each milliliter of solution contains 50 or 100 milligrams gentamicin sulfate.

(b) Sponsors. See Nos. 000061, 000859, 054628, 054771, 057561, 058005, and 061623 in §510.600(c) of this chapter.

(c) Conditions of use in horses—(1) Amount. Infuse 2 to 2.5 grams per day for 3 to 5 days during estrus.

(2) Indications for use. For control of bacterial infections of the uterus (metritis) and as an aid in improving conception in mares with uterine infections caused by bacteria sensitive to gentamicin.

(3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 529.1044a Gentamicin solution for infusion.

(a) Specifications. Each milliliter of solution contains 50 or 100 milligrams gentamicin sulfate.

(b) Sponsors. See Nos. 000061 and 054925 in §510.600(c) of this chapter.

(c) Conditions of use in turkeys—(1) Amount. The drug is added to clean water to provide a dip solution with a gentamicin concentration of 250 to 1,000 parts per million. A concentration of 500 parts per million is recommended. Clean eggs should be held submerged in the gentamicin solution under a vacuum of about 27.5 to 38 centimeters of mercury for 5 minutes followed by additional soaking in gentamicin solution for approximately 10 minutes at atmospheric pressure. Eggs can also be treated by warming them for 3 to 6 hours at approximately 37°C.

379
100 °F then immediately submerging them in gentamicin solution maintained at about 40 °F, keeping the eggs submerged for 10 to 15 minutes.

(2) Indications for use. As an aid in the reduction or elimination of the following microorganisms from turkey-hatching eggs: *Arizona hinshawii* (paracolon), *Salmonella Saintpaul*, and *Mycoplasma meleagridis*.

(3) Limitations. For use in the dipping treatment of turkey-hatching eggs only. Eggs which have been dipped in the drug shall not be used for food.


§ 529.1115 Halothane.

(a) Specifications. The drug is a colorless, odorless, nonflammable, nonexplosive, heavy liquid containing 0.01 percent thymol as a preservative.

(b) Sponsor. See Nos. 012164 and 054771 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. Two to 5 percent of inhaled atmosphere for induction of anesthesia; 0.5 to 2 percent for maintenance of anesthesia.

(2) Indications for use. For nonfood animals for the induction and maintenance of anesthesia.

(3) Limitations. Not for use in animals intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


§ 529.1150 Hydrogen peroxide.

(a) Specifications. Each milliliter of solution contains 396.1 milligrams (mg) hydrogen peroxide (a 35% w/w solution).

(b) Sponsor. See No. 050378 in §510.600(c) of this chapter.

(c) Conditions of use in finfish—(1) Amount—(i) Freshwater-reared finfish eggs: 500 to 1,000 mg per liter (L) of culture water for 15 minutes in a continuous flow system once per day on consecutive or alternate days until hatch for all coldwater species of freshwater-reared finfish eggs.

(ii) Freshwater-reared salmonids: 100 mg/L for 30 minutes or 50 to 100 mg/L for 60 minutes once per day on alternate days for three treatments in a continuous flow water supply or as a static bath.

(iii) Coolwater species of freshwater-reared finfish fingerlings and adults (except northern pike & paddlefish) and channel catfish fingerlings and adults: 50 to 75 mg/L for 60 minutes once per day on alternate days for three treatments in continuous flow water supply or as a static bath. Coolwater species of freshwater-reared finfish fry (except northern pike, pallid sturgeon & paddlefish) and channel catfish fry: 50 mg/L for 60 minutes once per day on alternate days for three treatments in continuous flow water supply or as a static bath.

(2) Indications for use. For control of mortality in freshwater-reared finfish eggs due to saprolegniasis; for control of mortality in freshwater-reared salmonids due to bacterial gill disease associated with *Flavobacterium branchiophilum*; and for control of mortality in freshwater-reared finfish and channel catfish due to external columnaris disease associated with *Flavobacterium columnare* (*Flexibacter columnaris*).

(3) Limitations. Initial bioassay on a small number is recommended before treating the entire group. Eggs: Some strains of rainbow trout eggs are sensitive to hydrogen peroxide treatment at a time during incubation concurrent with blastopore formation through closure, about 70 to 140 Daily Temperature Units, °C. Consider withholding treatment or using an alternate therapeutant during that sensitive time to reduce egg mortalities due to drug toxicity. Finfish: Use with caution on walleye. Preharvest withdrawal time: zero days.

[72 FR 5330, Feb. 6, 2007, as amended at 78 FR 73698, Dec. 9, 2013]

§ 529.1186 Isoflurane.

(a) Specifications. The drug is a clear, colorless, stable liquid.

(b) Sponsors. See Nos. 010019, 012164, 054771, 065085, and 066794 in §510.600(c) of this chapter.
conditions of use. administer by inhalation:

1. amount—
   i. horses: for induction of surgical anesthesia: 3 to 5 percent isoflurane (with oxygen) for 5 to 10 minutes. for maintenance of surgical anesthesia: 1.5 to 1.8 percent isoflurane (with oxygen).
   ii. dogs: for induction of surgical anesthesia: 2 to 2.5 percent isoflurane (with oxygen) for 5 to 10 minutes. for maintenance of surgical anesthesia: 1.5 to 1.8 percent isoflurane (with oxygen).

2. indications for use. for induction and maintenance of general anesthesia in horses and dogs.

3. limitations. do not use in horses intended for human consumption. federal law restricts this drug to use by or on the order of a licensed veterinarian.

§ 529.1350 meloxicam.

(a) specifications. each milliliter of solution contains 5 milligrams (mg) meloxicam.

(b) sponsor. see no. 054771 in § 510.600(c) of this chapter.

(c) conditions of use in dogs—
   1. amount. administer 0.1 mg per kilogram of body weight once daily using the metered dose pump.

   2. indications for use. for the control of pain and inflammation associated with osteoarthritis in dogs.

   3. limitations. federal law restricts this drug to use by or on the order of a licensed veterinarian.

[77 fr 76663, dec. 31, 2012, as amended at 80 fr 18776, apr. 8, 2015]

§ 529.1660 oxytetracycline.

(a) specifications—
   1. each gram of powder contains 366 milligrams (mg) oxytetracycline hydrochloride.

   2. each gram of powder contains 753 mg oxytetracycline hydrochloride.

(b) sponsors. see sponsors in § 510.600(c) of this chapter for use of products described in paragraph (a) of this section as in paragraph (d) of this section.

1. nos. 054771 and 061623 for use of product in paragraph (a)(1) of this section.

2. nos. 048164, 054771, and 061623 for use of product described in paragraph (a)(2) of this section.

(c) related tolerances. see § 556.540 of this chapter.

(d) conditions of use in finfish—
   1. amount. immerse fish in a solution containing 200 to 700 mg oxytetracycline hydrochloride (buffered) per liter of water for 2 to 6 hours.

   2. indications for use. for skeletal marking of finfish fry and fingerlings.


§ 529.1940 progesterone intravaginal inserts.

(a) specifications. each insert contains:

   1. 1.38 grams (g) progesterone in molded silicone over a nylon spine.

   2. 0.3 g progesterone in molded silicone over a flexible nylon spine.

(b) sponsor. see no. 054771 in § 510.600(c) of this chapter for use of the product described in paragraph (a)(1) of this section as in paragraph (e)(1) of this section; and the product described in paragraph (a)(2) of this section as in paragraph (e)(2) of this section.

(c) related tolerances. see § 556.540 of this chapter.

(d) special considerations. product labeling shall bear the following warning: “avoid contact with skin by wearing protective gloves when handling inserts. store removed inserts in a sealable container until they can be disposed of in accordance with applicable local, state, and federal regulations.”

(e) conditions of use—
   1. cows—

      1. amount. administer one intravaginal insert per animal for 7 days. when used for indications listed in paragraph (e)(1)(i)(a) of this section, administer 25 mg dinoprost as a single intramuscular injection 1 day prior to insert removal (day 6). when used for indications listed in paragraph (e)(1)(i)(b) of this section, administer 25 mg dinoprost as a single
intramuscular injection on the day of
insert removal (Day 7).

(ii) Indications for use—(A) For syn-
chronization of estrus in suckled beef
cows and replacement beef and dairy
heifers; for advancement of first
postpartum estrus in suckled beef
cows; and for advancement of first pu-
bertal estrus in replacement beef heif-
ers.

(B) For synchronization of estrus in
lactating dairy cows.

(C) For synchronization of the return
to estrus in lactating dairy cows in-
seminated at the immediately pre-
ceding estrus.

(D) For induction of estrous cycles in
anestrous lactating dairy cows.

(iii) Limitations. Do not use in beef or
dairy heifers of insufficient size or age
for breeding or in animals with abnor-
mal, immature, or infected genital
tracts. Do not use in beef cows that are
fewer than 20 days postpartum. Do not
use an insert more than once. To pre-
vent the potential transmission of ve-
nereal and bloodborne diseases, the in-
serts should be disposed after a single
use. Administration of vaginal inserts
for periods greater than 7 days may re-
result in reduced fertility. Dinoprost in-
jection for use in paragraphs
(e)(1)(ii)(A) and (e)(1)(ii)(B) of this sec-
tion as in §522.690 of this chapter, pro-
vided by No. 054771 in §510.600(c) of this
chapter.

§529.2150 Sevoflurane.

(a) Specifications. Sevoflurane liquid.

(b) Sponsors. See Nos. 012164, 054771,
and 066794 in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. For
induction of surgical anesthesia: up to
7 percent sevoflurane. For mainten-
ance of surgical anesthesia: 3.7 to 4 percent
sevoflurane with oxygen in the absence
of premedication and 3.3 to 3.6 percent
in the presence of premedication.

(2) Indications for use. For induction
and maintenance of general anesthesia
in dogs.

(3) Limitations. Federal law restricts
this drug to use by or on the order of a
licensed veterinarian.

§529.2154 Ticarcillin.

(a) Specifications. Each vial contains
ticarcillin disodium powder equivalent
to 6 grams of ticarcillin for recon-
stitution with 25 milliliters of sterile water
for injection or sterile physiological
saline.

(b) Sponsor. See No. 054771 in
§510.600(c) of this chapter.

(c) Conditions of use in horses—

(1) Amount. Administer 6 grams daily by
intrauterine infusion for 3 consecutive
days during estrus.

(2) Indications for use. For the treat-
ment of endometritis caused by beta-
hemolytic streptococci.

(3) Limitations. Do not use in horses
intended for human consumption. Fed-
eral law restricts this drug to use by or
on the order of a licensed veterinarian.

§529.2464 Tricaine methanesulfonate.

(a) Specifications. The drug is ethyl-m-
amino-benzoate methanesulfonate.

(b) Sponsor. See Nos. 050378 and 051212
in §510.600(c) of this chapter.

(c) Conditions of use—(1) Amount. It is
used as follows:

(i) Fish. The drug is added to ambient
water at a concentration of from 15 to
330 milligrams per liter depending upon
the degree of anesthetization or seda-
tion desired, the species and size of the
fish, and the temperature and softness
of the water. Preliminary tests of solu-
tions must be made with small num-
bers of fish to determine the desired
rates of sedation or anesthesia and the
appropriate exposure times for the specific lots of fish under prevailing conditions.

(ii) *Amphibians and other aquatic cold-blooded animals.* The drug is added to ambient water in concentrations of from 1:1000 to 1:20,000 depending upon species and stage of development.

(2) **Indications for use.** For the temporary immobilization of fish, amphibians, and other aquatic coldblooded animals (poikilotherms) as an aid in handling during manual spawning (fish stripping), weighing, measuring, marking, surgical operations, transport, photography, and research.

(3) **Limitations.** Do not use within 21 days of harvesting fish for food. Use in fish intended for food should be restricted to Ictaluridae, Salmonidae, Esocidae, and Percidae, and water temperature exceeding 10 °C (50 °F). In other fish and in coldblooded animals, the drug should be limited to hatchery or laboratory use.

[79 FR 10974, Feb. 27, 2014]

§ 529.2620 Triptorelin.

(a) **Specifications.** Each milliliter of gel contains 100 micrograms (mcg) triptorelin as triptorelin acetate.

(b) **Sponsor.** See No. 051233 in § 510.600(c) of this chapter.

(c) **Conditions of use in swine—(1) Amount.** Administer 200 mcg intravaginally approximately 96 hours after weaning.

(2) **Indications for use.** For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination.

(3) **Limitations.** Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals. Should not be used in sows with obvious reproductive tract abnormalities.

[77 FR 64717, Oct. 23, 2012]

### PART 530—EXTRALABEL DRUG USE IN ANIMALS

#### Subpart A—General Provisions

Sec. 530.1 Scope.
530.2 Purpose.
530.3 Definitions.
530.4 Advertising and promotion.
530.5 Veterinary records.

Subpart B—Rules and Provisions for Extralabel Uses of Drugs in Animals

530.10 Provision permitting extralabel use of animal drugs.
530.11 Limitations.
530.12 Labeling.
530.13 Extralabel use from compounding of approved new animal and approved human drugs.

Subpart C—Specific Provisions Relating to Extralabel Use of Animal and Human Drugs in Food-Producing Animals

530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals.
530.21 Prohibitions for food-producing animals.
530.22 Safe levels and analytical methods for food-producing animals.
530.23 Procedure for setting and announcing safe levels.
530.24 Procedure for announcing analytical methods for drug residue quantification.
530.25 Orders prohibiting extralabel uses for drugs in food-producing animals.

Subpart D—Extralabel Use of Human and Animal Drugs in Animals Not Intended for Human Consumption

530.30 Extralabel drug use in nonfood animals.

Subpart E—Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals

530.40 Safe levels and availability of analytical methods.
530.41 Drugs prohibited for extralabel use in animals.


SOURCE: 61 FR 57743, Nov. 7, 1996, unless otherwise noted.

Subpart A—General Provisions

§ 530.1 Scope.

This part applies to the extralabel use in an animal of any approved new animal drug or approved new human drug by or on the lawful order of a licensed veterinarian within the context of a valid veterinary-client-patient relationship.
§ 530.2 Purpose.

The purpose of this part is to establish conditions for extralabel use or intended extralabel use in animals by or on the lawful order of licensed veterinarians of Food and Drug Administration approved new animal drugs and approved new human drugs. Such use is limited to treatment modalities when the health of an animal is threatened or suffering or death may result from failure to treat. This section implements the Animal Medicinal Drug Use Clarification Act of 1994 (the AMDUCA) (Pub. L. 103–396).

§ 530.3 Definitions.

(a) Extralabel use means actual use or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling. This includes, but is not limited to, use in species not listed in the labeling, use for indications (disease or other conditions) not listed in the labeling, use at dosage levels, frequencies, or routes of administration other than those stated in the labeling, and deviation from the labeled withdrawal time based on these different uses.

(b) FDA means the U.S. Food and Drug Administration.

(c) The phrase a reasonable probability that a drug’s use may present a risk to the public health means that FDA has reason to believe that use of a drug may be likely to cause a potential adverse event.

(d) The phrase use of a drug may present a risk to the public health means that FDA has information that indicates that use of a drug may cause an adverse event.

(e) The phrase use of a drug presents a risk to the public health means that FDA has evidence that demonstrates that the use of a drug has caused or likely will cause an adverse event.

(f) A residue means any compound present in edible tissues that results from the use of a drug, and includes the drug, its metabolites, and any other substance formed in or on food because of the drug’s use.

(g) A safe level is a conservative estimate of a drug residue level in edible animal tissue derived from food safety data or other scientific information. Concentrations of residues in tissue below the safe level will not raise human food safety concerns. A safe level is not a safe concentration or a tolerance and does not indicate that an approval exists for the drug in that species or category of animal from which the food is derived.

(h) Veterinarian means a person licensed by a State or Territory to practice veterinary medicine.

(i) A valid veterinarian-client-patient relationship is one in which:

(1) A veterinarian has assumed the responsibility for making medical judgments regarding the health of (an) animal(s) and the need for medical treatment, and the client (the owner of the animal or animals or other caretaker) has agreed to follow the instructions of the veterinarian;

(2) There is sufficient knowledge of the animal(s) by the veterinarian to initiate at least a general or preliminary diagnosis of the medical condition of the animal(s); and

(3) The practicing veterinarian is readily available for followup in case of adverse reactions or failure of the regimen of therapy. Such a relationship can exist only when the veterinarian has recently seen and is personally acquainted with the keeping and care of the animal(s) by virtue of examination of the animal(s), and/or by medically appropriate and timely visits to the premises where the animal(s) are kept.

§ 530.4 Advertising and promotion.

Nothing in this part shall be construed as permitting the advertising or promotion of extralabel uses in animals of approved new animal drugs or approved human drugs.

§ 530.5 Veterinary records.

(a) As a condition of extralabel use permitted under this part, to permit FDA to ascertain any extralabel use or intended extralabel use of drugs that the agency has determined may present a risk to the public health, veterinarians shall maintain the following records of extralabel uses. Such records shall be legible, documented in an accurate and timely manner, and be readily accessible to permit prompt retrieval of information. Such records shall be adequate to substantiate the identification of the animals and shall
be maintained either as individual records or, in food animal practices, on a group, herd, flock, or per-client basis. Records shall be adequate to provide the following information:

1. The established name of the drug and its active ingredient, or if formulated from more than one ingredient, the established name of each ingredient;
2. The condition treated;
3. The species of the treated animal(s);
4. The dosage administered;
5. The duration of treatment;
6. The numbers of animals treated; and
7. The specified withdrawal, withholding, or discard time(s), if applicable, for meat, milk, eggs, or any food which might be derived from any food animals treated.

(b) A veterinarian shall keep all required records for 2 years or as otherwise required by Federal or State law, whichever is greater.

(c) Any person who is in charge, control, or custody of such records shall, upon request of a person designated by FDA, permit such person designated by FDA to, at all reasonable times, have access to, permit copying, and verify such records.

Subpart B—Rules and Provisions for Extralabel Uses of Drugs in Animals

§530.10 Provision permitting extralabel use of animal drugs.

An approved new animal drug or human drug intended to be used for an extralabel purpose in an animal is not unsafe under section 512 of the act and is exempt from the labeling requirements of section 502(f) of the act if such use is:

(a) By or on the lawful written or oral order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship; and
(b) In compliance with this part.

§530.11 Limitations.

In addition to uses which do not comply with the provision set forth in §530.10, the following specific extralabel uses are not permitted and result in the drug being deemed unsafe within the meaning of section 512 of the act:

(a) Extralabel use in an animal of an approved new animal drug or human drug by a lay person (except when under the supervision of a licensed veterinarian);
(b) Extralabel use of an approved new animal drug or human drug in or on an animal feed;
(c) Extralabel use resulting in any residue which may present a risk to the public health; and
(d) Extralabel use resulting in any residue above an established safe level, safe concentration or tolerance.

§530.12 Labeling.

Any human or animal drug prescribed and dispensed for extralabel use by a veterinarian or dispensed by a pharmacist on the order of a veterinarian shall bear or be accompanied by labeling information adequate to assure the safe and proper use of the product. Such information shall include the following:

(a) The name and address of the prescribing veterinarian. If the drug is dispensed by a pharmacy on the order of a veterinarian, the labeling shall include the name of the prescribing veterinarian and the name and address of the dispensing pharmacy, and may include the address of the prescribing veterinarian;
(b) The established name of the drug or, if formulated from more than one active ingredient, the established name of each ingredient;
(c) Any directions for use specified by the veterinarian, including the class/species or identification of the animal or herd, flock, pen, lot, or other group of animals being treated, in which the drug is intended to be used; the dosage, frequency, and route of administration; and the duration of therapy;
(d) Any cautionary statements; and
(e) The veterinarian’s specified withdrawal, withholding, or discard time for meat, milk, eggs, or any other food which might be derived from the treated animal or animals.
§ 530.13 Extralabel use from compounding of approved new animal and approved human drugs.

(a) This part applies to compounding of a product from approved animal or human drugs by a veterinarian or a pharmacist on the order of a veterinarian within the practice of veterinary medicine. Nothing in this part shall be construed as permitting compounding from bulk drugs.

(b) Extralabel use from compounding of approved new animal or human drugs is permitted if:

(1) All relevant portions of this part have been complied with;

(2) There is no approved new animal or approved new human drug that, when used as labeled or in conformity with criteria established in this part, will, in the available dosage form and concentration, appropriately treat the condition diagnosed. Compounding from a human drug for use in food-producing animals will not be permitted if an approved animal drug can be used for the compounding;

(3) The compounding is performed by a licensed pharmacist or veterinarian within the scope of a professional practice;

(4) Adequate procedures and processes are followed that ensure the safety and effectiveness of the compounded product;

(5) The scale of the compounding operation is commensurate with the established need for compounded products (e.g., similar to that of comparable practices); and

(6) All relevant State laws relating to the compounding of drugs for use in animals are followed.

(c) Guidance on the subject of compounding may be found in guidance documents issued by FDA.

Subpart C—Specific Provisions Relating to Extralabel Use of Animal and Human Drugs in Food-Producing Animals

§ 530.20 Conditions for permitted extralabel animal and human drug use in food-producing animals.

(a) The following conditions must be met for a permitted extralabel use in food-producing animals of approved new animal and human drugs:

(1) There is no approved new animal drug that is labeled for such use and that contains the same active ingredient which is in the required dosage form and concentration, except where a veterinarian finds, within the context of a valid veterinarian-client-patient relationship, that the approved new animal drug is clinically ineffective for its intended use.

(2) Prior to prescribing or dispensing an approved new animal or human drug for an extralabel use in food animals, the veterinarian must:

(i) Make a careful diagnosis and evaluation of the conditions for which the drug is to be used;

(ii) Establish a substantially extended withdrawal period prior to marketing of milk, meat, eggs, or other edible products supported by appropriate scientific information, if applicable;

(iii) Institute procedures to assure that the identity of the treated animal or animals is carefully maintained; and

(iv) Take appropriate measures to assure that assigned timeframes for withdrawal are met and no illegal drug residues occur in any food-producing animal subjected to extralabel treatment.

(b) The following additional conditions must be met for a permitted extralabel use of in food-producing animals an approved human drug, or of an animal drug approved only for use in animals not intended for human consumption:

(1) Such use must be accomplished in accordance with an appropriate medical rationale; and

(2) If scientific information on the human food safety aspect of the use of the drug in food-producing animals is not available, the veterinarian must take appropriate measures to assure that the animal and its food products will not enter the human food supply.

(c) Extralabel use of an approved human drug in a food-producing animal is not permitted under this part if an animal drug approved for use in food-producing animals can be used in an extralabel manner for the particular use.

§ 530.21 Prohibitions for food-producing animals.

(a) FDA may prohibit the extralabel use of an approved new animal or
human drug or class of drugs in food-producing animals if FDA determines that:

(1) An acceptable analytical method needs to be established and such method has not been established or cannot be established; or

(2) The extralabel use of the drug or class of drugs presents a risk to the public health.

(b) A prohibition may be a general ban on the extralabel use of the drug or class of drugs or may be limited to a specific species, indication, dosage form, route of administration, or combination of factors.

§ 530.22 Safe levels and analytical methods for food-producing animals.

(a) FDA may establish a safe level for extralabel use of an approved human drug or an approved new animal drug when the agency finds that there is a reasonable probability that an extralabel use may present a risk to the public health. FDA may:

(1) Establish a finite safe level based on residue and metabolism information from available sources;

(2) Establish a safe level based on the lowest level that can be measured by a practical analytical method; or

(3) Establish a safe level based on other appropriate scientific, technical, or regulatory criteria.

(b) FDA may require the development of an acceptable analytical method for the quantification of residues above any safe level established under this part. If FDA requires the development of such an acceptable analytical method, the agency will publish notice of that requirement in the FEDERAL REGISTER.

(c) The extralabel use of an animal drug or human drug that results in residues exceeding a safe level established under this part is an unsafe use of such drug.

(d) If the agency establishes a safe level for a particular species or category of animals and a tolerance or safe concentration for that species or category of animals, the safe level is superseded by the tolerance or safe concentration for that species or category of animals.

§ 530.23 Procedure for setting and announcing safe levels.

(a) FDA may issue an order establishing a safe level for a residue of an extralabel use of an approved human drug or an approved animal drug. The agency will publish in the FEDERAL REGISTER a notice of the order. The notice will include:

(1) A statement setting forth the agency's finding that there is a reasonable probability that extralabel use in animals of the human drug or animal drug may present a risk to the public health;

(2) A statement of the basis for that finding; and

(3) A request for public comments.

(b) A current listing of those drugs for which a safe level for extralabel drug use in food-producing animals has been established, the specific safe levels, and the availability, if any, of a specific analytical method or methods for drug residue detection will be codified in § 530.40.

§ 530.24 Procedure for announcing analytical methods for drug residue quantification.

(a) FDA may issue an order announcing a specific analytical method or methods for the quantification of extralabel use drug residues above the safe levels established under § 530.22 for extralabel use of an approved human drug or an approved animal drug. The agency will publish in the FEDERAL REGISTER a notice of the order, including the name of the specific analytical method or methods and the drug or drugs for which the method is applicable.

(b) Copies of analytical methods for the quantification of extralabel use drug residues above the safe levels established under § 530.22 will be available upon request from the Communications and Education Branch (HFV–12), Division of Program Communication and Administrative Management, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855. When an analytical method for the detection of extralabel use drug residues above the safe levels established under § 530.22 is
§ 530.25 Orders prohibiting extralabel uses for drugs in food-producing animals.

(a) FDA may issue an order prohibiting extralabel use of an approved new animal or human drug in food-producing animals if the agency finds, after providing an opportunity for public comment, that:

(1) An acceptable analytical method required under §530.22 has not been developed, submitted, and found to be acceptable by FDA or that such method cannot be established; or

(2) The extralabel use in animals presents a risk to the public health.

(b) After making a determination that the analytical method required under §530.22 has not been developed and submitted, or that such method cannot be established, or that an extralabel use in animals of a particular human drug or animal drug presents a risk to the public health, FDA will publish in the FEDERAL REGISTER, with a 90-day delayed effective date, an order of prohibition for an extralabel use of a drug in food-producing animals. Such order shall state that an acceptable analytical method required under §530.22 has not been developed, submitted, and found to be acceptable by FDA; that such method cannot be established; or that the extralabel use in animals presents a risk to the public health; and shall:

(1) Specify the nature and extent of the order of prohibition and the reasons for the prohibition;

(2) Request public comments; and

(3) Provide a period of not less than 60 days for comments.

(c) The order of prohibition will become effective 90 days after date of publication of the order unless FDA publishes a notice in the FEDERAL REGISTER prior to that date, that revokes the order of prohibition, modifies it, or extends the period of public comment.

(d) The agency may publish an order of prohibition with a shorter comment period and/or delayed effective date than specified in paragraph (b) of this section in exceptional circumstances (e.g., where there is immediate risk to the public health), provided that the order of prohibition states that the comment period and/or effective date have been abbreviated because there are exceptional circumstances, and the order of prohibition sets forth the agency’s rationale for taking such action.

(e) If FDA publishes a notice in the FEDERAL REGISTER modifying an order of prohibition, the agency will specify in the modified order of prohibition the nature and extent of the modified prohibition, the reasons for it, and the agency’s response to any comments on the original order of prohibition.

(f) A current listing of drugs prohibited for extralabel use in animals will be codified in §530.41.

(g) After the submission of appropriate information (i.e., adequate data, an acceptable method, approval of a new animal drug application for the prohibited extralabel use, or information demonstrating that the prohibition was based on incorrect data), FDA may, by publication of an appropriate notice in the FEDERAL REGISTER, remove a drug from the list of human and animal drugs prohibited for extralabel use in animals, or may modify a prohibition.

(h) FDA may prohibit extralabel use of a drug in food-producing animals without establishing a safe level.

Subpart D—Extralabel Use of Human and Animal Drugs in Animals Not Intended for Human Consumption

§ 530.30 Extralabel drug use in nonfood animals.

(a) Because extralabel use of animal and human drugs in nonfood-producing animals does not ordinarily pose a threat to the public health, extralabel use of animal and human drugs is permitted in nonfood-producing animal practice except when the public health is threatened. In addition, the provisions of §530.20(a)(1) will apply to the use of an approved animal drug.

(b) If FDA determines that an extralabel drug use in animals not intended for human consumption presents a risk to the public health, the agency may publish in the FEDERAL REGISTER a notice prohibiting such use.
following the procedures in §530.25. The prohibited extralabel drug use will be codified in §530.41.

Subpart E—Safe Levels for Extralabel Use of Drugs in Animals and Drugs Prohibited From Extralabel Use in Animals

§530.40 Safe levels and availability of analytical methods.

(a) In accordance with §530.22, the following safe levels for extralabel use of an approved animal drug or human drug have been established: (Reserved)

(b) In accordance with §530.22, the following analytical methods have been accepted by FDA: (Reserved)

§530.41 Drugs prohibited for extralabel use in animals.

(a) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in food-producing animals.

(1) Chloramphenicol;
(2) Clenbuterol;
(3) Diethylstilbestrol (DES);
(4) Dimetridazole;
(5) Ipronidazole;
(6) Other nitroimidazoles;
(7) Furazolidone.
(8) Nitrofurazone.
(9) Sulfonamide drugs in lactating dairy cattle (except approved use of sulfadimethoxine, sulfadiazine, and sulfathiazole);
(10) Fluoroquinolones; and
(11) Glycopeptides.

(b) The following drugs, families of drugs, and substances are prohibited for extralabel animal and human drug uses in nonfood-producing animals:

(1) Chloramphenicol;
(2) Clenbuterol;
(3) Diethylstilbestrol (DES);
(4) Dimetridazole;
(5) Ipronidazole;
(6) Other nitroimidazoles;
(7) Furazolidone.
(8) Nitrofurazone.

(c) The following drugs, or classes of drugs, that are approved for treating or preventing influenza A, are prohibited from extralabel use in chickens, turkeys, and ducks:

(1) Adamantanes.
(2) Neuraminidase inhibitors.

(d) The following drugs, or classes of drugs, that are approved for treating or preventing influenza A, are prohibited from extralabel use in chickens, turkeys, and ducks:

(1) Adamantanes.
(2) Neuraminidase inhibitors.

Subpart A—General Provisions

§ 556.1 General considerations; tolerances for residues of new animal drugs in food.

(a) Tolerances established in this part are based upon residues of drugs in edible products of food-producing animals treated with such drugs. Consideration of an appropriate tolerance for a drug shall result in a conclusion either that:

(1) Finite residues will be present in the edible products—in which case a finite tolerance is required; or

(2) It is not possible to determine whether finite residues will be incurred but there is reasonable expectation that they may be present—in which case a tolerance for negligible residue is required; or

(3) The drug induces cancer when ingested by man or animal or, after tests which are appropriate for the evaluation of the safety of such drug, has been shown to induce cancer in man or animal; however, such drug will not adversely affect the animals for which it is intended, and no residue of such drug will be found by prescribed methods of analysis in any edible portion of such animals after slaughter or in any food yielded by or derived from the living animal—in which case the accepted method of analysis shall be published or cited, if previously published and available elsewhere, in this part; or

(4) It may or may not be possible to determine whether finite residues will be incurred but there is no reasonable expectation that they may be present—in which case the establishment of a tolerance is not required; or

(5) The drug is such that it may be metabolized and/or assimilated in such form that any possible residue would be indistinguishable from normal tissue constituents—in which case the establishment of a tolerance is not required.

(b) No tolerance established pursuant to paragraph (a)(1) of this section will be set at any level higher than that reflected by the permitted use of the drug.

(c) Any tolerance required pursuant to this section will, in addition to the
toxicological considerations, be conditioned on the availability of a practicable analytical method to determine the quantity of residue. Such method must be sensitive to and reliable at the established tolerance level or, in certain instances, may be sensitive at a higher level where such level is also deemed satisfactory and safe in light of the toxicity of the drug residue and of the unlikelihood of such residue’s exceeding the tolerance.

Subpart B—Specific Tolerances for Residues of New Animal Drugs

§ 556.34 Albendazole.
(a) Acceptable daily intake (ADI). The ADI for total residues of albendazole is 5 micrograms per kilogram of body weight per day.
(b) Tolerances. The tolerances for albendazole 2-aminosulfone (marker residue) are:
   (1) Cattle—(i) Liver (target tissue): 0.2 parts per million (ppm).
       (ii) Muscle: 0.05 ppm.
   (2) Sheep—(i) Liver (target tissue): 0.25 ppm.
       (ii) Muscle: 0.05 ppm.
   (3) Goat—(i) Liver (target tissue): 0.25 ppm.
       (ii) [Reserved] (c) Related conditions of use. See §520.45 of this chapter.
[64 FR 1504, Jan. 11, 1999, as amended at 73 FR 11027, Feb. 29, 2008]

§ 556.36 Altrenogest.
(a) Acceptable Daily Intake (ADI). The ADI for total residues of altrenogest is 0.04 micrograms per kilogram of body weight per day.
(b) Tolerances. The tolerance for altrenogest (the marker residue) is 4 parts per billion (ppb).
   (i) Swine—(i) Liver (the target tissue). The tolerance for altrenogest (the marker residue) is 4 parts per billion (ppb).
   (ii) Muscle. The tolerance for altrenogest (the marker residue) is 1 ppb.
   (ii) [Reserved]
[58 FR 62007, Oct. 31, 2003]

§ 556.38 Amoxicillin.
A tolerance of 0.01 part per million is established for negligible residues of amoxicillin in milk and in the uncooked edible tissues of cattle.
[49 FR 45422, Nov. 16, 1984]

§ 556.40 Ampicillin.
A tolerance of 0.01 ppm is established for negligible residues of ampicillin in the uncooked edible tissues of swine and cattle and in milk.

§ 556.50 Amprolium.
Tolerances are established as follows for residues of amprolium (1-(4-amino-2-n-propyl-5-pyrimidinylmethyl)-2-picolinium chloride hydrochloride):
(a) In the edible tissues and in eggs of chickens and turkeys:
   (1) 1 part per million in uncooked liver and kidney.
   (2) 0.5 part per million in uncooked muscle tissue.
   (3) In eggs:
       (i) 8 parts per million in egg yolks.
       (ii) 4 parts per million in whole eggs.
(b) In the edible tissues of calves:
   (1) 2.0 parts per million in uncooked fat.
   (2) 0.5 part per million in uncooked muscle tissue, liver, and kidney.
   (c) In the edible tissues of pheasants:
       (1) 1 part per million in uncooked liver.
       (2) 0.5 part per million in uncooked muscle.
[40 FR 13942, Mar. 27, 1975, as amended at 50 FR 18472, May 1, 1985]

§ 556.52 Apramycin.
A tolerance of 0.1 part per million is established for parent apramycin (marker residue) in kidney (target tissue) of swine. The acceptable daily intake (ADI) for total residues of apramycin is 25 micrograms per kilogram of body weight per day.

§ 556.68 Avilamycin.
(a) Acceptable Daily Intake (ADI). The ADI for total residues of avilamycin is 1.1 milligram per kilogram of body weight per day.
(b) Tolerances. A tolerance for avilamycin is not required.
(c) Related conditions of use. See §558.68 of this chapter.
[80 FR 61297, Oct. 13, 2015]
§ 556.70 Bacitracin.

(a) Acceptable daily intake (ADI). The ADI for total residues of bacitracin is 0.05 milligram per kilogram of body weight per day.

(b) Tolerances. The tolerance for residues of bacitracin from zinc bacitracin or bacitracin methylene disalicylate in uncooked edible tissues of cattle, swine, chickens, turkeys, pheasants, and quail, and in milk and eggs is 0.5 part per million.

(c) Related conditions of use. See §§ 520.154a, 520.154c, 558.76, and 558.78 of this chapter.

§ 556.100 Caradox.

A tolerance of 30 parts per billion is established for residues of quinoxaline-2-carboxylic acid (marker residue) in liver (target tissue) of swine.

§ 556.110 Carbomycin.

A tolerance of zero is established for residues of carbomycin in the uncooked edible tissues of chickens.

§ 556.113 Ceftiofur.

(a) Acceptable daily intake and acceptable single-dose intake—(1) Acceptable daily intake (ADI). The ADI for total residues of ceftiofur is 30 micrograms per kilogram of body weight per day.

(2) Acceptable single-dose intake (ASDI). The ASDI total residues of ceftiofur is 0.830 milligrams per kilogram of body weight. The ASDI is the amount of total residues of ceftiofur that may safely be consumed in a single meal. The ASDI is used to derive the tolerance for residues of desfuroylceftiofur at the injection site.

(b) Tolerances—(1) Poultry, and sheep. A tolerance for residues of cephradine in edible tissue is not required.

(2) Swine. The tolerances for residues of cephradine (marker residue) are:

(i) Kidney (target tissue). 0.4 ppm.

(ii) Liver. 2 ppm.

(iii) Muscle. 1 ppm.

(iv) Milk. 0.1 ppm.

§ 556.115 Cepaprin.

A tolerance of 0.02 parts per million (ppm) is established for residues of cephradine in the milk and 0.1 ppm in the uncooked edible tissues of dairy cattle.

§ 556.118 Chloramine-T.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of chloramine-T is 5 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Fish—(i) Muscle/skin (target tissue). The tolerance for para-toluenesulfonamide (marker residue) is 0.90 parts per million.

(2) [Reserved]

(c) Related conditions of use. See § 529.382 of this chapter.

§ 556.120 Chlorhexidine.

A tolerance of zero is established for residues of chlorhexidine in the uncooked edible tissues of calves.

§ 556.150 Chlortetracycline.

(a) Acceptable daily intake (ADI). The ADI for total residues of tetracyclines including chlortetracycline, oxytetracycline, and tetracycline is 25 micrograms per kilogram of body weight per day.

(b) Tolerances. (1) Tolerances are established for the sum of tetracycline residues in tissues of beef cattle, non-lactating dairy cows, calves, swine, sheep, chickens, turkeys, and ducks, of 2 parts per million (ppm) in muscle, 6 ppm in liver, and 12 ppm in fat and kidney.

(2) A tolerance is established for residues of chlortetracycline in eggs of 0.4 ppm.

§ 556.160 Clopidol.

Tolerances for residues of clopidol (3,5-dichloro-2,6-dimethyl-4-pyridinol) in food are established as follows:

(a) In cereal grains, vegetables, and fruits: 0.2 part per million.
(b) In chickens and turkeys:
(1) 15 parts per million in uncooked liver and kidney.
(2) 5 parts per million in uncooked muscle.
(c) In cattle, sheep, and goats:
(1) 3 parts per million in uncooked kidney.
(2) 1.5 parts per million in uncooked liver.
(3) 0.2 part per million in uncooked muscle.
(d) In swine: 0.2 part per million in uncooked edible tissues.
(e) In milk: 0.02 part per million (negligible residue).

§ 556.163 Clorsulon.

(a) Acceptable daily intake (ADI). The ADI for total residues of clorsulon is 8 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Kidney (the target tissue). The tolerance for parent clorsulon (the marker residue) is 1.0 part per million.
(ii) Muscle. The tolerance for parent clorsulon (the marker residue) is 0.1 part per million.
(2) [Reserved]

[66 FR 35544, July 6, 2001]

§ 556.165 Cloxacillin.

A tolerance of 0.01 part per million is established for negligible residues of cloxacillin in the uncooked edible tissues of cattle and in milk.

[40 FR 28792, July 9, 1975]

§ 556.167 Colistimethate.

A tolerance for residues of colistimethate in the edible tissues of chickens is not required.

[83 FR 13121, Mar. 18, 1998]

§ 556.169 Danofloxacin.

(a) Acceptable daily intake (ADI). The ADI for total residues of danofloxacin is 2.4 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent danofloxacin (the marker residue) is 0.2 part per million (ppm).
(ii) Muscle. The tolerance for parent danofloxacin (the marker residue) is 0.2 ppm.
(2) [Reserved]

[67 FR 78973, Dec. 27, 2002]

§ 556.170 Decoquinate.

(a) Acceptable daily intake (ADI). The ADI for total residues of decoquinate is 75 micrograms per kilogram of body weight per day.

(b) Tolerances. Tolerances are established for residues of decoquinate in the uncooked, edible tissues of chickens, cattle, and goats as follows:
(1) 1 part per million (ppm) in skeletal muscle.
(2) 2 ppm in other tissues.

[64 FR 10103, Mar. 2, 1999]

§ 556.180 Dichlorvos.

A tolerance of 0.1 part per million is established for negligible residues of dichlorvos (2,2-dichlorovinyl dimethyl phosphate) in the edible tissues of swine.

§ 556.185 Diclazuril.

(a) Acceptable daily intake (ADI). The ADI for total residues of diclazuril is 25 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent diclazuril (the marker residue) is 3 parts per million (ppm).
(ii) Muscle. The tolerance for parent diclazuril (the marker residue) is 0.5 ppm.
(iii) Skin/fat. The tolerance for parent diclazuril (the marker residue) is 1 ppm.
(2) Turkeys—(1) Liver. The tolerance for parent diclazuril (the marker residue) is 3 ppm.
(ii) Muscle. The tolerance for parent diclazuril (the marker residue) is 0.5 ppm.
(iii) Skin/fat. The tolerance for parent diclazuril (the marker residue) is 1 ppm.

§ 556.200 Dihydrostreptomycin.

Tolerances are established for residues of dihydrostreptomycin in uncooked, edible tissues of cattle and swine of 2.0 parts per million (ppm) in kidney and 0.5 ppm in other tissues, and 0.125 ppm in milk.

[59 FR 41977, Aug. 16, 1994]

§ 556.225 Doramectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of doramectin is 0.75 microgram per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. A tolerance of 100 parts per billion is established for parent doramectin (marker residue) in liver (target tissue) and of 30 parts per billion for parent doramectin in muscle.

(2) Swine. A tolerance is established for parent doramectin (marker residue) in liver (target tissue) of 160 parts per billion.

[63 FR 68184, Dec. 10, 1998]

§ 556.226 Enrofloxacin.

(a) Acceptable daily intake (ADI). The ADI for total residues of enrofloxacin is 3 micrograms per kilogram of body weight per day.

(b) Tolerances. The tolerances for enrofloxacin are:

(1) Cattle—(i) Liver (target tissue). 0.1 part per million (ppm) desethylene ciprofloxacin (the marker residue).

(ii) [Reserved]

(2) Swine—(i) Liver (target tissue). 0.5 ppm enrofloxacin (the marker residue).

(ii) [Reserved]

(c) Related conditions of use. See §§522.814 and 524.814 of this chapter.

[73 FR 21819, Apr. 23, 2008]

§ 556.227 Eprinomectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of eprinomectin is 10 micrograms per kilogram of body weight per day.

(b) Tolerances. The tolerances for eprinomectin B1a (marker residue) are:

(1) Cattle—(i) Liver (target tissue): 1.5 parts per million.

(ii) Muscle: 100 parts per billion (ppb).

(iii) Milk: 12 ppb.

(2) [Reserved]

(c) Related conditions of use. See §§522.814 and 524.814 of this chapter.

[63 FR 59715, Nov. 5, 1998, as amended at 76 FR 72619, Nov. 20, 2011]

§ 556.230 Erythromycin.

Tolerances for residues of erythromycin in food are established as follows:

(a) 0.1 part per million in uncooked edible tissues of beef cattle and swine.

(b) Zero in milk.

(c) 0.025 part per million in uncooked eggs.

(d) 0.125 part per million (negligible residue) in uncooked edible tissues of chickens and turkeys.

[40 FR 13942, Mar. 27, 1975, as amended at 58 FR 43785, Aug. 18, 1993]

§ 556.240 Estradiol and related esters.

No residues of estradiol, resulting from the use of estradiol or any of the related esters, are permitted in excess of the following increments above the concentrations of estradiol naturally present in untreated animals:

(a) In uncooked edible tissues of heifers, steers, and calves:

(1) 120 parts per trillion for muscle.

(2) 480 parts per trillion for fat.

(3) 360 parts per trillion for kidney.

(4) 240 parts per trillion for liver.

(b) [Reserved]


§ 556.260 Ethopabate.

Tolerance for residues of ethopabate converted to metaphenetidine are established in the edible tissues of chickens as follows:

(a) 1.5 parts per million in uncooked liver and kidney.

(b) 0.5 part per million in uncooked muscle.

§ 556.273 Famphur.

Tolerances are established for residues of famphur including its oxygen analog in or on meat, fat, or meat by-products of cattle at 0.1 part per million.

Food and Drug Administration, HHS

§ 556.275 Fenbendazole.

(a) Acceptable daily intake (ADI). The ADI for total residues of fenbendazole is 40 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 0.8 part per million (ppm).

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 0.4 ppm.

(iii) Milk. The tolerance for fenbendazole sulfoxide metabolite (the marker residue in cattle milk) is 0.6 ppm.

(2) Swine—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 6 ppm.

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 2 ppm.

(3) Turkeys—(i) Liver (the target tissue). The tolerance for fenbendazole sulfone (the marker residue) is 2 ppm.

(ii) Muscle. The tolerance for fenbendazole sulfone (the marker residue) is 0.4 ppm.

(4) Goats—(i) Liver (the target tissue). The tolerance for parent fenbendazole (the marker residue) is 0.8 ppm.

(ii) Muscle. The tolerance for parent fenbendazole (the marker residue) is 0.4 ppm.


§ 556.277 Fenprostalene.

A tolerance for marker residue of fenprostalene in cattle is not needed. The safe concentrations for the total residues of fenprostalene in the uncooked edible tissues of cattle are 10 parts per billion in muscle, 20 parts per billion in liver, 40 parts per billion in kidney, 40 parts per billion in fat, and 100 parts per billion in the injection site. As used in this section “tolerance” refers to a concentration of a marker residue in the target tissue selected to monitor for total residues of the drug in the target animal, and “safe concentrations” refer to the concentrations of total residues considered safe in edible tissues.

[49 FR 26716, June 29, 1984]

§ 556.283 Florfenicol.

(a) Acceptable daily intake (ADI). The ADI for total residues of florfenicol is 10 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for florfenicol amine (the marker residue) is 3.7 parts per million (ppm).

(ii) Muscle. The tolerance for florfenicol amine (the marker residue) is 0.3 ppm.

(2) Swine—(i) Liver (the target tissue). The tolerance for parent florfenicol (the marker residue) is 2.5 ppm.

(ii) Muscle. The tolerance for parent florfenicol (the marker residue) is 0.2 ppm.

(3) Freshwater-reared finfish (other than catfish) and salmonids. The tolerance for florfenicol amine (the marker residue) in muscle/skin (the target tissues) is 1 ppm.

(4) Catfish. The tolerance for florfenicol amine (the marker residue) in muscle (the target tissues) is 1 ppm.

(c) Related conditions of use. See §§520.955, 522.955, 522.956, and 558.256 of this chapter.

[76 FR 16291, Mar. 23, 2011, as amended at 81 FR 17608, Mar. 30, 2016]

§ 556.286 Flunixin.

(a) Acceptable daily intake (ADI). The ADI for total residues of flunixin is 0.72 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. The tolerance for flunixin free acid (the marker residue) is:

(i) Liver (the target tissue). 125 parts per billion (ppb).

(ii) Muscle. 25 ppb.

(iii) Milk. 2 ppb 5-hydroxy flunixin.

(2) Swine. The tolerance for flunixin free acid (the marker residue) is:

(i) Liver (the target tissue). 30 ppb.

(ii) Muscle. 25 ppb.

(c) Related conditions of use. See §§522.956 and 522.970 of this chapter.


§ 556.292 Gamithromycin.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of
gamithromycin is 10 micrograms per kilogram of body weight per day.

(b) Tolerances. The tolerances for gamithromycin (the marker residue) are:

(1) Cattle—(i) Liver (the target tissue): 500 parts per billion (ppb).
(ii) Muscle: 150 ppb.
(2) [Reserved]

(c) Related conditions of use. See §522.1014 of this chapter.

[76 FR 57907, Sept. 19, 2011]

§ 556.300 Gentamicin sulfate.

(a) A tolerance of 0.1 part per million is established for negligible residues of gentamicin sulfate in the uncooked edible tissues of chickens and turkeys.

(b) Tolerances are established for total residues of gentamicin in edible tissues of swine as follows: 0.1 part per million in muscle, 0.3 part per million in liver, and 0.4 part per million in fat and kidney. A microbiological determinative procedure and an HPLC confirmatory procedure for gentamicin have been developed to assay gentamicin in kidney at 0.4 ppm. Since residues of gentamicin as the parent compound and total residues are equal, the marker (parent drug) residue concentration of 0.4 ppm in kidney corresponds to 0.4 ppm of total residue.


§ 556.304 Gonadotropin.

(a) Acceptable daily intake (ADI). The ADI for residues of total gonadotropins (human chorionic gonadotropin and pregnant mare serum gonadotropin) is 42.25 I.U. per kilogram of body weight per day.

(b) Tolerances. A tolerance for residues of gonadotropin in uncooked edible tissues of cattle or of fish is not required.

[64 FR 48545, Sept. 7, 1999]

§ 556.308 Halofuginone hydrobromide.

The marker residue selected to monitor for total residues of halofuginone hydrobromide in broilers and turkeys is parent halofuginone hydrobromide and the target tissue selected is liver. A tolerance is established in broilers of 0.16 part per million and in turkeys of 0.13 part per million for parent halofuginone hydrobromide in liver. These marker residue concentrations in liver correspond to total residue concentrations of 0.3 part per million in liver. The safe concentrations for total residues of halofuginone hydrobromide in the uncooked edible tissues of broilers and turkeys are 0.1 part per million in muscle, 0.3 part per million in liver, and 0.2 part per million in skin with adhering fat. As used in this section, “tolerance” refers to a concentration of a marker residue in the target tissue selected to monitor for total residues of the drug in the target animal, and “safe concentrations” refers to the concentrations of total residues considered safe in edible tissues.


§ 556.310 Haloxon.

A tolerance of 0.1 part per million is established for negligible residues of haloxon (3-chloro-7-hydroxy-4-methylcoumarin bis(2-chloroethyl) phosphate) in the edible tissues of cattle.

[40 FR 13942, Mar. 27, 1975, as amended at 45 FR 10333, Feb. 15, 1980]

§ 556.330 Hygromycin B.

A tolerance of zero is established for residues of hygromycin B in or on eggs and the uncooked edible tissues of swine and poultry.

§ 556.344 Ivermectin.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of ivermectin is 5 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Liver. A tolerance is established for 22,23-dihydroavermectin B₁ₐ (marker residue) in liver (target tissue) as follows:

(i) Cattle. 1.6 parts per million.
(ii) Swine. 20 parts per billion.
(iii) Sheep. 30 parts per billion.
(iv) Reindeer. 15 parts per billion.
(v) American bison. 15 parts per billion.

(2) Muscle. Muscle residues are not indicative of the safety of other edible tissues. A tolerance is established for 22,23-dihydroavermectin B₁ₐ (marker residue) in muscle as follows:

[76 FR 57907, Sept. 19, 2011]
Food and Drug Administration, HHS

§ 556.346 Laidlomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of laidlomycin is 7.5 micrograms per kilogram of body weight per day.

(b) Tolerance. The tolerance for parent laidlomycin (the marker residue) in the liver (the target tissue) of cattle is 0.2 part per million (ppm).

[68 FR 42590, July 18, 2003]

§ 556.347 Lasalocid.

(a) Acceptable daily intake (ADI). The ADI for total residues of lasalocid is 10 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle. The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 0.7 part per million (ppm).

(2) Chickens—(i) Skin with adhering fat (the target tissue). The tolerance for parent lasalocid (the marker residue) is 1.2 ppm.

(ii) Liver. The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.

(3) Turkeys—(i) Liver (the target tissue). The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.

(i) Skin with adhering fat. The tolerance for parent lasalocid (the marker residue) is 0.4 ppm.

(4) Rabbits. The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 0.7 ppm.

(5) Sheep. The tolerance for parent lasalocid (the marker residue) in liver (the target tissue) is 1.0 ppm.

[66 FR 19854, Apr. 18, 2001]

§ 556.350 Levamisole hydrochloride.

A tolerance of 0.1 part per million is established for negligible residues of levamisole hydrochloride in the edible tissues of cattle, sheep, and swine.

§ 556.360 Lincomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of lincomycin is 25 micrograms per kilogram of body weight per day.

(b) Chickens. A tolerance for residues of lincomycin in chickens is not required.

(c) Swine. Tolerances for lincomycin of 0.6 part per million in liver and 0.1 part per million in muscle are established.

[64 FR 13342, Mar. 18, 1999]

§ 556.375 Maduramicin ammonium.

A tolerance is established for residues of maduramicin ammonium in chickens as follows:

(a) A tolerance for maduramicin ammonium (marker residue) in chickens is 0.38 parts per million in fat (target tissue). A tolerance refers to the concentration of marker residues in the target tissue used to monitor for total drug residues in the target animals.

(b) The safe concentrations for total maduramic ammonium residues in uncooked edible chicken tissues are: 0.24 parts per million in muscle; 0.72 parts per million in liver; 0.48 parts per million in skin; and 0.48 parts per million in fat. A safe concentration refers to the total residue concentration considered safe in edible tissues.

[54 FR 5229, Feb. 2, 1989]

§ 556.380 Melengestrol acetate.

A tolerance of 25 parts per billion is established for residues of the parent compound, melengestrol acetate, in fat of cattle.

[59 FR 41241, Aug. 11, 1994]

§ 556.410 Metoserpate hydrochloride.

A tolerance of 0.02 part per million is established for negligible residues of metoserpate hydrochloride (methyl-o-methyl-18-epireserpate hydrochloride) in uncooked edible tissues of chickens.

[66 FR 19854, Apr. 18, 2001]

§ 556.420 Monensin.

(a) Acceptable daily intake (ADI). The ADI for total residues of monensin is 12.5 micrograms per kilogram of body weight per day.

(b) Tolerances. The tolerances for residues of monensin are:
§ 556.425 Morantel tartrate.

A tolerance of 0.7 part per million is established for N-methyl-1,3-propanediamine (MAPA, marker residue) in the liver (target tissue) of cattle and goats. A tolerance for residues of morantel tartrate in milk is not required.

[59 FR 17922, Apr. 15, 1994]

§ 556.426 Moxidectin.

(a) Acceptable daily intake (ADI). The ADI for total residues of moxidectin is 4 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Fat (the target tissue). The tolerance for parent moxidectin (the marker residue) is 900 parts per billion (ppb).

(ii) Liver. The tolerance for parent moxidectin (the marker residue) is 200 ppb.

(iii) Muscle. The tolerance for parent moxidectin (the marker residue) is 50 ppb.

(iv) Milk. The tolerance for parent moxidectin (the marker residue) is 40 ppb.

(2) Sheep—(i) Fat (the target tissue). The tolerance for parent moxidectin (the marker residue) is 900 parts per billion (ppb).

(ii) Liver. The tolerance for parent moxidectin (the marker residue) is 200 ppb.

(iii) Muscle. The tolerance for parent moxidectin (the marker residue) is 50 ppb.

(c) Related conditions of use. See §§ 550.1418 and 558.355 of this chapter.


§ 556.428 Narasin.

(a) Acceptable daily intake (ADI). The ADI for total residues of narasin is 5 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Chickens (abdominal fat). The tolerance for parent narasin (the marker residue) is 480 parts per billion.

(2) [Reserved]

[66 FR 23589, May 9, 2001]

§ 556.430 Neomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of neomycin is 6 micrograms per kilogram of body weight per day.

(b) Tolerances. Tolerances are established for residues of parent neomycin in uncooked edible tissues as follows:

(1) Cattle, swine, sheep, and goats. 7.2 parts per million (ppm) in kidney (target tissue) and fat, 3.6 ppm in liver, and 1.2 ppm in muscle.

(2) Turkeys. 7.2 ppm in skin with adhering fat, 3.6 ppm in liver, and 1.2 ppm in muscle.

(3) Milk. A tolerance is established for residues of parent neomycin of 0.15 ppm.

[64 FR 31498, June 11, 1999]

§ 556.440 Nequinate.

A tolerance of 0.1 part per million is established for negligible residues of nequinate in the uncooked edible tissues of chickens.

§ 556.445 Nicarbazin.

A tolerance of 4 parts per million is established for residues of nicarbazin in uncooked chicken muscle, liver, skin, and kidney.

[42 FR 56729, Oct. 28, 1977]

§ 556.460 Novobiocin.

Tolerances for residues of novobiocin are established at 0.1 part per million in milk from dairy animals and 1 part per million in the uncooked edible tissues of cattle, chickens, turkeys, and ducks.

[47 FR 18590, Apr. 30, 1982]

§ 556.470 Nystatin.

A tolerance of zero is established for residues of nystatin in or on eggs and

VerDate Sep<11>2014 10:06 Apr 14, 2016 Jkt 238075 PO 00000 Frm 00408 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31lpowell on DSK54DXVN1OFR with $$_JOB
the uncooked edible tissues of swine and poultry.

§ 556.480 Oleandomycin.

Tolerances are established for negligible residues of oleandomycin in uncooked edible tissues of chickens, turkeys, and swine at 0.15 part per million.

§ 556.490 Ormetoprim.

(a) [Reserved]

(b) Tolerances. A tolerance of 0.1 part per million (ppm) is established for negligible residues of ormetoprim in uncooked edible tissues of chickens, turkeys, ducks, salmonids, catfish, and chukar partridges.

[64 FR 26672, May 17, 1999]

§ 556.495 Oxfendazole.

Cattle: A tolerance is established for total oxfendazole residues in edible cattle tissues based on a marker residue concentration of 0.8 part per million (ppm) fenbendazole in the target liver tissue. A fenbendazole concentration of 0.8 ppm in liver corresponds to a total safe concentration of oxfendazole residues of 1.7 ppm in liver. The safe concentrations of total oxfendazole residues in other uncooked edible cattle tissues are: muscle, 0.84 ppm; kidney, 2.5 ppm; and fat, 3.3 ppm. A tolerance refers to the concentration of marker residue in the target tissue selected to monitor for total drug residue in the target animal. A safe concentration is the total residue considered safe in edible tissue.

[55 FR 46943, Nov. 8, 1990]

§ 556.500 Oxytetracycline.

(a) Acceptable daily intake (ADI). The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 micrograms per kilogram of body weight per day.

(b) Beef cattle, dairy cattle, calves, swine, sheep, chickens, turkeys, finfish, and lobster. Tolerances are established for the sum of residues of the tetracyclines including chlortetracycline, oxytetracycline, and tetracycline, in tissues and milk as follows:

(1) 2 parts per million (ppm) in muscle.

(2) 6 ppm in liver.

(3) 12 ppm in fat and kidney.

(4) 0.3 ppm in milk.


§ 556.510 Penicillin.

Tolerances are established for residues of penicillin and the salts of penicillin in food as follows:

(a) 0.05 part per million (negligible residue) in the uncooked edible tissues of cattle.

(b) Zero in the uncooked edible tissues of chickens, pheasants, quail, swine, and sheep; in eggs; and in milk or in any processed food in which such milk has been used.

(c) 0.01 part per million in the uncooked edible tissues of turkeys.

[40 FR 13942, Mar. 27, 1975, as amended at 43 FR 32749, July 28, 1978]

§ 556.513 Piperazine.

A tolerance of 0.1 part per million piperazine base is established for edible tissues of poultry and swine.

[64 FR 23019, Apr. 29, 1999]

§ 556.515 Pirlimycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of pirlimycin is 0.01 milligrams per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent pirlimycin (the marker residue) is 0.5 part per million (ppm).

(ii) Muscle. The tolerance for parent pirlimycin (the marker residue) is 0.3 ppm.

(iii) Milk. The tolerance for parent pirlimycin (the marker residue in cattle milk) is 0.4 ppm.

(2) [Reserved]

[65 FR 61091, Oct. 16, 2000]

§ 556.540 Progesterone.

(a) [Reserved]

(b) Tolerances. Residues of progesterone are not permitted in excess of the following increments above the concentrations of progesterone naturally present in untreated animals:

(1) Cattle and sheep—(i) Muscle: 5 parts per billion (ppb).

(ii) Liver: 15 ppb.
§ 556.560 Pyrantel tartrate.

Tolerances are established for residues of pyrantel tartrate in edible tissues of swine as follows:
(a) 10 parts per million in liver and kidney.
(b) 1 part per million in muscle.

§ 556.570 Ractopamine.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of ractopamine hydrochloride is 1.25 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for ractopamine hydrochloride (the marker residue) is 0.09 parts per million (ppm).
(ii) Muscle. The tolerance for ractopamine hydrochloride (the marker residue) is 0.03 ppm.
(2) Swine—(i) Liver (the target tissue). The tolerance for ractopamine hydrochloride (the marker residue) is 0.15 ppm.
(ii) Muscle. The tolerance for ractopamine hydrochloride (the marker residue) is 0.05 ppm.
(3) Turkeys—(i) Liver (the target tissue). The tolerance for ractopamine hydrochloride (the marker residue) is 0.45 ppm.
(ii) Muscle. The tolerance for ractopamine hydrochloride (the marker residue) is 0.1 ppm.

§ 556.580 Robenidine hydrochloride.

Tolerances are established for residues of robenidine hydrochloride in edible tissues of chickens as follows:
(a) 0.2 part per million in skin and fat.
(b) 0.1 part per million (negligible residue) in edible tissues other than skin and fat.

§ 556.592 Salinomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of salinomycin is 0.005 milligram per kilogram of body weight per day.

(b) [Reserved]

[56 FR 48296, Sept. 3, 1999]

§ 556.600 Spectinomycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of spectinomycin is 25 micrograms per kilogram of body weight per day.

(b) Chickens and turkeys. A tolerance of 0.1 part per million (ppm) for negligible residues of spectinomycin in uncooked edible tissues of chickens and turkeys is established.

(c) Cattle. A tolerance of 4 ppm for parent spectinomycin (marker residue) in kidney (target tissue) is established. A tolerance of 0.25 ppm for parent spectinomycin in cattle muscle is established.

[63 FR 4107, May 1, 1998; 63 FR 38304, July 16, 1998]

§ 556.610 Streptomycin.

Tolerances are established for residues of streptomycin in uncooked, edible tissues of chickens, swine, and calves of 2.0 parts per million (ppm) in kidney and 0.5 ppm in other tissues.

[58 FR 47211, Sept. 8, 1993]

§ 556.620 Sulfabromomethazine sodium.

Tolerances for residues of sulfabromomethazine sodium in food are established as follows:
(a) In the uncooked edible tissues of cattle at 0.1 part per million (negligible residue).
(b) In milk at 0.01 part per million (negligible residue).

[47 FR 30244, July 13, 1982]
§ 556.625 Sodium sulfachloropyrazine monohydrate.
A tolerance of zero is established for residues of sodium sulfachloropyrazine monohydrate in the uncooked edible tissues of chickens.

§ 556.630 Sulfachloropyridazine.
A tolerance of 0.1 part per million is established for negligible residues of sulfachloropyridazine in uncooked edible tissues of calves and swine.

§ 556.640 Sulfadimethoxine.
(a) [Reserved]
(b) Tolerances. (1) A tolerance of 0.1 part per million (ppm) is established for negligible residues of sulfadimethoxine in uncooked edible tissues of chickens, turkeys, cattle, ducks, salmonids, catfish, and chukar partridges.
(2) A tolerance of 0.01 ppm is established for negligible residues of sulfadimethoxine in milk.
[64 FR 26672, May 17, 1999]

§ 556.650 Sulfaethoxypyridazine.
Tolerances for residues of sulfaethoxypyridazine in food are established as follows:
(a) Zero in the uncooked edible tissues of swine and in milk.
(b) 0.1 part per million (negligible residue) in uncooked edible tissues of cattle.

§ 556.660 Sulfamerazine.
A tolerance of zero is established for residues of sulfamerazine (N1-[4-methyl-2-pyrimidinyl]sulfanilamide) in the uncooked edible tissues of trout.

§ 556.670 Sulfamethazine.
A tolerance of 0.1 part per million is established for negligible residues of sulfamethazine in the uncooked edible tissues of chickens, turkeys, cattle, and swine.
[47 FR 20323, June 11, 1982]

§ 556.685 Sulfafuinosaline.
A tolerance of 0.1 part per million is established for negligible residues of sulfafuinosaline in the uncooked edible tissues of chickens, turkeys, calves, and cattle.
[61 FR 24443, May 15, 1996]

§ 556.700 Sulfonyloxyn.
A tolerance of zero is established for residues of sulfonyloxyn (N-sulfomethyl-polymyxin B sodium salt) in uncooked edible tissues from chickens and turkeys.

§ 556.710 Testosterone propionate.
No residues of testosterone, resulting from the use of testosterone propionate, are permitted in excess of the following increments above the concentrations of testosterone naturally present in untreated animals:
(a) In uncooked edible tissues of heifers:
(1) 0.64 part per billion in muscle.
(2) 2.6 parts per billion in fat.
(3) 1.9 parts per billion in kidney.
(4) 1.3 parts per billion in liver.
(b) [Reserved]
[52 FR 27683, July 23, 1987]

§ 556.720 Tetracycline.
(a) Acceptable daily intake (ADI). The ADI for total tetracycline residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 micrograms per kilogram of body weight per day.
(b) Tolerances. Tolerances are established for the sum of tetracycline residues in tissues of calves, swine, sheep, chickens, and turkeys, of 2 parts per million (ppm) in muscle, 6 ppm in liver, and 12 ppm in fat and kidney.
[63 FR 57246, Oct. 27, 1998]

§ 556.730 Thiabendazole.
Tolerances are established at 0.1 part per million for negligible residues of thiabendazole in uncooked edible tissues of cattle, goats, sheep, pheasants, and swine, and at 0.05 part per million for negligible residues in milk.
[40 FR 13942, Mar. 27, 1975, as amended at 49 FR 29958, July 25, 1984]

§ 556.732 Tiamulin.
A tolerance of 0.6 part per million is established for 8-alpha-hydroxymutilin
§ 556.733 Tildipirosin.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of tildipirosin is 50 micrograms per kilogram of body weight per day.

(b) Tolerances. The tolerances for tildipirosin (the marker residue) are:

(1) Cattle—(i) Liver (the target tissue): 10 parts per million.

(2) [Reserved]

(c) Related conditions of use. See §522.2460 of this chapter.

[77 FR 39391, July 3, 2012, as amended at 78 FR 52854, Aug. 27, 2013]

§ 556.735 Tilmicosin.

(a) Acceptable daily intake (ADI). The ADI for total residues of tilmicosin is 25 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for parent tilmicosin (the marker residue) is 1.2 parts per million (ppm).

(ii) Muscle. The tolerance for parent tilmicosin (the marker residue) is 0.1 ppm.

(2) Swine—(i) Liver (the target tissue). The tolerance for parent tilmicosin (the marker residue) is 7.5 ppm.

(ii) Muscle. The tolerance for parent tilmicosin (the marker residue) is 0.1 ppm.

(3) Sheep—(i) Liver (the target tissue). The tolerance for parent tilmicosin (the marker residue) is 1.2 ppm.

(ii) Muscle. The tolerance for parent tilmicosin (the marker residue) is 0.1 ppm.


§ 556.739 Trenbolone.

(a) Acceptable daily intake (ADI). The ADI for total residues of trenbolone is 0.4 microgram per kilogram of body weight per day.

(b) Tolerances. A tolerance for total trenbolone residues in uncooked edible tissues of cattle is not needed.

[64 FR 18574, Apr. 15, 1999]

§ 556.740 Tylosin.

Tolerances are established for residues of tylosin in edible products of animals as follows:

(a) In chickens and turkeys: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(b) In cattle: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(c) In swine: 0.2 part per million (negligible residue) in uncooked fat, muscle, liver, and kidney.

(d) In milk: 0.05 part per million (negligible residue).

(e) In eggs: 0.2 part per million (negligible residue).

§ 556.741 Tripelennamine.

A tolerance of 200 parts per billion (ppb) is established for residues of tripelennamine in uncooked edible tissues of cattle and 20 ppb in milk.


§ 556.745 Tulathromycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of tulathromycin is 15 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for CP–60,300 (the marker residue) is 5.5 parts per million (ppm).

(ii) [Reserved]

(2) Swine—(i) Kidney (the target tissue). The tolerance for CP–60,300 (the marker residue) is 15 ppm.

(ii) [Reserved]

(c) Related conditions of use. See §522.2630 of this chapter.

[70 FR 39918, July 12, 2005]

§ 556.748 Tylosin.

(a) Acceptable Daily Intake (ADI). The ADI for total residues of tylosin is 47.7 micrograms per kilogram of body weight per day.

(b) Tolerances. A tolerance for tylosin in edible tissues of swine is not required.

(c) Related conditions of use. See §520.2645 of this chapter.

[77 FR 55415, Sept. 10, 2012]
§ 556.750 Virginiamycin.

(a) Acceptable daily intake (ADI). The ADI for total residues of virginiamycin is 250 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Swine. Tolerances are established for residues of virginiamycin in uncooked edible tissues of 0.4 part per million (ppm) in kidney, skin, and fat, 0.3 ppm in liver, and 0.1 ppm in muscle.

(2) Broiler chickens and cattle. A tolerance for residues of virginiamycin is not required.

[64 FR 48296, Sept. 3, 1999]

§ 556.760 Zeranol.

(a) Acceptable daily intake (ADI). The ADI for total residues of zeranol is 0.00125 milligrams per kilogram of body weight per day.

(b) Tolerances. The tolerances for residues of zeranol in edible tissues are:

(1) Cattle. A tolerance is not needed.

(2) Sheep. 20 parts per billion.

(c) Related conditions of use. See § 522.2680 of this chapter.


§ 556.765 Zilpaterol.

(a) Acceptable daily intake (ADI). The ADI for total residues of zilpaterol is 0.083 micrograms per kilogram of body weight per day.

(b) Tolerances—(1) Cattle—(i) Liver (the target tissue). The tolerance for zilpaterol (the marker residue) is 12 parts per billion (ppb).

(ii) Muscle. The tolerance for zilpaterol (the marker residue) is 10 ppb.

(2) [Reserved]

(c) Related conditions of use. See § 558.665 of this chapter.

[71 FR 53005, Sept. 8, 2006, as amended at 81 FR 17608, Mar. 30, 2016]

§ 556.770 Zoalene.

Tolerances are established for residues of zoalene (3,5-dinitro-o-toluamide) and its metabolite 3-amino-5-nitro-o-toluamide in food as follows:

(a) In edible tissues of chickens:

(1) 6 parts per million in uncooked liver and kidney.

(2) 3 parts per million in uncooked muscle tissue.

(3) 2 parts per million in uncooked fat.

(b) In edible tissues of turkeys: 3 parts per million in uncooked muscle tissue and liver.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

Subpart A—General Provisions

Sec. 558.3 Definitions and general considerations applicable to this part.
558.4 Requirement of a medicated feed mill license.
558.5 Requirements for liquid medicated feed.
558.6 Veterinary feed directive drugs.
558.15 Antibiotic, nitrofurans, and sulfonamide drugs in the feed of animals.

Subpart B—Specific New Animal Drugs For Use in Animal Feeds

558.55 Amprolium.
558.58 Amprolium and ethopabate.
558.59 Apramycin.
558.68 Avilamycin.
558.76 Bacitracin methylenedisalicylate.
558.78 Bacitracin zinc.
558.95 Bambermycins.
558.115 Carbadox.
558.128 Chlortetracycline.
558.140 Chlortetracycline and sulfamethazine.
558.145 Chlortetracycline, procaine penicillin, and sulfamethazine.
558.175 Clopidol.
558.185 Coumaphos.
558.195 Decoquinate.
558.198 Diclorovos.
558.205 Dichlorvos.
558.235 Efrotomycin.
558.248 Erythromycin.
558.254 Famphur.
558.258 Fenbendazole.
558.261 Florfenicol.
558.265 Halofuginone hydrobromide.
558.274 Hygromycin B.
558.285 Iodinated casein.
558.300 Ivermectin.
558.305 Laidlomycin.
558.311 Lasalocid.
558.325 Lincomycin.
558.340 Maduramicin.
558.342 Melengestrol.
558.348 Mibolerone.
558.355 Monensin.
558.360 Morantel tartrate.
558.363 Narasin.
558.364 Neomycin sulfate.
558.365 Nequinate.
§ 558.3 Definitions and general considerations applicable to this part.

(a) Regulations in this part provide for approved uses of drugs and combinations of drugs in animal feeds. Approved combinations of such drugs are specifically identified or incorporated by cross-reference. Unless specifically provided for by the regulations, a combination of two or more drugs is not approved.

(b) The following definitions apply to terms used in this part:

1. New animal drugs approved for use in animal feed are placed in two categories as follows:
   (i) Category I—These drugs require no withdrawal period at the lowest use level in each species for which they are approved.
   (ii) Category II—These drugs require a withdrawal period at the lowest use level for at least one species for which they are approved, or are regulated on a "no-residue" basis or with a zero tolerance because of a carcinogenic concern, regardless of whether a withdrawal period is required.

(2) A "Type A medicated article" is intended solely for use in the manufacture of another Type A medicated article or a Type B or Type C medicated feed. It consists of a new animal drug(s), with or without carrier (e.g., calcium carbonate, rice hull, corn, gluten) with or without inactive ingredients. The manufacture of a Type A medicated article requires an application approved under § 514.105 of this chapter or an index listing granted under § 516.151 of this chapter.

(3) A "Type B medicated feed" is intended solely for the manufacture of other medicated feeds (Type B or Type C). It contains a substantial quantity of nutrients including vitamins and/or minerals and/or other nutritional ingredients in an amount not less than 25 percent of the weight. It is manufactured by diluting a Type A medicated article or another Type B medicated feed. The maximum concentration of animal drug(s) in a Type B medicated feed is 200 times the highest continuous use level for Category I drugs and 100 times the highest continuous use level for Category II drugs. The term "highest continuous use level" means the highest dosage at which the drug is approved for continuous use (14 days or more), or, if the drug is not approved for continuous use, it means the highest level used for disease prevention or control. If the drug is approved for multiple species at different use levels, the highest approved level of use would govern under this definition. The manufacture of a Type B medicated feed from a Category II, Type A medicated article requires a medicated feed mill license application approved under § 515.20 of this chapter.

(4) A "Type C medicated feed" is intended as the complete feed for the animal or may be fed "top dressed" (added on top of usual ration) or offered "free-choice" (e.g., supplement) in conjunction with other animal feed. It contains a substantial quantity of nutrients including vitamins, minerals, and/or other nutritional ingredients. It is manufactured by diluting a Type A medicated article or a Type B medicated feed. A Type C medicated feed may be further diluted to produce another Type C medicated feed. The manufacture of a Type C medicated feed


SOURCE: 40 FR 13959, Mar. 27, 1975, unless otherwise noted.
§ 558.4 Requirement of a medicated feed mill license.

(a) A feed manufacturing facility must possess a medicated feed mill license in order to manufacture a Type B or Type C medicated feed from a Category II, Type A medicated article.

(b) The manufacture of the following types of feed are exempt from the required license, unless otherwise specified:

(1) A "veterinary feed directive (VFD) drug" is a drug intended for use in or on animal feed which is limited by an approved application filed pursuant to section 512(b) of the Federal Food, Drug, and Cosmetic Act, a conditionally approved application filed pursuant to section 571 of the Federal Food, Drug, and Cosmetic Act, or an index listing under section 572 of the Federal Food, Drug, and Cosmetic Act to use under the professional supervision of a licensed veterinarian. Use of animal feed bearing or containing a VFD drug must be authorized by a lawful veterinary feed directive.

(2) A "combination veterinary feed directive (VFD) drug" is a combination new animal drug (as defined in § 514.4(c)(1)(i) of this chapter) intended for use in or on animal feed which is limited by an approved application filed under section 512(b) of the Federal Food, Drug, and Cosmetic Act, a conditionally approved application filed under section 571 of the Federal Food, Drug, and Cosmetic Act, or an index listing under section 572 of the Federal Food, Drug, and Cosmetic Act to use under the professional supervision of a licensed veterinarian, and at least one of the new animal drugs in the combination is a VFD drug. Use of animal feed bearing or containing a combination VFD drug must be authorized by a lawful VFD.

(1) Type B or Type C medicated feed using Category I, Type A medicated articles or Category I, Type B or Type C medicated feeds; and

(2) Type B or Type C medicated feed using Category II, Type B or Type C medicated feeds.

(c) The use of Type B and Type C medicated feeds shall also conform to the conditions of use provided for in subpart B of this part and in §558.15 of this chapter.

d) This paragraph identifies each drug by category, the maximum level of drug in Type B medicated feeds, and the assay limits for the drug in Type A medicated articles and Type B and Type C medicated feeds, as follows:

### CATEGORY I

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type B maximum (200x)</th>
<th>Assay limits percent 1 type A</th>
<th>Assay limits percent 1 type B/C 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprolium with Ethopabate</td>
<td>94–114 22.75 g/lb (5.0%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Avilamycin</td>
<td>90–110 3.65 g/lb (0.8%)</td>
<td>80–110.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate</td>
<td>85–115 25.0 g/lb (5.5%)</td>
<td>70–130.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin zinc</td>
<td>84–115 5.0 g/lb (1.1%)</td>
<td>70–130.</td>
<td></td>
</tr>
<tr>
<td>Bambermycins</td>
<td>90–110 800 g/ton (0.09%)</td>
<td>80–120/70–130.</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline</td>
<td>85–115 40.0 g/lb (8.8%)</td>
<td>80–115/70–130.</td>
<td></td>
</tr>
<tr>
<td>Cucumarios</td>
<td>95–115 6.0 g/lb (1.3%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Decoquinate</td>
<td>90–105 2.72 g/lb (0.6%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Dichlorovincimid</td>
<td>90–120/80–130.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diclazuril</td>
<td>90–110 182 g/t (0.02%)</td>
<td>85–115/70–120.</td>
<td></td>
</tr>
<tr>
<td>Eflornithine</td>
<td>94–113 4.15 g/lb (0.32%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Erythromycin (chlortetracycline)</td>
<td>85–115 14.97 g/lb (2.04%)</td>
<td>&lt;20 g/ton 70–115/150–200 g/ton 75–125.</td>
<td></td>
</tr>
<tr>
<td>Iodinated casen</td>
<td>85–115 20.0 g/lb (4.4%)</td>
<td>75–125.</td>
<td></td>
</tr>
<tr>
<td>Laidlomycin propionate sodium potassium</td>
<td>90–110 1 g/lb (0.22%)</td>
<td>90–115/85–115.</td>
<td></td>
</tr>
<tr>
<td>Lasalocid</td>
<td>95–115 40.0 g/lb (8.8%)</td>
<td>80–130.</td>
<td></td>
</tr>
<tr>
<td>Lincomycin</td>
<td>90–110 20.0 g/lb (4.4%)</td>
<td>80–130.</td>
<td></td>
</tr>
<tr>
<td>Melengestrol acetate</td>
<td>90–110 10.0 g/ton (0.0011%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Morninol</td>
<td>85–115 40.0 g/lb (8.8%)</td>
<td>75–125.</td>
<td></td>
</tr>
<tr>
<td>Narasing</td>
<td>90–110 7.2 g/lb (1.6%)</td>
<td>85–115/70–125.</td>
<td></td>
</tr>
<tr>
<td>Nequinate</td>
<td>95–112 1.83 g/lb (0.4%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Nyatatin</td>
<td>85–125 5.0 g/lb (1.1%)</td>
<td>80–130.</td>
<td></td>
</tr>
<tr>
<td>Oleanomycin</td>
<td>85–120 1.125 g/lb (0.25%)</td>
<td>&lt;11.25 g/ton 70–130; &gt;11.25 g/ton 75–125.</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>90–120 20.0 g/lb (4.4%)</td>
<td>75–125/85–135.</td>
<td></td>
</tr>
<tr>
<td>Penicillin</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>65–135.</td>
<td></td>
</tr>
<tr>
<td>Poloxalene</td>
<td>90–110 5.48 g/lb (12.0%)</td>
<td>Liq. feed: 85–115.</td>
<td></td>
</tr>
<tr>
<td>Ractopamine</td>
<td>85–105 2.46 g/lb (0.54%)</td>
<td>80–110/75–125.</td>
<td></td>
</tr>
<tr>
<td>Salinomycin</td>
<td>90–110 6.0 g/lb (1.3%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Semduramicin (as semduramicin sodium)</td>
<td>90–110 2.27 g/lb (0.50%)</td>
<td>80–110.</td>
<td></td>
</tr>
<tr>
<td>Semduramicin (as semduramicin sodium biomass)</td>
<td>90–110 2.27 g/lb (0.50%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Tylosomal</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Virginiamycin</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>70–130.</td>
<td></td>
</tr>
<tr>
<td>Zoelene</td>
<td>92–104 13.55 g/lb (2.5%)</td>
<td>85–115.</td>
<td></td>
</tr>
</tbody>
</table>

1 Percent of labeled amount.

2 Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make Type C medicated feed.

### CATEGORY II

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type B maximum (100x)</th>
<th>Assay limits percent 1 type A</th>
<th>Assay limits percent 1 type B/C 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amprolium</td>
<td>94–114 11.35 g/lb (2.5%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Avilamycin</td>
<td>88–112 7.5 g/lb (1.65%)</td>
<td>80–120.</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylene disalicylate</td>
<td>90–110 2.5 g/lb (0.50%)</td>
<td>75–125.</td>
<td></td>
</tr>
<tr>
<td>Clopidol</td>
<td>94–106 11.4 g/lb (2.5%)</td>
<td>90–115/80–120.</td>
<td></td>
</tr>
<tr>
<td>Famphur</td>
<td>100–110 5.5 g/lb (1.21%)</td>
<td>90–115/80–120.</td>
<td></td>
</tr>
<tr>
<td>Fenbendazole</td>
<td>93–113 8.87 g/lb (1.96%)</td>
<td>75–125.</td>
<td></td>
</tr>
</tbody>
</table>
Food and Drug Administration, HHS §558.5

CATEGORY II—Continued

<table>
<thead>
<tr>
<th>Drug</th>
<th>Assay limits percent 1 Type A</th>
<th>Type B maximum (100x)</th>
<th>Assay limits percent 1 Type B/C2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Florfenicol</td>
<td>90–110 9.1 g/lb (2.0%)</td>
<td>Seine feed: 85–115, Catfish feed: 80–110, Salmonid feed: 80–110</td>
<td></td>
</tr>
<tr>
<td>Halofuginone hydrobromide</td>
<td>90–115 272.0 g/ton (0.3%)</td>
<td>65–135</td>
<td></td>
</tr>
<tr>
<td>Hygromycin B</td>
<td>90–110 1.200 g/ton (0.13%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Ivermectin</td>
<td>90–110 567.5 g/lb (1.25%)</td>
<td>85–115/75–125</td>
<td></td>
</tr>
<tr>
<td>Morantel tartrate</td>
<td>90–110 66.0 g/lb (14.25%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Neomycin</td>
<td>80–120 7.0 g/lb (1.54%)</td>
<td>70–125</td>
<td></td>
</tr>
<tr>
<td>Oxytetracycline</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>65–135</td>
<td></td>
</tr>
<tr>
<td>Neomycin sulfate</td>
<td>80–120 100 g/lb (22.0%)</td>
<td>70–125</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin (granular)</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td>85–115/75–125</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin (powder)</td>
<td>98–106 5.675 g/lb (1.25%)</td>
<td>85–115/80–120</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin (granular)</td>
<td>85–115 17.5 g/lb (3.85%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Pyrantel tartrate</td>
<td>90–110 36 g/lb (7.9%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Robenidine</td>
<td>95–115 1.5 g/lb (0.33%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Sulfadimethoxine</td>
<td>90–110 5.675 g/lb (1.25%)</td>
<td>85–115/75–125</td>
<td></td>
</tr>
<tr>
<td>Ormetoprim (5/3)</td>
<td>90–110 3.425 g/lb (0.75%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Ormetoprim (5/1)</td>
<td>90–110 17.0 g/lb (3.75%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfamerazine</td>
<td>85–115 18.6 g/lb (4.0%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Sulfamethazine</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130</td>
<td></td>
</tr>
<tr>
<td>Penicillin</td>
<td>85–115 5.0 g/lb (1.1%)</td>
<td>85–125/70–130</td>
<td></td>
</tr>
<tr>
<td>Sulfamethazine</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Chlorotetracycline</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>85–125/70–130</td>
<td></td>
</tr>
<tr>
<td>Sulfalexazine</td>
<td>85–115 10.0 g/lb (2.2%)</td>
<td>80–120</td>
<td></td>
</tr>
<tr>
<td>Tyllosin</td>
<td>80–120 10.0 g/lb (2.2%)</td>
<td>75–125</td>
<td></td>
</tr>
<tr>
<td>Sulfamerazine</td>
<td>85–115 11.2 g/lb (2.5%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Thiabendazole</td>
<td>94–106 45.4 g/lb (10.0%)</td>
<td>&gt;7% 85–115, &lt;7% 90–110</td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>90–115 10 g/lb</td>
<td>90–115/70–130</td>
<td></td>
</tr>
<tr>
<td>Dimethocarb</td>
<td>90–110 37.9 g/lb (8.3%)</td>
<td>85–115</td>
<td></td>
</tr>
<tr>
<td>Ziprothric</td>
<td>90–110 680 g/lb (0.075%)</td>
<td>80–110/75–115</td>
<td></td>
</tr>
</tbody>
</table>

1Percent of labeled amount.
2Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two range limit, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed. These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B medicated feed with lower assay limits to make a Type C medicated feed.

(e) When drugs from both categories are in combination, the Category II requirements will apply to the combination drug product.

[51 FR 7392, Mar. 3, 1986]

Editorial Note: For Federal Register citations affecting §558.4, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

Effective Date Note: At 81 FR 11665, Mar. 7, 2016, §558.4, paragraph (c) was amended by removing the phrase “and in §558.15 of this chapter”, effective Apr. 6, 2016.

§558.5 Requirements for liquid medicated feed.

(a) What types of liquid medicated feeds are covered by this section? This section covers the following types of liquid medicated feed:

(1) Type B feed that is intended for further manufacture of other medicated feeds (§558.3(b)(3)) or:
(2) Type C feed that is intended for the following:

(i) Further manufacture of another Type C feed, or
(ii) Top-dressing (adding on top of the usual ration) (§558.3(b)(4)).

(b) How is liquid free-choice medicated feed regulated? Liquid free-choice medicated feed is covered by this section and by §510.455.

(c) What is required for new animal drugs intended for use in liquid feed? Any new animal drug intended for use in liquid feed must be approved for such use under section 512 of the Federal Food, Drug, and Cosmetic Act (the act) or index listed under section 372 of the act. Such approvals under section 512 of the act must be:

(1) An original NADA,
(2) A supplemental NADA, or
(3) An abbreviated NADA.
(d) What are the approval requirements under section 512 of the act for new animal drugs intended for use in liquid feed? An approval under section 512 of the act for a new animal drug intended for use in liquid feed must contain the following information:
(1) Data, or a reference to data in a master file (MF), that shows the relevant ranges of conditions under which the drug will be chemically stable in liquid feed under field use conditions; and
(2) Data, or a reference to data in an MF, that shows that the drug is physically stable in liquid feed under field conditions; or
(3) Feed labeling with recirculation or agitation directions as follows:
(i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for not less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
(ii) For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.
(e) How are chemical and physical stability data to be submitted? The data must be submitted as follows:
(1) Directly in the NADA,
(2) By a sponsor, or
(3) To an MF that a sponsor may then reference in its NADA with written consent of the MF holder.
(f) What will be stated in the published approval for a new animal drug intended for use in liquid feed? The approval of a new animal drug intended for use in liquid feed as published in this subchapter will include the following requirements:
(1) The formula and/or specifications of the liquid medicated feed, where the owner of this information requests such publication; and/or
(2) A statement that the approval has been granted for a proprietary formula and/or specifications.
(g) When is a medicated feed mill license required for the manufacture of a liquid medicated feed? An approved medicated feed mill license is required for the manufacture of the following types of feeds:
(1) All liquid medicated feeds that contain a Category II drug, and
(2) Liquid medicated feeds that contain a Category I drug and use a proprietary formula and/or specifications.
(h) What measures are in place to prevent certain drugs, approved for use in animal feed or drinking water but not in liquid medicated feed, from being diverted to use in liquid feeds? Any product containing any form of bacitracin, oxytetracycline, or chlortetracycline, intended for oral administration via animal feed and/or drinking water, and not approved for use in a liquid medicated feed must include in its labeling the following statement: "FOR USE IN LIQUID MEDICATED FEEDS." The blank may be filled in with the words: "DRY FEEDS", "DRINKING WATER", or "DRY FEEDS AND DRINKING WATER".
(i) Can the labeling provisions of paragraph (h) of this section be waived, and how can I apply for a waiver? (1) The labeling provisions of paragraph (h) of this section may be waived if there is evidence to indicate that it is unlikely a new animal drug would be used in the manufacture of a liquid medicated feed.
(2) To obtain a waiver, you must submit a letter requesting a waiver to the Office of New Animal Drug Evaluation (HFV–100), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.
(3) The letter must include a copy of the product label; a description of the formulation; and information to establish that the physical, chemical, or other properties of the new animal drug are such that diversion to use in liquid medicated feed is unlikely.
(j) What else do I need to know about the labeling provisions of paragraph (h) of this section? The labeling provisions of paragraph (h) of this section may be implemented without prior approval as
§ 558.6 Veterinary feed directive drugs.

(a) General requirements related to veterinary feed directive (VFD) drugs. (1) Animal feed bearing or containing a VFD drug or a combination VFD drug (a VFD feed or combination VFD feed) may be fed to animals only by or upon a lawful VFD issued by a licensed veterinarian.

(2) A VFD feed or combination VFD feed must not be fed to animals after the expiration date on the VFD.

(3) Use and labeling of a VFD drug or a combination VFD drug in feed is limited to the approved, conditionally approved, or indexed conditions of use. Use of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted.

(4) All involved parties (the veterinarian, the distributor, and the client) must retain a copy of the VFD for 2 years. The veterinarian must retain the original VFD in its original form (electronic or hardcopy). The distributor and client copies may be kept as an electronic copy or hardcopy.

(5) All involved parties must make the VFD and any other records specified in this section available for inspection and copying by FDA upon request.

(6) All labeling and advertising for VFD drugs, combination VFD drugs, and feeds containing VFD drugs or combination VFD drugs must prominently and conspicuously display the following cautionary statement: “Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.”

(b) Responsibilities of the veterinarian issuing the VFD. (1) In order for a VFD to be lawful, the veterinarian issuing the VFD must:

(i) Be licensed to practice veterinary medicine; and

(ii) Be operating in the course of the veterinarian’s professional practice and in compliance with all applicable veterinary licensing and practice requirements, including issuing the VFD in the context of a veterinarian-client-patient relationship (VCPR) as defined by the State. If applicable VCPR requirements as defined by such State do not include the key elements of a valid VCPR as defined in §530.3(i) of this chapter, the veterinarian must issue the VFD in the context of a valid VCPR as defined in §530.3(i) of this chapter.

(2) The veterinarian must only issue a VFD that is in compliance with the conditions for use approved, conditionally approved, or indexed for the VFD drug or combination VFD drug.

(3) The veterinarian must ensure that the following information is fully and accurately included on the VFD:

(i) The veterinarian’s name, address, and telephone number;

(ii) The client’s name, business or home address, and telephone number;

(iii) The premises at which the animals specified in the VFD are located;

(iv) The date of VFD issuance;

(v) The expiration date of the VFD. This date must not extend beyond the expiration date specified in the approval, conditional approval, or index listing, if such date is specified. In cases where the expiration date is not specified in the approval, conditional approval, or index listing, the expiration date of the VFD must not exceed 6 months after the date of issuance;

(vi) The name of the VFD drug(s);

(vii) The species and production class of animals to be fed the VFD feed;

(viii) The approximate number of animals to be fed the VFD feed by the expiration date of the VFD. The approximate number of animals is the potential number of animals of the species and production class identified on the VFD that will be fed the VFD feed or combination VFD feed at the specified premises by the expiration date of the VFD;

(ix) The indication for which the VFD is issued;

(x) The level of VFD drug in the VFD feed and duration of use;

(xi) The withdrawal time, special instructions, and cautionary statements necessary for use of the drug in conformance with the approval;

(xii) The number of reorders (refills) authorized, if permitted by the drug
approval, conditional approval, or index listing. In cases where reorders (refills) are not specified on the labeling for an approved, conditionally approved, or index listed VFD drug, reorders (refills) are not permitted;

(xiii) The statement: “Use of feed containing this veterinary feed directive (VFD) drug in a manner other than as directed on the labeling (extralabel use) is not permitted.”;

(xiv) An affirmation of intent for combination VFD drugs as described in paragraph (6) of this section; and

(xv) The veterinarian’s electronic or written signature.

(4) The veterinarian may, at his or her discretion, enter the following information on the VFD to more specifically identify the animals authorized to be treated/fed the VFD feed:

(i) A more specific description of the location of animals (e.g., by site, pen, barn, stall, tank, or other descriptor that the veterinarian deems appropriate);

(ii) The approximate age range of the animals;

(iii) The approximate weight range of the animals; and

(iv) Any other information the veterinarian deems appropriate to identify the animals specified in the VFD.

(5) For VFDs intended to authorize the use of an approved, conditionally approved, or indexed combination VFD drug that includes more than one VFD drug, the veterinarian must include the drug-specific information required in paragraphs (b)(3)(vi), (ix), (x), and (xi) of this section for each VFD drug in the combination.

(6) The veterinarian may restrict VFD authorization to only include the VFD drug(s) cited on the VFD or may expand such authorization to allow the use of the cited VFD drug(s) along with one or more over-the-counter (OTC) animal drugs in an approved, conditionally approved, or indexed combination VFD drug. The veterinarian must affix his or her intent regarding combination VFD drugs by including one of the following statements on the VFD:

(i) “This VFD only authorizes the use of the VFD drug(s) cited in this order and is not intended to authorize the use of such drug(s) in combination with any other animal drugs.”

(ii) “This VFD authorizes the use of the VFD drug(s) cited in this order in the following FDA-approved, conditionally approved, or indexed combination(s) in medicated feed that contains the VFD drug(s) as a component.”

[List specific approved, conditionally approved, or indexed combination medicated feeds following this statement.]

(iii) “This VFD authorizes the use of the VFD drug(s) cited in this order in any FDA-approved, conditionally approved, or indexed combination(s) in medicated feed that contains the VFD drug(s) as a component.”

(7) The veterinarian must issue a written (nonverbal) VFD.

(8) The veterinarian must send a copy of the VFD to the distributor via hardcopy, facsimile (fax), or electronically. If in hardcopy, the veterinarian must send the copy of the VFD to the distributor either directly or through the client.

(9) The veterinarian must provide a copy of the VFD to the client.

(c) Responsibilities of any person who distributes an animal feed containing a VFD drug or a combination VFD drug.

(1) The distributor is permitted to fill a VFD only if the VFD contains all the information required in paragraph (b)(3) of this section.

(2) The distributor is permitted to distribute an animal feed containing a VFD drug or combination VFD drug only if it complies with the terms of the VFD and is manufactured and labeled in conformity with the approved, conditionally approved, or indexed conditions of use for such drug.

(3) The distributor must keep records of the receipt and distribution of all medicated animal feed containing a VFD drug for 2 years.

(4) In addition to other applicable recordkeeping requirements found in this section, if the distributor manufactures the animal feed bearing or containing the VFD drug, the distributor must also keep VFD feed manufacturing records for 1 year in accordance with part 225 of this chapter. Such records must be made available for inspection and copying by FDA upon request.

(5) A distributor of animal feed containing a VFD drug must notify FDA prior to the first time it distributes
animal feed containing a VFD drug. The notification is required one time per distributor and must include the following information:

(i) The distributor’s complete name and business address;

(ii) The distributor’s signature or the signature of the distributor’s authorized agent; and

(iii) The date the notification was signed.

(6) A distributor must also notify FDA within 30 days of any change in ownership, business name, or business address.

(7) The notifications cited in paragraphs (c)(5) and (c)(6) of this section must be submitted to the Food and Drug Administration, Center for Veterinary Medicine, Division of Animal Feeds (HFV–220), 7519 Standish Pl., Rockville, MD 20855, FAX: 240–453–6882.

(8) A distributor is permitted to distribute a VFD feed to another distributor only if the originating distributor (consignor) first obtains a written (nonverbal) acknowledgment letter, as defined in §558.3(b)(11), from the receiving distributor (consignee) before the feed is shipped. Consignor distributors must retain a copy of each consignee distributor’s acknowledgment letter for 2 years.

§558.15 Antibiotic, nitrofuran, and sulfonamide drugs in the feed of animals.

(a) The Commissioner of Food and Drugs will propose to revoke currently approved subtherapeutic (increased rate of gain, disease prevention, etc.) uses in animal feed of antibiotic and sulfonamide drugs whether granted by approval of new animal drug applications, master files and/or antibiotic or food additive regulations, by no later than April 20, 1975, or the nitrofuran drugs by no later than September 5, 1975, unless data are submitted which resolve conclusively the issues concerning their safety to man and animals and their effectiveness under specific criteria established by the Food and Drug Administration based on the guidelines included in the report of the FDA task force on the use of antibiotics in animal feeds. All persons or firms previously marketing identical, related, or similar products except the nitrofuran drugs not the subject of an approved new animal drug application must submit a new animal drug application by July 19, 1973, or by December 4, 1973, in the case of nitrofuran drugs, if marketing is to continue during the interim. New animal drug entities with antibacterial activity not previously marketed, now pending approval or submitted for approval prior to, on, or following the effective date of this publication, shall satisfy such criteria prior to approval.

(b) Any person interested in developing data which will support retaining approval for such uses of such antibiotic, nitrofuran, and sulfonamide drugs pursuant to section 512(1) of the Federal Food, Drug, and Cosmetic Act shall submit to the Commissioner the following:

(1) By July 19, 1973, records and reports of completed, ongoing, or planned studies, including protocols, on the tetracyclines, streptomycin, dihydrostreptomycin, penicillin, and the sulfonamides; for all other antibiotics by October 17, 1973; and for the nitrofuran drugs by March 4, 1974. The Food and Drug Administration encourages sponsors to consult with the Center for Veterinary Medicine on protocol design and plans for future studies.

(2) By April 20, 1974, data from completed studies on the tetracyclines, streptomycin, dihydrostreptomycin, the sulfonamides, and penicillin assessing the effect of the subtherapeutic use of the drug in feed on the salmonella reservoir in the target animal as compared to that in nonmedicated controls. Failure to complete the salmonella studies for any of these drugs by that time will be grounds for proceeding to immediately withdraw approval.

(3) By April 20, 1975, data satisfying all other specified criteria for safety and effectiveness, including the effect on the salmonella reservoir for any antibiotic or sulfonamide drugs and by September 5, 1975, for the nitrofuran drugs, approved for subtherapeutic use in animal feeds. Drug efficacy data shall be submitted for any feed-use combination product containing such drug and any feed-use single ingredient.
antibiotic, nitrofuran, or sulfonamide not reviewed by the National Academy of Sciences—National Research Council, Drug Efficacy Study covering drugs marketed between 1938 and 1962.

(4) Progress reports on studies underway every January 1 and July 1 until completion.

(c) Failure on the part of any sponsor to comply with any of the provisions of paragraph (b) of this section for any of the antibacterial drugs included in paragraph (b)(1) of this section, or interim results indicating a health hazard, will be considered as grounds for immediately proceeding to withdraw approval of that drug for use in animal feeds under section 512(l) of the act in the case of failure to submit required records and reports and under section 512(e) where new information shows that such drug is not shown to be safe.

(d) Criteria based upon the guidelines laid down by the task force may be obtained from the Food and Drug Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.

(e) Reports as specified in this section shall be submitted to: Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation (HFV–100), 7500 Standish Pl., Rockville, MD 20855.

(f) Following the completion of the requirements of paragraphs (a) and (b) of this section and the studies provided for therein:

(1) Those antibiotic, nitrofuran, and sulfonamide drugs which fail to meet the prescribed criteria for subtherapeutic uses but which are found to be effective for the therapeutic purposes will be permitted in feed only for high-level, short-term therapeutic use and only by or on the order of a licensed veterinarian.

(2) Animal feeds containing antibacterial drugs permitted to remain in use for subtherapeutic purposes shall be labeled to include a statement of the quantity of such drugs.

(g) The submission of applications and data required by paragraphs (a) and (b) of this section is not required for the continued manufacture of any Type A medicated article which is produced solely from a Type A article that is in compliance with the requirements of this section: Provided, That the Type A medicated article contains no drug ingredient whose use in or on animal feed requires an approved application pursuant to section 512(m) of the act and/or where the Type A article is approved by regulation in this part.

(1) The following antibacterial Type A articles manufactured by the designated sponsors are eligible for interim marketing based on their compliance with the requirements of this section:

<table>
<thead>
<tr>
<th>Drug sponsor</th>
<th>Type A article</th>
<th>Species</th>
<th>Use levels</th>
<th>Indications for use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fermenta Animal Health Co.</td>
<td>Bacitracin methylene disalicylate</td>
<td>Chicken, turkeys, swine, and cattle</td>
<td>Sec. 558.76</td>
<td>Sec. 558.76</td>
</tr>
</tbody>
</table>

(2) [Reserved]


EFFECTIVE DATE NOTE: At 81 FR 11665, Mar. 7, 2016, §558.15 was removed, effective Apr. 6, 2016.
§ 558.55 Amprolium.

(a) Approvals. Type A medicated articles: 25 percent to No. 016592 in §510.600(c) of this chapter for use as in paragraph (d) of this section.

(b) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(c) Related tolerances. See §556.50 of this chapter.

(d) Conditions of use—(1) Cattle. It is used as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 113.5 to 11, 350; to provide 5 milligrams per kilogram of body weight per day.</td>
<td>Calves: As an aid in the prevention of coccidiosis caused by Eimeria bovis and E. zuernii. Top-dress on or mix in the daily ration. Feed for 21 days when experience indicates that coccidiosis is likely to be a hazard, as the sole source of amprolium. Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.</td>
<td>016592</td>
<td></td>
</tr>
<tr>
<td>(ii) 113.5 to 11, 350; to provide 10 milligrams per kilogram of body weight per day.</td>
<td>Calves: As an aid in the treatment of coccidiosis caused by Eimeria bovis and E. zuernii. Top-dress on or mix in the daily ration. Feed for 5 days as the sole source of amprolium. Withdraw 24 hours before slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.</td>
<td>016592</td>
<td></td>
</tr>
</tbody>
</table>

(2) Chickens. It is used as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 36.3 to 113.5 ....</td>
<td>Replacement chickens: For development of active immunity to coccidiosis.</td>
<td>Feed continuously until onset of production as follows:</td>
<td>016592</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growing conditions</th>
<th>Up to 5 weeks of age</th>
<th>From 5 to 8 weeks of age</th>
<th>Over 8 weeks of age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe exposure to coccidiosis</td>
<td>----------------</td>
<td>113.5</td>
<td>72.6–113.5</td>
</tr>
<tr>
<td></td>
<td>(0.0125%)</td>
<td>(0.008%–0.0125%)</td>
<td>(0.004%–0.0125%)</td>
</tr>
<tr>
<td>Moderate exposure to coccidiosis</td>
<td>----------------</td>
<td>72.6–113.5</td>
<td>54.5–113.5</td>
</tr>
<tr>
<td></td>
<td>(0.008%–0.0125%)</td>
<td>(0.006%–0.0125%)</td>
<td>(0.004%–0.0125%)</td>
</tr>
<tr>
<td>Slight exposure to coccidiosis</td>
<td>----------------</td>
<td>36.3–113.5</td>
<td>36.3–113.5</td>
</tr>
<tr>
<td></td>
<td>(0.004%–0.0125%)</td>
<td>(0.004%–0.0125%)</td>
<td>(0.004%–0.0125%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) 36.3 to 113.5 .... Bacitracin methylenedisalicylate 4 to 50.</td>
<td>Replacement chickens: For development of active immunity to coccidiosis; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed according to suitable in item (i). Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>(iii) 72.6 to 113.5 ....</td>
<td>Broiler chickens: For prevention of coccidiosis caused by Eimeria tenella only. Feed continuously as the sole ration; as the sole source of amprolium.</td>
<td></td>
<td>016592</td>
<td></td>
</tr>
<tr>
<td>(iv) 72.6 to 113.5 .... Bambermycins 1 to 2.</td>
<td>Broiler chickens: For prevention of coccidiosis caused by Eimeria tenella only; and for increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>016592</td>
<td></td>
</tr>
<tr>
<td>(v) 113.5 .... 1. Laying chickens: For prevention of coccidiosis.</td>
<td></td>
<td>Feed continuously as the sole ration; as the sole source of amprolium.</td>
<td>016592</td>
<td></td>
</tr>
</tbody>
</table>
§ 558.58 Amprolium and ethopabate.

(a) Specifications. Type A medicated articles containing:

(1) 25 percent amprolium and 8 percent ethopabate or 5 percent amprolium and 1.6 percent ethopabate;

(2) 25 percent amprolium and 0.8 percent ethopabate or 5 percent amprolium and 0.16 percent ethopabate.

(b) Approvals. See No. 016592 in §510.600(c) of this chapter.

(c) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(d) Related tolerances. See §§556.50 and 556.260 of this chapter.

(e) Conditions of use. It is used in chicken feed as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(vi) 113.5 to 227</td>
<td></td>
<td>2. Laying chickens: For treatment of coccidiosis in moderate outbreaks.</td>
<td>Feed for 2 weeks.</td>
<td>016592</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Replacement chickens: For prevention of coccidiosis where immunity to coccidiosis is not desired.</td>
<td>Feed continuously from day-old until onset of production; as the sole source of amprolium.</td>
<td>016592</td>
</tr>
<tr>
<td>(vii) 113.5 to 227</td>
<td>Bambermycins 1 to 2.</td>
<td>2. Broiler chickens: For prevention of coccidiosis where immunity to coccidiosis is not desired; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium.</td>
<td>016592</td>
</tr>
<tr>
<td>(viii) 227</td>
<td></td>
<td>Laying chickens: For treatment of coccidiosis in severe outbreaks.</td>
<td>Feed for 2 weeks</td>
<td>016592</td>
</tr>
</tbody>
</table>

(3) Turkeys. It is used as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 113.5</td>
<td>Bambermycins 1 to 4.</td>
<td>Growing turkeys: For prevention of coccidiosis; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as the sole source of amprolium; bambermycins as provided by No. 016592 in §510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
<tr>
<td>(ii) 113.5 to 227</td>
<td></td>
<td>Turkeys: For prevention of coccidiosis.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium.</td>
<td>016592</td>
</tr>
</tbody>
</table>

(4) Pheasants. It is used as follows:

<table>
<thead>
<tr>
<th>Amprolium in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 159</td>
<td></td>
<td>Growing pheasants: For the prevention of coccidiosis caused by Eimeria coellichi, E. duodenalis, and E. phasiani.</td>
<td>Feed continuously as sole ration; use as sole source of amprolium.</td>
<td>016592</td>
</tr>
<tr>
<td>(ii) [Reserved]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprolium and ethopabate in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>(1) Amprolium 113.5 and ethopabate 3.6.</td>
<td></td>
<td>Broiler chickens: As an aid in the prevention of coccidiosis.</td>
<td>Feed continuously as sole ration; as sole source of amprolium. Not for laying chickens.</td>
<td>016592</td>
</tr>
<tr>
<td>(2) Amprolium 113.5 and ethopabate 3.6.</td>
<td>Lincomycin 2 to 4 ...</td>
<td>Broiler chickens: As an aid in the prevention of coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration; as sole source of amprolium. Not for laying chickens. Lincomycin as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(3) Amprolium 113.5 and ethopabate 36.3.</td>
<td></td>
<td>Broiler chickens and replacement chickens: where immunity to coccidiosis is not desired; As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur.</td>
<td>Feed continuously as sole ration; as sole source of amprolium. Not for chickens over 16 weeks of age.</td>
<td>016592</td>
</tr>
<tr>
<td>(4) Amprolium 113.5 and ethopabate 36.3.</td>
<td>Bacitracin 4 to 50 ...</td>
<td>1. Broiler chickens and replacement chickens: where immunity to coccidiosis is not desired; As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain in broiler chickens raised in floor pens.</td>
<td>Feed as the sole ration from the time chickens are placed on litter until past the time when coccidiosis is ordinarily a hazard. Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for outbreaks of coccidiosis. Bacitracin as bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
<tr>
<td>(5) Amprolium 113.5 and ethopabate 36.3.</td>
<td>Bacitracin 4 to 50 ...</td>
<td>2. Broiler chickens: As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for improved feed efficiency.</td>
<td>Feed as the sole ration from the time chickens are placed on litter until market weight. Not for chickens over 16 weeks of age; do not feed to laying chickens; as sole source of amprolium; not for use as a treatment for coccidiosis. Bacitracin zinc as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(6) Amprolium 113.5 and ethopabate 36.3.</td>
<td>Bambermycins 1 to 3.</td>
<td>Broiler chickens: As an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain, improved feed efficiency.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium. Bambermycins as provided by No. 016592 in §510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
<tr>
<td>(7) Amprolium 113.5 and ethopabate 36.3.</td>
<td>Virginiamycin 15 ....</td>
<td>Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain, improved feed efficiency.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium. Do not feed to laying chickens. Virginiamycin as provided by No. 066104 in §510.600(c) of this chapter.</td>
<td>066104</td>
</tr>
<tr>
<td>(8) Amprolium 113.5 and ethopabate 36.3.</td>
<td>Virginiamycin 5 to 15.</td>
<td>Broiler chickens; as an aid in the prevention of coccidiosis where severe exposure to coccidiosis from <em>Eimeria</em> acervulina, <em>E. maxima</em>, and <em>E. brunetti</em> is likely to occur; for increased rate of weight gain.</td>
<td>Feed continuously as the sole ration; as sole source of amprolium. Do not feed to laying chickens. Not for chickens over 16 weeks of age. Virginiamycin as provided by No. 066104 in §510.600(c) of this chapter.</td>
<td>066104</td>
</tr>
<tr>
<td>(9) Amprolium 327 and ethopabate 3.6.</td>
<td></td>
<td>For broiler chickens and replacement chickens where immunity to coccidiosis is not desired; prevention of coccidiosis.</td>
<td>Not for laying chickens .................</td>
<td>016592</td>
</tr>
</tbody>
</table>
§ 558.59 Apramycin.

(a) Approvals. Type A articles to sponsors identified in §510.600(c) of this chapter as follows:

(1) 000986 for 75 grams apramycin (as apramycin sulfate) per pound for use in paragraph (d)(1) of this section.

(2) [Reserved]

(b) [Reserved]

(c) Related tolerances. See §556.52 of this chapter.

(d) Conditions of use—(1) Swine—(1) Amount. 150 grams per ton.

(2) Indications for use. For control of porcine colibacillosis (weanling pig scours) caused by susceptible strains of Escherichia coli.

(3) Limitations. Use for 14 days. Withdraw 28 days before slaughter.

(2) [Reserved]

[51 FR 9190, Mar. 18, 1986]

§ 558.68 Avilamycin.

(a) Specifications. Each pound of Type A medicated article contains 90.7 grams of avilamycin.

(b) Sponsor. See No. 000986 in §510.600(c) of this chapter.

(c) Special considerations—(1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See §558.6 for additional requirements.

(2) The expiration date of VFDs for avilamycin medicated feeds must not exceed 90 days from the date of issuance. VFDs for avilamycin shall not be refilled.

(d) Related tolerances. See §556.68 of this chapter.

(e) Conditions of use in swine—(1) Amount. Feed at 75 grams avilamycin per ton of Type C medicated feed (80 ppm) as the sole ration for 21 consecutive days. The veterinarian may direct feeding for up to a total of 42 consecutive days, based on the clinical assessment.

(2) Indications for use. Weaned pigs less than 14 weeks of age: For the reduction in incidence and overall severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs.


§ 558.76 Bacitracin methylenedisalicylate.

(a) Specifications. (1) Type A medicated articles containing 10, 25, 30, 40, 50, 60, or 75 grams bacitracin methylenedisalicylate per pound.

(b) Type A medicated article containing 50 grams bacitracin methylenedisalicylate per pound.

(c) Sponsors. See sponsors in §510.600(c) of this chapter:

(1) No. 054771 for use of products in paragraph (a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(iii), (e)(1)(v) through (xiii), and (e)(1)(xv) of this section.
(2) No. 069254 for use of products in paragraphs (a)(2) of this section as in paragraphs (e)(1)(i), (e)(1)(iv), (e)(1)(xiii), and (e)(1)(xvi) of this section.

(c) Special considerations. The quantities of antibiotics are expressed in terms of the equivalent amount of antibiotic standard.

(d) Related tolerances. See §556.70 of this chapter.

(e) Conditions of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Bacitracin methylene-disalicylate amount</th>
<th>Combination in grams per ton (g/ton)</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4 to 50 g/ton</td>
<td></td>
<td>Chickens, turkeys, and pheasants: For increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 4 to 50 g/ton</td>
<td></td>
<td>Broiler and replacement chickens, growing turkeys, and growing pheasants: For increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>069254</td>
</tr>
<tr>
<td>(iii) 5 to 20 g/ton</td>
<td></td>
<td>Quail not over 5 weeks of age: For increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>054771</td>
</tr>
<tr>
<td>(iv) 5 to 20 g/ton</td>
<td></td>
<td>Growing quail: For increased rate of weight gain and improved feed efficiency.</td>
<td>For use in quail not over 5 weeks of age.</td>
<td>069254</td>
</tr>
<tr>
<td>(v) 10 to 25 g/ton</td>
<td></td>
<td>Chickens: For increased egg production and improved feed efficiency for egg production.</td>
<td>For first 7 months of production</td>
<td>054771</td>
</tr>
<tr>
<td>(vi) 10 to 30 g/ton</td>
<td></td>
<td>Swine: For increased rate of weight gain and improved feed efficiency.</td>
<td>For growing and finishing swine</td>
<td>054771</td>
</tr>
<tr>
<td>(vii) 10 to 30 g/ton</td>
<td>Chlortetracycline approximately 400, varying with body weight and food consumption to provide 10 milligrams (mg) per pound of body weight per day.</td>
<td>Swine: For increased rate of weight gain and improved feed efficiency; for treatment of bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis and bacterial pneumonia caused by Pasteurella multocida susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 days; bacitracin methylene-disalicylate provided by No. 054771; chlortetracycline provided by Nos. 054771 and 069254 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(viii) 10 to 30 g/ton</td>
<td></td>
<td>Swine: For control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 days; chlortetracycline and bacitracin methylene-disalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(ix) 50 g/ton</td>
<td></td>
<td>Broiler chickens: As an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin. Replacement chickens: As an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration</td>
<td>054771</td>
</tr>
<tr>
<td>(x) 100 to 200 g/ton</td>
<td></td>
<td>Broiler chickens: As an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin. Replacement chickens: As an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration. Start at first clinical signs of disease, vary dosage based on severity of infection, administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce medication to prevention level (50 g/ton).</td>
<td>054771</td>
</tr>
</tbody>
</table>
### Bacitracin methylenedisalicylate

<table>
<thead>
<tr>
<th>Combination in grams per ton (g/ton)</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(xi) 200 g/ton</td>
<td>Turkeys: As an aid in the control of transmissible enteritis in growing turkeys complicated by organisms susceptible to bacitracin methylenedisalicylate. Qualif: For the prevention of ulcerative enteritis in growing quail due to Clostridium colinum susceptible to bacitracin methylenedisalicylate. Feed continuously as the sole ration.</td>
<td>As the sole ration. Not for use in swine weighing more than 250 pounds. Diagnosis should be confirmed by a veterinarian when results are not satisfactory.</td>
<td>054771</td>
</tr>
<tr>
<td>(xii) 250 g/ton</td>
<td>1. Growing/finishing swine: For control of swine dysentery Treponema hyoenterica on premises with history of swine dysentery but where signs of the disease have not yet occurred; or following an approved treatment of the disease condition. 2. Pregnant sows: For control of clostridial enteritis caused by C. perfringens in suckling piglets.</td>
<td>As the sole ration. Feed to sows from 14 days before through 21 days after parturition on premises with a history of clostridial scours. Diagnosis should be confirmed by a veterinarian when results are not satisfactory.</td>
<td>054771</td>
</tr>
<tr>
<td>(xiii) To provide 70 mg per head per day</td>
<td>Feedlot beef cattle: For reduction in the number of liver condemnations due to abscesses.</td>
<td>Administer continuously throughout the feeding period.</td>
<td>054771</td>
</tr>
<tr>
<td>(xiv) To provide 70 mg per head per day</td>
<td>Beef steers and heifers fed in confinement for slaughter: For reduction in the number of liver condemnations due to abscesses.</td>
<td>Administer continuously throughout the feeding period.</td>
<td>054771</td>
</tr>
<tr>
<td>(xv) To provide 250 mg per head per day</td>
<td>Feedlot beef cattle: For reduction in the number of liver condemnations due to abscesses.</td>
<td>Administer continuously for 5 days then discontinue for subsequent 25 days, repeat the pattern during the feeding period.</td>
<td>054771</td>
</tr>
<tr>
<td>(xvi) To provide 250 mg per head per day</td>
<td>Beef steers and heifers fed in confinement for slaughter: For reduction in the number of liver condemnations due to abscesses.</td>
<td>Administer continuously for 5 days then discontinue for subsequent 25 days, repeat the pattern during the feeding period.</td>
<td>054771</td>
</tr>
</tbody>
</table>

(2) Bacitracin methylenedisalicylate may also be used in combination with:

(i) Amprolium as in § 558.55.
(ii) Amprolium and ethopabate as in § 558.56.
(iii) Clopidol as in § 558.175.
(iv) Decoquinate as in § 558.195.
(v) Diclazuril as in § 558.198.
(vi) Fenbendazole as in § 558.258.
(vii) Halofuginone hydrobromide as in § 558.265.
(viii) Ivermectin as in § 558.300.
(ix) Lasalocid as in § 558.311.
(x) Monensin as in § 558.355.
(xi) Narasin as in § 558.363.
(xii) Nicarbazin alone and with narasin as in § 558.396.
(xiii) Robenidine as in § 558.515.
(xiv) Salinomycin as in § 558.550.
(xv) Semduramicin as in § 558.555.
(xvi) Zoalene as in § 558.680.

[41 FR 10993, Mar. 15, 1976]
§ 558.78 Bacitracin zinc.

(a) Specifications. Type A medicated articles containing bacitracin zinc equivalent to 10, 25, 40, or 50 grams per pound bacitracin.

<table>
<thead>
<tr>
<th>Bacitracin zinc in grams per ton</th>
<th>Combinations in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4 to 50 .....................</td>
<td></td>
<td>Chickens: for increased rate of weight gain and improved feed efficiency.</td>
<td>Growing chickens .................</td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 4 to 50 ....................</td>
<td></td>
<td>Turkeys and pheasants; for increased rate of weight gain and improved feed efficiency.</td>
<td>Growing turkeys and pheasants</td>
<td>054771</td>
</tr>
<tr>
<td>(iii) 5 to 20 ...................</td>
<td></td>
<td>Quail; for increased rate of weight gain and improved feed efficiency.</td>
<td>Growing quail; feed as the Type C feed to starting quail through 5 weeks of age.</td>
<td>054771</td>
</tr>
<tr>
<td>(iv) 10 to 25 ...................</td>
<td></td>
<td>Laying chickens; improved feed efficiency and increased egg production.</td>
<td>In Type C feed .....................</td>
<td>054771</td>
</tr>
<tr>
<td>(v) 10 to 50 ....................</td>
<td></td>
<td>Swine; increased rate of weight gain and improved feed efficiency.</td>
<td>In Type C feed .....................</td>
<td>054771</td>
</tr>
<tr>
<td>(vi) 20 ..........................</td>
<td></td>
<td>Growing-finishing swine; increased rate of weight gain.</td>
<td>In Type C feed .....................</td>
<td>054771</td>
</tr>
<tr>
<td>(vii) 20 to 40 ..................</td>
<td></td>
<td>Growing-finishing swine; improved feed efficiency.</td>
<td>In Type C feed .....................</td>
<td>054771</td>
</tr>
</tbody>
</table>

(2) It is used in feed for growing cattle at 35 to 70 milligrams per head per day as follows:

(i) To aid in stimulating growth and improving feed efficiency.

(ii) For increased rate of weight gain and improved feed efficiency; see sponsor 054771.

(3) Bacitracin zinc may also be used in combination with:

(i) Amprolium and ethopabate as in § 558.58.

(ii) Clopidol as in § 558.175.

(iii) Decoquinate as in § 558.363.

(iv) Lasalocid as in § 558.355.

(v) Monensin as in § 558.363.

(vi) Naracimycin as in § 558.555.

(vii) [Reserved]

(viii) Robenidine as in § 558.15.

(ix) Salinomycin as in § 558.15.

(41 FR 10994, Mar. 15, 1976)

Editorial Note: For Federal Register citations affecting § 558.78, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

§ 558.95 Bambermycins.

(a) Approvals. See sponsors in § 510.600(c) of this chapter for use of Type A medicated articles as in paragraph (d) of this section:

(1) No. 016592: 2, 4, and 10 grams per pound for use as in paragraphs (d)(1), (d)(2), (d)(3), and (d)(4) of this section.

(2) No. 012286: 2 grams for use as in paragraph (d)(2) of this section and 0.4 and 2 grams per pound for use as in paragraph (d)(3).

(b) Special considerations. (1) Bambermycins liquid Type B feeds may be manufactured from dry bambermycins Type A articles. The liquid Type B feeds must have a pH of 3.8 to 7.5, moisture content of 30 to 45 percent.

(2) The expiration date for the liquid Type B feed is 8 weeks after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 1 week after date of manufacture.

(c) [Reserved]

(d) Conditions of use—(1) Chickens. Use in medicated feed as follows:
§ 558.95

21 CFR Ch. I (4–1–16 Edition)

Bambermycins in grams/ton Indications for use Limitations Sponsor

(i) 1 to 2 ......................... Broiler chickens: For increased rate of weight gain and improved feed efficiency. Feed continuously as the sole ration. 016592.
(ii) [Reserved].

(2) Turkeys. Use in medicated feed as follows:

Bambermycins in grams/ton Indications for use Limitations Sponsor

(i) 1 to 2 ......................... Growing turkeys: For improved feed efficiency. Feed continuously as the sole ration. 012286, 016592.
(ii) 2 ............................ Growing turkeys: For increased rate of weight gain and improved feed efficiency. Feed continuously as the sole ration. 012286, 016592.

(3) Swine. Use in medicated feed as follows:

Bambermycins in grams/ton Indications for use Limitations Sponsor

(i) 2 ............................. Growing-finishing swine: For increased rate of weight gain and improved feed efficiency. Feed continuously as the sole ration. 012286, 016592.
(ii) 2 to 4 ........................ Growing-finishing swine: For increased rate of weight gain. Feed continuously as the sole ration. 012286, 016592.

(4) Cattle.

Bambermycins in grams/ton Indications for use Limitations Sponsor

(i) 1 to 4 ........................ Cattle fed in confinement for slaughter: For increased rate of weight gain and improved feed efficiency. Feed continuously at a rate of 10 to 20 milligrams per head per day. 016592.
(ii) 2 to 80 ...................... Pasture cattle (slaughter, stocker, and feeder cattle, and dairy and beef replacement heifers): For increased rate of weight gain. Feed continuously on a hand-fed basis at a rate of 10 to 40 milligrams per head per day in 1 to 10 pounds of supplemental Type C medicated feed. 016592.

(iii) Used as a free-choice Type C medicated loose-mineral feed for pasture cattle (slaughter, stocker, and feeder cattle; and beef replacement heifers) as follows:

(a) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>International Feed No.</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deflorinated phosphate (20.5% calcium, 18.5% phosphorus)</td>
<td>6–01–080</td>
<td>42.50</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>6–04–152</td>
<td>20.10</td>
</tr>
<tr>
<td>Calcium carbonate (38% calcium)</td>
<td>6–01–069</td>
<td>15.24</td>
</tr>
<tr>
<td>Corn distillers dried grains w/solubles</td>
<td>6–02–756</td>
<td>9.57</td>
</tr>
<tr>
<td>Magnesium oxide</td>
<td>6–02–758</td>
<td>5.15</td>
</tr>
<tr>
<td>Vitamin and trace mineral premix *</td>
<td></td>
<td>100.00</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>6–01–720</td>
<td>1.00</td>
</tr>
<tr>
<td>Yeast (primary dehydrated yeast)</td>
<td>7–05–533</td>
<td>0.75</td>
</tr>
<tr>
<td>Bambermycins Type A article (10 g/lb)</td>
<td></td>
<td>0.60</td>
</tr>
<tr>
<td>Iron oxide</td>
<td>6–02–431</td>
<td>0.50</td>
</tr>
<tr>
<td>Magnesium sulfate (67%)</td>
<td>6–02–758</td>
<td>0.32</td>
</tr>
<tr>
<td>Selenium premix (270 mg/lb) *</td>
<td></td>
<td>0.21</td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>6–01–720</td>
<td>0.18</td>
</tr>
</tbody>
</table>
Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).

Formulation modifications require FDA approval prior to marketing.

Selenium must comply with 21 CFR 573.920.

Food and Drug Administration, HHS § 558.95

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>International Feed No.</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium sulfate (0.33%)</td>
<td>6–06–098</td>
<td>0.16</td>
</tr>
</tbody>
</table>

*(Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).)*

(b) Amount per ton. 120 grams.

(c) Indications for use. For increased rate of weight gain.

(d) Limitations. For free-choice feeding to pasture cattle (slaughter, stocker, and feeder cattle; and beef replacement heifers). Feed a nonmedicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 10.66 ounces per head per day. Feed continuously to provide 10 to 40 milligrams bambermycins per head per day. Daily bambermycins intakes in excess of 20 mg/head/day have not been shown to be more effective than 20 mg/head/day.

(iv) Use free-choice Type C medicated feeds for pasture cattle (slaughter, stocker, and feeder cattle; and beef replacement heifers) as follows:

(A) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>International Feed No.</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deionized phosphate (20.5% calcium, 18.5% phosphorus)</td>
<td>6–01–080</td>
<td>42.50</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>6–04–152</td>
<td>20.10</td>
</tr>
<tr>
<td>Calcium carbonate (38% calcium)</td>
<td>6–01–069</td>
<td>15.45</td>
</tr>
<tr>
<td>Corn distillers dried grains w/solubles</td>
<td>5–28–236</td>
<td>9.57</td>
</tr>
<tr>
<td>Magnesium oxide</td>
<td>6–02–756</td>
<td>5.15</td>
</tr>
<tr>
<td>Vitamin and trace mineral premix*</td>
<td>7–05–533</td>
<td>3.72</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>6–02–431</td>
<td>1.00</td>
</tr>
<tr>
<td>Yeast (primary dehydrated yeast)</td>
<td>6–02–758</td>
<td>0.75</td>
</tr>
<tr>
<td>Bambermycins Type A article (10 g/lb)</td>
<td>6–01–720</td>
<td>0.50</td>
</tr>
<tr>
<td>Iron oxide</td>
<td>6–02–431</td>
<td>0.50</td>
</tr>
<tr>
<td>Magnesium sulfate (67%)</td>
<td>6–02–758</td>
<td>0.32</td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>6–01–720</td>
<td>0.18</td>
</tr>
<tr>
<td>Potassium sulfate (0.33%)</td>
<td>6–06–098</td>
<td>0.16</td>
</tr>
</tbody>
</table>

*(Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).)*

(B) Amount per ton. 120 grams.

(C) Indications for use. For increased rate of weight gain.

(D) Limitations. For free-choice feeding to pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers). Feed a non-medicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 10.66 ounces per head per day. Feed continuously to provide 10 to 40 milligrams bambermycins per head per day. Daily bambermycins intakes in excess of 20 mg/head/day have not been shown to be more effective than 20 mg/head/day.

(v) Used as a free-choice Type C medicated loose mineral feed for pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers) as follows:

(A) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>International Feed No.</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deionized phosphate (20.5% calcium, 18.5% phosphorus)</td>
<td>6–01–080</td>
<td>42.50</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>6–04–152</td>
<td>20.10</td>
</tr>
<tr>
<td>Calcium carbonate (38% calcium)</td>
<td>6–01–069</td>
<td>15.45</td>
</tr>
<tr>
<td>Corn distillers dried grains w/solubles</td>
<td>5–28–236</td>
<td>9.57</td>
</tr>
<tr>
<td>Magnesium oxide</td>
<td>6–02–756</td>
<td>5.15</td>
</tr>
<tr>
<td>Vitamin and trace mineral premix*</td>
<td>7–05–533</td>
<td>3.72</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>6–02–431</td>
<td>1.00</td>
</tr>
<tr>
<td>Yeast (primary dehydrated yeast)</td>
<td>6–02–758</td>
<td>0.75</td>
</tr>
<tr>
<td>Bambermycins Type A article (10 g/lb)</td>
<td>6–01–720</td>
<td>0.50</td>
</tr>
<tr>
<td>Iron oxide</td>
<td>6–02–431</td>
<td>0.50</td>
</tr>
<tr>
<td>Magnesium sulfate (67%)</td>
<td>6–02–758</td>
<td>0.32</td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>6–01–720</td>
<td>0.18</td>
</tr>
<tr>
<td>Potassium sulfate (0.33%)</td>
<td>6–06–098</td>
<td>0.16</td>
</tr>
</tbody>
</table>

*(Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).)*

(B) Amount per ton. 120 grams.

(C) Indications for use. For increased rate of weight gain.

(D) Limitations. For free-choice feeding to pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers). Feed a non-medicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 10.66 ounces per head per day. Feed continuously to provide 10 to 40 milligrams bambermycins per head per day. Daily bambermycins intakes in excess of 20 mg/head/day have not been shown to be more effective than 20 mg/head/day.

(5) Bambermycins may also be used in combination with:

(i) Amprolium as in § 558.55.
(ii) Amprolium and ethopabate as in § 558.58.
(iii) Clopidal as in § 558.175.
(iv) Diclazuril as in § 558.198.
(v) Halofuginone as in § 558.265.
(vi) Lasalocid as in § 558.311.
(vii) Monensin as in § 558.355.
(viii) Narasin alone or with nicarbazin as in § 558.363.
(ix) Nicarbazin as in § 558.366.
§ 558.115 Carboxad.

(a) Approvals. Type A medicated articles: 2.2 percent (10 grams per pound) to 0.66104 in § 510.600(c) of this chapter.

(b) Related tolerances. See § 556.100 of this chapter.

(c) Special considerations. Do not use in Type B or Type C medicated feeds containing bentonite.

(d) Conditions of use. It is used for swine as follows:

1. Amount per ton. 10–25 grams (0.0011–0.00275 percent).
   
   (i) Indications for use. For increase in rate of weight gain and improvement of feed efficiency.
   
   (ii) Limitations. Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

2. Amount per ton. 50 grams (0.0055 percent).
   
   (i) Indications for use. For control of swine dysentery (vibriotic dysentery, bloody scours, or hemorrhagic dysentery); control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis); increased rate of weight gain and improved feed efficiency.
   
   (ii) Limitations. Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

3. Amount per ton. Carbadox 50 grams (0.0055 percent) plus pyrantel tartrate, 96 grams (0.0106 percent).
   
   (i) Indications for use. For control of swine dysentery (vibriotic dysentery, bloody scours, or hemorrhagic dysentery); control of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis); aid in the prevention of migration and establishment of large roundworm (Ascaris suum) infections; aid in the prevention of establishment of nodular worm (Oesophagostomum) infections.
   
   (ii) Limitations. Do not feed to swine over 75 pounds; do not feed within 10 weeks of slaughter; consult a veterinarian before feeding to severely debilitated animals; feed continuously as sole ration. Do not use in complete feeds containing less than 15 percent crude protein.

   (i) Indications for use. For treatment of bacterial enteritis caused by Escherichia coli and S. choleraesuis susceptible to oxytetracycline, for treatment of bacterial pneumonia caused by Pasteurella multocida susceptible to oxytetracycline; and for increased rate of weight gain and improved feed efficiency.

   (ii) Limitations. Feed continuously for 7 to 14 days. Not for use in pregnant swine or swine intended for breeding purposes. Do not feed to swine within 42 days of slaughter.

§ 558.128 Chlortetracycline.

(a) Specifications. Type A medicated articles containing either chlortetracycline calcium complex equivalent to chlortetracycline hydrochloride or, for products intended for use in milk replacer, chlortetracycline hydrochloride.

(b) Approvals. See sponsors in § 510.600(c) of this chapter for use as in paragraph (e) of this section.

1. Nos. 054771, 066104, and 069254: 50 to 100 grams per pound (g/lb) of Type A medicated article.

2. No. 069254: 50, 90, or 100 grams per pound of Type A medicated article.

(c) Related tolerances. See § 556.150 of this chapter.

(d) Special considerations. (1) In milk replacers or starter feed; include on labeling the warning: “A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.”

2. Manufacture for use in free-choice feeds as in paragraph (e)(4)(iii) of this section must conform to § 510.455 of this chapter.
Food and Drug Administration, HHS § 558.128

(3) When manufactured for use as in paragraph (e)(5)(iv) of this section, include on labeling the warning: “Psittacosis, avian chlamydiosis, or ornithosis is a reportable communicable disease, transmissible between wild and domestic birds, other animals, and man. Contact appropriate public health and regulatory officials.”

(e) Conditions of use—(1) Chickens. It is used as follows:

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 g/ton</td>
<td>Chickens: For increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to chickens producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(ii) 100 to 200 g/ton</td>
<td>Chickens: For control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline.</td>
<td>1. Feed continuously for 7 to 14 d. 2. Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iii) 200 to 400 g/ton</td>
<td>Chickens: For the control of chronic respiratory disease (CRD) and air sac infection caused by M. gallisepticum and Escherichia coli susceptible to chlortetracycline.</td>
<td>1. Feed continuously for 7 to 14 d. 2. Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iv) 500 g/ton</td>
<td>Chickens: For the reduction of mortality due to E. coli infections susceptible to chlortetracycline.</td>
<td>1. Feed for 5 d. To sponsor No. 054771 under NADA 048–761 and No. 069254 under ANADA 200–510: zero withdrawal time. 2. Feed for 5 d: withdraw 24 h prior to slaughter; do not feed to chickens producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
</tbody>
</table>

(2) Turkeys. It is used as follows:

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 g/ton</td>
<td>Growing turkeys: For increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to turkeys producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(ii) 200 g/ton</td>
<td>Turkeys: For control of infectious synovitis caused by M. synoviae susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iii) 400 g/ton</td>
<td>1. Turkeys: For control of hexamitiasis caused by Hexamita meleagridis susceptible to chlortetracycline. 2. Turkey pouls not over 4 weeks of age: For reduction of mortality due to paratyphoid caused by Salmonella typhimurium susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iv) 25 mg/lb of body weight.</td>
<td>Turkeys: For control of complicating bacterial organisms associated with bluecomb (transmissible enteritis; coronaviral enteritis) susceptible to chlortetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
</tbody>
</table>

(3) Swine. It is used as follows:

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 g/ton</td>
<td>Growing swine: For increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to turkeys producing eggs for human consumption.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(ii) 50 to 100 g/ton</td>
<td>Swine: For reducing the incidence of cervical lymphadenitis (jowl abscesses) caused by Group E. Streptococci susceptible to chlortetracycline.</td>
<td></td>
<td>054771, 066104, 069254.</td>
</tr>
</tbody>
</table>
### §558.128

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) 400 g/ton ..........</td>
<td>Breeding swine: For the control of leptospirosis (reducing the incidence of abortion and shedding of leptospirae) caused by <em>Leptospira pomona</em> susceptible to chlortetracycline.</td>
<td>Feed continuously for not more than 14 d.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iv) 10 mg/lb of body weight.</td>
<td>1. Swine: For the treatment of bacterial enteritis caused by <em>E. coli</em> and <em>S. choleraesuis</em> and bacterial pneumonia caused by <em>Pasteurella multocida</em> susceptible to chlortetracycline.</td>
<td>Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb per day. Feed for not more than 14 d; withdraw 5 d prior to slaughter for sponsor 069254.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td></td>
<td>2. Swine: For the control of porcine proliferative enteropathies (ileitis) caused by <em>Lawsonia intracellularis</em> susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 d.</td>
<td>054771.</td>
</tr>
</tbody>
</table>

### (4) Cattle

<table>
<thead>
<tr>
<th>Chlortetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 0.1 mg/lb of body weight daily.</td>
<td>Calves (up to 250 lb): For increased rate of weight gain and improved feed efficiency.</td>
<td>See paragraph (d)(1) of this section.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(ii) 0.5 mg/lb of body weight daily.</td>
<td>Beef cattle (over 700 lb); control of active infection of anaplasmosis caused by <em>Anaplasma marginale</em> susceptible to chlortetracycline.</td>
<td>Withdraw 48 h prior to slaughter. To sponsor Nos. 054771 and 069254: zero withdrawal time.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(iii) 0.5 to 2.0 mg/lb of body weight daily.</td>
<td>Beef cattle and nonlactating dairy cattle: As an aid in the control of active infection of anaplasmosis caused by <em>A. marginale</em> susceptible to chlortetracycline.</td>
<td>In free-choice cattle feeds such as feed blocks or salt-mineral mixes manufactured from approved Type A articles. See paragraph (d)(2) of this section.</td>
<td>054771.</td>
</tr>
<tr>
<td>(iv) 10 mg/lb of body weight daily.</td>
<td>1. Calves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> organisms susceptible to chlortetracycline.</td>
<td>Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb per day. Treat for not more than 5 d; in feed including milk replacers; withdraw 10 d prior to slaughter. To sponsor No. 069254: zero withdrawal time. See paragraph (d)(1) of this section.</td>
<td>066104, 069254.</td>
</tr>
<tr>
<td></td>
<td>2. Calves (up to 250 lb): For the treatment of bacterial enteritis caused by <em>E. coli</em> susceptible to chlortetracycline.</td>
<td>Feed for not more than 14 d. See paragraph (d)(1) of this section.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(v) 500 to 4,000 g/ton .......</td>
<td>Calves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> susceptible to chlortetracycline.</td>
<td>Feed continuously for not more than 5 days to provide 10 mg/lb body weight per day. To sponsor No. 054771 under NADA 046–699: 24-h withdrawal time. To sponsor No. 054771 under NADA 048–761 and No. 069254 under ANADA 200–510: Zero withdrawal time.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(vi) 4,000 to 20,000 g/ton</td>
<td>Calves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> organisms susceptible to chlortetracycline.</td>
<td>As a top dress, varying with body weight and feed consumption, to provide 10 mg/lb per day. Treat for not more than 5 days. See paragraph (d)(1) of this section.</td>
<td>054771.</td>
</tr>
<tr>
<td>(vii) 25 to 70 mg/head/day</td>
<td>Calves (250 to 400 lb): For increased rate of weight gain and improved feed efficiency.</td>
<td>See paragraph (d)(1) of this section.</td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(viii) 70 mg/head/day</td>
<td>Growing cattle (over 400 lb): For increased rate of weight gain, improved feed efficiency, and reduction of liver condemnation due to liver abscesses.</td>
<td>See paragraph (d)(1) of this section.</td>
<td>054771, 066104, 069254.</td>
</tr>
</tbody>
</table>
### Chlortetracycline amount

<table>
<thead>
<tr>
<th>Amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2. Beef cattle (under 700 lb): For control of active infection of anaplasmosis caused by <em>A. marginale</em> susceptible to chlortetracycline. Feed continuously for 45 d; each bird should consume daily an amount of medicated feed equal to one fifth of its body weight. See paragraph (d)(3) of this section.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (5) Minor species

- **Chlortetracycline amount**

<table>
<thead>
<tr>
<th>Amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 20 to 50 g/ton</td>
<td>Growing sheep; increased rate of weight gain and improved feed efficiency.</td>
<td></td>
<td>054771, 066104, 069254.</td>
</tr>
<tr>
<td>(ii) 80 mg/head/day</td>
<td>Breeding sheep; reducing the incidence of (vibriotic) abortion caused by <em>Campylobacter fetus</em> infection susceptible to chlortetracycline. Feed in complete ration to provide from 8 to 28 mg/lb of body weight per day depending upon age and severity of disease, for not more than 21 d. Do not feed to ducks producing eggs for human consumption.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iii) 200 to 400 g/ton</td>
<td>Ducks: For the control and treatment of fowl cholera caused by <em>P. multocida</em> susceptible to chlortetracycline. Feed continuously for 45 d; each bird should consume daily an amount of medicated feed equal to one fifth of its body weight. See paragraph (d)(3) of this section.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iv) 10 mg/g of finished feed daily</td>
<td>Psittacine birds (cockatoos, macaws, and parrots) suspected or known to be infected with <em>psittacosis caused by Chlamydia psittaci</em> sensitive to chlortetracycline.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (6) It is used as a free-choice, loose mineral Type C feed as follows:

- **Specifications.**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International Feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dicalcium Phosphate</td>
<td>46.20</td>
<td>6–26–335</td>
</tr>
<tr>
<td>Sodium Chloride (Salt)</td>
<td>15.00</td>
<td>6–04–152</td>
</tr>
<tr>
<td>Magnesium Oxide</td>
<td>10.67</td>
<td>6–02–756</td>
</tr>
<tr>
<td>Cottonseed Meal</td>
<td>10.00</td>
<td>5–01–625</td>
</tr>
<tr>
<td>Trace Mineral/Vitamin Premix1</td>
<td>3.80</td>
<td>6–01–069</td>
</tr>
<tr>
<td>Calcium Carbonate</td>
<td>3.50</td>
<td>4–04–695</td>
</tr>
<tr>
<td>Dried Cane Molasses</td>
<td>3.00</td>
<td>6–03–123</td>
</tr>
<tr>
<td>Potassium Chloride</td>
<td>2.00</td>
<td>6–02–431</td>
</tr>
<tr>
<td>Mineral Oil</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Chlortetracycline Type A medicated article (90 gram/lb)</td>
<td>3.33</td>
<td></td>
</tr>
</tbody>
</table>

1Content of vitamin and trace mineral premixes may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).

(ii) Amount. 6,000 grams per ton.

(iii) **Indications for use.** Beef and nonlactating dairy cattle: As an aid in the control of active infection of anaplasmosis caused by *Anaplasma marginale* susceptible to chlortetracycline.

(iv) **Limitations.** Feed continuously on a free-choice basis at a rate of 0.5 to 2.0 mg chlortetracycline per pound of body weight per day.

(v) **Sponsor.** See No. 054771 in §510.600(c) of this chapter.

(7) Chlortetracycline may also be used in combination with:

- (i) Amprolium and ethopabate as in §558.58.
- (ii) Bacitracin methylenedisalicylate as in §558.76.
- (iii) Clopidol as in §558.175.
- (iv) Decoquinate as in §558.195.
- (v) Hygromycin B as in §558.274.
- (vi) Laidlomycin as in §558.305.
- (vii) Lasalocid as in §558.311.
§ 558.140  Chlortetracycline and sulfamethazine.  

(a) Specifications. Type A medicated articles containing:

(1) 35 grams (g) per pound (/lb) each, chlortetracycline and sulfamethazine.

(2) 40 g/lb each, chlortetracycline and sulfamethazine.

(b) Sponsors. See sponsors numbers in §510.600(c) of this chapter as follow:

(1) Nos. 054771 and 069254 for use of product described in paragraph (a)(1) as in paragraph (d)(1) of this section.

(2) No. 054771 for use of product described in paragraph (a)(2) as in paragraph (d)(2) of this section.

(c) Related tolerances. See §§556.150 and 556.670 of this chapter.

(d) Conditions of use—(1) Cattle. It is used in feed for beef cattle as follows:

(i) Amount. 350 milligrams per head per day each, chlortetracycline and sulfamethazine.

(ii) Indications for use. Aid in the maintenance of weight gains in the presence of respiratory disease such as shipping fever.

(iii) Limitations. Feed for 28 days; withdraw 7 days prior to slaughter. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(2) Swine. It is used in swine feed as follows:

(i) Amount. 100 g/ton each, chlortetracycline and sulfamethazine.

(ii) Indications for use. For reduction of the incidence of cervical abscesses; treatment of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery); prevention of these diseases during times of stress; and maintenance of weight gains in the presence of atrophic rhinitis.

(iii) Limitations. Feed as the sole ration. Withdraw 15 days prior to slaughter.


§ 558.145  Chlortetracycline, procaine penicillin, and sulfamethazine.  

(a) Approvals. Type A medicated articles: (1) 20 grams of chlortetracycline per pound, 4.4 percent (20 grams) of sulfamethazine, and procaine penicillin equivalent in activity to 10 grams of penicillin per pound to 054771 in §510.600(c) of this chapter.

(2) 40 grams of chlortetracycline per pound, 8.8 percent of sulfamethazine, and penicillin procaine equivalent in activity to 20 grams of penicillin per pound to No. 069254 in §510.600(c) of this chapter.

(b) Specifications. (1) The antibiotic substance refers to the antibiotic or feed-grade antibiotic.

(2) The antibiotic activities are expressed in terms of the appropriate antibiotic standards.

(3) Type C medicated feed contains in each ton, 100 grams of chlortetracycline, 50 grams of penicillin as procaine penicillin, and 100 grams of sulfamethazine.

(c) Related tolerances. See §§556.150, 556.510, and 556.670 of this chapter.

(d) Conditions of use. (1) It is administered to swine in a Type C feed for reduction of the incidence of cervical abscesses; treatment of bacterial swine enteritis (salmonellosis or necrotic enteritis caused by Salmonella choleraesuis and vibrionic dysentery); prevention of these diseases during times of stress; maintenance of weight gains in the presence of atrophic rhinitis; growth promotion and increased feed efficiency in swine weighing up to 75 pounds.

(2) Withdraw 15 days prior to slaughter.

Food and Drug Administration, HHS § 558.175

§ 558.175 Clopidol. 

(a) Specifications. Type A medicated article containing 25 percent clopidol.

(b) Approvals. See No. 016592 in § 510.600(c) of this chapter.

(c) [Reserved]

(d) Conditions of use. It is used as follows:

<table>
<thead>
<tr>
<th>Clopidol in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) 113.5</td>
<td>…………………………</td>
<td>Broiler chickens and re-placement chickens intended for use as caged layers: As an aid in the prevention of coccidiosis caused by <em>E. tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; and for increased rate of weight gain.</td>
<td>Do not feed to chickens over 16 weeks of age.</td>
<td>016592</td>
</tr>
<tr>
<td>(2) 113.5</td>
<td>Bacitracin methylenedisalicylate 4 to 50.</td>
<td>Broiler chickens: As in paragraph (d)(1) of this section; for increased rate of weight gain.</td>
<td>Feed continuously as the sole ration from the time chicks are placed in floor pens until slaughter. Do not feed to chickens over 16 weeks of age; bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
<tr>
<td>(3) 113.5</td>
<td>Bacitracin zinc 5 to 25.</td>
<td>Broiler chickens: As in paragraph (d)(1) of this section; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration; bacitracin zinc as provided by No. 054771 in § 510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
<tr>
<td>(4) 113.5</td>
<td>Bambermycins 1 to 2</td>
<td>Broiler chickens: As an aid in prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age</td>
<td>016592</td>
</tr>
<tr>
<td>(5) 113.5</td>
<td>Chlortetracycline 100 to 200.</td>
<td>Broiler and replacement chickens: As in paragraph (d)(1) of this section; for control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlortetracycline.</td>
<td>Feed continuously as sole ration from the time chicks are placed in floor pens for 7 to 14 days.</td>
<td>016592</td>
</tr>
<tr>
<td>(6) 113.5</td>
<td>Lincomycin 2 to 4</td>
<td>Broiler chickens: As in paragraph (d)(1) of this section; for increased rate of weight gain and improved feed efficiency.</td>
<td>Do not feed to chickens over 16 weeks of age; as lincomycin hydrochloride monohydrate.</td>
<td>054771</td>
</tr>
<tr>
<td>(7) 227</td>
<td>…………………………</td>
<td>Broiler and replacement chickens intended for use as caged layers: As in paragraph (d)(1) of this section.</td>
<td>Feed continuously as the sole ration; feed up to 16 weeks of age if intended for use as caged layers; withdraw 5 days before slaughter if given at the level of 0.025 percent in feed or reduce level to 0.0125 percent 5 days before slaughter.</td>
<td>016592</td>
</tr>
<tr>
<td>(8) 227</td>
<td>Bambermycins 1 to 2</td>
<td>Broiler chickens: As an aid in prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration until 5 days before slaughter. Withdraw 5 days before slaughter or feed 113.5 g/ton clopidol and 1 to 2 g/ton bambermycins during those 5 days before slaughter. Do not feed to chickens over 16 weeks of age.</td>
<td>016592</td>
</tr>
<tr>
<td>(9) 113.5 or 227</td>
<td>…………………………</td>
<td>Turkeys: As an aid in the prevention of leucocytozoonosis caused by <em>Leucocytozoon smithi</em>.</td>
<td>For turkeys grown for meat purposes only; feed continuously as the sole ration at 0.0125 or 0.025 percent clopidol depending on management practices, degree of exposure, and amount of feed eaten; withdraw 5 days before slaughter.</td>
<td>016592</td>
</tr>
</tbody>
</table>
§ 558.185  Coumaphos.

(a) Specifications. Type A medicated articles containing 1.12, 2.0, 11.2, or 50 percent coumaphos.

(b) Approvals. See sponsors in § 510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) No. 000859 for use of Type A medicated articles containing 1.12, 2.0, 11.2, or 50 percent coumaphos as in paragraph (e)(2) and (e)(3) of this section.

(2) No. 051311 for use of Type A medicated articles containing 1.12 percent coumaphos as in paragraph (e)(1) of this section.

(c) Related tolerances. See 40 CFR 180.189.

(d) Special considerations. Labeling shall bear the following caution statement: “The active ingredient coumaphos is a cholinesterase inhibitor. Do not use this product on animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.” Also, see § 500.25 of this chapter.

(e) Conditions of use—(1) Beef and dairy cattle—(i) Amount. 0.0002 lb. (0.091 gram) per 100 lb. body weight per day for 6 consecutive days. Should conditions warrant, repeat treatment at 30-day intervals.

(ii) Indications for use. Control of gastrointestinal roundworms (Haemonchus spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Trichostrongylus spp.).

(iii) Limitations. In Type C feed; administer continuously as the total feed ration for 14 days; when reinfestation occurs, treatment may be repeated but not sooner than 3 weeks after the end of the previous treatment; do not feed to chickens within 10 days of vaccination or other conditions of stress; treatment of colored breeds of commercial layers should be avoided while in production since these breeds appear to be more sensitive to coumaphos than white breeds; as sole medication; medications in general should be avoided while birds are approaching peak production; such interruption of normal feeding practices may upset the flock and lower egg production; diagnosis by competent personnel is essential; flock condition and production records should be carefully evaluated prior to treatment.

(2) Laying chickens—(i) Amount. Coumaphos 27.2 grams per ton (0.003 percent).

(ii) Indications for use. For control of capillary worm (Capillaria obsignata) and as an aid in control of common roundworm (Ascaridia galli) and cecal worm (Heterakis gallinae).

(iii) Limitations. In Type C feed; administer continuously as the total feed ration for 14 days; when reinfestation occurs, treatment may be repeated but not sooner than 3 weeks after the end of the previous treatment; do not feed to chickens within 10 days of vaccination or other conditions of stress; treatment of colored breeds of commercial layers should be avoided while in production since these breeds appear to be more sensitive to coumaphos than white breeds; as sole medication; medications in general should be avoided while birds are approaching peak production; such interruption of normal feeding practices may upset the flock and lower egg production; diagnosis by competent personnel is essential; flock condition and production records should be carefully evaluated prior to treatment.

(3) Replacement pullets—(i) Amount. Coumaphos 36.3 grams per ton (0.004 percent).

(ii) Indications for use. For control of capillary worm (Capillaria obsignata) and as an aid in control of common roundworm (Ascaridia galli) and cecal worm (Heterakis gallinae).

(iii) Limitations. In Type C feed; administer before the onset of production; diagnosis by competent personnel is essential; administer continuously as total feed ration for from 10 to 14 days; do not feed to chickens under 8 weeks of age nor within 10 days of vaccination or other conditions of stress; if birds are maintained on contaminated litter or exposed to infected birds, a second 10 to 14 day treatment is recommended but not sooner than 3 weeks after the end of the previous treatment; as sole medication; if reinfection occurs after production begins, repeat treatment as recommended for laying flocks.

§ 558.195  Decoquinate.

(a) Specifications. Type A medicated article containing 6 percent decoquinate.
(b) Approvals. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.170 of this chapter.

(d) Special considerations. (1) Bentonite should not be used in decoquinate feeds.

(2) Type A medicated articles may be used to manufacture dry or liquid Type B cattle (including veal calf), sheep, and goat feeds as in paragraphs (e)(2) and (e)(3) of this section.

(3) Type C cattle feeds may be manufactured from decoquinate liquid Type B feeds having a pH between 5.0 to 6.5 and containing a suspending agent to maintain a viscosity of not less than 500 centipoises.

(e) Conditions of use. It is used as follows:

(1) Chickens.

<table>
<thead>
<tr>
<th>Decoquinate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 27.2 .................</td>
<td>............................</td>
<td>Broiler chickens: For prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. maxima</em>, and <em>E. brunetti</em>.</td>
<td>Do not feed to laying chickens.</td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 27.2 ...............</td>
<td>Bacitracin methylenedisalicylate 4 to 50.</td>
<td>Broiler chickens: As in paragraph (e)(1)(i) of this section; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration; do not feed to laying chickens. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(iii) 27.2 ..............</td>
<td>Bacitracin zinc 10 to 50.</td>
<td>Broiler chickens: As in paragraph (e)(1)(iii) of this section.</td>
<td>Feed continuously as sole ration; do not feed to laying chickens. Bacitracin zinc as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(iv) 27.2 ..............</td>
<td>Chlortetracycline 100 to 200.</td>
<td>Chickens: As in paragraph (e)(1)(ii) of this section; control of infectious synovitis caused by <em>Mycoplasma synoviae</em> susceptible to chlortetracycline.</td>
<td>As in paragraph (e)(1)(vi) of this section.</td>
<td>054771</td>
</tr>
<tr>
<td>(v) 27.2 ..............</td>
<td>Chlortetracycline 200 to 400.</td>
<td>Chickens: As in paragraph (e)(1)(i) of this section; and for control of chronic respiratory disease (CRD) and air sac infection caused by <em>M. gallisepticum</em> and <em>Escherichia coli</em> susceptible to chlortetracycline.</td>
<td>Feed as sole ration; do not feed to laying chickens; lincomycin provided by No. 000009 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(vi) 27.2 ..............</td>
<td>Lincomycin 2 ............</td>
<td>Broiler chickens: As in paragraph (e)(1)(iii) of this section.</td>
<td></td>
<td>054771</td>
</tr>
</tbody>
</table>

(2) Cattle.

<table>
<thead>
<tr>
<th>Decoquinate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 12.9 to 90.8 ..........</td>
<td>............................</td>
<td>Cattle (including ruminating and non-ruminating calves and veal calves): For prevention of coccidiosis caused by <em>Eimeria bovis</em> and <em>E. zuernii</em>.</td>
<td>Feed Type C feed or milk replacer to provide 22.7 milligrams (mg) per 100 pounds (lb) of body weight (0.5 mg/kg) per day. Feed at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to cows producing milk for food. See paragraph (d)(3) of this section.</td>
<td>054771</td>
</tr>
<tr>
<td>Decoquinate in grams/ton</td>
<td>Combination in grams/ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(ii) 12.9 to 90.8 ...</td>
<td>Chlortetracycline 500 to 4,000..</td>
<td>Calves, beef, and nonlactating dairy cattle: As in paragraph (e)(2)(i) of this section; for treatment of bacterial enteritis caused by <em>Escherichia coli</em>; and for treatment of bacterial pneumonia caused by <em>Pasteurella multocida</em> organisms susceptible to chlortetracycline..</td>
<td>Feed Type C feed to provide 22.7 mg decoquinate and 1 gram chlortetracycline per 100 lb body weight per day for not more than 5 days. When consumed, feed 22.7 mg decoquinate per 100 lb body weight/day for a total of 28 days to prevent coccidiosis. Withdraw 24 hours prior to slaughter when manufactured from CTC (chlortetracycline) Type A medicated articles under NADA 141–147. Zero withdrawal time when manufactured from AU-REOMYCIN (chlortetracycline) Type A medicated articles under NADA 141–185. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Do not feed to animals producing milk for food. Chlortetracycline as provided by No. 054771 in §510.600(c) of this chapter..</td>
<td>054771</td>
</tr>
<tr>
<td>(iii) 12.9 to 90.8 ..</td>
<td>Monensin 5 to 30 ...</td>
<td>Cattle fed in confinement for slaughter: As in paragraph (e)(2)(i) of this section; and for improved feed efficiency..</td>
<td>Feed only to cattle fed in confinement for slaughter. Feed continuously as the sole ration to provide 22.7 mg of decoquinate per 100 lb body weight per day and 50 to 360 mg of monensin per head per day. Feed at least 28 days during period of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to animals producing milk for food. Do not feed to lactating dairy cattle. Also see paragraph (d)(1) of this section and §558.355(d)(8). Monensin as provided by No. 000986 in §510.600(c) of this chapter..</td>
<td>054771</td>
</tr>
<tr>
<td>Decoquinate in grams/ton</td>
<td>Combination in grams/ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>--------------------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(iv) 13.6 to 27.2 ...</td>
<td>Chlortetracycline approximately 400 (varying with body weight and feed consumption to provide 10 mg/lb of body weight per day).</td>
<td>Calves, beef and nonlactating dairy cattle: As in paragraph (e)(2)(i) of this section; for treatment of bacterial enteritis caused by E. coli and for treatment of bacterial pneumonia caused by Pasteurella multocida organisms susceptible to chlortetracycline.</td>
<td>Feed Type C feed to provide 22.7 mg decoquinate and 1 gram (g) chlortetracycline per 100 lb body weight (0.5 mg/kg) per day for not more than 5 days. Type C feed may be prepared from Type B feed containing 535.8 to 5,440 g/ton decoquinate and 6,700 to 80,000 g/ton chlortetracycline. When consumed, feed 22.7 mg decoquinate per 100 lb body weight/day for a total of 28 days to prevent coccidiosis. Withdraw 24 hours prior to slaughter when manufactured from chlortetracycline Type A medicated articles under NADA 141–147 and ANADA 200–359. Zero withdrawal time when manufactured from AUREOMYCIN (chlortetracycline) Type A medicated articles under NADA 141–185. Do not feed to calves to be processed for veal. Do not feed to animals producing milk for food. Chlortetracycline as provided by Nos. 054771 and 069254 in §510.600(c) of this chapter.</td>
<td>054771 069254</td>
</tr>
<tr>
<td>(v) 13.6 to 27.2 ...</td>
<td>Monensin 5 to 30 plus tylosin 8 to 10.</td>
<td>Cattle fed in confinement for slaughter: As in paragraph (e)(2)(i) of this section; for improved feed efficiency; and for reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces (Corynebacterium) pyogenes.</td>
<td>Feed only to cattle fed in confinement for slaughter. Feed continuously as the sole ration to provide 22.7 mg of decoquinate per 100 lb body weight per day, 50 to 360 mg of monensin per head per day, and 60 to 90 mg of tylosin per head per day. Feed at least 28 days during period of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to animals producing milk for food. Also see paragraph (d)(1) of this section and §558.355(d)(8). Monensin as provided by No. 000986, and tylosin as provided by Nos. 000986 and 016592 in §510.600(c) of this chapter.</td>
<td>016592 054771</td>
</tr>
<tr>
<td>(vi) 90.9 to 535.7 ...</td>
<td>Cattle (including ruminating and non-ruminating calves and veal calves): As in paragraph (a)(2)(i) of this section.</td>
<td>Feed Type C medicated feed supplements as a top dress or mix into the daily ration to provide 22.7 mg per 100 lb of body weight (0.5 mg/kg) per day. Feed at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to cows producing milk for food. See paragraph (d)(3) of this section.</td>
<td>054771</td>
<td></td>
</tr>
</tbody>
</table>
### § 558.195

<table>
<thead>
<tr>
<th>Decoquinate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(vi) 90.9 to 535.7</td>
<td>Chlortetracycline 4,000 to 20,000..</td>
<td>Calves, beef, and nonlactating dairy cattle: As in paragraph (e)(2)(i) of this section; for treatment of bacterial enteritis caused by <em>Escherichia coli</em>; and for treatment of bacterial pneumonia caused by <em>Pasteurella multocida</em> organisms susceptible to chlortetracycline.. Feed Type C medicated feed supplements as a top dress or mix into the daily ration to provide 22.7 mg decoquinate and 1 gram chlortetracycline per 100 lb body weight per day for not more than 5 days. When consumed, feed 22.7 mg decoquinate per 100 lb body weight per day for a total of 28 days to prevent coccidiosis. Withdraw 24 hours prior to slaughter when manufactured from CTC (chlortetracycline) Type A medicated articles under NADA 141–147. Zero withdrawal time when manufactured from AUREOMYCIN (chlortetracycline) Type A medicated articles under NADA 141–185. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Do not feed to animals producing milk for food. Chlortetracycline as provided by No. 054771 in § 510.600(c) of this chapter..</td>
<td>054771</td>
<td></td>
</tr>
</tbody>
</table>

(3) **Minor species.**

<table>
<thead>
<tr>
<th>Decoquinate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 12.9 to 90.8 ..</td>
<td>........................................</td>
<td>1. Young sheep: For the prevention of coccidiosis caused by <em>Eimeria ovinaeidae</em>, <em>E. crandallis</em>, <em>E. parva</em>, and <em>E. bakuensis</em>..</td>
<td>Feed Type C feed or milk replacer at a rate to provide 22.7 mg per 100 lb of body weight (0.5 mg per kg) per day; feed for at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to sheep producing milk for food..</td>
<td>054771</td>
</tr>
<tr>
<td>........................</td>
<td>........................................</td>
<td>2. Young goats: For the prevention of coccidiosis caused by <em>E. christenseni</em> and <em>E. ninakohlyakimovae</em>..</td>
<td>Feed Type C feed or milk replacer at a rate to provide 22.7 mg per 100 lb of body weight (0.5 mg per kg) per day; feed for at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to goats producing milk for food..</td>
<td></td>
</tr>
<tr>
<td>(ii) 90.9 to 535.7</td>
<td>........................................</td>
<td>1. Young sheep: As in item 1 of paragraph (e)(3)(i) of this section..</td>
<td>Feed Type C medicated feed supplements as a top dress or mix into the daily ration to provide 22.7 mg per 100 lbs of body weight (0.5 mg per kg) per day; feed for at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to sheep producing milk for food..</td>
<td>054771</td>
</tr>
</tbody>
</table>
### Food and Drug Administration, HHS § 558.198

<table>
<thead>
<tr>
<th>Decoquinate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2. Young goats: As in item 2 of paragraph (e)(3)(i) of this section.</td>
<td>Feed Type C medicated feed supplements as a top dress or mix into the daily ration to provide 22.7 mg per 100 lbs of body weight (0.5 mg per kg) per day; feed for at least 28 days during periods of exposure to coccidiosis or when it is likely to be a hazard. Do not feed to goats producing milk for food.</td>
</tr>
</tbody>
</table>


### § 558.198 Diclazuril.

(a) **Specifications.** Type A medicated article containing 0.2 percent diclazuril.

(b) **Approvals.** See No. 016592 in § 510.600(c) of this chapter.

(c) **Related tolerances.** See § 556.185 of this chapter.

(d) **Conditions of use—(1) Chickens.** For chickens it is used as follows:

<table>
<thead>
<tr>
<th>Diclazuril grams/ton</th>
<th>Combination grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 0.91 (1 part per million (ppm)).</td>
<td></td>
<td>Broiler chickens: For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mitis</em> (mivati), and <em>E. maxima</em>. Because diclazuril is effective against <em>E. maxima</em> later in its life cycle, subclinical intestinal lesions may be present for a short time after infection. Diclazuril was shown in studies to reduce lesion scores and improve performance and health of birds challenged with <em>E. maxima</em>.</td>
<td>Feed continuously. Not for use in hens producing eggs for human food.</td>
</tr>
<tr>
<td>(ii) 0.91 (1 ppm) Bacitracin methylenedisalicylate 4 to 50.</td>
<td></td>
<td>Broiler chickens: As in item (i) of this table; for increased rate of weight gain and improved feed efficiency.</td>
<td>As in item (i) of this table. Bacitracin methylenedisalicylate provided by No. 054771.</td>
</tr>
<tr>
<td>(iii) 0.91 (1 ppm) Bambermycins 1 to 2</td>
<td></td>
<td>Broiler chickens: As in item (i) of this table; for increased rate of weight gain and improved feed efficiency.</td>
<td>As in item (i) of this table. Bambermycins provided by No. 057926.</td>
</tr>
<tr>
<td>(iv) 0.91 (1 ppm) Virginiamycin 5</td>
<td></td>
<td>Broiler chickens: As in item (i) of this table; for increased rate of weight gain and improved feed efficiency.</td>
<td>As in item (i) of this table. Virginiamycin provided by No. 066104.</td>
</tr>
<tr>
<td>(v) 0.91 (1 ppm) Virginiamycin 5 to 15</td>
<td></td>
<td>Broiler chickens: As in item (i) of this table; for increased rate of weight gain.</td>
<td>As in item (i) of this table. Virginiamycin provided by No. 066104.</td>
</tr>
</tbody>
</table>

(2) **Turkeys.** For turkeys it is used as follows:

<table>
<thead>
<tr>
<th>Diclazuril grams/ton</th>
<th>Combination grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 0.91 (1 ppm) Bacitracin methylenedisalicylate 4 to 50.</td>
<td></td>
<td>Broiler chickens: As in paragraph (d)(2)(i) of this section; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as the sole ration. Do not feed to breeding turkeys. Not for use in hens producing eggs for human consumption.</td>
</tr>
<tr>
<td>(ii) 0.91 (1 ppm) Bacitracin methylenedisalicylate 4 to 50.</td>
<td></td>
<td>Growing turkeys: For the prevention of coccidiosis caused by <em>E. adenoeides</em>, <em>E. gallapavonis</em> and <em>E. melagromos</em>.</td>
<td>As in paragraph (d)(2)(i) of this section. Bacitracin methylenedisalicylate provided by No. 054771 in § 510.600(c) of this chapter.</td>
</tr>
</tbody>
</table>

433
§ 558.205 Dichlorvos.

(a) Approvals. Type A medicated articles: 3.1 and 9.6 percent to 054628 in § 510.600(c) of this chapter.

(b) Special considerations. (1) Dichlorvos is to be included in meal or mash or mixed with feed in crumble form only after the crumble feed has been manufactured. Do not mix in feeds to be pelleted nor with pelleted feed. Do not soak the feed or administer as wet mash. Feed must be dry when administered. Do not use in animals other than swine. Do not allow fowl access to feed containing this preparation or to feces from treated animals.

(2) Dichlorvos is a cholinesterase inhibitor. Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals. If human or animal poisoning should occur, immediately consult a physician or a veterinarian. Atropine is antidotal.

(3) Labeling for Type A articles and Type B feeds must include a statement that containers or materials used in packaging such Type A articles and Type B feeds are not to be reused and all such packaging materials must be destroyed after the product has been used.

(c) Related tolerances. See § 556.180 of this chapter.

(d) Conditions of use. It is used in feed for swine as follows:

(1) Amount per ton. Dichlorvos, 348 grams (0.0384 percent).

(1) Indications for use. For the removal and control of mature, immature, and/or fourth-stage larvae of the whipworm (Trichuris suis), nodular worm (Oesophagostomum sp.), large roundworm (Ascaris suum) and the thick stomach worm (Ascarops strongylina) of the gastrointestinal tract.

(2) Limitations. For swine up to 70 pounds body weight, feed as sole ration for 2 consecutive days. For swine from 70 pounds to market weight, feed as sole ration at the rate of 8.4 pounds of feed per head until the medicated feed has been consumed. For boars, open or bred gilts, and sows, feed as sole ration at the rate of 4.2 pounds per head per day for 2 consecutive days.

(2) Amount per ton. Dichlorvos, 479 grams (0.0528 percent).

(i) Indications for use. For the removal and control of mature, immature, and/or fourth-stage larvae of the whipworm (Trichuris suis), nodular worm (Oesophagostomum sp.), large roundworm (Ascaris suum), and the thick stomach worm (Ascarops strongylina) of the gastrointestinal tract.

(ii) Limitations. For boars, open or bred gilts, and sows, feed as sole ration at the rate of 6 pounds per head for one feeding.

(2) Amount per ton. Dichlorvos, 334–500 grams (0.0366–0.0550 percent).

(i) Indications for use. An aid in improving litter production efficiency by increasing pigs born alive, birth weights, survival to market, and rate of weight gain. Treatment also removes and controls mature, immature and/or fourth stage larvae of whipworm (Trichuris suis), nodular worm (Oesophagostomum sp.), large roundworm (Ascaris suum), and the
thick stomach worm (Ascarops strongylina) occurring in the gastrointestinal tract of the sow or gilt.

(ii) Limitations. For pregnant swine; mix into a gestation feed to provide 1,000 milligrams per head daily during last 30 days of gestation.


§ 558.235 Efrotomycin.

(a) Approvals. Type A medicated article: 14.5 grams per pound to 050604 in § 510.600(c) of this chapter.

(b) Conditions of use—(1) Swine—(i) Amount. 3.6 grams per ton.

(A) Indications for use. For improved feed efficiency.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(ii) Amount. 3.6 to 14.5 grams per ton.

(A) Indications for use. For increased rate of weight gain.

(B) Limitations. Feed continuously as sole ration. Not to be used in swine weighing more than 250 pounds.

(2) [Reserved]


§ 558.248 Erythromycin.

(a) Approvals. Type A medicated articles: (1) 2.2 percent to 061623 in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(2) 5 and 10 percent to 061623 for use in paragraphs (d)(1)(i) and (ii) of this section.

(b) Special considerations. The levels of antibiotic are expressed in terms of erythromycin master standard. One gram of erythromycin thiocyanate is equivalent to 0.925 gram of erythromycin master standard.

(c) Related tolerances. See §556.230 of this chapter.

(d) Condition of use. (1) It is used as follows:

<table>
<thead>
<tr>
<th>Erythromycin thiocyanate in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4.6 to 18.5</td>
<td>Chicken; growth promotion and feed efficiency.</td>
<td></td>
<td></td>
<td>061623</td>
</tr>
<tr>
<td>(ii) 9.25 to 18.5</td>
<td>Turkey; growth promotion and feed efficiency.</td>
<td></td>
<td></td>
<td>061623</td>
</tr>
<tr>
<td>(iii) 9.25 to 64.75</td>
<td>Swine; increase in weight gain, improved feed efficiency in starter pigs (9.25 to 64.75) and grower-finisher pigs (9.25).</td>
<td></td>
<td></td>
<td>061623</td>
</tr>
<tr>
<td>(iv) 18.5</td>
<td>Laying chickens; aids in increasing egg production.</td>
<td>1. Chickens; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>Feed for 2 d before stress and 3 to 6 d after stress; withdraw 24 h before slaughter.</td>
<td>061623</td>
</tr>
<tr>
<td>(v) 92.5</td>
<td>1. Chickens; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td>2. Chickens; as an aid in the prevention of infectious coryza.</td>
<td>Feed for 7 to 14 d; withdraw 24 h before slaughter.</td>
<td>061623</td>
</tr>
<tr>
<td></td>
<td>3. Turkeys; as an aid in the prevention of chronic respiratory disease during periods of stress.</td>
<td></td>
<td></td>
<td>061623</td>
</tr>
<tr>
<td>(vi) 185</td>
<td>1. Chickens; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease.</td>
<td>2. Turkeys; as an aid in the prevention and reduction of lesions and in lowering severity of chronic respiratory disease.</td>
<td>Feed for 5 to 8 d; do not use in birds producing eggs for food purposes; withdraw 48 h before slaughter.</td>
<td>061623</td>
</tr>
</tbody>
</table>

VerDate Sep<11>2014 10:06 Apr 14, 2016 Jkt 238075 PO 00000 Frm 00445 Fmt 8010 Sfmt 8010 Q:\21\21V6.TXT 31lpowell on DSK54DXVN1OFR with $$_JOB
(2) In feed for feedlot beef cattle at 37 milligrams per head per day as an aid in stimulating growth and improving feed efficiency.


§558.254 Famphur.

(a) Approvals. Type A medicated articles: 13.2 and 33.3 percent to 000061 in §510.600(c) of this chapter.

(b) Special considerations. Famphur is a cholinesterase inhibitor. Do not use this product in animals simultaneously or within a few days before or after treatment with or exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.

(c) Related tolerances. See §556.273 of this chapter.

(d) Conditions of use. It is used in the feed for cattle as follows:

(i) Indications for use. For control of grubs and as an aid in control of sucking lice.

(ii) Limitations. For beef cattle and nonlactating dairy cows; feed for 30 days; withdraw from dry dairy cows and heifers 21 days prior to freshening; withdraw 4 days prior to slaughter.

(2) Amount. 2.3 milligrams per pound body weight per day.

(i) Indications for use. For control of grubs.

(ii) Limitations. For beef cattle and nonlactating dairy cows; feed for 10 days; withdraw from dry dairy cows and heifers 21 days prior to freshening; withdraw 4 days prior to slaughter.


§558.258 Fenbendazole.

(a) Specifications. Type A medicated articles: 4 percent (18.1 grams per pound (g/lb)), 8 percent (36.2 g/lb), and 20 percent (90.7 g/lb) fenbendazole.

(b) Approvals. See No. 000061 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.275 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use—(1) Turkeys.

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.5 (16 parts per million)</td>
<td>Growing turkeys: For the removal and control of gastrointestinal worms: roundworms, adult and larvae (Ascaridia dissimilis); cecal worms, adult and larvae (Heterakis gallinarum), an important vector of Histomonas meleagridis (Blackhead). Growing turkeys: For the removal and control of gastrointestinal worms: roundworms, adult and larvae (Ascaridia dissimilis); cecal worms, adult and larvae (Heterakis gallinarum), an important vector of Histomonas meleagridis (Blackhead).</td>
<td>Feed continuously as the sole ration for 6 days. For growing turkeys only.</td>
<td>000061</td>
<td></td>
</tr>
<tr>
<td>Amount fenbendazole in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(i) 10 to 300 (to provide 9 milligrams per kilogram (mg/kg) of body weight) given over a 3- to 12-day period.</td>
<td></td>
<td>For the removal and control of: Adult stage lungworms (Metastrongylus apri and M. pudendecteuts); adult and larvae (L3, 4 stages—liver, lung, intestinal forms) large roundworms (Ascaris suum); adult stage nodular worms (Oesophagostomum dentatum, O. quadriceps); adult stage small stomach worms (Hydrostrongylus rubidus); adult and larvae (L2, 3, 4 stages—intestinal mucosal forms) whipworms (Trichuris suis); adult and larvae kidney worms (Stephanurus dentatus).</td>
<td>Feed as sole ration</td>
<td>000061</td>
</tr>
<tr>
<td>(ii) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 20</td>
<td>As in paragraph (e)(2)(i) of this section; for increased rate of gain in growing-finishing swine.</td>
<td>Feed as sole ration. Do not feed to swine that weigh more than 250 pounds (lbs); lincomycin as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>000061</td>
</tr>
<tr>
<td>(iii) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 40</td>
<td>As in paragraph (e)(2)(i) of this section; for control of swine dysentery in animals on premises with a history of swine dysentery, but where symptoms have not yet occurred.</td>
<td>Feed as sole ration. Do not use within 6 days of slaughter. Do not feed to swine that weigh more than 250 lbs.; lincomycin as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>000061</td>
</tr>
<tr>
<td>(iv) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 100</td>
<td>As in paragraph (e)(2)(i) of this section; for the treatment of swine dysentery.</td>
<td>Feed as sole ration. Do not use within 6 days of slaughter. Do not feed to swine that weigh more than 250 lbs.; lincomycin as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>000061</td>
</tr>
<tr>
<td>(v) 10 to 80 (to provide 9 mg/kg of body weight).</td>
<td>Lincomycin 200</td>
<td>As in paragraph (e)(2)(i) of this section; for reduction in the severity of swine mycoplasmal pneumonia caused by Mycoplasma hyopneumoniae.</td>
<td>Feed as sole ration. Do not use within 6 days of slaughter. Do not feed to swine that weigh more than 250 pounds (lbs); lincomycin as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>000061</td>
</tr>
<tr>
<td>(vi) 10 to 300 (to provide 9 mg/kg of body weight).</td>
<td>Bacitracin methylenedisalicylate 10 to 30.</td>
<td>Growing/finishing swine: As in paragraph (e)(2)(i) of this section; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed as sole ration. Under conditions of continued exposure to parasites, retreatment may be needed after 4 to 6 weeks. Bacitracin methylenedisalicylate as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(vi) 10 to 300 (to provide 9 mg/kg of body weight).</td>
<td>Bacitracin methylenedisalicylate 250.</td>
<td>1. Growing/finishing swine: As in paragraph (e)(2)(i) of this section; for control of swine dysentery associated with Treponema hyodysenteriae on premises with a history of swine dysentery, but where signs of disease have not yet occurred; or following an approved treatment of the disease condition.</td>
<td>1. Growing/finishing swine: Feed as sole ration. Not for use in growing and finishing swine that weigh more than 250 lbs. Diagnosis of swine dysentery should be confirmed by a veterinarian when results are not satisfactory. Under conditions of continued exposure to parasites, retreatment may be needed after 4 to 6 weeks. Bacitracin methylenedisalicylate as provided by 054771 in § 510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
</tbody>
</table>
§ 558.258

21 CFR Ch. I (4–1–16 Edition)

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Pregnant sows: As in paragraph (e)(2)(i) of this section; for control of clostridial enteritis in suckling pigs caused by <em>Clostridium perfringens</em>.</td>
<td></td>
<td></td>
<td>2. Pregnant sows: Feed as sole ration. Diagnosis of clostridial enteritis should be confirmed by a veterinarian when results are not satisfactory. Under conditions of continued exposure to parasites, retreatment may be needed after 4 to 6 weeks. Bacitracin methylenedisalicylate as provided by 054771 in § 510.600(c) of this chapter.</td>
<td></td>
</tr>
</tbody>
</table>

(3) Cattle.

<table>
<thead>
<tr>
<th>Amount fenbendazole</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 5 mg/kg body weight (2.27 mg/lb)</td>
<td>Dairy and beef cattle: For the removal and control of: Lungworms (<em>Dictyocaulus viviparus</em>); Stomach worms: barberpole worms (<em>Haemonchus contortus</em>), brown stomach worms (<em>Ostertagia ostertagi</em>), small stomach worms (<em>Trichostrongylus axei</em>); Intestinal worms: hookworms (<em>Bunostomum phlebotomum</em>), thread-necked intestinal worms (<em>Nematodirus helvetianus</em>), small intestinal worms (<em>Coopencia oncophora</em> and <em>C. punctata</em>); Bankrupt worms (<em>Trichostrongylus colubriformis</em>); and Nodular worms (<em>Oesophagostomum radiatum</em>).</td>
<td>Feed as the sole ration or as a top dress for one day. Retreatment may be needed after 4 to 6 weeks. Cattle must not be slaughtered within 13 days following last treatment. For dairy cattle the milk discard time is zero hours. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.</td>
<td>000061</td>
</tr>
<tr>
<td>(ii) [Reserved]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(iii) Free-choice feeds—(A) Amount. 5 mg/kg body weight (2.27 mg/lb), including the following formulations:

<table>
<thead>
<tr>
<th>Ingredient†</th>
<th>Percent</th>
<th>International Feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Free-choice, dry Type C feed:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salt (sodium chloride)</td>
<td>59.00</td>
<td>6–04–152</td>
</tr>
<tr>
<td>Monosodium phosphate</td>
<td>31.16</td>
<td>6–04–288</td>
</tr>
<tr>
<td>Dried cane molasses</td>
<td>3.12</td>
<td>6–05–656</td>
</tr>
<tr>
<td>Zinc sulfate</td>
<td>0.76</td>
<td>6–01–720</td>
</tr>
<tr>
<td>Copper sulfate</td>
<td>0.45</td>
<td>n/a</td>
</tr>
<tr>
<td>Fenbendazole 20% Type A article</td>
<td>5.51</td>
<td></td>
</tr>
<tr>
<td>(2) Free-choice, dry Type C feed:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salt (sodium chloride)</td>
<td>35.93</td>
<td>6–04–152</td>
</tr>
<tr>
<td>Dicalcium phosphate (18.5% P)</td>
<td>32.44</td>
<td>6–00–080</td>
</tr>
<tr>
<td>Calcium carbonate (38% Ca)</td>
<td>15.16</td>
<td>6–01–069</td>
</tr>
<tr>
<td>Magnesium oxide (56% Mg)</td>
<td>10.14</td>
<td>6–02–756</td>
</tr>
<tr>
<td>Zinc sulfate</td>
<td>1.47</td>
<td>6–05–656</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>1.00</td>
<td>8–03–123</td>
</tr>
<tr>
<td>Dried cane molasses (46% sugars)</td>
<td>0.98</td>
<td>4–04–695</td>
</tr>
</tbody>
</table>
### Food and Drug Administration, HHS

**§ 558.258**

<table>
<thead>
<tr>
<th>Ingredient¹</th>
<th>Percent</th>
<th>International Feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium iodide</td>
<td>0.01</td>
<td>6–03–759</td>
</tr>
<tr>
<td>Fenbendazole 20% Type A article</td>
<td>2.10</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>Free-choice, liquid Type C feed:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cane molasses²</td>
<td>80.902</td>
<td>4–13–251</td>
</tr>
<tr>
<td>Water</td>
<td>9.36</td>
<td>n/a</td>
</tr>
<tr>
<td>Urea solution, 55%</td>
<td>7.05</td>
<td>5–05–707</td>
</tr>
<tr>
<td>Phosphoric acid 75% (feed grade)</td>
<td>2.00</td>
<td>6–03–707</td>
</tr>
<tr>
<td>Xantham gum</td>
<td>0.20</td>
<td>8–15–818</td>
</tr>
<tr>
<td>Trace minerals</td>
<td>0.20</td>
<td>n/a</td>
</tr>
<tr>
<td>Vitamin premix</td>
<td>0.01</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Arts. 20% Type A article | 0.278 | n/a |

¹The content of any added vitamin and trace mineral may be varied, however, they should be comparable to those used by the manufacturer for other free-choice cattle feeds. Formulation modifications require FDA approval prior to marketing. Selenium is not approved for the free-choice formulations described in paragraph (e)(3)(iii) of this section. Free-choice cattle feeds containing selenium must comply with published regulations.

²The percentage of cane molasses and water in the formulation may be adjusted as needed in order to bring the brix value of the molasses to the industry standard of 79.5 brix.

---

**B. Indications for use.** As in paragraph (e)(3)(i) of this section.

**C. Limitations.** Feed a total of 5 mg of fenbendazole per kg (2.27 mg/lb) of body weight to cattle over a 3- to 6-day period. Retreatment may be needed after 4 to 6 weeks. Cattle must not be slaughtered within 13 days following last treatment. For dairy cattle the milk discard time is zero hours. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(4) **Horses.**

<table>
<thead>
<tr>
<th>Amount fenbendazole in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 4.540 ..........................</td>
<td>5 mg/kg body weight (2.27 mg/lb) for the control of large strongyles (Strongylus edentatus, S. equinus, S. vulgaris, Trichobothrium spp.), small strongyles (Oxyroctisoma spp., Cylcopus spp., Cylcophillus spp.), and pinworms (Oxyuris equi); 10 mg/kg body weight (4.54 mg/lb) for the control of ascarids (Parascaris equorum...)</td>
<td>Feed at the rate of 0.1 lb of feed per 100 lb of body weight to provide 2.27 mg fenbendazole/lb of body weight in a 1-day treatment or 0.2 lb of feed per 100 lb of body weight to provide 4.54 mg fenbendazole/lb of body weight in a 1-day treatment. All horses must be eating normally to ensure that each animal consumes an adequate amount of the medicated feed. Regular deworming at intervals of 6 to 8 weeks may be required due to the possibility of reinfection. Do not use in horses intended for human consumption...</td>
<td>000061</td>
</tr>
<tr>
<td>(ii) [Reserved] ......................</td>
<td>..............................</td>
<td>........................</td>
<td>........................</td>
</tr>
</tbody>
</table>

---

(5) **Zoo and wildlife animals.**

<table>
<thead>
<tr>
<th>Species/Class</th>
<th>Amount fenbendazole</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) Ruminants (subfamily Antilopinae, Hippotraginae, Caprinae)</td>
<td>2.5 mg/kg/day for 3 days...</td>
<td>For the removal and control of small stomach worm (Trichostrongylus spp.), thread necked intestinal worm (Heterodinium spp.), barberpole worm (Haemonchus spp.), whipworm (Trichuris spp.)...</td>
<td>Use as complete feed. Prior withdrawal of feed or water is not necessary. Retreatment may be required in 6 weeks. Do not use 14 days before or during the hunting season...</td>
<td>000061</td>
</tr>
</tbody>
</table>

---

Selected terms are italicized. For the meaning of these terms, see 21 CFR 573.920.
### § 558.261 Florfenicol.

(a) **Specifications.** Type A medicated articles containing florfenicol in the following concentrations:

1. 40 grams per kilogram for use as in paragraph (e)(1) of this section.
2. 500 grams per kilogram for use as in paragraph (e)(2) of this section.

(b) **Sponsor.** See No. 000061 in § 510.600(c) of this chapter.

(c) **Special considerations.**

1. Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.

2. The expiration date of VFDs for florfenicol medicated feeds:

   - For swine must not exceed 90 days from the date of issuance.
   - For fish must not exceed 6 months from the date of issuance.

3. VFDs for florfenicol shall not be refilled.

4. Type A medicated articles and medicated feeds intended for use in fish shall bear the following: “Not for use in animals intended for breeding purposes. The effects of florfenicol on reproductive performance have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy.”

(d) **Related tolerances.** See § 556.283 of this chapter.

(e) **Conditions of use.**

1. **Swine—**

   - Florfenicol in grams/ton of feed: 182
   - Indications for use: For the control of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Streptococcus suis*, and *Bordetella bronchiseptica* in groups of swine in buildings experiencing an outbreak of SRD.
   - Limitations: Feed continuously as a sole ration for 5 consecutive days. The safety of florfenicol on swine reproductive performance, pregnancy, and lactation have not been determined. Feeds containing florfenicol must be withdrawn 13 days prior to slaughter.

2. **Fish—**

   - Florfenicol in grams/ton of feed: 182 to 2,724
   - Indications for use: Catfish: For the control of mortality due to enteric septicemia of catfish associated with *Edwardsiella ictaluri*.
   - Limitations: Feed as a sole ration for 10 consecutive days to deliver 10 to 15 milligrams (mg) florfenicol per kilogram (kg) of fish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. A dose-related decrease in hematopoietic/lymphopoietic tissue may occur. The time required for hematopoietic/lymphopoietic tissues to regenerate was not evaluated. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.
## §558.265 Halofuginone.

(a) Specifications. Type A medicated articles containing 6 grams of halofuginone hydrobromide per kilogram.

(b) Approvals. See No. 016592 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.308 of this chapter.

(d) Conditions of use. (1) It is used in feed for broiler chickens as follows:

(i) Amount. 2.72 grams per ton.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*.

(B) Limitations. Feed continuously as sole ration; withdraw 4 days before slaughter; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.

(ii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus bambermycins 1 to 2 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria tenella*, *E. necatrix*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*; for increased rate of weight gain and improved feed efficiency.

(B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; do not feed to layers.

### Table 558.265-1: Halofuginone Indications and Limitations

<table>
<thead>
<tr>
<th>Florfenicol in grams/ton of feed</th>
<th>Indications for use</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ii) 182 to 1,816 ...............</td>
<td>Freshwater-reared salmonids: For the control of mortality due to coldwater disease associated with <em>Flavobacterium psychrophilum</em> and furunculosis associated with <em>Aeromonas salmonicida</em>.</td>
<td>Feed as a sole ration for 10 consecutive days to deliver 10 to 15 mg florfenicol per kg of fish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.</td>
</tr>
<tr>
<td>(iii) 182 to 2,724 .............</td>
<td>Freshwater-reared finfish: For the control of mortality due to columnaris disease associated with <em>Flavobacterium columnare</em>.</td>
<td>Feed as a sole ration for 10 consecutive days to deliver 10 to 15 mg florfenicol per kg of fish for freshwater-reared warmwater finfish and other freshwater-reared finfish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. For catfish, a dose-related decrease in hematopoietic/lymphopoietic tissue may occur. The time required for hematopoietic/lymphopoietic tissues to regenerate was not evaluated. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.</td>
</tr>
<tr>
<td>(iv) 273 to 2,724 .............</td>
<td>Freshwater-reared warmwater finfish: For the control of mortality due to streptococcal septicemia associated with <em>Streptococcus iniae</em>.</td>
<td>Feed as a sole ration for 10 consecutive days to deliver 15 mg florfenicol per kg of fish. Feed containing florfenicol shall not be fed for more than 10 days. Following administration, fish should be reevaluated by a licensed veterinarian before initiating a further course of therapy. For catfish, a dose-related decrease in hematopoietic/lymphopoietic tissue may occur. The time required for hematopoietic/lymphopoietic tissues to regenerate was not evaluated. The effects of florfenicol on reproductive performance have not been determined. Feeds containing florfenicol must be withdrawn 15 days prior to slaughter.</td>
</tr>
</tbody>
</table>

(iii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus virginiamycin 5 grams.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain and improved feed efficiency.

(B) Limitations. Feed continuously as sole ration; withdraw 6 days before slaughter; do not feed to layers.

(iv) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus virginiamycin 5 to 15 grams.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. meleagrimitis, and E. maxima; for increased rate of weight gain.

(B) Limitations. Feed continuously as sole ration; withdraw 6 days before slaughter; do not feed to layers.

(v) [Reserved]

(vi) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus bacitracin methylenedisalicylate 10 to 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. meleagrimitis, E. maxima and for improved feed efficiency.

(B) Limitations. Feed continuously as sole ration; withdraw 5 days before slaughter; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.

(vii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus lincomycin 2 to 4 grams.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria adenoides, E. meleagrimitis, E. maxima and for improved feed efficiency.

(B) Limitations. Feed continuously as sole ration; withdraw 4 days before slaughter; do not feed to layers; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.

(viii) [Reserved]

(2) It is used in feed for turkeys as follows:

(i) Amount per ton. 1.36 to 2.72 grams.

(A) Indications for use. For the prevention of coccidiosis in growing turkeys caused by Eimeria adenoides, E. meleagrimitis, and E. gallopavonis.

(B) Limitations. Feed continuously as sole ration; withdraw 7 days before slaughter; do not feed to layers or water fowl; avoid contact with skin, eyes, or clothing; keep out of lakes, ponds, or streams.

(ii) Amount per ton. Halofuginone hydrobromide 1.36 to 2.72 grams plus bacitracin methylenedisalicylate 10 to 50 grams.

(A) Indications for use. For prevention of coccidiosis caused by Eimeria adenoides, E. meleagrimitis, and E. gallopavonis, and for increased rate of weight gain in growing turkeys.

(B) Limitations. Feed continuously as sole ration. Withdraw 7 days before slaughter. Do not feed to laying chickens or water fowl. Keep out of lakes, ponds, and streams. Halofuginone is toxic to fish and aquatic life. Halofuginone is an irritant to eyes and skin. Avoid contact with skin, eyes, or clothing.

(iii) Amount per ton. 1.36 to 2.72 grams of halofuginone hydrobromide plus 2 grams of bambermycins.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria adenoides, E. meleagrimitis, and E. gallopavonis, and for increased rate of weight gain in growing turkeys.

(B) Limitations. Feed continuously as sole ration. Withdraw 7 days before slaughter. Do not feed to laying chickens or water fowl. Halofuginone hydrobromide is toxic to fish and other aquatic life. Keep out of lakes, ponds, and streams. Halofuginone hydrobromide is an eye and skin irritant. Avoid contact with skin, eyes, and clothing.

(3) It is used in feed for replacement cage laying chickens and replacement breeder chickens as follows:

(i) Amount per ton. 2.72 grams.

(A) Indications for use. For the prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. mivati/E. mitis, and E. brunetti.

(B) Limitations. Feed continuously as sole ration to replacement cage laying chickens until 20 weeks of age. Feed continuously as sole ration to replacement breeder chickens until 16 weeks of age. Withdraw 4 days before slaughter. Do not feed to laying chickens or water fowl. Halofuginone...
Food and Drug Administration, HHS § 558.295

Hydromycin B.

(a) Approvals. See sponsor numbers in §510.600(c) of this chapter for Type A medicated articles as follows:

(1) No. 000986: 2.4 and 8 grams per pound (g/lb).

(2) No. 054771: 0.6 and 1.6 g/lb.

(b) Related tolerances. See §556.330 of this chapter.

(c) Conditions of use. It is used in feed as follows:

(1) **Chickens**—

<table>
<thead>
<tr>
<th>Hygromycin B in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 8 to 12 ................</td>
<td>........................................</td>
<td>Chickens: For control of infestation of large roundworms (<em>Ascaris galli</em>), cecal worms (<em>Heterakis gallinae</em>), and capillary worms (<em>Capillaria obsignata</em>).</td>
<td>Withdraw 3 days before slaughter.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) 8 to 12 ...............</td>
<td>Tylosin 4 to 50 ....</td>
<td>Chickens: For control of infestations of large roundworms (<em>Ascaris galli</em>), cecal worms (<em>Heterakis gallinae</em>), and capillary worms (<em>Capillaria obsignata</em>); growth promotion and feed efficiency.</td>
<td>Withdraw 3 days before slaughter.</td>
<td>000986</td>
</tr>
</tbody>
</table>

(2) **Swine**—

<table>
<thead>
<tr>
<th>Hygromycin B in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 12 ...................</td>
<td>........................................</td>
<td>Swine: For control of infestation of large roundworms (<em>Ascaris suis</em>), nodular worms (<em>Oesophagostomum dentatum</em>), and whipworms (<em>Trichuris suis</em>).</td>
<td>Withdraw 15 days before slaughter.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) 12 ..................</td>
<td>Tylosin 10 to 100 ..........</td>
<td>Swine: For control of infestations of large roundworms (<em>Ascaris suis</em>), nodular worms (<em>Oesophagostomum dentatum</em>), and whipworms (<em>Trichuris suis</em>); growth promotion and feed efficiency.</td>
<td>Feed continuously as follows: Animal weight (lbs.): Up to 40 . . . 20 to 100 1. 41 to 100 . . . 20 to 40 1. 101 to market weight . . . 10 to 20 1. Withdraw 15 days before slaughter. Tylosin as tylosin phosphate as provided by No. 000986 in §510.600 of this chapter.</td>
<td>000986</td>
</tr>
</tbody>
</table>

1 Amount of Tylosin (g/t).

(b) **NAS/NRC status.** The use of this drug is NAS/NRC reviewed and found effective. Applications for these uses need not include efficacy data as required by §514.111 of this chapter but

§ 558.274 Iodinated casein.

(a) **Approvals.** See sponsor numbers in §510.600(c) of this chapter.
may require bioequivalency or safety data.

(c) Conditions of use—(1) Ducks—(i) Amount per ton. 100 to 200 grams.
   (ii) Indications for use. For increased rate of weight gain and improved feathering in growing ducks.

(2) Dairy cows—(i) Amount per pound. ½ to 1½ grams per 100 lb of body weight.
   (ii) Indications for use. For increased milk production in dairy cows.
   (iii) Limitations. This drug is effective for limited periods of time, and the effectiveness is limited to the declining phase of lactation. Administration must be accompanied with increased feed intake; administration may increase heat sensitivity of the animal.

[45 FR 41631, June 20, 1980]

§ 558.300 Ivermectin.

(a) Specifications. Type A medicated article containing 2.72 grams ivermectin per pound (g/lb).

(b) Sponsor. See No. 050604 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.344 of this chapter.

(d) Special considerations. See §500.25 of this chapter.

(e) Conditions of use in swine. It is used in feed as follows:

<table>
<thead>
<tr>
<th>Ivermectin in g/ton of feed</th>
<th>Combination in g/ton of feed</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) 1.8 (to provide 0.1 milligram per kilogram (mg/kg) of body weight per day)</td>
<td>Bacitracin methylenedisalicylate, 10 to 30</td>
<td>Weaned, growing-finishing swine: For treatment and control of gastrointestinal roundworms (Ascaris suum, adults and fourth-stage larvae; Ascaropsis strongyliina, adults; Hysterorhabditis rubida, adults and fourth-stage larvae; Oesophagostomum spp., adults and fourth-stage larvae); kidneyworms (Stephanurus dentatus, adults and fourth-stage larvae); lungworms (Metastrongylus spp., adults); threadworms (Strongyloides ransomi, adults and somatic larvae); lice (Haematopinus suis); and mange mites (Sarcoptes scabiei var. suis).</td>
<td>Feed as the only feed for 7 consecutive days. Withdraw 5 days before slaughter.</td>
<td>050604</td>
</tr>
<tr>
<td>(2) 1.8 (to provide 0.1 mg/kg of body weight per day)</td>
<td>Bacitracin methylenedisalicylate, 250</td>
<td>Weaned, growing-finishing swine: As in paragraph (e)(1) of this section; and for control of swine dysentery associated with Treponema hyodysenteriae on premises with a history of swine dysentery, but where symptoms have not yet occurred, or following an approved treatment of disease condition.</td>
<td>For use in swine feed only. Feed as the only feed for 7 consecutive days. Withdraw 5 days before slaughter.</td>
<td>050604</td>
</tr>
<tr>
<td>(3) 1.8 (to provide 0.1 mg/kg of body weight per day)</td>
<td>Bacitracin methylenedisalicylate, 10 to 30</td>
<td>Weaned, growing-finishing swine: As in paragraph (e)(1) of this section; and for control of swine dysentery associated with Treponema hyodysenteriae on premises with a history of swine dysentery, but where symptoms have not yet occurred, or following an approved treatment of disease condition.</td>
<td>For use in swine feed only. Feed as the only feed for 7 consecutive days. Withdraw 5 days before slaughter.</td>
<td>050604</td>
</tr>
<tr>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feed as the only feed for 7 consecutive days. Not to be fed to swine that weigh more than 250 lbs. Withdraw 5 days before slaughter. Also see paragraphs (c)(1) and (c)(2) in §558.325 of this chapter.</td>
<td>050604</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feed the only feed for 7 consecutive days. Not to be fed to swine that weigh more than 250 lbs. Also see paragraphs (c)(1) and (c)(2) in §558.325 of this chapter. Withdraw 5 days before slaughter. A separate feed containing 40 g/ton lincomycin may be continued to complete the lincomycin treatment.</td>
<td>050604</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feed as the only feed for 7 consecutive days followed by a separate feed containing 100 g/ton lincomycin for an additional 14 days to complete the lincomycin treatment. Withdraw 6 days before slaughter. Not to be fed to swine that weigh more than 250 lbs. Also see paragraphs (c)(1) and (c)(2) in §558.325 of this chapter.</td>
<td>050604</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feed as the only feed for 7 consecutive days followed by a separate feed containing 200 g/ton lincomycin for an additional 14 days to complete the lincomycin treatment. Withdraw 6 days before slaughter. Not to be fed to swine that weigh more than 250 lbs. Also see paragraphs (c)(1) and (c)(2) in §558.325 of this chapter.</td>
<td>050604</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivermectin in g/ton of feed</td>
<td>Combination in g/ton of feed</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(8) 1.8 to 11.8 (to provide 0.1 mg/kg of body weight per day)</td>
<td>Adult and breeding swine: For treatment and control of gastrointestinal roundworms (<em>Ascaris suum</em>, adults and fourth-stage larvae; <em>Ascarops strongylina</em>, adults; <em>Hyostrongylus rubidus</em>, adults and fourth-stage larvae; <em>Oesophagostomum spp.</em>, adults and fourth-stage larvae); kidneyworms (<em>Stephanurus dentatus</em>, adults and fourth-stage larvae); lungworms (<em>Metastrongylus spp.</em>, adults); threadworms (<em>Strongyloides ransomi</em>, adults and somatic larvae, and prevention of transmission of infective larvae to piglets, via the colostrum or milk, when fed during gestation); lice (<em>Haematopinus suis</em>); and mange mites (<em>Sarcoptes scabiei var. suis</em>).</td>
<td>Feed as the only feed for 7 consecutive days. Withdraw 5 days before slaughter.</td>
<td>050604</td>
<td></td>
</tr>
<tr>
<td>(9) 1.8 to 11.8 (to provide 0.1 mg/kg of body weight per day)</td>
<td>Bacitracin methylenedisalicylate, 250</td>
<td>Pregnant sows: As in paragraph (e)(8) of this section; and for control of clostridial enteritis caused by <em>Clostridium perfringens</em> in suckling piglets.</td>
<td>Feed as the only feed for 7 consecutive days. Withdraw 5 days before slaughter. Feed bacitracin methylenedisalicylate Type C medicated feed to sows from 14 days before through 21 days after farrowing on premises with a history of clostridial scours.</td>
<td>050604</td>
</tr>
<tr>
<td>(10) 18.2 to 120 (to provide 0.1 mg/kg of body weight per day)</td>
<td>Adult and breeding swine: As in paragraph (e)(8) of this section.</td>
<td>Top dress on daily ration for individual treatment for 7 consecutive days. Withdraw 5 days before slaughter.</td>
<td>050604</td>
<td></td>
</tr>
</tbody>
</table>

§ 558.305 Laidlomycin.

(a) Specifications. Type A medicated articles containing 50 grams laidlomycin propionate potassium per pound.

(b) Approvals. See No. 054771 in § 510.600(c) of this chapter.

(c) Tolerances. See §556.346 of this chapter.

(d) Special considerations. (1) Laidlomycin liquid Type B feeds may be manufactured from dry laidlomycin Type A articles. The liquid Type B feeds must have a pH of 6.0 to 8.0, dry matter of 62 to 75 percent, and bear appropriate mixing directions as follows:
   (i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
   (ii) For liquid feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(ii) The expiration date for the liquid Type B feed is 21 days after date of manufacture. The expiration date for the dry Type C feed made from the liquid Type B feed is 7 days after date of manufacture.

(3) Labeling for all Type B feeds (liquid and dry) and Type C feeds containing laidlomycin shall bear the following statements:
   (i) Do not allow horses or other equines access to feeds containing laidlomycin propionate potassium.
(i) The safety of laidlomycin propionate potassium in unapproved species has not been established.

(iii) Not for use in animals intended for breeding.

(e) Conditions of use. It is used in cattle being fed in confinement for slaughter as follows:

<table>
<thead>
<tr>
<th>Laidlomycin in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) 5 ..........................</td>
<td>............................</td>
<td>For improved feed efficiency and increased rate of weight gain.</td>
<td>Feed continuously in a Type C feed at a rate of 30 to 75 mg/head/day.</td>
<td>054771</td>
</tr>
<tr>
<td>(2) 5 ....................</td>
<td>Chlortetracycline10 mg/lb body weight.</td>
<td>For improved feed efficiency and increased rate of weight gain; and for treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>Pasteurella multocida</em> organisms susceptible to chlortetracycline.</td>
<td>Feed continuously at a rate of 30 to 75 mg laidlomycin propionate potassium per head per day for not more than 5 days. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.</td>
<td>054771</td>
</tr>
<tr>
<td>(3) 5 ..........................</td>
<td>Chlortetracycline 350 mg/head/day.</td>
<td>For improved feed efficiency and increased rate of weight gain; and for control of bacterial pneumonia associated with shipping fever complex caused by <em>Pasteurella spp.</em> susceptible to chlortetracycline.</td>
<td>Feed continuously at a rate of 30 to 75 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.</td>
<td>054771</td>
</tr>
<tr>
<td>(4) 5 to 10 ..........................</td>
<td>............................</td>
<td>For improved feed efficiency.</td>
<td>Feed continuously in a Type C feed at a rate of 30 to 150 milligrams/head/day.</td>
<td>054771</td>
</tr>
<tr>
<td>(5) 5 to 10 ..........................</td>
<td>Chlortetracycline 10 mg/pound body weight.</td>
<td>For improved feed efficiency; and for treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> organisms susceptible to chlortetracycline.</td>
<td>Feed continuously at a rate of 30 to 150 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.</td>
<td>054771</td>
</tr>
<tr>
<td>(6) 5 to 10 ..........................</td>
<td>Chlortetracycline 350 mg/head/day.</td>
<td>For improved feed efficiency; and for control of bacterial pneumonia associated with shipping fever complex caused by <em>Pasteurella spp.</em> susceptible to chlortetracycline.</td>
<td>Feed continuously at a rate of 30 to 150 mg laidlomycin propionate potassium per head per day. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.</td>
<td>054771</td>
</tr>
</tbody>
</table>

§ 558.311 Lasalocid.

(a) Specifications. A minimum of 90 percent of lasalocid activity is derived from lasalocid A.

(b) Approvals. Type A medicated articles approved for sponsors identified in §510.600(c) of this chapter for use as in paragraphs (e) of this section as follows:

1. 3.0, 3.3, 3.8, 4.0, 4.3, 4.4, 5.0, 5.1, 5.5, 5.7, 6.0, 6.3, 6.7, 7.2, 7.5, 8.0, 8.3, 10.0, 12.5, 15, 20, and 50 percent activity to No. 054771 for use as in paragraphs (e)(1)(i), (ii), (iii), (iv), and (x) of this section.

2. 15 percent activity to No. 066104 as provided by No. 054771 for use as in paragraph (e)(1)(v) of this section.

3. 15, 20, 33.1, and 50 percent activity to No. 054771 for use in cattle feeds as in paragraphs (e)(1)(vi), (vii), (ix), (xi), (xii), and (xv) of this section, and for use in sheep as in paragraph (e)(1)(viii) of this section.
(4) 15 percent activity to No. 054771 for use in Type C rabbit feeds as in paragraph (e)(1)(xvi) of this section and for use in ruminant free-choice Type C feeds as in paragraphs (e)(2), (e)(3), and (e)(4) of this section.

(5) 15 and 20 percent activity to Nos. 012286 and 017800 for use in free-choice mineral feeds for cattle as in paragraph (e)(1)(xviii) of this section.

(6) 20 percent activity as a liquid Type A article to No. 054771 for use in cattle feeds as in paragraphs (e)(1)(vi), (e)(1)(vii), (e)(1)(ix), (e)(1)(xi), (e)(1)(xii), and (e)(1)(xiii) of this section, and for use in sheep feeds as in paragraph (e)(1)(viii) of this section.

(7) 20 percent activity to No. 054771 for use as follows:
   (i) Chukar partridges as in paragraph (e)(1)(xiii).
   (ii) Turkeys as in paragraph (e)(1)(xiv).
   (iii) Rabbits as in paragraph (e)(1)(xvi).

(8) [Reserved]

(9) 15 percent activity to No. 068287 for use in free-choice protein blocks for cattle as in paragraphs (e)(1)(xix) of this section.

(c) Related tolerance. See §556.347 of this chapter.

(d) Special considerations.
   (1) Type C cattle and sheep feeds may be manufactured from lasalocid liquid Type B feeds which have a pH of 4.0 to 8.0 and bear appropriate mixing directions as follows:
      (i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.
      (ii) For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

   (2) A physically stable lasalocid liquid feed will not be subject to the requirements for mixing directions prescribed in paragraph (d)(1) of this section provided it has a pH of 4.0 to 8.0 and contains a suspending agent(s) sufficient to maintain a viscosity of not less than 300 centipoises per second for 3 months.

   (3) If a manufacturer is unable to meet the requirements of paragraph (d)(1) or (d)(2) of this section, the manufacturer may secure approval of a positionally stable liquid feed by:
      (i) Either filing a new animal drug application for the product or establishing a master file containing data to support the stability of its product;
      (ii) Authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental new animal drug application to establish physical stability; and
      (iii) Requesting the sponsor of an approved new animal drug application to file a supplement to provide for use of its lasalocid Type A article in the manufacture of the liquid feed specified in the appropriate master file. If the data demonstrate the stability of the liquid feed described in the master file, the supplemental new animal drug application will be approved. The approval will provide a basis for the individual liquid feed manufacturer to manufacture under a medicated feed license the liquid mediated feed described in the master file. A manufacturer who seeks to market a physically unstable lasalocid liquid feed with mixing directions different from the standard directions established in paragraph (d)(1) of this section may also follow this procedure.

   (4) If adequate information is submitted to show that a particular liquid feed containing lasalocid is stable outside the pH of 4.0 to 8.0, the pH restrictions described in paragraphs (d)(1) and (d)(2) of this section may be waived.

   (5) Required label statements:
      (i) For liquid Type B feed (cattle and sheep): Mix thoroughly with grain and/or roughage prior to feeding. Feeding undiluted, mixing errors, or inadequate mixing (recirculation or agitation) may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species has not been established.
(ii) For Type A articles or Type B feeds (cattle and sheep): Feeding undiluted or mixing errors may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species has not been established.

(iii) For Type A articles, Type B or Type C feeds (cattle): A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

(6) Lasalocid Type A medicated articles containing lasalocid dried fermentation residue are for use in cattle and sheep feed only.

(7) Each use in a free-choice Type C cattle feed as in paragraphs (e)(1)(xii) and (e)(1)(xviii) of this section must be the subject of an approved NADA or supplemental NADA as provided in §510.455 of this chapter.

(e)(1) Conditions of use. It is used as follows:

<table>
<thead>
<tr>
<th>Lasalocid sodium activity in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bambermycins 1 to 2</td>
<td>For the prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>. For broiler or fryer chickens only; feed continuously as the sole ration.</td>
<td>Feed continuously as sole ration. Bambermycins provided by No. 016592 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 68 (0.0075 pct)</td>
<td>Lincomycin 2 (0.00022 pct)</td>
<td>Broiler or fryer chickens; for the prevention of coccidiosis caused by <em>Eimeria mivati</em>, <em>E. brunetti</em>, <em>E. tenella</em>, <em>E. acervulina</em>, <em>E. maxima</em>, and <em>E. necatrix</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>For broiler and fryer chickens only; feed continuously as sole ration; withdraw 5 d before slaughter; Type C feed must be used within 4 weeks of manufacture; as lincomycin hydrochloride monohydrate.</td>
<td>054771</td>
</tr>
<tr>
<td>(iv) 68 (0.0075 percent)</td>
<td>Bacitracin 10 to 50 ..</td>
<td>For prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and for increased rate of weight gain and improved feed efficiency. For broiler or fryer chickens only; feed continuously as the sole ration; bacitracin methylenedisalicylate provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>For broiler and fryer chickens only; feed continuously as sole ration; do not feed to laying chickens; lasalocid sodium provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(v) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Virginiamycin 20 ..</td>
<td>For prevention of coccidiosis caused by <em>Eimeria tenella</em> <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. brunetti</em>, <em>E. mivati</em>, and <em>E. maxima</em>; and for increased rate of weight gain and improved feed efficiency. In Type C feeds; for cattle fed in confinement for slaughter only; feed continuously in complete feed to provide not less than 100 mg nor more than 360 mg of lasalocid sodium activity per head per day.</td>
<td>In Type C feeds; for beef cattle fed in confinement for slaughter; feed continuously at 100 to 360 mg/head/day lasalocid and 75 mg/head/day oxytetracycline. As monoalkyl (C₈–C₁₈) trimethyl ammonium oxytetracycline.</td>
<td>054771</td>
</tr>
<tr>
<td>(vi) 10 (0.0011 pct) to 30 (0.0033 pct)</td>
<td>Oxytetracycline 7.5 ..</td>
<td>Cattle; for improved feed efficiency and reduction of incidence and severity of liver abscesses.</td>
<td>In Type C feeds, for beef cattle fed in confinement for slaughter; feed continuously at 100 to 360 mg/head/day lasalocid and 75 mg/head/day oxytetracycline. As monoalkyl (C₈–C₁₈) trimethyl ammonium oxytetracycline.</td>
<td>054771</td>
</tr>
<tr>
<td>Lasalocid sodium activity in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(vi) 25 (0.0027 pct) to 30 (0.0033 pct)</td>
<td></td>
<td>Cattle; for improved feed efficiency and increased rate of weight gain.</td>
<td>In Type C feeds; for cattle fed in confinement for slaughter only; feed continuously in complete feed to provide not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day.</td>
<td>054771</td>
</tr>
<tr>
<td></td>
<td>Oxytetracycline 7.5</td>
<td>Cattle; for improved feed efficiency, increased rate of weight gain, and reduction of incidence and severity of liver abscesses.</td>
<td>In Type C feeds, for beef cattle fed in confinement for slaughter; feed continuously at 250 to 360 mg/head/day lasalocid and 75 mg/head/day oxytetracycline. As monoalkyl (C₈-C₁₀) trimethyl ammonium oxytetracycline.</td>
<td>054771</td>
</tr>
<tr>
<td>(vii) 20 (0.0022 pct) to 30 (0.0033 pct)</td>
<td></td>
<td>Sheep; for the prevention of coccidiosis caused by Eimeria ovina, E. crandallis, E. ovirudalis (E. ninakohlyakimovae), E. parva, and E. intricata.</td>
<td>Feed continuously at a rate of not less than 60 mg or more than 300 mg of lasalocid sodium activity per head per day depending on body weight.</td>
<td>054771</td>
</tr>
<tr>
<td>(ix)</td>
<td></td>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td>Feed continuously at a rate of not less than 60 mg or more than 300 mg of lasalocid per head per day when on pasture; the drug must be contained in at least 1 pound of feed.</td>
<td>054771</td>
</tr>
<tr>
<td>(x) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bacitracin 4 to 50</td>
<td>Broiler chickens; for prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for improved feed efficiency.</td>
<td>For broiler chickens only; feed continuously as the sole ration; bacitracin methylenedisalicylate provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(xi) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td>Bacitracin zinc 4 to 50</td>
<td>Broiler chickens. For prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima, and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Bacitracin zinc and lasalocid sodium as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
</tr>
<tr>
<td>(xii)</td>
<td></td>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td>Feed continuously on a free-choice basis at a rate of not less than 60 mg or more than 300 mg of lasalocid per head per day.</td>
<td>054771</td>
</tr>
<tr>
<td>(xiii)</td>
<td></td>
<td>Cattle; for control of coccidiosis caused by Eimeria bovis and Eimeria zuernii.</td>
<td>For cattle; hand feed at a rate of 1 mg of lasalocid per 2.2 pounds body weight per day to cattle weighing up to 800 pounds with a maximum of 360 mg of lasalocid per head per day.</td>
<td>054771</td>
</tr>
<tr>
<td>(xiv) 113 (0.0125 pct)</td>
<td></td>
<td>Chukar partridges; for prevention of coccidiosis caused by Eimeria legionensis.</td>
<td>Feed continuously as sole ration up to 8 weeks of age.</td>
<td>054771</td>
</tr>
<tr>
<td>(xv) 68 (0.0075 pct) to 113 (0.0125 pct)</td>
<td></td>
<td>Growing turkeys; for prevention of coccidiosis caused by E. melagruminis, E. galliappaonis, and E. adenoideae.</td>
<td>Feed continuously as sole ration.</td>
<td>054771</td>
</tr>
<tr>
<td>Lasalocid sodium activity in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>........................ Bacitracin 4 to 50 ...</td>
<td>Growing turkeys; for prevention of coccidiosis caused by <em>E. meleagrimitis</em>, <em>E. gallopavonis</em>, and <em>E. adenoeides</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>........................ Bacitracin methylenedisalicylate 4 to 50.</td>
<td>Growing turkeys; for prevention of coccidiosis caused by <em>E. meleagrimitis</em>, <em>E. gallopavonis</em>, and <em>E. adenoeides</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>........................ Virginiamycin 10 to 20.</td>
<td>Growing turkeys; for prevention of coccidiosis caused by <em>E. meleagrimitis</em>, <em>E. gallopavonis</em>, and <em>E. adenoeides</em>, and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. As lasalocid sodium provided by 063238 and virginiamycin provided by 066104.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>Replacement calves; for control of coccidiosis caused by <em>E. bovis</em> and <em>E. zuernii</em>.</td>
<td>In milk replacer powder; hand feed at a rate of 1 mg of lasalocid per 2.2 lb body weight per day; include on labeling warning: “A withdrawal period has not been established for lasalocid in pre-ruminating calves. Do not use in calves to be processed for veal”.</td>
<td>054771</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(xvii) 113 (0.0125 pct).</td>
<td>Rabbits; for prevention of coccidiosis caused by <em>Eimeria stiedae</em>.</td>
<td>Feed continuously as sole ration up to 6½ weeks of age.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain.</td>
<td>Feed continuously on a free-choice basis at a rate of not less than 60 mg nor more than 200 mg of lasalocid per head per day.</td>
<td>021930 017800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers); for increased rate of weight gain.</td>
<td>Feed continuously on a free-choice basis at a rate of not less than 60 mg nor more than 200 mg of lasalocid per head per day.</td>
<td>068287</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Chlortetracycline 25 to 100. | 1. Cattle fed in confinement for slaughter: For improved feed efficiency; and for control of bacterial pneumonia associated with shipping fever complex caused by *Pasteurella* spp. susceptible to chlortetracycline.  
2. Cattle under 700 pounds fed in confinement for slaughter: For improved feed efficiency; and for control of active infection of anaplasmosis caused by *Anaplasma marginale* susceptible to chlortetracycline. | Feed continuously in complete feed at a rate of 350 mg chlortetracycline and not less than 100 mg nor more than 360 mg of lasalocid sodium activity per head per day. | 054771 |
<p>| Chlortetracycline 250 to 2000. | Cattle fed in confinement for slaughter: For improved feed efficiency; and for treatment of bacterial enteritis caused by <em>E. coli</em> and bacterial pneumonia caused by <em>P. multocida</em> organisms susceptible to chlortetracycline. | Feed continuously in complete feed at a rate of 350 mg chlortetracycline and not less than 100 mg nor more than 360 mg of lasalocid sodium activity per head per day. | 054771 |
| Chlortetracycline 25 to 42.2. | 1. Cattle fed in confinement for slaughter: For increased rate of weight gain and improved feed efficiency; and for control of bacterial pneumonia associated with shipping fever complex caused by <em>Pasteurella</em> spp. susceptible to chlortetracycline. | Feed continuously in complete feed at a rate of 350 mg chlortetracycline and not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day. | 054771 |</p>
<table>
<thead>
<tr>
<th>Lasalocid sodium activity in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(xxii) 25 to 30 ..</td>
<td>Chlortetracycline 500 to 1200</td>
<td>Feed continuously in complete feed at a rate of 350 mg chlortetracycline and not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day. Hand feed continuously at a rate of 350 mg chlortetracycline per lb body weight per day and not less than 2800 mg of lasalocid per head per day.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>(xxiv) 30 to 181.8</td>
<td>Chlortetracycline 25 to 2800</td>
<td>Feed continuously in complete feed for not more than 5 days to provide 10 mg chlortetracycline per lb body weight per day and not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day. Hand feed continuously at a rate of 350 mg chlortetracycline per lb body weight per day with a maximum of 360 mg lasalocid per head per day.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>(xxv) 30 to 181.8</td>
<td>Chlortetracycline 500 to 4000</td>
<td>Cattle feed continuously at a rate of 350 mg chlortetracycline per lb body weight per day and 1 mg lasalocid per 2.2 lb body weight per day with a maximum of 360 mg lasalocid per head per day. Hand feed continuously for not more than 5 days to provide 10 mg chlortetracycline per lb body weight per day and not less than 250 mg nor more than 360 mg of lasalocid sodium activity per head per day. Hand feed continuously at a rate of 350 mg chlortetracycline per lb body weight per day and 1 mg lasalocid per 2.2 lb body weight per day with a maximum of 360 mg lasalocid per head per day.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>(xxvi) 30 to 600 ..</td>
<td>Chlortetracycline 25 to 700</td>
<td>Cattle feed continuously at a rate of 350 mg chlortetracycline and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 lb of feed. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day. Hand feed continuously at a rate of 350 mg chlortetracycline per lb body weight per day and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 lb of feed. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>(xxvii) 30 to 1100.</td>
<td>Chlortetracycline 25 to 1100</td>
<td>Cattle feed continuously at a rate of 350 mg chlortetracycline and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 lb of feed. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day. Hand feed continuously at a rate of 0.5 mg chlortetracycline per lb body weight per day and not less than 60 mg or more than 300 mg lasalocid per head daily in at least 1 lb of feed. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.</td>
<td>054771</td>
<td></td>
</tr>
</tbody>
</table>
(2) It is used as a free-choice mineral liquid Type C feed as follows:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defluorinated phosphate (20.5% Ca, 18.5% P)</td>
<td>35.9</td>
<td>6-01-080</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>20.0</td>
<td>6-04-152</td>
</tr>
<tr>
<td>Calcium carbonate (38% Ca)</td>
<td>18.0</td>
<td>6-01-069</td>
</tr>
<tr>
<td>Cottonseed meal</td>
<td>10.0</td>
<td>5-01-621</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>3.0</td>
<td>6-03-755</td>
</tr>
<tr>
<td>Selenium premix (0.02 percent Se)</td>
<td></td>
<td>3.0</td>
</tr>
<tr>
<td>Dried cane molasses (46% sugars)</td>
<td>2.5</td>
<td>4-04-695</td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td>1.7</td>
<td>6-02-758</td>
</tr>
<tr>
<td>Vitamin premix1</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>Magnesium oxide (58% Mg)</td>
<td>1.2</td>
<td>6-02-756</td>
</tr>
<tr>
<td>Potassium sulfate</td>
<td>1.2</td>
<td>6-06-098</td>
</tr>
<tr>
<td>Trace mineral premix1</td>
<td>1.04</td>
<td></td>
</tr>
<tr>
<td>Lasalocid Type A medicated article (68 g/lb)2</td>
<td>1.06</td>
<td></td>
</tr>
</tbody>
</table>

1 Content of the vitamin and trace mineral premixes may be varied; however, they should be comparable to those used by the firm for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).

2 To provide 1,440 g lasalocid per ton, use 21.2 lbs (1.06%) of a lasalocid Type A medicated article containing 68 g/lb. If using a lasalocid Type A medicated article containing 90.7 g/lb, use 15.88 lbs per ton (0.794%), adding molasses.

(1) Amount. 1,440 grams per ton.

(3) It is used as a ruminant free-choice liquid Type C feed as follows:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cane molasses</td>
<td>55.167</td>
<td>4-13-241</td>
</tr>
<tr>
<td>Condensed molasses fermentation solubles</td>
<td>24.0</td>
<td></td>
</tr>
<tr>
<td>50% Urea Solution (23% N)</td>
<td>12.0</td>
<td></td>
</tr>
<tr>
<td>Ammonium polyphosphate solution</td>
<td>1.0</td>
<td>6-08-42</td>
</tr>
<tr>
<td>Phosphoric acid (54%)</td>
<td>3.0</td>
<td>6-03-707</td>
</tr>
<tr>
<td>Xanthan gum</td>
<td>0.05</td>
<td>8-15-818</td>
</tr>
<tr>
<td>Water</td>
<td>4.0</td>
<td></td>
</tr>
<tr>
<td>Trace mineral premix1</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Vitamin premix1</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>Lasalocid Type A medicated article (90.7 g/lb)2</td>
<td>0.083</td>
<td></td>
</tr>
</tbody>
</table>

1 Content of the vitamin and trace mineral premixes may be varied; however, they should be comparable to those used by the firm for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).
(ii) Amount. 150 grams per ton.

(iii) Indications for use. Pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers): for increased rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day have not been shown to be more effective than 200 mg/head/day.

(iv) Limitations. For pasture cattle (slaughter, stocker, feeder cattle, and dairy and beef replacement heifers). Feed continuously on a free-choice basis at a rate of 60 to 300 milligrams lasalocid per head per day.

(v) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(4) It is used as a free-choice, loose mineral Type C feed as follows:

(i) Specifications.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocalcium phosphate (21% P)</td>
<td>57.70</td>
<td>6-01-082</td>
</tr>
<tr>
<td>Salt</td>
<td>17.55</td>
<td>6-04-152</td>
</tr>
<tr>
<td>Distillers dried grains w/ solubles</td>
<td>5.40</td>
<td>5-28-236</td>
</tr>
<tr>
<td>Dried cane molasses</td>
<td>5.20</td>
<td>4-04-695</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>4.90</td>
<td>6-03-755</td>
</tr>
<tr>
<td>Trace mineral/vitamin premix1</td>
<td>3.35</td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate (38% Ca)</td>
<td>2.95</td>
<td>6-01-069</td>
</tr>
<tr>
<td>Mineral oil</td>
<td>1.05</td>
<td>6-03-123</td>
</tr>
<tr>
<td>Magnesium oxide (58% Mg)</td>
<td>1.00</td>
<td>6-02-756</td>
</tr>
<tr>
<td>Iron oxide (62% Fe)</td>
<td>0.10</td>
<td>6-02-431</td>
</tr>
<tr>
<td>Lasalocid Type A medicated article (68 g/lb)2</td>
<td>0.80</td>
<td></td>
</tr>
</tbody>
</table>

1 Content of the vitamin and trace mineral premixes may be varied; however, they should be comparable to those used by the firm for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Selenium must comply with 21 CFR 573.920. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).

2 To provide 1,088 g lasalocid per ton, use 16 lbs (0.80%) of a lasalocid Type A medicated article containing 68 g/lb. If using a lasalocid Type A medicated article containing 68 g/lb, use 2.206 lbs per ton (0.111%), replacing molasses.

§ §558.325 Lincomycin.

(a) Specifications. Type A medicated articles containing 20 or 50 grams per pound lincomycin as lincomycin hydrochloride.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.360 of this chapter.

(d) Special considerations.—(1) Labeling of Type A medicated articles and Type B and Type C medicated feeds containing lincomycin shall bear the following directions: “CAUTION: Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects.”

(2) Labeling of Type A medicated articles and Type B and Type C medicated feeds containing lincomycin intended for use in swine shall bear the following directions: “CAUTION: Occasionally, swine fed lincomycin may within the first 2 days after the onset of treatment develop diarrhea and/or...
swelling of the anus. On rare occasions, some pigs may show reddening of the skin and irritable behavior. These conditions have been self-correcting within 5 to 8 days without discontinuing the lincomycin treatment.’’

(3) Labeling of Type A medicated articles and single-ingredient Type B and Type C medicated feeds containing lincomycin intended for use in swine shall bear the following directions:

(i) No. 054771: ‘‘CAUTION: The effects of lincomycin on swine reproductive performance, pregnancy, and lactation have not been determined. Not for use in swine intended for breeding when lincomycin is fed at 20 grams per ton of complete feed.’’

(ii) No. 051311: ‘‘CAUTION: Not to be fed to swine that weigh more than 250 lb.’’

(e) Conditions of use—(1) Chickens. It is used in feed as follows:

<table>
<thead>
<tr>
<th>Lincomycin grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 2</td>
<td>Broilers: For control of necrotic enteritis caused by Clostridium spp. or other susceptible organisms..</td>
<td>As lincomycin hydrochloride monohydrate.</td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 2 to 4</td>
<td>Broilers: For increased rate of weight gain and improved feed efficiency.</td>
<td>As lincomycin hydrochloride monohydrate.</td>
<td>054771</td>
</tr>
</tbody>
</table>

(2) Swine. It is used in feed as follows:

<table>
<thead>
<tr>
<th>Lincomycin grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 20</td>
<td>Growing-finishing swine: For increased rate of weight gain.</td>
<td>Feed as sole ration.</td>
<td>054771</td>
</tr>
<tr>
<td>(ii) 40</td>
<td>1. For control of swine dysentery. ...</td>
<td>Feed as sole ration; for use in swine on premises with a history of swine dysentery but where symptoms have not yet occurred, or following use of lincomycin at 100 grams (g)/ton for treatment of swine dysentery.</td>
<td>054771</td>
</tr>
<tr>
<td></td>
<td>2. For control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis.</td>
<td>Feed as sole ration, or following use of lincomycin at 100 g/ton for control of porcine proliferative enteropathies (ileitis).</td>
<td>054771</td>
</tr>
<tr>
<td>(iii) 100</td>
<td>1. For treatment of swine dysentery. ...</td>
<td>Feed as sole ration for 3 weeks or until signs of disease disappear.</td>
<td>054771</td>
</tr>
<tr>
<td></td>
<td>2. For control of porcine proliferative enteropathies (ileitis) caused by Lawsonia intracellularis.</td>
<td>Feed as sole ration for 3 weeks or until signs of disease disappear.</td>
<td>054771</td>
</tr>
<tr>
<td>(iv) 200</td>
<td>For reduction in the severity of swine mycoplasmal pneumonia caused by Mycoplasma hyopneumoniae.</td>
<td>Feed as sole ration for 3 weeks.</td>
<td>054771</td>
</tr>
</tbody>
</table>

(3) Lincomycin may also be used in combination with:

(i) Amprolium and ethopabate as in §558.58.

(ii) Clopidol as in §558.175.

(iii) Decoquinate as in §558.195.

(iv) Fenbendazole as in §588.258.

(v) Halofuginone as in §558.265.

(vi) Ivermectin as in §558.300.

(vii) Lasalocid sodium as in §558.311.

(viii) Monensin as in §558.355.

(ix) Nicarbazin alone and with narasin as in §558.366.

(x) Pyrantel as in §558.485.

(xi) Robenidine as in §558.515.

(xii) Salinomycin as in §558.550.

(xiii) Zoalene as in §558.680.

[40 FR 13959, Mar. 27, 1975]

EDITORIAL NOTE: For Federal Register citations affecting §558.325, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.
§ 558.342 Melengestrol.

(a) Specifications. (1) Dry Type A medicated articles containing 100 or 200 milligrams (mg) melengestrol acetate per pound.

(2) Liquid Type A medicated article containing 500 mg melengestrol acetate per pound.

(b) Approvals. See sponsors in § 510.600(c) of this chapter for use as in paragraph (e) of this section.

(1) No. 054771 for use of products described in paragraph (a) of this section.

(2) No. 000986 for use of product described in paragraph (a)(2) of this section.

(c) Related tolerances. See § 556.380 of this chapter.

(d) Special considerations. (1) Type B or C medicated feeds may be manufactured from melengestrol acetate liquid Type A articles or Type B or C medicated feeds which have a pH of 4.0 to 8.0 and bear appropriate mixing directions as follows:

(i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid feeds stored in mechanical, air, or other agitation type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.

(2) A physically stable melengestrol acetate liquid Type B or C feed will not be subject to the requirements for mixing directions prescribed in paragraph (d)(1) of this section provided it has a pH of 4.0 to 8.0 and contains a suspending agent(s) sufficient to maintain a viscosity of not less than 300 centipoises per second for 3 months.

(3) Combination Type B or C medicated feeds containing lasalocid must be labeled in accordance with § 558.311(d)(5) of this chapter.

(4) Liquid combination Type B or C medicated feeds containing melengestrol acetate and lasalocid must be manufactured in accordance with § 558.311(d) of this chapter.

(5) Combination Type B or C medicated feeds containing monensin must be labeled in accordance with § 558.355(d) of this chapter.

(6) Liquid combination Type B or C medicated feeds containing melengestrol acetate and monensin must be manufactured in accordance with § 558.355(f)(3)(i) of this chapter.

(7) Liquid combination Type B or C medicated feeds containing melengestrol acetate and tylosin must be manufactured in accordance with § 558.625(c) of this chapter.

(8) Liquid melengestrol acetate may not be mixed with oxytetracycline in a common liquid feed supplement.

(e) Conditions of use—(1) Cattle.

<table>
<thead>
<tr>
<th>Melengestrol acetate in mg/head/day</th>
<th>Combination in mg/head/day</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25 to 0.5</td>
<td></td>
<td>Heifers fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and suppression of estrus (heat).</td>
<td>Administer 0.5 to 2.0 pounds (b)head/day of medicated feed containing 0.125 to 1.0 mg melengestrol acetate/b to provide 0.25 to 0.5 mg melengestrol acetate/head/day.</td>
<td>054771, 000986</td>
</tr>
<tr>
<td>Melengestrol acetate in mg/head/day</td>
<td>Combination in mg/head/day</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(ii) 0.5</td>
<td>.............................</td>
<td>Heifers intended for breeding: For suppression of estrus (heat)....</td>
<td>Administer 0.5 to 2.0 lb/head/day of Type C feed containing 0.25 to 1.0 mg melengestrol acetate/lb to provide 0.5 mg melengestrol acetate/head/day. Do not exceed 24 days of feeding.</td>
<td>054771, 000986</td>
</tr>
<tr>
<td>(iii) 0.25 to 0.5</td>
<td>Lasalocid 100 to 360</td>
<td>Heifers fed in confinement for slaughter: As in paragraph (e)(1)(i) of this section.</td>
<td>Add at the rate of 0.5 to 2.0 lb/head/day a medicated feed (liquid or dry) containing 0.125 to 1.0 mg melengestrol acetate/lb to a feed containing 10 to 30 grams (g) of lasalocid per ton; or add at the rate of 0.5 to 2.0 lb/head/day a medicated feed (liquid or dry) containing 0.125 to 1.0 mg melengestrol acetate plus 50 to 720 mg lasalocid/lb to a ration of nonmedicated feed to provide 0.25 to 0.5 mg melengestrol acetate and 100 to 360 mg lasalocid/head/day. Lasalocid provided by No. 054771 in § 510.600(c) of this chapter.</td>
<td>054771, 000986</td>
</tr>
<tr>
<td>(iv) 0.25 to 0.5</td>
<td>Lasalocid 100 to 360 plus tylosin 90</td>
<td>Heifers fed in confinement for slaughter: As in paragraph (e)(1)(i) of this section; and for reduced incidence of liver abscesses caused by Fusobacterium necrophorum and Actinomyces (Corynebacterium) pyogenes. To administer 0.25 to 0.5 mg melengestrol acetate plus 100 to 360 mg lasalocid plus 90 mg tylosin/head/day: 1. Add 0.5 to 2.0 lb/head/day of a liquid or dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate/lb to a medicated feed containing 10 to 30 g lasalocid and 8 to 10 g tylosin per ton; or. 2. Add 0.5 to 2.0 lb/head/day of a liquid or dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate plus 50 to 720 mg lasalocid/lb to 4.5 to 18 lb of a dry medicated feed containing 10 to 40 g tylosin per ton; or. 3. Add 0.5 to 2.0 lb/head/day of a dry pelleted medicated feed containing 0.125 to 1.0 mg melengestrol acetate (from a dry Type A article), 50 to 720 mg lasalocid, and 45 to 180 mg tylosin/lb to a ration of nonmedicated feed. Lasalocid provided by No. 054771, and tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter.</td>
<td>054771, 000986, 016592</td>
<td></td>
</tr>
<tr>
<td>(v) Reserved.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(vi)–(vii) Reserved.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melengestrol acetate in mg/head/day</td>
<td>Combination in mg/head/day</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>(vii) 0.25 to 0.5 ...</td>
<td>Oxytetracycline 75 ...</td>
<td>Heifers fed in confinement for slaughter; As in paragraph (e)(1)(i) of this section; and for reduction of liver condemnation due to liver abcesses.</td>
<td>Add at the rate of 0.5 to 2.0 lb/head/day a medicated feed (liquid or dry) containing 0.125 to 1.0 mg melengestrol acetate/lb per pound to a feed containing 6 to 10 g oxytetracycline per ton; or add at the rate of 0.5 to 2.0 lb/head/day a dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate plus 37.5 to 150 mg oxytetracycline/lb to provide 0.25 to 0.5 mg melengestrol acetate and 75 mg oxytetracycline/head/day.</td>
<td>054771</td>
</tr>
<tr>
<td>(ix) 0.25 to 0.5 ...</td>
<td>Tylosin 60 to 90 ......</td>
<td>Heifers fed in confinement for slaughter: As in paragraph (e)(1)(i) of this section; and for reduced incidence of liver abscesses caused by <em>F. necrophorum</em> and <em>Actinomyces (Corynebacterium) pyogenes</em>.</td>
<td>To administer 0.25 to 0.5 mg melengestrol acetate with 60 to 90 mg tylosin/head/day: 1. Add 0.5 to 2.0 lb/head/day of a liquid or dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate/lb to a medicated feed containing 8 to 10 g tylosin per ton; or 2. Add 0.5 to 2.0 lb/head/day of a liquid or dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate/lb to 4.5 to 18 pounds of a dry medicated feed containing 10 to 40 g tylosin per ton; or 3. Add 0.5 to 2.0 lb/head/day of a liquid or dry medicated feed containing 0.125 to 1.0 mg melengestrol acetate (from a dry Type A article) plus 45 to 180 mg tylosin/lb to a ration of nonmedicated feed. Tylosin provided by Nos. 000986 and 016592 in §510.600(c) of this chapter.</td>
<td>054771 000986 016592</td>
</tr>
<tr>
<td>(x) 0.25 to 0.5 ......</td>
<td>Monensin 50 to 480.</td>
<td>Heifers fed in confinement for slaughter: As in paragraph (e)(1)(i) of this section; and for the prevention and control of coccidiosis due to <em>Eimeria bovis</em> and <em>E. zuernii</em>.</td>
<td>Add at the rate of 0.5 to 2.0 lb/head/day a medicated feed (liquid or dry) containing 0.125 to 1.0 mg melengestrol acetate/lb to a feed containing 10 to 40 g of monensin per ton to provide 0.25 to 0.5 mg melengestrol acetate/head/day and 0.14 to 0.42 mg monensin/lb body weight, depending on severity of coccidiosis challenge, up to 480 mg monensin/head/day. Monensin provided by No. 000986 in §510.600(c) of this chapter.</td>
<td>054771 000986</td>
</tr>
</tbody>
</table>
### § 558.355 Monensin.

<table>
<thead>
<tr>
<th>Melengestrol acetate in mg/head/day</th>
<th>Combination in mg/head/day</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(xi) 0.25 to 0.5 ...</td>
<td>Monensin 50 to 480, plus tylosin 60 to 90.</td>
<td>Hellers fed in confinement for slaughter: As in paragraph (e)(1)(i) of this section; for the prevention and control of coccidiosis due to <em>Eimeria bovis</em> and <em>E. zuernii</em>; and for reduction of incidence of liver abscesses caused by <em>Fusobacterium necrophorum</em> and <em>Arcanobacterium pyogenes</em>.</td>
<td>Feed continuously as sole ration (liquid or dry) at a rate of 0.5 to 2.0 lb/head/day to provide 0.25 to 0.5 mg/head/day melengestrol acetate; 0.14 to 0.42 mg monensin/lb body weight/day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day; and 60 to 90 mg/head/day tylosin. The melengestrol acetate portion of this Type C medicated feed must be mixed into a complete feed containing 10 to 40 g/ton monensin and 8 to 10 g/ton tylosin in the amount of complete feed consumed by an animal per day.</td>
<td>054771 016592</td>
</tr>
</tbody>
</table>

(2) Melengestrol may also be used with:

1. Ractopamine as in § 558.500 of this chapter.
2. Zilpaterol as in § 558.665 of this chapter.

[42 FR 28535, June 3, 1977]

Editorial Note: For Federal Register citations affecting § 558.342, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

### § 558.348 Mibolerone.

(a) Approvals. To No. 054771 in § 510.600(c) of this chapter for a canned dog food, each 6 1/2 ounce can containing 30 or 60 micrograms of mibolerone.

(b) Conditions of use—(1) Amount. 30 micrograms for animals weighing up to 25 pounds; 60 micrograms for animals weighing 26 to 50 pounds; 120 micrograms for animals weighing 51 to 100 pounds; 180 micrograms for animals weighing over 100 pounds, or German Shepherds or German Shepherd mix weighing 30 to 80 pounds.

(2) Indications for use. For the prevention of estrus (heat) in adult female dogs not intended primarily for breeding purposes.

(3) Limitations. Administer daily at least 30 days before expected initiation of heat and continue as long as desired, but for not more than 12 months. Mibolerone should not be used in bitches before first estrous period or in purebred Bedlington terriers. It is not intended for animals being used primarily for breeding purposes. Use orally in adult female dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


### § 558.355 Monensin.

(a) Specifications. Type A medicated articles containing monensin, USP.

(b) Approvals. Approvals for Type A medicated articles containing the specified levels of monensin activity granted to firms identified by sponsor numbers in § 510.600(c) of this chapter for the conditions of use indicated in paragraph (f) of this section are as follows:

1. To No. 000986: 36.3 (for export only), 44, 45, 60, or 90.7 grams per pound for use as in paragraphs (f)(1)(i) and (f)(4) of this section.
2. To 000986: 110 grams per lb., paragraphs (f)(1)(i), (iii), (iv), (v), (ix), and (x).
3. [Reserved]
(4) To No. 000986: 45, 60, or 90.7 grams per pound for use as in paragraph (f)(2) of this section.

(5) To 066104: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xiii), (xx), and (xxi) of this section.

(6) To No. 000986: 45, 60, or 90.7 grams per pound for use as in paragraph (f)(6) of this section.

(7) To 000986: 20, 30, 45, 60, 80, and 90.7 grams per pound, as monensin sodium, paragraph (f)(3) of this section.

(8) To 054771: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraph (f)(1)(xiv) of this section.

(9) To 054771: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xv) and (xvi) of this section.

(10) To 016592: 45 and 60 grams per pound, as monensin sodium, paragraph (f)(1)(xvii) of this section.

(11) To 054771: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraphs (f)(1)(xviii), (xix), (xxii), (xxiv), (xxv), (xxvi), and (xxvii) of this section.

(12) To 066104: 45 and 60 grams per pound, as monensin sodium provided by No. 000986, paragraph (f)(1)(xxiv) of this section.

(13) To No. 012286: 60 and 80 grams per pound, paragraph (f)(3)(v) of this section.

(14) To 000986: 60, 80, and 90.7 grams per pound, as monensin sodium, paragraph (f)(6) of this section.

(c) [Reserved]

(d) Special considerations. (1) Type C chicken feed containing monensin in the mycelial cake shall bear an expiration date of 90 days after its date of manufacture.

(2) To 066104: 45 and 60 grams per pound, as monensin sodium, paragraph (f)(1)(xvii) of this section.

(3) To No. 012286: 60 and 80 grams per pound, paragraph (f)(3)(v) of this section.

(4) Liquid Type B feeds shall bear an expiration date of 8 weeks after its date of manufacture.

(5) All Type A medicated articles containing monensin shall bear the following warning statement: When mixing and handling monensin Type A medicated articles, use protective clothing, impervious gloves, and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse thoroughly with water.

(6) All formulations containing monensin shall bear the following caution statement: Do not allow horses or other equines access to feed containing monensin. Ingestion of monensin by horses has been fatal.

(7) Type A medicated articles containing monensin intended for use in cattle and goats shall bear, in addition to the caution statement in paragraph (d)(6) of this section, the following statements:

(i) Monensin medicated cattle and goat feeds are safe for use in cattle and goats only. Consumption by unapproved species may result in toxic reactions.

(ii) Feeding undiluted or mixing errors resulting in high concentrations of monensin has been fatal to cattle and could be fatal to goats.

(iii) Must be thoroughly mixed in feeds before use.

(iv) Do not feed undiluted.

(v) Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result.

(vi) Do not feed to lactating goats.

(vii) If feed refusals containing monensin are fed to other groups of cattle, the concentration of monensin in the refusals and amount of refusals should be taken into consideration to prevent monensin overdosing (see paragraphs (d)(10)(i) and (d)(10)(ii) of this section).

(viii) A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

(ix) You may notice the following: Reduced voluntary feed intake in dairy cows fed monensin. This reduction increases with higher doses of monensin fed. Rule out monensin as the cause of reduced feed intake before attributing to other causes such as illness, feed management, or the environment. Reduced milk fat percentage in dairy cows fed monensin. This reduction increases with higher doses of monensin fed. Increased incidence of cystic ovaries and metritis in dairy cows fed monensin. Reduced conception rates, increased services per animal, and extended days open and corresponding
Food and Drug Administration, HHS

§ 558.355

Calving intervals in dairy cows fed monensin. Have a comprehensive and ongoing nutritional, reproductive, and herd health program in place when feeding monensin to dairy cows.

(x) Inadequate mixing (recirculation or agitation) of monensin liquid Type B or Type C medicated feeds has resulted in increased monensin concentration which has been fatal to cattle and could be fatal to goats.

(8) Type A medicated articles containing monensin intended for use in chickens, turkeys, and quail shall bear the following statements:

(i) Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal.

(ii) Must be thoroughly mixed in feeds before use.

(iii) Do not feed undiluted.

(iv) Do not feed to laying chickens.

(v) Do not feed to chickens over 16 weeks of age.

(vi) For replacement chickens intended for use as cage layers only.

(vii) Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis.

(viii) In the absence of coccidiosis in broiler chickens the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain.

(9) Type B feeds containing monensin shall bear the statements specified in the following paragraphs of this section when intended for use in:

(i) Cattle (as described in paragraphs (f)(3)(i) through (f)(3)(xii) of this section): See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), (d)(7)(vii), and (d)(7)(viii) of this section. Paragraph (d)(7)(vii) of this section does not apply to free-choice Type C medicated feeds as defined in § 510.455 of this chapter.

(ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and (f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i), (d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section. Paragraph (d)(7)(vii) of this section does not apply to free-choice Type C medicated feeds as defined in § 510.455 of this chapter.

(iii) Goats: See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), and (d)(7)(vi) of this section.

(iv) Chickens: See paragraphs (d)(8)(i), (d)(8)(iv), (d)(8)(v), (d)(8)(vi), and (d)(8)(viii) of this section.

(v) Turkeys: See paragraphs (d)(8)(i), (d)(8)(ii), (d)(8)(iii), and (d)(8)(vii) of this section.

(vi) Quail: See paragraphs (d)(8)(i), (d)(8)(ii), and (d)(8)(iii) of this section.

(10) Type C feeds containing monensin shall bear the statements specified in the following paragraphs of this section when intended for use in:

(i) Cattle (as described in paragraphs (f)(3)(i) through (f)(3)(xii) of this section): See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), (d)(7)(vii), and (d)(7)(viii) of this section.

(ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and (f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i), (d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section. Paragraph (d)(7)(vii) of this section does not apply to free-choice Type C medicated feeds as defined in § 510.455 of this chapter.

(iii) Goats: See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), and (d)(7)(vi) of this section.

(iv) Chickens: See paragraphs (d)(8)(i), (d)(8)(iv), (d)(8)(v), (d)(8)(vi), and (d)(8)(viii) of this section.

(v) Turkeys: See paragraphs (d)(8)(i) and (d)(8)(vii) of this section.

(vi) Quail: See paragraph (d)(8)(i) of this section.

(11) Type B and Type C liquid feeds requiring recirculation or agitation that contain monensin and are intended for use in cattle (including dairy cows) and goats shall bear the caution statement specified in paragraph (d)(7)(x) of this section.

(12) Mixing directions for liquid feeds requiring recirculation or agitation:

(i) For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for not less than 10 minutes, moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as described even when not used.

(ii) For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than 10 minutes, creating a turbulence at the bottom of the tank that is visible at the
top. Agitate daily as described even when not used.
(e) Related tolerances. See §556.120 of this chapter.
(f) Conditions of use. It is used as follows:
(1) Broiler chickens—(i) Amount per ton. Monensin, 90–110 grams.
   (a) Indications for use. As an aid in the prevention of coccidiosis caused by
   (b) Limitations. Do not feed to laying chickens; feed continuously as sole ra-
   tion; in the absence of coccidiosis, the use of monensin with no withdrawal
   period may limit feed intake resulting in reduced weight gain; as zinc bac-
   tracin provided by No. 054771 in §510.600(c) of this chapter; as monensin
   sodium.
   (vi) Amount per ton. Monensin, 90 to 110 grams; plus bambermycins, 1 to 2
   grams.
   (a) Indications for use. For increased rate of weight gain and improved feed
   efficiency; and as an aid in the prevention of coccidiosis caused by E.
   (b) Limitations. Feed continuously as sole ration; do not feed to laying chick-
   ens. Bambermycins provided by No. 016592 in §510.600(c) of this chapter.
   (vii) [Reserved]
   (viii) Amount per ton. Monensin, 90 to 110 grams plus oxytetracycline, 200
   grams.
   (a) Indications for use. As an aid in the prevention of coccidiosis caused by
   Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E.
   maxima; and for the control of complicated chronic respiratory disease
   (CRD or air-sac infection) caused by Mycoplasma gallisepticum and Esch-
   erichia coli.
   (b) Limitations. In the absence of coccidiosis, the use of monensin with no
   withdrawal period may limit feed intake resulting in reduced weight gain;
   do not feed to laying chickens; feed continuously as sole ration; as
   monensin sodium.
(xi) Amount per ton. Monensin, 90–110 grams plus lincomycin, 2 grams.
   (a) Indications for use. For increased rate of weight gain and improved feed
   efficiency; as an aid in the prevention of coccidiosis caused by E.
   (b) Limitations. Do not feed to laying chickens; to be fed as a sole ration; in
   the absence of coccidiosis, the use of monensin with no withdrawal period
   may limit feed intake resulting in reduced weight gain; as monensin so-
   dium.
(xii) Monensin, 90 to 110 grams, plus 5 grams virginiamycin.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. maxima, and E. mivati; for increased rate of weight gain and improved feed efficiency.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; as monensin sodium provided by No. 000986 in §510.600(c) of this chapter; virginiamycin provided by No. 066104 in §510.600 of this chapter.

(xiv) Monensin, 90 to 110 grams, plus 500 grams chlortetracycline.

(a) Indications for use. As an aid in the reduction of mortality due to Escherichia coli infections susceptible to such treatment. As an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed for 5 days as the sole ration; withdraw 24 hours before slaughter; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; not to be fed continuously for more than 5 days; as monensin sodium; as chlortetracycline hydrochloride provided by Nos. 054771 and 069254 in §510.600(c) of this chapter.

(xxiv) Monensin, 90 to 110 grams, plus bacitracin methylenedisalicylate, 4 to 50 grams.

(xxv) Monensin, 90 to 110 grams plus bacitracin, 4 to 50 grams.

(a) Indications for use. For increased rate of weight gain and improved feed efficiency; as an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima.

(b) Limitations. Do not feed to laying chickens; feed continuously as sole ration; in the absence of coccidiosis, the use of monensin with no withdrawal period may limit feed intake resulting in reduced weight gain; as bacitracin zinc provided by No. 054771 in §510.600(c) of this chapter, as monensin sodium.

(xxvi)-(xxvii) [Reserved]

(xxviii) Monensin, 90 to 110 grams, plus tylosin phosphate, 4 to 50 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; as an aid in the prevention of mortality due to air-sacculities (air-sac infection) caused by Escherichia coli sensitive to oxytetracycline.

(b) Limitations. Do not feed to laying chickens. Withdraw 24 hours before slaughter. Feed for 5 days as sole ration. Do not feed to laying chickens. As monensin sodium provided by No. 000986 in §510.600(c) of this chapter. As mono-alkyl (C₈-C₁₈) trimethylammonium oxytetracycline provided by No. 066104 in §510.600(c) of this chapter.
E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to laying chickens. As monensin sodium provided by No. 054771 in § 510.600(c) of this chapter.

(3xx) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylenedisalicylate, 100 to 200 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to laying chickens. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). As monensin provided by No. 000986; bacitracin methylenedisalicylate as provided by 054771 in § 510.600(c) of this chapter.

(3x) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylenedisalicylate, 100 to 200 grams.

(a) Indications for use. Broiler chickens: As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for prevention of necrotic enteritis caused by Clostridium perfringens susceptible to virginiamycin.

(b) Limitations. Feed continuously as sole ration. Do not feed to laying chickens. See paragraph (d) of this section. As monensin provided by No. 000986; virginiamycin as provided by No. 006104 in § 510.600(c) of this chapter.

Amount per ton.

(a) Indications for use. For the prevention of coccidiosis in turkeys caused by E. adenoideae, E. meleagrimitis, and E. gallopavonis.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis.

Amount per ton. Monensin, 54 to 90 grams, and bacitracin methylenedisalicylate, 4 to 50 grams.

(a) Indications for use. For prevention of coccidiosis caused by Eimeria adenoideae, E. meleagrimitis, and E. gallopavonis, for increased rate of weight gain, and for improved feed efficiency.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis.

Amount per ton. Monensin, 54 to 90 grams, and bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter.

(iii) Amount per ton. Monensin, 54 to 90 grams, and bacitracin methylenedisalicylate, 200 grams.

(a) Indications for use. For the prevention of coccidiosis caused by Eimeria adenoideae, E. meleagrimitis, and E. gallopavonis, and as an aid in the control of transmissible enteritis complicated by organisms susceptible to bacitracin methylenedisalicylate.

(b) Limitations. For growing turkeys only; as monensin sodium; feed continuously as sole ration. Do not allow horses, other equines, mature turkeys or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with
Food and Drug Administration, HHS

§ 558.355

development of immunity to turkey coccidiosis. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.

(iv) Amount per ton. Monensin, 54 to 90 grams, with virginiamycin, 10 to 20 grams.

(a) Indications for use. For the prevention of coccidiosis caused by *Eimeria adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, and for increased rate of weight gain and improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only. Feed continuously as sole ration. Do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin. Ingestion of monensin by horses, mature turkeys, and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Virginiamycin as provided by No. 066104 in §510.600(c) of this chapter.

(v) Amount per ton. Monensin, 54 to 90 grams, plus bambermycins, 1 to 2 grams.

(a) Indications for use. For the prevention of coccidiosis in turkeys caused by *E. adenoeides*, *E. meleagrimitis*, and *E. gallopavonis*, and for improved feed efficiency in growing turkeys.

(b) Limitations. For growing turkeys only. Feed continuously as sole ration. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis. Bambermycins as provided by No. 016592 in §510.600(c) of this chapter.


(a) Indications for use. Improved feed efficiency.

(b) Limitations. (1) Feed only to cattle being fed in confinement for slaughter. Feed continuously in complete feed at a rate of 50 to 480 milligrams of monensin per head per day. No additional improvement in feed efficiency has been shown from feeding monensin at levels greater than 30 grams per ton (360 milligrams per head per day). Complete feeds may be manufactured from monensin liquid Type B feeds. The liquid Type B feeds have a pH of 4.3 to 7.1 and their labels must bear appropriate mixing directions as defined in paragraph (d)(12) of this section. The liquid feed must bear caution statement as follows: Inadequate mixing, (recirculation or agitation), of liquid feeds has resulted in increased monensin concentration which has been fatal to cattle.

(2) An approved physically stable monensin liquid feed will not be subject to the requirements for mixing directions defined in paragraph (d)(12) of this section. A manufacturer may secure approval of a physically stable liquid feed by:

(i) Either filing an NADA for the product or by establishing a master file containing data to support the stability of its product;

(ii) Authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental NADA to establish physical stability; and

(iii) Requesting No. 000986 in §510.600(c) of this chapter to file a supplemental NADA to provide for the use of its monensin Type A article in the manufacture of the liquid feed specified in the appropriate master file. If the data demonstrate the stability of the liquid feed described in the master file, the agency will approve the supplemental NADA. The approval will provide a basis for the individual liquid feed manufacturer to manufacture the liquid medicated feed under a medicated feed mill license described in the master file. A manufacturer who seeks to market a physically unstable
monensin liquid feed with mixing directions different from the standard established in paragraph (d)(12) of this section may also follow this procedure.

(ii) Amount per ton. Monensin, 5 to 40 grams; plus tylosin, 8 to 10 grams.

(a) Indications for use. Cattle fed in confinement for slaughter: For improved feed efficiency; and reduction of incidence of liver abscesses caused by Fusobacterium necrophorum and Arcanobacterium (Actinomyces) pyogenes.

(b) Limitations. Feed only to cattle being fed in confinement for slaughter. Feed continuously as sole ration at the rate of 50 to 480 milligrams of monensin and 60 to 90 milligrams of tylosin per head per day. Combination drug liquid Type B medicated feeds may be used to manufacture dry Type C medicated feeds and shall conform to mixing instructions as in 558.625(c) of this chapter. Tylosin provided by Nos. 000986 and 016592 in §510.600(c) of this chapter.

(iii) Amount per ton. Monensin, 15 to 400 grams.

(a) Indications for use. Growing cattle on pasture or in dry lot (stocker and feeder cattle and dairy and beef replacement heifers): For increased rate of weight gain; for prevention and control of coccidiosis due to Eimeria bovis and E. zuernii.

(b) Limitations. For increased rate of weight gain, feed at a rate of 50 to 200 milligrams monensin per head per day in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams per head per day every other day in not less than 2 pounds of feed. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending on severity of challenge, up to 200 milligrams per head per day. During first 5 days of feeding, cattle should receive no more than 100 milligrams per head per day.

(v) Amount per ton. Monensin, 25 to 400 grams.

(a) Indications for use. For improved feed efficiency; for prevention and control of coccidiosis due to E. bovis and E. zuernii.

(b) Limitations. Feed to mature reproducing beef cows. Feed as supplemental feed, either hand-fed in a minimum of 1 pound of feed or mixed in a total ration. For improved feed efficiency, feed continuously at a rate of 50 to 200 milligrams monensin per head per day. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending upon severity of challenge, up to a maximum of 200 milligrams per head per day. During first 5 days of feeding, cattle should receive no more than 100 milligrams per head per day.

(vi) Amount per ton. Monensin, 10 to 40 grams.

(a) Indications for use. For prevention and control of coccidiosis due to E. bovis and E. zuernii.

(b) Limitations. For cattle fed in confinement for slaughter, feed at a rate of 0.14 to 0.42 milligram per pound of body weight per day, depending upon the severity of challenge, up to maximum of 480 milligrams per head per day.

(x) Amount per ton. 1,620 grams monensin, USP.

(a) Indications for use. Growing cattle on pasture or in dry lot (stocker and feeder cattle and dairy and beef replacement heifers): For increased rate of weight gain; for prevention and control of coccidiosis due to Eimeria bovis and E. zuernii.
of weight gain: for prevention and control of coccidiosis due to *Eimeria bovis* and *E. zuernii*.

(b) Specifications. Use as free-choice Type C medicated feed formulated as mineral granules as follows:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Percent</th>
<th>International feed No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocacium phosphate (21% phosphorus, 15% calcium)</td>
<td>29.49</td>
<td>6-01-082</td>
</tr>
<tr>
<td>Sodium chloride (salt)</td>
<td>24.37</td>
<td>6-04-152</td>
</tr>
<tr>
<td>Dried cane molasses</td>
<td>20.0</td>
<td>4-04-695</td>
</tr>
<tr>
<td>Ground limestone (53% calcium) or calcium carbonate (38% calcium)</td>
<td>13.75</td>
<td>6-02-632</td>
</tr>
<tr>
<td>Cane molasses</td>
<td>3.0</td>
<td>4-04-696</td>
</tr>
<tr>
<td>Processed grain by-products (as approved by AAFCO)</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>Monensin Type A article, 90.7 grams per pound</td>
<td>0.89</td>
<td></td>
</tr>
<tr>
<td>Antidusting oil</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

*(xiii) Content of the vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. The amount of selenium and ethylenediamine dihydroiodide (EDDI) must comply with the published requirements. (For selenium see 21 CFR 573.920; for EDDI see 51 FR 11483 (April 3, 1986).)*

(c) Limitations. Feed at a rate of 50 to 200 milligrams per head per day. During the first 5 days of feeding, cattle should receive no more than 100 milligrams per day. Do not feed additional salt or minerals. Do not mix with grain or other feeds. Monensin is toxic to cattle when consumed at higher than approved levels. Stressed and/or feed- and/or water-deprived cattle should be adapted to the pasture and to unmedicated mineral supplement before using the monensin mineral supplement. The product’s effectiveness in suckling and control of coccidiosis due to *E. zuernii.*

Feed only to cattle being fed in confinement for slaughter. For prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 milligrams monensin per pound of body weight per day, depending upon the severity of challenge, up to maximum of 480 milligrams per head per day; and 60 to 90 milligrams of tylosin per head per day. Tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter.

(xiii) Amount per ton. Monensin, 11 to 22 grams.

(A) Indications for use. For increased milk production efficiency (production of marketable solids-corrected milk per unit of feed intake) in dairy cows.

(B) Limitations. Feed continuously to dry and lactating dairy cows in a total mixed ration (“complete feed”). See special labeling considerations in paragraph (d) of this section.

(xiv) Amount per ton. Monensin, 11 to 400 grams.

(A) Indications for use. For increased milk production efficiency (production of marketable solids-corrected milk per unit of feed intake) in dairy cows.

(B) Limitations. Feed continuously to dry and lactating dairy cows in a component feeding system (including top dress). The Type C medicated feed must be fed in a minimum of 1 lb of feed to provide 185 to 660 mg/head/day monensin to lactating cows or 115 to 410 mg/head/day monensin to dry cows. See special labeling considerations in paragraph (d) of this section.

(4) Replacement chickens intended for use as cage layers—(i) Amount per ton. Monensin, 90 to 110 grams.

(1)(a) Indications for use. As an aid in the prevention of coccidiosis caused by *E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati,* and *E. maxima.*
(ii) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylenedisalicylate, 4 to 50 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; for increased rate of weight gain, and improved feed efficiency.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. As monensin sodium provided by 000986; bacitracin methylenedisalicylate as provided by 054771 in §510.600(c) of this chapter.

(iii) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylenedisalicylate, 50 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. As monensin sodium provided by 000986; bacitracin methylenedisalicylate as provided by 054771 in §510.600(c) of this chapter.

(iv) Limitations. Do not feed to laying chickens; feed continuously as sole ration; as monensin sodium; do not feed to chickens over 16 weeks of age.

(v) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin methylenedisalicylate, 100 to 200 grams.

(a) Indications for use. As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin.

(b) Limitations. Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 grams per ton). As monensin sodium provided by 000986; bacitracin methylenedisalicylate as provided by 054771 in §510.600(c) of this chapter.

(vi)–(vii) [Reserved]

(5) Bobwhite quail—(i) Amount per ton. Monensin, 73 grams.

(a) Indications for use. For the prevention of coccidiosis in growing bobwhite quail caused by Eimeria dispersa and E. Lettyae.

(b) Limitations. Feed continuously as the sole ration; do not allow horses, other equines, mature turkeys, or guinea fowl access to feed containing monensin.


(a) Indications for use. For the prevention of coccidiosis caused by Eimeria crandallis, E. christensenii, and E. ninakohlyakimovae.

(b) Limitations—(1) Feed continuously. Feed only to goats being fed in confinement. Do not feed to lactating goats. Type C feeds may be manufactured from monensin liquid Type B feeds. The liquid Type B feeds have a pH of 4.3 to 7.1 and their labels must bear appropriate mixing directions, as defined in paragraph (d)(12) of this section. See special labeling considerations in paragraph (d) of this section.

(2) An approved physically stable monensin liquid feed will not be subject to the requirements for mixing directions defined in paragraph (d)(12) of this section. A manufacturer may secure approval of a physically stable liquid feed by:

(i) Either filing an NADA for the product or by establishing a master file containing data to support the stability of its product;

(ii) Authorizing the agency to reference and rely upon the data in the master file to support approval of a supplemental NADA to establish physical stability; and

(iii) Requesting No. 000986 in §510.600(c) of this chapter to file a supplemental NADA to provide for the use of its monensin Type A article in the manufacture of the liquid feed specified in the appropriate master file. If the data demonstrate the stability of the liquid feed described in the master file,
the agency will approve the supplemental NADA. The approval will provide a basis for the individual liquid feed manufacturer to manufacture the liquid medicated feed under a medicated feed mill license described in the master file. A manufacturer who seeks to market a physically unstable monensin liquid feed with mixing directions different from the standard established in paragraph (d)(12) of this section may also follow this procedure.

(ii) [Reserved]

(7) Free-choice feeds—(i) Amount. 150 milligrams per pound of protein-mineral block (0.033 percent).

(a) [Reserved]

(b) Conditions of use—(1) Indications for use. For increased rate of weight gain; and for prevention and control of coccidiosis caused by Eimeria bovis and E. zuernii in pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers) which may require supplemental feed.

(2) Limitations. Provide 50 to 200 milligrams of monensin (0.34 to 1.33 pounds of block) per head per day, at least 1 block per 10 to 12 head of cattle. Roughage must be available at all times. Do not allow animals access to other protein blocks, salt or mineral, while being fed this product. The effectiveness of this block in cull cows and bulls has not been established. See paragraph (d)(10)(i) of this section.

(ii) Amount. 400 milligrams per pound of protein-mineral block (0.088 percent).

(a) Sponsor. See No. 067949 in §510.600(c) of this chapter.

(b) Conditions of use—(1) Indications for use. For increased rate of weight gain in pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers) which may require supplemental feed.

(2) Limitations. Provide 40 to 200 milligrams of monensin (0.25 to 1.33 pounds or 4 to 18 ounces of block) per head per day, at least 1 block per 4 head of cattle. Do not allow cattle access to salt or mineral while being fed this product. Ingestion by cattle of monensin at levels of 600 milligrams per head per day and higher has been fatal. The effectiveness of this block in cull cows and bulls has not been established. See paragraph (d)(10)(i) of this section.

(iv) Amount. 400 milligrams per pound of block (0.088 percent).

(a) Sponsor. See No. 051267 in §510.600(c) of this chapter.

(b) Conditions of use—(1) Indications for use. For increased rate of weight gain in pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers).

(2) Limitations. Provide 40 to 200 milligrams of monensin (2 to 8 ounces of block) per head per day, at least 1 block per 5 head of cattle. Feed blocks continuously. Do not feed salt or mineral supplements in addition to the blocks. Ingestion by cattle of monensin at levels of 600 milligrams per head per day and higher has been fatal. The effectiveness of this block in cull cows and bulls has not been established. See paragraph (d)(10)(i) of this section.

(8) Monensin may also be used in combination with:

(i) Decoquinate alone or with tylosin as in §558.195.

(ii) Melengestrol acetate alone or with tylosin as in §558.342.

(iii) Ractopamine alone or in combination as in §558.500.

(iv) Tilmicosin alone or in combination as in §558.618.

(v) Zilpaterol alone or in combination as in §558.665.

[40 FR 13959, Mar. 27, 1975]

Editorial Notes: 1. For Federal Register citations affecting §558.355, see the List of CFR Sections Affected, which appears in the Finding Aids section of the printed volume and at www.fdsys.gov.

2. At 79 FR 13845, Mar. 11, 2014, §558.355 was amended; however, the amendments to
§ 558.360 Morantel tartrate.

(a) Approvals. Type A medicated articles: 88 grams per pound to 066104 in § 510.600(c) of this chapter.

(b) Related tolerances. See § 556.425 of this chapter.

(c) Special considerations. (1) Do not use in Type B or Type C medicated feeds containing bentonite.

(2) Consult your veterinarian before using in severely debilitated animals and for assistance in the diagnosis, treatment, and control of parasitism.

(d) Conditions of use—(1) Amount. 0.44 to 4.4 grams of morantel tartrate per pound of feed.

(2) Indications for use—(i) Cattle. For removal and control of mature gastrointestinal nematode infections of cattle including stomach worms (Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms of the small intestine (Cooperia spp., Trichostrongylus spp., Nematodirus spp.), and worms of the large intestine (Oesophagostomum radiatum).

(ii) Goats. For removal and control of mature gastrointestinal nematode infections of goats including Haemonchus contortus, Ostertagia (Teladorsagia) circumcincta, and Trichostrongylus axei.

(3) Limitations. Feed as a single therapeutic treatment at 0.44 gram of morantel tartrate per 100 pounds of body weight. Fresh water should be available at all times. When medicated feed is consumed, resume normal feeding. Conditions of constant worm exposure may require retreatment in 2 to 4 weeks. Do not treat cattle within 14 days of slaughter; do not treat goats within 30 days of slaughter.

§ 558.363 Narasin.

(a) Approvals. Type A medicated articles containing specified levels of narasin approved for sponsors identified in § 510.600(c) of this chapter for use as in paragraph (d) of this section are as follows:

1. To 000986: 36, 45, 54, 72, and 90 grams per pound, paragraph (d)(1)(i) of this section.

2. [Reserved]

3. To 000986: 36 grams per pound, with 36 grams per pound nicarbazin, paragraph (d)(1)(iii) of this section.

4. To 016592: 36, 45, 54, 72, and 90 grams per pound, with 2 and 10 grams per pound bambermycins, paragraph (d)(1)(iv) of this section.

5. [Reserved]

6. To 054771: 36, 45, 54, 72, or 90 grams per pound, with 10, 25, 40, or 50 grams per pound bacitracin zinc, paragraph (d)(1)(v) of this section.

7. [Reserved]

8. To 000986: 45.4 grams per pound for use as in paragraph (d)(2) of this section.

(b) Tolerances. See § 556.428 of this chapter.

(c) Special considerations. An expiration date of 2 months (8 weeks) is required for narasin Type C medicated swine feeds.

(d) Conditions of use. It is used as follows:


(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Withdraw 5 days before slaughter. The 2 drugs can be combined only at a 1:1 ratio for the 27 to 45 grams per ton range. Only granular nicarbazin as provided by No. 000986 in § 510.600(c) of this chapter may be used in the combination.

2. [Reserved]
Food and Drug Administration, HHS

§ 558.363

(iii) Amount per ton. Narasin, 54 to 72 grams, plus bambermycins, 1 to 2 grams.

(A) Indications for use. For prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, and for increased rate of weight gain and improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal.

Narasin and tylosin as provided by No. 000986 in §510.600(c) of this chapter.

(iv) Amount per ton. Narasin 54 to 72 grams, and bacitracin methylenedisalicylate 10 to 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria acervulina*, *E. brunetti*, *E. maxima*, *E. mivati*, *E. necatrix*, and *E. tenella*, for increased rate of weight gain, and for improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not feed to laying hens. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Narasin as provided by 000986 in §510.600(c) of this chapter.

(v) Amount per ton. Narasin, 54 to 72 grams and bacitracin zinc, 4 to 50 grams.

(A) Indications for use. For the prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, and for increased rate of weight gain and improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Narasin as provided by 000986, bacitracin zinc by 046573 in §510.600(c) of this chapter.

(vi) Amount per ton. Narasin, 54 to 72 grams, plus tylosin, 4 to 50 grams.

(A) Indications for use. As an aid in the prevention of coccidiosis caused by *Eimeria necatrix*, *E. tenella*, *E. acervulina*, *E. brunetti*, *E. mivati*, and *E. maxima*, for increased rate of weight gain, and improved feed efficiency.

(B) Limitations. For broiler chickens only. Feed continuously as sole ration. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin and tylosin. Ingestion of narasin and tylosin by these species has been fatal. Narasin and tylosin as provided by 000986 in §510.600(c) of this chapter.

(2) Growing-finishing swine—(i) Amount per ton. Narasin, 13.6 to 27.2 grams.

(A) Indications for use. For increased rate of weight gain when fed for at least 4 weeks.

(B) Limitations. Feed continuously for at least 4 weeks to swine during the growing-finishing period as the sole ration. No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 13.6 g/ton. Effectiveness has not been demonstrated when fed for durations less than 4 weeks. Do not allow adult turkeys, horses, or other equines access to formulations containing pleuromutilins (e.g., tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

(ii) Amount per ton. Narasin, 18.1 to 27.2 grams.

(A) Indications for use. For increased rate of weight gain and improved feed efficiency when fed for at least 4 weeks.

(B) Limitations. Feed continuously for at least 4 weeks to swine during the growing-finishing period as the sole ration. No increased benefit in rate of weight gain has been shown when narasin concentrations in the diet are greater than 13.6 g/ton. Effectiveness has not been demonstrated when fed for durations less than 4 weeks. Do not allow adult turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals. Swine being fed with narasin should not have access to feeds containing pleuromutilins (e.g., tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.
containing pleuromutilins (e.g., tiamulin) as adverse reactions may occur. If signs of toxicity occur, discontinue use.

(3) Narasin may also be used for broilers in combination with:
   (i) Nicarbazin with lincomycin as in § 558.366.
   (ii) Nicarbazin and bacitracin methylenedisalicylate as in § 558.366.

§ 558.364 Neomycin sulfate.

(a) Approvals. Type A medicated article: 325 grams per pound to 054771 in § 510.600(c) of this chapter.

(b) Related tolerances. See § 556.430 of this chapter.

(d) Conditions of use. Neomycin sulfate is used as follows:

<table>
<thead>
<tr>
<th>Neomycin Sulfate</th>
<th>Combination</th>
<th>Indications for Use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) 250 to 2,250 grams per ton (g/t) of dry type C feed.</td>
<td>Cattle, swine, sheep, and goats. For treatment and control of colibacillosis (bacterial enteritis) caused by Escherichia coli susceptible to neomycin.</td>
<td>To provide 10 milligrams (mg) of neomycin sulfate per pound of body weight per day for a maximum of 14 days. The concentration of neomycin sulfate required in medicated feed must be adjusted to compensate for variation in age and weight of animal, the nature and severity of disease signs, and environmental temperature and humidity, each of which affects feed consumption. If symptoms persist after using for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms. Discontinue treatment prior to slaughter as follows: Cattle 1 day, swine 3 days, sheep 2 days, and goats 3 days. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. A milk discard time has not been established for use in lactating dairy cattle or lactating dairy goats. Do not use in female dairy cattle 20 months of age or older or female dairy goats 12 months of age or older. For use in dry feeds only. Not for use in liquid feed supplements.</td>
<td>054771</td>
<td></td>
</tr>
</tbody>
</table>
Neomycin Sulfate

<table>
<thead>
<tr>
<th>Combination</th>
<th>Indications for Use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) 400 to 2,000 g/t of type C milk replacer.</td>
<td>Do.</td>
<td>To provide 10 mg of neomycin sulfate per pound of body weight per day for a maximum of 14 days. Amount consumed will vary depending on animal's consumption and weight. If symptoms persist after using for 2 or 3 days, consult a veterinarian. Treatment should continue 24 to 48 hours beyond remission of disease symptoms. Discontinue treatment prior to slaughter as follows: Cattle 1 day, swine 3 days, sheep 2 days, and goats 3 days. A withdrawal period has not been established for use in preruminating calves. Do not use in Type B or Type C medicated feeds containing bentonite. Do not use in female dairy cattle 20 months of age or older or female dairy goats 12 months of age or older. For use in milk replacers only.</td>
<td>054771</td>
</tr>
</tbody>
</table>

§ 558.366 Nicarbazin.

(a) Specifications. Type A medicated articles containing 25 percent nicarbazin.

(b) Approvals. See Nos. 000986, 060728, and 096104 in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(c) Related tolerances. See § 556.445 of this chapter.

(d) Conditions of use. It is used in chicken feed as follows:

(ii) Indications for use. An aid in the prevention of coccidiosis caused by *E. tenella*, *E. necatrix*, *E. acervulina*, *E. maxima*, *E. brunetti*, and *E. mivati*.

(iii) Limitations. Feed continuously as sole ration; do not feed to chickens over 16 weeks of age.

<table>
<thead>
<tr>
<th>Nicarbazin in grams per ton</th>
<th>Combination in grams per ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 to 45</td>
<td>Narasin 27 to 45 .......</td>
<td>Broiler chickens; prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, <em>E. mivati</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Narasin and nicarbazin as provided by 000986, bacitracin methylenedisalicylate by 054771.</td>
<td>000986</td>
</tr>
<tr>
<td>Narasin 27 to 45 and bacitracin methylenedisalicylate 4 to 50.</td>
<td>Broiler chickens for prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; as an aid in the control of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughte. Do not allow turkeys, horses or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Narasin and nicarbazin as provided by 000986, bacitracin methylenedisalicylate by 054771.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>Narasin 27 to 45 and bacitracin methylenedisalicylate 50..</td>
<td>Broiler chickens for prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; as an aid in the control of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin.</td>
<td>To control necrotic enteritis, start medication at first clinical signs of disease; vary dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Do not feed to laying hens. Withdraw 5 days before slaughter. Do not allow turkeys, horses or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Narasin and nicarbazin as provided by No. 000986, bacitracin methylenedisalicylate by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>Narasin 27 to 45 and bacitracin methylenedisalicylate 100 to 200..</td>
<td>Broiler chickens: For prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; as an aid in the control of necrotic enteritis caused or complicated by <em>Clostridium</em> spp. or other organisms susceptible to bacitracin.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter. Bambermycins provided by No. 016592; nicarbazin and narasin by No. 066104 in §510.600(c) of this chapter.</td>
<td>000986</td>
<td></td>
</tr>
<tr>
<td>Narasin 27 to 45, and bambermycins 1 to 2.</td>
<td>Broiler chickens: As an aid in preventing outbreaks of cecal (<em>Eimeria tenella</em>) and intestinal (<em>E. acervulina</em>, <em>E. maxima</em>, <em>E. necatrix</em>, and <em>E. brunetti</em>) coccidiosis; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter. Bambermycins provided by No. 016592; nicarbazin and narasin by No. 066104 in §510.600(c) of this chapter.</td>
<td>000986</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>----------------------------</td>
<td>------------------------------</td>
<td>--------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>Narasin 27 to 45 and Lincomycin 2 to 4.</td>
<td>Broiler chickens: prevention of coccidiosis caused by <em>Eimeria tenella</em>, <em>E. necatrix</em>, <em>E. acervulina</em>, <em>E. maxima</em>, <em>E. brunetti</em>, and <em>E. mivati</em>; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Withdraw 5 days before slaughter. Do not allow turkeys, horses, or other equines access to formulations containing narasin. Ingestion of narasin by these species has been fatal. Do not feed to laying hens. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to feeds containing lincomycin. Ingestion by these species may result in severe gastrointestinal effects. Narasin and nicarbazin as provided by 000986, lincomycin by054771.</td>
<td>000986</td>
<td></td>
</tr>
<tr>
<td>90.8 to 181.6 (0.01 to 0.02 pct.)</td>
<td>Broiler chickens: As an aid in preventing outbreaks of cecal (<em>Eimeria tenella</em>) and intestinal (<em>E. acervulina</em>, <em>E. maxima</em>, <em>E. necatrix</em>, and <em>E. brunetti</em>) coccidiosis.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylenedisalicylate 4 to 50.</td>
<td>Broiler chickens: As an aid in preventing outbreaks of cecal (<em>Eimeria tenella</em>) and intestinal (<em>E. acervulina</em>, <em>E. maxima</em>, <em>E. necatrix</em>, and <em>E. brunetti</em>) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>054771</td>
<td></td>
</tr>
<tr>
<td>Bacitracin methylenedisalicylate 30.</td>
<td>Broiler chickens: As an aid in preventing outbreaks of cecal (<em>Eimeria tenella</em>) and intestinal (<em>E. acervulina</em>, <em>E. maxima</em>, <em>E. necatrix</em>, and <em>E. brunetti</em>) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylenedisalicylate as provided by No. 054771 in §510.600(c) of this chapter.</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>Nicarbazin in grams per ton</td>
<td>Combination in grams per ton</td>
<td>Indications for use</td>
<td>Limitations</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>113.5 (0.0125 pct.)</td>
<td>Bacitracin methylenedisalicylate 50.</td>
<td>Broiler chickens: As an aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; discontinuate medication 4 days before marketing the birds for human consumption to allow for elimination of the drug from edible tissue. Do not feed to laying hens in production. Nicarbazin as provided by 057926, bacitracin zinc by 066104, bambermycins by 054771,</td>
<td>054771</td>
</tr>
<tr>
<td>0500986</td>
<td>060728</td>
<td>Bacitracin methylenedisalicylate 30.</td>
<td>Chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis.</td>
<td>060728</td>
</tr>
<tr>
<td>060728</td>
<td>Bacitracin zinc 4 to 50.</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis, for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; withdraw 4 days before slaughter.</td>
<td>066104</td>
</tr>
<tr>
<td>054771</td>
<td>Bacitracin zinc 4 to 50.</td>
<td>For broiler chickens only. Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter.</td>
<td>Nicarbazin as provided by 057926, bacitracin zinc by 054771.</td>
<td>054771</td>
</tr>
<tr>
<td>057926</td>
<td>Bambermycins 1 to 2</td>
<td>Broiler chickens; aid in preventing outbreaks of cecal (Eimeria tenella) and intestinal (E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis, for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter. Nicarbazin as provided by 057926, bacitracin zinc by 054771.</td>
<td>016592</td>
</tr>
<tr>
<td>057926</td>
<td>Bambermycins 1 to 2</td>
<td>Broiler chickens: For prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. maxima; and for increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously as sole ration. Bambermycins provided by No. 016592 in §510.600(c) of this chapter.</td>
<td>016592</td>
</tr>
</tbody>
</table>
Food and Drug Administration, HHS

§ 558.415

Nicarbazin in grams per ton

| Combination in grams per ton | Lincomycin 2 (0.00044 pct.) | Fed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard; do not use as a treatment for coccidiosis; do not use in flushing mash; do not feed to laying hens; withdraw 4 days before slaughter. |

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.460 of this chapter.

(d) Conditions of use. It is used in animal feeds as follows:

(1) Chickens—(i) Amount. Novobiocin, 6–7 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) Amount. Novobiocin, 10–14 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(2) Turkeys—(i) Amount. Novobiocin, 4–5 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) Amount. Novobiocin, 5–8 mgs. per lb. body weight per day. (a) Indications for use. Aid in the control of recurring outbreaks of fowl cholera caused by strains of Pasteurella multocida susceptible to novobiocin following initial treatment with 7–8 mgs. per pound body weight per day. (b) Limitations. Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(iii) Amount. Novobiocin, 7–8 mgs. per lb. body weight per day. (a) Indications for use. Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(a) Specifications. Type A medicated article containing 25 grams of novobiocin activity per pound.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.460 of this chapter.

(d) Conditions of use. It is used in animal feeds as follows:

(1) Chickens—(i) Amount. Novobiocin, 6–7 mgs. per lb. body weight per day.

(a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) Amount. Novobiocin, 10–14 mgs. per lb. body weight per day.

(a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(2) Turkeys—(i) Amount. Novobiocin, 4–5 mgs. per lb. body weight per day.

(a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(iii) Amount. Novobiocin, 7–8 mgs. per lb. body weight per day.

(a) Indications for use. Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin; treatment of acute outbreaks of fowl cholera caused by strains of Pasteurella multocida susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(3) Pigs—(i) Amount. Novobiocin, 3–4 mgs. per lb. body weight per day.

(a) Indications for use. Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(a) Specifications. Type A medicated article containing 25 grams of novobiocin activity per pound.

(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.

(c) Related tolerances. See § 556.460 of this chapter.

(d) Conditions of use. It is used in animal feeds as follows:

(1) Chickens—(i) Amount. Novobiocin, 6–7 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 200 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(ii) Amount. Novobiocin, 10–14 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.

(2) Turkeys—(i) Amount. Novobiocin, 4–5 mgs. per lb. body weight per day. (a) Indications for use. Aid in the treatment of breast blisters associated with staphylococcal infections susceptible to novobiocin. (b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(iii) Amount. Novobiocin, 7–8 mgs. per lb. body weight per day. (a) Indications for use. Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin; treatment of acute outbreaks of fowl cholera caused by strains of Pasteurella multocida susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.

(3) Pigs—(i) Amount. Novobiocin, 3–4 mgs. per lb. body weight per day. (a) Indications for use. Treatment of staphylococcal synovitis and generalized staphylococcal infections susceptible to novobiocin.

(b) Limitations. Administer, as sole ration, feed which contains not less than 350 grams of novobiocin activity per ton of feed; not for laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.
§ 558.430

Nystatin.

(a) Specifications. Type A medicated article containing 20 grams of nystatin activity per pound.

(b) Sponsor. See No. 054771 in §510.600(c) of this chapter.

(c) Related tolerances. See §556.470 of this chapter.

(d) Conditions of use. It is used for chickens and turkeys as follows:

(1) Amount. 50 grams per ton.

(2) Indications for use. Chickens and turkeys; aid in control of crop mycosis and mycotic diarrhea (Candida albicans).

(ii) Limitations. Growing and laying chickens; growing turkeys; to be fed for 7 to 10 days.

§ 558.435 Oleandomycin.

(a) Approvals. Type A medicated articles: 5 grams of activity per pound to 066104 in §510.600(c) of this chapter.

(b) Related tolerances. See §556.480 of this chapter.

(c) Special considerations. Do not use bentonite in Type B or Type C medicated feeds containing oleandomycin. Oleandomycin refers to oleandomycin or feed-grade oleandomycin.

(d) Conditions of use. It is used in animal feed as follows:

(1) Chickens and turkeys—(i) Amount per ton. Oleandomycin, 1 to 2 grams.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency for broiler chickens and growing turkeys.

(2) Swine—(i) Amount per ton. Oleandomycin, 5 to 11.25 grams.

(ii) Indications for use. For increased rate of weight gain and improved feed efficiency in growing-finishing swine.

§ 558.450 Oxytetracycline.

(a) Approvals. Type A medicated articles:

(1) 10, 20, 30, 50, 100, and 200 grams per pound to No. 066104 in §510.600(c) of this chapter.

(2) 50, 100, and 200 grams per pound to No. 069254 in §510.600(c) of this chapter.

(b) Special considerations. (1) In accordance with §558.5 labeling shall bear the statement: “FOR USE IN DRY ANIMAL FEED ONLY. NOT FOR USE IN LIQUID FEED SUPPLEMENTS.”

(2) The articles in paragraph (a)(1) of this section contain an amount of mono-alkyl (C₈–C₁₈) trimethylammonium oxytetracycline expressed in terms of an equivalent amount of oxytetracycline hydrochloride or an amount of oxytetracycline dihydrate base expressed in
terms of an equivalent amount of oxytetracycline hydrochloride. Another 100-gram per pound article in paragraph (a)(2) of this section contains oxytetracycline hydrochloride.

(c) Related tolerances. See §556.500 of this chapter.

(d) Conditions of use—(1) Chickens—

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 grams per ton (g/ton).</td>
<td>Chickens: For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously; do not feed to chickens producing eggs for human consumption.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(ii) 100 to 200 g/ton</td>
<td>Chickens: For control of infectious synovitis caused by Mycoplasma synoviae and control of fowl cholera caused by Pasteurella multocida susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 days (d); do not feed to chickens producing eggs for human consumption; in low calcium feeds, withdraw 3 d before slaughter.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(iii) 400 g/ton</td>
<td>Chickens: For control of chronic respiratory disease (CRD) and air sac infection caused by Mycoplasma gallisepticum and Escherichia coli susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to chickens producing eggs for human consumption; in low calcium feeds, withdraw 3 d before slaughter.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(iv) 500 g/ton</td>
<td>Chickens: For reduction of mortality due to air sacculitis (air sac infection) caused by E. coli susceptible to oxytetracycline.</td>
<td>Feed continuously for 5 d; do not feed to chickens producing eggs for human consumption; withdraw 24 hours before slaughter; in low calcium feeds, withdraw 3 d before slaughter.</td>
<td>066104, 069254</td>
</tr>
</tbody>
</table>

(2) Turkeys—

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 50 g/ton</td>
<td>Growing turkeys: For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(ii) 100 g/ton</td>
<td>Turkeys: For control of hexamitiasis caused by Hexamita meleagridis susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(iii) 200 g/ton</td>
<td>Turkeys: For control of infectious synovitis caused by M. synoviae susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; for No. 066104 withdraw 5 d before slaughter; for No. 069254 zero-day withdrawal time; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(iv) 25 milligrams/ pound (mg/lb) of body weight daily.</td>
<td>Turkeys: For control of complicating bacterial organisms associated with bluecomb (transmissible enteritis; coronaviral enteritis) susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; for No. 066104 withdraw 5 d before slaughter; for No. 069254 zero-day withdrawal time; do not feed to turkeys producing eggs for human consumption.</td>
<td>066104, 069254</td>
</tr>
</tbody>
</table>

(3) Swine—

---

Food and Drug Administration, HHS § 558.450
### § 558.450

#### (4) Cattle—

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 0.05 to 0.1 mg/lb of body weight daily.</td>
<td>Calves (up to 250 lb): For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously in milk replacer or starter feed.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(ii) 10 mg/lb of body weight daily.</td>
<td>1. Calves and beef and nonlactating dairy cattle: For treatment of bacterial enteritis caused by E. coli and bacterial pneumonia (shipping fever complex) caused by P. multocida susceptible to oxytetracycline.</td>
<td>Feed continuously for 7 to 14 d; for No. 069254, withdraw 5 d before slaughter; for No. 066104, zero-day withdrawal time.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td></td>
<td>2. Calves: For treatment of bacterial enteritis caused by E. coli susceptible to oxytetracycline.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(iii) 25 mg/head/day.</td>
<td>Calves (250 to 400 lb): For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(iv) 75 mg/head/day.</td>
<td>Growing cattle (over 400 lb): For increased rate of weight gain, improved feed efficiency, and reduction of liver condemnation due to liver abscesses.</td>
<td>Feed continuously.</td>
<td>066104, 069254</td>
</tr>
</tbody>
</table>
Food and Drug Administration, HHS

§ 558.450

Oxytetracycline amount

<table>
<thead>
<tr>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(v) 0.5 to 2.0 g/ head/day</td>
<td>Cattle: For prevention and treatment of the early stages of shipping fever complex. Feed 3 to 5 d before and after arrival in feedlots.</td>
<td>066104, 069254</td>
</tr>
</tbody>
</table>

(5) Minor species—

<table>
<thead>
<tr>
<th>Oxytetracycline amount</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 10 to 20 g/ton ...</td>
<td>Sheep: For increased rate of weight gain and improved feed efficiency.</td>
<td>Feed continuously.</td>
<td>066104, 069254</td>
</tr>
<tr>
<td>(ii) 10 mg/lb of body weight daily.</td>
<td>Sheep: For treatment of bacterial enteritis caused by E. coli and bacterial pneumonia caused by P. multocida susceptible to oxytetracycline. Feed continuously for 7 to 14 d; withdraw 5 d before slaughter.</td>
<td>066104, 069254</td>
<td></td>
</tr>
<tr>
<td>(iii) 200 mg/colony</td>
<td>Honey bees: For control of American foulbrood caused by Paenibacillus larvae and European foulbrood caused by Streptococcus pluton susceptible to oxytetracycline. Remove at least 6 weeks prior to main honey flow.</td>
<td>066104, 069254</td>
<td></td>
</tr>
<tr>
<td>(iv) 250 mg/100 lb of fish/day</td>
<td>Pacific salmon: For marking of skeletal tissue. For salmon not over 30 g body weight; administer as sole ration for 4 consecutive days; fish not to be liberated for at least 7 d following the last administration of medicated feed.</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>(v) 2.5 to 3.75 g/100 lb of fish/day.</td>
<td>1. Salmonids: For control of ulcer disease caused by Haemophilus piscium, furunculosis caused by Aeromonas salmonicida, bacterial hemorrhagic septicemia caused by A. liquefaciens, and pseudomonas disease. Administer in mixed ration for 10 d; do not liberate fish or slaughter fish for food for 21 d following the last administration of medicated feed.</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Catfish: For control of bacterial hemorrhagic septicemia caused by A. liquefaciens and pseudomonas disease. Administer in mixed ration for 10 d; do not liberate fish or slaughter fish for food for 21 d following the last administration of medicated feed; do not administer when water temperature is below 16.7 ºC (62 ºF).</td>
<td>066104</td>
<td></td>
</tr>
<tr>
<td>(vi) 3.75 g/100 lb of fish/day.</td>
<td>1. Freshwater-reared salmonids: For control of mortality due to coldwater disease associated with Flavobacterium psychrophilum. Administer in mixed ration for 10 d; do not liberate fish or slaughter fish for food for 21 d following the last administration of medicated feed.</td>
<td>066104</td>
<td></td>
</tr>
</tbody>
</table>